{"data": [{"Element": "<div class=\"WordSection1\">\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\nI</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Annex\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"text-transform:uppercase\">Invirase\n500\u00a0</span><span lang=\"EN-GB\">mg </span>film-coated tablets<span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND QUANTITATIVE\nCOMPOSITION</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">One film-coated tablet contains 500\u00a0mg\nof saquinavir as saquinavir mesilate.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Excipient </span><u><span lang=\"EN-GB\">with\nknown effect</span></u><span lang=\"EN-GB\">: Lactose monohydrate: 38.5\u00a0mg.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For the full list of excipients, see\nsection 6.1.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Film-coated tablet<span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Light orange to greyish or brownish orange\nfilm-coated tablet of oval cylindrical biconvex shape with the marking\n\"SQV 500\" on the one side and \"ROCHE\" on the other side.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CLINICAL PARTICULARS</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications</span></b></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase is indicated for the treatment of\nHIV-1 infected adult patients. Invirase should only be given in combination\nwith ritonavir and other antiretroviral medicinal products (see section 4.2).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of administration</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Posology</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Therapy with Invirase should be initiated\nby a physician experienced in the management of HIV infection.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">In combination with ritonavir</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended dose of Invirase is\n1000\u00a0mg (2 x 500\u00a0mg </span>film-coated tablets<span lang=\"EN-GB\">) two\ntimes daily with ritonavir 100\u00a0mg two times daily in combination with\nother antiretroviral agents. For treatment-naive patients initiating treatment\nwith Invirase/ritonavir, the starting recommended dose of Invirase is\n500\u00a0mg (1 x 500\u00a0mg film-coated tablet) two times daily with ritonavir\n100\u00a0mg two times daily in combination with other antiretroviral agents for\nthe first 7 days of treatment. After 7 days, the recommended dose of Invirase\nis 1000\u00a0mg two times daily with ritonavir 100\u00a0mg two times daily in\ncombination with other antiretroviral agents. Patients switching immediately\nfrom treatment with another protease inhibitor taken with ritonavir or from a\nnon-nucleoside reverse transcriptase inhibitor based regimen, except\nrilpivirine (see section 4.5), without a wash-out period, should however\ninitiate and continue Invirase at the standard recommended dose of 1000\u00a0mg\ntwo times daily with ritonavir 100\u00a0mg two times daily.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Renal impairment:</span></i></b><b><span lang=\"EN-GB\"><br/>\n</span></b><span lang=\"EN-GB\">No dosage adjustment is necessary for patients with\nmild to moderate renal impairment. Caution should be exercised in patients with\nsevere renal impairment (see section 4.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Hepatic impairment:</span></i></b><b><span lang=\"EN-GB\"><br/>\n</span></b><span lang=\"EN-GB\">No dosage adjustment is necessary for HIV-infected\npatients with mild hepatic impairment. </span>No dosage adjustment seems\nwarranted for patients with moderate hepatic impairment based on limited data.\nClose monitoring of safety (including signs of cardiac arrhythmia) and of\nvirologic response is recommended due to increased variability of the exposure\nin this population.<span style='font-size:10.0pt;font-family:\"Arial\",sans-serif'>\n</span><span lang=\"EN-GB\">Invirase/ritonavir is contraindicated in patients with\ndecompensated hepatic impairment (see sections 4.3 and 4.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Paediatric population:</span></i></b></p>\n<p class=\"MsoNormal\">The safety and activity of saquinavir boosted with ritonavir\nin HIV-infected patients less than 2 years have not been established. No dose\nrecommendations for paediatric patients \u22652 years of age could be\nestablished that are both effective and below thresholds of concern for QT and\nPR interval prolongation.</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Adults over 60 years:</span></i></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The experience with </span><span lang=\"EN-GB\">Invirase in adults over 60\u00a0years </span><span lang=\"EN-GB\">is\nlimited.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Method of administration</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase </span>film-coated tablets<span lang=\"EN-GB\"> should be swallowed whole and taken at the same time as ritonavir\nwith or after food (see section 5.2). </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Invirase is contraindicated in patients with:</p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 hypersensitivity\nto the active substance or to any of the excipients</span> listed in section\n6.1</p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 decompensated\nliver disease<span lang=\"EN-GB\"> (see section 4.4)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.25in\"><b><span style=\"font-family:Symbol\">\u00b7</span></b><b>\u00a0\u00a0\u00a0 congenital\nor documented acquired QT prolongation </b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.25in\"><b><span style=\"font-family:Symbol\">\u00b7</span></b><b>\u00a0\u00a0\u00a0 electrolyte\ndisturbances, particularly uncorrected hypokalaemia</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.25in\"><b><span style=\"font-family:Symbol\">\u00b7</span></b><b>\u00a0\u00a0\u00a0 clinically\nrelevant bradycardia</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.25in\"><b><span style=\"font-family:Symbol\">\u00b7</span></b><b>\u00a0\u00a0\u00a0 clinically\nrelevant heart failure with reduced left-ventricular ejection fraction</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.25in\"><b><span style=\"font-family:Symbol\">\u00b7</span></b><b>\u00a0\u00a0\u00a0 previous\nhistory of symptomatic arrhythmias</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 concurrent therapy\nwith any of the following drugs, which may interact and result in potentially\nlife-threatening undesirable effects (see sections 4.4, 4.5 and 4.8):</p>\n<p class=\"MsoNormal\" style=\"margin-left:49.7pt;text-indent:-.2in\"><b>-\u00a0\u00a0\u00a0 drugs\nthat prolong the QT and/or PR interval</b><b><span lang=\"EN-GB\"> (see sections\n4.4 and 4.5)</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:49.7pt;text-indent:-.2in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 midazolam</span><span lang=\"EN-GB\"> </span>administered\norally (for caution on parenterally administered midazolam, see section 4.5)<span lang=\"EN-GB\">, triazolam (potential for prolonged or increased sedation, respiratory\ndepression)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:49.7pt;text-indent:-.2in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 simvastatin, lovastatin (increased risk of\nmyopathy including rhabdomyolysis)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:49.7pt;text-indent:-.2in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 ergot alkaloids (e.g. ergotamine,\ndihydroergotamine, ergonovine, and methylergonovine) (potential for acute ergot\ntoxicity)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:49.7pt;text-indent:-.2in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 rifampicin (risk of severe hepatocellular\ntoxicity) (see sections 4.4, 4.5, and 4.8)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:49.7pt;text-indent:-.2in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 quetiapine (risk of coma, see section 4.5). </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:49.7pt;text-indent:-.2in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 lurasidone (potential for serious and/or\nlife-threatening reactions, see section 4.5)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Considerations when initiating\nInvirase therapy:</span></i></b><span lang=\"EN-GB\"> Invirase should not be given\nas the sole protease inhibitor. Invirase should only be given in combination\nwith ritonavir (see section 4.2). Invirase is not recommended for use in\ncombination with cobicistat as dosing recommendations for this combination have\nnot been established.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients should be informed that saquinavir\nis not a cure for HIV infection and that they may continue to acquire illnesses\nassociated with advanced HIV infection, including opportunistic infections. While\neffective viral suppression with antiretroviral therapy has been proven to\nsubstantially reduce the risk of sexual transmission, a residual risk cannot be\nexcluded. Precautions to prevent transmission should be taken in accordance\nwith national guidelines.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients should also be advised that they\nmight experience undesirable effects associated with co-administered\nmedications. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i>Cardiac conduction and\nrepolarisation abnormalities:</i></b><b> </b></p>\n<p class=\"MsoNormal\">Dose-dependent prolongations of QT and PR intervals have\nbeen observed in healthy volunteers receiving ritonavir-boosted Invirase (see\nsection 5.1).<b> Concomitant use of ritonavir-boosted Invirase with other\nmedicinal products that prolong the QT and/or PR interval is therefore\ncontraindicated (see section 4.3).</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Since the magnitude of QT and PR prolongation increases with\nincreasing concentrations of saquinavir, the recommended dose of\nritonavir-boosted Invirase should not be exceeded. Ritonavir-boosted Invirase\nat a dose of 2000\u00a0mg once daily with ritonavir 100\u00a0mg once daily has\nnot been studied with regard to the risk of QT prolongation and is not\nrecommended. Other medicinal products known to increase the plasma\nconcentration of ritonavir-boosted Invirase should be used with caution.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Women and elderly patients may be more susceptible to\ndrug-associated effects on the QT and/or PR interval.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><b><u><span style=\"font-family:Symbol\">\u00b7</span></u></b><b><u>\u00a0\u00a0\u00a0 Clinical\nManagement:</u></b></p>\n<p class=\"MsoNormal\">Consideration should be given for performing baseline and\nfollow-up electrocardiograms after initiation of treatment, e.g. in patients\ntaking concomitant medication known to increase the exposure of saquinavir (see\nsection 4.5). If signs or symptoms suggesting cardiac arrhythmia occur,\ncontinuous monitoring of ECG should be performed. Ritonavir-boosted Invirase\nshould be discontinued if arrhythmias are demonstrated, or if prolongation\noccurs in the QT or PR interval.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b>Patients initiating therapy with ritonavir-boosted\nInvirase</b>:</p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\">-\u00a0\u00a0\u00a0\u00a0 An\nECG should be performed on all patients prior to initiation of treatment:\npatients with a QT interval &gt;\u00a0450 msec should not use ritonavir-boosted\nInvirase. For patients with a QT interval &lt; 450 msec, an on treatment ECG is\nrecommended.</p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\">-\u00a0\u00a0\u00a0\u00a0 For\ntreatment-na\u00efve patients initiating treatment with Invirase/ritonavir\n500/100 mg two times daily for the first 7 days of treatment followed by Invirase\n1000 mg two times daily with ritonavir 100 mg two times daily after 7 days and\nwith a baseline QT interval &lt; 450 msec, an on-treatment ECG is suggested\nafter approximately 10 days of therapy.</p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\">-\u00a0\u00a0\u00a0\u00a0 Patients\ndemonstrating a subsequent increase in QT-interval to &gt; 480 msec or\nprolongation over pre-treatment by &gt; 20 msec should discontinue\nritonavir-boosted Invirase.</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>Patients stable on ritonavir-boosted Invirase and\nrequiring concomitant medication with potential to increase the exposure of\nsaquinavir or patients on medication with potential to increase the exposure of\nsaquinavir and requiring concomitant ritonavir-boosted Invirase where no\nalternative therapy is available and the benefits outweigh the risks:</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\">-\u00a0\u00a0\u00a0\u00a0 An\nECG should be performed prior to initiation of the concomitant therapy:\npatients with a QT interval &gt; 450 msec should not initiate the concomitant\ntherapy (see section 4.5).</p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\">-\u00a0\u00a0\u00a0\u00a0 For\npatients with a baseline QT interval &lt; 450 msec, an on-treatment ECG should\nbe performed. For patients demonstrating a subsequent increase in QT-interval\nto &gt; 480 msec or increase by &gt; 20 msec after commencing concomitant\ntherapy, the physician should use best clinical judgment to discontinue either\nritonavir-boosted Invirase or the concomitant therapy or both.</p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><b><u><span style=\"font-family:Symbol\">\u00b7</span></u></b><b><u>\u00a0\u00a0\u00a0 Essential\nPatient Information:</u></b></p>\n<p class=\"MsoNormal\"><i>Prescribers must ensure that patients</i> <i><span lang=\"EN-GB\">are fully informed</span></i><span lang=\"EN-GB\"> <i>regarding the\nfollowing information on cardiac conduction and repolarisation abnormalities: </i></span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0 Patients </span>initiating therapy with\nritonavir boosted Invirase should be warned of the arrhythmogenic risk\nassociated with QT and PR prolongation and told to report any sign or symptom\nsuspicious of cardiac arrhythmia (e.g., chest palpitations, syncope,\npresyncope) to their physician.</p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0 Physicians should enquire about any known\nfamilial history of sudden death at a young age as this may be suggestive of\ncongenital QT prolongation.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0 Patients should be advised of the\nimportance not to exceed the recommended dose.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0 Each patient (or patient\u2019s\ncaregiver) should be reminded to read the Package Leaflet included in the\nInvirase Package.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Liver disease:</span></i></b><span lang=\"EN-GB\"> The safety and efficacy of saquinavir/ritonavir has not been\nestablished in patients with significant underlying liver disorders, therefore\nsaquinavir/ritonavir should be used cautiously in this patient population.\nInvirase/ritonavir is contraindicated in patients with decompensated liver\ndisease (see section 4.3). Patients with chronic hepatitis B or C and treated\nwith combination antiretroviral therapy are at an increased risk for severe and\npotentially fatal hepatic adverse events. In case of concomitant antiviral\ntherapy for hepatitis B or C, please refer also to the relevant product\ninformation for these medicinal products.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients with pre-existing liver\ndysfunction including chronic active hepatitis have an increased frequency of\nliver function abnormalities during combination antiretroviral therapy and\nshould be monitored according to standard practice. If there is evidence of\nworsening liver disease in such patients, interruption or discontinuation of\ntreatment must be considered.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">No dosage adjustment seems warranted for patients with\nmoderate hepatic impairment based on limited data. Close monitoring of safety\n(including signs of cardiac arrhythmia) and of virologic response is\nrecommended due to increased variability of the exposure in this population\n(see sections 4.2 and 5.2). <span lang=\"EN-GB\">There have been reports of\nexacerbation of chronic liver dysfunction, including portal hypertension, in\npatients with underlying hepatitis B or C, cirrhosis and other underlying liver\nabnormalities.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Renal impairment:</span></i></b><span lang=\"EN-GB\"> Renal clearance is only a minor elimination pathway, the principal\nroute of metabolism and excretion for saquinavir being via the liver.\nTherefore, no initial dose adjustment is necessary for patients with renal\nimpairment. However, patients with severe renal impairment have not been\nstudied and caution should be exercised when prescribing saquinavir/ritonavir\nin this population. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Patients with chronic diarrhoea or\nmalabsorption:</span></i></b><span lang=\"EN-GB\"> No information on boosted\nsaquinavir and only limited information on the safety and efficacy of unboosted\nsaquinavir is available for patients suffering from chronic diarrhoea or\nmalabsorption. It is unknown whether patients with such conditions could\nreceive subtherapeutic saquinavir levels.</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Paediatric population:</span></i></b><b><span lang=\"EN-GB\"> </span></b>The safety and activity of saquinavir boosted with\nritonavir in HIV-infected patients less than 2 years have not been established.\nNo dose recommendations for paediatric patients \u22652 years of age could be\nestablished that are both effective and below thresholds of concern for QT and\nPR interval prolongation. Therefore, use in this population is not recommended.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Adults over 60 years:</span></i></b><span lang=\"EN-GB\"> The experience with </span><span lang=\"EN-GB\">Invirase in adults over\n60\u00a0years is limited. </span>Elderly patients may be more susceptible to\ndrug-associated effects on the QT and/or PR interval.</p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Lactose intolerance:</span></i></b><span lang=\"EN-GB\"> Invirase 500\u00a0mg </span>film-coated tablets<span lang=\"EN-GB\">\ncontain lactose. Patients with rare hereditary problems of galactose\nintolerance, the Lapp lactase deficiency or glucose-galactose malabsorption\nshould not take this medicine.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Patients with haemophilia: </span></i></b><span lang=\"EN-GB\">There have been reports of increased bleeding, including spontaneous\nskin haematomas and haemarthroses, in haemophiliac patients type A and B\ntreated with protease inhibitors. In some patients additional<b> </b>factor\nVIII was given. In more than half<b> </b>of the reported cases, treatment with\nprotease inhibitors was continued<b> </b>or reintroduced if treatment had been\ndiscontinued. A causal relationship has been evoked, although the mechanism of\naction has not been elucidated.<b> </b>Haemophiliac patients should therefore\nbe made aware of the possibility of increased bleeding.</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b><i>Weight and metabolic parameters: </i></b>An increase\nin weight and in levels of blood lipids and glucose may occur during antiretroviral\ntherapy. Such changes may in part be linked to disease control and lifestyle.\nFor lipids, there is in some cases evidence for a treatment effect, while for\nweight gain there is no strong evidence relating this to any particular\ntreatment. For monitoring of blood lipids and glucose reference is made to\nestablished HIV treatment guidelines. Lipid disorders should be managed as\nclinically appropriate.</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><i><span lang=\"EN-GB\">Osteonecrosis:</span></i></b><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">Although the aetiology is considered to be\nmultifactorial (including corticosteroid use, alcohol consumption, severe\nimmunosuppression, higher body mass index), cases of osteonecrosis have been\nreported particularly in patients with advanced HIV\u2013disease and/or\nlong-term exposure to combination antiretroviral therapy (CART). Patients should\nbe advised to seek medical advice if they experience joint aches and pain,\njoint stiffness or difficulty in movement.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Immune Reactivation Syndrome:</span></i></b><span lang=\"EN-GB\"> In HIV-infected patients with severe immune deficiency at the time\nof institution of combination antiretroviral therapy (CART), an inflammatory\nreaction to asymptomatic or residual opportunistic pathogens may arise and\ncause serious clinical conditions, or aggravation of symptoms. Typically, such\nreactions have been observed within the first few weeks or months of initiation\nof CART. Relevant examples are cytomegalovirus retinitis, generalised and/or\nfocal mycobacterial infections, and Pneumocystis carinii pneumonia. Any\ninflammatory symptoms should be evaluated and treatment instituted when\nnecessary.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Autoimmune disorders (such as Graves\u2019\ndisease and autoimmune hepatitis) have also been reported to occur in the\nsetting of immune reactivation; however, the reported time to onset is more\nvariable and can occur many months after initiation of treatment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">CYP3A4 Interactions</span></i></b><span lang=\"EN-GB\">: Saquinavir could interact and modify the pharmacokinetics of other\ndrugs that are substrates for CYP3A4 and/or P-gp and should be used with\ncaution. Conversely, other drugs that induce CYP3A4 may also reduce saquinavir\nplasma concentrations. Monitoring of saquinavir plasma concentration might be\nindicated. See table 1, section 4.5, for drugs known and/or having the\npotential to interact with saquinavir and specific recommendations.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Interaction\nwith ritonavir:</span></i></b><span lang=\"EN-GB\"> The recommended dose of\nInvirase and ritonavir is 1000\u00a0mg Invirase plus 100\u00a0mg ritonavir </span>twice\ndaily<span lang=\"EN-GB\">. Higher doses of ritonavir have been shown to be\nassociated with an increased incidence of adverse events. Co-administration of\nsaquinavir and ritonavir has led to severe adverse events, mainly diabetic\nketoacidosis and liver disorders, especially in patients with pre-existing\nliver disease. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Interaction with tipranavir: </span></i></b>Concomitant\nuse of boosted saquinavir and tipranavir, co-administered with low dose\nritonavir in a dual-boosted regimen, results in a significant decrease in\nsaquinavir plasma concentrations (see section 4.5). Therefore, the\nco-administration of boosted saquinavir and tipranavir, co-administered with\nlow dose ritonavir, is not recommended.</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i>Interaction with HMG-CoA reductase inhibitors:</i></b><i>\n</i>Caution must be exercised if Invirase/ritonavir is used concurrently with\natorvastatin, which is metabolised to a lesser extent by CYP3A4. In this\nsituation a reduced dose of atorvastatin should be considered. If treatment\nwith a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is\nrecommended with careful monitoring (see section 4.5).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b><i>Oral contraceptives:</i></b><i> </i>Because\nconcentration of ethinyl estradiol may be decreased when co-administered with\nInvirase/ritonavir, alternative or additional contraceptive measures should be\nused when oestrogen-based oral contraceptives are co-administered (see section\n4.5).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b><i>Glucocorticoids: </i></b>Concomitant use of boosted\nsaquinavir and fluticasone or other glucocorticoids that are metabolised by\nCYP3A4 is not recommended unless the potential benefit of treatment outweighs\nthe risk of systemic corticosteroid effects, including Cushing's syndrome and\nadrenal suppression (see section 4.5).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><i>Interaction with\nefavirenz:</i></b> The combination of saquinavir and ritonavir with efavirenz\nhas been shown to be associated with an increased risk of liver toxicity; liver\nfunction should be monitored when saquinavir and ritonavir are co-administered\nwith efavirenz. No clinically significant alterations of either saquinavir or efavirenz\nconcentration were noted in studies in healthy volunteers or in HIV-infected\npatients (see section 4.5).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other\nmedicinal products and other forms of interaction</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Most drug\ninteraction studies with saquinavir have been completed with unboosted Invirase\nor unboosted saquinavir soft capsules. A limited number of studies have been\ncompleted with ritonavir boosted Invirase or ritonavir boosted saquinavir soft\ncapsules.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Observations\nfrom drug interaction studies done with unboosted saquinavir might not be\nrepresentative of the effects seen with saquinavir/ritonavir therapy.\nFurthermore, results seen with saquinavir soft capsules may not predict the\nmagnitude of these interactions with Invirase/ritonavir.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The metabolism of saquinavir is mediated by\ncytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90\u00a0%\nof the hepatic metabolism. Additionally, <i>in vitro</i> studies have shown\nthat saquinavir is a substrate and an inhibitor for P-glycoprotein (P-gp).\nTherefore, medicinal products that either share this metabolic pathway or\nmodify CYP3A4 and/or P-gp activity (see <i>\"Other potential\ninteractions\"</i>) may modify the pharmacokinetics of saquinavir.\nSimilarly, saquinavir might also modify the pharmacokinetics of other medicinal\nproducts that are substrates for CYP3A4 or P-gp.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ritonavir can affect the pharmacokinetics\nof other medicinal products because it is a potent inhibitor of CYP3A4 and\nP-gp. Therefore, when saquinavir is co-administered with ritonavir,\nconsideration should be given to the potential effects of ritonavir on other\nmedicinal products (see the Summary of Product Characteristics for Norvir).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Based on the finding of dose-dependent prolongations of QT\nand PR intervals in healthy volunteers receiving Invirase/ritonavir (see\nsections 4.3, 4.4 and 5.1), additive effects on QT and PR interval prolongation\nmay occur. Therefore, concomitant use of ritonavir-boosted Invirase with other\nmedicinal products that prolong the QT and/or PR interval is contraindicated.\nThe combination of Invirase/ritonavir with drugs known to increase the exposure\nof saquinavir is not recommended and should be avoided when alternative\ntreatment options are available. If concomitant use is deemed necessary because\nthe potential benefit to the patient outweighs the risk, particular caution is\nwarranted (see section 4.4; for information on individual drugs, see Table 1).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Table\u00a01: Interactions\nand dose recommendations with other medicinal products</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"650\">\n<thead>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Medicinal product by\n   therapeutic area (dose of Invirase used in study)</b></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Interaction</b></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Recommendations\n   concerning co-administration</b></p>\n</td>\n</tr>\n</thead>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><u>Antiretroviral\n  agents<br/>\n</u>Nucleoside reverse transcriptase inhibitors (NRTIs)</i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Zalcitabine and/or<br/>\n  Zidovudine<br/>\n<br/>\n</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">No pharmacokinetic\n  interaction studies have been completed. </p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Use of\n  unboosted saquinavir with zalcitabine and/or zidovudine has been studied in\n  adults. Absorption, distribution and elimination of each of the drugs are\n  unchanged when they are used together.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  zalcitabine is unlikely due to different routes of metabolism and excretion.<br/>\n  For zidovudine (200\u00a0mg every 8 hours) a 25\u00a0% decrease in AUC was\n  reported when combined with ritonavir (300\u00a0mg every 6 hours). The\n  pharmacokinetics of ritonavir remained unchanged.</p>\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">No dose adjustment </span>required<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Didanosine<br/>\n  400\u00a0mg single dose<br/>\n  (saquinavir/ritonavir 1600/100\u00a0mg qd)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 30%<br/>\n  Saquinavir C<sub>max</sub> </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 25%<br/>\n  Saquinavir C<sub>min </sub></span><span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Tenofovir disoproxil fumarate 300\u00a0mg qd<br/>\n  (<span lang=\"EN-GB\">saquinavir/ritonavir</span> 1000/100\u00a0mg bid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 1%<br/>\n  Saquinavir C<sub>max</sub> </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 7%<br/>\n  Saquinavir C<sub>min </sub></span><span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Non-nucleoside\n  reverse transcriptase inhibitors (NNRTIs)</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Delavirdine<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Delavirdine<br/>\n  (unboosted saquinavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC \u2191\n  348%.<br/>\n  There are limited safety and no efficacy data available from the use of this\n  combination. In a small, preliminary study, hepatocellular enzyme elevations\n  occurred in 13\u00a0% of subjects during the first several weeks of the\n  delavirdine and saquinavir combination (6\u00a0% Grade 3 or 4).</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatocellular\n  changes should be monitored frequently if this combination is prescribed.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Efavirenz 600\u00a0mg qd<br/>\n  (<span lang=\"EN-GB\">saquinavir/ritonavir</span> 1600/200\u00a0mg qd, <i><u>or</u></i><br/>\n<span lang=\"EN-GB\">saquinavir/ritonavir 1000/100\u00a0mg</span><span lang=\"EN-GB\"> bid, <i><u>or</u></i> </span><br/>\n  saquinavir/ritonavir 1200/100\u00a0mg qd)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Saquinavir </span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"PT-BR\"><br/>\n  Efavirenz </span><span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required. </span>Liver\n  function should be monitored (see section 4.4).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Rilpivirine</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Switching directly from a\n  rilpivirine containing regimen to Invirase/ritonavir is contraindicated as is\n  concomitant use due to the potential for life threatening cardiac arrhythmia\n  (see sections 4.3 and 4.4).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Nevirapine<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:12.6pt;text-indent:-12.6pt;\n  page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Nevirapine<br/>\n  (unboosted saquinavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC <span style=\"font-family:Symbol\">\u00af</span> 24%<br/>\n  Nevirapine AUC <span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">No dose adjustment required.</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"IT\">HIV protease inhibitors (PIs)</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Atazanavir\n  300\u00a0mg qd<br/>\n  (saquinavir/ritonavir 1600/100\u00a0mg qd)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Saquinavir\n  AUC \u2191 60%<br/>\n  Saquinavir C<sub>max</sub> \u2191 42%</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Ritonavir\n  AUC \u2191 41%<br/>\n  Ritonavir C<sub>max</sub> \u2191 34%<br/>\n  Atazanavir </span><span style=\"font-family:Symbol\">\u00ab</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">No clinical data\n  available for the combination of <span lang=\"EN-GB\">saquinavir/ritonavir</span>\n  1000/100\u00a0mg bid and atazanavir.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Fosamprenavir<br/>\n  700\u00a0mg bid</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">(saquinavir/ritonavir\n  1000/100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC <span style=\"font-family:Symbol\">\u00af</span> 15%<br/>\n  Saquinavir C<sub>max</sub> <span style=\"font-family:Symbol\">\u00af</span> 9%</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir C<sub>min</sub>\n<span style=\"font-family:Symbol\">\u00af</span> 24% (remained above the target\n  threshold for effective therapy.)</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">No dose\n  adjustment required</span><span lang=\"EN-GB\"> for Invirase/ritonavir</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Indinavir<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Low dose ritonavir\n  increases the concentration of indinavir.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Increased\n  concentrations of indinavir may result in nephrolithiasis.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Indinavir 800\u00a0mg tid<br/>\n  (saquinavir 600-1200\u00a0mg single dose)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC \u2191\n  4.6-7.2 fold<br/>\n  Indinavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  No safety and efficacy data available for this combination. Appropriate doses\n  of combination not established.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Lopinavir/ritonavir 400/100\u00a0mg bid<br/>\n  (<span lang=\"EN-GB\">saquinavir</span> 1000\u00a0mg bid in combination with 2 or\n  3 NRTIs)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Saquinavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  Ritonavir <span style=\"font-family:Symbol\">\u00af</span> (effectiveness as\n  boosting agent not modified).</p>\n<p class=\"MsoNormal\">Lopinavir <span style=\"font-family:Symbol\">\u00ab</span>\n  (based on historical comparison with unboosted lopinavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">\u00a0Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the potential for life\n  threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Nelfinavir 1250\u00a0mg bid<br/>\n  (saquinavir/ritonavir 1000/100\u00a0mg bid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC \u2191\n  13%<br/>\n  (90% CI: 27<span style=\"font-family:Symbol\">\u00af</span> - 74\u2191)<br/>\n  Saquinavir Cmax \u2191 9%<br/>\n  (90% CI: 27<span style=\"font-family:Symbol\">\u00af</span> - 61\u2191 )<br/>\n  Nelfinavir AUC <span style=\"font-family:Symbol\">\u00af</span> 6%<br/>\n  (90% CI: 28<span style=\"font-family:Symbol\">\u00af</span> - 22\u2191)<br/>\n  Nelfinavir Cmax <span style=\"font-family:Symbol\">\u00af</span> 5%<br/>\n  (90% CI: 23<span style=\"font-family:Symbol\">\u00af</span> - 16\u2191)</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;page-break-after:avoid\">Combination\n  not recommended.</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Ritonavir 100\u00a0mg bid<br/>\n  (saquinavir 1000\u00a0mg bid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir \u2191</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Ritonavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n<span lang=\"EN-GB\">In HIV-infected patients, Invirase or saquinavir soft\n  capsules in combination with ritonavir at doses of 1000/100\u00a0mg twice\n  daily provide a systemic exposure of saquinavir over a 24 hour period similar\n  to or greater than that achieved with saquinavir soft capsules 1200\u00a0mg\n  three times daily (see section 5.2).</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">This is\n  the approved combination regimen. No dose adjustment is recommended.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Tipranavir/ritonavir<br/>\n  (<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Saquinavir C<sub>min</sub> <span style=\"font-family:\n  Symbol\">\u00af</span> 78%<br/>\n  Dual-boosted protease inhibitor combination therapy in multiple-treatment\n  experienced HIV-positive adults.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Concomitant administration of tipranavir,\n  co-administered with low dose ritonavir, with saquinavir/ritonavir, is not\n  recommended. If the combination is considered necessary, monitoring of the\n  saquinavir plasma levels is strongly encouraged (see section 4.4).</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"IT\">HIV fusion inhibitor</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Enfuvirtide<br/>\n  (saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Saquinavir <span style=\"font-family:Symbol\">\u00ab</span></p>\n<p class=\"Normal11pt0\">Enfuvirtide <span style=\"font-family:Symbol\">\u00ab</span><br/>\n<span lang=\"EN-GB\">No clinically significant interaction was noted.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required.</span></p>\n</td>\n</tr>\n<tr style=\"height:12.9pt\">\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">HIV </span></i></b><b><i>CCR5\n  antagonist</i></b></p>\n</td>\n</tr>\n<tr style=\"height:53.85pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"177\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Maraviroc\n  100\u00a0mg bid</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">(saquinavir/ritonavir\n  1000/100\u00a0mg bid)</span></p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"236\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Maraviroc AUC<sub>12</sub>\n  \u2191 8.77</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Maraviroc C<sub>max</sub>:\n  \u2191 3.78</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir/ritonavir\n  concentrations not measured, no effect is expected.</p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"237\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">No dose\n  adjustment of saquinavir/ritonavir is required. Dose of maraviroc should be decreased\n  to 150\u00a0mg bid with monitoring.</span></p>\n</td>\n</tr>\n<tr style=\"height:12.9pt\">\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Cobicistat\n  containing medicinal products</span></i></b></p>\n</td>\n</tr>\n<tr style=\"height:53.85pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"177\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Cobicistat</span></p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"236\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied. Cobicistat is not recommended in combination\n  with regimens containing ritonavir due to similar effects of cobicistat and\n  ritonavir on CYP3A.</p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"237\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">It is\n  not recommended to coadminister Invirase/ritonavir with cobicistat containing\n  products (see section 4.4). <a name=\"_GoBack\"></a></span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><u>Other medicinal\n  products<br/>\n</u></i></b><b><i><span lang=\"IT\">\u00a0Alpha-1 adrenoreceptor antagonist</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:66.0pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:66.0pt\" valign=\"top\" width=\"177\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Alfuzosin\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:66.0pt\" valign=\"top\" width=\"236\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Concomitant use\n  of alfuzosin and saquinavir/ritonavir is expected to increase plasma levels\n  of alfuzosin.</span></p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:66.0pt\" valign=\"top\" width=\"237\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Contraindicated\n  in combination with Invirase/ritonavir due to potential increase in alfuzosin\n  concentration which can result in hypotension and potentially\n  life-threatening cardiac arrhythmia.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Antiarrhythmics</i></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Bepridil<br/>\n  Lidocaine (systemic) Quinidine<br/>\n  Hydroquinidine<br/>\n</span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of bepridil</span>, systemic<span lang=\"EN-GB\"><br/>\n  lidocaine, quinidine or hydroquinidine may be increased when co-administered\n  with Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"ES\">Amiodarone<br/>\n  flecainide<br/>\n  propafenone<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of </span>amiodarone,\n  flecainide or propafenone<span lang=\"EN-GB\"> may be increased when\n  co-administered with Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">saquinavir/ritonavir</span>\n  due to potentially life threatening cardiac arrhythmia (see section 4.3).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Dofetilide<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to potentially\n  life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Ibutilide<br/>\n  Sotalol<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Anticoagulant</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Warfarin</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of warfarin may be affected </span>when co-administered with\n  Invirase/ritonavir<span lang=\"EN-GB\">.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">INR\n  (international normalised ratio) monitoring recommended.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Anticonvulsants</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\"><span lang=\"IT\">-\u00a0 Carbamazepine Phenobarbital<br/>\n  Phenytoin<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">These\n  medicinal products will induce CYP3A4 and may therefore decrease saquinavir\n  concentrations</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution.</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Monitoring of saquinavir\n  plasma concentration is recommended (see section 4.4)</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Antidepressants</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Tricyclic\n  antidepressants <br/>\n  (e.g. amitriptyline, imipramine, clomipramine) (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase/ritonavir</span>\n  may increase concentrations of tricyclic antidepressants.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Maprotiline</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Maprotiline\u2019s\n  metabolism appears to involve the cytochrome P450 isozymes CYP2D6 and CYP 1A2</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Associated\n  with a prolongation of QTc intervals.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with Invirase/ritonavir due to potentially life threatening\n  cardiac arrhythmia (see sections 4.3 and 4.4).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Nefazodone<u><br/>\n</u></span><span lang=\"IT\">(saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with saquinavir/ritonavir not evaluated.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nefazodone\n  inhibits CYP3A4. Saquinavir concentrations may be increased.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Combination not\n  recommended. Use with caution due to possible cardiac arrhythmias. Monitoring\n  for saquinavir toxicity recommended (see section 4.4).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Trazodone<br/>\n</span><span lang=\"IT\">(saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Plasma concentrations of\n  trazodone may increase.<br/>\n  Adverse events of nausea, dizziness, hypotension and syncope have been\n  observed following coadministration of trazodone and ritonavir.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr style=\"height:12.9pt\">\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Anti-gout\n  preparation</span></i></b></p>\n</td>\n</tr>\n<tr style=\"height:53.1pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.1pt\" valign=\"top\" width=\"177\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Colchicine</p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.1pt\" valign=\"top\" width=\"236\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Concomitant use of\n  colchicine and saquinavir/ritonavir is expected to increase plasma levels of\n  colchicine due to P-gp and/or CYP3A4 inhibition by the protease inhibitor.</p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.1pt\" valign=\"top\" width=\"237\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Because of a potential increase\n  of colchicine-related toxicity (neuromuscular events including\n  rhabdomyolysis), its concomitant use with saquinavir/ritonavir is not\n  recommended, especially in the case of renal or hepatic impairment (see\n  section 4.4).</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Antihistamines</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Terfenadine<br/>\n  Astemizole<u><br/>\n</u></span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Terfenadine AUC </span>\u2191, <span lang=\"EN-GB\">associated with a prolongation of QTc intervals.<br/>\n  A similar interaction with astemizole is likely.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with Invirase/ritonavir\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Mizolastine<br/>\n  (</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Anti-infectives</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Clarithromycin<u><br/>\n</u></span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Interaction with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Clarithromycin is a\n  CYP3A4 substrate and is associated with QT prolongation.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Contraindicated\n  in combination with Invirase/ritonavir due to the potential for life\n  threatening cardiac arrhythmia (see sections 4.3 and 4.4).</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Clarithromycin<br/>\n  500\u00a0mg bid<u><br/>\n</u></span>(unboosted saquinavir <span lang=\"EN-GB\">1200\u00a0mg tid</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Saquinavir\n  AUC </span>\u2191 <span lang=\"EN-GB\">177 %<br/>\n  Saquinavir C<sub>max </sub></span>\u2191 <span lang=\"EN-GB\">187</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">%<br/>\n  Clarithromycin AUC </span>\u2191 <span lang=\"EN-GB\">40 %<br/>\n  Clarithromycin C<sub>max</sub> </span>\u2191 <span lang=\"EN-GB\">40 %</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Erythromycin<u><br/>\n</u></span><span lang=\"IT\">(saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\">Erythromycin is a CYP3A4 substrate and is associated\n  with QT prolongation.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Erythromycin<br/>\n  250\u00a0mg qid<br/>\n</span>(unboosted saquinavir <span lang=\"EN-GB\">1200\u00a0mg tid</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Saquinavir\n  AUC </span>\u2191 <span lang=\"EN-GB\">99 %<br/>\n  Saquinavir C<sub>max </sub></span>\u2191 <span lang=\"EN-GB\">106</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">%<br/>\n<br/>\n</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\"><span lang=\"IT\">Fusidic acid</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\"><span lang=\"IT\">(saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Not studied. Co-administration of\n  fusidic acid and Invirase/ritonavir can cause increased plasma concentration\n  of both fusidic acid and saquinavir/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Streptogramin antibiotics<u><br/>\n</u></span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Streptogramin\n  antibiotics such as quinupristin/dalfopristin inhibit CYP3A4. </span><span lang=\"IT\">Saquinavir concentrations may be increased.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution due to\n  possible cardiac arrhythmias. <span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\"><span lang=\"FR-CH\">-\u00a0 Halofantrine<br/>\n  Pentamidine<br/>\n  Sparfloxacin<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\"><span lang=\"FR-CH\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"text-indent:.45pt;page-break-after:avoid\">Contraindicated\n  in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Antifungals</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Ketoconazole 200\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Saquinavir C<sub>max </sub></span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Ritonavir AUC </span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Ritonavir C<sub>max </sub></span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Ketoconazole AUC \u2191 168%<br/>\n  (90% CI 146%-193%)<br/>\n  Ketoconazole C<sub>max </sub>\u2191 45%<br/>\n  (90% CI 32%-59%)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required when\n  saquinavir/ritonavir combined with </span><span style=\"font-family:Symbol\">\u00a3</span>\u00a0200\u00a0mg/day\n  ketoconazole<span lang=\"EN-GB\">. </span>High doses of ketoconazole<br/>\n  (&gt; 200\u00a0mg/day) are not recommended.</p>\n</td>\n</tr>\n<tr style=\"height:76.4pt\">\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 Itraconazole<br/>\n  (saquinavir/ritonavir)</p>\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 </p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 Interaction\n  with Invirase/ritonavir not studied.</p>\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 Itraconazole\n  is a moderately potent inhibitor of CYP3A4. An interaction is possible.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution due to\n  possible cardiac arrhythmias. <span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Fluconazole/miconazole</span><u><br/>\n</u>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied. Both drugs are CYP3A4 inhibitors and may\n  increase the plasma concentration of saquinavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution due to\n  possible cardiac arrhythmias. <span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Antimycobacterials</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Rifampicin 600\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">In a clinical study 11 of\n  17 (65\u00a0%) healthy volunteers developed severe hepatocellular toxicity\n  with transaminase elevations up to &gt;\u00a020-fold the upper limit of\n  normal after 1 to 5 days of co-administration.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Rifampicin is\n  contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span><br/>\n  (see section 4.3).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Rifabutin <span lang=\"IT\">150\u00a0mg\n  q3d<br/>\n</span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span> 1000/100\u00a0mg bid) in\n  healthy volunteers</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC<sub>0-12</sub>\n<span style=\"font-family:Symbol\">\u00af</span> 13%<br/>\n  (90% CI: 31<span style=\"font-family:Symbol\">\u00af</span> - 9\u2191)<br/>\n  Saquinavir C<sub>max </sub><span style=\"font-family:Symbol\">\u00af</span> 15%<br/>\n  (90% CI: 32<span style=\"font-family:Symbol\">\u00af</span> - 7\u2191)<br/>\n  Ritonavir AUC<sub>0-12</sub> <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  (90% CI: 10<span style=\"font-family:Symbol\">\u00af</span> - 9\u2191)<br/>\n  Ritonavir C<sub>max </sub><span style=\"font-family:Symbol\">\u00ab</span><br/>\n  (90% CI: 8<span style=\"font-family:Symbol\">\u00af</span> - 7\u2191)<br/>\n<br/>\n  Rifabutin active moiety*<br/>\n  AUC<sub>0-72</sub> \u2191 134%<br/>\n  (90% CI 109%-162%)<br/>\n  Rifabutin active moiety*<br/>\n  C<sub>max </sub>\u2191 130%<br/>\n  (90% CI 98%-167%)</p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">Rifabutin AUC<sub>0-72</sub> \u2191\n  53%</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">(90% CI 36%-73%)</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">Rifabutin C<sub>max </sub>\u2191\n  86%</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\">(90% CI 57%-119%)</p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\">\u00a0</p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\">*\u00a0 Sum of rifabutin + 25-O-desacetyl rifabutin\n  metabolite </p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">To prevent possible\n  development of rifabutin resistance in TB and HIV co-infected patients, the\n  recommended dose of rifabutin is 150\u00a0mg every other day or three times\n  per week, with the dose of saquinavir/ritonavir unchanged (1000/100\u00a0mg\n  bid). </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Monitoring of neutropenia\n  and liver enzyme levels is recommended due to an expected increase in\n  exposure to rifabutin.</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><b><i>Antipsychotics</i></b></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt\">\u00a0</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Lurasidone</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Due to CYP3A inhibition by saquinavir/ritonavir,\n  concentrations of lurasidone are expected to increase.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Concomitant administration of Invirase and lurasidone is\n  contra-indicated as it may increase lurasidone-related toxicity (see section\n  4.3).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Quetiapine</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Due to CYP3A inhibition by saquinavir/ritonavir,\n  concentrations of quetiapine are expected to increase.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Concomitant administration of Invirase and quetiapine is\n  contra-indicated as it may increase quetiapine-related toxicity. Increased\n  plasma concentrations of quetiapine may lead to coma (see sectin 4.3).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Pimozide<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Concentrations of\n  pimozide may be increased when co-administered with Invirase/ritonavir.</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Pimozide is a CYP3A4\n  substrate and is associated with QT prolongation,</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with Invirase/ritonavir due to the potential for life threatening\n  cardiac arrhythmia (see sections 4.3 and 4.4).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Clozapine<br/>\n  Haloperidol</p>\n<p class=\"Normal11pt0\">Chlorpromazine<br/>\n  Mesoridazine<br/>\n  Phenothiazines<br/>\n  Sertindole<br/>\n  Sultopride<br/>\n  Thioridazine<br/>\n  Ziprasidone<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with Invirase/ritonavir\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4).</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Benzodiazepines</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Midazolam\n  7.5\u00a0mg<br/>\n  single dose (oral)<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Midazolam\n  AUC \u2191 12.4 fold<br/>\n  Midazolam C<sub>max </sub>\u2191 4.3 fold</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Midazolam t<sub>1/2 </sub>\u2191\n  from 4.7 h to 14.9\u00a0h<br/>\n  No data are available on concomitant use of ritonavir boosted saquinavir with\n  intravenous midazolam. <span style=\"font-size:12.0pt\">Studies of other CYP3A\n  modulators and i.v. midazolam</span> suggest a possible 3-4 fold increase in\n  midazolam plasma levels.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Co-administration of\n  Invirase/ritonavir with orally administered<b> </b>midazolam is\n  contraindicated (see section 4.3). <span style=\"color:black\">Caution should\n  be used with co-administration of Invirase and parenteral midazolam.<br/>\n</span><span lang=\"EN-GB\">If Invirase is co-administered with parenteral\n  midazolam it should be done in an intensive care unit (ICU) or similar\n  setting which ensures close clinical monitoring and appropriate medical management\n  in case of respiratory depression and/or prolonged sedation. Dosage\n  adjustment should be considered, especially if more than a single dose of\n  midazolam is administered.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Alprazolam<br/>\n  Clorazepate<br/>\n  Diazepam<br/>\n  Flurazepam<u><br/>\n</u>(saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of these medicinal products may be increased when co-administered with\n  Invirase/ritonavir. </span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Careful\n  monitoring of patients with regard to sedative effects is warranted. A\n  decrease in the dose of the benzodiazepine may be required.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Triazolam<u><br/>\n</u><span lang=\"PT-BR\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"PT-BR\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Concentrations of triazolam may be increased when\n  co-administered with <span lang=\"EN-GB\">Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">saquinavir/ritonavir</span>,\n  due to the risk of potentially prolonged or increased sedation and\n  respiratory depression (see section 4.3).</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Calcium\n  channel blockers</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Felodipine, nifedipine, nicardipine,\n  diltiazem, nimodipine, verapamil, amlodipine, nisoldipine, isradipine<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of these medicinal\n  products may be increased when co-administered with Invirase/ritonavir. </span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Caution is warranted and clinical\n  monitoring of patients is recommended.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Corticosteroids</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:76.4pt\">\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Dexamethasone<br/>\n</span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Dexamethasone\n  induces CYP3A4 and may </span>decrease<span lang=\"EN-GB\"> saquinavir\n  concentrations.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Use with caution. Monitoring of saquinavir plasma\n  concentration is recommended (see section 4.4).</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Fluticasone\n  propionate<br/>\n  50 mcg qid, intranasal<br/>\n  (ritonavir 100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Fluticasone <span lang=\"EN-GB\">propionate</span> \u2191</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Intrinsic cortisol <span style=\"font-family:Symbol\">\u00af</span> 86%<br/>\n  (90% CI 82%-89%)<br/>\n<span lang=\"EN-GB\">Greater effects may be expected when fluticasone propionate\n  is inhaled. Systemic corticosteroid effects including Cushing\u2019s\n  syndrome and adrenal suppression have been reported in patients receiving\n  ritonavir and inhaled or intranasally administered fluticasone propionate;\n  this could also occur with other corticosteroids metabolised via the P450 3A\n  pathway e.g. budesonide.<br/>\n<br/>\n  Effects of high fluticasone systemic exposure on ritonavir plasma levels yet\n  unknown.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concomitant\n  administration of boosted saquinavir and fluticasone propionate and other\n  corticosteroids metabolised via the P450 3A pathway (e.g. budesonide) is not\n  recommended unless the potential benefit of treatment outweighs the risk of\n  systemic corticosteroid effects (see section 4.4).<br/>\n  Dose reduction of the glucocorticoid should be considered with close\n  monitoring of local and systemic effects or a switch to a glucocorticoid,\n  which is not a substrate for CYP3A4 (e.g. beclomethasone).<br/>\n  In case of withdrawal of glucocorticoids progressive dose reduction may have\n  to be performed over a longer period.</span></p>\n</td>\n</tr>\n<tr style=\"height:12.9pt\">\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Endothelin\n  receptor antagonist</span></i></b></p>\n</td>\n</tr>\n<tr style=\"height:46.2pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:46.2pt\" valign=\"top\" width=\"177\">\n<p class=\"Paragraph\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Bosentan\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:46.2pt\" valign=\"top\" width=\"236\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Not studied.\n  Concomitant use of bosentan and saquinavir/ritonavir may increase plasma\n  levels of bosentan and may decrease plasma levels of saquinavir/ritonavir.</span></p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:46.2pt\" valign=\"top\" width=\"237\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Dose adjustment\n  of bosentan may be required. When bosentan is administered concomitantly with\n  saquinavir/ritonavir, the patient\u2019s tolerability of bosentan should be\n  monitored. Monitoring of the patient\u2019s HIV therapy is also recommended.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"MsoNormal\"><b><i><u>Medicinal products that are substrates of\n  P-glycoprotein</u></i></b></p>\n<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Digitalis glycosides</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Digoxin 0.5\u00a0mg<br/>\n  single dose</span></p>\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">(saquinavir/ritonavir 1000/100\u00a0mg\n  bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Digoxin AUC<sub>0-72</sub> \u2191 49%</p>\n<p class=\"Normal11pt0\">Digoxin C<sub>max </sub>\u2191 27%<br/>\n<span style=\"color:black\">Digoxin levels may differ over time. Large\n  increments of digoxin may be expected when saquinavir/ritonavir is introduced\n  in patients already treated with digoxin.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Caution should be exercised when\n  Invirase/ritonavir and digoxin are co-administered. The serum concentration\n  of digoxin should be monitored and a dose reduction of digoxin should be\n  considered if necessary.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Histamine\n  H<sub>2</sub>-receptor antagonist</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:76.4pt\">\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">-\u00a0 Ranitidine<u><br/>\n</u></span><span lang=\"PT-BR\">(</span><span lang=\"FR-CH\">saquinavir/ritonavir</span><span lang=\"PT-BR\">)</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">-\u00a0 Ranitidine<u><br/>\n</u></span><span lang=\"PT-BR\">(</span><span lang=\"FR-CH\">unboosted saquinavir</span><span lang=\"PT-BR\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Saquinavir\n  AUC </span>\u2191 <span lang=\"EN-GB\">67\u00a0% </span><span lang=\"PT-BR\"><br/>\n<br/>\n</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Increase not thought to be clinically relevant. No\n  dose adjustment of saquinavir recommended.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">HMG-CoA\n  reductase inhibitors</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pravastatin<br/>\n  Fluvastatin<br/>\n  (</span><span lang=\"EN-GB\">saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Interaction not studied. Metabolism of\n  pravastatin and fluvastatin is not dependent on CYP3A4. </span>Interaction\n  via effects on transport proteins cannot be excluded.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Interaction unknown. If no alternative\n  treatment is available, use with careful monitoring (see section 4.4).</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Simvastatin<br/>\n  Lovastatin<u><br/>\n</u>(</span><span lang=\"EN-GB\">saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Simvastatin</span> \u2191\u2191</p>\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Lovastatin </span>\u2191\u2191</p>\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Plasma concentrations highly dependent\n  on CYP3A4 metabolism. </span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Increased concentrations of simvastatin\n  and lovastatin have been associated with rhabdomyolysis. These medicinal\n  products are contraindicated for use with Invirase/ritonavir (see section\n  4.3).</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Atorvastatin</span><span lang=\"EN-GB\"><br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Atorvastatin</span><span lang=\"EN-GB\"> is\n  less dependent on CYP3A4 for metabolism.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">When used with Invirase/ritonavir, the\n  lowest possible dose of atorvastatin should be administered and the patient\n  should be carefully monitored for signs/symptoms of myopathy (muscle\n  weakness, muscle pain, rising plasma creatinine kinase, see section 4.4).</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Immunosuppressants</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT\">Tacrolimus</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Tacrolimus is a substrate of CYP3A4 and P-glycoprotein.\n  Concomitant use of tacrolimus and saquinavir/ritonavir is expected to\n  increase plasma levels of tacrolimus.</p>\n<p class=\"Normal11pt0\">Tacrolimus may be associated with torsades de pointes<span lang=\"EN-GB\">.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Contraindicated in combination with\n  Invirase/ritonavir due to the potential for life threatening cardiac\n  arrhythmia (see sections 4.3 and 4.4).</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Ciclosporin<br/>\n<br/>\n  Rapamycin<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of these medicinal\n  products increase several fold when co-administered with Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Careful therapeutic drug monitoring is\n  necessary for these immunosuppressants when co-administered with\n  Invirase/ritonavir.</span></p>\n</td>\n</tr>\n<tr style=\"height:12.9pt\">\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Long-acting\n  beta2-adrenergic agonist</span></i></b></p>\n</td>\n</tr>\n<tr style=\"height:89.85pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:89.85pt\" valign=\"top\" width=\"177\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Salmeterol</span></p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:89.85pt\" valign=\"top\" width=\"236\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Concomitant use\n  of salmeterol and saquinavir/ritonavir is expected to increase plasma levels\n  of salmeterol.</span></p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:89.85pt\" valign=\"top\" width=\"237\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Combination not\n  recommended as may result in increased risk of cardiovascular adverse events\n  associated with salmeterol, including QT prolongation, palpitations, and\n  sinus tachycardia (see section 4,4). </span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Narcotic\n  analgesics</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Methadone </span><span lang=\"IT\">60-120\u00a0mg qd</span><span lang=\"IT\"><br/>\n  (saquinavir/ritonavir </span><span lang=\"IT\">1000/100\u00a0mg bid</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Methadone AUC <span style=\"font-family:Symbol\">\u00af</span> <span lang=\"EN-GB\">19\u00a0%<br/>\n  (90\u00a0% CI 9\u00a0% to 29\u00a0%)<br/>\n  None of the 12 patients experienced withdrawal symptoms.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Oral\n  contraceptives</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Ethinyl estradiol<br/>\n</span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentration of ethinyl estradiol may\n  be decreased when co-administered with Invirase/ritonavir. </span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Alternative or additional contraceptive\n  measures should be used when oestrogen-based oral contraceptives are\n  co-administered (see section 4.4).</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Phosphodiesterase type 5 (PDE5)\n  inhibitors</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">\u00a0Sildenafil</p>\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">(saquinavir/ritonavir)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sildenafil\n  100\u00a0mg<br/>\n  (single dose)<br/>\n  (unboosted saquinavir 1200\u00a0mg tid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt\">Interaction with\n  Invirase/ritonavir not studied.</p>\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt\">Saquinavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  Sildenafil Cmax \u2191 140\u00a0%<br/>\n  Sildenafil AUC \u2191 210\u00a0%</p>\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt\">-Sildenafil is a substrate of\n  CYP3A4.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt\">Contraindicated\n  in combination with Invirase/ritonavir due to the potential for life\n  threatening cardiac arrhythmia (see sections 4.3 and 4.4).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vardenafil<u><br/>\n</u></span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of vardenafil may be increased when co-administered with Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Tadalafil<u><br/>\n</u></span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of tadalafil may be\n  increased when co-administered with Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Proton pump\n  inhibitors</i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Omeprazole\n  40\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Saquinavir\n  AUC \u2191 82%<br/>\n  (90\u00a0% CI 44-131\u00a0%)</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Saquinavir\n  C<sub>max</sub> \u2191 75%<br/>\n  (90\u00a0% CI 38-123\u00a0%)<br/>\n  Ritonavir </span><span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Combination not\n  recommended.</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Other proton pump\n  inhibitors (saquinavir/ritonavir 1000/100\u00a0mg bid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">No data are available on\n  the concomitant administration of Invirase/ritonavir and other proton pump\n  inhibitors.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Combination not\n  recommended.</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Tyrosine kinase\n  inhibitors</i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">All tyrosine kinase\n  inhibitors with a risk of QT prolongation </p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">e.g. dasatinib,\n  </span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">sunitinib</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with Invirase/ritonavir due to the potential for life threatening\n  cardiac arrhythmia (see sections 4.3 and 4.4).</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Others</i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Ergot\n  alkaloids (e.g. ergotamine, dihydroergotamine, ergonovine, and\n  methylergonovine)<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Invirase/ritonavir may\n  increase ergot alkaloids exposure, and consequently, increase the potential\n  for acute ergot toxicity.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">The concomitant use of\n  Invirase/ritonavir and ergot alkaloids is contra-indicated (see section 4.3).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Grapefruit\n  juice<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Interaction with Invirase/ritonavir not studied.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Grapefruit\n  juice<br/>\n  (single dose)<br/>\n  (unboosted saquinavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Saquinavir \u2191 50% (normal strength grapefruit\n  juice)</p>\n<p class=\"Normal11pt0\">Saquinavir \u2191 100% (double strength grapefruit\n  juice)</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt\">Increase not thought to be\n  clinically relevant. No dose adjustment required.</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Garlic\n  capsules<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Interaction with Invirase/ritonavir not studied.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Garlic\n  capsules<br/>\n  (dose approx. equivalent to two 4\u00a0g cloves of garlic daily)<br/>\n  (unboosted saquinavir 1200\u00a0mg tid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"FR-CH\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"FR-CH\"> 51\u00a0%<br/>\n  Saquinavir Ctrough </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"FR-CH\"> 49\u00a0% (8 hours post dose)<br/>\n  Saquinavir Cmax </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"FR-CH\"> 54\u00a0%.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt\">Patients on saquinavir\n  treatment must not take garlic capsules due to the risk of decreased plasma\n  concentrations and loss of virological response and possible resistance to\n  one or more components of the antiretroviral regimen.</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">St. John\u2019s wort <br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt;page-break-after:avoid\"><span lang=\"EN-GB\">Interaction with Invirase/ritonavir not studied.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:12.6pt;text-indent:-9.35pt;\n  page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">St. John\u2019s wort </span><br/>\n  (unboosted saquinavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt;page-break-after:avoid\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <span lang=\"EN-GB\">Plasma levels of unboosted saquinavir can be reduced by\n  concomitant use of the herbal preparation St. John\u2019s wort <i>(Hypericum\n  perforatum)</i>. This is due to induction of drug metabolising enzymes and/or\n  transport proteins by St. John\u2019s wort.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Herbal\n  preparations containing St. John\u2019s wort must not be used concomitantly\n  with Invirase. If a patient is already taking St. John\u2019s wort, stop St.\n  John\u2019s wort, check viral levels and if possible saquinavir levels.\n  Saquinavir levels may increase on stopping St. John\u2019s wort, and the\n  dose of saquinavir may need adjusting. The inducing effect of St.\n  John\u2019s wort may persist for at least 2 weeks after cessation of\n  treatment.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><u><span lang=\"EN-GB\">Other\n  potential interactions</span></u></i></b></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Medicinal\n  products that are substrates of CYP3A4</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">e.g.\n  dapsone, disopyramide, quinine, fentanyl, and alfentanyl</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"IT\">Gastroenterological medicinal\n  products</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Metoclopramide</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">It is unknown whether medicinal\n  products which reduce the gastrointestinal transit time could lead to lower\n  saquinavir plasma concentrations.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Cisapride<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to potentially\n  life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Diphemanil<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to potentially life threatening cardiac arrhythmia (see sections 4.3 and\n  4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Vasodilators\n  (peripheral)</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vincamine\n  i.v.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr height=\"0\">\n<td style=\"border:none\" width=\"175\"></td>\n<td style=\"border:none\" width=\"2\"></td>\n<td style=\"border:none\" width=\"236\"></td>\n<td style=\"border:none\" width=\"2\"></td>\n<td style=\"border:none\" width=\"200\"></td>\n<td style=\"border:none\" width=\"16\"></td>\n<td style=\"border:none\" width=\"19\"></td>\n</tr>\n</table>\n<p class=\"MsoNormal\"><i><u>Key:</u></i> <span style=\"font-family:Symbol\">\u00af</span>\nreduced, \u2191 increased, <span style=\"font-family:Symbol\">\u00ab</span>\nunchanged, \u2191\u2191 markedly increased</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy and\nlactation</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Pregnancy</span></i></b><b><span lang=\"EN-GB\">: </span></b><span lang=\"EN-GB\">Evaluation of experimental animal\nstudies does not indicate direct or indirect harmful effects with respect to\nthe development of the embryo or foetus, the course of gestation and peri- and\npost-natal development. Clinical experience in pregnant women is limited:\nCongenital malformations, birth defects and other disorders (without a\ncongenital malformation) have been reported rarely in pregnant women who had\nreceived saquinavir in combination with other antiretroviral agents. However,\nso far the available data are insufficient and do not identify specific risks\nfor the unborn child. Saquinavir should be used during pregnancy only if the\npotential benefit justifies the potential risk to the foetus (see section 5.3).</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Breast-feeding</span></i></b><b><span lang=\"EN-GB\">: </span></b><span lang=\"EN-GB\">There are no laboratory animal or\nhuman data available on secretion of saquinavir in breast milk. The potential\nfor adverse reactions to saquinavir in nursing infants cannot be assessed, and\ntherefore, breast-feeding should be discontinued prior to receiving saquinavir.\nIt is recommended that HIV-infected women do not breast feed their infants\nunder any circumstances in order to avoid transmission of HIV.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to\ndrive and use machines</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase may\nhave a minor influence on the ability to drive and use machines. Dizziness,\nfatigue and visual impairment have been reported during treatment with\nInvirase.</span><span lang=\"EN-GB\"> No studies on the effects on the ability to\ndrive and use machines have been performed.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><i>a.\nSummary of the safety profile</i></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Limited data is available from two clinical\nstudies where the safety of saquinavir soft capsule (1000\u00a0mg twice daily)\nused in combination with low dose ritonavir (100\u00a0mg twice daily) for at\nleast 48 weeks was studied in 311 patients. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The following adverse events with an at\nleast possible relationship to ritonavir boosted saquinavir (i.e. adverse\nreactions) were reported most frequently: nausea, diarrhoea, fatigue, vomiting,\nflatulence, and abdominal pain.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The following adverse events were reported\nwith the highest severity (grades 3 and 4): anaemia, diabetes mellitus,\ndiarrhoea, nausea, vomiting and fatigue. </span></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">For comprehensive dose adjustment recommendations and\ndrug-associated adverse reactions for ritonavir and other medicinal products\nused in combination with saquinavir, physicians should refer to the Summary of\nProduct Characteristics for each of these medicinal products.</span></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><i>b.\nTabulated list of adverse reactions</i></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Adverse reactions from two pivotal studies\nof saquinavir soft capsule (1000\u00a0mg twice daily) used in combination with\nlow dose ritonavir (100\u00a0mg twice daily) for at least 48 weeks are\nsummarised in Table 2.\u00a0 Also included are serious and non-serious adverse\nreactions from post-marketing spontaneous reports for which a causal\nrelationship to saquinavir cannot be excluded. </span></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">Adverse reactions are\npresented according to the MedDRA system organ classification. The frequency\ngroupings according to MedDRA convention are: Very common (\u2265 1/10);\ncommon (\u2265 1/100 to &lt;1/10); uncommon (\u2265 1/1,000 to &lt;1/100);\nrare (\u2265 1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known\n(frequency cannot be estimated from the available data).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:42.55pt;text-indent:-41.15pt;page-break-after:\navoid\"><span lang=\"EN-GB\">Table 2: Incidences of Adverse Reactions and marked\nlaboratory abnormalities in </span><span lang=\"EN-GB\">clinical studies and\npost-marketing experience in adult patients</span><span lang=\"EN-GB\">. </span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<thead>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><i><span lang=\"EN-GB\">Body System</span></i></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Frequency of reaction</span></b></p>\n</td>\n<td style=\"width:231.1pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Adverse reactions</span></b></p>\n</td>\n</tr>\n</thead>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Blood and the lymphatic system disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Decreased platelet count</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Anaemia, decreased haemoglobin, decreased lymphocyte count,\n  decreased white blood cell count</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Neutropenia</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Eye Disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Visual impairment</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Immune System Disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Hypersensitivity\u00a0 </span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Metabolism and nutrition disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Increased blood cholesterol, increased blood triglycerides</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Diabetes mellitus, anorexia, increased appetite</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Decreased appetite</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Psychiatric Disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Decreased libido, sleep disorder</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Nervous System Disorder</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Paraesthesia, peripheral neuropathy, dizziness, dysgeusia,\n  headache</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Somnolence, convulsions</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Dyspnoea</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Gastrointestinal disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Diarrhoea, nausea</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Vomiting, abdominal distension, abdominal pain, upper abdominal\n  pain, constipation, dry mouth, dyspepsia, eructation, flatulence, lip dry,\n  loose stools</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Pancreatitis</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Hepato-biliary disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\">Increased\n  alanine aminotransferase, increased aspartate aminotransferase, increased low\n  density lipoprotein</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\">Increased\n  blood bilirubin, increased blood amylase</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\">Hepatitis,\n  jaundice</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Renal and urinary disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Increased blood creatinine</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Renal impairment</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Alopecia, dry skin, eczema, lipoatrophy, pruritus, rash</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"FR-CH\">Stevens Johnson syndrome, dermatitis bullous</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Musculoskeletal and connective tissue disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Muscle spasms</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">General disorders and administration site conditions</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Asthenia, fatigue, increased fat tissue, malaise</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Mucosal ulceration</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i>c. Description of\nselected adverse reactions</i></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><i>Metabolic parameters</i></p>\n<p class=\"MsoNormal\">Weight and levels of blood lipids and glucose may increase\nduring antiretroviral therapy (see section 4.4).</p>\n<p class=\"MsoNormal\" style=\"margin-left:.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.1pt\"><span lang=\"EN-GB\">There have been\nreports of increased bleeding, including spontaneous skin haematomas and\nhaemarthroses, in haemophilic patients type A and B treated with protease\ninhibitors (see section 4.4).</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.1pt;text-autospace:none\"><span lang=\"EN-GB\">Increased CPK, myalgia, myositis and rarely, rhabdomyolysis have\nbeen reported with protease inhibitors, particularly in combination with\nnucleoside analogues. </span><span lang=\"EN-GB\">Cases of osteonecrosis have been\nreported, particularly in patients with generally acknowledged risk factors,\nadvanced HIV disease or long-term exposure to combination antiretroviral\ntherapy (CART). The frequency of this is unknown (see section 4.4).</span><span lang=\"EN-GB\"> </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.1pt;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.1pt;text-autospace:none\"><span lang=\"EN-GB\">In HIV-infected patients with severe immune deficiency at the time\nof initiation of combination antiretroviral therapy (CART), an inflammatory\nreaction to asymptomatic or residual opportunistic infections may arise.</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">Autoimmune disorders (such as\nGraves\u2019disease and autoimmune hepatitis) have also been reported;\nhowever, the reported time to onset is more variable and these events can occur\nmany months after initiation of treatment (see section 4.4).</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><i><span lang=\"EN-GB\">d.\nPaediatric population</span></i></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Limited safety\ndata are available from a paediatric study (NV20911, n=18) in which the safety\nof saquinavir hard capsules (50\u00a0mg/kg bid, not to exceed 1000\u00a0mg bid)\nused in combination with low dose ritonavir oral solution (3\u00a0mg/kg bid for\nbody weight from 5 to &lt;15\u00a0kg, 2.5\u00a0mg/kg bid for body weight from\n15 to 40\u00a0kg and 100\u00a0mg bid for body weight &gt;40\u00a0kg) has been\nstudied in paediatric patients aged 4 months to 6 years old.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Four patients\nin the study experienced five adverse events that were considered related to\ntrial treatment. These events were vomiting (3 patients), abdominal pain (1\npatient) and diarrhoea (1 patient). </span>No unexpected adverse events were\nobserved in this study.</p>\n<p class=\"MsoNormal\" style=\"margin-left:.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after\nauthorisation of the medicinal product is important. It allows continued\nmonitoring of the benefit/risk balance of the medicinal product. </span>Healthcare\nprofessionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in </span><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:silver\">Appendix V</span></a><span lang=\"EN-GB\" style=\"background:silver\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">There is limited experience of overdose\nwith saquinavir. Whereas acute or chronic overdose of saquinavir alone did not\nresult in major complications, in combination with other protease inhibitors,\noverdose symptoms and signs such as general weakness, fatigue, diarrhoea,\nnausea, vomiting, hair loss, dry mouth, hyponatraemia, weight loss and\northostatic hypotension have been observed. There is no specific antidote for\noverdose with saquinavir. Treatment of overdose with saquinavir should consist\nof general supportive measures, including monitoring of vital signs and ECG,\nand observations of the patient\u2019s clinical status. If indicated,\nprevention of further absorption can be considered. Since saquinavir is highly\nprotein bound, dialysis is unlikely to be beneficial in significant removal of\nthe active substance.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></b><b><span lang=\"EN-GB\">PHARMACOLOGICAL PROPERTIES</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pharmaco-therapeutic\ngroup: Antiviral agent, ATC code J05A E01</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Mechanism of action:</span></i></b><i><span lang=\"EN-GB\"> </span></i><span lang=\"EN-GB\" style=\"color:black\">The HIV\nprotease\u00a0is an essential viral enzyme required for\u00a0the specific\ncleavage of viral\u00a0gag and gag-pol polyproteins.\nSaquinavir\u00a0selectively\u00a0inhibits the HIV protease, thereby preventing\nthe creation of\u00a0mature infectious virus particles<strong><span style=\"font-weight:normal\">.</span></strong></span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">QT and PR prolongation on\nelectrocardiogram:</span></i></b><i><span lang=\"EN-GB\"> </span></i>The effects of\ntherapeutic (1000/100\u00a0mg twice daily) and supra-therapeutic\n(1500/100\u00a0mg twice daily) doses of Invirase/ritonavir on the QT interval\nwere evaluated in a 4-way crossover, double-blind, placebo- and active-controlled\n(moxifloxacin 400\u00a0mg) study in healthy male and female volunteers aged 18\nto 55 years old (N=59). On Day 3 of dosing, ECG measurements were done over a\nperiod of 20\u00a0hours. The Day 3 timepoint was chosen since the pharmacokinetic\nexposure was maximum on that day in a previous 14-day multiple dose\npharmacokinetic study. On Day 3, mean C<sub>max </sub>values were approximately\n3\u2011fold and 4\u2011fold higher with the therapeutic and supra-therapeutic\ndoses, respectively, relative to the mean C<sub>max </sub>observed at steady\nstate with the therapeutic dose administered to HIV patients. On Day\u00a03,\nthe upper 1-sided 95% confidence interval of the maximum mean difference in\npre-dose baseline-corrected QTcS (study specific heart rate corrected QT)\nbetween the active drug and placebo arms was &gt; 10 msec for the two\nritonavir-boosted Invirase treatment groups (see results in Table 3). While the\nsupra-therapeutic dose of Invirase/ritonavir appeared to have a greater effect\non the QT interval than the therapeutic dose of Invirase/ritonavir, it is not\nsure if maximum effect for both doses has been observed. In the therapeutic and\nthe supra-therapeutic arm 11% and 18% of subjects, respectively, had a QTcS\nbetween 450 and 480 msec. There was no QT prolongation &gt; 500 msec and no\ntorsade de pointes in the study (see also section 4.4).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:42.55pt;text-indent:-42.55pt\">Table 3:\nMaximum mean of ddQTcS<sup>\u2020</sup> (msec) on day 3 for therapeutic dose\nof Invirase/ritonavir, supra-therapeutic dose of Invirase/ritonavir and active\ncontrol moxifloxacin in healthy volunteers in Thorough QT (TQT) Study</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:453.4pt;border-collapse:collapse;border:none\" width=\"605\">\n<tr>\n<td style=\"width:102.35pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"136\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Treatment</span></b></p>\n</td>\n<td style=\"width:89.6pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Post-Dose</span></b></p>\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Time Point</span></b></p>\n</td>\n<td style=\"width:98.25pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Mean </span></b></p>\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">ddQTcS</span></b></p>\n</td>\n<td style=\"width:1.0in;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"96\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Standard Error</span></b></p>\n</td>\n<td style=\"width:91.2pt;border-top:solid black 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:none;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Upper 95%-CI of\n  ddQTcS</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:102.35pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"136\">\n<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Invirase/ritonavir\n  1000/100\u00a0mg BID</span></p>\n</td>\n<td style=\"width:89.6pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span style=\"font-size:11.0pt\">12 hours</span></p>\n</td>\n<td style=\"width:98.25pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">18.86</span></p>\n</td>\n<td style=\"width:1.0in;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"96\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">1.91</span></p>\n</td>\n<td style=\"width:91.2pt;border:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">22.01</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:102.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"136\">\n<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Invirase/ritonavir</span></p>\n<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">1500/100\u00a0mg\n  BID</span></p>\n</td>\n<td style=\"width:89.6pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span style=\"font-size:11.0pt\">20 hours</span></p>\n</td>\n<td style=\"width:98.25pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">30.22</span></p>\n</td>\n<td style=\"width:1.0in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"96\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">1.91</span></p>\n</td>\n<td style=\"width:91.2pt;border:none;border-top:solid windowtext 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">33.36</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:102.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"136\">\n<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Moxifloxacin^</span></p>\n</td>\n<td style=\"width:89.6pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span style=\"font-size:11.0pt\">4 hours</span></p>\n</td>\n<td style=\"width:98.25pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">12.18</span></p>\n</td>\n<td style=\"width:1.0in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"96\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">1.93</span></p>\n</td>\n<td style=\"width:91.2pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:none;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">15.36</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\"><b><sup>\u2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </sup></b>Derived\ndifference of pre-dose baseline corrected QTcS between active treatment and\nplacebo arms</p>\n<p class=\"MsoNormal\">^\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 400\u00a0mg\nwas administered only on Day 3</p>\n<p class=\"MsoNormal\">Note: QTcS in this study was QT/RR<sup>0.319</sup> for males\nand QT/RR<sup>0.337</sup> for females, which are similar to Fridericia\u2019s correction\n(QTcF=QT/RR<sup>0.333</sup>).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">In this study, PR interval of &gt; 200 msec was also\nobserved in 40% and 47% of subjects receiving Invirase/ritonavir\n1000/100\u00a0mg twice daily and 1500/100\u00a0mg twice daily, respectively, on\nDay 3. PR intervals of &gt; 200\u00a0msec were seen in 3% of subjects in the\nactive control group (moxifloxacin) and 5% in the placebo arm. The maximum mean\nPR interval changes relative to the pre-dose baseline value were 25 msec and 34\nmsec in the two ritonavir-boosted Invirase treatment groups, 1000/100\u00a0mg\ntwice daily and 1500/100\u00a0mg twice daily, respectively (also see section\n4.4).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Events of syncope/presyncope occurred at a higher than\nexpected rate and were seen more frequently under treatment with saquinavir (11\nof 13). The clinical relevance of these findings from this study in healthy\nvolunteers to the use of Invirase/ritonavir in HIV-infected patients is unclear,\nbut doses exceeding Invirase/ritonavir 1000/100\u00a0mg twice daily should be\navoided.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">The effect of treatment initiation with a dosing regimen of\nInvirase/ritonavir 500\u00a0/100 mg twice daily in combination with 2 NRTIs for\nthe first 7 days of treatment followed by Invirase/ritonavir 1000\u00a0/ 100 mg\ntwice daily in combination with 2 NRTIs in the subsequent 7 days on QTc\ninterval, PK, and viral load was evaluated in an open-label 2-week\nobservational study in 23 HIV-1 infected, treatment-na\u00efve patients\ninitiating Invirase/ritonavir therapy. ECG and PK measurements were collected\non Days 3, 4, 7, 10, and 14 of treatment with the modified Invirase/ritonavir\ntreatment. The primary study variable was maximal change from dense predose\nbaseline in QTcF (\u0394QTcFdense). The modified Invirase/ritonavir regimen\nreduced mean maximum \u0394QTcF<sub>dense</sub> in the first week of treatment\ncompared with the same value in healthy volunteers receiving the standard\nInvirase/ritonavir dosing regimen in the TQT study on Day 3, (Table 4) based on\ncross-study comparison in a different population. Only 2/21 (9%) patients\nacross all study days had maximum QTcF change from dense predose baseline\n\u2265 30 ms following administration of the modified Invirase/ritonavir\nregimen in the treatment-na\u00efve HIV-1 infected patient population; and the\nmaximum mean change from dense predose baseline in QTcF was &lt; 10 ms across\nall study days. These results suggest that the QTc liability is reduced with\nthe modified Invirase/ritonavir dosing regimen, based on a cross-study\ncomparison in a different population (Table 4). The proportion of patients with\na reported PR interval prolongation &gt; 200 ms in this study ranged from 3/22\n(14%) (day 3) to 8/21 (38%) (day14).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Following the modified Invirase/ritonavir regimen,\nsaquinavir exposure during the first week peaked on Day 3 and declined to the\nlowest exposure on Day 7 with ritonavir induction effects, while Day 14\nsaquinavir PK parameters (following full doses of Invirase/ritonavir in the\nsecond week) approached the range of historical mean values for saquinavir\nsteady-state values in HIV-1 infected patients (Table 9). Mean Invirase C<sub>max</sub>\nwith the modified Invirase/ritonavir regimen was approximately 53-83% lower\nacross study days in the HIV-1 infected patients relative to the mean C<sub>max</sub>\nachieved in healthy volunteers in the TQT study on Day 3. Continuous declines\nin HIV-RNA were observed in all treatment-na\u00efve patients receiving the\nmodified Invirase/ritonavir dosing regimen over the 2-week treatment period,\nsuggesting HIV viral suppression during the time of the study. No long-term\nefficacy was evaluated with the modified regimen. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Table 4: Summary of Electrocardiogram Parameters following administration\nof the Modified Invirase/ritonavir Regimen in Treatment Na\u00efve HIV-1\ninfected Patients initiating treatment with Invirase/ritonavir</p>\n<div align=\"right\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:472.7pt;border-collapse:collapse\" width=\"630\">\n<tr style=\"height:31.9pt\">\n<td style=\"width:122.9pt;border:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"164\">\n<p class=\"MsoNormal\"><b>Parameter</b></p>\n</td>\n<td style=\"width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><b>Day 3</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=22)</b></p>\n</td>\n<td style=\"width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><b>Day 4</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><b>Day 7</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:63.0pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"84\">\n<p class=\"MsoNormal\"><b>Day 10</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:58.5pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"78\">\n<p class=\"MsoNormal\"><b>Day 14</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:66.3pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"88\">\n<p class=\"MsoNormal\"><b>TQT Study </b></p>\n<p class=\"MsoNormal\"><b>Day 3*</b></p>\n<p class=\"MsoNormal\"><b>(n=57)</b></p>\n</td>\n</tr>\n<tr style=\"height:19.95pt\">\n<td style=\"width:122.9pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:19.95pt\" valign=\"top\" width=\"164\">\n<p class=\"MsoNormal\"><span style=\"color:black\">Mean Maximal \u0394QTcF<sub><span style=\"position:relative;top:3.5pt\">dense</span></sub>\u00a0ms (SD)</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">3.26 \u00b1 7.01</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0.52 \u00b1 9.25 </span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">7.13 \u00b1 7.36</span></p>\n</td>\n<td style=\"width:63.0pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"84\">\n<p class=\"MsoNormal\"><span style=\"color:black\">11.97 \u00b1 11.55</span></p>\n</td>\n<td style=\"width:58.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"78\">\n<p class=\"MsoNormal\"><span style=\"color:black\">7.48 \u00b1 8.46</span></p>\n</td>\n<td style=\"width:66.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"88\">\n<p class=\"MsoNormal\"><span style=\"color:black\">32.2 \u00b1 13.4</span></p>\n</td>\n</tr>\n<tr style=\"height:11.5pt\">\n<td style=\"width:122.9pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:11.5pt\" valign=\"top\" width=\"164\">\n<p class=\"MsoNormal\"><span style=\"color:black\">Patients with maximal \u0394QTcF<sub><span style=\"position:relative;top:3.5pt\">dense</span></sub>\u00a0\u2265 30 ms (%)</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>\n<td style=\"width:63.0pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"84\">\n<p class=\"MsoNormal\"><span style=\"color:black\">2/21 (9%)</span></p>\n</td>\n<td style=\"width:58.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"78\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>\n<td style=\"width:66.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"88\">\n<p class=\"MsoNormal\"><span style=\"color:black\">29/57 (51%)</span></p>\n</td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\">*Historical data from the thorough QT study conducted in\nhealthy volunteers</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Antiviral activity in vitro:</span></i></b><span lang=\"EN-GB\"> </span><span style=\"color:black\">Saquinavir\u00a0demonstrates\nantiviral activity against a panel of laboratory strains and clinical isolates\nof HIV-1 with typical EC<sub>50</sub> and\u00a0EC<sub>90</sub> values in the\nrange 1-10 nM and 5-50 nM, respectively, </span><span lang=\"EN-GB\" style=\"color:black\">with no apparent difference between subtype B and non-B\nclades. The corresponding serum (50% human serum) adjusted EC<sub>50</sub>\nranged from 25-250 nM. Clinical isolates of HIV-2 demonstrated EC<sub>50</sub>\nvalues in the range of 0.3-2.4 nM.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i>Resistance</i></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Antiviral activity\naccording to baseline genotype and phenotype:</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em>\u00a0</em></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><span style=\"font-style:\nnormal\">Genotypic and phenotypic clinical cut-offs predicting the clinical\nefficacy of ritonavir boosted saquinavir have been derived from retrospective\nanalyses of the RESIST 1 and 2 clinical studies and analysis of a large\nhospital cohort (Marcelin et al 2007). </span></em></p>\n<p class=\"MsoNormal\"><em><span style=\"font-style:normal\">\u00a0</span></em></p>\n<p class=\"MsoNormal\"><em><span style=\"font-style:normal\">Baseline saquinavir\nphenotype (shift in susceptibility relative to reference, PhenoSense Assay) was\nshown to be a predictive factor of virological outcome. Virological response\nwas first observed to decrease when the fold shift exceeded 2.3-fold; whereas\nvirological benefit was not observed when the fold shift exceeded 12-fold.</span></em></p>\n<p class=\"MsoNormal\"><em><span style=\"font-style:normal\">\u00a0</span></em></p>\n<p class=\"MsoNormal\"><em><span style=\"font-style:normal\">Marcelin et al (2007)\nidentified nine protease codons (L10F/I/M/R/V, I15A/V, K20I/M/R/T, L24I, I62V,\nG73S/T, V82A/F/S/T, I84V, L90M) that were associated with decreased virological\nresponse to saquinavir/ritonavir (1000/100\u00a0mg twice daily) in 138\nsaquinavir naive patients. The presence of 3 or more mutations was associated\nwith reduced response to saquinavir/ritonavir.</span></em><em><span style=\"font-style:normal\"> </span></em><em><span style=\"font-style:normal\">The\nassociation between the number of these saquinavir-associated resistance\nmutations and virological response was confirmed in an independent clinical\nstudy (RESIST 1 and 2) involving a more heavily treatment experienced patient\npopulation, including 54% who had received prior saquinavir (p=0.0133, see\nTable\u00a05). The G48V mutation, previously identified </span></em><em>in\nvitro</em><em><span style=\"font-style:normal\"> as a saquinavir signature\nmutation, was present at baseline in virus from three patients, none of whom\nresponded to therapy.</span></em></p>\n<p class=\"MsoNormal\"><em><span style=\"font-style:normal\">\u00a0</span></em></p>\n<p class=\"MsoNormal\" style=\"margin-left:39.15pt;text-indent:-39.15pt;page-break-after:\navoid\"><em><span style=\"font-style:normal\">Table 5: Virological response to\nsaquinavir/ritonavir stratified by the number of baseline saquinavir-associated\nresistance mutations</span></em></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><span lang=\"EN-GB\" style=\"font-style:normal\">\u00a0</span></em></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td rowspan=\"3\" style=\"width:70.0pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Number of Saquinavir Associated Resistance Mutations\n  at Baseline*</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:2.45in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"235\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Marcelin et al (2007)</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:181.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"242\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">RESIST 1 &amp; 2</span></b></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:2.45in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"235\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">SQV Naive Population</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:181.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"242\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">SQV Naive/Experienced Population</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">N=138</span></b></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Change in Baseline Plasma HIV-1 RNA at<br/>\n<u>Weeks 12-20</u></span></b></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">N=114</span></b></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Change in Baseline Plasma HIV-1 RNA at<br/>\n<u>Week 4</u></span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">35</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-2.24</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">2</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-2.04</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">1</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">29</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.88</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">3</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.69</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">2</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">24</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.43</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">14</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.57</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">3</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">30</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.52</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">28</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.41</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">4</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">9</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.18</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">40</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.75</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">5</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">6</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.11</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">17</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.44</span></p>\n</td>\n</tr>\n<tr style=\"height:16.15pt\">\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">6</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">5</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.30</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">9</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0.08</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">7</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">1</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0.24</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"margin-left:24.0pt;text-indent:-24.0pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">*\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><em><span lang=\"EN-GB\">Saquinavir Mutation Score Mutations: L10F/I/M/R/V, I15A/V,\nK20I/M/R/T, L24I, I62V, G73S/T, V82A/F/S/T, I84V, L90M</span></em></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt;page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Clinical results from studies with treatment na\u00efve and\nexperienced patients</span></i></b></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the MaxCmin1 study, the safety and\nefficacy of saquinavir soft capsules/ritonavir 1000/100\u00a0mg twice daily\nplus 2 NRTIs/<span style=\"layout-grid-mode:line\">Non-Nucleoside Reverse\nTranscriptase Inhibitors (</span>NNRTIs) was compared to indinavir/ritonavir\n800/100\u00a0mg twice daily plus 2 NRTIs/NNRTIs in over 300 (both protease\ninhibitor treatment na\u00efve and experienced) subjects. The combination of\nsaquinavir and ritonavir exhibited a superior virological activity compared\nwith the indinavir and ritonavir arm when switch from the assigned treatment\nwas counted as virological failure. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the MaxCmin2 study, the safety and\nefficacy of saquinavir soft capsules/ritonavir 1000/100\u00a0mg twice daily\nplus 2\u00a0NRTIs/NNRTIs was compared with lopinavir/ritonavir 400/100\u00a0mg\ntwice daily plus 2 NRTIs/NNRTIs in 324 (both protease inhibitor treatment\nna\u00efve and experienced) subjects. None of the subjects in the\nlopinavir/ritonavir arm had been exposed to lopinavir prior to randomisation\nwhereas 16 of the subjects in the saquinavir/ritonavir arm had previously been\nexposed to saquinavir.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Table\u00a06: Subject\nDemographics MaxCmin1 and MaxCmin2<sup>\u2020</sup></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:135.0pt;border-top:solid black 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">MaxCmin1</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:135.0pt;border-top:solid black 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">MaxCmin2</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border-top:none;border-left:\n  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">SQV/r</span></b></p>\n</td>\n<td style=\"width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">IDV/r</span></b></p>\n</td>\n<td style=\"width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">SQV/r</span></b></p>\n</td>\n<td style=\"width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">LPV/r</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=148</span></b></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=158</span></b></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=161</span></b></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=163</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Sex</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Male</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">82%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">74%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">81%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">76%</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Race\n  (White/Black/Asian) %</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">86/9/1</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">82/12/4</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">75/19/1</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">74/19/2</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Age,\n  median, yrs</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">39</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">40</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">40</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">40</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">CDC\n  Category C (%)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">32%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">32%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">31%</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Antiretroviral\n  na\u00efve (%)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">22%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">31%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">34%</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">PI\n  na\u00efve (%)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">41%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">38%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">48%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">48%</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">Median\n  Baseline HIV-1 RNA, log<sub>10</sub> copies/ml (IQR)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">4.0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(1.7-5.1)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">3.9</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(1.7-5.2)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">4.4 </span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(3.1-5.1)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">4.6</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(3.5-5.3)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  Baseline CD4<sup>+</sup> Cell Count, cells/mm<sup>3</sup> (IQR)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">272</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(135-420)\n  </span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">280</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(139-453)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">241</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(86-400)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">239</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(95-420)</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\"><sup>\u2020 </sup>data from clinical study report</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Table\u00a07: Outcomes at\nWeek 48 MaxCmin1 and MaxCmin2<sup>\u2020</sup></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"619\">\n<tr style=\"page-break-inside:avoid;height:18.4pt\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Outcomes</b></p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>MaxCmin1</b></p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>MaxCmin2</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:14.35pt\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>SQV/r</b></p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>IDV/r</b></p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>SQV/r</b></p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>LPV/r</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Initiated assigned\n  treatment, </p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">n (%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">148</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(94%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">158</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(99%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">161</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(94%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">163</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(98%)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Discontinued assigned\n  treatment, n (%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">40</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(27%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">64</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(41%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">48</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(30%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">23</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(14%)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.01</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.001</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Virological failure\n  ITT/e*<sup>#</sup></p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">36/148 (24%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">41/158 (26%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">53/161 (33%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">29/163 (18%)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.76</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.002</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Proportion with VL &lt;\n  50 copies/ml at week 48, ITT/e<sup>#</sup></p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">97/144<br/>\n  (67%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">106/154<br/>\n  (69%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">90/158<br/>\n  (57%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">106/162<br/>\n  (65%)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:14.35pt\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P &gt;0.05<sup>\u2021</sup></p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.12</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Proportion with VL &lt;\n  50 copies/ml at week 48,</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">On Treatment</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">82/104<br/>\n  (79%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">73/93<br/>\n  (78%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">84/113<br/>\n  (74%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">97/138<br/>\n  (70%)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P&gt;0.05<sup>\u2021</sup></p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.48</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Median increase in CD4\n  cell count at week 48 (cells/mm<sup>3</sup>)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">85</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">73</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">110</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">106</p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"margin-left:24.0pt;text-indent:-24.0pt;page-break-after:\navoid\">*\u00a0\u00a0\u00a0\u00a0\u00a0 For both studies: For patients entering study\nwith VL\u00a0&lt;\u00a0200\u00a0copies/ml, VF defined as <u>&gt;</u>\u00a0200\u00a0copies/ml.\nMaxCmin1: For those entering with VL\u00a0<u>&gt;</u>\u00a0200 copies/ml, VF\ndefined as any increase <u>&gt;</u>\u00a00.5\u00a0logs and/or VL\u00a0<u>&gt;\u00a0</u>50,000\ncopies/ml at week 4, <u>&gt;\u00a0</u>5,000\u00a0copies/ml at week 12, or <u>&gt;</u>\u00a0200\u00a0copies/ml\nat week 24 or thereafter. MaxCmin2: any rise <u>&gt;</u>\u00a00.5\u00a0log at a\nspecific visit; <u>&lt;</u>\u00a00.5\u00a0log reduction if VL\u00a0<u>&gt;</u>\u00a0200\u00a0copies/ml\nat week 4; <u>&lt;</u>\u00a01.0\u00a0log reduction from base line if VL\u00a0<u>&gt;</u>\u00a0200\u00a0copies/ml\nat week 12; and a VL\u00a0<u>&gt;</u>\u00a0200 copies/ml at week 24.</p>\n<p class=\"MsoNormal\" style=\"margin-left:24.0pt;text-indent:-24.0pt\"><sup>#</sup>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ITT/e\n= Intent-to-treat/exposed</p>\n<p class=\"MsoNormal\" style=\"margin-left:24.0pt;text-indent:-24.0pt\"><sup>\u2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </sup>Data\nfrom clinical study report</p>\n<p class=\"MsoNormal\" style=\"margin-left:24.0pt;text-indent:-24.0pt\"><sup>\u2021\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </sup>Data\nfrom<b> </b>MaxCmin1 publication</p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Clinical results from paediatric\nstudies</span></i></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">The pharmacokinetics, safety and activity of saquinavir have\nbeen evaluated in an open label, multicenter study in 18 children aged 4 months\nto less than 6 years old in which saquinavir (50\u00a0mg/kg bid up to the adult\ndose of 1000\u00a0mg bid) was administered in combination with ritonavir oral\nsolution (3\u00a0mg/kg bid for body weight from 5 to &lt;15\u00a0kg,\n2.5\u00a0mg/kg bid for body weight from 15 to 40\u00a0kg and 100\u00a0mg bid\nfor body weight &gt;40\u00a0kg) plus \u22652 background ARVs. The infants and\nyoung children were stratified into 2 groups: Group A \u201cLow Age\nGroup\u201d 4 months to less than 2 years old (n=5) and Group B \u201cHigh\nAge Group\u201d children 2 years to less than 6 years old (n=13). </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">In the \u201cHigh Age Group\u201d, the number of patients\nwith a viral load &lt;400 copies/mL at week 48 was 11 of 13.\u00a0 The number\nof patients with viral load &lt;50 copies/mL was 9 of 13 for the same\nperiod.\u00a0 The CD4 lymphocyte count expressed as percentage mean CD4\nincreased by a mean of 2.97% over the same 48 week period. The size of the\nstudy was too small to allow conclusions on clinical benefit.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties</span></b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Saquinavir is essentially completely metabolised by CYP3A4.\nRitonavir inhibits the metabolism of saquinavir, thereby increasing\n(\"boosting\") the plasma levels of saquinavir. </p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Absorption:</span></i></b><span lang=\"EN-GB\"> In HIV-infected adult patients, Invirase in combination with\nritonavir at doses of 1000/100\u00a0mg twice daily provides saquinavir systemic\nexposures over a 24-hour period similar to or greater than those achieved with saquinavir\nsoft capsules 1200\u00a0mg tid (see Table 8). The pharmacokinetics of\nsaquinavir is stable during long-term treatment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:42.55pt;text-indent:-42.55pt;page-break-after:\navoid\"><span lang=\"EN-GB\">Table 8: Mean (% CV) AUC, C<sub>max</sub> and C<sub>min</sub>\nof saquinavir in patients following multiple dosing of Invirase, saquinavir\nsoft capsules, Invirase/ritonavir, and saquinavir soft capsules/ritonavir</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Treatment</span></b></p>\n</td>\n<td style=\"width:.4in;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">N</span></b></p>\n</td>\n<td style=\"width:91.7pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">AUC\u03c4 (ng\u00b7h/ml)</span></b></p>\n</td>\n<td style=\"width:63.8pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">AUC<sub>0-24 </sub>(ng\u00b7h/ml)</span></b><sup>\n  \u2020</sup></p>\n</td>\n<td style=\"width:76.55pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">C<sub>max</sub></span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(ng/ml)</span></b></p>\n</td>\n<td style=\"width:77.35pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">C<sub>min</sub></span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(ng/ml)</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase </span>(hard\n  capsule)<span lang=\"EN-GB\"><br/>\n  600\u00a0mg tid</span></p>\n</td>\n<td style=\"width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoEndnoteText\" style=\"text-align:center;line-height:\n  13.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">10</span></p>\n</td>\n<td style=\"width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">866 (62)</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">2,598</span></p>\n</td>\n<td style=\"width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">197 (75)</span></p>\n</td>\n<td style=\"width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">75 (82)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FR-CH\">saquinavir\n  soft capsule</span><span lang=\"FR-CH\"><br/>\n  1200\u00a0mg tid</span></p>\n</td>\n<td style=\"width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31</span></p>\n</td>\n<td style=\"width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7,249 (85)</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">21,747</span></p>\n</td>\n<td style=\"width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">2,181 (74)</span></p>\n</td>\n<td style=\"width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">216 (84)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase </span>(tablet)<br/>\n<span lang=\"EN-GB\">1000\u00a0mg bid plus ritonavir 100\u00a0mg bid*<br/>\n  (fasting condition)</span></p>\n</td>\n<td style=\"width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">22</span></p>\n</td>\n<td style=\"width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">10,320</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(2,530-30,327)</p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">20,640</p>\n</td>\n<td style=\"width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">1,509</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(355-4,101)</span></p>\n</td>\n<td style=\"width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">313</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(70-1,725)<sup> \u2020\u2020</sup></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase </span>(tablet)<br/>\n<span lang=\"EN-GB\">1000\u00a0mg bid plus ritonavir 100\u00a0mg bid*<br/>\n  (high fat meal)</span></p>\n</td>\n<td style=\"width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">22</span></p>\n</td>\n<td style=\"width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">34,926</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(11,826-105,992)</p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">69,852</p>\n</td>\n<td style=\"width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5,208</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(1,536-14,369)</span></p>\n</td>\n<td style=\"width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1,179</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(334-5,176)<sup> \u2020\u2020</sup></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u03c4 =\ndosing interval, i.e. 8 hour for tid and 12 h for bid dosing.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">C</span><sub><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>min</span></sub><span lang=\"EN-GB\">\n= the observed plasma concentration at the end of the dose interval.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">bid = twice\ndaily</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">tid = three\ntimes daily</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">* results\nare geometric mean (min - max) </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup>\u2020 </sup><span lang=\"EN-GB\">derived from tid or bid dosing schedule</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup>\u2020\u2020 </sup><span lang=\"EN-GB\">C<sub>trough</sub></span><span lang=\"EN-GB\"> values</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Absolute bioavailability averaged 4\u00a0%\n(CV 73\u00a0%, range: 1\u00a0% to 9\u00a0%) in 8 healthy volunteers who\nreceived a single 600\u00a0mg dose (3 x 200\u00a0mg</span> hard capsule<span lang=\"EN-GB\">) of Invirase following a heavy breakfast. The low bioavailability\nis thought to be due to a combination of incomplete absorption and extensive\nfirst-pass metabolism. Gastric pH has been shown to be only a minor component\nin the large increase in bioavailability seen when given with food. The\nabsolute bioavailability of saquinavir co-administered with ritonavir has not\nbeen established in humans.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In combination with ritonavir,\nbioequivalence of Invirase hard capsules and film-coated tablets was\ndemonstrated under fed conditions.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Effective therapy in treatment na\u00efve\npatients is associated with a C<sub>min</sub> of approximately 50\u00a0ng/ml\nand an AUC<sub>0-24</sub> of about 20,000\u00a0ng\u00b7h/ml. <span style=\"layout-grid-mode:line\">Effective therapy in treatment experienced\npatients is associated with a C<sub>min</sub> of approximately 100 ng/ml and an\nAUC<sub>0-24</sub> of about 20,000\u00a0ng</span>\u00b7<span style=\"layout-grid-mode:line\">h/ml.</span></span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\">In treatment-na\u00efve HIV-1 infected patients initiating\nInvirase/ritonavir treatment with a modified Invirase/ritonavir dosing regimen\nof <span lang=\"EN-GB\">Invirase 500\u00a0mg two times daily with ritonavir\n100\u00a0mg two times daily for the first 7 days of treatment and increased to\nInvirase 1000\u00a0mg two times daily with ritonavir 100\u00a0mg two times\ndaily in the subsequent 7 days, </span>saquinavir systemic exposures generally\napproached or exceeded the range of historical steady-state values with the\nstandard Invirase/ritonavir 1000\u00a0mg/100\u00a0mg bid dosing regimen across\nstudy days <span lang=\"EN-GB\">(see Tables 9 and 8)</span>. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Table 9: Mean (CV%) PK Parameters following administration\nof the Modified Invirase/ritonavir Regimen in Treatment Na\u00efve HIV-1\ninfected Patients initiating treatment with Invirase/ritonavir</p>\n<div align=\"right\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:465.15pt;border-collapse:collapse;border:none\" width=\"620\">\n<tr style=\"height:36.95pt\">\n<td style=\"width:80.6pt;border:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\"><b>Parameter</b></p>\n</td>\n<td style=\"width:78.45pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\"><b>Day 3</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=22)</b></p>\n</td>\n<td style=\"width:73.9pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\"><b>Day 4</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:73.9pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\"><b>Day 7</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:79.15pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\"><b>Day 10</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:79.15pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\"><b>Day 14</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n</tr>\n<tr style=\"height:15.2pt\">\n<td style=\"width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\">AUC<sub>0-12</sub><b><sub> </sub></b><b><span lang=\"EN-GB\">(ng*hr/ml)</span></b></p>\n</td>\n<td style=\"width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\">27100 (35.7)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:15.2pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">20300 (39.9)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:15.2pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">12600 (54.5)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">34200 (48.4)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">31100 (49.6)</p>\n</td>\n</tr>\n<tr style=\"height:13.3pt\">\n<td style=\"width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\">C<sub>max</sub> (ng/ml)</p>\n</td>\n<td style=\"width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\">4030 (29.1)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">2960 (40.2)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">1960 (53.3)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">5300 (36.0)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">4860 (46.8)</p>\n</td>\n</tr>\n<tr style=\"height:13.3pt\">\n<td style=\"width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\">C<b><sub><span lang=\"EN-GB\">12</span></sub></b><b><span lang=\"EN-GB\"> (ng/ml)</span></b></p>\n</td>\n<td style=\"width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\">899 (64.9)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">782 (62.4)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">416 (98.5)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">1220 (91.6)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">1120 (80.9)</p>\n</td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">In vitro</span></i><span lang=\"EN-GB\">\nstudies have shown that saquinavir is a substrate for P-glycoprotein (P-gp).</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Effect of food:</span></i></b><span lang=\"EN-GB\"> </span>In a cross-over study in 22 HIV-infected patients treated\nwith Invirase/ritonavir 1000\u00a0mg/100\u00a0mg twice daily and receiving\nthree consecutive doses under fasting conditions or after a high-fat,\nhigh-calorie meal (46 g fat, 1,091 Kcal), the AUC<sub>0-12</sub>, C<sub>max</sub>\nand C<sub>trough</sub> values of saquinavir under fasting conditions were about\n70 per cent lower than with a high-fat meal. All but one of the patients\nachieved C<sub>trough</sub> values of saquinavir above the therapeutic\nthreshold (100 ng/ml) in the fasted state. There were no clinically significant\ndifferences in the pharmacokinetic profile of ritonavir in fasting and fed\nconditions but the ritonavir C<sub>trough</sub> (geometric mean 245 vs. 348\nng/ml) was lower in the fasting state compared to the administration with a\nmeal. Invirase/ritonavir should be administered with or after food.</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Distribution in adults:</span></i></b><span lang=\"EN-GB\"> Saquinavir partitions extensively into the tissues. The mean\nsteady-state volume of distribution following intravenous administration of a\n12\u00a0mg dose of saquinavir was 700\u00a0l (CV 39\u00a0%). It has been shown\nthat saquinavir is approximately 97\u00a0% bound to plasma proteins up to\n30\u00a0</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">m</span><span lang=\"EN-GB\">g/ml. In two patients receiving Invirase 600\u00a0mg three times\ndaily, cerebrospinal fluid concentrations of saquinavir were negligible when\ncompared to concentrations from matching plasma samples.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Biotransformation and elimination in\nadults:</span></i></b><b><span lang=\"EN-GB\"> </span></b><i><span lang=\"EN-GB\">In\nvitro</span></i><span lang=\"EN-GB\"> studies using human liver microsomes have\nshown that the metabolism of saquinavir is cytochrome P450 mediated with the\nspecific isoenzyme, CYP3A4, responsible for more than 90\u00a0% of the hepatic\nmetabolism. Based on <i>in vitro</i> studies, saquinavir is rapidly metabolised\nto a range of mono- and di-hydroxylated inactive compounds. In a mass balance\nstudy using 600\u00a0mg 14C-saquinavir (n = 8), 88\u00a0% and 1\u00a0% of the\norally administered radioactivity, was recovered in faeces and urine, respectively,\nwithin 4 days of dosing. In an additional four subjects administered\n10.5\u00a0mg 14C-saquinavir intravenously, 81\u00a0% and 3\u00a0% of the\nintravenously administered radioactivity was recovered in faeces and urine,\nrespectively, within 4\u00a0days of dosing. 13\u00a0% of circulating saquinavir\nin plasma was present as unchanged compound after oral administration and the\nremainder as metabolites. Following intravenous administration 66\u00a0% of\ncirculating saquinavir was present as unchanged compound and the remainder as\nmetabolites, suggesting that saquinavir undergoes extensive first pass\nmetabolism. <i>In vitro</i> experiments have shown that the hepatic metabolism\nof saquinavir becomes saturable at concentrations above 2 </span><span lang=\"EN-GB\" style=\"font-family:Symbol\">m</span><span lang=\"EN-GB\">g/ml.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Systemic clearance of saquinavir was high,\n1.14 l/h/kg (CV 12\u00a0%), slightly above the hepatic plasma flow, and\nconstant after intravenous doses of 6, 36 and 72\u00a0mg. The mean residence\ntime of saquinavir was 7 hours (n = 8).</span></p>\n<p class=\"MsoNormal\"><b><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><u><span lang=\"EN-GB\">Special\npopulations</span></u></i></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i>\u00a0</i></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i>Effect of gender\nfollowing treatment with Invirase/ritonavir:</i></b> A gender difference was\nobserved with females showing higher saquinavir exposure than males (AUC on\naverage 56\u00a0% higher and C<sub>max</sub> on average 26\u00a0% higher) in\nthe bioequivalence study comparing Invirase 500\u00a0mg film coated tablets\nwith Invirase 200\u00a0mg hard capsules both in combination with ritonavir.\nThere was no evidence that age and body-weight explained the gender difference\nin this study. Limited data from controlled clinical studies with the approved\ndosage regimen do not indicate a major difference in the efficacy and safety\nprofile between men and women.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b><i>Patients with hepatic impairment: </i></b>The effect\nof hepatic impairment on the steady state pharmacokinetics of\nsaquinavir/ritonavir (1000\u00a0mg/100\u00a0mg twice daily for 14 days) was\ninvestigated in 7 HIV-infected patients with moderate liver impairment (Child\nPugh Grade B score 7 to 9). The study included a control group consisting of 7\nHIV-infected patients with normal hepatic function matched with the hepatically\nimpaired patients for age, gender, weight and tobacco use. The mean\n(%\u00a0coefficient of variation in parentheses) values for saquinavir AUC<sub>0-12</sub>\nand C<sub>max</sub> were 24.3 (102%)\u00a0\u00b5g\u00b7hr/ml and 3.6 (83%)\n\u00b5g/ml, respectively, for HIV-infected patients with moderate hepatic\nimpairment. The corresponding values in the control group were 28.5 (71%)\n\u00b5g\u00b7hr/ml and 4.3 (68%)\u00a0\u00b5g/ml. The geometric mean ratio\n(ratio of pharmacokinetic parameters in hepatically impaired patients to\npatients with normal liver function) (90% confidence interval) was 0.7 (0.3 to\n1.6) for both AUC<sub>0-12</sub> and C<sub>max</sub>, which suggests\napproximately 30% reduction in the pharmacokinetic exposure in patients with\nmoderate hepatic impairment. Results are based on total concentrations\n(protein-bound and unbound). Concentrations unbound at steady-state were not\nassessed. No dosage adjustment seems warranted for patients with moderate\nhepatic impairment based on limited data. Close monitoring of safety (including\nsigns of cardiac arrhythmia) and of virologic response is recommended due to\nincreased variability of the exposure in this population<i><span style='font-size:10.0pt;font-family:\"Arial\",sans-serif'> </span></i><span lang=\"EN-GB\">(see sections 4.2 and 4.4)</span>.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><i><span lang=\"EN-GB\">Paediatric\nPatients</span></i></b><span lang=\"EN-GB\">: Steady state pharmacokinetic\ninformation is available from HIV-infected paediatric patients from study\nNV20911. In this study, 5 patients were &lt;2 years and 13 between 2 to &lt;6\nyears and received 50\u00a0mg/kg saquinavir bid (not to exceed 1000\u00a0mg\nbid) boosted with ritonavir at 3\u00a0mg/kg for patients with body weight\nranging from 5 to &lt;15\u00a0kg or 2.5\u00a0mg/kg for patients with body\nweight ranging from 15 to 40\u00a0kg (not to exceed 100\u00a0mg bid).</span><span lang=\"EN-GB\"> Sixteen of 18 children could not swallow Invirase hard capsules and\nreceived medication by opening the capsules and mixing the contents with\ndifferent vehicles.</span><span lang=\"EN-GB\"> The pharmacokinetic exposure\nparameters for </span><span lang=\"EN-GB\">the \u201cHigh Age Group\u201d </span><span lang=\"EN-GB\">are listed in Table 10. </span><span lang=\"EN-GB\">Results of the\n\u201cLow Age Group\u201d are not shown as data are limited due to the small\nsize of the group.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:TimesNewRomanPSMT\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Table\u00a010:\nPharmacokinetic parameters of saquinavir at steady-state in HIV-infected\npediatric patients</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td colspan=\"3\" style=\"width:221.4pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"295\">\n<p class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt\">\u00a0</p>\n</td>\n<td colspan=\"3\" style=\"width:221.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"295\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>Mean \u00b1 SD Saquinavir (%CV) Pharmacokinetic\n  Parameters*</b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:95.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt\"><b>Study</b></p>\n</td>\n<td style=\"width:78.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:14.0pt\"><b>Age</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:14.0pt\"><b>Group</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:14.0pt\">(Years)</p>\n</td>\n<td style=\"width:48.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"64\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>N</b></p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>AUC<sub>0-12h</sub> (ng\u2022h/mL)</b></p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>C<sub>trough</sub> (ng/mL)</b></p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>C<sub>max </sub>(ng/mL)</b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:95.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt\">NV20911</p>\n</td>\n<td style=\"width:78.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">2 to &lt; 6 years</p>\n</td>\n<td style=\"width:48.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"64\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">13</p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">38000 \u00b1 18100</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">(48%)</p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">1860 \u00b1 1060</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">(57%)</p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">5570 \u00b1 2780</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">(50%)</p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">* All parameters normalized to a 50\u00a0mg/kg dose</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span style=\"color:black\">Steady state saquinavir exposures\nobserved in paediatric trials were substantially higher than historical data in\nadults where dose- and exposure-dependent QTc and PR prolongation were observed\n(see section 4.4).</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">A<i>cute\nand chronic toxicity:</i></span></b><span lang=\"EN-GB\"> Saquinavir was well\ntolerated in oral acute and chronic toxicity studies in mice, rats, dogs and\nmarmosets.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Mutagenesis:</span></i></b><i><span lang=\"EN-GB\"> </span></i>Mutagenicity and genotoxicity studies, with and without\nmetabolic activation where appropriate, have shown that saquinavir has no\nmutagenic activity <i>in vitro</i> in either bacterial (Ames test) or mammalian\ncells (Chinese hamster lung V79/HPRT test). Saquinavir does not induce\nchromosomal damage <i>in vivo</i> in the mouse micronucleus assay or <i>in\nvitro</i> in human peripheral blood lymphocytes and does not induce primary DNA\ndamage <i>in vitro</i> in the unscheduled DNA synthesis test.</p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Carcinogenesis:</span></i></b><i><span lang=\"EN-GB\"> </span></i><span lang=\"EN-GB\">There was no evidence of carcinogenic\nactivity after the administration of saquinavir mesilate for 96 to 104 weeks to\nrats and mice. The plasma exposures (AUC values) in </span>rats (maximum dose\n1000\u00a0mg/kg/day) and in mice (maximum dose 2500\u00a0mg/kg/day) were lower\nthan<span lang=\"EN-GB\"> the expected plasma exposures obtained in humans at the\nrecommended clinical dose of ritonavir boosted Invirase. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Reproductive toxicity:</span></i></b><i><span lang=\"EN-GB\"> </span></i><span lang=\"EN-GB\">Fertility, peri- and postnatal\ndevelopment were not affected, and e</span>mbryotoxic / teratogenic effects\nwere not observed in rats or rabbits at plasma exposures lower than those\nachieved in humans <span lang=\"EN-GB\" style=\"layout-grid-mode:line\">at the\nrecommended clinical dose</span> of <span lang=\"EN-GB\">ritonavir boosted\nInvirase. Distribution studies in these species showed that the placental transfer\nof saquinavir is low (less than 5% of maternal plasma concentrations).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><i><span lang=\"EN-GB\">Safety\npharmacology:</span></i></b><b><span lang=\"EN-GB\"> </span></b><span lang=\"EN-GB\">C</span><span lang=\"EN-GB\">loned human cardiac potassium channel (hERG) trafficking <i>in vitro</i>\nwas inhibited by 75% at 30</span><span lang=\"DE\">\u03bc</span><span lang=\"EN-GB\">M\nof saquinavir. Saquinavir inhibited both hERG current and L-type Ca++ channel\ncurrent with respective IC50s of 4.7 and 6.3 </span><span lang=\"DE\">\u03bc</span><span lang=\"EN-GB\">M. In a myocardial distribution study in the rat an approximately\n2-fold accumulation of saquinavir was observed in the heart compared to plasma\nafter coadministration of saquinavir and ritonavir. The clinical relevance of\nthese preclinical results are unknown, however cardiac conduction and\nrepolarisation abnormalities in humans have been observed with saquinavir and\nritonavir combination therapy (see section 4.4 and 5.1).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nPARTICULARS</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of excipients</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Tablet core: </i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"IT\">Microcrystalline\ncellulose,</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Croscarmellose sodium,</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Povidone,</span></p>\n<p class=\"MsoNormal\">Lactose (monohydrate),</p>\n<p class=\"MsoNormal\">Magnesium stearate.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><i>Tablet coat:</i></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Hypromellose,</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Titanium dioxide (E 171),</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Talc,</span></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Glycerol triacetate,</span></p>\n<p class=\"MsoNormal\">Iron oxide yellow and red (E172).</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not applicable.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">3 years.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for storage</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">This medicinal product does not require any\nspecial storage conditions.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of container</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Plastic bottles (HDPE) containing 120 tablets.</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0 Special precautions for disposal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">No special requirements for disposal.</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION HOLDER</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Roche Registration GmbH </p>\n<p class=\"MsoNormal\">Emil-Barell-Strasse 1</p>\n<p class=\"MsoNormal\">79639 Grenzach-Wyhlen</p>\n<p class=\"MsoNormal\">Germany</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION\nNUMBER </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/96/026/002</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST\nAUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Date of\nfirst authorisation: 04 October 1996</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of latest renewal: 04 October 2006</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE TEXT</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\">Detailed information on this product is available on the\nwebsite of the European Medicines Agency <a href=\"http://www.ema.europa.eu/\">http://www.ema.europa.eu</a></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\nII</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) RESPONSIBLE FOR\nBATCH RELEASE</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:56.7pt;margin-bottom:.0001pt\"><b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR </span></b><b>RESTRICTIONS REGARDING \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SUPPLY\nAND USE</b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:56.7pt;margin-bottom:.0001pt\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:56.7pt;margin-bottom:.0001pt\"><b>C. \u00a0\u00a0\u00a0\u00a0 OTHER\nCONDITIONS AND REQUIREMENTS OF THE \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION</b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:56.7pt;margin-bottom:.0001pt\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt\"><b>D.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <span style=\"text-transform:uppercase\">conditions or restrictions with regard to the\nsafe and effective use of the medicinal product</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:56.7pt;margin-bottom:.0001pt\"><b>\u00a0</b></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p class=\"AnnexHeading\"><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S)\nRESPONSIBLE FOR BATCH RELEASE</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:70.8pt;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Name and address of the manufacturer\nresponsible for batch release</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-right:70.8pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG<br/>\nEmil-Barell-Str. </span><span lang=\"EN-GB\">1,<br/>\n79639 Grenzach-Wyhlen,<br/>\nGermany.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"AnnexHeading\"><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS REGARDING SUPPLY AND USE </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicinal product subject to restricted\nmedical prescription (See Annex I: Summary of Product Characteristics, section\n4.2).</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"AnnexHeading\"><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER </span>CONDITIONS\nAND REQUIREMENTS OF THE MARKETING AUTHORISATION</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:13.0pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><b>Periodic\nSafety Update Reports </b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><span lang=\"EN-GB\">The\nrequirements for submission of periodic safety update reports for this\nmedicinal product are set out in the list of Union reference dates (EURD list)\nprovided for under Article 107c(7) of Directive 2001/83/EC and any subsequent\nupdates published on the European medicines web-portal.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"AnnexHeading\"><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\nPRODUCT\u00a0 </span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:13.0pt;\ntext-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><b>Risk\nManagement Plan (RMP)</b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">The MAH shall perform the\nrequired pharmacovigilance activities and interventions detailed in the agreed\nRMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed\nsubsequent updates of the RMP.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">An updated RMP should be\nsubmitted:</p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in;text-autospace:\nnone\">-\u00a0\u00a0\u00a0\u00a0 At the request of the European Medicines\nAgency;</p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in;text-autospace:\nnone\">-\u00a0\u00a0\u00a0\u00a0 Whenever the risk management system is\nmodified, especially as the result of new information being received that may lead\nto a significant change to the benefit/risk profile or as the result of an\nimportant (pharmacovigilance or risk minimisation) milestone being reached.</p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in;text-autospace:\nnone\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt\">\u00a0</p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\nIII</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">LABELLING\nAND PACKAGE LEAFLET</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Annex\"><span lang=\"EN-GB\">A. LABELLING</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\" style=\"background:white\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>\n<p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span style=\"color:black\">TEXT FOR THE OUTER CARTON</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase 500\u00a0mg </span>film-coated\ntablets</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Saquinavir</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each </span>film-coated tablet<span lang=\"EN-GB\"> contains 500\u00a0mg of saquinavir as saquinavir mesilate.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Also contains lactose (</span>monohydrate<span lang=\"EN-GB\">) </span>38.5\u00a0<span lang=\"EN-GB\">mg, colourants (titanium dioxide\nE 171, iron oxide E 172) and other constituents. See package leaflet for\nfurther information.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">120 film-coated tablets</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Oral use</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The film-coated tablets should be swallowed\nwhole</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Registration GmbH </span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Emil-Barell-Strasse 1</span></p>\n<p class=\"MsoNormal\">79639 Grenzach-Wyhlen</p>\n<p class=\"MsoNormal\">Germany</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/96/026/002</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicinal product subject to medical\nprescription</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN\nBRAILLE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">invirase 500\u00a0mg</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">&lt;2D barcode\ncarrying the unique identifier included.&gt;</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"EN-GB\">PC: </span></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"EN-GB\">SN: </span></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"EN-GB\">NN: </span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING</span></b></p>\n<p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span style=\"color:black\">TEXT FOR THE BOTTLE LABEL </span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase 500\u00a0mg </span>film-coated\ntablets</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Saquinavir</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each </span>film-coated tablet<span lang=\"EN-GB\"> contains 500\u00a0mg of saquinavir as saquinavir mesilate.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Also contains lactose (</span>monohydrate<span lang=\"EN-GB\">) </span>38.5\u00a0<span lang=\"EN-GB\">mg, colourants (titanium dioxide\nE 171, iron oxide E 172) and other constituents. See package leaflet for further\ninformation.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">120 film-coated tablets</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Oral use</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The film-coated tablets should be swallowed\nwhole</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Registration GmbH </span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Emil-Barell-Strasse 1</span></p>\n<p class=\"MsoNormal\">79639 Grenzach-Wyhlen</p>\n<p class=\"MsoNormal\">Germany</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/96/026/002</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicinal product subject to medical\nprescription</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN\nBRAILLE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not applicable</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not applicable</span></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Annex\"><span lang=\"EN-GB\">B. PACKAGE LEAFLET</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>Package Leaflet:\nInformation for the user</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Invirase\n500\u00a0mg </span>film-coated tablet</b><b><span lang=\"EN-GB\">s</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Saquinavir</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">Read all of\nthis leaflet carefully before you start taking this medicine </span>because it\ncontains important information for you</b><b><span lang=\"EN-GB\">.</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 Keep\nthis leaflet. You may need to read it again.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 If\nyou have any further questions, ask your doctor or pharmacist.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 This\nmedicine has been prescribed for you only. Do not pass it on to others. It may\nharm them, even if their signs of illness are the same as yours.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 If you get any\nside effects, talk to your doctor or pharmacist. This includes any possible\nside effects not listed in this leaflet. See section 4.</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">What is in this leaflet:</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nInvirase is and what it is used for</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>What\nyou need to know b<span lang=\"EN-GB\">efore you take Invirase</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto take Invirase</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Invirase</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>Contents\nof the pack and other <span lang=\"EN-GB\">information</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Invirase\nis and what it is used for</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase contains the active substance saquinavir\nwhich is an antiviral agent. It is a member of a class of medicines called\nprotease inhibitors. It is for the treatment of infection with the human\nimmunodeficiency virus (HIV).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase is used by HIV-1-infected adults.\nInvirase is prescribed for use in combination with ritonavir (Norvir) and other\nantiretroviral medicines.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need\nto know before you take Invirase</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Do not\ntake Invirase if you have:</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 an\nallergy to saquinavir, ritonavir or any of the other ingredients</span> (see\n\u201cInvirase contains lactose\u201d later in this section and \u201cWhat\nInvirase contains\u201d in Section 6)</p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span style=\"color:black\">\u00a0\u00a0\u00a0\u00a0\u00a0 any\nheart problems that show on an electrocardiogram (ECG, electrical recording of\nthe heart)</span><span lang=\"EN-GB\"> - you may have been born with that</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span style=\"color:black\">\u00a0\u00a0\u00a0\u00a0\u00a0 a\nvery slow heart rate (bradycardia)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span style=\"color:black\">\u00a0\u00a0\u00a0\u00a0\u00a0 a\nweak heart (heart failure)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span style=\"color:black\">\u00a0\u00a0\u00a0\u00a0\u00a0 a\nhistory of an irregular heart beat (arrhythmias)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span style=\"color:black\">\u00a0\u00a0\u00a0\u00a0 a\nsalt imbalance in your blood, especially low blood concentrations of potassium\n(hypokalaemia), which is not currently controlled by treatment</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 severe\nliver problems such as jaundice, hepatitis</span> or liver failure - where your\nbelly fills with fluid, you get confused or your oesophagus (the tube that runs\nfrom your mouth to your stomach) bleeds</p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 recently\ntaken the HIV medicine rilpivirine</span>.</p>\n<p class=\"MsoNormal\">Do not take Invirase if any of the above applies to you. If\nyou are not sure, talk to your doctor or pharmacist before taking Invirase.</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Do not take Invirase <span style=\"color:black\">if you are taking any of the following medicines:</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span style=\"color:black\">Any\nmedicine that can change your heart beat, </span></b><span style=\"color:black\">such\nas:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain medicines for HIV - such as\natazanavir, lopinavir, rilpivirine</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nheart medicines - </span>amiodarone, bepridil, disopyramide, dofetilide,\nflecainide, hydroquinidine, ibutilide, lidocaine, propafenone, quinidine,\nsotalol</p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nmedicines for depression - amitriptyline, imipramine, trazodone, maprotiline</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nfor other severe mental health problems - such as </span>clozapine, haloperidol,<br/>\nmesoridazine, phenothiazines, sertindole, sultopride, thioridazine, ziprasidone</p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nmedicines for infection - such as clarithromycin, dapsone, erythromycin,\nhalofantrine, pentamidine, sparfloxacin</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nstrong pain killers (narcotics)</span> - such as alfentanyl, fentanyl, methadone</p>\n<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 medicines\nfor erectile dysfunction - sildenafil, vardenafil, tadalafil</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0 certain\nmedicines that may be used for a variety of things: cisapride, diphemanil,\nmizolastine, quinine, vincamine.</p>\n<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 </span>certain\nmedicines used to prevent rejection of new organs after a transplant operation\nsuch as tacrolimus</p>\n<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0 certain medicines\nused to treat the symptoms of Benign Prostatic Hyperplasia (an increase in size\nof the prostate) such as alfuzosin</p>\n<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0 certain\nmedicines <span lang=\"EN-GB\">commonly used for allergy symptoms such as terfenadine\nand astemizole</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0 certain\nmedicines <span lang=\"EN-GB\">for severe mental health problems such as pimozide </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0 certain\nmedicines <span lang=\"EN-GB\">(so called tyrosine kinase inhibitors) used to treat\ndifferent types of cancer such as dasatinib and sunitinib</span>.</p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Any of these other medicines:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 ergot\nalkaloids - for migraine attacks</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 triazolam\nand midazolam </span>(taken by mouth)<span lang=\"EN-GB\"> - to help you sleep or\nfor anxiety</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 rifampicin\n- for preventing or treating tuberculosis</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 simvastatin\nand lovastatin - for lowering blood cholesterol</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-21.3pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">quetiapine \u2013 used to treat schizophrenia, bipolar disorder and\nmajor depressive disorder</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-21.3pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">lurasidone \u2013 used to treat schizophrenia.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-21.3pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not take Invirase with any other drug\nunless you have talked to your doctor first.\u00a0 The drugs listed above might\ncause serious side effects if you take them together with Invirase.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not take Invirase if any of the above\napplies to you. If you are not sure, talk to your doctor or pharmacist before\ntaking Invirase.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings\nand precautions</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">You should know that Invirase/ritonavir is\nnot a cure for HIV infection and that you may continue to develop infections or\nother illnesses associated with HIV disease. You should, therefore, remain\nunder the care of your doctor while taking Invirase/ritonavir.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">You can still pass on HIV when taking this\nmedicine, although the risk is lowered by effective antiretroviral therapy.\nDiscuss with your physician the precautions needed to avoid infecting other\npeople.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">At present, there is only limited\ninformation on the use of Invirase/ritonavir in children and in adults over the\nage of 60\u00a0years.</span></p>\n<p class=\"MsoNormal\"><b><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></b></p>\n<p class=\"MsoNormal\"><b><u>Abnormal heart rhythms (arrhythmias):</u></b></p>\n<p class=\"MsoNormal\">Invirase can change how your heart beats - this can be\nserious. This can happen especially if you are female or elderly. </p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 If you\nare taking any medicine that decreases your blood potassium levels talk to your\ndoctor before taking Invirase. </p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><b><span style=\"font-family:Symbol\">\u00b7</span></b><b>\u00a0\u00a0\u00a0\u00a0 Contact\nyour doctor immediately, if you get palpitations or an irregular heart beat\nduring treatment.</b> Your doctor may wish to do an ECG to check your heart\nbeat.</p>\n<p class=\"MsoNormal\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other conditions</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">There are certain conditions, which you may\nhave, or have had, which require special care before or while taking\nInvirase/ritonavir. Therefore, before taking this medicine, you should have\ntold your doctor if you suffer from diarrhoea, or if you have allergies (see\nSection 4)</span> or if you have an intolerance to some sugars (see section \u201cInvirase\ncontains lactose\u201d)<span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Kidney\ndisease: Consult your doctor if you have a history of kidney disease.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></s></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Liver\ndisease: Please speak with your doctor if you have a history of liver disease.\nPatients with chronic hepatitis B or C and treated with antiretroviral agents\nare at increased risk of severe and potentially fatal liver adverse events and\nmay require blood tests for control of liver function.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Infection: In some patients with advanced HIV infection\n(AIDS) and a history of opportunistic infection, signs and symptoms of\ninflammation from previous infections may occur soon after anti-HIV treatment\nis started. It is believed that these symptoms are due to an improvement in the\nbody\u2019s immune response, enabling the body to fight infections that may\nhave been present with no obvious symptoms. If you notice any symptoms of\ninfection, please inform your doctor immediately (see Section 4).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In addition to the opportunistic\ninfections, autoimmune disorders (a condition that occurs when the immune\nsystem attacks healthy body tissue) may also occur after you start taking\nmedicines for the treatment of your HIV infection. Autoimmune disorders may\noccur many months after the start of treatment. If you notice any symptoms of\ninfection or other symptoms such as muscle weakness, weakness beginning in the\nhands and feet and moving up towards the trunk of the body, palpitations,\ntremor or hyperactivity, please inform your doctor immediately to seek\nnecessary treatment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bone problems: </span><span lang=\"EN-GB\">Some\npatients taking combination antiretroviral therapy may develop a bone disease\ncalled osteonecrosis (death of bone tissue caused by loss of blood supply to\nthe bone). The length of combination antiretroviral therapy, corticosteroid\nuse, alcohol consumption, severe immunosuppression, higher body mass index,\namong others, may be some of the many risk factors for developing this disease.\nSigns of osteonecrosis are joint stiffness, aches and pains (especially of the\nhip, knee and shoulder) and difficulty in movement. If you notice any of these\nsymptoms please inform your doctor. </span></p>\n<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Other\nmedicines and Invirase</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor or pharmacist if you are\ntaking, have recently taken or might take any other medicines. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase/ritonavir <i>may be taken</i> with\na number of other medications that are commonly used in HIV infection.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">There are some medications that must not\nbe taken with Invirase/ritonavir (see section \"Do not take Invirase if you\nare taking any of the following medicines:\" above)</span></u><span lang=\"EN-GB\">. There are also some medicines that <i>require dosage reduction</i>\nof that medicine or Invirase or ritonavir (see section \u201cMedicines that\ncan interact with saquinavir or ritonavir include:\u201d below). Ask your\ndoctor or pharmacist for more information about taking Invirase/ritonavir with\nother medicines.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicines that can interact with saquinavir\nor ritonavir include:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 other\nHIV medicines - such as nelfinavir, indinavir, nevirapine, delavirdine,\nefavirenz, maraviroc, cobicistat</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 some\nmedicines affecting the immune system - such as ciclosporin, sirolimus\n(rapamycin), tacrolimus</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 various\nsteroids - such as dexamethasone, ethinyl estradiol, fluticasone</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nheart medicines - such as calcium channel blockers, quinidine, digoxin</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nused to lower blood cholesterol - such as statins</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 antifungals\n- ketoconazole, itraconazole, fluconazole, miconazole</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 anticonvulsants\n- such as phenobarbital, phenytoin, carbamazepine</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 sedative\nagents - such as midazolam administered by injection</p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"FR\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nantibiotics <span lang=\"EN-GB\">- such as </span>quinupristin/dalfopristin,\nrifabutin, fusidic acid</p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nto treat depression - such as nefazodone, tricyclic antidepressants</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nfor anticoagulation - warfarin</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 herbal\npreparations containing St. John\u2019s wort or garlic capsules</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 some\nmedicines that treat diseases related to the acid in the stomach <span lang=\"EN-GB\">- such as </span>omeprazole or other proton pump inhibitors</p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nused to treat asthma or other chest illness such as Chronic Obstructive\nPulmonary Disease (COPD) such as salmeterol</p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nfor gout, such as colchicine</p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nused to treat high blood pressure in the arteries of the lungs (a disease known\nas pulmonary arterial hypertension) such as bosentan.</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Therefore\nyou should not take Invirase/ritonavir with other medicines without your\ndoctor\u2019s consent. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you are taking an oral contraceptive to\nprevent pregnancy, you should use an additional or different type of\ncontraception since ritonavir may reduce the effectiveness of oral\ncontraceptives.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Invirase\nwith food and drink</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase must be taken together with\nritonavir and with or after food. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Pregnancy\nand breast-feeding</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ask your doctor or pharmacist for advice\nbefore taking any medicine. Inform your doctor if you are pregnant or planning\nto become pregnant. This medicine should be taken during pregnancy only after\nconsultation with your doctor.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">You should not breast-feed your baby if you\nare taking Invirase/ritonavir.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Driving\nand using machines</span></b></p>\n<p class=\"MsoNormal\">Invirase has not been tested for its effect on your ability\nto drive a car or operate machinery. However, dizziness, fatigue and visual\nimpairment have been reported during treatment with Invirase. Do not drive or\noperate machines if you experience these symptoms.</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b>Invirase contains lactose</b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each </span>film-coated tablet<span lang=\"EN-GB\"> contains lactose (</span>monohydrate<span lang=\"EN-GB\">) </span>38.5<span lang=\"EN-GB\">\u00a0mg. If you have been told by your doctor that you have an\nintolerance to some sugars, contact your doctor before taking this medicine.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to take\nInvirase</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Always take this medicine exactly as your\ndoctor has told you. Check with your doctor or pharmacist if you are not sure.\nInvirase comes as a 500\u00a0mg </span>film-coated tablet.<span lang=\"EN-GB\">\nYour doctor will prescribe Invirase in combination with ritonavir (Norvir) and\nother HIV medicines.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">How to take</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Take\nInvirase at the same time as your ritonavir (Norvir) capsules.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Take\nyour Invirase film-coated tablets with or after food.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Swallow\nthem whole with water.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">How much to take</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Standard dose</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0 Take\ntwo 500\u00a0mg </span>film-coated tablets<span lang=\"EN-GB\"> of Invirase twice a\nday.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0 Take\none 100\u00a0mg capsule of ritonavir (Norvir) twice a day. </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">If this\nis your first medicine for HIV or the first time you are taking ritonavir\n(Norvir)</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">You need to\ntake a lower dose of Invirase for your first week. </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in;page-break-after:\navoid\"><span lang=\"EN-GB\">Week 1:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Take one 500\u00a0mg film-coated\ntablet of Invirase twice a day.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Take\none 100\u00a0mg capsule of ritonavir (Norvir) twice a day. </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week 2 onwards:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Continue\nwith the standard dose.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">If you\ntake more Invirase than you should<i> </i></span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you have taken more than the prescribed\ndose of Invirase/ritonavir you must contact your doctor or pharmacist.</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">If you\nforget to take Invirase</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not take a double dose to make up for a\nforgotten individual dose. If you forget to take one dose, take this dose as\nsoon as you remember together with some food. Then go on with the regular\nschedule as prescribed. Do not change the prescribed dose yourself.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">If you\nstop taking Invirase<i> </i></span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Continue to take this medicine until your\ndoctor tells you otherwise.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you have any further questions on the\nuse of this medicine, ask your doctor or pharmascist.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side\neffects</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Like all\nmedicines, this medicine can cause side effects, </span>although not everybody\ngets them<span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">During HIV therapy there may be an increase in weight and in\nlevels of blood lipids and glucose. This is partly linked to restored health\nand lifestyle, and in the case of blood lipids sometimes to the HIV medicines\nthemselves. Your doctor will test for these changes. </p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">When treating\nHIV infection it is not always possible to differentiate between unwanted\neffects caused by Invirase or by any other medicines you take at the same time\nor by the complications of the infection. For these reasons it is very\nimportant to inform your doctor of any change in your condition.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The most frequently <i>(in more than ten in\na hundred persons) </i>reported side effects of saquinavir taken with ritonavir\nconcern the gastrointestinal tract, with feeling sick, diarrhoea, tiredness,\nvomiting, wind and abdominal pain being the most common. Also, changes in\nlaboratory markers </span>(e.g., blood or urine tests)<span lang=\"EN-GB\"> have\nbeen reported very commonly.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Other reported side effects (<i>in more\nthan one in a hundred but less than one in ten persons)</i>, which may occur\nare: rash, itching, eczema and dry skin, hair loss, dry mouth, headache,\nperipheral neuropathy (a disturbance of the nerves in the feet and hands that\nmay take the form of numbness, pins and needles, shooting or burning pain),\nweakness, dizziness, libido problems, taste alteration, mouth ulcers, dry lips,\nabdominal discomfort, indigestion, weight loss,constipation, increased\nappetite,\u00a0 muscle spasms and shortness of breath. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0Other less frequently reported side effects\n(<i>in more than one in one thousand persons but less than one in a hundred\npersons) </i>include: decreased appetite, visual disturbance, inflammation of\nthe liver, fits, allergic reactions, blisters, sleepiness, abnormal renal\nfunction, inflammation of the pancreas, yellowing of the skin or whites of the\neyes caused by liver problems and Steven\u2019s Johnson syndrome (a serious\nillness with blistering of the skin, eyes, mouth and genitals). </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients with haemophilia type A and B,\nthere have been reports of increased bleeding while taking this treatment or\nanother protease inhibitor. Should this happen to you, seek immediate advice\nfrom your doctor.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">There have been reports of muscle pain,\ntenderness or weakness, particularly with combination antiretroviral therapy\nincluding protease inhibitors and nucleoside analogues. On rare occasions these\nmuscle disorders have been serious (rhabdomyolysis).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b>Reporting of side effects</b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you get any side effects, talk to your\ndoctor, pharmacist or nurse.\u00a0 This includes any possible side effects not\nlisted in this leaflet. </span>You can also report side effects directly via <span style=\"background:silver\">the national reporting system listed in </span><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:silver\">Appendix V</span></a><span lang=\"EN-GB\" style=\"background:silver\">.</span><span lang=\"EN-GB\"> By reporting side effects\nyou can help provide more information on the safety of this medicine.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store\nInvirase</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Keep this\nmedicine out of the sight and reach of children.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Do not use this medicine\nafter the expiry date (EXP) which is stated on the bottle and carton. The\nexpiry date refers to the last day of that month.</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase does not require any special\nstorage conditions.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Do not throw away any medicines via wastewater or household\nwaste. Ask your pharmacist how to throw away medicines you no longer use. These\nmeasures will help to protect the environment.</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of\nthe pack and other information</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b>What Invirase contains</b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 The\nactive substance is saquinavir. One </span>film-coated tablet<span lang=\"EN-GB\">\nof Invirase contains </span>500<span lang=\"EN-GB\">\u00a0mg of saquinavir as\nsaquinavir mesilate.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 The\nother ingredients (excipients) are</span> microcrystalline cellulose,\ncroscarmellose sodium, povidone, lactose (monohydrate) 38.5\u00a0mg, magnesium\nstearate, hypromellose, titanium dioxide (E171), talc, glycerol triacetate,\niron oxide yellow (E172) and iron oxide red (E172).</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>What Invirase looks like and contents of the pack</b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\">Invirase 500\u00a0mg film-coated tablet<span lang=\"EN-GB\">s\nare light orange to greyish or brownish orange tablets of oval shape with the\nmarking \"SQV 500\" on one side and \"ROCHE\" on the other\nside. One </span>plastic (HDPE) bottle contains 120 tablets.</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Marketing Authorisation\nHolder and Manufacturer</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder</span></b></p>\n<p class=\"MsoNormal\">Roche Registration GmbH </p>\n<p class=\"MsoNormal\">Emil-Barell-Strasse 1</p>\n<p class=\"MsoNormal\">79639 Grenzach-Wyhlen</p>\n<p class=\"MsoNormal\">Germany</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Manufacturer </b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE-CH\">Roche Pharma\nAG, </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE-CH\">Emil-Barell-Strasse\n1,</span></p>\n<p class=\"MsoNormal\">79639 Grenzach-Wyhlen,</p>\n<p class=\"MsoNormal\">Germany.</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">For any\ninformation about this medicine, please contact the local representative of the\nMarketing Authorisation Holder:</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"FR\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FR\">N.V. Roche\n  S.A.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FR\">T\u00e9l/Tel:\n  +32 (0) 2 525 82 11</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"FR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Lietuva</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">UAB \u201cRoche Lietuva\u201d</span></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">Tel: +370 5 </span><span lang=\"DE-CH\">2546799</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"BG\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u0420\u043e\u0448\n  \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u0422\u0435\u043b:\n  +359 2\u00a0818 44 44</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE-CH\">(Voir/siehe\n  Belgique/Belgien)</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"CS\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"CS\">Roche s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"CS\">Tel: +420 - 2 20382111</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Magyarorsz</b><b><span lang=\"CS\">\u00e1g</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"CS\">Roche\n  (Magyarorsz\u00e1g) Kft.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"CS\">Tel: +36 - 23\n  446 800</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Danmark</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +45 - 36 39 99 99</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(See </span>Ireland<span lang=\"EN-GB\">)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"NL\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"NL\">Roche Nederland B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +31 (</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">0) 348 438050</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Eesti</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">Roche Eesti O\u00dc</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 372 - 6 177 380</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Roche Norge\n  AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Tlf: +47 -\n  22 78 90 00</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche (Hellas) A.E. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +30 210 61 66 100</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Austria GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Roche Farma S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +34 - 91 324 81 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PL\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PL\">Roche Polska Sp.z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +48 - 22 345 18 88</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">France</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">Roche</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">T\u00e9l: +33 (0) 1 47 61 40 00</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT\">Portugal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">Roche Farmac\u00eautica Qu\u00edmica, Lda</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">Tel: +351 - 21 425 70 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 385 1 47 22 333</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">Roche Rom\u00e2nia S.R.L.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +40 21 206 47 01</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products (Ireland) Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +353 (0) 1 469 0700</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche farmacevtska dru\u017eba d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +386 - 1 360 26 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">\u00cdsland\n  </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">c/o Icepharma hf</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">S</span><span lang=\"CS\">\u00ed</span><span lang=\"PT-BR\">mi</span><span lang=\"PT\" style=\"layout-grid-mode:line\">: +354 540\n  8000</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"PT\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT\">Slovensk\u00e1 republika </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SK\">Roche Slovensko, s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">Tel: +421 - 2 52638201</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"PT\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche S.p.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +39 - 039 2471</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">K</span></b><b><span lang=\"EL\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b><span lang=\"EL\" style='font-size:10.0pt;font-family:\"Arial\",sans-serif'> </span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u0393.\u0391.\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2\n  &amp; \u03a3\u03b9\u03b1 \u039b\u03c4\u03b4.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb</span>: +357 - 22 76 62\n  76</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Sverige</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche AB</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +46 (0) 8 726 1200</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Latvija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"LV\">Roche Latvija SIA</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 \u2013 6 7039831</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"IT\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 (0) 1707 366000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">This leaflet was last revised in </span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b>Other sources of information</b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\">Detailed information on this medicine is available on the\nEuropean Medicines Agency web site: <a href=\"http://www.ema.europa.eu/\">http://www.ema.europa.eu</a></p>\n<p class=\"MsoNormal\"><span style=\"color:blue\">\u00a0</span></p>\n<p class=\"MsoNormal\">This leaflet is available in all EU/EEA languages on the\nEuropean Medicines Agency website.</p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</div>", "ID": "18c87d4c-3ee1-49c5-b180-e82be687ae29", "Styles": "None", "Classes": "['WordSection1']", "Text": "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ", "ParentId": "ad3ae730-cc97-4586-bf25-ae46814e0929"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "dced5259-60a2-430e-9f9a-a176a73e5d4a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4e4a04ca-25d8-4c1d-b041-afde7902a51f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2bcc4e33-d997-4491-8d62-d5c0bc26516c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4e4a04ca-25d8-4c1d-b041-afde7902a51f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ceb27db6-52ca-4022-b7c3-61582c8d885a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d93983d8-9ac4-482b-8270-760def9132ae", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ceb27db6-52ca-4022-b7c3-61582c8d885a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4b6f3cdb-3d3b-49b5-8902-6e3cca8a6bd0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5dec217d-8979-4344-8a3c-496ebdc2a7f4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4b6f3cdb-3d3b-49b5-8902-6e3cca8a6bd0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ded161c2-e790-4510-a8cc-c489b632d716", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2509d704-c122-425b-8ed7-7b4ccfc3b342", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ded161c2-e790-4510-a8cc-c489b632d716"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "58edf1b0-b3e7-4feb-8d1f-db530e39dfc1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "88e030c1-5270-475e-9a4f-1b4ecfb74efd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "58edf1b0-b3e7-4feb-8d1f-db530e39dfc1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "24858fbf-efe1-43ae-b0bf-3f72670eca7b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2782e18f-b1e1-4ff0-9518-5adb570ceaf8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "24858fbf-efe1-43ae-b0bf-3f72670eca7b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c5361d34-9f0e-4c9c-9c2d-a7f7eba01184", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b62887e2-e493-4534-af11-abfa0320d9ee", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c5361d34-9f0e-4c9c-9c2d-a7f7eba01184"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6e36cdd9-e7f5-4517-8f0a-95f7cb58a348", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3d09628d-4cdc-4098-bd16-40b90a46d180", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6e36cdd9-e7f5-4517-8f0a-95f7cb58a348"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f0c0002e-6cf6-4e2e-b52e-00ca59089d62", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a7555d9f-ce4c-4fc2-8a52-a336cb39d8e9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f0c0002e-6cf6-4e2e-b52e-00ca59089d62"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bd8d9835-0c27-4023-9820-abcb8e0fe7ac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d9463ad3-47ba-4c92-94ef-b0c7768a7c4b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bd8d9835-0c27-4023-9820-abcb8e0fe7ac"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c65746f2-a72b-403d-b9fa-6796f24a3dc9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "545134e7-f89d-41ab-b7ed-88c8beab09c5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c65746f2-a72b-403d-b9fa-6796f24a3dc9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5e7030ac-8b61-47c6-a1f0-b78f1e66b8c6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5bc81350-f1cf-4eac-a975-0fa026007a12", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5e7030ac-8b61-47c6-a1f0-b78f1e66b8c6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "60a9ce37-699d-41f5-a19f-8d5bf40058ff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9596368e-6f6e-45fe-b91c-1f5c64cbded0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "60a9ce37-699d-41f5-a19f-8d5bf40058ff"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a54a4e63-a2aa-4f87-bde1-2452471f045a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7a5db41b-bc08-4749-af31-e82ae4accfc5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a54a4e63-a2aa-4f87-bde1-2452471f045a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a16aea08-07e2-49ae-b32a-83668e3cd351", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "261dd90b-cd2b-46d6-a76b-a302e09ace66", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a16aea08-07e2-49ae-b32a-83668e3cd351"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eeb7fd27-d4dd-4387-831e-b5cf1d3d183a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1789682a-9ec3-429d-93d5-5e0b637ce21b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eeb7fd27-d4dd-4387-831e-b5cf1d3d183a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "147af457-e83b-4e6c-82a4-c6e9fa862a15", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ed2f7d5a-b810-451d-8b0d-daa2b9ee7639", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "147af457-e83b-4e6c-82a4-c6e9fa862a15"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fae0b81b-f1cf-4d97-bacc-eeda9ef6f092", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "87f20fc0-8b7a-4623-8d2d-82c6fd221387", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fae0b81b-f1cf-4d97-bacc-eeda9ef6f092"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "39d86103-a583-49f0-9bcb-a3b906e6357a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a4d943f6-8627-4b9a-84e4-fd00d0efe654", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "39d86103-a583-49f0-9bcb-a3b906e6357a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5e3fe129-d3c7-43d2-a172-f60ac7080ff8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b3cfc66b-6117-4ee5-b050-b16fea533377", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5e3fe129-d3c7-43d2-a172-f60ac7080ff8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1ce0e3c7-6e83-4bf0-bc63-40c2a732d1ae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7c734901-1961-4944-bf2a-6257efa9a5de", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1ce0e3c7-6e83-4bf0-bc63-40c2a732d1ae"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8fd3a86c-2983-4fb2-bf4d-6689702eda47", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cd00aa49-5969-4ab9-ae02-27dc0cd00d6d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8fd3a86c-2983-4fb2-bf4d-6689702eda47"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\nI</span></b></p>", "ID": "ffd64fe7-4bb5-423b-abf2-0409f80df6ea", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">ANNEX\nI</span></b>", "ID": "9f42d601-6c33-4fc4-a592-b58f4bedaeec", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ffd64fe7-4bb5-423b-abf2-0409f80df6ea"}, {"Element": "<span lang=\"EN-GB\">ANNEX\nI</span>", "ID": "670fd6c8-b57d-4e27-ace5-8aa1ec90d25f", "Styles": "None", "Classes": "None", "Text": "ANNEX I", "ParentId": "9f42d601-6c33-4fc4-a592-b58f4bedaeec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3d23dbda-b88a-42b6-bfaa-c43e27482336", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b363ea82-4a5a-4fc0-8dc2-eb38e50085ca", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3d23dbda-b88a-42b6-bfaa-c43e27482336"}, {"Element": "<p class=\"Annex\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS</span></p>", "ID": "9e5eeff4-a0ea-4809-99ed-e96c91831d61", "Styles": "None", "Classes": "['Annex']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS</span>", "ID": "84286c19-a78a-4ece-93af-0ac8ba49c188", "Styles": "None", "Classes": "None", "Text": "SUMMARY OF PRODUCT CHARACTERISTICS", "ParentId": "9e5eeff4-a0ea-4809-99ed-e96c91831d61"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "068c5dc0-fb1b-4c63-80d7-007e22f1f472", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "b6cec1f2-97a0-4c31-95cc-b991f67d3f2b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "068c5dc0-fb1b-4c63-80d7-007e22f1f472"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6db7b63c-3eda-4b62-bf97-61edd6b15848", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b6cec1f2-97a0-4c31-95cc-b991f67d3f2b"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "b5b1691e-e7b1-4f80-b7ee-a0cb6eef714c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "ac279bf7-f6db-4f58-9b5a-cc0f4bafe51d", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "b5b1691e-e7b1-4f80-b7ee-a0cb6eef714c"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "1f99fb69-80a7-491e-85ad-fec81d7981ad", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "ac279bf7-f6db-4f58-9b5a-cc0f4bafe51d"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "43b2dac4-8a9b-44b2-ab8e-5e7a70be3792", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "3a770fc6-7369-40b9-a2bf-0b5d7ede5d67", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "43b2dac4-8a9b-44b2-ab8e-5e7a70be3792"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ecd22d3a-5e3d-4aba-a847-54af985d29c3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3a770fc6-7369-40b9-a2bf-0b5d7ede5d67"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "e826ff1d-905e-4838-a1e7-16de289ce9c8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "aae1aba9-cd3f-4726-afad-d0f225862d1d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e826ff1d-905e-4838-a1e7-16de289ce9c8"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5417becf-84ce-4728-8737-1bf2f893a112", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aae1aba9-cd3f-4726-afad-d0f225862d1d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b></p>", "ID": "aed2c4f7-00f8-4980-a686-0854242c6327", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span></b>", "ID": "1c548c7d-ff1c-4a1f-9ec0-83ea2c348925", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "aed2c4f7-00f8-4980-a686-0854242c6327"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT</span>", "ID": "c170cc34-68fa-4877-9168-21d667f8aced", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT", "ParentId": "1c548c7d-ff1c-4a1f-9ec0-83ea2c348925"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c51c6d05-b96c-4541-8392-3c414c807d8d", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6181c0d7-dbec-42a5-a4d6-847e200901bb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c51c6d05-b96c-4541-8392-3c414c807d8d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"text-transform:uppercase\">Invirase\n500\u00a0</span><span lang=\"EN-GB\">mg </span>film-coated tablets<span lang=\"EN-GB\">.</span></p>", "ID": "6dd367f7-f10a-4a50-951d-82835ae5c985", "Styles": "None", "Classes": "['MsoNormal']", "Text": "film-coated tablets", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"text-transform:uppercase\">Invirase\n500\u00a0</span>", "ID": "92e63705-f02b-445f-8465-afd3488dd8cf", "Styles": "text-transform:uppercase", "Classes": "None", "Text": "Invirase 500\u00a0", "ParentId": "6dd367f7-f10a-4a50-951d-82835ae5c985"}, {"Element": "<span lang=\"EN-GB\">mg </span>", "ID": "124ac7fb-7e5f-4b89-b586-346e16c35f98", "Styles": "None", "Classes": "None", "Text": "mg ", "ParentId": "6dd367f7-f10a-4a50-951d-82835ae5c985"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "3dae5934-ba93-45a0-a089-66de80084f60", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "6dd367f7-f10a-4a50-951d-82835ae5c985"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "758e9bb3-fdec-444a-b52b-89f30317f45b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eaba831d-e579-42b1-b96f-c7a898c6a508", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "758e9bb3-fdec-444a-b52b-89f30317f45b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7b55c593-f610-4f81-add8-f9b63c0354b0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "68c146be-1a97-47c1-96df-e124e2ea4cc6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7b55c593-f610-4f81-add8-f9b63c0354b0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND QUANTITATIVE\nCOMPOSITION</span></b></p>", "ID": "b460b65a-84d4-443d-b992-95b9f12b927a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND QUANTITATIVE\nCOMPOSITION</span></b>", "ID": "71e1c37d-61c1-43c9-bd5d-bc540855a18c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b460b65a-84d4-443d-b992-95b9f12b927a"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND QUANTITATIVE\nCOMPOSITION</span>", "ID": "a74dda1a-d7ea-4dfa-9836-ec7e6e0d60b8", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND QUANTITATIVE COMPOSITION", "ParentId": "71e1c37d-61c1-43c9-bd5d-bc540855a18c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1227fc57-97a5-4d0e-8e43-08143d6e3726", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "24fa1fa8-54b7-4d31-a749-20ed81f81e6d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1227fc57-97a5-4d0e-8e43-08143d6e3726"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">One film-coated tablet contains 500\u00a0mg\nof saquinavir as saquinavir mesilate.</span></p>", "ID": "9ba651c1-2cfb-4ad6-8527-50280fa8b22d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">One film-coated tablet contains 500\u00a0mg\nof saquinavir as saquinavir mesilate.</span>", "ID": "ac7f5a3d-088b-430b-96eb-f62d30837868", "Styles": "None", "Classes": "None", "Text": "One film-coated tablet contains 500\u00a0mg of saquinavir as saquinavir mesilate.", "ParentId": "9ba651c1-2cfb-4ad6-8527-50280fa8b22d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8c610862-d825-49c2-8225-85ea8605b349", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8b4ee23b-f227-4212-a78a-f7909b6c7636", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8c610862-d825-49c2-8225-85ea8605b349"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Excipient </span><u><span lang=\"EN-GB\">with\nknown effect</span></u><span lang=\"EN-GB\">: Lactose monohydrate: 38.5\u00a0mg.</span></p>", "ID": "6b0347a0-3579-4b91-b443-fefb6d207f46", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Excipient </span>", "ID": "e5743ea4-fade-4e26-8413-d34be045e9e8", "Styles": "None", "Classes": "None", "Text": "Excipient ", "ParentId": "6b0347a0-3579-4b91-b443-fefb6d207f46"}, {"Element": "<u><span lang=\"EN-GB\">with\nknown effect</span></u>", "ID": "6b5dc967-2fca-477c-a0c7-90d6e19fb988", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6b0347a0-3579-4b91-b443-fefb6d207f46"}, {"Element": "<span lang=\"EN-GB\">with\nknown effect</span>", "ID": "d77023d7-d47d-4b30-9644-6981e14ec8d3", "Styles": "None", "Classes": "None", "Text": "with known effect", "ParentId": "6b5dc967-2fca-477c-a0c7-90d6e19fb988"}, {"Element": "<span lang=\"EN-GB\">: Lactose monohydrate: 38.5\u00a0mg.</span>", "ID": "57fff14b-cc4c-4403-8728-b929ea2afaec", "Styles": "None", "Classes": "None", "Text": ": Lactose monohydrate: 38.5\u00a0mg.", "ParentId": "6b0347a0-3579-4b91-b443-fefb6d207f46"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a071c48f-9eac-4d82-b16b-98b1d3aae145", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "21f4841e-4774-4f68-9de2-aa499cf52515", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a071c48f-9eac-4d82-b16b-98b1d3aae145"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For the full list of excipients, see\nsection 6.1.</span></p>", "ID": "94e1d579-7934-453c-bcf4-eff6680ab0b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">For the full list of excipients, see\nsection 6.1.</span>", "ID": "bd901c27-e2be-41d4-a0e3-f4fb14d0daab", "Styles": "None", "Classes": "None", "Text": "For the full list of excipients, see section 6.1.", "ParentId": "94e1d579-7934-453c-bcf4-eff6680ab0b8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ede948ba-7e73-41f1-93e4-40260be6a3ad", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d9538ed7-7bae-4d62-80e1-97eb2419902c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ede948ba-7e73-41f1-93e4-40260be6a3ad"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fbb55d37-0d5b-4411-9cb9-21de22276d21", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ad5019dc-9f05-4d85-9c44-89f6781c3bf2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fbb55d37-0d5b-4411-9cb9-21de22276d21"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM</span></b></p>", "ID": "dcfe703b-49d0-46b5-a574-cdd4651d3ee2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM</span></b>", "ID": "2da044f1-6451-4521-8e90-88db920b741e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dcfe703b-49d0-46b5-a574-cdd4651d3ee2"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM</span>", "ID": "16c8bdb6-d8fa-451c-b5d5-5f377955b655", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM", "ParentId": "2da044f1-6451-4521-8e90-88db920b741e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5504eade-fb18-48ec-a336-086f996df06f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a5d431c2-d225-4517-a9fd-177d4510af25", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5504eade-fb18-48ec-a336-086f996df06f"}, {"Element": "<p class=\"MsoNormal\">Film-coated tablet<span lang=\"EN-GB\">.</span></p>", "ID": "25c211df-2514-43bc-ba99-a8cf9c313dc9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Film-coated tablet", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "e1c346a3-e7e9-4c98-9bcf-c2f7250f50e8", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "25c211df-2514-43bc-ba99-a8cf9c313dc9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3f16e63e-6dc2-41fb-88bb-72b04401cb5f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8c52e2d3-b0a2-4449-a535-c7cba4a32620", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3f16e63e-6dc2-41fb-88bb-72b04401cb5f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Light orange to greyish or brownish orange\nfilm-coated tablet of oval cylindrical biconvex shape with the marking\n\"SQV 500\" on the one side and \"ROCHE\" on the other side.</span></p>", "ID": "a6f59582-d887-4a68-94d9-3082f5a4d777", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Light orange to greyish or brownish orange\nfilm-coated tablet of oval cylindrical biconvex shape with the marking\n\"SQV 500\" on the one side and \"ROCHE\" on the other side.</span>", "ID": "621ca5e1-afbd-402c-8865-749ff514cb03", "Styles": "None", "Classes": "None", "Text": "Light orange to greyish or brownish orange film-coated tablet of oval cylindrical biconvex shape with the marking \"SQV 500\" on the one side and \"ROCHE\" on the other side.", "ParentId": "a6f59582-d887-4a68-94d9-3082f5a4d777"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ac8ec758-773c-4d1a-b82b-b7f2513fdf31", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f8852770-076a-4847-bd8b-6d06af9b1e55", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ac8ec758-773c-4d1a-b82b-b7f2513fdf31"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0431b59e-803e-4585-918f-6a24f247575c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a873a8ff-7dec-4327-b58d-0202d7383398", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0431b59e-803e-4585-918f-6a24f247575c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CLINICAL PARTICULARS</span></b></p>", "ID": "9e08efa0-1a1a-4231-bca8-b190328d0a08", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CLINICAL PARTICULARS</span></b>", "ID": "be6fe203-6ca2-430f-b2d5-08e0a2edf78a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9e08efa0-1a1a-4231-bca8-b190328d0a08"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CLINICAL PARTICULARS</span>", "ID": "a0ff2c02-677a-4a3a-8368-93754d7ea5a2", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CLINICAL PARTICULARS", "ParentId": "be6fe203-6ca2-430f-b2d5-08e0a2edf78a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8afc2639-212b-490c-a98f-97775631cf65", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f5d86715-0652-4806-bf0c-d77293601935", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8afc2639-212b-490c-a98f-97775631cf65"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications</span></b></p>", "ID": "9f899a54-3251-41ba-a76d-361046349c14", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications</span></b>", "ID": "0933183d-9e1c-44c6-b693-36e82514ffc8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9f899a54-3251-41ba-a76d-361046349c14"}, {"Element": "<span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications</span>", "ID": "be238e6a-c779-4f54-b60a-1e01b834473d", "Styles": "None", "Classes": "None", "Text": "4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications", "ParentId": "0933183d-9e1c-44c6-b693-36e82514ffc8"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "026b73ea-ce8f-4862-96cf-0c2e0468ab8b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "fa05c71f-6644-4fbc-bb72-fc139f52b37c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "026b73ea-ce8f-4862-96cf-0c2e0468ab8b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2d60c2d0-ea5c-4ede-9c15-5e98f927489b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fa05c71f-6644-4fbc-bb72-fc139f52b37c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase is indicated for the treatment of\nHIV-1 infected adult patients. Invirase should only be given in combination\nwith ritonavir and other antiretroviral medicinal products (see section 4.2).</span></p>", "ID": "0502150c-12f4-4f66-a4db-4cc57c34c807", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Invirase is indicated for the treatment of\nHIV-1 infected adult patients. Invirase should only be given in combination\nwith ritonavir and other antiretroviral medicinal products (see section 4.2).</span>", "ID": "4cf4ec9f-18df-44be-8ce6-7679eada84a3", "Styles": "None", "Classes": "None", "Text": "Invirase is indicated for the treatment of HIV-1 infected adult patients. Invirase should only be given in combination with ritonavir and other antiretroviral medicinal products (see section 4.2).", "ParentId": "0502150c-12f4-4f66-a4db-4cc57c34c807"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b6219a3a-d782-49fe-b6e8-33366a0b29c7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1d5f03db-5081-4fb5-8d35-7306693b8227", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b6219a3a-d782-49fe-b6e8-33366a0b29c7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of administration</span></b></p>", "ID": "7d575be4-cb97-4450-bcf0-d656034230f4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of administration</span></b>", "ID": "837d1508-f213-43f4-9b95-3c67f3245be0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7d575be4-cb97-4450-bcf0-d656034230f4"}, {"Element": "<span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of administration</span>", "ID": "5c95a7b8-45a4-45e7-8c6c-76f934f6c8dd", "Styles": "None", "Classes": "None", "Text": "4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of administration", "ParentId": "837d1508-f213-43f4-9b95-3c67f3245be0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "45824d06-6d10-4e13-8215-3b253354866e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "025692d5-b9f4-4f0e-a48a-10ca8ca8294b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "45824d06-6d10-4e13-8215-3b253354866e"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Posology</span></u></p>", "ID": "28f0eb3e-2b52-463c-b5fd-d9aa3e580d15", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<u><span lang=\"EN-GB\">Posology</span></u>", "ID": "3e38fa58-f8f6-431a-9821-c39ea9b3f284", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "28f0eb3e-2b52-463c-b5fd-d9aa3e580d15"}, {"Element": "<span lang=\"EN-GB\">Posology</span>", "ID": "8549f0ce-abb5-4427-bc3a-2f99841fb2ce", "Styles": "None", "Classes": "None", "Text": "Posology", "ParentId": "3e38fa58-f8f6-431a-9821-c39ea9b3f284"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Therapy with Invirase should be initiated\nby a physician experienced in the management of HIV infection.</span></p>", "ID": "49b7d411-a967-4df9-9590-e6efc6c3e344", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Therapy with Invirase should be initiated\nby a physician experienced in the management of HIV infection.</span>", "ID": "3daaf59d-40bf-461b-9bb2-5b60b1b606a3", "Styles": "None", "Classes": "None", "Text": "Therapy with Invirase should be initiated by a physician experienced in the management of HIV infection.", "ParentId": "49b7d411-a967-4df9-9590-e6efc6c3e344"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dc80b5ec-3595-4a25-83fd-85c9f04224d4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "06f8d1f3-ff4e-4d24-8efc-5ad49ce96dc1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dc80b5ec-3595-4a25-83fd-85c9f04224d4"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">In combination with ritonavir</span></i></p>", "ID": "b534b24c-8c04-4a3b-9b09-ffdcea01f384", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<i><span lang=\"EN-GB\">In combination with ritonavir</span></i>", "ID": "c92ef1d6-45ac-4983-8d74-b7fe6233116b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b534b24c-8c04-4a3b-9b09-ffdcea01f384"}, {"Element": "<span lang=\"EN-GB\">In combination with ritonavir</span>", "ID": "5be9730d-bd7f-4b1f-af04-46033aa1d5bd", "Styles": "None", "Classes": "None", "Text": "In combination with ritonavir", "ParentId": "c92ef1d6-45ac-4983-8d74-b7fe6233116b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended dose of Invirase is\n1000\u00a0mg (2 x 500\u00a0mg </span>film-coated tablets<span lang=\"EN-GB\">) two\ntimes daily with ritonavir 100\u00a0mg two times daily in combination with\nother antiretroviral agents. For treatment-naive patients initiating treatment\nwith Invirase/ritonavir, the starting recommended dose of Invirase is\n500\u00a0mg (1 x 500\u00a0mg film-coated tablet) two times daily with ritonavir\n100\u00a0mg two times daily in combination with other antiretroviral agents for\nthe first 7 days of treatment. After 7 days, the recommended dose of Invirase\nis 1000\u00a0mg two times daily with ritonavir 100\u00a0mg two times daily in\ncombination with other antiretroviral agents. Patients switching immediately\nfrom treatment with another protease inhibitor taken with ritonavir or from a\nnon-nucleoside reverse transcriptase inhibitor based regimen, except\nrilpivirine (see section 4.5), without a wash-out period, should however\ninitiate and continue Invirase at the standard recommended dose of 1000\u00a0mg\ntwo times daily with ritonavir 100\u00a0mg two times daily.</span></p>", "ID": "cc287d08-6501-4133-b640-5a0583439bf1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "film-coated tablets", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">The recommended dose of Invirase is\n1000\u00a0mg (2 x 500\u00a0mg </span>", "ID": "476c5c4f-eb33-485e-98dd-0639448952a0", "Styles": "None", "Classes": "None", "Text": "The recommended dose of Invirase is 1000\u00a0mg (2 x 500\u00a0mg ", "ParentId": "cc287d08-6501-4133-b640-5a0583439bf1"}, {"Element": "<span lang=\"EN-GB\">) two\ntimes daily with ritonavir 100\u00a0mg two times daily in combination with\nother antiretroviral agents. For treatment-naive patients initiating treatment\nwith Invirase/ritonavir, the starting recommended dose of Invirase is\n500\u00a0mg (1 x 500\u00a0mg film-coated tablet) two times daily with ritonavir\n100\u00a0mg two times daily in combination with other antiretroviral agents for\nthe first 7 days of treatment. After 7 days, the recommended dose of Invirase\nis 1000\u00a0mg two times daily with ritonavir 100\u00a0mg two times daily in\ncombination with other antiretroviral agents. Patients switching immediately\nfrom treatment with another protease inhibitor taken with ritonavir or from a\nnon-nucleoside reverse transcriptase inhibitor based regimen, except\nrilpivirine (see section 4.5), without a wash-out period, should however\ninitiate and continue Invirase at the standard recommended dose of 1000\u00a0mg\ntwo times daily with ritonavir 100\u00a0mg two times daily.</span>", "ID": "ad6f1408-dba3-4585-8a67-130fb33f59d1", "Styles": "None", "Classes": "None", "Text": ") two times daily with ritonavir 100\u00a0mg two times daily in combination with other antiretroviral agents. For treatment-naive patients initiating treatment with Invirase/ritonavir, the starting recommended dose of Invirase is 500\u00a0mg (1 x 500\u00a0mg film-coated tablet) two times daily with ritonavir 100\u00a0mg two times daily in combination with other antiretroviral agents for the first 7 days of treatment. After 7 days, the recommended dose of Invirase is 1000\u00a0mg two times daily with ritonavir 100\u00a0mg two times daily in combination with other antiretroviral agents. Patients switching immediately from treatment with another protease inhibitor taken with ritonavir or from a non-nucleoside reverse transcriptase inhibitor based regimen, except rilpivirine (see section 4.5), without a wash-out period, should however initiate and continue Invirase at the standard recommended dose of 1000\u00a0mg two times daily with ritonavir 100\u00a0mg two times daily.", "ParentId": "cc287d08-6501-4133-b640-5a0583439bf1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a7eb7bec-78f9-4a9e-bbb5-1ca892d7f47b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c68d88fa-7825-4457-8345-b1c42dedcc65", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a7eb7bec-78f9-4a9e-bbb5-1ca892d7f47b"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Renal impairment:</span></i></b><b><span lang=\"EN-GB\"><br/>\n</span></b><span lang=\"EN-GB\">No dosage adjustment is necessary for patients with\nmild to moderate renal impairment. Caution should be exercised in patients with\nsevere renal impairment (see section 4.4).</span></p>", "ID": "46be34d8-75f0-476a-a79f-95017147dc46", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Renal impairment:</span></i></b>", "ID": "1882f3ec-5d2e-4ac4-9277-b1f199d87eb1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "46be34d8-75f0-476a-a79f-95017147dc46"}, {"Element": "<i><span lang=\"EN-GB\">Renal impairment:</span></i>", "ID": "c817eba0-08a3-4903-aa8f-333474d04631", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1882f3ec-5d2e-4ac4-9277-b1f199d87eb1"}, {"Element": "<span lang=\"EN-GB\">Renal impairment:</span>", "ID": "1dc7090a-0fb5-47fe-aec9-a9c3550392df", "Styles": "None", "Classes": "None", "Text": "Renal impairment:", "ParentId": "c817eba0-08a3-4903-aa8f-333474d04631"}, {"Element": "<b><span lang=\"EN-GB\"><br/>\n</span></b>", "ID": "fd3f3f5d-e4e4-4404-8cf0-7c5229b7bb38", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "46be34d8-75f0-476a-a79f-95017147dc46"}, {"Element": "<span lang=\"EN-GB\"><br/>\n</span>", "ID": "67cf852c-6af7-4ce1-b2d7-2d5e4c616310", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "fd3f3f5d-e4e4-4404-8cf0-7c5229b7bb38"}, {"Element": "<br/>", "ID": "31d2d7a9-0f84-4731-94e2-bd70d325a96f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "67cf852c-6af7-4ce1-b2d7-2d5e4c616310"}, {"Element": "<span lang=\"EN-GB\">No dosage adjustment is necessary for patients with\nmild to moderate renal impairment. Caution should be exercised in patients with\nsevere renal impairment (see section 4.4).</span>", "ID": "e0a46a35-4216-4654-86c4-8e47d8734ef4", "Styles": "None", "Classes": "None", "Text": "No dosage adjustment is necessary for patients with mild to moderate renal impairment. Caution should be exercised in patients with severe renal impairment (see section 4.4).", "ParentId": "46be34d8-75f0-476a-a79f-95017147dc46"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8803b5d2-ba2b-403e-b56b-b4b29ce39bb3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a90bf5b1-2e9d-4efa-8b9a-1ef6ff878e73", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8803b5d2-ba2b-403e-b56b-b4b29ce39bb3"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Hepatic impairment:</span></i></b><b><span lang=\"EN-GB\"><br/>\n</span></b><span lang=\"EN-GB\">No dosage adjustment is necessary for HIV-infected\npatients with mild hepatic impairment. </span>No dosage adjustment seems\nwarranted for patients with moderate hepatic impairment based on limited data.\nClose monitoring of safety (including signs of cardiac arrhythmia) and of\nvirologic response is recommended due to increased variability of the exposure\nin this population.<span style='font-size:10.0pt;font-family:\"Arial\",sans-serif'>\n</span><span lang=\"EN-GB\">Invirase/ritonavir is contraindicated in patients with\ndecompensated hepatic impairment (see sections 4.3 and 4.4).</span></p>", "ID": "dc73534a-402e-4acc-8869-24ba6faa358c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "No dosage adjustment seems warranted for patients with moderate hepatic impairment based on limited data. Close monitoring of safety (including signs of cardiac arrhythmia) and of virologic response is recommended due to increased variability of the exposure in this population.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Hepatic impairment:</span></i></b>", "ID": "b634d8b1-5c01-4f4f-a140-ad97e2516675", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dc73534a-402e-4acc-8869-24ba6faa358c"}, {"Element": "<i><span lang=\"EN-GB\">Hepatic impairment:</span></i>", "ID": "56137225-80df-4d08-acfe-39b99ad39ddc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b634d8b1-5c01-4f4f-a140-ad97e2516675"}, {"Element": "<span lang=\"EN-GB\">Hepatic impairment:</span>", "ID": "ca3c20b5-f456-4336-9e0d-bae0e4d3067f", "Styles": "None", "Classes": "None", "Text": "Hepatic impairment:", "ParentId": "56137225-80df-4d08-acfe-39b99ad39ddc"}, {"Element": "<b><span lang=\"EN-GB\"><br/>\n</span></b>", "ID": "5c39ca50-b67a-4076-9494-2557175a6204", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dc73534a-402e-4acc-8869-24ba6faa358c"}, {"Element": "<span lang=\"EN-GB\"><br/>\n</span>", "ID": "ed49b5f1-e023-4f86-9d90-3d990288340e", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "5c39ca50-b67a-4076-9494-2557175a6204"}, {"Element": "<br/>", "ID": "63ab625c-cf4e-4538-88e0-7e03b60e4653", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ed49b5f1-e023-4f86-9d90-3d990288340e"}, {"Element": "<span lang=\"EN-GB\">No dosage adjustment is necessary for HIV-infected\npatients with mild hepatic impairment. </span>", "ID": "5a00b621-ed94-4058-ac3b-8d4360f88510", "Styles": "None", "Classes": "None", "Text": "No dosage adjustment is necessary for HIV-infected patients with mild hepatic impairment. ", "ParentId": "dc73534a-402e-4acc-8869-24ba6faa358c"}, {"Element": "<span style='font-size:10.0pt;font-family:\"Arial\",sans-serif'>\n</span>", "ID": "753d697b-23f0-4a32-b41f-a7916f5286af", "Styles": "font-size:10.0pt;font-family:\"Arial\",sans-serif", "Classes": "None", "Text": " ", "ParentId": "dc73534a-402e-4acc-8869-24ba6faa358c"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir is contraindicated in patients with\ndecompensated hepatic impairment (see sections 4.3 and 4.4).</span>", "ID": "a76d8256-5a8f-44eb-a37d-b76409888d01", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir is contraindicated in patients with decompensated hepatic impairment (see sections 4.3 and 4.4).", "ParentId": "dc73534a-402e-4acc-8869-24ba6faa358c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8c08b9c2-7ca3-4862-9532-a6c5d0cfd45e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a4fe1428-94d8-473f-b001-59c5bafe46ad", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8c08b9c2-7ca3-4862-9532-a6c5d0cfd45e"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Paediatric population:</span></i></b></p>", "ID": "5dc7c193-74c6-4c82-8401-5dc06baaccbb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Paediatric population:</span></i></b>", "ID": "0c1f8eda-6031-4d97-a506-624d7d8d290d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5dc7c193-74c6-4c82-8401-5dc06baaccbb"}, {"Element": "<i><span lang=\"EN-GB\">Paediatric population:</span></i>", "ID": "574cdb78-13a0-4e46-bbb2-a224babe172c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0c1f8eda-6031-4d97-a506-624d7d8d290d"}, {"Element": "<span lang=\"EN-GB\">Paediatric population:</span>", "ID": "bb4e85cb-4233-47aa-b007-742092884cc3", "Styles": "None", "Classes": "None", "Text": "Paediatric population:", "ParentId": "574cdb78-13a0-4e46-bbb2-a224babe172c"}, {"Element": "<p class=\"MsoNormal\">The safety and activity of saquinavir boosted with ritonavir\nin HIV-infected patients less than 2 years have not been established. No dose\nrecommendations for paediatric patients \u22652 years of age could be\nestablished that are both effective and below thresholds of concern for QT and\nPR interval prolongation.</p>", "ID": "101cfe4b-463c-448e-ab2d-9e60e73b1586", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The safety and activity of saquinavir boosted with ritonavir in HIV-infected patients less than 2 years have not been established. No dose recommendations for paediatric patients \u22652 years of age could be established that are both effective and below thresholds of concern for QT and PR interval prolongation.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2d01a3f1-72d9-4850-ae90-329c94758ca1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4d537de0-874b-4de9-8fa9-897ccc6b44e4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2d01a3f1-72d9-4850-ae90-329c94758ca1"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Adults over 60 years:</span></i></b></p>", "ID": "59427072-0b25-4cd9-b09f-f42b35b2c9b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Adults over 60 years:</span></i></b>", "ID": "2f334446-608c-4735-ae24-b9637146f09d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "59427072-0b25-4cd9-b09f-f42b35b2c9b4"}, {"Element": "<i><span lang=\"EN-GB\">Adults over 60 years:</span></i>", "ID": "051692c9-cc7e-4cda-90df-a5e4b44df2a9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2f334446-608c-4735-ae24-b9637146f09d"}, {"Element": "<span lang=\"EN-GB\">Adults over 60 years:</span>", "ID": "c8068844-605c-4a32-a9af-a8ea80282ea9", "Styles": "None", "Classes": "None", "Text": "Adults over 60 years:", "ParentId": "051692c9-cc7e-4cda-90df-a5e4b44df2a9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The experience with </span><span lang=\"EN-GB\">Invirase in adults over 60\u00a0years </span><span lang=\"EN-GB\">is\nlimited.</span></p>", "ID": "dbaadfeb-799c-4c06-aafd-023063474d74", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">The experience with </span>", "ID": "401c261c-534c-4161-b8f0-786c3c686f2b", "Styles": "None", "Classes": "None", "Text": "The experience with ", "ParentId": "dbaadfeb-799c-4c06-aafd-023063474d74"}, {"Element": "<span lang=\"EN-GB\">Invirase in adults over 60\u00a0years </span>", "ID": "0605e4f8-615d-4d8a-a3d1-6922c78f003b", "Styles": "None", "Classes": "None", "Text": "Invirase in adults over 60\u00a0years ", "ParentId": "dbaadfeb-799c-4c06-aafd-023063474d74"}, {"Element": "<span lang=\"EN-GB\">is\nlimited.</span>", "ID": "d9936b7f-f52b-4270-badb-1b5c66623ef1", "Styles": "None", "Classes": "None", "Text": "is limited.", "ParentId": "dbaadfeb-799c-4c06-aafd-023063474d74"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0d59e603-5d00-4889-ac4d-0a3d90793a37", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aa8a277c-0f16-423e-976c-45c994e91aa1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0d59e603-5d00-4889-ac4d-0a3d90793a37"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Method of administration</span></u></p>", "ID": "ac001c5e-0182-4e81-abee-53c6056ccfe0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<u><span lang=\"EN-GB\">Method of administration</span></u>", "ID": "09ec62dc-5ee4-4b97-8af3-bebbd6cd4d1a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ac001c5e-0182-4e81-abee-53c6056ccfe0"}, {"Element": "<span lang=\"EN-GB\">Method of administration</span>", "ID": "673d4683-f20f-4f21-aa3e-252fad8d56f7", "Styles": "None", "Classes": "None", "Text": "Method of administration", "ParentId": "09ec62dc-5ee4-4b97-8af3-bebbd6cd4d1a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase </span>film-coated tablets<span lang=\"EN-GB\"> should be swallowed whole and taken at the same time as ritonavir\nwith or after food (see section 5.2). </span></p>", "ID": "6379a8e1-831d-4d85-b810-b88b9239c089", "Styles": "None", "Classes": "['MsoNormal']", "Text": "film-coated tablets", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Invirase </span>", "ID": "e88e35cf-bb8f-4029-9134-84a1b4f73c6c", "Styles": "None", "Classes": "None", "Text": "Invirase ", "ParentId": "6379a8e1-831d-4d85-b810-b88b9239c089"}, {"Element": "<span lang=\"EN-GB\"> should be swallowed whole and taken at the same time as ritonavir\nwith or after food (see section 5.2). </span>", "ID": "09c15aa4-af7b-4f5f-b421-99e975e7da62", "Styles": "None", "Classes": "None", "Text": " should be swallowed whole and taken at the same time as ritonavir with or after food (see section 5.2). ", "ParentId": "6379a8e1-831d-4d85-b810-b88b9239c089"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5bb258c2-abfc-497b-951d-10e6d6c23c3a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "211da987-4411-4406-9c3d-512d76f493d7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5bb258c2-abfc-497b-951d-10e6d6c23c3a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</span></b></p>", "ID": "e5d39461-71ae-43b1-9163-6811648d961a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</span></b>", "ID": "0bfdcaff-4bc5-4c3e-b1d4-104671a84953", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e5d39461-71ae-43b1-9163-6811648d961a"}, {"Element": "<span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</span>", "ID": "f54991fd-8c18-4256-8ed4-bcf0169a9592", "Styles": "None", "Classes": "None", "Text": "4.3\u00a0\u00a0\u00a0\u00a0 Contraindications", "ParentId": "0bfdcaff-4bc5-4c3e-b1d4-104671a84953"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f445a924-df4d-4d23-a6dd-2cfcfe057517", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9456c605-29c2-43b6-8e6e-bff75d1c7005", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f445a924-df4d-4d23-a6dd-2cfcfe057517"}, {"Element": "<p class=\"MsoNormal\">Invirase is contraindicated in patients with:</p>", "ID": "01f3e62f-ad26-4706-9b60-a363eb7dad37", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Invirase is contraindicated in patients with:", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 hypersensitivity\nto the active substance or to any of the excipients</span> listed in section\n6.1</p>", "ID": "651a05f9-cb7a-4789-9ed8-6c7ff5d68878", "Styles": "margin-left:.5in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": " listed in section 6.1", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "6c3c0ac7-9213-48c5-bf81-ed28a81caa67", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "651a05f9-cb7a-4789-9ed8-6c7ff5d68878"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 hypersensitivity\nto the active substance or to any of the excipients</span>", "ID": "ea4c443d-805e-4df9-a51c-d43c795e3bc5", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 hypersensitivity to the active substance or to any of the excipients", "ParentId": "651a05f9-cb7a-4789-9ed8-6c7ff5d68878"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 decompensated\nliver disease<span lang=\"EN-GB\"> (see section 4.4)</span></p>", "ID": "08b18102-68ab-4edf-8a40-aa8f5aff8956", "Styles": "margin-left:.5in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 decompensated liver disease", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "53a243a7-32b2-4c36-8a14-ab48838ac229", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "08b18102-68ab-4edf-8a40-aa8f5aff8956"}, {"Element": "<span lang=\"EN-GB\"> (see section 4.4)</span>", "ID": "0675afaf-1605-4222-9e80-3f33df9d6342", "Styles": "None", "Classes": "None", "Text": " (see section 4.4)", "ParentId": "08b18102-68ab-4edf-8a40-aa8f5aff8956"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.25in\"><b><span style=\"font-family:Symbol\">\u00b7</span></b><b>\u00a0\u00a0\u00a0 congenital\nor documented acquired QT prolongation </b></p>", "ID": "c361c242-7cae-4b26-9f67-4973c17a5d41", "Styles": "margin-left:.5in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span style=\"font-family:Symbol\">\u00b7</span></b>", "ID": "95175af5-9356-407e-bf78-0c83c15f1f6f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c361c242-7cae-4b26-9f67-4973c17a5d41"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "9a23996d-9b80-4607-aeec-8c1939d4d763", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "95175af5-9356-407e-bf78-0c83c15f1f6f"}, {"Element": "<b>\u00a0\u00a0\u00a0 congenital\nor documented acquired QT prolongation </b>", "ID": "29a669dc-22ce-46c5-b5fa-88e8e4698925", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 congenital or documented acquired QT prolongation ", "ParentId": "c361c242-7cae-4b26-9f67-4973c17a5d41"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.25in\"><b><span style=\"font-family:Symbol\">\u00b7</span></b><b>\u00a0\u00a0\u00a0 electrolyte\ndisturbances, particularly uncorrected hypokalaemia</b></p>", "ID": "a5ce7a2b-85be-4fd2-9b43-5c8c8cc36533", "Styles": "margin-left:.5in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span style=\"font-family:Symbol\">\u00b7</span></b>", "ID": "285a5317-0b86-49d7-af82-6ef2bd50f568", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a5ce7a2b-85be-4fd2-9b43-5c8c8cc36533"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "636d0574-d1a0-4acd-b1ba-31198205401e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "285a5317-0b86-49d7-af82-6ef2bd50f568"}, {"Element": "<b>\u00a0\u00a0\u00a0 electrolyte\ndisturbances, particularly uncorrected hypokalaemia</b>", "ID": "29ef72cf-2275-418d-8800-49ca059f3de8", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 electrolyte disturbances, particularly uncorrected hypokalaemia", "ParentId": "a5ce7a2b-85be-4fd2-9b43-5c8c8cc36533"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.25in\"><b><span style=\"font-family:Symbol\">\u00b7</span></b><b>\u00a0\u00a0\u00a0 clinically\nrelevant bradycardia</b></p>", "ID": "2295088f-8fc9-4c4d-b44d-c2cfa9583688", "Styles": "margin-left:.5in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span style=\"font-family:Symbol\">\u00b7</span></b>", "ID": "a9967650-ea3b-4f76-a409-0abdd98c9d62", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2295088f-8fc9-4c4d-b44d-c2cfa9583688"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "ddf91179-30db-4f98-b9a4-11e91be6bd10", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a9967650-ea3b-4f76-a409-0abdd98c9d62"}, {"Element": "<b>\u00a0\u00a0\u00a0 clinically\nrelevant bradycardia</b>", "ID": "40d60666-8a5e-42b5-8265-9a7b02d79845", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 clinically relevant bradycardia", "ParentId": "2295088f-8fc9-4c4d-b44d-c2cfa9583688"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.25in\"><b><span style=\"font-family:Symbol\">\u00b7</span></b><b>\u00a0\u00a0\u00a0 clinically\nrelevant heart failure with reduced left-ventricular ejection fraction</b></p>", "ID": "3eeccb7f-c8aa-40a5-bbd0-5ee0d8ff9432", "Styles": "margin-left:.5in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span style=\"font-family:Symbol\">\u00b7</span></b>", "ID": "613e2d97-7772-4643-aff2-616f4ac11e5e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3eeccb7f-c8aa-40a5-bbd0-5ee0d8ff9432"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "5046c2cc-c390-4ba2-a6e1-b9251533bd34", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "613e2d97-7772-4643-aff2-616f4ac11e5e"}, {"Element": "<b>\u00a0\u00a0\u00a0 clinically\nrelevant heart failure with reduced left-ventricular ejection fraction</b>", "ID": "3cc8815c-524e-416b-a3fa-c70873f52e04", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 clinically relevant heart failure with reduced left-ventricular ejection fraction", "ParentId": "3eeccb7f-c8aa-40a5-bbd0-5ee0d8ff9432"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.25in\"><b><span style=\"font-family:Symbol\">\u00b7</span></b><b>\u00a0\u00a0\u00a0 previous\nhistory of symptomatic arrhythmias</b></p>", "ID": "7c4adea8-4a8e-40bc-9d66-c19dba23430d", "Styles": "margin-left:.5in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span style=\"font-family:Symbol\">\u00b7</span></b>", "ID": "2643b558-bdea-41ba-8e66-9321246a86f5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7c4adea8-4a8e-40bc-9d66-c19dba23430d"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "dfbab8ed-e9c9-4bde-978e-761012eee7b2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "2643b558-bdea-41ba-8e66-9321246a86f5"}, {"Element": "<b>\u00a0\u00a0\u00a0 previous\nhistory of symptomatic arrhythmias</b>", "ID": "4bf7a475-1727-46cb-9ffa-64ec944d282d", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 previous history of symptomatic arrhythmias", "ParentId": "7c4adea8-4a8e-40bc-9d66-c19dba23430d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 concurrent therapy\nwith any of the following drugs, which may interact and result in potentially\nlife-threatening undesirable effects (see sections 4.4, 4.5 and 4.8):</p>", "ID": "406ab4b7-2b13-48f5-b371-14dd4ccaee33", "Styles": "margin-left:.5in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 concurrent therapy with any of the following drugs, which may interact and result in potentially life-threatening undesirable effects (see sections 4.4, 4.5 and 4.8):", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "3c894dbe-5d9c-48dc-b45e-61025fcb7161", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "406ab4b7-2b13-48f5-b371-14dd4ccaee33"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:49.7pt;text-indent:-.2in\"><b>-\u00a0\u00a0\u00a0 drugs\nthat prolong the QT and/or PR interval</b><b><span lang=\"EN-GB\"> (see sections\n4.4 and 4.5)</span></b></p>", "ID": "de9f5bb8-4569-4d6a-8493-28ed16638072", "Styles": "margin-left:49.7pt;text-indent:-.2in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>-\u00a0\u00a0\u00a0 drugs\nthat prolong the QT and/or PR interval</b>", "ID": "87504075-bced-44b9-bcb1-772d5dccad8d", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0 drugs that prolong the QT and/or PR interval", "ParentId": "de9f5bb8-4569-4d6a-8493-28ed16638072"}, {"Element": "<b><span lang=\"EN-GB\"> (see sections\n4.4 and 4.5)</span></b>", "ID": "57376c1e-56ef-4fa3-9317-4a3516fb5c7d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "de9f5bb8-4569-4d6a-8493-28ed16638072"}, {"Element": "<span lang=\"EN-GB\"> (see sections\n4.4 and 4.5)</span>", "ID": "6d6d56d8-7905-4281-b40e-7858df81729c", "Styles": "None", "Classes": "None", "Text": " (see sections 4.4 and 4.5)", "ParentId": "57376c1e-56ef-4fa3-9317-4a3516fb5c7d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:49.7pt;text-indent:-.2in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 midazolam</span><span lang=\"EN-GB\"> </span>administered\norally (for caution on parenterally administered midazolam, see section 4.5)<span lang=\"EN-GB\">, triazolam (potential for prolonged or increased sedation, respiratory\ndepression)</span></p>", "ID": "777ef76c-18d8-48da-ab99-3f0829b26a92", "Styles": "margin-left:49.7pt;text-indent:-.2in", "Classes": "['MsoNormal']", "Text": "administered orally (for caution on parenterally administered midazolam, see section 4.5)", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 midazolam</span>", "ID": "59b9e1ea-a9cb-4538-8d21-956f9e5885f8", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0 midazolam", "ParentId": "777ef76c-18d8-48da-ab99-3f0829b26a92"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "299a7d3e-4e5c-4a2e-b32c-e2d09a1ae968", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "777ef76c-18d8-48da-ab99-3f0829b26a92"}, {"Element": "<span lang=\"EN-GB\">, triazolam (potential for prolonged or increased sedation, respiratory\ndepression)</span>", "ID": "a6bd3164-5123-4e0d-9d07-98a2758a82ca", "Styles": "None", "Classes": "None", "Text": ", triazolam (potential for prolonged or increased sedation, respiratory depression)", "ParentId": "777ef76c-18d8-48da-ab99-3f0829b26a92"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:49.7pt;text-indent:-.2in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 simvastatin, lovastatin (increased risk of\nmyopathy including rhabdomyolysis)</span></p>", "ID": "14ea0002-a2f7-465f-94fb-88c6da706281", "Styles": "margin-left:49.7pt;text-indent:-.2in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 simvastatin, lovastatin (increased risk of\nmyopathy including rhabdomyolysis)</span>", "ID": "8ce92432-d7df-4a03-b449-e08d5eb16075", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0 simvastatin, lovastatin (increased risk of myopathy including rhabdomyolysis)", "ParentId": "14ea0002-a2f7-465f-94fb-88c6da706281"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:49.7pt;text-indent:-.2in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 ergot alkaloids (e.g. ergotamine,\ndihydroergotamine, ergonovine, and methylergonovine) (potential for acute ergot\ntoxicity)</span></p>", "ID": "4e637f57-9fce-4ab8-8463-4792ef6e7124", "Styles": "margin-left:49.7pt;text-indent:-.2in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 ergot alkaloids (e.g. ergotamine,\ndihydroergotamine, ergonovine, and methylergonovine) (potential for acute ergot\ntoxicity)</span>", "ID": "c1a7e42f-9139-43dc-816c-04bf25f21d41", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0 ergot alkaloids (e.g. ergotamine, dihydroergotamine, ergonovine, and methylergonovine) (potential for acute ergot toxicity)", "ParentId": "4e637f57-9fce-4ab8-8463-4792ef6e7124"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:49.7pt;text-indent:-.2in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 rifampicin (risk of severe hepatocellular\ntoxicity) (see sections 4.4, 4.5, and 4.8)</span></p>", "ID": "a9189f0f-4a06-40ef-8eb9-eddbce0a4b61", "Styles": "margin-left:49.7pt;text-indent:-.2in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 rifampicin (risk of severe hepatocellular\ntoxicity) (see sections 4.4, 4.5, and 4.8)</span>", "ID": "3b441017-cd51-427a-af10-b15d1f2d70d6", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0 rifampicin (risk of severe hepatocellular toxicity) (see sections 4.4, 4.5, and 4.8)", "ParentId": "a9189f0f-4a06-40ef-8eb9-eddbce0a4b61"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:49.7pt;text-indent:-.2in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 quetiapine (risk of coma, see section 4.5). </span></p>", "ID": "28443089-821d-44a8-9d6a-111bb8d22eae", "Styles": "margin-left:49.7pt;text-indent:-.2in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 quetiapine (risk of coma, see section 4.5). </span>", "ID": "cb012054-8929-4c51-885e-59d36246ab37", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0 quetiapine (risk of coma, see section 4.5). ", "ParentId": "28443089-821d-44a8-9d6a-111bb8d22eae"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:49.7pt;text-indent:-.2in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 lurasidone (potential for serious and/or\nlife-threatening reactions, see section 4.5)</span></p>", "ID": "1e5b5ff8-bc8f-440b-883b-28994878255f", "Styles": "margin-left:49.7pt;text-indent:-.2in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">-\u00a0\u00a0\u00a0 lurasidone (potential for serious and/or\nlife-threatening reactions, see section 4.5)</span>", "ID": "130cd213-88ab-44de-8e84-1bd5d239ceff", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0 lurasidone (potential for serious and/or life-threatening reactions, see section 4.5)", "ParentId": "1e5b5ff8-bc8f-440b-883b-28994878255f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "df566f46-95bc-487f-98e3-fc3061b10244", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a6feab7f-4e65-421f-b748-1dccf702cbf4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "df566f46-95bc-487f-98e3-fc3061b10244"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use</span></b></p>", "ID": "e2c5c300-ed10-483f-85c8-24ca6b700a02", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use</span></b>", "ID": "0cb9016d-8f70-4390-a844-2856ebb6265d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e2c5c300-ed10-483f-85c8-24ca6b700a02"}, {"Element": "<span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use</span>", "ID": "b5cd242d-0b8c-427c-8787-4d24367a2957", "Styles": "None", "Classes": "None", "Text": "4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use", "ParentId": "0cb9016d-8f70-4390-a844-2856ebb6265d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fc7932d1-2b8c-4308-8129-d471a51f4981", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d8090dc7-d191-482c-b164-5b34c9c205cc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fc7932d1-2b8c-4308-8129-d471a51f4981"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Considerations when initiating\nInvirase therapy:</span></i></b><span lang=\"EN-GB\"> Invirase should not be given\nas the sole protease inhibitor. Invirase should only be given in combination\nwith ritonavir (see section 4.2). Invirase is not recommended for use in\ncombination with cobicistat as dosing recommendations for this combination have\nnot been established.</span></p>", "ID": "1bfba7d3-6c96-4e35-8e16-f6550b3720dd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Considerations when initiating\nInvirase therapy:</span></i></b>", "ID": "b9acbedf-1e8d-499a-8885-4047d4e1cdd7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1bfba7d3-6c96-4e35-8e16-f6550b3720dd"}, {"Element": "<i><span lang=\"EN-GB\">Considerations when initiating\nInvirase therapy:</span></i>", "ID": "4d4ad896-92c9-4a01-a685-9b65c30985e4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b9acbedf-1e8d-499a-8885-4047d4e1cdd7"}, {"Element": "<span lang=\"EN-GB\">Considerations when initiating\nInvirase therapy:</span>", "ID": "78be9e68-da09-4792-89e6-fde1d28d7f00", "Styles": "None", "Classes": "None", "Text": "Considerations when initiating Invirase therapy:", "ParentId": "4d4ad896-92c9-4a01-a685-9b65c30985e4"}, {"Element": "<span lang=\"EN-GB\"> Invirase should not be given\nas the sole protease inhibitor. Invirase should only be given in combination\nwith ritonavir (see section 4.2). Invirase is not recommended for use in\ncombination with cobicistat as dosing recommendations for this combination have\nnot been established.</span>", "ID": "140666e4-6b09-4e4c-b684-cb55176f31c7", "Styles": "None", "Classes": "None", "Text": " Invirase should not be given as the sole protease inhibitor. Invirase should only be given in combination with ritonavir (see section 4.2). Invirase is not recommended for use in combination with cobicistat as dosing recommendations for this combination have not been established.", "ParentId": "1bfba7d3-6c96-4e35-8e16-f6550b3720dd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6c4d8eb5-c319-4729-84fc-56d6e96bc1dc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4ca96a62-7a52-4dbf-a0b0-25c169db47c1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6c4d8eb5-c319-4729-84fc-56d6e96bc1dc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients should be informed that saquinavir\nis not a cure for HIV infection and that they may continue to acquire illnesses\nassociated with advanced HIV infection, including opportunistic infections. While\neffective viral suppression with antiretroviral therapy has been proven to\nsubstantially reduce the risk of sexual transmission, a residual risk cannot be\nexcluded. Precautions to prevent transmission should be taken in accordance\nwith national guidelines.</span></p>", "ID": "e8671f00-078a-46e2-b704-76e7e86dae40", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Patients should be informed that saquinavir\nis not a cure for HIV infection and that they may continue to acquire illnesses\nassociated with advanced HIV infection, including opportunistic infections. While\neffective viral suppression with antiretroviral therapy has been proven to\nsubstantially reduce the risk of sexual transmission, a residual risk cannot be\nexcluded. Precautions to prevent transmission should be taken in accordance\nwith national guidelines.</span>", "ID": "6024cb0d-2860-419e-a693-f7f1558a4f95", "Styles": "None", "Classes": "None", "Text": "Patients should be informed that saquinavir is not a cure for HIV infection and that they may continue to acquire illnesses associated with advanced HIV infection, including opportunistic infections. While effective viral suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission, a residual risk cannot be excluded. Precautions to prevent transmission should be taken in accordance with national guidelines.", "ParentId": "e8671f00-078a-46e2-b704-76e7e86dae40"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "03d12636-6bc4-4644-adaf-3011620bf021", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7ffac618-0c11-44fa-8ee3-c5de19eeee62", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "03d12636-6bc4-4644-adaf-3011620bf021"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients should also be advised that they\nmight experience undesirable effects associated with co-administered\nmedications. </span></p>", "ID": "d93995ae-d025-48b5-9ccf-f701690284ba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Patients should also be advised that they\nmight experience undesirable effects associated with co-administered\nmedications. </span>", "ID": "0675ebbe-fb87-433a-8ae8-71af3c600df8", "Styles": "None", "Classes": "None", "Text": "Patients should also be advised that they might experience undesirable effects associated with co-administered medications. ", "ParentId": "d93995ae-d025-48b5-9ccf-f701690284ba"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2cd53d1f-98af-4ace-8461-ad3ce03a3b05", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "465600fb-d133-44b4-896c-5e0901bcc0d2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2cd53d1f-98af-4ace-8461-ad3ce03a3b05"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i>Cardiac conduction and\nrepolarisation abnormalities:</i></b><b> </b></p>", "ID": "2476356e-ac7a-4bc2-8603-9f430e5a2404", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i>Cardiac conduction and\nrepolarisation abnormalities:</i></b>", "ID": "c24f2460-ccd8-44c6-81d0-198443b624d3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2476356e-ac7a-4bc2-8603-9f430e5a2404"}, {"Element": "<i>Cardiac conduction and\nrepolarisation abnormalities:</i>", "ID": "929b457a-83ce-462a-a559-97ec614c8d77", "Styles": "None", "Classes": "None", "Text": "Cardiac conduction and repolarisation abnormalities:", "ParentId": "c24f2460-ccd8-44c6-81d0-198443b624d3"}, {"Element": "<b> </b>", "ID": "b0f89708-d0f3-4725-9468-8aef4febdbd5", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "2476356e-ac7a-4bc2-8603-9f430e5a2404"}, {"Element": "<p class=\"MsoNormal\">Dose-dependent prolongations of QT and PR intervals have\nbeen observed in healthy volunteers receiving ritonavir-boosted Invirase (see\nsection 5.1).<b> Concomitant use of ritonavir-boosted Invirase with other\nmedicinal products that prolong the QT and/or PR interval is therefore\ncontraindicated (see section 4.3).</b></p>", "ID": "e7031b11-cf54-4444-8b4e-48b1babd3b66", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Dose-dependent prolongations of QT and PR intervals have been observed in healthy volunteers receiving ritonavir-boosted Invirase (see section 5.1).", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b> Concomitant use of ritonavir-boosted Invirase with other\nmedicinal products that prolong the QT and/or PR interval is therefore\ncontraindicated (see section 4.3).</b>", "ID": "5487e559-8435-44c9-9d65-78f8265d476f", "Styles": "None", "Classes": "None", "Text": " Concomitant use of ritonavir-boosted Invirase with other medicinal products that prolong the QT and/or PR interval is therefore contraindicated (see section 4.3).", "ParentId": "e7031b11-cf54-4444-8b4e-48b1babd3b66"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "36269072-86ab-4e5c-9770-698d39ab36ac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">Since the magnitude of QT and PR prolongation increases with\nincreasing concentrations of saquinavir, the recommended dose of\nritonavir-boosted Invirase should not be exceeded. Ritonavir-boosted Invirase\nat a dose of 2000\u00a0mg once daily with ritonavir 100\u00a0mg once daily has\nnot been studied with regard to the risk of QT prolongation and is not\nrecommended. Other medicinal products known to increase the plasma\nconcentration of ritonavir-boosted Invirase should be used with caution.</p>", "ID": "d5a6f2ea-0e61-475d-a513-e1041909f070", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Since the magnitude of QT and PR prolongation increases with increasing concentrations of saquinavir, the recommended dose of ritonavir-boosted Invirase should not be exceeded. Ritonavir-boosted Invirase at a dose of 2000\u00a0mg once daily with ritonavir 100\u00a0mg once daily has not been studied with regard to the risk of QT prolongation and is not recommended. Other medicinal products known to increase the plasma concentration of ritonavir-boosted Invirase should be used with caution.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "256dd39e-2440-4975-838a-8472d50a9eb0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">Women and elderly patients may be more susceptible to\ndrug-associated effects on the QT and/or PR interval.</p>", "ID": "b6d4a4e4-4887-47a3-ae5f-5b444e4b36de", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Women and elderly patients may be more susceptible to drug-associated effects on the QT and/or PR interval.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "1f5426a6-4a71-4d65-ae83-c0514c53b8ff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><b><u><span style=\"font-family:Symbol\">\u00b7</span></u></b><b><u>\u00a0\u00a0\u00a0 Clinical\nManagement:</u></b></p>", "ID": "6ab67893-9405-4fa1-931c-e6aebf3f4dc8", "Styles": "margin-left:.25in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><u><span style=\"font-family:Symbol\">\u00b7</span></u></b>", "ID": "f5429e14-89fe-4f3d-87cf-3c510197b5fc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6ab67893-9405-4fa1-931c-e6aebf3f4dc8"}, {"Element": "<u><span style=\"font-family:Symbol\">\u00b7</span></u>", "ID": "53113089-d425-4e66-9d41-ad72f77cc5eb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f5429e14-89fe-4f3d-87cf-3c510197b5fc"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "2f03a9d3-12e7-415d-b284-4c99d3116a0c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "53113089-d425-4e66-9d41-ad72f77cc5eb"}, {"Element": "<b><u>\u00a0\u00a0\u00a0 Clinical\nManagement:</u></b>", "ID": "e6c00d7b-fdc7-45cd-8946-5f8876eaf83d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6ab67893-9405-4fa1-931c-e6aebf3f4dc8"}, {"Element": "<u>\u00a0\u00a0\u00a0 Clinical\nManagement:</u>", "ID": "26dca58b-0aae-4346-92e7-06fe5169d80a", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 Clinical Management:", "ParentId": "e6c00d7b-fdc7-45cd-8946-5f8876eaf83d"}, {"Element": "<p class=\"MsoNormal\">Consideration should be given for performing baseline and\nfollow-up electrocardiograms after initiation of treatment, e.g. in patients\ntaking concomitant medication known to increase the exposure of saquinavir (see\nsection 4.5). If signs or symptoms suggesting cardiac arrhythmia occur,\ncontinuous monitoring of ECG should be performed. Ritonavir-boosted Invirase\nshould be discontinued if arrhythmias are demonstrated, or if prolongation\noccurs in the QT or PR interval.</p>", "ID": "c9563f44-17c8-4df7-8931-c358b6226798", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Consideration should be given for performing baseline and follow-up electrocardiograms after initiation of treatment, e.g. in patients taking concomitant medication known to increase the exposure of saquinavir (see section 4.5). If signs or symptoms suggesting cardiac arrhythmia occur, continuous monitoring of ECG should be performed. Ritonavir-boosted Invirase should be discontinued if arrhythmias are demonstrated, or if prolongation occurs in the QT or PR interval.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "bbf1dc32-0950-4614-af17-8448fd510481", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><b>Patients initiating therapy with ritonavir-boosted\nInvirase</b>:</p>", "ID": "d4324fd7-cc1f-45dd-82f7-010bf3342b25", "Styles": "None", "Classes": "['MsoNormal']", "Text": ":", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>Patients initiating therapy with ritonavir-boosted\nInvirase</b>", "ID": "cfbc86a9-9b9d-437a-b740-1269e745f4a0", "Styles": "None", "Classes": "None", "Text": "Patients initiating therapy with ritonavir-boosted Invirase", "ParentId": "d4324fd7-cc1f-45dd-82f7-010bf3342b25"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\">-\u00a0\u00a0\u00a0\u00a0 An\nECG should be performed on all patients prior to initiation of treatment:\npatients with a QT interval &gt;\u00a0450 msec should not use ritonavir-boosted\nInvirase. For patients with a QT interval &lt; 450 msec, an on treatment ECG is\nrecommended.</p>", "ID": "5b475ca1-52ba-4e20-bd7f-82d185ded93b", "Styles": "margin-left:.75in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "-\u00a0\u00a0\u00a0\u00a0 An ECG should be performed on all patients prior to initiation of treatment: patients with a QT interval >\u00a0450 msec should not use ritonavir-boosted Invirase. For patients with a QT interval < 450 msec, an on treatment ECG is recommended.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\">-\u00a0\u00a0\u00a0\u00a0 For\ntreatment-na\u00efve patients initiating treatment with Invirase/ritonavir\n500/100 mg two times daily for the first 7 days of treatment followed by Invirase\n1000 mg two times daily with ritonavir 100 mg two times daily after 7 days and\nwith a baseline QT interval &lt; 450 msec, an on-treatment ECG is suggested\nafter approximately 10 days of therapy.</p>", "ID": "e6f836be-f8bf-46f4-877a-7623144d8513", "Styles": "margin-left:.75in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "-\u00a0\u00a0\u00a0\u00a0 For treatment-na\u00efve patients initiating treatment with Invirase/ritonavir 500/100 mg two times daily for the first 7 days of treatment followed by Invirase 1000 mg two times daily with ritonavir 100 mg two times daily after 7 days and with a baseline QT interval < 450 msec, an on-treatment ECG is suggested after approximately 10 days of therapy.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\">-\u00a0\u00a0\u00a0\u00a0 Patients\ndemonstrating a subsequent increase in QT-interval to &gt; 480 msec or\nprolongation over pre-treatment by &gt; 20 msec should discontinue\nritonavir-boosted Invirase.</p>", "ID": "95cdbae9-7db2-4d91-b132-c799aaf96d19", "Styles": "margin-left:.75in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "-\u00a0\u00a0\u00a0\u00a0 Patients demonstrating a subsequent increase in QT-interval to > 480 msec or prolongation over pre-treatment by > 20 msec should discontinue ritonavir-boosted Invirase.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "3c004482-b483-45e3-9656-5dacae31f532", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>\u00a0</b>", "ID": "25183046-e1d5-4376-9b76-459b613837d0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3c004482-b483-45e3-9656-5dacae31f532"}, {"Element": "<p class=\"MsoNormal\"><b>Patients stable on ritonavir-boosted Invirase and\nrequiring concomitant medication with potential to increase the exposure of\nsaquinavir or patients on medication with potential to increase the exposure of\nsaquinavir and requiring concomitant ritonavir-boosted Invirase where no\nalternative therapy is available and the benefits outweigh the risks:</b></p>", "ID": "71f7d382-1763-43d9-914f-5a68a32fd31e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>Patients stable on ritonavir-boosted Invirase and\nrequiring concomitant medication with potential to increase the exposure of\nsaquinavir or patients on medication with potential to increase the exposure of\nsaquinavir and requiring concomitant ritonavir-boosted Invirase where no\nalternative therapy is available and the benefits outweigh the risks:</b>", "ID": "60bb53d2-a330-4cfe-abb8-1ccf0923fe61", "Styles": "None", "Classes": "None", "Text": "Patients stable on ritonavir-boosted Invirase and requiring concomitant medication with potential to increase the exposure of saquinavir or patients on medication with potential to increase the exposure of saquinavir and requiring concomitant ritonavir-boosted Invirase where no alternative therapy is available and the benefits outweigh the risks:", "ParentId": "71f7d382-1763-43d9-914f-5a68a32fd31e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\">-\u00a0\u00a0\u00a0\u00a0 An\nECG should be performed prior to initiation of the concomitant therapy:\npatients with a QT interval &gt; 450 msec should not initiate the concomitant\ntherapy (see section 4.5).</p>", "ID": "83519760-5bf9-4f3b-b44c-1905d6db840e", "Styles": "margin-left:.75in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "-\u00a0\u00a0\u00a0\u00a0 An ECG should be performed prior to initiation of the concomitant therapy: patients with a QT interval > 450 msec should not initiate the concomitant therapy (see section 4.5).", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\">-\u00a0\u00a0\u00a0\u00a0 For\npatients with a baseline QT interval &lt; 450 msec, an on-treatment ECG should\nbe performed. For patients demonstrating a subsequent increase in QT-interval\nto &gt; 480 msec or increase by &gt; 20 msec after commencing concomitant\ntherapy, the physician should use best clinical judgment to discontinue either\nritonavir-boosted Invirase or the concomitant therapy or both.</p>", "ID": "45111db6-cb7e-4161-aff6-b0b603a5962b", "Styles": "margin-left:.75in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "-\u00a0\u00a0\u00a0\u00a0 For patients with a baseline QT interval < 450 msec, an on-treatment ECG should be performed. For patients demonstrating a subsequent increase in QT-interval to > 480 msec or increase by > 20 msec after commencing concomitant therapy, the physician should use best clinical judgment to discontinue either ritonavir-boosted Invirase or the concomitant therapy or both.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fff402f7-c57a-4f6a-ba8a-9b9d3038e2af", "Styles": "margin-left:.75in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9f630c80-be51-4b3a-9d12-5e89c0f15918", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fff402f7-c57a-4f6a-ba8a-9b9d3038e2af"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><b><u><span style=\"font-family:Symbol\">\u00b7</span></u></b><b><u>\u00a0\u00a0\u00a0 Essential\nPatient Information:</u></b></p>", "ID": "998888dd-7813-4527-9a2a-0efc62d56115", "Styles": "margin-left:.25in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><u><span style=\"font-family:Symbol\">\u00b7</span></u></b>", "ID": "0d98db61-c344-41f0-bcf6-deac3934a897", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "998888dd-7813-4527-9a2a-0efc62d56115"}, {"Element": "<u><span style=\"font-family:Symbol\">\u00b7</span></u>", "ID": "d208a77a-981f-488a-9089-64d7bd61dc78", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0d98db61-c344-41f0-bcf6-deac3934a897"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "3b62ca09-4357-47a8-9ddf-f53281991904", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d208a77a-981f-488a-9089-64d7bd61dc78"}, {"Element": "<b><u>\u00a0\u00a0\u00a0 Essential\nPatient Information:</u></b>", "ID": "b5bced00-383b-45fb-a637-b139e89d4e9e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "998888dd-7813-4527-9a2a-0efc62d56115"}, {"Element": "<u>\u00a0\u00a0\u00a0 Essential\nPatient Information:</u>", "ID": "41111f1b-9281-427b-9f5b-9eb9158c4105", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 Essential Patient Information:", "ParentId": "b5bced00-383b-45fb-a637-b139e89d4e9e"}, {"Element": "<p class=\"MsoNormal\"><i>Prescribers must ensure that patients</i> <i><span lang=\"EN-GB\">are fully informed</span></i><span lang=\"EN-GB\"> <i>regarding the\nfollowing information on cardiac conduction and repolarisation abnormalities: </i></span></p>", "ID": "fe7e0c71-adbb-4410-b798-e0e77ce70f89", "Styles": "None", "Classes": "['MsoNormal']", "Text": " ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<i>Prescribers must ensure that patients</i>", "ID": "f76ebaeb-66dc-40e4-8137-ddc4c6d77ed2", "Styles": "None", "Classes": "None", "Text": "Prescribers must ensure that patients", "ParentId": "fe7e0c71-adbb-4410-b798-e0e77ce70f89"}, {"Element": "<i><span lang=\"EN-GB\">are fully informed</span></i>", "ID": "dcc6aee7-0220-4a84-8d3f-7a601c2738f1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fe7e0c71-adbb-4410-b798-e0e77ce70f89"}, {"Element": "<span lang=\"EN-GB\">are fully informed</span>", "ID": "3a803317-775d-45e5-b5e8-bfd7cdadaf98", "Styles": "None", "Classes": "None", "Text": "are fully informed", "ParentId": "dcc6aee7-0220-4a84-8d3f-7a601c2738f1"}, {"Element": "<span lang=\"EN-GB\"> <i>regarding the\nfollowing information on cardiac conduction and repolarisation abnormalities: </i></span>", "ID": "f866a6eb-c6c8-49d0-9e36-79931c1236ba", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "fe7e0c71-adbb-4410-b798-e0e77ce70f89"}, {"Element": "<i>regarding the\nfollowing information on cardiac conduction and repolarisation abnormalities: </i>", "ID": "bae3517f-058c-460b-a19e-a401c48961d9", "Styles": "None", "Classes": "None", "Text": "regarding the following information on cardiac conduction and repolarisation abnormalities: ", "ParentId": "f866a6eb-c6c8-49d0-9e36-79931c1236ba"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0 Patients </span>initiating therapy with\nritonavir boosted Invirase should be warned of the arrhythmogenic risk\nassociated with QT and PR prolongation and told to report any sign or symptom\nsuspicious of cardiac arrhythmia (e.g., chest palpitations, syncope,\npresyncope) to their physician.</p>", "ID": "4c783fca-726e-4aff-90b5-857fef94d50a", "Styles": "margin-left:.75in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "initiating therapy with ritonavir boosted Invirase should be warned of the arrhythmogenic risk associated with QT and PR prolongation and told to report any sign or symptom suspicious of cardiac arrhythmia (e.g., chest palpitations, syncope, presyncope) to their physician.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0 Patients </span>", "ID": "ea094684-9c2d-47dc-a23a-a9381ad751cc", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0\u00a0 Patients ", "ParentId": "4c783fca-726e-4aff-90b5-857fef94d50a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0 Physicians should enquire about any known\nfamilial history of sudden death at a young age as this may be suggestive of\ncongenital QT prolongation.</span></p>", "ID": "c2ca2c60-6b38-44a2-8c48-f8ddf90cadaa", "Styles": "margin-left:.75in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0 Physicians should enquire about any known\nfamilial history of sudden death at a young age as this may be suggestive of\ncongenital QT prolongation.</span>", "ID": "62651155-3677-4d1b-9164-11e990c6459c", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0\u00a0 Physicians should enquire about any known familial history of sudden death at a young age as this may be suggestive of congenital QT prolongation.", "ParentId": "c2ca2c60-6b38-44a2-8c48-f8ddf90cadaa"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0 Patients should be advised of the\nimportance not to exceed the recommended dose.</span></p>", "ID": "3ee9aca1-8439-48f4-bd9e-3d81fad8c764", "Styles": "margin-left:.75in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0 Patients should be advised of the\nimportance not to exceed the recommended dose.</span>", "ID": "a03fd261-b053-4ed8-ad92-d176727b53b9", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0\u00a0 Patients should be advised of the importance not to exceed the recommended dose.", "ParentId": "3ee9aca1-8439-48f4-bd9e-3d81fad8c764"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0 Each patient (or patient\u2019s\ncaregiver) should be reminded to read the Package Leaflet included in the\nInvirase Package.</span></p>", "ID": "4b1d01e5-8bfe-4a5f-a86a-e2762356171d", "Styles": "margin-left:.75in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0 Each patient (or patient\u2019s\ncaregiver) should be reminded to read the Package Leaflet included in the\nInvirase Package.</span>", "ID": "fed0667f-6b75-400a-b169-c66f8671e36c", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0\u00a0 Each patient (or patient\u2019s caregiver) should be reminded to read the Package Leaflet included in the Invirase Package.", "ParentId": "4b1d01e5-8bfe-4a5f-a86a-e2762356171d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8bb9b7e2-4440-41be-b8a0-28026801c7f4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c0e5bd31-5338-48ca-af7f-bedcfb292fcd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8bb9b7e2-4440-41be-b8a0-28026801c7f4"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Liver disease:</span></i></b><span lang=\"EN-GB\"> The safety and efficacy of saquinavir/ritonavir has not been\nestablished in patients with significant underlying liver disorders, therefore\nsaquinavir/ritonavir should be used cautiously in this patient population.\nInvirase/ritonavir is contraindicated in patients with decompensated liver\ndisease (see section 4.3). Patients with chronic hepatitis B or C and treated\nwith combination antiretroviral therapy are at an increased risk for severe and\npotentially fatal hepatic adverse events. In case of concomitant antiviral\ntherapy for hepatitis B or C, please refer also to the relevant product\ninformation for these medicinal products.</span></p>", "ID": "3d337cc5-2d8f-413c-8ad8-c25145bea176", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Liver disease:</span></i></b>", "ID": "6430a34c-118c-42b4-a6a3-52ffd64221e7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3d337cc5-2d8f-413c-8ad8-c25145bea176"}, {"Element": "<i><span lang=\"EN-GB\">Liver disease:</span></i>", "ID": "4b3c00e6-d70b-4887-be98-2184ad55da6f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6430a34c-118c-42b4-a6a3-52ffd64221e7"}, {"Element": "<span lang=\"EN-GB\">Liver disease:</span>", "ID": "1a08c0e4-beb5-44bd-b208-f78089a5d58f", "Styles": "None", "Classes": "None", "Text": "Liver disease:", "ParentId": "4b3c00e6-d70b-4887-be98-2184ad55da6f"}, {"Element": "<span lang=\"EN-GB\"> The safety and efficacy of saquinavir/ritonavir has not been\nestablished in patients with significant underlying liver disorders, therefore\nsaquinavir/ritonavir should be used cautiously in this patient population.\nInvirase/ritonavir is contraindicated in patients with decompensated liver\ndisease (see section 4.3). Patients with chronic hepatitis B or C and treated\nwith combination antiretroviral therapy are at an increased risk for severe and\npotentially fatal hepatic adverse events. In case of concomitant antiviral\ntherapy for hepatitis B or C, please refer also to the relevant product\ninformation for these medicinal products.</span>", "ID": "52d76c91-dcc4-4425-89e9-c4e636c8f519", "Styles": "None", "Classes": "None", "Text": " The safety and efficacy of saquinavir/ritonavir has not been established in patients with significant underlying liver disorders, therefore saquinavir/ritonavir should be used cautiously in this patient population. Invirase/ritonavir is contraindicated in patients with decompensated liver disease (see section 4.3). Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events. In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.", "ParentId": "3d337cc5-2d8f-413c-8ad8-c25145bea176"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1af14390-3a27-4916-9ec8-f657e4a24b17", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "581fab70-2db6-4bfd-a227-e2bd308f1728", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1af14390-3a27-4916-9ec8-f657e4a24b17"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients with pre-existing liver\ndysfunction including chronic active hepatitis have an increased frequency of\nliver function abnormalities during combination antiretroviral therapy and\nshould be monitored according to standard practice. If there is evidence of\nworsening liver disease in such patients, interruption or discontinuation of\ntreatment must be considered.</span></p>", "ID": "3340b74d-93fa-44e8-90b5-b4456fde6f59", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Patients with pre-existing liver\ndysfunction including chronic active hepatitis have an increased frequency of\nliver function abnormalities during combination antiretroviral therapy and\nshould be monitored according to standard practice. If there is evidence of\nworsening liver disease in such patients, interruption or discontinuation of\ntreatment must be considered.</span>", "ID": "78d1868a-692d-4788-99b0-5571814aed8c", "Styles": "None", "Classes": "None", "Text": "Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.", "ParentId": "3340b74d-93fa-44e8-90b5-b4456fde6f59"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3e06f5a1-aa0e-46df-bdfb-e1d330626a81", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6fc51d46-9e99-4b19-922b-aff4e7e84801", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3e06f5a1-aa0e-46df-bdfb-e1d330626a81"}, {"Element": "<p class=\"MsoNormal\">No dosage adjustment seems warranted for patients with\nmoderate hepatic impairment based on limited data. Close monitoring of safety\n(including signs of cardiac arrhythmia) and of virologic response is\nrecommended due to increased variability of the exposure in this population\n(see sections 4.2 and 5.2). <span lang=\"EN-GB\">There have been reports of\nexacerbation of chronic liver dysfunction, including portal hypertension, in\npatients with underlying hepatitis B or C, cirrhosis and other underlying liver\nabnormalities.</span></p>", "ID": "005f6141-0e70-4625-95c6-21222d8b9876", "Styles": "None", "Classes": "['MsoNormal']", "Text": "No dosage adjustment seems warranted for patients with moderate hepatic impairment based on limited data. Close monitoring of safety (including signs of cardiac arrhythmia) and of virologic response is recommended due to increased variability of the exposure in this population (see sections 4.2 and 5.2). ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">There have been reports of\nexacerbation of chronic liver dysfunction, including portal hypertension, in\npatients with underlying hepatitis B or C, cirrhosis and other underlying liver\nabnormalities.</span>", "ID": "7b0a660c-0a2f-4eaf-8e70-0d2b5cabcac8", "Styles": "None", "Classes": "None", "Text": "There have been reports of exacerbation of chronic liver dysfunction, including portal hypertension, in patients with underlying hepatitis B or C, cirrhosis and other underlying liver abnormalities.", "ParentId": "005f6141-0e70-4625-95c6-21222d8b9876"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6a568d7d-cf8e-48b5-9fa4-48d56a3ac1a7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c29a42a3-df37-4714-834f-341aeabdee32", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6a568d7d-cf8e-48b5-9fa4-48d56a3ac1a7"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Renal impairment:</span></i></b><span lang=\"EN-GB\"> Renal clearance is only a minor elimination pathway, the principal\nroute of metabolism and excretion for saquinavir being via the liver.\nTherefore, no initial dose adjustment is necessary for patients with renal\nimpairment. However, patients with severe renal impairment have not been\nstudied and caution should be exercised when prescribing saquinavir/ritonavir\nin this population. </span></p>", "ID": "186c051a-84bc-432b-a4f9-9a2c02b8de7b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Renal impairment:</span></i></b>", "ID": "710b2a42-11d4-413f-bf72-7c967c1c38d0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "186c051a-84bc-432b-a4f9-9a2c02b8de7b"}, {"Element": "<i><span lang=\"EN-GB\">Renal impairment:</span></i>", "ID": "ac3a83ee-29b1-4eee-a662-1af7963ce1fd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "710b2a42-11d4-413f-bf72-7c967c1c38d0"}, {"Element": "<span lang=\"EN-GB\">Renal impairment:</span>", "ID": "e46e56fe-6a01-4781-bbf6-b9251aa61171", "Styles": "None", "Classes": "None", "Text": "Renal impairment:", "ParentId": "ac3a83ee-29b1-4eee-a662-1af7963ce1fd"}, {"Element": "<span lang=\"EN-GB\"> Renal clearance is only a minor elimination pathway, the principal\nroute of metabolism and excretion for saquinavir being via the liver.\nTherefore, no initial dose adjustment is necessary for patients with renal\nimpairment. However, patients with severe renal impairment have not been\nstudied and caution should be exercised when prescribing saquinavir/ritonavir\nin this population. </span>", "ID": "5e0f5a49-bbc0-4863-bf0e-805d26ef3683", "Styles": "None", "Classes": "None", "Text": " Renal clearance is only a minor elimination pathway, the principal route of metabolism and excretion for saquinavir being via the liver. Therefore, no initial dose adjustment is necessary for patients with renal impairment. However, patients with severe renal impairment have not been studied and caution should be exercised when prescribing saquinavir/ritonavir in this population. ", "ParentId": "186c051a-84bc-432b-a4f9-9a2c02b8de7b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b09574b2-b76a-4ae7-89bc-e959135b7577", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ee92be12-294e-41bf-97ec-57e7a4fa61eb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b09574b2-b76a-4ae7-89bc-e959135b7577"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Patients with chronic diarrhoea or\nmalabsorption:</span></i></b><span lang=\"EN-GB\"> No information on boosted\nsaquinavir and only limited information on the safety and efficacy of unboosted\nsaquinavir is available for patients suffering from chronic diarrhoea or\nmalabsorption. It is unknown whether patients with such conditions could\nreceive subtherapeutic saquinavir levels.</span></p>", "ID": "17a63de3-44bb-42d1-89af-57eb208afdaf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Patients with chronic diarrhoea or\nmalabsorption:</span></i></b>", "ID": "556d8e6c-1961-46a1-8304-2237865583ed", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "17a63de3-44bb-42d1-89af-57eb208afdaf"}, {"Element": "<i><span lang=\"EN-GB\">Patients with chronic diarrhoea or\nmalabsorption:</span></i>", "ID": "aedd2511-f506-4ab0-b4d6-544c50275f93", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "556d8e6c-1961-46a1-8304-2237865583ed"}, {"Element": "<span lang=\"EN-GB\">Patients with chronic diarrhoea or\nmalabsorption:</span>", "ID": "63116489-c9d7-42bf-a700-f4060e03cf46", "Styles": "None", "Classes": "None", "Text": "Patients with chronic diarrhoea or malabsorption:", "ParentId": "aedd2511-f506-4ab0-b4d6-544c50275f93"}, {"Element": "<span lang=\"EN-GB\"> No information on boosted\nsaquinavir and only limited information on the safety and efficacy of unboosted\nsaquinavir is available for patients suffering from chronic diarrhoea or\nmalabsorption. It is unknown whether patients with such conditions could\nreceive subtherapeutic saquinavir levels.</span>", "ID": "53e8832c-a4d9-4ff5-a5ae-85c85da432a1", "Styles": "None", "Classes": "None", "Text": " No information on boosted saquinavir and only limited information on the safety and efficacy of unboosted saquinavir is available for patients suffering from chronic diarrhoea or malabsorption. It is unknown whether patients with such conditions could receive subtherapeutic saquinavir levels.", "ParentId": "17a63de3-44bb-42d1-89af-57eb208afdaf"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "2690978e-873c-4d4c-8d4c-bfd5f38344c7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "d67605ac-1959-463a-8aff-a4cb352f2d05", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2690978e-873c-4d4c-8d4c-bfd5f38344c7"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9550518f-b605-4dac-bde1-4733871e9712", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d67605ac-1959-463a-8aff-a4cb352f2d05"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Paediatric population:</span></i></b><b><span lang=\"EN-GB\"> </span></b>The safety and activity of saquinavir boosted with\nritonavir in HIV-infected patients less than 2 years have not been established.\nNo dose recommendations for paediatric patients \u22652 years of age could be\nestablished that are both effective and below thresholds of concern for QT and\nPR interval prolongation. Therefore, use in this population is not recommended.</p>", "ID": "e794febc-2f84-417f-88ca-f52da0ab30cd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The safety and activity of saquinavir boosted with ritonavir in HIV-infected patients less than 2 years have not been established. No dose recommendations for paediatric patients \u22652 years of age could be established that are both effective and below thresholds of concern for QT and PR interval prolongation. Therefore, use in this population is not recommended.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Paediatric population:</span></i></b>", "ID": "26dc688c-96e2-448f-b3bd-5bc13b032847", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e794febc-2f84-417f-88ca-f52da0ab30cd"}, {"Element": "<i><span lang=\"EN-GB\">Paediatric population:</span></i>", "ID": "b73ac14c-6f9c-4d96-974b-708fb091039d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "26dc688c-96e2-448f-b3bd-5bc13b032847"}, {"Element": "<span lang=\"EN-GB\">Paediatric population:</span>", "ID": "6e832861-f7fe-4a95-9fcd-24aeecfc7038", "Styles": "None", "Classes": "None", "Text": "Paediatric population:", "ParentId": "b73ac14c-6f9c-4d96-974b-708fb091039d"}, {"Element": "<b><span lang=\"EN-GB\"> </span></b>", "ID": "0918b126-13f9-4104-be71-7a09876d47eb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e794febc-2f84-417f-88ca-f52da0ab30cd"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "3d9a8673-a2ce-4b6c-bcfb-c6be1cd0b404", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "0918b126-13f9-4104-be71-7a09876d47eb"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f50b231f-7d4e-4884-8184-28036f379b4f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Adults over 60 years:</span></i></b><span lang=\"EN-GB\"> The experience with </span><span lang=\"EN-GB\">Invirase in adults over\n60\u00a0years is limited. </span>Elderly patients may be more susceptible to\ndrug-associated effects on the QT and/or PR interval.</p>", "ID": "067ff3f5-5745-4c3a-8d64-ed353df193b7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Elderly patients may be more susceptible to drug-associated effects on the QT and/or PR interval.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Adults over 60 years:</span></i></b>", "ID": "261a19a3-14e4-4516-8355-1bcd53da588f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "067ff3f5-5745-4c3a-8d64-ed353df193b7"}, {"Element": "<i><span lang=\"EN-GB\">Adults over 60 years:</span></i>", "ID": "f02f5c0e-3a88-4428-88c4-c70f4e08ffc5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "261a19a3-14e4-4516-8355-1bcd53da588f"}, {"Element": "<span lang=\"EN-GB\">Adults over 60 years:</span>", "ID": "15b74bbf-ca52-46f0-9e85-6408cb579979", "Styles": "None", "Classes": "None", "Text": "Adults over 60 years:", "ParentId": "f02f5c0e-3a88-4428-88c4-c70f4e08ffc5"}, {"Element": "<span lang=\"EN-GB\"> The experience with </span>", "ID": "9bbd1d5d-27b6-471c-be0f-59edf6b1576b", "Styles": "None", "Classes": "None", "Text": " The experience with ", "ParentId": "067ff3f5-5745-4c3a-8d64-ed353df193b7"}, {"Element": "<span lang=\"EN-GB\">Invirase in adults over\n60\u00a0years is limited. </span>", "ID": "175563c1-7a38-48d5-a032-08271d831631", "Styles": "None", "Classes": "None", "Text": "Invirase in adults over 60\u00a0years is limited. ", "ParentId": "067ff3f5-5745-4c3a-8d64-ed353df193b7"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>", "ID": "38504e51-ef3c-43a8-895a-d66dc2d31aaa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">\u00a0</span></i></b>", "ID": "4e9cf861-b3b8-4ea4-b942-bbe9101d1834", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "38504e51-ef3c-43a8-895a-d66dc2d31aaa"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "765f6f5c-46b7-4a6a-b199-34b96363cffe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4e9cf861-b3b8-4ea4-b942-bbe9101d1834"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3f030c51-ec0f-4efa-b9d5-3ec529c242b8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "765f6f5c-46b7-4a6a-b199-34b96363cffe"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Lactose intolerance:</span></i></b><span lang=\"EN-GB\"> Invirase 500\u00a0mg </span>film-coated tablets<span lang=\"EN-GB\">\ncontain lactose. Patients with rare hereditary problems of galactose\nintolerance, the Lapp lactase deficiency or glucose-galactose malabsorption\nshould not take this medicine.</span></p>", "ID": "8dc89f45-894b-404f-b2a9-10007d0c0b96", "Styles": "None", "Classes": "['MsoNormal']", "Text": "film-coated tablets", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Lactose intolerance:</span></i></b>", "ID": "6e9a02bb-49f0-423d-9ecb-eeba93610390", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8dc89f45-894b-404f-b2a9-10007d0c0b96"}, {"Element": "<i><span lang=\"EN-GB\">Lactose intolerance:</span></i>", "ID": "66f68829-d12b-4b61-87e3-ca8941d6164a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6e9a02bb-49f0-423d-9ecb-eeba93610390"}, {"Element": "<span lang=\"EN-GB\">Lactose intolerance:</span>", "ID": "ea54893e-29e9-468f-8b3f-176d7a9c9342", "Styles": "None", "Classes": "None", "Text": "Lactose intolerance:", "ParentId": "66f68829-d12b-4b61-87e3-ca8941d6164a"}, {"Element": "<span lang=\"EN-GB\"> Invirase 500\u00a0mg </span>", "ID": "c0f282bd-5f7b-41d2-98d6-c37f4983b5a6", "Styles": "None", "Classes": "None", "Text": " Invirase 500\u00a0mg ", "ParentId": "8dc89f45-894b-404f-b2a9-10007d0c0b96"}, {"Element": "<span lang=\"EN-GB\">\ncontain lactose. Patients with rare hereditary problems of galactose\nintolerance, the Lapp lactase deficiency or glucose-galactose malabsorption\nshould not take this medicine.</span>", "ID": "9d609d19-3361-4270-94af-6fd1d3d7d08c", "Styles": "None", "Classes": "None", "Text": " contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.", "ParentId": "8dc89f45-894b-404f-b2a9-10007d0c0b96"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "823aa37d-ef3a-4acc-bbef-5080481f083b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2b11d5da-5bca-4c82-9ba7-88e3ea77df15", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "823aa37d-ef3a-4acc-bbef-5080481f083b"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Patients with haemophilia: </span></i></b><span lang=\"EN-GB\">There have been reports of increased bleeding, including spontaneous\nskin haematomas and haemarthroses, in haemophiliac patients type A and B\ntreated with protease inhibitors. In some patients additional<b> </b>factor\nVIII was given. In more than half<b> </b>of the reported cases, treatment with\nprotease inhibitors was continued<b> </b>or reintroduced if treatment had been\ndiscontinued. A causal relationship has been evoked, although the mechanism of\naction has not been elucidated.<b> </b>Haemophiliac patients should therefore\nbe made aware of the possibility of increased bleeding.</span></p>", "ID": "d877ab5d-b021-4835-a863-4ef8caefebda", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Patients with haemophilia: </span></i></b>", "ID": "7ba1eeae-8e24-4f2e-b936-3b72c0f990c9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d877ab5d-b021-4835-a863-4ef8caefebda"}, {"Element": "<i><span lang=\"EN-GB\">Patients with haemophilia: </span></i>", "ID": "0291448a-a806-4068-b093-882f94be748f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7ba1eeae-8e24-4f2e-b936-3b72c0f990c9"}, {"Element": "<span lang=\"EN-GB\">Patients with haemophilia: </span>", "ID": "bd7dfbf3-8f52-43fc-8687-dd30786f7f80", "Styles": "None", "Classes": "None", "Text": "Patients with haemophilia: ", "ParentId": "0291448a-a806-4068-b093-882f94be748f"}, {"Element": "<span lang=\"EN-GB\">There have been reports of increased bleeding, including spontaneous\nskin haematomas and haemarthroses, in haemophiliac patients type A and B\ntreated with protease inhibitors. In some patients additional<b> </b>factor\nVIII was given. In more than half<b> </b>of the reported cases, treatment with\nprotease inhibitors was continued<b> </b>or reintroduced if treatment had been\ndiscontinued. A causal relationship has been evoked, although the mechanism of\naction has not been elucidated.<b> </b>Haemophiliac patients should therefore\nbe made aware of the possibility of increased bleeding.</span>", "ID": "99bae000-56b7-4bf5-9cea-11dfd2bf0227", "Styles": "None", "Classes": "None", "Text": "There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in haemophiliac patients type A and B treated with protease inhibitors. In some patients additionalfactor VIII was given. In more than halfof the reported cases, treatment with protease inhibitors was continuedor reintroduced if treatment had been discontinued. A causal relationship has been evoked, although the mechanism of action has not been elucidated.Haemophiliac patients should therefore be made aware of the possibility of increased bleeding.", "ParentId": "d877ab5d-b021-4835-a863-4ef8caefebda"}, {"Element": "<b> </b>", "ID": "0cf97c5d-deff-446e-9eef-c1100a0666b6", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "99bae000-56b7-4bf5-9cea-11dfd2bf0227"}, {"Element": "<b> </b>", "ID": "534c6dfb-4840-4627-a257-a0b39ed4b2f8", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "99bae000-56b7-4bf5-9cea-11dfd2bf0227"}, {"Element": "<b> </b>", "ID": "5d037595-7d7c-436f-9d22-86e09f374111", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "99bae000-56b7-4bf5-9cea-11dfd2bf0227"}, {"Element": "<b> </b>", "ID": "aee519a6-cadf-4b4b-85fd-61aebff2ef75", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "99bae000-56b7-4bf5-9cea-11dfd2bf0227"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "4a7bec1b-f3d8-44f9-be15-85e8f23f9bef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "7a4229e7-13cb-4063-ae1f-bff4e098ef23", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4a7bec1b-f3d8-44f9-be15-85e8f23f9bef"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fe16bdb9-25b7-465e-b52c-edc84aa2051e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7a4229e7-13cb-4063-ae1f-bff4e098ef23"}, {"Element": "<p class=\"MsoNormal\"><b><i>Weight and metabolic parameters: </i></b>An increase\nin weight and in levels of blood lipids and glucose may occur during antiretroviral\ntherapy. Such changes may in part be linked to disease control and lifestyle.\nFor lipids, there is in some cases evidence for a treatment effect, while for\nweight gain there is no strong evidence relating this to any particular\ntreatment. For monitoring of blood lipids and glucose reference is made to\nestablished HIV treatment guidelines. Lipid disorders should be managed as\nclinically appropriate.</p>", "ID": "b40f63d5-e168-4c28-8ddc-53bf78d0f1ac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. Such changes may in part be linked to disease control and lifestyle. For lipids, there is in some cases evidence for a treatment effect, while for weight gain there is no strong evidence relating this to any particular treatment. For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. Lipid disorders should be managed as clinically appropriate.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i>Weight and metabolic parameters: </i></b>", "ID": "b221d628-b01e-4d23-9116-21c20df35b9f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b40f63d5-e168-4c28-8ddc-53bf78d0f1ac"}, {"Element": "<i>Weight and metabolic parameters: </i>", "ID": "8754705f-6ed1-4c4a-89fe-d201ee66e452", "Styles": "None", "Classes": "None", "Text": "Weight and metabolic parameters: ", "ParentId": "b221d628-b01e-4d23-9116-21c20df35b9f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2ef5adb1-a8e5-42eb-b300-cddfc1dedbb7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "42682a1a-813f-45d5-8636-3b1c23cbad86", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2ef5adb1-a8e5-42eb-b300-cddfc1dedbb7"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><i><span lang=\"EN-GB\">Osteonecrosis:</span></i></b><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">Although the aetiology is considered to be\nmultifactorial (including corticosteroid use, alcohol consumption, severe\nimmunosuppression, higher body mass index), cases of osteonecrosis have been\nreported particularly in patients with advanced HIV\u2013disease and/or\nlong-term exposure to combination antiretroviral therapy (CART). Patients should\nbe advised to seek medical advice if they experience joint aches and pain,\njoint stiffness or difficulty in movement.</span></p>", "ID": "722747ee-3534-4825-8c59-90ac7746eb93", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Osteonecrosis:</span></i></b>", "ID": "b57a2ef0-2618-40ae-8eb4-bd26113a5430", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "722747ee-3534-4825-8c59-90ac7746eb93"}, {"Element": "<i><span lang=\"EN-GB\">Osteonecrosis:</span></i>", "ID": "e15b8b25-38da-4945-8c27-119a92015524", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b57a2ef0-2618-40ae-8eb4-bd26113a5430"}, {"Element": "<span lang=\"EN-GB\">Osteonecrosis:</span>", "ID": "0af84347-51ed-45b5-b1b5-824a857d88ce", "Styles": "None", "Classes": "None", "Text": "Osteonecrosis:", "ParentId": "e15b8b25-38da-4945-8c27-119a92015524"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "3da317e0-7707-442e-827f-5fb4731ad7b9", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "722747ee-3534-4825-8c59-90ac7746eb93"}, {"Element": "<span lang=\"EN-GB\">Although the aetiology is considered to be\nmultifactorial (including corticosteroid use, alcohol consumption, severe\nimmunosuppression, higher body mass index), cases of osteonecrosis have been\nreported particularly in patients with advanced HIV\u2013disease and/or\nlong-term exposure to combination antiretroviral therapy (CART). Patients should\nbe advised to seek medical advice if they experience joint aches and pain,\njoint stiffness or difficulty in movement.</span>", "ID": "1cf9ff0b-f479-454b-bf41-9fd88e36cf7c", "Styles": "None", "Classes": "None", "Text": "Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV\u2013disease and/or long-term exposure to combination antiretroviral therapy (CART). Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.", "ParentId": "722747ee-3534-4825-8c59-90ac7746eb93"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "889ab686-f72b-44b8-a8f2-50bb1172dad5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e0d6fc3b-639d-4e48-9cc7-37331b70307f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "889ab686-f72b-44b8-a8f2-50bb1172dad5"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Immune Reactivation Syndrome:</span></i></b><span lang=\"EN-GB\"> In HIV-infected patients with severe immune deficiency at the time\nof institution of combination antiretroviral therapy (CART), an inflammatory\nreaction to asymptomatic or residual opportunistic pathogens may arise and\ncause serious clinical conditions, or aggravation of symptoms. Typically, such\nreactions have been observed within the first few weeks or months of initiation\nof CART. Relevant examples are cytomegalovirus retinitis, generalised and/or\nfocal mycobacterial infections, and Pneumocystis carinii pneumonia. Any\ninflammatory symptoms should be evaluated and treatment instituted when\nnecessary.</span></p>", "ID": "7fd0f629-75cc-40b1-9cf4-8edfa10d1044", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Immune Reactivation Syndrome:</span></i></b>", "ID": "d10202d5-26f2-4068-9c6d-5d71e5bce60f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7fd0f629-75cc-40b1-9cf4-8edfa10d1044"}, {"Element": "<i><span lang=\"EN-GB\">Immune Reactivation Syndrome:</span></i>", "ID": "0865d96f-50b4-43f9-b85f-976c01b70f74", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d10202d5-26f2-4068-9c6d-5d71e5bce60f"}, {"Element": "<span lang=\"EN-GB\">Immune Reactivation Syndrome:</span>", "ID": "8e209a69-9e7e-4b47-9684-cffe50314b10", "Styles": "None", "Classes": "None", "Text": "Immune Reactivation Syndrome:", "ParentId": "0865d96f-50b4-43f9-b85f-976c01b70f74"}, {"Element": "<span lang=\"EN-GB\"> In HIV-infected patients with severe immune deficiency at the time\nof institution of combination antiretroviral therapy (CART), an inflammatory\nreaction to asymptomatic or residual opportunistic pathogens may arise and\ncause serious clinical conditions, or aggravation of symptoms. Typically, such\nreactions have been observed within the first few weeks or months of initiation\nof CART. Relevant examples are cytomegalovirus retinitis, generalised and/or\nfocal mycobacterial infections, and Pneumocystis carinii pneumonia. Any\ninflammatory symptoms should be evaluated and treatment instituted when\nnecessary.</span>", "ID": "f9d401fd-354b-4231-b5be-8d37b3a35021", "Styles": "None", "Classes": "None", "Text": " In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis carinii pneumonia. Any inflammatory symptoms should be evaluated and treatment instituted when necessary.", "ParentId": "7fd0f629-75cc-40b1-9cf4-8edfa10d1044"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "35b24c9e-5b3a-44a4-a1a5-a7a4e1ff8c61", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "01eebdf5-4bae-4ce8-89d6-6426b363c17b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "35b24c9e-5b3a-44a4-a1a5-a7a4e1ff8c61"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Autoimmune disorders (such as Graves\u2019\ndisease and autoimmune hepatitis) have also been reported to occur in the\nsetting of immune reactivation; however, the reported time to onset is more\nvariable and can occur many months after initiation of treatment.</span></p>", "ID": "ceb02de9-af79-45e8-881b-328c4f8170cd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Autoimmune disorders (such as Graves\u2019\ndisease and autoimmune hepatitis) have also been reported to occur in the\nsetting of immune reactivation; however, the reported time to onset is more\nvariable and can occur many months after initiation of treatment.</span>", "ID": "3fdc3bfc-f6bd-4a92-9521-54943d907d56", "Styles": "None", "Classes": "None", "Text": "Autoimmune disorders (such as Graves\u2019 disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and can occur many months after initiation of treatment.", "ParentId": "ceb02de9-af79-45e8-881b-328c4f8170cd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4f48fa72-0603-4cd3-89cd-4be0b2687fb1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "00d3e383-9b1a-4e02-b309-36832aed0b6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4f48fa72-0603-4cd3-89cd-4be0b2687fb1"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">CYP3A4 Interactions</span></i></b><span lang=\"EN-GB\">: Saquinavir could interact and modify the pharmacokinetics of other\ndrugs that are substrates for CYP3A4 and/or P-gp and should be used with\ncaution. Conversely, other drugs that induce CYP3A4 may also reduce saquinavir\nplasma concentrations. Monitoring of saquinavir plasma concentration might be\nindicated. See table 1, section 4.5, for drugs known and/or having the\npotential to interact with saquinavir and specific recommendations.</span></p>", "ID": "907c8f16-8fb1-49d8-979d-8e37d65b8e6b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">CYP3A4 Interactions</span></i></b>", "ID": "1a1a880e-ef47-4fe2-b6ce-a32e779c9b06", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "907c8f16-8fb1-49d8-979d-8e37d65b8e6b"}, {"Element": "<i><span lang=\"EN-GB\">CYP3A4 Interactions</span></i>", "ID": "657ff9c1-3dd9-4e89-99cc-86db8b955ee7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1a1a880e-ef47-4fe2-b6ce-a32e779c9b06"}, {"Element": "<span lang=\"EN-GB\">CYP3A4 Interactions</span>", "ID": "36ad2851-5577-4acd-bf8f-ecf0094ceb54", "Styles": "None", "Classes": "None", "Text": "CYP3A4 Interactions", "ParentId": "657ff9c1-3dd9-4e89-99cc-86db8b955ee7"}, {"Element": "<span lang=\"EN-GB\">: Saquinavir could interact and modify the pharmacokinetics of other\ndrugs that are substrates for CYP3A4 and/or P-gp and should be used with\ncaution. Conversely, other drugs that induce CYP3A4 may also reduce saquinavir\nplasma concentrations. Monitoring of saquinavir plasma concentration might be\nindicated. See table 1, section 4.5, for drugs known and/or having the\npotential to interact with saquinavir and specific recommendations.</span>", "ID": "1d61d5e7-0242-47f2-bd79-aba28ce4d669", "Styles": "None", "Classes": "None", "Text": ": Saquinavir could interact and modify the pharmacokinetics of other drugs that are substrates for CYP3A4 and/or P-gp and should be used with caution. Conversely, other drugs that induce CYP3A4 may also reduce saquinavir plasma concentrations. Monitoring of saquinavir plasma concentration might be indicated. See table 1, section 4.5, for drugs known and/or having the potential to interact with saquinavir and specific recommendations.", "ParentId": "907c8f16-8fb1-49d8-979d-8e37d65b8e6b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e5783a61-d8f9-4e1e-bfce-11b477eab19f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Interaction\nwith ritonavir:</span></i></b><span lang=\"EN-GB\"> The recommended dose of\nInvirase and ritonavir is 1000\u00a0mg Invirase plus 100\u00a0mg ritonavir </span>twice\ndaily<span lang=\"EN-GB\">. Higher doses of ritonavir have been shown to be\nassociated with an increased incidence of adverse events. Co-administration of\nsaquinavir and ritonavir has led to severe adverse events, mainly diabetic\nketoacidosis and liver disorders, especially in patients with pre-existing\nliver disease. </span></p>", "ID": "e979aee7-9d8e-49dc-a4e5-3a03bc2fa9f6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "twice daily", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Interaction\nwith ritonavir:</span></i></b>", "ID": "edf5ca26-02b2-4c44-ac16-24f09b113e05", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e979aee7-9d8e-49dc-a4e5-3a03bc2fa9f6"}, {"Element": "<i><span lang=\"EN-GB\">Interaction\nwith ritonavir:</span></i>", "ID": "12bec570-ba73-4049-92ef-c63f474081bd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "edf5ca26-02b2-4c44-ac16-24f09b113e05"}, {"Element": "<span lang=\"EN-GB\">Interaction\nwith ritonavir:</span>", "ID": "9587c7ba-57ca-41a6-852b-7cf24f54ce57", "Styles": "None", "Classes": "None", "Text": "Interaction with ritonavir:", "ParentId": "12bec570-ba73-4049-92ef-c63f474081bd"}, {"Element": "<span lang=\"EN-GB\"> The recommended dose of\nInvirase and ritonavir is 1000\u00a0mg Invirase plus 100\u00a0mg ritonavir </span>", "ID": "b259cccd-18b2-4bb5-9f6c-cea35761aed1", "Styles": "None", "Classes": "None", "Text": " The recommended dose of Invirase and ritonavir is 1000\u00a0mg Invirase plus 100\u00a0mg ritonavir ", "ParentId": "e979aee7-9d8e-49dc-a4e5-3a03bc2fa9f6"}, {"Element": "<span lang=\"EN-GB\">. Higher doses of ritonavir have been shown to be\nassociated with an increased incidence of adverse events. Co-administration of\nsaquinavir and ritonavir has led to severe adverse events, mainly diabetic\nketoacidosis and liver disorders, especially in patients with pre-existing\nliver disease. </span>", "ID": "b69e2ecc-4857-45a7-a1d3-243ccf6d536c", "Styles": "None", "Classes": "None", "Text": ". Higher doses of ritonavir have been shown to be associated with an increased incidence of adverse events. Co-administration of saquinavir and ritonavir has led to severe adverse events, mainly diabetic ketoacidosis and liver disorders, especially in patients with pre-existing liver disease. ", "ParentId": "e979aee7-9d8e-49dc-a4e5-3a03bc2fa9f6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0344d12f-3f5a-4e6f-81ed-d496b4f7a84e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e7903ce2-47fe-4421-bf2a-69e311a58551", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0344d12f-3f5a-4e6f-81ed-d496b4f7a84e"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Interaction with tipranavir: </span></i></b>Concomitant\nuse of boosted saquinavir and tipranavir, co-administered with low dose\nritonavir in a dual-boosted regimen, results in a significant decrease in\nsaquinavir plasma concentrations (see section 4.5). Therefore, the\nco-administration of boosted saquinavir and tipranavir, co-administered with\nlow dose ritonavir, is not recommended.</p>", "ID": "06dd31f1-26bf-44bd-bc80-d1846a6d64a7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Concomitant use of boosted saquinavir and tipranavir, co-administered with low dose ritonavir in a dual-boosted regimen, results in a significant decrease in saquinavir plasma concentrations (see section 4.5). Therefore, the co-administration of boosted saquinavir and tipranavir, co-administered with low dose ritonavir, is not recommended.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Interaction with tipranavir: </span></i></b>", "ID": "cc494bcc-050b-4bde-9771-a71f8295cbdc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "06dd31f1-26bf-44bd-bc80-d1846a6d64a7"}, {"Element": "<i><span lang=\"EN-GB\">Interaction with tipranavir: </span></i>", "ID": "fccf8550-1a81-400e-8b44-fae1bd36b89d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cc494bcc-050b-4bde-9771-a71f8295cbdc"}, {"Element": "<span lang=\"EN-GB\">Interaction with tipranavir: </span>", "ID": "5171db2c-eca8-4eec-a5c1-3f74189d523b", "Styles": "None", "Classes": "None", "Text": "Interaction with tipranavir: ", "ParentId": "fccf8550-1a81-400e-8b44-fae1bd36b89d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "95331c70-017c-48a6-bcf1-f48552714248", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6192d8e2-1106-43e0-a4d7-f1512e5180f4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "95331c70-017c-48a6-bcf1-f48552714248"}, {"Element": "<p class=\"MsoNormal\"><b><i>Interaction with HMG-CoA reductase inhibitors:</i></b><i>\n</i>Caution must be exercised if Invirase/ritonavir is used concurrently with\natorvastatin, which is metabolised to a lesser extent by CYP3A4. In this\nsituation a reduced dose of atorvastatin should be considered. If treatment\nwith a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is\nrecommended with careful monitoring (see section 4.5).</p>", "ID": "6b0dd563-b635-42f1-a34d-bd953b7ceec3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Caution must be exercised if Invirase/ritonavir is used concurrently with atorvastatin, which is metabolised to a lesser extent by CYP3A4. In this situation a reduced dose of atorvastatin should be considered. If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended with careful monitoring (see section 4.5).", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i>Interaction with HMG-CoA reductase inhibitors:</i></b>", "ID": "456b727f-fb30-4570-aa79-46e3e03956d8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6b0dd563-b635-42f1-a34d-bd953b7ceec3"}, {"Element": "<i>Interaction with HMG-CoA reductase inhibitors:</i>", "ID": "97c5f68e-7fef-4f03-9c59-abaf342dd80b", "Styles": "None", "Classes": "None", "Text": "Interaction with HMG-CoA reductase inhibitors:", "ParentId": "456b727f-fb30-4570-aa79-46e3e03956d8"}, {"Element": "<i>\n</i>", "ID": "d4648c88-945e-433b-a566-0416267519b4", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "6b0dd563-b635-42f1-a34d-bd953b7ceec3"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "35ed6a9f-33b1-4dfd-a921-ba80b6267eb6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><b><i>Oral contraceptives:</i></b><i> </i>Because\nconcentration of ethinyl estradiol may be decreased when co-administered with\nInvirase/ritonavir, alternative or additional contraceptive measures should be\nused when oestrogen-based oral contraceptives are co-administered (see section\n4.5).</p>", "ID": "4eba0164-ace4-4a7f-aeab-32e316993bfe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Because concentration of ethinyl estradiol may be decreased when co-administered with Invirase/ritonavir, alternative or additional contraceptive measures should be used when oestrogen-based oral contraceptives are co-administered (see section 4.5).", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i>Oral contraceptives:</i></b>", "ID": "77b174bc-ba3a-483f-9082-2f21daff5698", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4eba0164-ace4-4a7f-aeab-32e316993bfe"}, {"Element": "<i>Oral contraceptives:</i>", "ID": "f4e4204c-cad9-452e-a2c3-c38088c11963", "Styles": "None", "Classes": "None", "Text": "Oral contraceptives:", "ParentId": "77b174bc-ba3a-483f-9082-2f21daff5698"}, {"Element": "<i> </i>", "ID": "ed0c129e-af99-489f-a638-d208445b2fae", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "4eba0164-ace4-4a7f-aeab-32e316993bfe"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "5d09c6ef-33c2-4135-857e-cc9c3fdcae0c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><b><i>Glucocorticoids: </i></b>Concomitant use of boosted\nsaquinavir and fluticasone or other glucocorticoids that are metabolised by\nCYP3A4 is not recommended unless the potential benefit of treatment outweighs\nthe risk of systemic corticosteroid effects, including Cushing's syndrome and\nadrenal suppression (see section 4.5).</p>", "ID": "a8c6a463-4e39-47ae-b123-7b0963f4d907", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Concomitant use of boosted saquinavir and fluticasone or other glucocorticoids that are metabolised by CYP3A4 is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression (see section 4.5).", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i>Glucocorticoids: </i></b>", "ID": "3f8c2800-f2da-44b7-832c-8006eb01f95f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a8c6a463-4e39-47ae-b123-7b0963f4d907"}, {"Element": "<i>Glucocorticoids: </i>", "ID": "a783a0e3-a162-46ac-b0ef-f3a8fbc6a9be", "Styles": "None", "Classes": "None", "Text": "Glucocorticoids: ", "ParentId": "3f8c2800-f2da-44b7-832c-8006eb01f95f"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "96d69fad-c274-427a-bfde-e489e4662ad4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><i>Interaction with\nefavirenz:</i></b> The combination of saquinavir and ritonavir with efavirenz\nhas been shown to be associated with an increased risk of liver toxicity; liver\nfunction should be monitored when saquinavir and ritonavir are co-administered\nwith efavirenz. No clinically significant alterations of either saquinavir or efavirenz\nconcentration were noted in studies in healthy volunteers or in HIV-infected\npatients (see section 4.5).</p>", "ID": "11dbe647-4d49-4e6c-911b-d8eb36dbf187", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": " The combination of saquinavir and ritonavir with efavirenz has been shown to be associated with an increased risk of liver toxicity; liver function should be monitored when saquinavir and ritonavir are co-administered with efavirenz. No clinically significant alterations of either saquinavir or efavirenz concentration were noted in studies in healthy volunteers or in HIV-infected patients (see section 4.5).", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i>Interaction with\nefavirenz:</i></b>", "ID": "9aefc11b-83c3-472f-89b6-245c1cec6e16", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "11dbe647-4d49-4e6c-911b-d8eb36dbf187"}, {"Element": "<i>Interaction with\nefavirenz:</i>", "ID": "73b2a1d0-3c30-4e2b-b4c9-d14371464d89", "Styles": "None", "Classes": "None", "Text": "Interaction with efavirenz:", "ParentId": "9aefc11b-83c3-472f-89b6-245c1cec6e16"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "edd4d49a-4788-4731-9875-b2238372ac6f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other\nmedicinal products and other forms of interaction</span></b></p>", "ID": "a54ebee5-9536-439e-afa9-22ca622ef4ca", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other\nmedicinal products and other forms of interaction</span></b>", "ID": "5728f88a-1976-499c-b2b2-dd11e033f401", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a54ebee5-9536-439e-afa9-22ca622ef4ca"}, {"Element": "<span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other\nmedicinal products and other forms of interaction</span>", "ID": "72346142-41e0-41a9-be48-c6e28b13bad8", "Styles": "None", "Classes": "None", "Text": "4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other medicinal products and other forms of interaction", "ParentId": "5728f88a-1976-499c-b2b2-dd11e033f401"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bce7bf7b-8e2c-44a5-a092-e567a3d18f04", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "70066fb9-3231-4f6b-b5f9-1e4466113a50", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bce7bf7b-8e2c-44a5-a092-e567a3d18f04"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Most drug\ninteraction studies with saquinavir have been completed with unboosted Invirase\nor unboosted saquinavir soft capsules. A limited number of studies have been\ncompleted with ritonavir boosted Invirase or ritonavir boosted saquinavir soft\ncapsules.</span></p>", "ID": "303b36ba-0154-44e1-9c5e-94671a812ec3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Most drug\ninteraction studies with saquinavir have been completed with unboosted Invirase\nor unboosted saquinavir soft capsules. A limited number of studies have been\ncompleted with ritonavir boosted Invirase or ritonavir boosted saquinavir soft\ncapsules.</span>", "ID": "76ef3d4a-691a-490e-a27b-33006b46b427", "Styles": "None", "Classes": "None", "Text": "Most drug interaction studies with saquinavir have been completed with unboosted Invirase or unboosted saquinavir soft capsules. A limited number of studies have been completed with ritonavir boosted Invirase or ritonavir boosted saquinavir soft capsules.", "ParentId": "303b36ba-0154-44e1-9c5e-94671a812ec3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "499eb7c6-b09d-4245-ad07-c844c118dad6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8d928c75-78d8-474e-a9c3-7a647ca2c3dd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "499eb7c6-b09d-4245-ad07-c844c118dad6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Observations\nfrom drug interaction studies done with unboosted saquinavir might not be\nrepresentative of the effects seen with saquinavir/ritonavir therapy.\nFurthermore, results seen with saquinavir soft capsules may not predict the\nmagnitude of these interactions with Invirase/ritonavir.</span></p>", "ID": "a71ab759-6ab2-48ce-b829-c3d40f7f9e68", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Observations\nfrom drug interaction studies done with unboosted saquinavir might not be\nrepresentative of the effects seen with saquinavir/ritonavir therapy.\nFurthermore, results seen with saquinavir soft capsules may not predict the\nmagnitude of these interactions with Invirase/ritonavir.</span>", "ID": "9b35f9b7-97fd-4162-af4f-5b13a399459b", "Styles": "None", "Classes": "None", "Text": "Observations from drug interaction studies done with unboosted saquinavir might not be representative of the effects seen with saquinavir/ritonavir therapy. Furthermore, results seen with saquinavir soft capsules may not predict the magnitude of these interactions with Invirase/ritonavir.", "ParentId": "a71ab759-6ab2-48ce-b829-c3d40f7f9e68"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8e732a21-3c87-4ac3-8538-9535aea99cd3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2da4eaf4-3c5c-4846-9947-ddb57c2b2cb9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8e732a21-3c87-4ac3-8538-9535aea99cd3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The metabolism of saquinavir is mediated by\ncytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90\u00a0%\nof the hepatic metabolism. Additionally, <i>in vitro</i> studies have shown\nthat saquinavir is a substrate and an inhibitor for P-glycoprotein (P-gp).\nTherefore, medicinal products that either share this metabolic pathway or\nmodify CYP3A4 and/or P-gp activity (see <i>\"Other potential\ninteractions\"</i>) may modify the pharmacokinetics of saquinavir.\nSimilarly, saquinavir might also modify the pharmacokinetics of other medicinal\nproducts that are substrates for CYP3A4 or P-gp.</span></p>", "ID": "2b7369bf-3422-4a7e-ae3d-a60e31702e20", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">The metabolism of saquinavir is mediated by\ncytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90\u00a0%\nof the hepatic metabolism. Additionally, <i>in vitro</i> studies have shown\nthat saquinavir is a substrate and an inhibitor for P-glycoprotein (P-gp).\nTherefore, medicinal products that either share this metabolic pathway or\nmodify CYP3A4 and/or P-gp activity (see <i>\"Other potential\ninteractions\"</i>) may modify the pharmacokinetics of saquinavir.\nSimilarly, saquinavir might also modify the pharmacokinetics of other medicinal\nproducts that are substrates for CYP3A4 or P-gp.</span>", "ID": "1c34006d-f545-4bef-8627-2701b360c8a1", "Styles": "None", "Classes": "None", "Text": "The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90\u00a0% of the hepatic metabolism. Additionally,  studies have shown that saquinavir is a substrate and an inhibitor for P-glycoprotein (P-gp). Therefore, medicinal products that either share this metabolic pathway or modify CYP3A4 and/or P-gp activity (see ) may modify the pharmacokinetics of saquinavir. Similarly, saquinavir might also modify the pharmacokinetics of other medicinal products that are substrates for CYP3A4 or P-gp.", "ParentId": "2b7369bf-3422-4a7e-ae3d-a60e31702e20"}, {"Element": "<i>in vitro</i>", "ID": "f3e9558e-0539-4181-9438-fdecc96418c6", "Styles": "None", "Classes": "None", "Text": "in vitro", "ParentId": "1c34006d-f545-4bef-8627-2701b360c8a1"}, {"Element": "<i>\"Other potential\ninteractions\"</i>", "ID": "006a6a21-48df-44a5-b7fc-21db10bfc327", "Styles": "None", "Classes": "None", "Text": "\"Other potential interactions\"", "ParentId": "1c34006d-f545-4bef-8627-2701b360c8a1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d23e4e53-be9c-4dec-8b82-69bb65768819", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "62c0b8a6-8ced-4c57-9e9f-bfef0fd9ce61", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d23e4e53-be9c-4dec-8b82-69bb65768819"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ritonavir can affect the pharmacokinetics\nof other medicinal products because it is a potent inhibitor of CYP3A4 and\nP-gp. Therefore, when saquinavir is co-administered with ritonavir,\nconsideration should be given to the potential effects of ritonavir on other\nmedicinal products (see the Summary of Product Characteristics for Norvir).</span></p>", "ID": "13189830-0944-44bb-8f50-eca6a8e21ac3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Ritonavir can affect the pharmacokinetics\nof other medicinal products because it is a potent inhibitor of CYP3A4 and\nP-gp. Therefore, when saquinavir is co-administered with ritonavir,\nconsideration should be given to the potential effects of ritonavir on other\nmedicinal products (see the Summary of Product Characteristics for Norvir).</span>", "ID": "3a921f05-faee-4b53-ba52-a56dab663434", "Styles": "None", "Classes": "None", "Text": "Ritonavir can affect the pharmacokinetics of other medicinal products because it is a potent inhibitor of CYP3A4 and P-gp. Therefore, when saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on other medicinal products (see the Summary of Product Characteristics for Norvir).", "ParentId": "13189830-0944-44bb-8f50-eca6a8e21ac3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "66ec3fb7-c522-4921-a942-d9563c6f0f68", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "abe7e11b-07c9-4a11-94a6-00198eb15ec7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "66ec3fb7-c522-4921-a942-d9563c6f0f68"}, {"Element": "<p class=\"MsoNormal\">Based on the finding of dose-dependent prolongations of QT\nand PR intervals in healthy volunteers receiving Invirase/ritonavir (see\nsections 4.3, 4.4 and 5.1), additive effects on QT and PR interval prolongation\nmay occur. Therefore, concomitant use of ritonavir-boosted Invirase with other\nmedicinal products that prolong the QT and/or PR interval is contraindicated.\nThe combination of Invirase/ritonavir with drugs known to increase the exposure\nof saquinavir is not recommended and should be avoided when alternative\ntreatment options are available. If concomitant use is deemed necessary because\nthe potential benefit to the patient outweighs the risk, particular caution is\nwarranted (see section 4.4; for information on individual drugs, see Table 1).</p>", "ID": "97e56371-2d14-487b-93bb-ab9072da5716", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Based on the finding of dose-dependent prolongations of QT and PR intervals in healthy volunteers receiving Invirase/ritonavir (see sections 4.3, 4.4 and 5.1), additive effects on QT and PR interval prolongation may occur. Therefore, concomitant use of ritonavir-boosted Invirase with other medicinal products that prolong the QT and/or PR interval is contraindicated. The combination of Invirase/ritonavir with drugs known to increase the exposure of saquinavir is not recommended and should be avoided when alternative treatment options are available. If concomitant use is deemed necessary because the potential benefit to the patient outweighs the risk, particular caution is warranted (see section 4.4; for information on individual drugs, see Table 1).", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "9072f50a-02c3-4589-b719-e81c238c78b0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Table\u00a01: Interactions\nand dose recommendations with other medicinal products</p>", "ID": "d715e4bb-0495-4c1e-bec2-329924d33353", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Table\u00a01: Interactions and dose recommendations with other medicinal products", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "7126b7a3-ce3b-4354-832c-477f28e066c4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"650\">\n<thead>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Medicinal product by\n   therapeutic area (dose of Invirase used in study)</b></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Interaction</b></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Recommendations\n   concerning co-administration</b></p>\n</td>\n</tr>\n</thead>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><u>Antiretroviral\n  agents<br/>\n</u>Nucleoside reverse transcriptase inhibitors (NRTIs)</i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Zalcitabine and/or<br/>\n  Zidovudine<br/>\n<br/>\n</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">No pharmacokinetic\n  interaction studies have been completed. </p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Use of\n  unboosted saquinavir with zalcitabine and/or zidovudine has been studied in\n  adults. Absorption, distribution and elimination of each of the drugs are\n  unchanged when they are used together.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  zalcitabine is unlikely due to different routes of metabolism and excretion.<br/>\n  For zidovudine (200\u00a0mg every 8 hours) a 25\u00a0% decrease in AUC was\n  reported when combined with ritonavir (300\u00a0mg every 6 hours). The\n  pharmacokinetics of ritonavir remained unchanged.</p>\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">No dose adjustment </span>required<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Didanosine<br/>\n  400\u00a0mg single dose<br/>\n  (saquinavir/ritonavir 1600/100\u00a0mg qd)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 30%<br/>\n  Saquinavir C<sub>max</sub> </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 25%<br/>\n  Saquinavir C<sub>min </sub></span><span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Tenofovir disoproxil fumarate 300\u00a0mg qd<br/>\n  (<span lang=\"EN-GB\">saquinavir/ritonavir</span> 1000/100\u00a0mg bid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 1%<br/>\n  Saquinavir C<sub>max</sub> </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 7%<br/>\n  Saquinavir C<sub>min </sub></span><span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Non-nucleoside\n  reverse transcriptase inhibitors (NNRTIs)</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Delavirdine<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Delavirdine<br/>\n  (unboosted saquinavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC \u2191\n  348%.<br/>\n  There are limited safety and no efficacy data available from the use of this\n  combination. In a small, preliminary study, hepatocellular enzyme elevations\n  occurred in 13\u00a0% of subjects during the first several weeks of the\n  delavirdine and saquinavir combination (6\u00a0% Grade 3 or 4).</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatocellular\n  changes should be monitored frequently if this combination is prescribed.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Efavirenz 600\u00a0mg qd<br/>\n  (<span lang=\"EN-GB\">saquinavir/ritonavir</span> 1600/200\u00a0mg qd, <i><u>or</u></i><br/>\n<span lang=\"EN-GB\">saquinavir/ritonavir 1000/100\u00a0mg</span><span lang=\"EN-GB\"> bid, <i><u>or</u></i> </span><br/>\n  saquinavir/ritonavir 1200/100\u00a0mg qd)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Saquinavir </span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"PT-BR\"><br/>\n  Efavirenz </span><span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required. </span>Liver\n  function should be monitored (see section 4.4).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Rilpivirine</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Switching directly from a\n  rilpivirine containing regimen to Invirase/ritonavir is contraindicated as is\n  concomitant use due to the potential for life threatening cardiac arrhythmia\n  (see sections 4.3 and 4.4).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Nevirapine<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:12.6pt;text-indent:-12.6pt;\n  page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Nevirapine<br/>\n  (unboosted saquinavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC <span style=\"font-family:Symbol\">\u00af</span> 24%<br/>\n  Nevirapine AUC <span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">No dose adjustment required.</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"IT\">HIV protease inhibitors (PIs)</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Atazanavir\n  300\u00a0mg qd<br/>\n  (saquinavir/ritonavir 1600/100\u00a0mg qd)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Saquinavir\n  AUC \u2191 60%<br/>\n  Saquinavir C<sub>max</sub> \u2191 42%</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Ritonavir\n  AUC \u2191 41%<br/>\n  Ritonavir C<sub>max</sub> \u2191 34%<br/>\n  Atazanavir </span><span style=\"font-family:Symbol\">\u00ab</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">No clinical data\n  available for the combination of <span lang=\"EN-GB\">saquinavir/ritonavir</span>\n  1000/100\u00a0mg bid and atazanavir.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Fosamprenavir<br/>\n  700\u00a0mg bid</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">(saquinavir/ritonavir\n  1000/100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC <span style=\"font-family:Symbol\">\u00af</span> 15%<br/>\n  Saquinavir C<sub>max</sub> <span style=\"font-family:Symbol\">\u00af</span> 9%</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir C<sub>min</sub>\n<span style=\"font-family:Symbol\">\u00af</span> 24% (remained above the target\n  threshold for effective therapy.)</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">No dose\n  adjustment required</span><span lang=\"EN-GB\"> for Invirase/ritonavir</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Indinavir<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Low dose ritonavir\n  increases the concentration of indinavir.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Increased\n  concentrations of indinavir may result in nephrolithiasis.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Indinavir 800\u00a0mg tid<br/>\n  (saquinavir 600-1200\u00a0mg single dose)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC \u2191\n  4.6-7.2 fold<br/>\n  Indinavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  No safety and efficacy data available for this combination. Appropriate doses\n  of combination not established.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Lopinavir/ritonavir 400/100\u00a0mg bid<br/>\n  (<span lang=\"EN-GB\">saquinavir</span> 1000\u00a0mg bid in combination with 2 or\n  3 NRTIs)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Saquinavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  Ritonavir <span style=\"font-family:Symbol\">\u00af</span> (effectiveness as\n  boosting agent not modified).</p>\n<p class=\"MsoNormal\">Lopinavir <span style=\"font-family:Symbol\">\u00ab</span>\n  (based on historical comparison with unboosted lopinavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">\u00a0Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the potential for life\n  threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Nelfinavir 1250\u00a0mg bid<br/>\n  (saquinavir/ritonavir 1000/100\u00a0mg bid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC \u2191\n  13%<br/>\n  (90% CI: 27<span style=\"font-family:Symbol\">\u00af</span> - 74\u2191)<br/>\n  Saquinavir Cmax \u2191 9%<br/>\n  (90% CI: 27<span style=\"font-family:Symbol\">\u00af</span> - 61\u2191 )<br/>\n  Nelfinavir AUC <span style=\"font-family:Symbol\">\u00af</span> 6%<br/>\n  (90% CI: 28<span style=\"font-family:Symbol\">\u00af</span> - 22\u2191)<br/>\n  Nelfinavir Cmax <span style=\"font-family:Symbol\">\u00af</span> 5%<br/>\n  (90% CI: 23<span style=\"font-family:Symbol\">\u00af</span> - 16\u2191)</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;page-break-after:avoid\">Combination\n  not recommended.</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Ritonavir 100\u00a0mg bid<br/>\n  (saquinavir 1000\u00a0mg bid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir \u2191</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Ritonavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n<span lang=\"EN-GB\">In HIV-infected patients, Invirase or saquinavir soft\n  capsules in combination with ritonavir at doses of 1000/100\u00a0mg twice\n  daily provide a systemic exposure of saquinavir over a 24 hour period similar\n  to or greater than that achieved with saquinavir soft capsules 1200\u00a0mg\n  three times daily (see section 5.2).</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">This is\n  the approved combination regimen. No dose adjustment is recommended.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Tipranavir/ritonavir<br/>\n  (<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Saquinavir C<sub>min</sub> <span style=\"font-family:\n  Symbol\">\u00af</span> 78%<br/>\n  Dual-boosted protease inhibitor combination therapy in multiple-treatment\n  experienced HIV-positive adults.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Concomitant administration of tipranavir,\n  co-administered with low dose ritonavir, with saquinavir/ritonavir, is not\n  recommended. If the combination is considered necessary, monitoring of the\n  saquinavir plasma levels is strongly encouraged (see section 4.4).</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"IT\">HIV fusion inhibitor</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Enfuvirtide<br/>\n  (saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Saquinavir <span style=\"font-family:Symbol\">\u00ab</span></p>\n<p class=\"Normal11pt0\">Enfuvirtide <span style=\"font-family:Symbol\">\u00ab</span><br/>\n<span lang=\"EN-GB\">No clinically significant interaction was noted.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required.</span></p>\n</td>\n</tr>\n<tr style=\"height:12.9pt\">\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">HIV </span></i></b><b><i>CCR5\n  antagonist</i></b></p>\n</td>\n</tr>\n<tr style=\"height:53.85pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"177\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Maraviroc\n  100\u00a0mg bid</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">(saquinavir/ritonavir\n  1000/100\u00a0mg bid)</span></p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"236\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Maraviroc AUC<sub>12</sub>\n  \u2191 8.77</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Maraviroc C<sub>max</sub>:\n  \u2191 3.78</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir/ritonavir\n  concentrations not measured, no effect is expected.</p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"237\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">No dose\n  adjustment of saquinavir/ritonavir is required. Dose of maraviroc should be decreased\n  to 150\u00a0mg bid with monitoring.</span></p>\n</td>\n</tr>\n<tr style=\"height:12.9pt\">\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Cobicistat\n  containing medicinal products</span></i></b></p>\n</td>\n</tr>\n<tr style=\"height:53.85pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"177\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Cobicistat</span></p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"236\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied. Cobicistat is not recommended in combination\n  with regimens containing ritonavir due to similar effects of cobicistat and\n  ritonavir on CYP3A.</p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"237\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">It is\n  not recommended to coadminister Invirase/ritonavir with cobicistat containing\n  products (see section 4.4). <a name=\"_GoBack\"></a></span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><u>Other medicinal\n  products<br/>\n</u></i></b><b><i><span lang=\"IT\">\u00a0Alpha-1 adrenoreceptor antagonist</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:66.0pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:66.0pt\" valign=\"top\" width=\"177\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Alfuzosin\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:66.0pt\" valign=\"top\" width=\"236\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Concomitant use\n  of alfuzosin and saquinavir/ritonavir is expected to increase plasma levels\n  of alfuzosin.</span></p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:66.0pt\" valign=\"top\" width=\"237\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Contraindicated\n  in combination with Invirase/ritonavir due to potential increase in alfuzosin\n  concentration which can result in hypotension and potentially\n  life-threatening cardiac arrhythmia.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Antiarrhythmics</i></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Bepridil<br/>\n  Lidocaine (systemic) Quinidine<br/>\n  Hydroquinidine<br/>\n</span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of bepridil</span>, systemic<span lang=\"EN-GB\"><br/>\n  lidocaine, quinidine or hydroquinidine may be increased when co-administered\n  with Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"ES\">Amiodarone<br/>\n  flecainide<br/>\n  propafenone<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of </span>amiodarone,\n  flecainide or propafenone<span lang=\"EN-GB\"> may be increased when\n  co-administered with Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">saquinavir/ritonavir</span>\n  due to potentially life threatening cardiac arrhythmia (see section 4.3).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Dofetilide<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to potentially\n  life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Ibutilide<br/>\n  Sotalol<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Anticoagulant</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Warfarin</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of warfarin may be affected </span>when co-administered with\n  Invirase/ritonavir<span lang=\"EN-GB\">.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">INR\n  (international normalised ratio) monitoring recommended.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Anticonvulsants</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\"><span lang=\"IT\">-\u00a0 Carbamazepine Phenobarbital<br/>\n  Phenytoin<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">These\n  medicinal products will induce CYP3A4 and may therefore decrease saquinavir\n  concentrations</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution.</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Monitoring of saquinavir\n  plasma concentration is recommended (see section 4.4)</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Antidepressants</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Tricyclic\n  antidepressants <br/>\n  (e.g. amitriptyline, imipramine, clomipramine) (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase/ritonavir</span>\n  may increase concentrations of tricyclic antidepressants.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Maprotiline</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Maprotiline\u2019s\n  metabolism appears to involve the cytochrome P450 isozymes CYP2D6 and CYP 1A2</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Associated\n  with a prolongation of QTc intervals.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with Invirase/ritonavir due to potentially life threatening\n  cardiac arrhythmia (see sections 4.3 and 4.4).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Nefazodone<u><br/>\n</u></span><span lang=\"IT\">(saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with saquinavir/ritonavir not evaluated.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nefazodone\n  inhibits CYP3A4. Saquinavir concentrations may be increased.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Combination not\n  recommended. Use with caution due to possible cardiac arrhythmias. Monitoring\n  for saquinavir toxicity recommended (see section 4.4).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Trazodone<br/>\n</span><span lang=\"IT\">(saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Plasma concentrations of\n  trazodone may increase.<br/>\n  Adverse events of nausea, dizziness, hypotension and syncope have been\n  observed following coadministration of trazodone and ritonavir.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr style=\"height:12.9pt\">\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Anti-gout\n  preparation</span></i></b></p>\n</td>\n</tr>\n<tr style=\"height:53.1pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.1pt\" valign=\"top\" width=\"177\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Colchicine</p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.1pt\" valign=\"top\" width=\"236\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Concomitant use of\n  colchicine and saquinavir/ritonavir is expected to increase plasma levels of\n  colchicine due to P-gp and/or CYP3A4 inhibition by the protease inhibitor.</p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.1pt\" valign=\"top\" width=\"237\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Because of a potential increase\n  of colchicine-related toxicity (neuromuscular events including\n  rhabdomyolysis), its concomitant use with saquinavir/ritonavir is not\n  recommended, especially in the case of renal or hepatic impairment (see\n  section 4.4).</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Antihistamines</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Terfenadine<br/>\n  Astemizole<u><br/>\n</u></span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Terfenadine AUC </span>\u2191, <span lang=\"EN-GB\">associated with a prolongation of QTc intervals.<br/>\n  A similar interaction with astemizole is likely.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with Invirase/ritonavir\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Mizolastine<br/>\n  (</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Anti-infectives</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Clarithromycin<u><br/>\n</u></span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Interaction with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Clarithromycin is a\n  CYP3A4 substrate and is associated with QT prolongation.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Contraindicated\n  in combination with Invirase/ritonavir due to the potential for life\n  threatening cardiac arrhythmia (see sections 4.3 and 4.4).</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Clarithromycin<br/>\n  500\u00a0mg bid<u><br/>\n</u></span>(unboosted saquinavir <span lang=\"EN-GB\">1200\u00a0mg tid</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Saquinavir\n  AUC </span>\u2191 <span lang=\"EN-GB\">177 %<br/>\n  Saquinavir C<sub>max </sub></span>\u2191 <span lang=\"EN-GB\">187</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">%<br/>\n  Clarithromycin AUC </span>\u2191 <span lang=\"EN-GB\">40 %<br/>\n  Clarithromycin C<sub>max</sub> </span>\u2191 <span lang=\"EN-GB\">40 %</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Erythromycin<u><br/>\n</u></span><span lang=\"IT\">(saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\">Erythromycin is a CYP3A4 substrate and is associated\n  with QT prolongation.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Erythromycin<br/>\n  250\u00a0mg qid<br/>\n</span>(unboosted saquinavir <span lang=\"EN-GB\">1200\u00a0mg tid</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Saquinavir\n  AUC </span>\u2191 <span lang=\"EN-GB\">99 %<br/>\n  Saquinavir C<sub>max </sub></span>\u2191 <span lang=\"EN-GB\">106</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">%<br/>\n<br/>\n</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\"><span lang=\"IT\">Fusidic acid</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\"><span lang=\"IT\">(saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Not studied. Co-administration of\n  fusidic acid and Invirase/ritonavir can cause increased plasma concentration\n  of both fusidic acid and saquinavir/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Streptogramin antibiotics<u><br/>\n</u></span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Streptogramin\n  antibiotics such as quinupristin/dalfopristin inhibit CYP3A4. </span><span lang=\"IT\">Saquinavir concentrations may be increased.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution due to\n  possible cardiac arrhythmias. <span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\"><span lang=\"FR-CH\">-\u00a0 Halofantrine<br/>\n  Pentamidine<br/>\n  Sparfloxacin<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\"><span lang=\"FR-CH\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"text-indent:.45pt;page-break-after:avoid\">Contraindicated\n  in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Antifungals</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Ketoconazole 200\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Saquinavir C<sub>max </sub></span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Ritonavir AUC </span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Ritonavir C<sub>max </sub></span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Ketoconazole AUC \u2191 168%<br/>\n  (90% CI 146%-193%)<br/>\n  Ketoconazole C<sub>max </sub>\u2191 45%<br/>\n  (90% CI 32%-59%)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required when\n  saquinavir/ritonavir combined with </span><span style=\"font-family:Symbol\">\u00a3</span>\u00a0200\u00a0mg/day\n  ketoconazole<span lang=\"EN-GB\">. </span>High doses of ketoconazole<br/>\n  (&gt; 200\u00a0mg/day) are not recommended.</p>\n</td>\n</tr>\n<tr style=\"height:76.4pt\">\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 Itraconazole<br/>\n  (saquinavir/ritonavir)</p>\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 </p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 Interaction\n  with Invirase/ritonavir not studied.</p>\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 Itraconazole\n  is a moderately potent inhibitor of CYP3A4. An interaction is possible.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution due to\n  possible cardiac arrhythmias. <span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Fluconazole/miconazole</span><u><br/>\n</u>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied. Both drugs are CYP3A4 inhibitors and may\n  increase the plasma concentration of saquinavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution due to\n  possible cardiac arrhythmias. <span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Antimycobacterials</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Rifampicin 600\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">In a clinical study 11 of\n  17 (65\u00a0%) healthy volunteers developed severe hepatocellular toxicity\n  with transaminase elevations up to &gt;\u00a020-fold the upper limit of\n  normal after 1 to 5 days of co-administration.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Rifampicin is\n  contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span><br/>\n  (see section 4.3).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Rifabutin <span lang=\"IT\">150\u00a0mg\n  q3d<br/>\n</span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span> 1000/100\u00a0mg bid) in\n  healthy volunteers</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC<sub>0-12</sub>\n<span style=\"font-family:Symbol\">\u00af</span> 13%<br/>\n  (90% CI: 31<span style=\"font-family:Symbol\">\u00af</span> - 9\u2191)<br/>\n  Saquinavir C<sub>max </sub><span style=\"font-family:Symbol\">\u00af</span> 15%<br/>\n  (90% CI: 32<span style=\"font-family:Symbol\">\u00af</span> - 7\u2191)<br/>\n  Ritonavir AUC<sub>0-12</sub> <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  (90% CI: 10<span style=\"font-family:Symbol\">\u00af</span> - 9\u2191)<br/>\n  Ritonavir C<sub>max </sub><span style=\"font-family:Symbol\">\u00ab</span><br/>\n  (90% CI: 8<span style=\"font-family:Symbol\">\u00af</span> - 7\u2191)<br/>\n<br/>\n  Rifabutin active moiety*<br/>\n  AUC<sub>0-72</sub> \u2191 134%<br/>\n  (90% CI 109%-162%)<br/>\n  Rifabutin active moiety*<br/>\n  C<sub>max </sub>\u2191 130%<br/>\n  (90% CI 98%-167%)</p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">Rifabutin AUC<sub>0-72</sub> \u2191\n  53%</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">(90% CI 36%-73%)</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">Rifabutin C<sub>max </sub>\u2191\n  86%</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\">(90% CI 57%-119%)</p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\">\u00a0</p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\">*\u00a0 Sum of rifabutin + 25-O-desacetyl rifabutin\n  metabolite </p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">To prevent possible\n  development of rifabutin resistance in TB and HIV co-infected patients, the\n  recommended dose of rifabutin is 150\u00a0mg every other day or three times\n  per week, with the dose of saquinavir/ritonavir unchanged (1000/100\u00a0mg\n  bid). </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Monitoring of neutropenia\n  and liver enzyme levels is recommended due to an expected increase in\n  exposure to rifabutin.</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><b><i>Antipsychotics</i></b></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt\">\u00a0</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Lurasidone</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Due to CYP3A inhibition by saquinavir/ritonavir,\n  concentrations of lurasidone are expected to increase.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Concomitant administration of Invirase and lurasidone is\n  contra-indicated as it may increase lurasidone-related toxicity (see section\n  4.3).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Quetiapine</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Due to CYP3A inhibition by saquinavir/ritonavir,\n  concentrations of quetiapine are expected to increase.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Concomitant administration of Invirase and quetiapine is\n  contra-indicated as it may increase quetiapine-related toxicity. Increased\n  plasma concentrations of quetiapine may lead to coma (see sectin 4.3).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Pimozide<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Concentrations of\n  pimozide may be increased when co-administered with Invirase/ritonavir.</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Pimozide is a CYP3A4\n  substrate and is associated with QT prolongation,</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with Invirase/ritonavir due to the potential for life threatening\n  cardiac arrhythmia (see sections 4.3 and 4.4).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Clozapine<br/>\n  Haloperidol</p>\n<p class=\"Normal11pt0\">Chlorpromazine<br/>\n  Mesoridazine<br/>\n  Phenothiazines<br/>\n  Sertindole<br/>\n  Sultopride<br/>\n  Thioridazine<br/>\n  Ziprasidone<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with Invirase/ritonavir\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4).</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Benzodiazepines</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Midazolam\n  7.5\u00a0mg<br/>\n  single dose (oral)<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Midazolam\n  AUC \u2191 12.4 fold<br/>\n  Midazolam C<sub>max </sub>\u2191 4.3 fold</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Midazolam t<sub>1/2 </sub>\u2191\n  from 4.7 h to 14.9\u00a0h<br/>\n  No data are available on concomitant use of ritonavir boosted saquinavir with\n  intravenous midazolam. <span style=\"font-size:12.0pt\">Studies of other CYP3A\n  modulators and i.v. midazolam</span> suggest a possible 3-4 fold increase in\n  midazolam plasma levels.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Co-administration of\n  Invirase/ritonavir with orally administered<b> </b>midazolam is\n  contraindicated (see section 4.3). <span style=\"color:black\">Caution should\n  be used with co-administration of Invirase and parenteral midazolam.<br/>\n</span><span lang=\"EN-GB\">If Invirase is co-administered with parenteral\n  midazolam it should be done in an intensive care unit (ICU) or similar\n  setting which ensures close clinical monitoring and appropriate medical management\n  in case of respiratory depression and/or prolonged sedation. Dosage\n  adjustment should be considered, especially if more than a single dose of\n  midazolam is administered.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Alprazolam<br/>\n  Clorazepate<br/>\n  Diazepam<br/>\n  Flurazepam<u><br/>\n</u>(saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of these medicinal products may be increased when co-administered with\n  Invirase/ritonavir. </span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Careful\n  monitoring of patients with regard to sedative effects is warranted. A\n  decrease in the dose of the benzodiazepine may be required.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Triazolam<u><br/>\n</u><span lang=\"PT-BR\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"PT-BR\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Concentrations of triazolam may be increased when\n  co-administered with <span lang=\"EN-GB\">Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">saquinavir/ritonavir</span>,\n  due to the risk of potentially prolonged or increased sedation and\n  respiratory depression (see section 4.3).</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Calcium\n  channel blockers</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Felodipine, nifedipine, nicardipine,\n  diltiazem, nimodipine, verapamil, amlodipine, nisoldipine, isradipine<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of these medicinal\n  products may be increased when co-administered with Invirase/ritonavir. </span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Caution is warranted and clinical\n  monitoring of patients is recommended.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Corticosteroids</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:76.4pt\">\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Dexamethasone<br/>\n</span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Dexamethasone\n  induces CYP3A4 and may </span>decrease<span lang=\"EN-GB\"> saquinavir\n  concentrations.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Use with caution. Monitoring of saquinavir plasma\n  concentration is recommended (see section 4.4).</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Fluticasone\n  propionate<br/>\n  50 mcg qid, intranasal<br/>\n  (ritonavir 100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Fluticasone <span lang=\"EN-GB\">propionate</span> \u2191</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Intrinsic cortisol <span style=\"font-family:Symbol\">\u00af</span> 86%<br/>\n  (90% CI 82%-89%)<br/>\n<span lang=\"EN-GB\">Greater effects may be expected when fluticasone propionate\n  is inhaled. Systemic corticosteroid effects including Cushing\u2019s\n  syndrome and adrenal suppression have been reported in patients receiving\n  ritonavir and inhaled or intranasally administered fluticasone propionate;\n  this could also occur with other corticosteroids metabolised via the P450 3A\n  pathway e.g. budesonide.<br/>\n<br/>\n  Effects of high fluticasone systemic exposure on ritonavir plasma levels yet\n  unknown.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concomitant\n  administration of boosted saquinavir and fluticasone propionate and other\n  corticosteroids metabolised via the P450 3A pathway (e.g. budesonide) is not\n  recommended unless the potential benefit of treatment outweighs the risk of\n  systemic corticosteroid effects (see section 4.4).<br/>\n  Dose reduction of the glucocorticoid should be considered with close\n  monitoring of local and systemic effects or a switch to a glucocorticoid,\n  which is not a substrate for CYP3A4 (e.g. beclomethasone).<br/>\n  In case of withdrawal of glucocorticoids progressive dose reduction may have\n  to be performed over a longer period.</span></p>\n</td>\n</tr>\n<tr style=\"height:12.9pt\">\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Endothelin\n  receptor antagonist</span></i></b></p>\n</td>\n</tr>\n<tr style=\"height:46.2pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:46.2pt\" valign=\"top\" width=\"177\">\n<p class=\"Paragraph\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Bosentan\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:46.2pt\" valign=\"top\" width=\"236\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Not studied.\n  Concomitant use of bosentan and saquinavir/ritonavir may increase plasma\n  levels of bosentan and may decrease plasma levels of saquinavir/ritonavir.</span></p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:46.2pt\" valign=\"top\" width=\"237\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Dose adjustment\n  of bosentan may be required. When bosentan is administered concomitantly with\n  saquinavir/ritonavir, the patient\u2019s tolerability of bosentan should be\n  monitored. Monitoring of the patient\u2019s HIV therapy is also recommended.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"MsoNormal\"><b><i><u>Medicinal products that are substrates of\n  P-glycoprotein</u></i></b></p>\n<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Digitalis glycosides</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Digoxin 0.5\u00a0mg<br/>\n  single dose</span></p>\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">(saquinavir/ritonavir 1000/100\u00a0mg\n  bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Digoxin AUC<sub>0-72</sub> \u2191 49%</p>\n<p class=\"Normal11pt0\">Digoxin C<sub>max </sub>\u2191 27%<br/>\n<span style=\"color:black\">Digoxin levels may differ over time. Large\n  increments of digoxin may be expected when saquinavir/ritonavir is introduced\n  in patients already treated with digoxin.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Caution should be exercised when\n  Invirase/ritonavir and digoxin are co-administered. The serum concentration\n  of digoxin should be monitored and a dose reduction of digoxin should be\n  considered if necessary.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Histamine\n  H<sub>2</sub>-receptor antagonist</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:76.4pt\">\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">-\u00a0 Ranitidine<u><br/>\n</u></span><span lang=\"PT-BR\">(</span><span lang=\"FR-CH\">saquinavir/ritonavir</span><span lang=\"PT-BR\">)</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">-\u00a0 Ranitidine<u><br/>\n</u></span><span lang=\"PT-BR\">(</span><span lang=\"FR-CH\">unboosted saquinavir</span><span lang=\"PT-BR\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Saquinavir\n  AUC </span>\u2191 <span lang=\"EN-GB\">67\u00a0% </span><span lang=\"PT-BR\"><br/>\n<br/>\n</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Increase not thought to be clinically relevant. No\n  dose adjustment of saquinavir recommended.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">HMG-CoA\n  reductase inhibitors</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pravastatin<br/>\n  Fluvastatin<br/>\n  (</span><span lang=\"EN-GB\">saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Interaction not studied. Metabolism of\n  pravastatin and fluvastatin is not dependent on CYP3A4. </span>Interaction\n  via effects on transport proteins cannot be excluded.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Interaction unknown. If no alternative\n  treatment is available, use with careful monitoring (see section 4.4).</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Simvastatin<br/>\n  Lovastatin<u><br/>\n</u>(</span><span lang=\"EN-GB\">saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Simvastatin</span> \u2191\u2191</p>\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Lovastatin </span>\u2191\u2191</p>\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Plasma concentrations highly dependent\n  on CYP3A4 metabolism. </span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Increased concentrations of simvastatin\n  and lovastatin have been associated with rhabdomyolysis. These medicinal\n  products are contraindicated for use with Invirase/ritonavir (see section\n  4.3).</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Atorvastatin</span><span lang=\"EN-GB\"><br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Atorvastatin</span><span lang=\"EN-GB\"> is\n  less dependent on CYP3A4 for metabolism.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">When used with Invirase/ritonavir, the\n  lowest possible dose of atorvastatin should be administered and the patient\n  should be carefully monitored for signs/symptoms of myopathy (muscle\n  weakness, muscle pain, rising plasma creatinine kinase, see section 4.4).</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Immunosuppressants</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT\">Tacrolimus</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Tacrolimus is a substrate of CYP3A4 and P-glycoprotein.\n  Concomitant use of tacrolimus and saquinavir/ritonavir is expected to\n  increase plasma levels of tacrolimus.</p>\n<p class=\"Normal11pt0\">Tacrolimus may be associated with torsades de pointes<span lang=\"EN-GB\">.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Contraindicated in combination with\n  Invirase/ritonavir due to the potential for life threatening cardiac\n  arrhythmia (see sections 4.3 and 4.4).</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Ciclosporin<br/>\n<br/>\n  Rapamycin<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of these medicinal\n  products increase several fold when co-administered with Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Careful therapeutic drug monitoring is\n  necessary for these immunosuppressants when co-administered with\n  Invirase/ritonavir.</span></p>\n</td>\n</tr>\n<tr style=\"height:12.9pt\">\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Long-acting\n  beta2-adrenergic agonist</span></i></b></p>\n</td>\n</tr>\n<tr style=\"height:89.85pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:89.85pt\" valign=\"top\" width=\"177\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Salmeterol</span></p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:89.85pt\" valign=\"top\" width=\"236\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Concomitant use\n  of salmeterol and saquinavir/ritonavir is expected to increase plasma levels\n  of salmeterol.</span></p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:89.85pt\" valign=\"top\" width=\"237\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Combination not\n  recommended as may result in increased risk of cardiovascular adverse events\n  associated with salmeterol, including QT prolongation, palpitations, and\n  sinus tachycardia (see section 4,4). </span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Narcotic\n  analgesics</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Methadone </span><span lang=\"IT\">60-120\u00a0mg qd</span><span lang=\"IT\"><br/>\n  (saquinavir/ritonavir </span><span lang=\"IT\">1000/100\u00a0mg bid</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Methadone AUC <span style=\"font-family:Symbol\">\u00af</span> <span lang=\"EN-GB\">19\u00a0%<br/>\n  (90\u00a0% CI 9\u00a0% to 29\u00a0%)<br/>\n  None of the 12 patients experienced withdrawal symptoms.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Oral\n  contraceptives</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Ethinyl estradiol<br/>\n</span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentration of ethinyl estradiol may\n  be decreased when co-administered with Invirase/ritonavir. </span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Alternative or additional contraceptive\n  measures should be used when oestrogen-based oral contraceptives are\n  co-administered (see section 4.4).</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Phosphodiesterase type 5 (PDE5)\n  inhibitors</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">\u00a0Sildenafil</p>\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">(saquinavir/ritonavir)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sildenafil\n  100\u00a0mg<br/>\n  (single dose)<br/>\n  (unboosted saquinavir 1200\u00a0mg tid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt\">Interaction with\n  Invirase/ritonavir not studied.</p>\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt\">Saquinavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  Sildenafil Cmax \u2191 140\u00a0%<br/>\n  Sildenafil AUC \u2191 210\u00a0%</p>\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt\">-Sildenafil is a substrate of\n  CYP3A4.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt\">Contraindicated\n  in combination with Invirase/ritonavir due to the potential for life\n  threatening cardiac arrhythmia (see sections 4.3 and 4.4).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vardenafil<u><br/>\n</u></span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of vardenafil may be increased when co-administered with Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Tadalafil<u><br/>\n</u></span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of tadalafil may be\n  increased when co-administered with Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Proton pump\n  inhibitors</i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Omeprazole\n  40\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Saquinavir\n  AUC \u2191 82%<br/>\n  (90\u00a0% CI 44-131\u00a0%)</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Saquinavir\n  C<sub>max</sub> \u2191 75%<br/>\n  (90\u00a0% CI 38-123\u00a0%)<br/>\n  Ritonavir </span><span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Combination not\n  recommended.</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Other proton pump\n  inhibitors (saquinavir/ritonavir 1000/100\u00a0mg bid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">No data are available on\n  the concomitant administration of Invirase/ritonavir and other proton pump\n  inhibitors.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Combination not\n  recommended.</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Tyrosine kinase\n  inhibitors</i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">All tyrosine kinase\n  inhibitors with a risk of QT prolongation </p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">e.g. dasatinib,\n  </span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">sunitinib</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with Invirase/ritonavir due to the potential for life threatening\n  cardiac arrhythmia (see sections 4.3 and 4.4).</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Others</i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Ergot\n  alkaloids (e.g. ergotamine, dihydroergotamine, ergonovine, and\n  methylergonovine)<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Invirase/ritonavir may\n  increase ergot alkaloids exposure, and consequently, increase the potential\n  for acute ergot toxicity.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">The concomitant use of\n  Invirase/ritonavir and ergot alkaloids is contra-indicated (see section 4.3).</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Grapefruit\n  juice<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Interaction with Invirase/ritonavir not studied.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Grapefruit\n  juice<br/>\n  (single dose)<br/>\n  (unboosted saquinavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Saquinavir \u2191 50% (normal strength grapefruit\n  juice)</p>\n<p class=\"Normal11pt0\">Saquinavir \u2191 100% (double strength grapefruit\n  juice)</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt\">Increase not thought to be\n  clinically relevant. No dose adjustment required.</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Garlic\n  capsules<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Interaction with Invirase/ritonavir not studied.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Garlic\n  capsules<br/>\n  (dose approx. equivalent to two 4\u00a0g cloves of garlic daily)<br/>\n  (unboosted saquinavir 1200\u00a0mg tid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"FR-CH\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"FR-CH\"> 51\u00a0%<br/>\n  Saquinavir Ctrough </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"FR-CH\"> 49\u00a0% (8 hours post dose)<br/>\n  Saquinavir Cmax </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"FR-CH\"> 54\u00a0%.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt\">Patients on saquinavir\n  treatment must not take garlic capsules due to the risk of decreased plasma\n  concentrations and loss of virological response and possible resistance to\n  one or more components of the antiretroviral regimen.</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">St. John\u2019s wort <br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt;page-break-after:avoid\"><span lang=\"EN-GB\">Interaction with Invirase/ritonavir not studied.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:12.6pt;text-indent:-9.35pt;\n  page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">St. John\u2019s wort </span><br/>\n  (unboosted saquinavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt;page-break-after:avoid\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <span lang=\"EN-GB\">Plasma levels of unboosted saquinavir can be reduced by\n  concomitant use of the herbal preparation St. John\u2019s wort <i>(Hypericum\n  perforatum)</i>. This is due to induction of drug metabolising enzymes and/or\n  transport proteins by St. John\u2019s wort.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Herbal\n  preparations containing St. John\u2019s wort must not be used concomitantly\n  with Invirase. If a patient is already taking St. John\u2019s wort, stop St.\n  John\u2019s wort, check viral levels and if possible saquinavir levels.\n  Saquinavir levels may increase on stopping St. John\u2019s wort, and the\n  dose of saquinavir may need adjusting. The inducing effect of St.\n  John\u2019s wort may persist for at least 2 weeks after cessation of\n  treatment.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><u><span lang=\"EN-GB\">Other\n  potential interactions</span></u></i></b></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Medicinal\n  products that are substrates of CYP3A4</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">e.g.\n  dapsone, disopyramide, quinine, fentanyl, and alfentanyl</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"IT\">Gastroenterological medicinal\n  products</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Metoclopramide</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">It is unknown whether medicinal\n  products which reduce the gastrointestinal transit time could lead to lower\n  saquinavir plasma concentrations.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Cisapride<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to potentially\n  life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Diphemanil<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to potentially life threatening cardiac arrhythmia (see sections 4.3 and\n  4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Vasodilators\n  (peripheral)</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vincamine\n  i.v.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr height=\"0\">\n<td style=\"border:none\" width=\"175\"></td>\n<td style=\"border:none\" width=\"2\"></td>\n<td style=\"border:none\" width=\"236\"></td>\n<td style=\"border:none\" width=\"2\"></td>\n<td style=\"border:none\" width=\"200\"></td>\n<td style=\"border:none\" width=\"16\"></td>\n<td style=\"border:none\" width=\"19\"></td>\n</tr>\n</table>", "ID": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "                                                                                                                           ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<thead>\n<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Medicinal product by\n   therapeutic area (dose of Invirase used in study)</b></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Interaction</b></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Recommendations\n   concerning co-administration</b></p>\n</td>\n</tr>\n</thead>", "ID": "e96034d3-71d7-4f10-b1c6-1c268880238a", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Medicinal product by\n   therapeutic area (dose of Invirase used in study)</b></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Interaction</b></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Recommendations\n   concerning co-administration</b></p>\n</td>\n</tr>", "ID": "d4b597a7-5e83-4325-9da4-7828436e99bb", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "e96034d3-71d7-4f10-b1c6-1c268880238a"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Medicinal product by\n   therapeutic area (dose of Invirase used in study)</b></p>\n</td>", "ID": "3627583b-016f-4a7e-9951-85e327d20bc6", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d4b597a7-5e83-4325-9da4-7828436e99bb"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Medicinal product by\n   therapeutic area (dose of Invirase used in study)</b></p>", "ID": "44af92c3-64ab-4565-ac5c-20e4384a0eb3", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "3627583b-016f-4a7e-9951-85e327d20bc6"}, {"Element": "<b>Medicinal product by\n   therapeutic area (dose of Invirase used in study)</b>", "ID": "e7e5cc22-dde2-4549-a7ec-d1acaed87c96", "Styles": "None", "Classes": "None", "Text": "Medicinal product by    therapeutic area (dose of Invirase used in study)", "ParentId": "44af92c3-64ab-4565-ac5c-20e4384a0eb3"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Interaction</b></p>\n</td>", "ID": "68ad460c-e0f9-4ae7-b2a9-a7fe7ca4146c", "Styles": "width:2.5in;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d4b597a7-5e83-4325-9da4-7828436e99bb"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Interaction</b></p>", "ID": "81995fe3-4624-47a7-89bf-aeba99bb1ad4", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "68ad460c-e0f9-4ae7-b2a9-a7fe7ca4146c"}, {"Element": "<b>Interaction</b>", "ID": "992d7e37-0caa-4c45-a7db-89f5e4241cc9", "Styles": "None", "Classes": "None", "Text": "Interaction", "ParentId": "81995fe3-4624-47a7-89bf-aeba99bb1ad4"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Recommendations\n   concerning co-administration</b></p>\n</td>", "ID": "a9fccdb9-7f69-4157-ac1b-8f48259c290a", "Styles": "width:176.2pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d4b597a7-5e83-4325-9da4-7828436e99bb"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Recommendations\n   concerning co-administration</b></p>", "ID": "f4a1bb94-bc18-4a09-bd98-031ec8c7cca0", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "a9fccdb9-7f69-4157-ac1b-8f48259c290a"}, {"Element": "<b>Recommendations\n   concerning co-administration</b>", "ID": "976c8218-f36e-46a8-b58d-502c8b0043cd", "Styles": "None", "Classes": "None", "Text": "Recommendations    concerning co-administration", "ParentId": "f4a1bb94-bc18-4a09-bd98-031ec8c7cca0"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><u>Antiretroviral\n  agents<br/>\n</u>Nucleoside reverse transcriptase inhibitors (NRTIs)</i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "c7031f51-417f-4b5f-bce9-0efdc6d8fc10", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><u>Antiretroviral\n  agents<br/>\n</u>Nucleoside reverse transcriptase inhibitors (NRTIs)</i></b></p>\n</td>", "ID": "b1da8a8f-fac9-426b-81a6-286f09bb006e", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c7031f51-417f-4b5f-bce9-0efdc6d8fc10"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><u>Antiretroviral\n  agents<br/>\n</u>Nucleoside reverse transcriptase inhibitors (NRTIs)</i></b></p>", "ID": "914bb60d-56cb-462e-b58c-e477ad4b4a0f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "b1da8a8f-fac9-426b-81a6-286f09bb006e"}, {"Element": "<b><i><u>Antiretroviral\n  agents<br/>\n</u>Nucleoside reverse transcriptase inhibitors (NRTIs)</i></b>", "ID": "c43c5741-8eb2-41f4-bd06-1e8b06693e69", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "914bb60d-56cb-462e-b58c-e477ad4b4a0f"}, {"Element": "<i><u>Antiretroviral\n  agents<br/>\n</u>Nucleoside reverse transcriptase inhibitors (NRTIs)</i>", "ID": "078b3419-e4d1-464e-8029-d44fc7a9ecb2", "Styles": "None", "Classes": "None", "Text": "Nucleoside reverse transcriptase inhibitors (NRTIs)", "ParentId": "c43c5741-8eb2-41f4-bd06-1e8b06693e69"}, {"Element": "<u>Antiretroviral\n  agents<br/>\n</u>", "ID": "30a943ec-2ad8-4989-957a-370a4f2ae576", "Styles": "None", "Classes": "None", "Text": "Antiretroviral   agents ", "ParentId": "078b3419-e4d1-464e-8029-d44fc7a9ecb2"}, {"Element": "<br/>", "ID": "014234a7-b425-4798-904d-5395000f604f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "30a943ec-2ad8-4989-957a-370a4f2ae576"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "174a23a2-9281-4ccd-b981-c2253c892e1a", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c7031f51-417f-4b5f-bce9-0efdc6d8fc10"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "24285b26-cd85-4b3c-a133-02dee72de478", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "174a23a2-9281-4ccd-b981-c2253c892e1a"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "b90041ff-c9a2-4c59-a20e-f7315ca2a4c5", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c7031f51-417f-4b5f-bce9-0efdc6d8fc10"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "cd579397-180d-4438-839a-cdee9751acc5", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "b90041ff-c9a2-4c59-a20e-f7315ca2a4c5"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Zalcitabine and/or<br/>\n  Zidovudine<br/>\n<br/>\n</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">No pharmacokinetic\n  interaction studies have been completed. </p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Use of\n  unboosted saquinavir with zalcitabine and/or zidovudine has been studied in\n  adults. Absorption, distribution and elimination of each of the drugs are\n  unchanged when they are used together.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  zalcitabine is unlikely due to different routes of metabolism and excretion.<br/>\n  For zidovudine (200\u00a0mg every 8 hours) a 25\u00a0% decrease in AUC was\n  reported when combined with ritonavir (300\u00a0mg every 6 hours). The\n  pharmacokinetics of ritonavir remained unchanged.</p>\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">No dose adjustment </span>required<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "35830432-3769-4966-86b8-7e8e26ec5a69", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Zalcitabine and/or<br/>\n  Zidovudine<br/>\n<br/>\n</p>\n</td>", "ID": "edcb7830-f114-4399-853d-faa9c830c18c", "Styles": "width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "35830432-3769-4966-86b8-7e8e26ec5a69"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Zalcitabine and/or<br/>\n  Zidovudine<br/>\n<br/>\n</p>", "ID": "928655f7-12b3-4a84-a96d-0bb6a12f7848", "Styles": "margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 Zalcitabine and/or   Zidovudine  ", "ParentId": "edcb7830-f114-4399-853d-faa9c830c18c"}, {"Element": "<br/>", "ID": "efcadb93-bc45-4b3a-bbac-eadc811592ce", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "928655f7-12b3-4a84-a96d-0bb6a12f7848"}, {"Element": "<br/>", "ID": "839b2d57-6d0e-4f0f-993f-d0ca5f7fd48e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "928655f7-12b3-4a84-a96d-0bb6a12f7848"}, {"Element": "<br/>", "ID": "777ec236-cd8a-414e-a9e6-974be9b93400", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "928655f7-12b3-4a84-a96d-0bb6a12f7848"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">No pharmacokinetic\n  interaction studies have been completed. </p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Use of\n  unboosted saquinavir with zalcitabine and/or zidovudine has been studied in\n  adults. Absorption, distribution and elimination of each of the drugs are\n  unchanged when they are used together.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  zalcitabine is unlikely due to different routes of metabolism and excretion.<br/>\n  For zidovudine (200\u00a0mg every 8 hours) a 25\u00a0% decrease in AUC was\n  reported when combined with ritonavir (300\u00a0mg every 6 hours). The\n  pharmacokinetics of ritonavir remained unchanged.</p>\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "5fa45840-1467-4faa-bd36-fc946b6e6504", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "35830432-3769-4966-86b8-7e8e26ec5a69"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">No pharmacokinetic\n  interaction studies have been completed. </p>", "ID": "3b65cd5b-e8df-4be7-9621-524671a6a638", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "No pharmacokinetic   interaction studies have been completed. ", "ParentId": "5fa45840-1467-4faa-bd36-fc946b6e6504"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Use of\n  unboosted saquinavir with zalcitabine and/or zidovudine has been studied in\n  adults. Absorption, distribution and elimination of each of the drugs are\n  unchanged when they are used together.</span></p>", "ID": "1c886830-a024-447a-b6b9-d6767aeee0b6", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "5fa45840-1467-4faa-bd36-fc946b6e6504"}, {"Element": "<span lang=\"EN-GB\">Use of\n  unboosted saquinavir with zalcitabine and/or zidovudine has been studied in\n  adults. Absorption, distribution and elimination of each of the drugs are\n  unchanged when they are used together.</span>", "ID": "4bd72e0c-039a-4eec-82ef-a8bf446c2e7c", "Styles": "None", "Classes": "None", "Text": "Use of   unboosted saquinavir with zalcitabine and/or zidovudine has been studied in   adults. Absorption, distribution and elimination of each of the drugs are   unchanged when they are used together.", "ParentId": "1c886830-a024-447a-b6b9-d6767aeee0b6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "1f8a7e95-e890-4fdc-b95a-98c3b7a55acb", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "5fa45840-1467-4faa-bd36-fc946b6e6504"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  zalcitabine is unlikely due to different routes of metabolism and excretion.<br/>\n  For zidovudine (200\u00a0mg every 8 hours) a 25\u00a0% decrease in AUC was\n  reported when combined with ritonavir (300\u00a0mg every 6 hours). The\n  pharmacokinetics of ritonavir remained unchanged.</p>", "ID": "9f8586ad-d96c-4d90-b8a5-f268239efa08", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Interaction with   zalcitabine is unlikely due to different routes of metabolism and excretion.   For zidovudine (200\u00a0mg every 8 hours) a 25\u00a0% decrease in AUC was   reported when combined with ritonavir (300\u00a0mg every 6 hours). The   pharmacokinetics of ritonavir remained unchanged.", "ParentId": "5fa45840-1467-4faa-bd36-fc946b6e6504"}, {"Element": "<br/>", "ID": "62f01877-53ac-436b-9733-2986ddd5098b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9f8586ad-d96c-4d90-b8a5-f268239efa08"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">\u00a0</p>", "ID": "04bff982-50d6-4bce-b779-0a9b875f62ab", "Styles": "margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "5fa45840-1467-4faa-bd36-fc946b6e6504"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">No dose adjustment </span>required<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "edb3ddb9-d065-4030-85c7-588143167ca0", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "35830432-3769-4966-86b8-7e8e26ec5a69"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">No dose adjustment </span>required<span lang=\"EN-GB\">.</span></p>", "ID": "d9e6350d-355a-4fc1-b1b8-1e379f649120", "Styles": "margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid", "Classes": "['Normal11pt0']", "Text": "required", "ParentId": "edb3ddb9-d065-4030-85c7-588143167ca0"}, {"Element": "<span lang=\"EN-GB\">No dose adjustment </span>", "ID": "872c4c07-e5f8-474e-a9c7-66597ee14ad0", "Styles": "None", "Classes": "None", "Text": "No dose adjustment ", "ParentId": "d9e6350d-355a-4fc1-b1b8-1e379f649120"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "37cc4c21-d6f2-4dea-aefa-ad5d73ac96fc", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "d9e6350d-355a-4fc1-b1b8-1e379f649120"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Didanosine<br/>\n  400\u00a0mg single dose<br/>\n  (saquinavir/ritonavir 1600/100\u00a0mg qd)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 30%<br/>\n  Saquinavir C<sub>max</sub> </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 25%<br/>\n  Saquinavir C<sub>min </sub></span><span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required.</span></p>\n</td>\n</tr>", "ID": "a3fe838b-4578-4d18-8952-b951c956907c", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Didanosine<br/>\n  400\u00a0mg single dose<br/>\n  (saquinavir/ritonavir 1600/100\u00a0mg qd)</span></p>\n</td>", "ID": "e41954b2-4ded-45fc-a5e9-25d20f4245ad", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a3fe838b-4578-4d18-8952-b951c956907c"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Didanosine<br/>\n  400\u00a0mg single dose<br/>\n  (saquinavir/ritonavir 1600/100\u00a0mg qd)</span></p>", "ID": "c00591b8-19af-48fe-83df-d63e3a680d63", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "e41954b2-4ded-45fc-a5e9-25d20f4245ad"}, {"Element": "<span lang=\"PT-BR\">Didanosine<br/>\n  400\u00a0mg single dose<br/>\n  (saquinavir/ritonavir 1600/100\u00a0mg qd)</span>", "ID": "eba5e59f-b8cb-49d4-b64a-620ad381302c", "Styles": "None", "Classes": "None", "Text": "Didanosine   400\u00a0mg single dose   (saquinavir/ritonavir 1600/100\u00a0mg qd)", "ParentId": "c00591b8-19af-48fe-83df-d63e3a680d63"}, {"Element": "<br/>", "ID": "af119563-ce20-4469-bc4e-d6c9dd3d4244", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "eba5e59f-b8cb-49d4-b64a-620ad381302c"}, {"Element": "<br/>", "ID": "88035616-3aee-4eb1-81f3-c31f6012f93b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "eba5e59f-b8cb-49d4-b64a-620ad381302c"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 30%<br/>\n  Saquinavir C<sub>max</sub> </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 25%<br/>\n  Saquinavir C<sub>min </sub></span><span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>", "ID": "ea296935-6688-4326-8c86-7a857859a3f6", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a3fe838b-4578-4d18-8952-b951c956907c"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 30%<br/>\n  Saquinavir C<sub>max</sub> </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 25%<br/>\n  Saquinavir C<sub>min </sub></span><span style=\"font-family:Symbol\">\u00ab</span></p>", "ID": "198f7383-2a79-4beb-aa76-53736dee9b7f", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "ea296935-6688-4326-8c86-7a857859a3f6"}, {"Element": "<span lang=\"PT-BR\">Saquinavir AUC </span>", "ID": "110bc6ae-7cd3-483b-aaa6-90f605623056", "Styles": "None", "Classes": "None", "Text": "Saquinavir AUC ", "ParentId": "198f7383-2a79-4beb-aa76-53736dee9b7f"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "a6400928-2321-461d-8f6f-277532cecc75", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "198f7383-2a79-4beb-aa76-53736dee9b7f"}, {"Element": "<span lang=\"PT-BR\"> 30%<br/>\n  Saquinavir C<sub>max</sub> </span>", "ID": "7c6f976d-446e-4690-b184-8f49d824724b", "Styles": "None", "Classes": "None", "Text": " 30%   Saquinavir C ", "ParentId": "198f7383-2a79-4beb-aa76-53736dee9b7f"}, {"Element": "<br/>", "ID": "576ccc8e-49e1-4474-9a40-a68e7c9d9561", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7c6f976d-446e-4690-b184-8f49d824724b"}, {"Element": "<sub>max</sub>", "ID": "9b2b9616-e6d0-49c6-9bd4-69c570eb84ac", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "7c6f976d-446e-4690-b184-8f49d824724b"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "9d271ac0-775c-4c65-8ba8-1c851d235863", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "198f7383-2a79-4beb-aa76-53736dee9b7f"}, {"Element": "<span lang=\"PT-BR\"> 25%<br/>\n  Saquinavir C<sub>min </sub></span>", "ID": "f6b6034b-0c8d-4beb-aadf-d723475b1c1b", "Styles": "None", "Classes": "None", "Text": " 25%   Saquinavir C", "ParentId": "198f7383-2a79-4beb-aa76-53736dee9b7f"}, {"Element": "<br/>", "ID": "42ec8814-11ff-4f99-a776-3dfae7ba425b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f6b6034b-0c8d-4beb-aadf-d723475b1c1b"}, {"Element": "<sub>min </sub>", "ID": "87011313-75ab-4ee1-b796-ceeb423e7834", "Styles": "None", "Classes": "None", "Text": "min ", "ParentId": "f6b6034b-0c8d-4beb-aadf-d723475b1c1b"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "68d0b531-0eb2-489b-a719-97f2299113d2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "198f7383-2a79-4beb-aa76-53736dee9b7f"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required.</span></p>\n</td>", "ID": "6a90f03d-154c-4a32-bfda-d65679519e27", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a3fe838b-4578-4d18-8952-b951c956907c"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required.</span></p>", "ID": "005ffeb2-6354-4c82-a85e-ff55ef96c01f", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "6a90f03d-154c-4a32-bfda-d65679519e27"}, {"Element": "<span lang=\"EN-GB\">No dose adjustment required.</span>", "ID": "427c21dd-9055-47f8-913f-3de04adf6ce2", "Styles": "None", "Classes": "None", "Text": "No dose adjustment required.", "ParentId": "005ffeb2-6354-4c82-a85e-ff55ef96c01f"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Tenofovir disoproxil fumarate 300\u00a0mg qd<br/>\n  (<span lang=\"EN-GB\">saquinavir/ritonavir</span> 1000/100\u00a0mg bid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 1%<br/>\n  Saquinavir C<sub>max</sub> </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 7%<br/>\n  Saquinavir C<sub>min </sub></span><span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required.</span></p>\n</td>\n</tr>", "ID": "44fd29b8-ce39-4815-80a5-a35782f3cae7", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Tenofovir disoproxil fumarate 300\u00a0mg qd<br/>\n  (<span lang=\"EN-GB\">saquinavir/ritonavir</span> 1000/100\u00a0mg bid)</p>\n</td>", "ID": "dc80f1f2-1b5f-4646-bde5-2e0c5f1ffdfb", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "44fd29b8-ce39-4815-80a5-a35782f3cae7"}, {"Element": "<p class=\"Normal11pt0\">Tenofovir disoproxil fumarate 300\u00a0mg qd<br/>\n  (<span lang=\"EN-GB\">saquinavir/ritonavir</span> 1000/100\u00a0mg bid)</p>", "ID": "d11d0869-e450-4594-b9ac-314394027a3e", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Tenofovir disoproxil fumarate 300\u00a0mg qd   ( 1000/100\u00a0mg bid)", "ParentId": "dc80f1f2-1b5f-4646-bde5-2e0c5f1ffdfb"}, {"Element": "<br/>", "ID": "4da2f550-4e6b-4dd4-8bad-c262681790a1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d11d0869-e450-4594-b9ac-314394027a3e"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "e9952ff1-af23-42ad-8fcb-c4e416e1823c", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "d11d0869-e450-4594-b9ac-314394027a3e"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 1%<br/>\n  Saquinavir C<sub>max</sub> </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 7%<br/>\n  Saquinavir C<sub>min </sub></span><span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>", "ID": "6ff56232-874d-4920-87ce-00258d695d8a", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "44fd29b8-ce39-4815-80a5-a35782f3cae7"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 1%<br/>\n  Saquinavir C<sub>max</sub> </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"PT-BR\"> 7%<br/>\n  Saquinavir C<sub>min </sub></span><span style=\"font-family:Symbol\">\u00ab</span></p>", "ID": "18de26ff-8c5b-42ba-91a4-7820d7ec4f7a", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "6ff56232-874d-4920-87ce-00258d695d8a"}, {"Element": "<span lang=\"PT-BR\">Saquinavir AUC </span>", "ID": "0bea0474-9065-4d50-8fa6-831d0902701f", "Styles": "None", "Classes": "None", "Text": "Saquinavir AUC ", "ParentId": "18de26ff-8c5b-42ba-91a4-7820d7ec4f7a"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "150601cc-f910-41a3-b849-5e1840298079", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "18de26ff-8c5b-42ba-91a4-7820d7ec4f7a"}, {"Element": "<span lang=\"PT-BR\"> 1%<br/>\n  Saquinavir C<sub>max</sub> </span>", "ID": "4cb680ff-a5b3-4d2f-a3ee-96af77c793e6", "Styles": "None", "Classes": "None", "Text": " 1%   Saquinavir C ", "ParentId": "18de26ff-8c5b-42ba-91a4-7820d7ec4f7a"}, {"Element": "<br/>", "ID": "6855cdca-f2b6-4a10-aa9d-e7281b460c55", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4cb680ff-a5b3-4d2f-a3ee-96af77c793e6"}, {"Element": "<sub>max</sub>", "ID": "f5b6bd26-eee1-4e54-967c-712080e77fdd", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "4cb680ff-a5b3-4d2f-a3ee-96af77c793e6"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "d9061405-03f2-41d2-b35e-a3b1fdaaa95c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "18de26ff-8c5b-42ba-91a4-7820d7ec4f7a"}, {"Element": "<span lang=\"PT-BR\"> 7%<br/>\n  Saquinavir C<sub>min </sub></span>", "ID": "fa342198-745a-45de-9098-7b243398686e", "Styles": "None", "Classes": "None", "Text": " 7%   Saquinavir C", "ParentId": "18de26ff-8c5b-42ba-91a4-7820d7ec4f7a"}, {"Element": "<br/>", "ID": "58c07964-5df6-45bf-a805-8634424d9b66", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fa342198-745a-45de-9098-7b243398686e"}, {"Element": "<sub>min </sub>", "ID": "6c4b1ace-a248-4873-ad81-858614bb992c", "Styles": "None", "Classes": "None", "Text": "min ", "ParentId": "fa342198-745a-45de-9098-7b243398686e"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "f3f8353c-7faf-4b09-9de3-17604133c7ed", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "18de26ff-8c5b-42ba-91a4-7820d7ec4f7a"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required.</span></p>\n</td>", "ID": "15c49692-6af1-4543-94c7-92ee115040bb", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "44fd29b8-ce39-4815-80a5-a35782f3cae7"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required.</span></p>", "ID": "7385cfaa-5513-4d3f-9300-ad59e173f931", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "15c49692-6af1-4543-94c7-92ee115040bb"}, {"Element": "<span lang=\"EN-GB\">No dose adjustment required.</span>", "ID": "201e44d9-01ad-4acb-941f-16cd03faa420", "Styles": "None", "Classes": "None", "Text": "No dose adjustment required.", "ParentId": "7385cfaa-5513-4d3f-9300-ad59e173f931"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Non-nucleoside\n  reverse transcriptase inhibitors (NNRTIs)</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "fc918a04-c60d-494b-ac72-9d17a1f45d2a", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Non-nucleoside\n  reverse transcriptase inhibitors (NNRTIs)</span></i></b></p>\n</td>", "ID": "f0e1a57a-441f-4b04-b749-750a926fa108", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fc918a04-c60d-494b-ac72-9d17a1f45d2a"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Non-nucleoside\n  reverse transcriptase inhibitors (NNRTIs)</span></i></b></p>", "ID": "a7e0fe5f-da4f-4914-add0-af34ca828583", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "f0e1a57a-441f-4b04-b749-750a926fa108"}, {"Element": "<b><i><span lang=\"IT\">Non-nucleoside\n  reverse transcriptase inhibitors (NNRTIs)</span></i></b>", "ID": "127828dd-476c-4c98-b968-f6c0e6b0297f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a7e0fe5f-da4f-4914-add0-af34ca828583"}, {"Element": "<i><span lang=\"IT\">Non-nucleoside\n  reverse transcriptase inhibitors (NNRTIs)</span></i>", "ID": "17cd4d6d-4d20-4af8-a114-ce489954d535", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "127828dd-476c-4c98-b968-f6c0e6b0297f"}, {"Element": "<span lang=\"IT\">Non-nucleoside\n  reverse transcriptase inhibitors (NNRTIs)</span>", "ID": "bd740956-79f0-4ea7-8294-96e668f168cb", "Styles": "None", "Classes": "None", "Text": "Non-nucleoside   reverse transcriptase inhibitors (NNRTIs)", "ParentId": "17cd4d6d-4d20-4af8-a114-ce489954d535"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "f05d3898-8f05-462d-ae3f-3c4ce9a841ee", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fc918a04-c60d-494b-ac72-9d17a1f45d2a"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "6f04486a-fc7f-4d63-b15b-89397b182016", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "f05d3898-8f05-462d-ae3f-3c4ce9a841ee"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "2c5910b0-3ace-4fe4-b13e-9697b4097978", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6f04486a-fc7f-4d63-b15b-89397b182016"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "00956808-f3d7-47e1-a3d6-89a574a47182", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fc918a04-c60d-494b-ac72-9d17a1f45d2a"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "92e768fb-ee08-43ed-8c49-3915f43b39aa", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "00956808-f3d7-47e1-a3d6-89a574a47182"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "b4b9c402-99df-4ed1-aa63-5ca0eafb6ce1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "92e768fb-ee08-43ed-8c49-3915f43b39aa"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Delavirdine<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n</tr>", "ID": "f26bf584-e498-4e4e-af7b-0d1d662a6748", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Delavirdine<br/>\n  (saquinavir/ritonavir)</p>\n</td>", "ID": "273126ea-ba5f-43fe-b18b-44bb5fa2bf91", "Styles": "width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f26bf584-e498-4e4e-af7b-0d1d662a6748"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Delavirdine<br/>\n  (saquinavir/ritonavir)</p>", "ID": "69831ebb-02f0-404b-869a-941f276392c4", "Styles": "margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 Delavirdine   (saquinavir/ritonavir)", "ParentId": "273126ea-ba5f-43fe-b18b-44bb5fa2bf91"}, {"Element": "<br/>", "ID": "60b0e68c-3b3e-482b-8ffb-ca570b7f0d31", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "69831ebb-02f0-404b-869a-941f276392c4"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied.</p>\n</td>", "ID": "fd2743a1-7d3b-4ba0-983e-0d7a0a84d0c3", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f26bf584-e498-4e4e-af7b-0d1d662a6748"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied.</p>", "ID": "869339a4-faa4-478e-a14f-15524a71d1e0", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Interaction with   Invirase/ritonavir not studied.", "ParentId": "fd2743a1-7d3b-4ba0-983e-0d7a0a84d0c3"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>", "ID": "7521350d-dc87-4818-a02a-3ddcb24b05a9", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f26bf584-e498-4e4e-af7b-0d1d662a6748"}, {"Element": "<p class=\"Normal11pt0\">\u00a0</p>", "ID": "abf9bef9-b721-4032-95ab-b036656a881a", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "7521350d-dc87-4818-a02a-3ddcb24b05a9"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Delavirdine<br/>\n  (unboosted saquinavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC \u2191\n  348%.<br/>\n  There are limited safety and no efficacy data available from the use of this\n  combination. In a small, preliminary study, hepatocellular enzyme elevations\n  occurred in 13\u00a0% of subjects during the first several weeks of the\n  delavirdine and saquinavir combination (6\u00a0% Grade 3 or 4).</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatocellular\n  changes should be monitored frequently if this combination is prescribed.</span></p>\n</td>\n</tr>", "ID": "f2c6bf68-117b-4e22-b0f3-acc6175bb1c6", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Delavirdine<br/>\n  (unboosted saquinavir)</p>\n</td>", "ID": "24dfff47-01ae-41aa-9962-95406e0f037e", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f2c6bf68-117b-4e22-b0f3-acc6175bb1c6"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Delavirdine<br/>\n  (unboosted saquinavir)</p>", "ID": "36814a6a-578d-45a1-9267-d3fd97a0e3ad", "Styles": "margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 Delavirdine   (unboosted saquinavir)", "ParentId": "24dfff47-01ae-41aa-9962-95406e0f037e"}, {"Element": "<br/>", "ID": "6ccf7443-35ff-4f1b-9ea5-daf629ef9c50", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "36814a6a-578d-45a1-9267-d3fd97a0e3ad"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC \u2191\n  348%.<br/>\n  There are limited safety and no efficacy data available from the use of this\n  combination. In a small, preliminary study, hepatocellular enzyme elevations\n  occurred in 13\u00a0% of subjects during the first several weeks of the\n  delavirdine and saquinavir combination (6\u00a0% Grade 3 or 4).</p>\n</td>", "ID": "de67d12c-a2b6-4422-b32c-ba32f4939841", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f2c6bf68-117b-4e22-b0f3-acc6175bb1c6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC \u2191\n  348%.<br/>\n  There are limited safety and no efficacy data available from the use of this\n  combination. In a small, preliminary study, hepatocellular enzyme elevations\n  occurred in 13\u00a0% of subjects during the first several weeks of the\n  delavirdine and saquinavir combination (6\u00a0% Grade 3 or 4).</p>", "ID": "264febac-9c33-4559-85ce-0b1394b8e280", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Saquinavir AUC \u2191   348%.   There are limited safety and no efficacy data available from the use of this   combination. In a small, preliminary study, hepatocellular enzyme elevations   occurred in 13\u00a0% of subjects during the first several weeks of the   delavirdine and saquinavir combination (6\u00a0% Grade 3 or 4).", "ParentId": "de67d12c-a2b6-4422-b32c-ba32f4939841"}, {"Element": "<br/>", "ID": "128ab497-f21c-4cb6-aff4-a5e5f70600e9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "264febac-9c33-4559-85ce-0b1394b8e280"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatocellular\n  changes should be monitored frequently if this combination is prescribed.</span></p>\n</td>", "ID": "1295ffbe-8268-48cf-86ed-91b0707063b2", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f2c6bf68-117b-4e22-b0f3-acc6175bb1c6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatocellular\n  changes should be monitored frequently if this combination is prescribed.</span></p>", "ID": "402e2c4a-e2d4-469e-a855-b082ddb8acb1", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "1295ffbe-8268-48cf-86ed-91b0707063b2"}, {"Element": "<span lang=\"EN-GB\">Hepatocellular\n  changes should be monitored frequently if this combination is prescribed.</span>", "ID": "9013b1ce-8ed0-421e-a15f-978d88f77ec8", "Styles": "None", "Classes": "None", "Text": "Hepatocellular   changes should be monitored frequently if this combination is prescribed.", "ParentId": "402e2c4a-e2d4-469e-a855-b082ddb8acb1"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Efavirenz 600\u00a0mg qd<br/>\n  (<span lang=\"EN-GB\">saquinavir/ritonavir</span> 1600/200\u00a0mg qd, <i><u>or</u></i><br/>\n<span lang=\"EN-GB\">saquinavir/ritonavir 1000/100\u00a0mg</span><span lang=\"EN-GB\"> bid, <i><u>or</u></i> </span><br/>\n  saquinavir/ritonavir 1200/100\u00a0mg qd)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Saquinavir </span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"PT-BR\"><br/>\n  Efavirenz </span><span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required. </span>Liver\n  function should be monitored (see section 4.4).</p>\n</td>\n</tr>", "ID": "1aa765b6-ba90-4fe5-80b4-685d07e5e545", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Efavirenz 600\u00a0mg qd<br/>\n  (<span lang=\"EN-GB\">saquinavir/ritonavir</span> 1600/200\u00a0mg qd, <i><u>or</u></i><br/>\n<span lang=\"EN-GB\">saquinavir/ritonavir 1000/100\u00a0mg</span><span lang=\"EN-GB\"> bid, <i><u>or</u></i> </span><br/>\n  saquinavir/ritonavir 1200/100\u00a0mg qd)</p>\n</td>", "ID": "1f5851df-2dfe-43c5-bacd-5cfc9776bbe7", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1aa765b6-ba90-4fe5-80b4-685d07e5e545"}, {"Element": "<p class=\"Normal11pt0\">Efavirenz 600\u00a0mg qd<br/>\n  (<span lang=\"EN-GB\">saquinavir/ritonavir</span> 1600/200\u00a0mg qd, <i><u>or</u></i><br/>\n<span lang=\"EN-GB\">saquinavir/ritonavir 1000/100\u00a0mg</span><span lang=\"EN-GB\"> bid, <i><u>or</u></i> </span><br/>\n  saquinavir/ritonavir 1200/100\u00a0mg qd)</p>", "ID": "b0e99472-720e-4813-8bda-5f4dc9d71da2", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Efavirenz 600\u00a0mg qd   ( 1600/200\u00a0mg qd,     saquinavir/ritonavir 1200/100\u00a0mg qd)", "ParentId": "1f5851df-2dfe-43c5-bacd-5cfc9776bbe7"}, {"Element": "<br/>", "ID": "4be55b9b-5308-4f83-b79a-530cc248a1cc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b0e99472-720e-4813-8bda-5f4dc9d71da2"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "6b9d5633-8e89-4417-98fb-c8c40bdce23e", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "b0e99472-720e-4813-8bda-5f4dc9d71da2"}, {"Element": "<i><u>or</u></i>", "ID": "3d2bbe54-c0b3-4046-90a0-6754629694bc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b0e99472-720e-4813-8bda-5f4dc9d71da2"}, {"Element": "<u>or</u>", "ID": "857f1d67-2323-4c56-af81-636aa30e1640", "Styles": "None", "Classes": "None", "Text": "or", "ParentId": "3d2bbe54-c0b3-4046-90a0-6754629694bc"}, {"Element": "<br/>", "ID": "f42e4dfe-e666-46c6-aec1-ccbc2eb0a83d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b0e99472-720e-4813-8bda-5f4dc9d71da2"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir 1000/100\u00a0mg</span>", "ID": "77f486ad-93c3-42bc-87eb-b117d6bf3102", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir 1000/100\u00a0mg", "ParentId": "b0e99472-720e-4813-8bda-5f4dc9d71da2"}, {"Element": "<span lang=\"EN-GB\"> bid, <i><u>or</u></i> </span>", "ID": "83001c6a-c6a5-4da3-a3d0-925c677c69eb", "Styles": "None", "Classes": "None", "Text": " bid,  ", "ParentId": "b0e99472-720e-4813-8bda-5f4dc9d71da2"}, {"Element": "<i><u>or</u></i>", "ID": "edbd6d61-12bb-4c7f-a6f4-fc3303e12d0c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "83001c6a-c6a5-4da3-a3d0-925c677c69eb"}, {"Element": "<u>or</u>", "ID": "54eb93ef-9acb-41aa-aca5-3eee8adeab67", "Styles": "None", "Classes": "None", "Text": "or", "ParentId": "edbd6d61-12bb-4c7f-a6f4-fc3303e12d0c"}, {"Element": "<br/>", "ID": "c4f9da6d-80bf-475f-b2d7-3d219e66f187", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b0e99472-720e-4813-8bda-5f4dc9d71da2"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Saquinavir </span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"PT-BR\"><br/>\n  Efavirenz </span><span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>", "ID": "708c3f15-3fb2-4cbd-b9bd-3f22411ce03c", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1aa765b6-ba90-4fe5-80b4-685d07e5e545"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Saquinavir </span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"PT-BR\"><br/>\n  Efavirenz </span><span style=\"font-family:Symbol\">\u00ab</span></p>", "ID": "b323a0b5-4210-4110-9a30-c943ccc0d52d", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "708c3f15-3fb2-4cbd-b9bd-3f22411ce03c"}, {"Element": "<span lang=\"PT-BR\">Saquinavir </span>", "ID": "85bd6b5a-5101-4551-99b5-f59aea556dc8", "Styles": "None", "Classes": "None", "Text": "Saquinavir ", "ParentId": "b323a0b5-4210-4110-9a30-c943ccc0d52d"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "1cb30464-71d6-49db-9439-c70759e3b1ee", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "b323a0b5-4210-4110-9a30-c943ccc0d52d"}, {"Element": "<span lang=\"PT-BR\"><br/>\n  Efavirenz </span>", "ID": "8b378932-2737-43b5-9424-0279f41c2bcf", "Styles": "None", "Classes": "None", "Text": "   Efavirenz ", "ParentId": "b323a0b5-4210-4110-9a30-c943ccc0d52d"}, {"Element": "<br/>", "ID": "c3ce0b08-38d8-4285-b56b-e97ca755da65", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8b378932-2737-43b5-9424-0279f41c2bcf"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "46794a77-688c-4a76-acd7-e88715045796", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "b323a0b5-4210-4110-9a30-c943ccc0d52d"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required. </span>Liver\n  function should be monitored (see section 4.4).</p>\n</td>", "ID": "f535ef6d-d1af-4a39-9d63-e426aad4d99b", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1aa765b6-ba90-4fe5-80b4-685d07e5e545"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required. </span>Liver\n  function should be monitored (see section 4.4).</p>", "ID": "80338464-d861-4a18-b1ab-46a84c2e755f", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Liver   function should be monitored (see section 4.4).", "ParentId": "f535ef6d-d1af-4a39-9d63-e426aad4d99b"}, {"Element": "<span lang=\"EN-GB\">No dose adjustment required. </span>", "ID": "295637b1-ef1f-4dd1-9929-2c4a3c56dd5c", "Styles": "None", "Classes": "None", "Text": "No dose adjustment required. ", "ParentId": "80338464-d861-4a18-b1ab-46a84c2e755f"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Rilpivirine</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Switching directly from a\n  rilpivirine containing regimen to Invirase/ritonavir is contraindicated as is\n  concomitant use due to the potential for life threatening cardiac arrhythmia\n  (see sections 4.3 and 4.4).</p>\n</td>\n</tr>", "ID": "eb911b2a-4a4f-4d4b-9025-c87c2108bd5a", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Rilpivirine</p>\n</td>", "ID": "0ce712f1-959e-4593-badf-777fabe0479c", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eb911b2a-4a4f-4d4b-9025-c87c2108bd5a"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Rilpivirine</p>", "ID": "e8109149-ab2f-4089-b4d9-33d9c00b9670", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Rilpivirine", "ParentId": "0ce712f1-959e-4593-badf-777fabe0479c"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">\u00a0</span></p>\n</td>", "ID": "5f75639c-6f4f-4eb2-8605-c7c710fbed7d", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eb911b2a-4a4f-4d4b-9025-c87c2108bd5a"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">\u00a0</span></p>", "ID": "415e277c-bb22-4736-b449-19dbfb515907", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "5f75639c-6f4f-4eb2-8605-c7c710fbed7d"}, {"Element": "<span lang=\"PT-BR\">\u00a0</span>", "ID": "3588185a-ea97-4253-8fa6-e79ce11b4e95", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "415e277c-bb22-4736-b449-19dbfb515907"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Switching directly from a\n  rilpivirine containing regimen to Invirase/ritonavir is contraindicated as is\n  concomitant use due to the potential for life threatening cardiac arrhythmia\n  (see sections 4.3 and 4.4).</p>\n</td>", "ID": "0d6ff15e-2e01-4ed3-9e96-11c1a5481767", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eb911b2a-4a4f-4d4b-9025-c87c2108bd5a"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Switching directly from a\n  rilpivirine containing regimen to Invirase/ritonavir is contraindicated as is\n  concomitant use due to the potential for life threatening cardiac arrhythmia\n  (see sections 4.3 and 4.4).</p>", "ID": "873c403d-c801-4048-ae3f-ce8c97ee78a1", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Switching directly from a   rilpivirine containing regimen to Invirase/ritonavir is contraindicated as is   concomitant use due to the potential for life threatening cardiac arrhythmia   (see sections 4.3 and 4.4).", "ParentId": "0d6ff15e-2e01-4ed3-9e96-11c1a5481767"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Nevirapine<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:12.6pt;text-indent:-12.6pt;\n  page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "845a022d-7678-4915-afcc-4202ae18f941", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Nevirapine<br/>\n  (saquinavir/ritonavir)</p>\n</td>", "ID": "789746ac-1a95-4e1f-bf6d-26cbec63734f", "Styles": "width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "845a022d-7678-4915-afcc-4202ae18f941"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Nevirapine<br/>\n  (saquinavir/ritonavir)</p>", "ID": "70bc027d-755c-43f1-8004-076e76e92001", "Styles": "margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 Nevirapine   (saquinavir/ritonavir)", "ParentId": "789746ac-1a95-4e1f-bf6d-26cbec63734f"}, {"Element": "<br/>", "ID": "230a57fa-9083-4c40-b9e1-bac6d0af00e2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "70bc027d-755c-43f1-8004-076e76e92001"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied.</p>\n</td>", "ID": "bdbb50d8-9d2b-47b9-9bc6-522e40717a77", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "845a022d-7678-4915-afcc-4202ae18f941"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied.</p>", "ID": "01a52d80-d725-43cb-96e4-6e56fc35cf9d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Interaction with   Invirase/ritonavir not studied.", "ParentId": "bdbb50d8-9d2b-47b9-9bc6-522e40717a77"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:12.6pt;text-indent:-12.6pt;\n  page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "cbb991c0-89dd-4c68-b8c7-fe177968bdb5", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "845a022d-7678-4915-afcc-4202ae18f941"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:12.6pt;text-indent:-12.6pt;\n  page-break-after:avoid\">\u00a0</p>", "ID": "23d4030e-6c5d-489c-adcb-bc8b14f5ba36", "Styles": "margin-left:12.6pt;text-indent:-12.6pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "cbb991c0-89dd-4c68-b8c7-fe177968bdb5"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Nevirapine<br/>\n  (unboosted saquinavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC <span style=\"font-family:Symbol\">\u00af</span> 24%<br/>\n  Nevirapine AUC <span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">No dose adjustment required.</p>\n</td>\n</tr>", "ID": "a6d9d72e-febf-4eee-97c5-447943afae64", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Nevirapine<br/>\n  (unboosted saquinavir)</p>\n</td>", "ID": "355cd216-7364-4e8b-bb87-0a0aebd9dd46", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a6d9d72e-febf-4eee-97c5-447943afae64"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Nevirapine<br/>\n  (unboosted saquinavir)</p>", "ID": "9a90cb24-a1ea-4835-8e21-66b163dcb9e7", "Styles": "margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 Nevirapine   (unboosted saquinavir)", "ParentId": "355cd216-7364-4e8b-bb87-0a0aebd9dd46"}, {"Element": "<br/>", "ID": "517dd08d-7e0b-4477-9973-29fa6b2818ae", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9a90cb24-a1ea-4835-8e21-66b163dcb9e7"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC <span style=\"font-family:Symbol\">\u00af</span> 24%<br/>\n  Nevirapine AUC <span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>", "ID": "681f1eb8-7573-4f82-bba6-795f979a1c62", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a6d9d72e-febf-4eee-97c5-447943afae64"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC <span style=\"font-family:Symbol\">\u00af</span> 24%<br/>\n  Nevirapine AUC <span style=\"font-family:Symbol\">\u00ab</span></p>", "ID": "fe3f0f63-9b14-4d86-9516-da726e95a23f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Saquinavir AUC  24%   Nevirapine AUC ", "ParentId": "681f1eb8-7573-4f82-bba6-795f979a1c62"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "eb551ad9-4e03-4b16-8ed3-b941eb1dd72b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "fe3f0f63-9b14-4d86-9516-da726e95a23f"}, {"Element": "<br/>", "ID": "e826281b-bf8c-4f43-afde-e2e447698a84", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fe3f0f63-9b14-4d86-9516-da726e95a23f"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "11cbaa26-a759-4d41-a14c-312a8ade100b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "fe3f0f63-9b14-4d86-9516-da726e95a23f"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">No dose adjustment required.</p>\n</td>", "ID": "44a5be62-1784-4c0f-9839-d0a6b437efd9", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a6d9d72e-febf-4eee-97c5-447943afae64"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">No dose adjustment required.</p>", "ID": "0f91f0ae-91b4-47d7-8c5b-339f82838b9d", "Styles": "margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "No dose adjustment required.", "ParentId": "44a5be62-1784-4c0f-9839-d0a6b437efd9"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"IT\">HIV protease inhibitors (PIs)</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "476b7807-959b-4151-a851-771a2c945ade", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"IT\">HIV protease inhibitors (PIs)</span></i></b></p>\n</td>", "ID": "0b769c15-6240-41a1-95ec-9c5c37dfa94c", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "476b7807-959b-4151-a851-771a2c945ade"}, {"Element": "<p class=\"Normal11pt0\"><b><i><span lang=\"IT\">HIV protease inhibitors (PIs)</span></i></b></p>", "ID": "6a4f932a-affa-4271-8fa5-f2fb6c0a8f87", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "0b769c15-6240-41a1-95ec-9c5c37dfa94c"}, {"Element": "<b><i><span lang=\"IT\">HIV protease inhibitors (PIs)</span></i></b>", "ID": "623ce951-4b3d-4cd0-ab45-cca389fcafa2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6a4f932a-affa-4271-8fa5-f2fb6c0a8f87"}, {"Element": "<i><span lang=\"IT\">HIV protease inhibitors (PIs)</span></i>", "ID": "e0845156-b2e9-4505-9a9d-70d77f214a34", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "623ce951-4b3d-4cd0-ab45-cca389fcafa2"}, {"Element": "<span lang=\"IT\">HIV protease inhibitors (PIs)</span>", "ID": "23fffabf-ef33-4870-8b04-d6fbaf024a27", "Styles": "None", "Classes": "None", "Text": "HIV protease inhibitors (PIs)", "ParentId": "e0845156-b2e9-4505-9a9d-70d77f214a34"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "6730f35c-1141-49a0-ba9c-1e3b73e96b79", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "476b7807-959b-4151-a851-771a2c945ade"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "99dab533-53ce-4ed2-a1f8-69e027257099", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "6730f35c-1141-49a0-ba9c-1e3b73e96b79"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "3592973e-3d42-4ed3-ac29-b60ec03cd49c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "99dab533-53ce-4ed2-a1f8-69e027257099"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "7ce95cde-ffaf-445f-a04f-5f21101289f3", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "476b7807-959b-4151-a851-771a2c945ade"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "275a0806-7a41-4b31-af9d-e9857f5aa1f4", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "7ce95cde-ffaf-445f-a04f-5f21101289f3"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "d8e5efba-b477-4999-a31f-477fc214b9cc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "275a0806-7a41-4b31-af9d-e9857f5aa1f4"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Atazanavir\n  300\u00a0mg qd<br/>\n  (saquinavir/ritonavir 1600/100\u00a0mg qd)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Saquinavir\n  AUC \u2191 60%<br/>\n  Saquinavir C<sub>max</sub> \u2191 42%</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Ritonavir\n  AUC \u2191 41%<br/>\n  Ritonavir C<sub>max</sub> \u2191 34%<br/>\n  Atazanavir </span><span style=\"font-family:Symbol\">\u00ab</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">No clinical data\n  available for the combination of <span lang=\"EN-GB\">saquinavir/ritonavir</span>\n  1000/100\u00a0mg bid and atazanavir.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "f0dbf341-978f-43f2-9c79-cfd08bf97cc9", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Atazanavir\n  300\u00a0mg qd<br/>\n  (saquinavir/ritonavir 1600/100\u00a0mg qd)</span></p>\n</td>", "ID": "9e032313-068f-4c2b-bf8f-ac7de2faf702", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f0dbf341-978f-43f2-9c79-cfd08bf97cc9"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Atazanavir\n  300\u00a0mg qd<br/>\n  (saquinavir/ritonavir 1600/100\u00a0mg qd)</span></p>", "ID": "2d643fdc-689b-482d-b5b2-8a49b63b73ce", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "9e032313-068f-4c2b-bf8f-ac7de2faf702"}, {"Element": "<span lang=\"PT-BR\">Atazanavir\n  300\u00a0mg qd<br/>\n  (saquinavir/ritonavir 1600/100\u00a0mg qd)</span>", "ID": "f29ad221-7365-469a-9e20-0ccb4e8cc4d9", "Styles": "None", "Classes": "None", "Text": "Atazanavir   300\u00a0mg qd   (saquinavir/ritonavir 1600/100\u00a0mg qd)", "ParentId": "2d643fdc-689b-482d-b5b2-8a49b63b73ce"}, {"Element": "<br/>", "ID": "2cf59180-4c8f-45be-b00b-09a822f270b2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f29ad221-7365-469a-9e20-0ccb4e8cc4d9"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Saquinavir\n  AUC \u2191 60%<br/>\n  Saquinavir C<sub>max</sub> \u2191 42%</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Ritonavir\n  AUC \u2191 41%<br/>\n  Ritonavir C<sub>max</sub> \u2191 34%<br/>\n  Atazanavir </span><span style=\"font-family:Symbol\">\u00ab</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">No clinical data\n  available for the combination of <span lang=\"EN-GB\">saquinavir/ritonavir</span>\n  1000/100\u00a0mg bid and atazanavir.</p>\n</td>", "ID": "07de8065-ce1d-440a-a33b-59806510544c", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "f0dbf341-978f-43f2-9c79-cfd08bf97cc9"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Saquinavir\n  AUC \u2191 60%<br/>\n  Saquinavir C<sub>max</sub> \u2191 42%</span></p>", "ID": "8228883c-880b-46de-9ea9-bb430ade5307", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "07de8065-ce1d-440a-a33b-59806510544c"}, {"Element": "<span lang=\"PT-BR\">Saquinavir\n  AUC \u2191 60%<br/>\n  Saquinavir C<sub>max</sub> \u2191 42%</span>", "ID": "c82f8c37-2dee-41d0-9ea7-19b5f5562ac2", "Styles": "None", "Classes": "None", "Text": "Saquinavir   AUC \u2191 60%   Saquinavir C \u2191 42%", "ParentId": "8228883c-880b-46de-9ea9-bb430ade5307"}, {"Element": "<br/>", "ID": "3a0b07e8-fec0-4979-b26f-5f71c8006ce4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c82f8c37-2dee-41d0-9ea7-19b5f5562ac2"}, {"Element": "<sub>max</sub>", "ID": "99db8961-cc26-4f22-89e9-45eed6e25d3e", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "c82f8c37-2dee-41d0-9ea7-19b5f5562ac2"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Ritonavir\n  AUC \u2191 41%<br/>\n  Ritonavir C<sub>max</sub> \u2191 34%<br/>\n  Atazanavir </span><span style=\"font-family:Symbol\">\u00ab</span></p>", "ID": "6c7f5d10-f729-4ec7-9e2b-ca1f90baf5bf", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "07de8065-ce1d-440a-a33b-59806510544c"}, {"Element": "<span lang=\"PT-BR\">Ritonavir\n  AUC \u2191 41%<br/>\n  Ritonavir C<sub>max</sub> \u2191 34%<br/>\n  Atazanavir </span>", "ID": "bd34e8c8-84da-49de-9f1d-cc6c3cc3a4cc", "Styles": "None", "Classes": "None", "Text": "Ritonavir   AUC \u2191 41%   Ritonavir C \u2191 34%   Atazanavir ", "ParentId": "6c7f5d10-f729-4ec7-9e2b-ca1f90baf5bf"}, {"Element": "<br/>", "ID": "ceb92f97-b126-44a9-ad3b-d8d82a85b503", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bd34e8c8-84da-49de-9f1d-cc6c3cc3a4cc"}, {"Element": "<sub>max</sub>", "ID": "7d20ac9b-f572-4d33-ba59-8873bbd0a08f", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "bd34e8c8-84da-49de-9f1d-cc6c3cc3a4cc"}, {"Element": "<br/>", "ID": "3ac6698e-a160-4638-afc9-e64c8bf40262", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bd34e8c8-84da-49de-9f1d-cc6c3cc3a4cc"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "e7ad5ff3-ebd9-48e5-b3b1-3b2f39d16c2f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "6c7f5d10-f729-4ec7-9e2b-ca1f90baf5bf"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">No clinical data\n  available for the combination of <span lang=\"EN-GB\">saquinavir/ritonavir</span>\n  1000/100\u00a0mg bid and atazanavir.</p>", "ID": "dd2b805f-12a0-4fa6-a0e1-b4eb8b460385", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "No clinical data   available for the combination of    1000/100\u00a0mg bid and atazanavir.", "ParentId": "07de8065-ce1d-440a-a33b-59806510544c"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "c9b2d590-a9af-4461-8c9d-b00f6372c23f", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "dd2b805f-12a0-4fa6-a0e1-b4eb8b460385"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "b6aad3a4-7d77-448f-a7c6-b0ab0921c073", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f0dbf341-978f-43f2-9c79-cfd08bf97cc9"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "e48555e2-c90d-4bd9-be27-e2d5e4fa7afa", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated in   combination with  due to the   potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)", "ParentId": "b6aad3a4-7d77-448f-a7c6-b0ab0921c073"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "6729f56a-4c31-40bf-bb26-318e8356b5e3", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "e48555e2-c90d-4bd9-be27-e2d5e4fa7afa"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "b0517610-4f19-4d39-b138-2579fac77d2f", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "e48555e2-c90d-4bd9-be27-e2d5e4fa7afa"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Fosamprenavir<br/>\n  700\u00a0mg bid</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">(saquinavir/ritonavir\n  1000/100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC <span style=\"font-family:Symbol\">\u00af</span> 15%<br/>\n  Saquinavir C<sub>max</sub> <span style=\"font-family:Symbol\">\u00af</span> 9%</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir C<sub>min</sub>\n<span style=\"font-family:Symbol\">\u00af</span> 24% (remained above the target\n  threshold for effective therapy.)</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">No dose\n  adjustment required</span><span lang=\"EN-GB\"> for Invirase/ritonavir</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "02e14aa7-5829-41fb-ad14-85a0a7082bf6", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Fosamprenavir<br/>\n  700\u00a0mg bid</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">(saquinavir/ritonavir\n  1000/100\u00a0mg bid)</span></p>\n</td>", "ID": "2c37490b-3c23-466e-84b3-9eccd4bde180", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "02e14aa7-5829-41fb-ad14-85a0a7082bf6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Fosamprenavir<br/>\n  700\u00a0mg bid</span></p>", "ID": "75b38c93-44ee-4183-8418-731c7a5a589e", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "2c37490b-3c23-466e-84b3-9eccd4bde180"}, {"Element": "<span lang=\"PT-BR\">Fosamprenavir<br/>\n  700\u00a0mg bid</span>", "ID": "ce357960-12e7-424a-9f16-decdfd817481", "Styles": "None", "Classes": "None", "Text": "Fosamprenavir   700\u00a0mg bid", "ParentId": "75b38c93-44ee-4183-8418-731c7a5a589e"}, {"Element": "<br/>", "ID": "4ab95431-0c30-4c20-90dd-d7f0d7628150", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ce357960-12e7-424a-9f16-decdfd817481"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">(saquinavir/ritonavir\n  1000/100\u00a0mg bid)</span></p>", "ID": "53cb875e-d12a-4e41-90b3-df4e7632c190", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "2c37490b-3c23-466e-84b3-9eccd4bde180"}, {"Element": "<span lang=\"PT-BR\">(saquinavir/ritonavir\n  1000/100\u00a0mg bid)</span>", "ID": "e3672dcc-b18d-4261-a97d-e14a9ff77aff", "Styles": "None", "Classes": "None", "Text": "(saquinavir/ritonavir   1000/100\u00a0mg bid)", "ParentId": "53cb875e-d12a-4e41-90b3-df4e7632c190"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC <span style=\"font-family:Symbol\">\u00af</span> 15%<br/>\n  Saquinavir C<sub>max</sub> <span style=\"font-family:Symbol\">\u00af</span> 9%</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir C<sub>min</sub>\n<span style=\"font-family:Symbol\">\u00af</span> 24% (remained above the target\n  threshold for effective therapy.)</p>\n</td>", "ID": "be74a7bd-a408-439b-b6da-37b608db0a00", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "02e14aa7-5829-41fb-ad14-85a0a7082bf6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC <span style=\"font-family:Symbol\">\u00af</span> 15%<br/>\n  Saquinavir C<sub>max</sub> <span style=\"font-family:Symbol\">\u00af</span> 9%</p>", "ID": "82cb724a-0daa-4b2e-9585-93c2f77e1929", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Saquinavir AUC  15%   Saquinavir C  9%", "ParentId": "be74a7bd-a408-439b-b6da-37b608db0a00"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "8f90c0f0-19f5-45cb-bec0-02ecc6b31aa8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "82cb724a-0daa-4b2e-9585-93c2f77e1929"}, {"Element": "<br/>", "ID": "7416b368-9534-453f-857f-bc9a141fe2b2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "82cb724a-0daa-4b2e-9585-93c2f77e1929"}, {"Element": "<sub>max</sub>", "ID": "b9285775-0c18-4c2a-9487-3df30c1d6163", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "82cb724a-0daa-4b2e-9585-93c2f77e1929"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "2a767472-0569-4ec6-bad9-486dce9878bf", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "82cb724a-0daa-4b2e-9585-93c2f77e1929"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir C<sub>min</sub>\n<span style=\"font-family:Symbol\">\u00af</span> 24% (remained above the target\n  threshold for effective therapy.)</p>", "ID": "7f871fe8-dbb5-49c9-97f9-b839bf7640e1", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Saquinavir C  24% (remained above the target   threshold for effective therapy.)", "ParentId": "be74a7bd-a408-439b-b6da-37b608db0a00"}, {"Element": "<sub>min</sub>", "ID": "241a23bf-903b-4465-a491-0d980535bc2b", "Styles": "None", "Classes": "None", "Text": "min", "ParentId": "7f871fe8-dbb5-49c9-97f9-b839bf7640e1"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "b7872469-0e55-4462-a5fb-734fa62b3e36", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "7f871fe8-dbb5-49c9-97f9-b839bf7640e1"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">No dose\n  adjustment required</span><span lang=\"EN-GB\"> for Invirase/ritonavir</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "7904f47b-41ea-4dce-9a08-a1d3c032dff5", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "02e14aa7-5829-41fb-ad14-85a0a7082bf6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">No dose\n  adjustment required</span><span lang=\"EN-GB\"> for Invirase/ritonavir</span><span lang=\"EN-GB\">.</span></p>", "ID": "4ca0c1f4-d926-4304-a386-09b1e4c348d6", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "7904f47b-41ea-4dce-9a08-a1d3c032dff5"}, {"Element": "<span lang=\"EN-GB\">No dose\n  adjustment required</span>", "ID": "4ab454b8-7229-4f13-99e2-8d4463e1f861", "Styles": "None", "Classes": "None", "Text": "No dose   adjustment required", "ParentId": "4ca0c1f4-d926-4304-a386-09b1e4c348d6"}, {"Element": "<span lang=\"EN-GB\"> for Invirase/ritonavir</span>", "ID": "26dde659-f9a0-4477-bd5d-a067666cddcf", "Styles": "None", "Classes": "None", "Text": " for Invirase/ritonavir", "ParentId": "4ca0c1f4-d926-4304-a386-09b1e4c348d6"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "b5ca97e3-d86f-41c7-9e1c-f9cd841a4488", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "4ca0c1f4-d926-4304-a386-09b1e4c348d6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "eb2b7cdc-30e4-4749-9dd0-f7d706796055", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "7904f47b-41ea-4dce-9a08-a1d3c032dff5"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Indinavir<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Low dose ritonavir\n  increases the concentration of indinavir.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Increased\n  concentrations of indinavir may result in nephrolithiasis.</span></p>\n</td>\n</tr>", "ID": "4e1acdf4-7c4e-4375-8b35-a404dbbc6602", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Indinavir<br/>\n  (saquinavir/ritonavir)</p>\n</td>", "ID": "275d176c-f43a-44cc-9049-796fb2a34e24", "Styles": "width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4e1acdf4-7c4e-4375-8b35-a404dbbc6602"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Indinavir<br/>\n  (saquinavir/ritonavir)</p>", "ID": "6e108f7c-1db3-42a0-ba86-fb102a02034d", "Styles": "margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 Indinavir   (saquinavir/ritonavir)", "ParentId": "275d176c-f43a-44cc-9049-796fb2a34e24"}, {"Element": "<br/>", "ID": "66bd7115-c448-4cd4-a40e-ef4ba3ce35ca", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6e108f7c-1db3-42a0-ba86-fb102a02034d"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Low dose ritonavir\n  increases the concentration of indinavir.</p>\n</td>", "ID": "c52ed575-275b-4ff5-adeb-a80773aa1d18", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4e1acdf4-7c4e-4375-8b35-a404dbbc6602"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Low dose ritonavir\n  increases the concentration of indinavir.</p>", "ID": "215f03ff-7e26-4ead-9ca1-6c1e74dffc9d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Low dose ritonavir   increases the concentration of indinavir.", "ParentId": "c52ed575-275b-4ff5-adeb-a80773aa1d18"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Increased\n  concentrations of indinavir may result in nephrolithiasis.</span></p>\n</td>", "ID": "da75545b-d328-4dd5-a8c9-a834bd1027d5", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4e1acdf4-7c4e-4375-8b35-a404dbbc6602"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Increased\n  concentrations of indinavir may result in nephrolithiasis.</span></p>", "ID": "0ae5f2e3-8a69-4a78-8890-9f89f8328d9d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "da75545b-d328-4dd5-a8c9-a834bd1027d5"}, {"Element": "<span lang=\"EN-GB\">Increased\n  concentrations of indinavir may result in nephrolithiasis.</span>", "ID": "0b4be546-c5ec-4f79-9c59-85a4cf6b46df", "Styles": "None", "Classes": "None", "Text": "Increased   concentrations of indinavir may result in nephrolithiasis.", "ParentId": "0ae5f2e3-8a69-4a78-8890-9f89f8328d9d"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Indinavir 800\u00a0mg tid<br/>\n  (saquinavir 600-1200\u00a0mg single dose)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC \u2191\n  4.6-7.2 fold<br/>\n  Indinavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  No safety and efficacy data available for this combination. Appropriate doses\n  of combination not established.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "d34c3e6c-ac86-45ac-93f6-0955448d2bec", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Indinavir 800\u00a0mg tid<br/>\n  (saquinavir 600-1200\u00a0mg single dose)</p>\n</td>", "ID": "a405b077-3fdb-4fea-b1f4-acfac36b48e0", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d34c3e6c-ac86-45ac-93f6-0955448d2bec"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Indinavir 800\u00a0mg tid<br/>\n  (saquinavir 600-1200\u00a0mg single dose)</p>", "ID": "3af59257-6ba6-4338-8b10-69aef05b4872", "Styles": "margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 Indinavir 800\u00a0mg tid   (saquinavir 600-1200\u00a0mg single dose)", "ParentId": "a405b077-3fdb-4fea-b1f4-acfac36b48e0"}, {"Element": "<br/>", "ID": "09aee24e-9e78-4034-993b-b50cafdefbad", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3af59257-6ba6-4338-8b10-69aef05b4872"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC \u2191\n  4.6-7.2 fold<br/>\n  Indinavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  No safety and efficacy data available for this combination. Appropriate doses\n  of combination not established.</p>\n</td>", "ID": "304e2cf4-d364-431e-aa60-f1cb9ede844f", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d34c3e6c-ac86-45ac-93f6-0955448d2bec"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC \u2191\n  4.6-7.2 fold<br/>\n  Indinavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  No safety and efficacy data available for this combination. Appropriate doses\n  of combination not established.</p>", "ID": "7d1919f6-e6ad-4b87-8e50-f931ad978d57", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Saquinavir AUC \u2191   4.6-7.2 fold   Indinavir    No safety and efficacy data available for this combination. Appropriate doses   of combination not established.", "ParentId": "304e2cf4-d364-431e-aa60-f1cb9ede844f"}, {"Element": "<br/>", "ID": "677f0d5f-984f-4bf4-8957-710fe9e19920", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7d1919f6-e6ad-4b87-8e50-f931ad978d57"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "a50f7203-6890-4a6e-ae14-466001a5efcd", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "7d1919f6-e6ad-4b87-8e50-f931ad978d57"}, {"Element": "<br/>", "ID": "ba474d74-c3c7-4cdf-b1a7-d7afeef63e35", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7d1919f6-e6ad-4b87-8e50-f931ad978d57"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "7e8084e0-f338-42cb-91ff-6271845cff7f", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d34c3e6c-ac86-45ac-93f6-0955448d2bec"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8ee73ff6-6923-45e4-a57b-95e09d014ec4", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "7e8084e0-f338-42cb-91ff-6271845cff7f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cf008c71-7927-46f6-8b3b-70fecc855df1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8ee73ff6-6923-45e4-a57b-95e09d014ec4"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Lopinavir/ritonavir 400/100\u00a0mg bid<br/>\n  (<span lang=\"EN-GB\">saquinavir</span> 1000\u00a0mg bid in combination with 2 or\n  3 NRTIs)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Saquinavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  Ritonavir <span style=\"font-family:Symbol\">\u00af</span> (effectiveness as\n  boosting agent not modified).</p>\n<p class=\"MsoNormal\">Lopinavir <span style=\"font-family:Symbol\">\u00ab</span>\n  (based on historical comparison with unboosted lopinavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">\u00a0Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the potential for life\n  threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "4a66b0ac-70d6-48e8-82f9-710f03f81def", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Lopinavir/ritonavir 400/100\u00a0mg bid<br/>\n  (<span lang=\"EN-GB\">saquinavir</span> 1000\u00a0mg bid in combination with 2 or\n  3 NRTIs)</p>\n</td>", "ID": "0cc8b1eb-28bf-4601-bf93-2eb9377e9aff", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4a66b0ac-70d6-48e8-82f9-710f03f81def"}, {"Element": "<p class=\"Normal11pt0\">Lopinavir/ritonavir 400/100\u00a0mg bid<br/>\n  (<span lang=\"EN-GB\">saquinavir</span> 1000\u00a0mg bid in combination with 2 or\n  3 NRTIs)</p>", "ID": "bacd782d-f056-471e-9bdf-381dfe4bec25", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Lopinavir/ritonavir 400/100\u00a0mg bid   ( 1000\u00a0mg bid in combination with 2 or   3 NRTIs)", "ParentId": "0cc8b1eb-28bf-4601-bf93-2eb9377e9aff"}, {"Element": "<br/>", "ID": "eaba8ad6-ebb3-4823-a442-ab256528e173", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bacd782d-f056-471e-9bdf-381dfe4bec25"}, {"Element": "<span lang=\"EN-GB\">saquinavir</span>", "ID": "c49a2f71-2a60-40a9-9cb0-bf3bee532936", "Styles": "None", "Classes": "None", "Text": "saquinavir", "ParentId": "bacd782d-f056-471e-9bdf-381dfe4bec25"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Saquinavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  Ritonavir <span style=\"font-family:Symbol\">\u00af</span> (effectiveness as\n  boosting agent not modified).</p>\n<p class=\"MsoNormal\">Lopinavir <span style=\"font-family:Symbol\">\u00ab</span>\n  (based on historical comparison with unboosted lopinavir)</p>\n</td>", "ID": "141b644f-df4a-4185-91dd-804d6cc08d52", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "4a66b0ac-70d6-48e8-82f9-710f03f81def"}, {"Element": "<p class=\"Normal11pt0\">Saquinavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  Ritonavir <span style=\"font-family:Symbol\">\u00af</span> (effectiveness as\n  boosting agent not modified).</p>", "ID": "5b04746a-9a8e-4d1c-9929-eb4dedd5c3d9", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Saquinavir    Ritonavir  (effectiveness as   boosting agent not modified).", "ParentId": "141b644f-df4a-4185-91dd-804d6cc08d52"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "93e46901-7e40-435f-b31c-ea31dbc2de7e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "5b04746a-9a8e-4d1c-9929-eb4dedd5c3d9"}, {"Element": "<br/>", "ID": "0146ec9c-ce90-4b86-a994-81c2941fe279", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5b04746a-9a8e-4d1c-9929-eb4dedd5c3d9"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "2c170839-0d37-4a2c-8d84-a27eb6fe9439", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "5b04746a-9a8e-4d1c-9929-eb4dedd5c3d9"}, {"Element": "<p class=\"MsoNormal\">Lopinavir <span style=\"font-family:Symbol\">\u00ab</span>\n  (based on historical comparison with unboosted lopinavir)</p>", "ID": "ced7a22c-b805-4668-9696-ca1cddf85cc1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Lopinavir    (based on historical comparison with unboosted lopinavir)", "ParentId": "141b644f-df4a-4185-91dd-804d6cc08d52"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "916e9ffd-9dad-43c6-ae38-c25cd53b25dd", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "ced7a22c-b805-4668-9696-ca1cddf85cc1"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">\u00a0Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the potential for life\n  threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "0d05b219-8d61-4436-b30e-3fb8ebde8838", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4a66b0ac-70d6-48e8-82f9-710f03f81def"}, {"Element": "<p class=\"Normal11pt0\">\u00a0Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the potential for life\n  threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "9d44f18e-a62c-468b-8d23-b448450a6580", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "\u00a0Contraindicated in combination with  due to the potential for life   threatening cardiac arrhythmia (see sections 4.3 and 4.4)", "ParentId": "0d05b219-8d61-4436-b30e-3fb8ebde8838"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "e4b1cfa6-f121-438d-ab4d-eabf335fdd66", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "9d44f18e-a62c-468b-8d23-b448450a6580"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "daa190ed-55d1-4a7f-b80d-7b7ff32e20ae", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "9d44f18e-a62c-468b-8d23-b448450a6580"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Nelfinavir 1250\u00a0mg bid<br/>\n  (saquinavir/ritonavir 1000/100\u00a0mg bid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC \u2191\n  13%<br/>\n  (90% CI: 27<span style=\"font-family:Symbol\">\u00af</span> - 74\u2191)<br/>\n  Saquinavir Cmax \u2191 9%<br/>\n  (90% CI: 27<span style=\"font-family:Symbol\">\u00af</span> - 61\u2191 )<br/>\n  Nelfinavir AUC <span style=\"font-family:Symbol\">\u00af</span> 6%<br/>\n  (90% CI: 28<span style=\"font-family:Symbol\">\u00af</span> - 22\u2191)<br/>\n  Nelfinavir Cmax <span style=\"font-family:Symbol\">\u00af</span> 5%<br/>\n  (90% CI: 23<span style=\"font-family:Symbol\">\u00af</span> - 16\u2191)</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;page-break-after:avoid\">Combination\n  not recommended.</p>\n</td>\n</tr>", "ID": "f6e45f8e-be99-4bd3-89f2-2e20454a1d43", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Nelfinavir 1250\u00a0mg bid<br/>\n  (saquinavir/ritonavir 1000/100\u00a0mg bid)</p>\n</td>", "ID": "c33ff836-8b4c-4a24-974d-c2bd97a9119f", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f6e45f8e-be99-4bd3-89f2-2e20454a1d43"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 Nelfinavir 1250\u00a0mg bid<br/>\n  (saquinavir/ritonavir 1000/100\u00a0mg bid)</p>", "ID": "3eeee126-b8e6-4b2c-9ed0-c73df08ae171", "Styles": "margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 Nelfinavir 1250\u00a0mg bid   (saquinavir/ritonavir 1000/100\u00a0mg bid)", "ParentId": "c33ff836-8b4c-4a24-974d-c2bd97a9119f"}, {"Element": "<br/>", "ID": "92f1296e-3526-4ead-ba2f-7f00859ad5df", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3eeee126-b8e6-4b2c-9ed0-c73df08ae171"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC \u2191\n  13%<br/>\n  (90% CI: 27<span style=\"font-family:Symbol\">\u00af</span> - 74\u2191)<br/>\n  Saquinavir Cmax \u2191 9%<br/>\n  (90% CI: 27<span style=\"font-family:Symbol\">\u00af</span> - 61\u2191 )<br/>\n  Nelfinavir AUC <span style=\"font-family:Symbol\">\u00af</span> 6%<br/>\n  (90% CI: 28<span style=\"font-family:Symbol\">\u00af</span> - 22\u2191)<br/>\n  Nelfinavir Cmax <span style=\"font-family:Symbol\">\u00af</span> 5%<br/>\n  (90% CI: 23<span style=\"font-family:Symbol\">\u00af</span> - 16\u2191)</p>\n</td>", "ID": "f651a915-e508-4399-8cfc-ea8268737cad", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f6e45f8e-be99-4bd3-89f2-2e20454a1d43"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC \u2191\n  13%<br/>\n  (90% CI: 27<span style=\"font-family:Symbol\">\u00af</span> - 74\u2191)<br/>\n  Saquinavir Cmax \u2191 9%<br/>\n  (90% CI: 27<span style=\"font-family:Symbol\">\u00af</span> - 61\u2191 )<br/>\n  Nelfinavir AUC <span style=\"font-family:Symbol\">\u00af</span> 6%<br/>\n  (90% CI: 28<span style=\"font-family:Symbol\">\u00af</span> - 22\u2191)<br/>\n  Nelfinavir Cmax <span style=\"font-family:Symbol\">\u00af</span> 5%<br/>\n  (90% CI: 23<span style=\"font-family:Symbol\">\u00af</span> - 16\u2191)</p>", "ID": "624b8320-ffeb-4a82-ae0a-b8025bfc3a8a", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Saquinavir AUC \u2191   13%   (90% CI: 27 - 74\u2191)   Saquinavir Cmax \u2191 9%   (90% CI: 27 - 61\u2191 )   Nelfinavir AUC  6%   (90% CI: 28 - 22\u2191)   Nelfinavir Cmax  5%   (90% CI: 23 - 16\u2191)", "ParentId": "f651a915-e508-4399-8cfc-ea8268737cad"}, {"Element": "<br/>", "ID": "9c5c0111-0eef-4003-b7b1-021e5beb5faa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "624b8320-ffeb-4a82-ae0a-b8025bfc3a8a"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "0303a53c-4a2a-4236-b800-1584baaf7be5", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "624b8320-ffeb-4a82-ae0a-b8025bfc3a8a"}, {"Element": "<br/>", "ID": "0a0475d1-6547-4d9a-aa82-2f872cda67ea", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "624b8320-ffeb-4a82-ae0a-b8025bfc3a8a"}, {"Element": "<br/>", "ID": "a782ca3c-cfe6-4864-af28-801f16fd2074", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "624b8320-ffeb-4a82-ae0a-b8025bfc3a8a"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "00698336-0dee-4cb5-8505-526a9e4dc739", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "624b8320-ffeb-4a82-ae0a-b8025bfc3a8a"}, {"Element": "<br/>", "ID": "adaa0967-a766-4588-a064-825e0f6d418b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "624b8320-ffeb-4a82-ae0a-b8025bfc3a8a"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "70ad2a34-e7a8-4781-954f-883326e2c3ff", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "624b8320-ffeb-4a82-ae0a-b8025bfc3a8a"}, {"Element": "<br/>", "ID": "b764e16d-d3e7-40b0-9ac9-ca45d20deac6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "624b8320-ffeb-4a82-ae0a-b8025bfc3a8a"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "196455c3-652a-4897-a718-f6187d1725fd", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "624b8320-ffeb-4a82-ae0a-b8025bfc3a8a"}, {"Element": "<br/>", "ID": "700cda97-78eb-43bb-b690-b96885069076", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "624b8320-ffeb-4a82-ae0a-b8025bfc3a8a"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "837ddffe-50d7-4f17-b2e3-c4adf8382580", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "624b8320-ffeb-4a82-ae0a-b8025bfc3a8a"}, {"Element": "<br/>", "ID": "379ace20-7cda-4a34-9b9e-480fe0512ae1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "624b8320-ffeb-4a82-ae0a-b8025bfc3a8a"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "21af753a-0e98-426f-9298-883a39bdff7f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "624b8320-ffeb-4a82-ae0a-b8025bfc3a8a"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;page-break-after:avoid\">Combination\n  not recommended.</p>\n</td>", "ID": "e23a84a8-27eb-4b14-a400-ed4d3655e0d1", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f6e45f8e-be99-4bd3-89f2-2e20454a1d43"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:.45pt;page-break-after:avoid\">Combination\n  not recommended.</p>", "ID": "06bed2ff-71a6-43d5-b188-c8f9af97ecc4", "Styles": "margin-left:.45pt;page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Combination   not recommended.", "ParentId": "e23a84a8-27eb-4b14-a400-ed4d3655e0d1"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Ritonavir 100\u00a0mg bid<br/>\n  (saquinavir 1000\u00a0mg bid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir \u2191</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Ritonavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n<span lang=\"EN-GB\">In HIV-infected patients, Invirase or saquinavir soft\n  capsules in combination with ritonavir at doses of 1000/100\u00a0mg twice\n  daily provide a systemic exposure of saquinavir over a 24 hour period similar\n  to or greater than that achieved with saquinavir soft capsules 1200\u00a0mg\n  three times daily (see section 5.2).</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">This is\n  the approved combination regimen. No dose adjustment is recommended.</span></p>\n</td>\n</tr>", "ID": "0335a47b-b736-4a33-a3de-dd2597c61414", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Ritonavir 100\u00a0mg bid<br/>\n  (saquinavir 1000\u00a0mg bid)</p>\n</td>", "ID": "317e2990-3c41-400d-bcaa-f7d9ad07e20a", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0335a47b-b736-4a33-a3de-dd2597c61414"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Ritonavir 100\u00a0mg bid<br/>\n  (saquinavir 1000\u00a0mg bid)</p>", "ID": "b1c01f24-8092-481c-a9ce-be07c516f680", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Ritonavir 100\u00a0mg bid   (saquinavir 1000\u00a0mg bid)", "ParentId": "317e2990-3c41-400d-bcaa-f7d9ad07e20a"}, {"Element": "<br/>", "ID": "1151d881-2bc6-40c3-9821-bfa5a08d0ccd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b1c01f24-8092-481c-a9ce-be07c516f680"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir \u2191</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Ritonavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n<span lang=\"EN-GB\">In HIV-infected patients, Invirase or saquinavir soft\n  capsules in combination with ritonavir at doses of 1000/100\u00a0mg twice\n  daily provide a systemic exposure of saquinavir over a 24 hour period similar\n  to or greater than that achieved with saquinavir soft capsules 1200\u00a0mg\n  three times daily (see section 5.2).</span></p>\n</td>", "ID": "ce021d7b-da59-441f-bf89-cc9df16c8ffc", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "0335a47b-b736-4a33-a3de-dd2597c61414"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir \u2191</p>", "ID": "8757fb50-9112-46e9-9ada-74fc51564f2d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Saquinavir \u2191", "ParentId": "ce021d7b-da59-441f-bf89-cc9df16c8ffc"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Ritonavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n<span lang=\"EN-GB\">In HIV-infected patients, Invirase or saquinavir soft\n  capsules in combination with ritonavir at doses of 1000/100\u00a0mg twice\n  daily provide a systemic exposure of saquinavir over a 24 hour period similar\n  to or greater than that achieved with saquinavir soft capsules 1200\u00a0mg\n  three times daily (see section 5.2).</span></p>", "ID": "2fcc4ec6-816e-4275-bc6c-07ee5a28ea28", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Ritonavir  ", "ParentId": "ce021d7b-da59-441f-bf89-cc9df16c8ffc"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "675302fe-e608-4f42-9e60-5a48660b0fa3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "2fcc4ec6-816e-4275-bc6c-07ee5a28ea28"}, {"Element": "<br/>", "ID": "93feca15-8b89-4294-a7a9-94817d763eb8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2fcc4ec6-816e-4275-bc6c-07ee5a28ea28"}, {"Element": "<span lang=\"EN-GB\">In HIV-infected patients, Invirase or saquinavir soft\n  capsules in combination with ritonavir at doses of 1000/100\u00a0mg twice\n  daily provide a systemic exposure of saquinavir over a 24 hour period similar\n  to or greater than that achieved with saquinavir soft capsules 1200\u00a0mg\n  three times daily (see section 5.2).</span>", "ID": "b8b65350-691b-439a-9ed7-cdacb6d6ac5a", "Styles": "None", "Classes": "None", "Text": "In HIV-infected patients, Invirase or saquinavir soft   capsules in combination with ritonavir at doses of 1000/100\u00a0mg twice   daily provide a systemic exposure of saquinavir over a 24 hour period similar   to or greater than that achieved with saquinavir soft capsules 1200\u00a0mg   three times daily (see section 5.2).", "ParentId": "2fcc4ec6-816e-4275-bc6c-07ee5a28ea28"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">This is\n  the approved combination regimen. No dose adjustment is recommended.</span></p>\n</td>", "ID": "355e2be1-511e-44d3-889d-08468e930cdf", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0335a47b-b736-4a33-a3de-dd2597c61414"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">This is\n  the approved combination regimen. No dose adjustment is recommended.</span></p>", "ID": "725a06d6-6ef3-40ca-8fce-833d4fce3b9b", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "355e2be1-511e-44d3-889d-08468e930cdf"}, {"Element": "<span lang=\"EN-GB\">This is\n  the approved combination regimen. No dose adjustment is recommended.</span>", "ID": "3600e161-de70-42f9-a2e8-9364d8be9e10", "Styles": "None", "Classes": "None", "Text": "This is   the approved combination regimen. No dose adjustment is recommended.", "ParentId": "725a06d6-6ef3-40ca-8fce-833d4fce3b9b"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Tipranavir/ritonavir<br/>\n  (<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Saquinavir C<sub>min</sub> <span style=\"font-family:\n  Symbol\">\u00af</span> 78%<br/>\n  Dual-boosted protease inhibitor combination therapy in multiple-treatment\n  experienced HIV-positive adults.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Concomitant administration of tipranavir,\n  co-administered with low dose ritonavir, with saquinavir/ritonavir, is not\n  recommended. If the combination is considered necessary, monitoring of the\n  saquinavir plasma levels is strongly encouraged (see section 4.4).</p>\n</td>\n</tr>", "ID": "edee935a-b06f-4e01-b854-20f239f38cc7", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Tipranavir/ritonavir<br/>\n  (<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>", "ID": "8ddb6be7-1ed6-4f2f-abfc-73d54eb234e1", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "edee935a-b06f-4e01-b854-20f239f38cc7"}, {"Element": "<p class=\"Normal11pt0\">Tipranavir/ritonavir<br/>\n  (<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>", "ID": "5178e890-a5f4-4b75-9b50-78e148eca53a", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Tipranavir/ritonavir   ()", "ParentId": "8ddb6be7-1ed6-4f2f-abfc-73d54eb234e1"}, {"Element": "<br/>", "ID": "e288bba3-95ad-4d03-a636-86bff4b7e471", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5178e890-a5f4-4b75-9b50-78e148eca53a"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "80a3129a-1b49-425f-88f9-799cd924369f", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "5178e890-a5f4-4b75-9b50-78e148eca53a"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Saquinavir C<sub>min</sub> <span style=\"font-family:\n  Symbol\">\u00af</span> 78%<br/>\n  Dual-boosted protease inhibitor combination therapy in multiple-treatment\n  experienced HIV-positive adults.</p>\n</td>", "ID": "ff7d64fc-aefe-4da7-9742-6f216e29ceb2", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "edee935a-b06f-4e01-b854-20f239f38cc7"}, {"Element": "<p class=\"Normal11pt0\">Saquinavir C<sub>min</sub> <span style=\"font-family:\n  Symbol\">\u00af</span> 78%<br/>\n  Dual-boosted protease inhibitor combination therapy in multiple-treatment\n  experienced HIV-positive adults.</p>", "ID": "b38b675c-8928-4f8a-b90c-8a1863182cb3", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Saquinavir C  78%   Dual-boosted protease inhibitor combination therapy in multiple-treatment   experienced HIV-positive adults.", "ParentId": "ff7d64fc-aefe-4da7-9742-6f216e29ceb2"}, {"Element": "<sub>min</sub>", "ID": "0aff6d90-1230-491f-92fa-4e2c4a081540", "Styles": "None", "Classes": "None", "Text": "min", "ParentId": "b38b675c-8928-4f8a-b90c-8a1863182cb3"}, {"Element": "<span style=\"font-family:\n  Symbol\">\u00af</span>", "ID": "a279f16e-af57-44fc-a42e-96f15645f0dc", "Styles": "font-family:\n  Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "b38b675c-8928-4f8a-b90c-8a1863182cb3"}, {"Element": "<br/>", "ID": "ea0ff74b-39d9-4479-b60e-e8af51294137", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b38b675c-8928-4f8a-b90c-8a1863182cb3"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Concomitant administration of tipranavir,\n  co-administered with low dose ritonavir, with saquinavir/ritonavir, is not\n  recommended. If the combination is considered necessary, monitoring of the\n  saquinavir plasma levels is strongly encouraged (see section 4.4).</p>\n</td>", "ID": "419eb7a4-60dc-4156-b658-c5392caf1ba5", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "edee935a-b06f-4e01-b854-20f239f38cc7"}, {"Element": "<p class=\"Normal11pt0\">Concomitant administration of tipranavir,\n  co-administered with low dose ritonavir, with saquinavir/ritonavir, is not\n  recommended. If the combination is considered necessary, monitoring of the\n  saquinavir plasma levels is strongly encouraged (see section 4.4).</p>", "ID": "84585871-ca87-4bfb-b4b5-b51269732149", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Concomitant administration of tipranavir,   co-administered with low dose ritonavir, with saquinavir/ritonavir, is not   recommended. If the combination is considered necessary, monitoring of the   saquinavir plasma levels is strongly encouraged (see section 4.4).", "ParentId": "419eb7a4-60dc-4156-b658-c5392caf1ba5"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"IT\">HIV fusion inhibitor</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "f3312fac-393f-47e0-a55d-7c8746ac4545", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"IT\">HIV fusion inhibitor</span></i></b></p>\n</td>", "ID": "3cedf1b6-e08c-4e39-8535-5dc93280e14b", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f3312fac-393f-47e0-a55d-7c8746ac4545"}, {"Element": "<p class=\"Normal11pt0\"><b><i><span lang=\"IT\">HIV fusion inhibitor</span></i></b></p>", "ID": "3030a912-797b-4d6e-97f7-d859bd53f499", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "3cedf1b6-e08c-4e39-8535-5dc93280e14b"}, {"Element": "<b><i><span lang=\"IT\">HIV fusion inhibitor</span></i></b>", "ID": "905bda6e-7c39-4436-99e4-200f346c28a5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3030a912-797b-4d6e-97f7-d859bd53f499"}, {"Element": "<i><span lang=\"IT\">HIV fusion inhibitor</span></i>", "ID": "71df1866-94bf-41a1-b308-7e07e102150b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "905bda6e-7c39-4436-99e4-200f346c28a5"}, {"Element": "<span lang=\"IT\">HIV fusion inhibitor</span>", "ID": "23ce65ab-94b2-44fe-8419-d24b74184501", "Styles": "None", "Classes": "None", "Text": "HIV fusion inhibitor", "ParentId": "71df1866-94bf-41a1-b308-7e07e102150b"}, {"Element": "<td style=\"width:11.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "d3a82679-9b80-45e3-be43-46f49fb3036d", "Styles": "width:11.8pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f3312fac-393f-47e0-a55d-7c8746ac4545"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "f4cb17eb-0aff-4e69-b127-1fdf95d5a43f", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "d3a82679-9b80-45e3-be43-46f49fb3036d"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "5adb2923-abef-4966-93e4-c557903481e9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f4cb17eb-0aff-4e69-b127-1fdf95d5a43f"}, {"Element": "<td style=\"width:14.2pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "a85b54b0-fd37-49da-8c81-3fa8ce0a995f", "Styles": "width:14.2pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f3312fac-393f-47e0-a55d-7c8746ac4545"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "5731763e-2b4f-4316-acee-0ab02d4a8ab2", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "a85b54b0-fd37-49da-8c81-3fa8ce0a995f"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "9b123ce1-cc22-4e46-a5fd-bad8923cd87a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5731763e-2b4f-4316-acee-0ab02d4a8ab2"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Enfuvirtide<br/>\n  (saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Saquinavir <span style=\"font-family:Symbol\">\u00ab</span></p>\n<p class=\"Normal11pt0\">Enfuvirtide <span style=\"font-family:Symbol\">\u00ab</span><br/>\n<span lang=\"EN-GB\">No clinically significant interaction was noted.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required.</span></p>\n</td>\n</tr>", "ID": "61616294-349a-4602-a684-403738026415", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Enfuvirtide<br/>\n  (saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n</td>", "ID": "7ee93726-51d5-4ffe-80c2-e5bf9d5c9416", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "61616294-349a-4602-a684-403738026415"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Enfuvirtide<br/>\n  (saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>", "ID": "3885be76-d6ae-4a20-bbf8-ee9d4e851857", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "7ee93726-51d5-4ffe-80c2-e5bf9d5c9416"}, {"Element": "<span lang=\"PT-BR\">Enfuvirtide<br/>\n  (saquinavir/ritonavir 1000/100\u00a0mg bid)</span>", "ID": "44dfcafd-31d6-4e5b-93a3-0d9e7437a3cd", "Styles": "None", "Classes": "None", "Text": "Enfuvirtide   (saquinavir/ritonavir 1000/100\u00a0mg bid)", "ParentId": "3885be76-d6ae-4a20-bbf8-ee9d4e851857"}, {"Element": "<br/>", "ID": "b03c6bbe-1095-4f94-bb9b-b03eb5c3ce18", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "44dfcafd-31d6-4e5b-93a3-0d9e7437a3cd"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Saquinavir <span style=\"font-family:Symbol\">\u00ab</span></p>\n<p class=\"Normal11pt0\">Enfuvirtide <span style=\"font-family:Symbol\">\u00ab</span><br/>\n<span lang=\"EN-GB\">No clinically significant interaction was noted.</span></p>\n</td>", "ID": "760db55b-e96f-4cbd-b0a0-c0dded54343e", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "61616294-349a-4602-a684-403738026415"}, {"Element": "<p class=\"Normal11pt0\">Saquinavir <span style=\"font-family:Symbol\">\u00ab</span></p>", "ID": "f023701e-dac5-49a4-a662-cecd86fc22db", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Saquinavir ", "ParentId": "760db55b-e96f-4cbd-b0a0-c0dded54343e"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "164011a7-670c-45ab-ab9d-ba179af18eed", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "f023701e-dac5-49a4-a662-cecd86fc22db"}, {"Element": "<p class=\"Normal11pt0\">Enfuvirtide <span style=\"font-family:Symbol\">\u00ab</span><br/>\n<span lang=\"EN-GB\">No clinically significant interaction was noted.</span></p>", "ID": "db858deb-3937-4144-970e-e985815f43b0", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Enfuvirtide  ", "ParentId": "760db55b-e96f-4cbd-b0a0-c0dded54343e"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "57d7fafd-e303-4042-b839-5cf7a2eedc1d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "db858deb-3937-4144-970e-e985815f43b0"}, {"Element": "<br/>", "ID": "dfa87fb9-5634-44ad-be99-9ba42bda9969", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "db858deb-3937-4144-970e-e985815f43b0"}, {"Element": "<span lang=\"EN-GB\">No clinically significant interaction was noted.</span>", "ID": "e4e56dfa-60f1-49fc-8de2-5b1be7bb2128", "Styles": "None", "Classes": "None", "Text": "No clinically significant interaction was noted.", "ParentId": "db858deb-3937-4144-970e-e985815f43b0"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required.</span></p>\n</td>", "ID": "cbcca5a4-7694-4a50-9744-8663b3ffcb8c", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "61616294-349a-4602-a684-403738026415"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required.</span></p>", "ID": "85d08e74-1e5f-490f-a9ca-a32408587006", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "cbcca5a4-7694-4a50-9744-8663b3ffcb8c"}, {"Element": "<span lang=\"EN-GB\">No dose adjustment required.</span>", "ID": "0bb87dfe-2099-4d7c-8fed-3f35692066db", "Styles": "None", "Classes": "None", "Text": "No dose adjustment required.", "ParentId": "85d08e74-1e5f-490f-a9ca-a32408587006"}, {"Element": "<tr style=\"height:12.9pt\">\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">HIV </span></i></b><b><i>CCR5\n  antagonist</i></b></p>\n</td>\n</tr>", "ID": "81c3adf0-796b-478c-9496-53b590e4d876", "Styles": "height:12.9pt", "Classes": "None", "Text": "  ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">HIV </span></i></b><b><i>CCR5\n  antagonist</i></b></p>\n</td>", "ID": "89bc4949-3018-47f0-baef-10eebb6ddee6", "Styles": "width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt", "Classes": "None", "Text": "  ", "ParentId": "81c3adf0-796b-478c-9496-53b590e4d876"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">HIV </span></i></b><b><i>CCR5\n  antagonist</i></b></p>", "ID": "f7f40ee7-f1dd-4035-8822-f8c60d939013", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "89bc4949-3018-47f0-baef-10eebb6ddee6"}, {"Element": "<b><i><span lang=\"IT\">HIV </span></i></b>", "ID": "1f5de9ae-6e5b-4800-948f-7c941dc32841", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f7f40ee7-f1dd-4035-8822-f8c60d939013"}, {"Element": "<i><span lang=\"IT\">HIV </span></i>", "ID": "07aa8d1c-06e0-45e5-b036-8f703545d62d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1f5de9ae-6e5b-4800-948f-7c941dc32841"}, {"Element": "<span lang=\"IT\">HIV </span>", "ID": "b6797563-1a82-4b63-8ace-37313c826080", "Styles": "None", "Classes": "None", "Text": "HIV ", "ParentId": "07aa8d1c-06e0-45e5-b036-8f703545d62d"}, {"Element": "<b><i>CCR5\n  antagonist</i></b>", "ID": "0f2e5adf-5052-497c-9174-b4808d6c038a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f7f40ee7-f1dd-4035-8822-f8c60d939013"}, {"Element": "<i>CCR5\n  antagonist</i>", "ID": "61ea59d7-a1b0-4cee-975f-7ace18eb1aa0", "Styles": "None", "Classes": "None", "Text": "CCR5   antagonist", "ParentId": "0f2e5adf-5052-497c-9174-b4808d6c038a"}, {"Element": "<tr style=\"height:53.85pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"177\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Maraviroc\n  100\u00a0mg bid</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">(saquinavir/ritonavir\n  1000/100\u00a0mg bid)</span></p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"236\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Maraviroc AUC<sub>12</sub>\n  \u2191 8.77</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Maraviroc C<sub>max</sub>:\n  \u2191 3.78</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir/ritonavir\n  concentrations not measured, no effect is expected.</p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"237\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">No dose\n  adjustment of saquinavir/ritonavir is required. Dose of maraviroc should be decreased\n  to 150\u00a0mg bid with monitoring.</span></p>\n</td>\n</tr>", "ID": "a89413ec-43bc-41eb-8ebd-4e76c87e2c8e", "Styles": "height:53.85pt", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"177\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Maraviroc\n  100\u00a0mg bid</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">(saquinavir/ritonavir\n  1000/100\u00a0mg bid)</span></p>\n</td>", "ID": "3aaf7cfd-61cb-4b43-af73-ed10425909d3", "Styles": "width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.85pt", "Classes": "None", "Text": "   ", "ParentId": "a89413ec-43bc-41eb-8ebd-4e76c87e2c8e"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Maraviroc\n  100\u00a0mg bid</span></p>", "ID": "e9a02ec6-bf65-4231-b2fb-8c07daa8bbe1", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "3aaf7cfd-61cb-4b43-af73-ed10425909d3"}, {"Element": "<span lang=\"PT-BR\">Maraviroc\n  100\u00a0mg bid</span>", "ID": "367da677-1d4e-4911-a21d-16305c50c798", "Styles": "None", "Classes": "None", "Text": "Maraviroc   100\u00a0mg bid", "ParentId": "e9a02ec6-bf65-4231-b2fb-8c07daa8bbe1"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">(saquinavir/ritonavir\n  1000/100\u00a0mg bid)</span></p>", "ID": "5d4ce309-3c9a-4d44-9341-4941933328ac", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "3aaf7cfd-61cb-4b43-af73-ed10425909d3"}, {"Element": "<span lang=\"PT-BR\">(saquinavir/ritonavir\n  1000/100\u00a0mg bid)</span>", "ID": "8711f7e7-d32b-4702-a9f1-4881a94bbf2f", "Styles": "None", "Classes": "None", "Text": "(saquinavir/ritonavir   1000/100\u00a0mg bid)", "ParentId": "5d4ce309-3c9a-4d44-9341-4941933328ac"}, {"Element": "<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"236\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Maraviroc AUC<sub>12</sub>\n  \u2191 8.77</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Maraviroc C<sub>max</sub>:\n  \u2191 3.78</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir/ritonavir\n  concentrations not measured, no effect is expected.</p>\n</td>", "ID": "e2fcdccc-3c9d-4a53-9b5b-d0dac5fe765f", "Styles": "width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt", "Classes": "None", "Text": "    ", "ParentId": "a89413ec-43bc-41eb-8ebd-4e76c87e2c8e"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Maraviroc AUC<sub>12</sub>\n  \u2191 8.77</p>", "ID": "b4b58e71-4d8f-4bf8-8b04-c26b574222c0", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Maraviroc AUC   \u2191 8.77", "ParentId": "e2fcdccc-3c9d-4a53-9b5b-d0dac5fe765f"}, {"Element": "<sub>12</sub>", "ID": "62d989aa-2f37-4216-9bb8-b3a4a4ac4e18", "Styles": "None", "Classes": "None", "Text": "12", "ParentId": "b4b58e71-4d8f-4bf8-8b04-c26b574222c0"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Maraviroc C<sub>max</sub>:\n  \u2191 3.78</p>", "ID": "a2ec6627-7fb8-47d2-b8fd-ff37d9e4546f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Maraviroc C:   \u2191 3.78", "ParentId": "e2fcdccc-3c9d-4a53-9b5b-d0dac5fe765f"}, {"Element": "<sub>max</sub>", "ID": "7a37fc10-398c-4e31-b75c-c7378c23f5c8", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "a2ec6627-7fb8-47d2-b8fd-ff37d9e4546f"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir/ritonavir\n  concentrations not measured, no effect is expected.</p>", "ID": "b7c3c516-a0d0-4061-a790-95f60d043c84", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Saquinavir/ritonavir   concentrations not measured, no effect is expected.", "ParentId": "e2fcdccc-3c9d-4a53-9b5b-d0dac5fe765f"}, {"Element": "<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"237\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">No dose\n  adjustment of saquinavir/ritonavir is required. Dose of maraviroc should be decreased\n  to 150\u00a0mg bid with monitoring.</span></p>\n</td>", "ID": "fabc8bfb-3246-4f56-977d-16a6af6bdbea", "Styles": "width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt", "Classes": "None", "Text": "  ", "ParentId": "a89413ec-43bc-41eb-8ebd-4e76c87e2c8e"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">No dose\n  adjustment of saquinavir/ritonavir is required. Dose of maraviroc should be decreased\n  to 150\u00a0mg bid with monitoring.</span></p>", "ID": "fcb7a336-8452-4d9e-ba55-760ad7e72db5", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "fabc8bfb-3246-4f56-977d-16a6af6bdbea"}, {"Element": "<span lang=\"EN-GB\">No dose\n  adjustment of saquinavir/ritonavir is required. Dose of maraviroc should be decreased\n  to 150\u00a0mg bid with monitoring.</span>", "ID": "1b88c32c-1c98-4cdf-8dbc-896f90ee50fa", "Styles": "None", "Classes": "None", "Text": "No dose   adjustment of saquinavir/ritonavir is required. Dose of maraviroc should be decreased   to 150\u00a0mg bid with monitoring.", "ParentId": "fcb7a336-8452-4d9e-ba55-760ad7e72db5"}, {"Element": "<tr style=\"height:12.9pt\">\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Cobicistat\n  containing medicinal products</span></i></b></p>\n</td>\n</tr>", "ID": "5efafe28-95e1-428e-ad63-e1b5beafcebf", "Styles": "height:12.9pt", "Classes": "None", "Text": "  ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Cobicistat\n  containing medicinal products</span></i></b></p>\n</td>", "ID": "b0658278-b7f3-453f-a700-f121fd932177", "Styles": "width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt", "Classes": "None", "Text": "  ", "ParentId": "5efafe28-95e1-428e-ad63-e1b5beafcebf"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Cobicistat\n  containing medicinal products</span></i></b></p>", "ID": "b86284a1-14bd-4dce-99c8-c99b72dae374", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "b0658278-b7f3-453f-a700-f121fd932177"}, {"Element": "<b><i><span lang=\"IT\">Cobicistat\n  containing medicinal products</span></i></b>", "ID": "edf6ab45-be70-4272-bb35-f605d4c48eb2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b86284a1-14bd-4dce-99c8-c99b72dae374"}, {"Element": "<i><span lang=\"IT\">Cobicistat\n  containing medicinal products</span></i>", "ID": "aa5d8357-774d-45c1-b86d-ad96fcd4d5d5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "edf6ab45-be70-4272-bb35-f605d4c48eb2"}, {"Element": "<span lang=\"IT\">Cobicistat\n  containing medicinal products</span>", "ID": "fa511177-b4f3-4b2e-a651-c12d7756929f", "Styles": "None", "Classes": "None", "Text": "Cobicistat   containing medicinal products", "ParentId": "aa5d8357-774d-45c1-b86d-ad96fcd4d5d5"}, {"Element": "<tr style=\"height:53.85pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"177\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Cobicistat</span></p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"236\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied. Cobicistat is not recommended in combination\n  with regimens containing ritonavir due to similar effects of cobicistat and\n  ritonavir on CYP3A.</p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"237\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">It is\n  not recommended to coadminister Invirase/ritonavir with cobicistat containing\n  products (see section 4.4). <a name=\"_GoBack\"></a></span></p>\n</td>\n</tr>", "ID": "77afd511-e94b-4514-ac60-a587b5916a90", "Styles": "height:53.85pt", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"177\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Cobicistat</span></p>\n</td>", "ID": "e2b96d4b-f7a9-4085-a3b7-cf9462362fc5", "Styles": "width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.85pt", "Classes": "None", "Text": "  ", "ParentId": "77afd511-e94b-4514-ac60-a587b5916a90"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Cobicistat</span></p>", "ID": "1651e09c-ba52-4cf4-8680-e51beeec9bbc", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "e2b96d4b-f7a9-4085-a3b7-cf9462362fc5"}, {"Element": "<span lang=\"PT-BR\">Cobicistat</span>", "ID": "4de58bb6-9aec-449c-95c5-581a5e0b2951", "Styles": "None", "Classes": "None", "Text": "Cobicistat", "ParentId": "1651e09c-ba52-4cf4-8680-e51beeec9bbc"}, {"Element": "<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"236\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied. Cobicistat is not recommended in combination\n  with regimens containing ritonavir due to similar effects of cobicistat and\n  ritonavir on CYP3A.</p>\n</td>", "ID": "dc9d6530-b964-4548-95e8-ea90df40267d", "Styles": "width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt", "Classes": "None", "Text": "  ", "ParentId": "77afd511-e94b-4514-ac60-a587b5916a90"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied. Cobicistat is not recommended in combination\n  with regimens containing ritonavir due to similar effects of cobicistat and\n  ritonavir on CYP3A.</p>", "ID": "68db9a00-7533-4fc4-b2c8-9f7a27d9302a", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Interaction with   Invirase/ritonavir not studied. Cobicistat is not recommended in combination   with regimens containing ritonavir due to similar effects of cobicistat and   ritonavir on CYP3A.", "ParentId": "dc9d6530-b964-4548-95e8-ea90df40267d"}, {"Element": "<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt\" valign=\"top\" width=\"237\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">It is\n  not recommended to coadminister Invirase/ritonavir with cobicistat containing\n  products (see section 4.4). <a name=\"_GoBack\"></a></span></p>\n</td>", "ID": "ab7f3ee7-3321-4f62-a7e8-69b0ef56ce8b", "Styles": "width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.85pt", "Classes": "None", "Text": "  ", "ParentId": "77afd511-e94b-4514-ac60-a587b5916a90"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">It is\n  not recommended to coadminister Invirase/ritonavir with cobicistat containing\n  products (see section 4.4). <a name=\"_GoBack\"></a></span></p>", "ID": "b2f4fb38-6d99-4a24-aaee-5dd58ffbef1d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "ab7f3ee7-3321-4f62-a7e8-69b0ef56ce8b"}, {"Element": "<span lang=\"EN-GB\">It is\n  not recommended to coadminister Invirase/ritonavir with cobicistat containing\n  products (see section 4.4). <a name=\"_GoBack\"></a></span>", "ID": "794692fa-751b-4bca-987b-15e59fa7accb", "Styles": "None", "Classes": "None", "Text": "It is   not recommended to coadminister Invirase/ritonavir with cobicistat containing   products (see section 4.4). ", "ParentId": "b2f4fb38-6d99-4a24-aaee-5dd58ffbef1d"}, {"Element": "<a name=\"_GoBack\"></a>", "ID": "07c8513d-e12f-4d10-863e-0ae874b5d0bc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "794692fa-751b-4bca-987b-15e59fa7accb"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><u>Other medicinal\n  products<br/>\n</u></i></b><b><i><span lang=\"IT\">\u00a0Alpha-1 adrenoreceptor antagonist</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "3c56c0fb-32e9-4f14-81a7-04c488fe1cf6", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><u>Other medicinal\n  products<br/>\n</u></i></b><b><i><span lang=\"IT\">\u00a0Alpha-1 adrenoreceptor antagonist</span></i></b></p>\n</td>", "ID": "83a3b950-760d-4e2c-8e17-16a0525cc1be", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3c56c0fb-32e9-4f14-81a7-04c488fe1cf6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><u>Other medicinal\n  products<br/>\n</u></i></b><b><i><span lang=\"IT\">\u00a0Alpha-1 adrenoreceptor antagonist</span></i></b></p>", "ID": "830332c4-ea91-417f-a0b6-ed643a76bb7e", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "83a3b950-760d-4e2c-8e17-16a0525cc1be"}, {"Element": "<b><i><u>Other medicinal\n  products<br/>\n</u></i></b>", "ID": "4cc99842-2ea9-4297-ab48-0e44c5cc372e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "830332c4-ea91-417f-a0b6-ed643a76bb7e"}, {"Element": "<i><u>Other medicinal\n  products<br/>\n</u></i>", "ID": "ae5cc201-ecb7-466e-8efb-c5a8b9da86d8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4cc99842-2ea9-4297-ab48-0e44c5cc372e"}, {"Element": "<u>Other medicinal\n  products<br/>\n</u>", "ID": "070c1174-04d0-44e2-ab70-2310414e44d3", "Styles": "None", "Classes": "None", "Text": "Other medicinal   products ", "ParentId": "ae5cc201-ecb7-466e-8efb-c5a8b9da86d8"}, {"Element": "<br/>", "ID": "43bb020b-043b-452e-9d62-90d71604c0d8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "070c1174-04d0-44e2-ab70-2310414e44d3"}, {"Element": "<b><i><span lang=\"IT\">\u00a0Alpha-1 adrenoreceptor antagonist</span></i></b>", "ID": "1fc45f5c-e025-4175-8a73-49ee92061596", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "830332c4-ea91-417f-a0b6-ed643a76bb7e"}, {"Element": "<i><span lang=\"IT\">\u00a0Alpha-1 adrenoreceptor antagonist</span></i>", "ID": "b835a945-0be7-4d8e-bb25-59c691739430", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1fc45f5c-e025-4175-8a73-49ee92061596"}, {"Element": "<span lang=\"IT\">\u00a0Alpha-1 adrenoreceptor antagonist</span>", "ID": "f15ededd-4e6f-496e-ba7a-6cfbbc61db28", "Styles": "None", "Classes": "None", "Text": "\u00a0Alpha-1 adrenoreceptor antagonist", "ParentId": "b835a945-0be7-4d8e-bb25-59c691739430"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "8e5080b3-d192-4ac5-8134-a9e446577276", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3c56c0fb-32e9-4f14-81a7-04c488fe1cf6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "56f4e5a4-3dd6-4a3b-9f2d-7a0b2922cc3f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "8e5080b3-d192-4ac5-8134-a9e446577276"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "df920129-d386-4eac-be1f-af5e39439c5b", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3c56c0fb-32e9-4f14-81a7-04c488fe1cf6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "ef9b2da8-7e36-44be-a891-382194e22cfe", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "df920129-d386-4eac-be1f-af5e39439c5b"}, {"Element": "<tr style=\"height:66.0pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:66.0pt\" valign=\"top\" width=\"177\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Alfuzosin\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:66.0pt\" valign=\"top\" width=\"236\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Concomitant use\n  of alfuzosin and saquinavir/ritonavir is expected to increase plasma levels\n  of alfuzosin.</span></p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:66.0pt\" valign=\"top\" width=\"237\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Contraindicated\n  in combination with Invirase/ritonavir due to potential increase in alfuzosin\n  concentration which can result in hypotension and potentially\n  life-threatening cardiac arrhythmia.</span></p>\n</td>\n</tr>", "ID": "ec4b74d1-37e4-44dc-b7c8-d99f0e594d17", "Styles": "height:66.0pt", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:66.0pt\" valign=\"top\" width=\"177\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Alfuzosin\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n</td>", "ID": "f08f5fad-8cb8-4068-aded-99d2f49bd531", "Styles": "width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:66.0pt", "Classes": "None", "Text": "  ", "ParentId": "ec4b74d1-37e4-44dc-b7c8-d99f0e594d17"}, {"Element": "<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Alfuzosin\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>", "ID": "6010c3e5-30cd-4165-abdf-ee5494afc30e", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['Paragraph']", "Text": "", "ParentId": "f08f5fad-8cb8-4068-aded-99d2f49bd531"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Alfuzosin\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "989e501f-7a91-4bf6-911b-0121bde974ed", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Alfuzosin\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "6010c3e5-30cd-4165-abdf-ee5494afc30e"}, {"Element": "<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:66.0pt\" valign=\"top\" width=\"236\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Concomitant use\n  of alfuzosin and saquinavir/ritonavir is expected to increase plasma levels\n  of alfuzosin.</span></p>\n</td>", "ID": "83d31f5c-6a4e-42c3-a67c-c643cb83a470", "Styles": "width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:66.0pt", "Classes": "None", "Text": "  ", "ParentId": "ec4b74d1-37e4-44dc-b7c8-d99f0e594d17"}, {"Element": "<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Concomitant use\n  of alfuzosin and saquinavir/ritonavir is expected to increase plasma levels\n  of alfuzosin.</span></p>", "ID": "7ac6e5b2-7b40-4666-b204-9c5c85b4bf64", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['Paragraph']", "Text": "", "ParentId": "83d31f5c-6a4e-42c3-a67c-c643cb83a470"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Concomitant use\n  of alfuzosin and saquinavir/ritonavir is expected to increase plasma levels\n  of alfuzosin.</span>", "ID": "b5ee619c-66b9-47c2-9e98-cc2e629d5f43", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Concomitant use   of alfuzosin and saquinavir/ritonavir is expected to increase plasma levels   of alfuzosin.", "ParentId": "7ac6e5b2-7b40-4666-b204-9c5c85b4bf64"}, {"Element": "<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:66.0pt\" valign=\"top\" width=\"237\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Contraindicated\n  in combination with Invirase/ritonavir due to potential increase in alfuzosin\n  concentration which can result in hypotension and potentially\n  life-threatening cardiac arrhythmia.</span></p>\n</td>", "ID": "5a66e35a-5a80-4480-afd4-fac6aeeb7db4", "Styles": "width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:66.0pt", "Classes": "None", "Text": "  ", "ParentId": "ec4b74d1-37e4-44dc-b7c8-d99f0e594d17"}, {"Element": "<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Contraindicated\n  in combination with Invirase/ritonavir due to potential increase in alfuzosin\n  concentration which can result in hypotension and potentially\n  life-threatening cardiac arrhythmia.</span></p>", "ID": "442f53c5-b84f-49ba-a869-b07310b2232c", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['Paragraph']", "Text": "", "ParentId": "5a66e35a-5a80-4480-afd4-fac6aeeb7db4"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Contraindicated\n  in combination with Invirase/ritonavir due to potential increase in alfuzosin\n  concentration which can result in hypotension and potentially\n  life-threatening cardiac arrhythmia.</span>", "ID": "f95de0c9-bb18-4287-8246-4585d9416747", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Contraindicated   in combination with Invirase/ritonavir due to potential increase in alfuzosin   concentration which can result in hypotension and potentially   life-threatening cardiac arrhythmia.", "ParentId": "442f53c5-b84f-49ba-a869-b07310b2232c"}, {"Element": "<tr>\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Antiarrhythmics</i></b></p>\n</td>\n</tr>", "ID": "7555cf69-0297-4d56-b6b5-61bdfea9f4cf", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Antiarrhythmics</i></b></p>\n</td>", "ID": "9f29baf2-83d0-45b0-86e1-603596a3dd6c", "Styles": "width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7555cf69-0297-4d56-b6b5-61bdfea9f4cf"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Antiarrhythmics</i></b></p>", "ID": "7b29ee0e-0952-4943-adff-a1810109c603", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "9f29baf2-83d0-45b0-86e1-603596a3dd6c"}, {"Element": "<b><i>Antiarrhythmics</i></b>", "ID": "ffdfc28c-2409-4524-8ddf-31b5a9ec1b5e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7b29ee0e-0952-4943-adff-a1810109c603"}, {"Element": "<i>Antiarrhythmics</i>", "ID": "70265a0f-e9b2-4f28-bdf2-8d2b90070aaa", "Styles": "None", "Classes": "None", "Text": "Antiarrhythmics", "ParentId": "ffdfc28c-2409-4524-8ddf-31b5a9ec1b5e"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Bepridil<br/>\n  Lidocaine (systemic) Quinidine<br/>\n  Hydroquinidine<br/>\n</span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of bepridil</span>, systemic<span lang=\"EN-GB\"><br/>\n  lidocaine, quinidine or hydroquinidine may be increased when co-administered\n  with Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "eb5105a2-61e2-4076-9085-7977f2f38f61", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Bepridil<br/>\n  Lidocaine (systemic) Quinidine<br/>\n  Hydroquinidine<br/>\n</span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>", "ID": "f973deeb-4df0-4085-939e-db667823fe11", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eb5105a2-61e2-4076-9085-7977f2f38f61"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Bepridil<br/>\n  Lidocaine (systemic) Quinidine<br/>\n  Hydroquinidine<br/>\n</span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>", "ID": "0a41f03d-badf-4876-bf9e-9c2f6f072955", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "()", "ParentId": "f973deeb-4df0-4085-939e-db667823fe11"}, {"Element": "<span lang=\"EN-GB\">Bepridil<br/>\n  Lidocaine (systemic) Quinidine<br/>\n  Hydroquinidine<br/>\n</span>", "ID": "fa91af88-0130-4ab0-a645-587f876a9ebe", "Styles": "None", "Classes": "None", "Text": "Bepridil   Lidocaine (systemic) Quinidine   Hydroquinidine ", "ParentId": "0a41f03d-badf-4876-bf9e-9c2f6f072955"}, {"Element": "<br/>", "ID": "bc0824f8-931d-4f69-b6a9-01a2db0b9613", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fa91af88-0130-4ab0-a645-587f876a9ebe"}, {"Element": "<br/>", "ID": "d18e9880-832c-420f-bcb6-4ba7ddbe1ce7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fa91af88-0130-4ab0-a645-587f876a9ebe"}, {"Element": "<br/>", "ID": "9e6cce58-3ece-4666-b8e5-96db9fa9c104", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fa91af88-0130-4ab0-a645-587f876a9ebe"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "4db3ae23-9967-4ca6-91d2-b385381876b0", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "0a41f03d-badf-4876-bf9e-9c2f6f072955"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of bepridil</span>, systemic<span lang=\"EN-GB\"><br/>\n  lidocaine, quinidine or hydroquinidine may be increased when co-administered\n  with Invirase/ritonavir.</span></p>\n</td>", "ID": "3a968518-25a5-47aa-b28a-9b36f5100402", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eb5105a2-61e2-4076-9085-7977f2f38f61"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of bepridil</span>, systemic<span lang=\"EN-GB\"><br/>\n  lidocaine, quinidine or hydroquinidine may be increased when co-administered\n  with Invirase/ritonavir.</span></p>", "ID": "9e8191f3-99ba-4801-acf1-9756be419877", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": ", systemic", "ParentId": "3a968518-25a5-47aa-b28a-9b36f5100402"}, {"Element": "<span lang=\"EN-GB\">Concentrations\n  of bepridil</span>", "ID": "c4175649-284b-4ba8-8d47-ce37e0ff6404", "Styles": "None", "Classes": "None", "Text": "Concentrations   of bepridil", "ParentId": "9e8191f3-99ba-4801-acf1-9756be419877"}, {"Element": "<span lang=\"EN-GB\"><br/>\n  lidocaine, quinidine or hydroquinidine may be increased when co-administered\n  with Invirase/ritonavir.</span>", "ID": "9622f7e8-197f-4bb6-810f-399cc4a49e51", "Styles": "None", "Classes": "None", "Text": "   lidocaine, quinidine or hydroquinidine may be increased when co-administered   with Invirase/ritonavir.", "ParentId": "9e8191f3-99ba-4801-acf1-9756be419877"}, {"Element": "<br/>", "ID": "e97cde00-08e1-4840-91fe-900095d24003", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9622f7e8-197f-4bb6-810f-399cc4a49e51"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "0d064400-5554-4b9f-b814-cbba09242106", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eb5105a2-61e2-4076-9085-7977f2f38f61"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "7d26eaec-00fc-44b9-8fd8-3e296917ffcc", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated in   combination with  due to   potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)", "ParentId": "0d064400-5554-4b9f-b814-cbba09242106"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "b28848c1-58c0-4707-91ae-dfe896d287ec", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "7d26eaec-00fc-44b9-8fd8-3e296917ffcc"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "d760682a-5a11-4b59-a972-49fd0fcffff0", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "7d26eaec-00fc-44b9-8fd8-3e296917ffcc"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"ES\">Amiodarone<br/>\n  flecainide<br/>\n  propafenone<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of </span>amiodarone,\n  flecainide or propafenone<span lang=\"EN-GB\"> may be increased when\n  co-administered with Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">saquinavir/ritonavir</span>\n  due to potentially life threatening cardiac arrhythmia (see section 4.3).</p>\n</td>\n</tr>", "ID": "88e308da-0c8d-4891-8d7b-c422937cda1b", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"ES\">Amiodarone<br/>\n  flecainide<br/>\n  propafenone<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>", "ID": "c3736a8c-6ac1-472c-a204-75fb79665fbe", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "88e308da-0c8d-4891-8d7b-c422937cda1b"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"ES\">Amiodarone<br/>\n  flecainide<br/>\n  propafenone<br/>\n  (saquinavir/ritonavir)</span></p>", "ID": "c3d0913b-d99c-4e17-a445-8459ae83de94", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "c3736a8c-6ac1-472c-a204-75fb79665fbe"}, {"Element": "<span lang=\"ES\">Amiodarone<br/>\n  flecainide<br/>\n  propafenone<br/>\n  (saquinavir/ritonavir)</span>", "ID": "3e07f41f-3cd0-4600-870f-6d05087e29e4", "Styles": "None", "Classes": "None", "Text": "Amiodarone   flecainide   propafenone   (saquinavir/ritonavir)", "ParentId": "c3d0913b-d99c-4e17-a445-8459ae83de94"}, {"Element": "<br/>", "ID": "2cb6b935-4bf4-4715-8e23-6e9ce896e51b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3e07f41f-3cd0-4600-870f-6d05087e29e4"}, {"Element": "<br/>", "ID": "05168517-1b03-4dd0-b77c-40a7c06c488b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3e07f41f-3cd0-4600-870f-6d05087e29e4"}, {"Element": "<br/>", "ID": "b531fd0e-84a0-4616-b666-e3169372bb24", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3e07f41f-3cd0-4600-870f-6d05087e29e4"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of </span>amiodarone,\n  flecainide or propafenone<span lang=\"EN-GB\"> may be increased when\n  co-administered with Invirase/ritonavir.</span></p>\n</td>", "ID": "7188c3a3-3c71-459e-8fd6-e373581b31af", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "88e308da-0c8d-4891-8d7b-c422937cda1b"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of </span>amiodarone,\n  flecainide or propafenone<span lang=\"EN-GB\"> may be increased when\n  co-administered with Invirase/ritonavir.</span></p>", "ID": "a2ed752c-cd97-4326-a47a-1f384c129945", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "amiodarone,   flecainide or propafenone", "ParentId": "7188c3a3-3c71-459e-8fd6-e373581b31af"}, {"Element": "<span lang=\"EN-GB\">Concentrations of </span>", "ID": "7b8e5ca3-a55f-435a-8daa-5be3667cc32a", "Styles": "None", "Classes": "None", "Text": "Concentrations of ", "ParentId": "a2ed752c-cd97-4326-a47a-1f384c129945"}, {"Element": "<span lang=\"EN-GB\"> may be increased when\n  co-administered with Invirase/ritonavir.</span>", "ID": "1d8096e3-54ac-4f01-bd72-829c327bd7bb", "Styles": "None", "Classes": "None", "Text": " may be increased when   co-administered with Invirase/ritonavir.", "ParentId": "a2ed752c-cd97-4326-a47a-1f384c129945"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">saquinavir/ritonavir</span>\n  due to potentially life threatening cardiac arrhythmia (see section 4.3).</p>\n</td>", "ID": "2eba328f-4b29-4a46-9072-804c1e44bd89", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "88e308da-0c8d-4891-8d7b-c422937cda1b"}, {"Element": "<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">saquinavir/ritonavir</span>\n  due to potentially life threatening cardiac arrhythmia (see section 4.3).</p>", "ID": "b520638d-d1c7-427a-9b6b-cf16e096ce76", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Contraindicated in combination with    due to potentially life threatening cardiac arrhythmia (see section 4.3).", "ParentId": "2eba328f-4b29-4a46-9072-804c1e44bd89"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "290925d0-cc03-49db-8cbc-a634c748f648", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "b520638d-d1c7-427a-9b6b-cf16e096ce76"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Dofetilide<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to potentially\n  life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "43220563-37b7-4a64-8777-f3ccfb53d53c", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Dofetilide<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>", "ID": "f704f8df-a547-4be7-b936-78c864e458aa", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "43220563-37b7-4a64-8777-f3ccfb53d53c"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Dofetilide<br/>\n  (saquinavir/ritonavir)</span></p>", "ID": "7105d7c7-a4ac-4025-91d5-a26012a82472", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "f704f8df-a547-4be7-b936-78c864e458aa"}, {"Element": "<span lang=\"PT-BR\">Dofetilide<br/>\n  (saquinavir/ritonavir)</span>", "ID": "b9b0afaf-149f-4d85-9f98-b92e3d224cff", "Styles": "None", "Classes": "None", "Text": "Dofetilide   (saquinavir/ritonavir)", "ParentId": "7105d7c7-a4ac-4025-91d5-a26012a82472"}, {"Element": "<br/>", "ID": "730bcacd-077e-4166-ba31-ffff1f49512b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b9b0afaf-149f-4d85-9f98-b92e3d224cff"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span></p>\n</td>", "ID": "2f25fa42-e77b-4537-b83b-83f455f559c5", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "43220563-37b7-4a64-8777-f3ccfb53d53c"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span></p>", "ID": "61be467e-5805-4db9-9039-d940016f1d1f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "2f25fa42-e77b-4537-b83b-83f455f559c5"}, {"Element": "<span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span>", "ID": "c543a012-f563-4eab-8361-37ee8ef2df38", "Styles": "None", "Classes": "None", "Text": "Although   specific studies have not been performed, co-administration of   Invirase/ritonavir with medicinal products that are mainly metabolised by   CYP3A4 pathway may result in elevated plasma concentrations of these   medicinal products.", "ParentId": "61be467e-5805-4db9-9039-d940016f1d1f"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to potentially\n  life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "76c1cb5f-148e-4319-ba2d-62adda6efc13", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "43220563-37b7-4a64-8777-f3ccfb53d53c"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to potentially\n  life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "d5809475-efa9-4498-b2c8-f0077b4a505a", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated in   combination with  due to potentially   life threatening cardiac arrhythmia (see sections 4.3 and 4.4)", "ParentId": "76c1cb5f-148e-4319-ba2d-62adda6efc13"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "a752c612-ac2c-42ab-b083-f5f0bf555dcc", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "d5809475-efa9-4498-b2c8-f0077b4a505a"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "96251524-cd27-49bb-b1fe-f5380d795daa", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "d5809475-efa9-4498-b2c8-f0077b4a505a"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Ibutilide<br/>\n  Sotalol<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "8baf8aa8-650a-4654-981f-3c7eaaa820fc", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Ibutilide<br/>\n  Sotalol<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>", "ID": "56f7af51-6dfe-43c7-aa4a-858e3a8c0036", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8baf8aa8-650a-4654-981f-3c7eaaa820fc"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Ibutilide<br/>\n  Sotalol<br/>\n  (saquinavir/ritonavir)</span></p>", "ID": "34c55212-b62c-4b87-acc1-000e83657859", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "56f7af51-6dfe-43c7-aa4a-858e3a8c0036"}, {"Element": "<span lang=\"PT-BR\">Ibutilide<br/>\n  Sotalol<br/>\n  (saquinavir/ritonavir)</span>", "ID": "df3b0d92-cc59-4cf6-b3a2-83ac0c3daa0d", "Styles": "None", "Classes": "None", "Text": "Ibutilide   Sotalol   (saquinavir/ritonavir)", "ParentId": "34c55212-b62c-4b87-acc1-000e83657859"}, {"Element": "<br/>", "ID": "e86a41eb-a595-447c-8e7c-d499f5bce01d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "df3b0d92-cc59-4cf6-b3a2-83ac0c3daa0d"}, {"Element": "<br/>", "ID": "5c9dc226-e727-46df-bf9d-66b286d85fd1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "df3b0d92-cc59-4cf6-b3a2-83ac0c3daa0d"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "a5fbe5dd-218a-48db-a2c5-f47622397303", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8baf8aa8-650a-4654-981f-3c7eaaa820fc"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "860fc2fc-51ea-4009-8b90-e6757eba928d", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "a5fbe5dd-218a-48db-a2c5-f47622397303"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "30a24714-e495-4937-a74f-afbf39e3b78e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "860fc2fc-51ea-4009-8b90-e6757eba928d"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "33dc3637-2b4f-4822-87e3-34bb94566ea4", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8baf8aa8-650a-4654-981f-3c7eaaa820fc"}, {"Element": "<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "fba65cd3-20ab-4ee0-8d61-4b987b1ef0ec", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Contraindicated in combination with    due to the potential for life threatening cardiac arrhythmia (see sections   4.3 and 4.4)", "ParentId": "33dc3637-2b4f-4822-87e3-34bb94566ea4"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "40971892-f75c-437f-86e4-12e1d85b4ad9", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "fba65cd3-20ab-4ee0-8d61-4b987b1ef0ec"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "93ba8ca2-6bba-4783-b4cc-1fa69743d4e8", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "fba65cd3-20ab-4ee0-8d61-4b987b1ef0ec"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Anticoagulant</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "cad7bbd1-bfaf-4225-acf0-80d0b28ac895", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Anticoagulant</span></i></b></p>\n</td>", "ID": "4408ade7-d42a-439d-83a4-4bddd0c93102", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cad7bbd1-bfaf-4225-acf0-80d0b28ac895"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Anticoagulant</span></i></b></p>", "ID": "26811c20-9450-43ee-b8f3-5a6554225d2b", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "4408ade7-d42a-439d-83a4-4bddd0c93102"}, {"Element": "<b><i><span lang=\"IT\">Anticoagulant</span></i></b>", "ID": "0a12d919-be3c-434b-9afa-bd52b4a58490", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "26811c20-9450-43ee-b8f3-5a6554225d2b"}, {"Element": "<i><span lang=\"IT\">Anticoagulant</span></i>", "ID": "ca21a4b7-fe9e-4874-9cee-f356da4ed394", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0a12d919-be3c-434b-9afa-bd52b4a58490"}, {"Element": "<span lang=\"IT\">Anticoagulant</span>", "ID": "9b41003b-a358-47bc-b5ac-6f797614ad07", "Styles": "None", "Classes": "None", "Text": "Anticoagulant", "ParentId": "ca21a4b7-fe9e-4874-9cee-f356da4ed394"}, {"Element": "<td style=\"width:11.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "38c0888e-e14a-4c7c-8cb7-7f9ee23f0a59", "Styles": "width:11.8pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cad7bbd1-bfaf-4225-acf0-80d0b28ac895"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "cc3045e4-938f-4ef0-a146-a0c5ca34d573", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "38c0888e-e14a-4c7c-8cb7-7f9ee23f0a59"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "f629198a-1704-40cb-8fde-5319af2d5104", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cc3045e4-938f-4ef0-a146-a0c5ca34d573"}, {"Element": "<td style=\"width:14.2pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "841944d1-04d6-4e54-8400-f77e2e1314e0", "Styles": "width:14.2pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cad7bbd1-bfaf-4225-acf0-80d0b28ac895"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "97af5351-8a1d-4155-a7b0-c141d24e8baa", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "841944d1-04d6-4e54-8400-f77e2e1314e0"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "084299c2-ec5d-4b4a-b809-5a18fed5679c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "97af5351-8a1d-4155-a7b0-c141d24e8baa"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Warfarin</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of warfarin may be affected </span>when co-administered with\n  Invirase/ritonavir<span lang=\"EN-GB\">.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">INR\n  (international normalised ratio) monitoring recommended.</span></p>\n</td>\n</tr>", "ID": "b34347cf-543e-472f-8e14-cd1542ea5392", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Warfarin</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>", "ID": "d9781623-7336-4419-931a-5b37674b4b23", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "b34347cf-543e-472f-8e14-cd1542ea5392"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Warfarin</span></p>", "ID": "6dbb1a01-feb8-428a-add0-34ce326b8d02", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "d9781623-7336-4419-931a-5b37674b4b23"}, {"Element": "<span lang=\"EN-GB\">Warfarin</span>", "ID": "5e19e26d-34de-483f-b0aa-15bc56ade3ec", "Styles": "None", "Classes": "None", "Text": "Warfarin", "ParentId": "6dbb1a01-feb8-428a-add0-34ce326b8d02"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>", "ID": "6996d52e-90eb-4e8a-abf6-dd3dcfc0821c", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "()", "ParentId": "d9781623-7336-4419-931a-5b37674b4b23"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "bf3146d1-054e-490e-a080-7ec19f4c18ce", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "6996d52e-90eb-4e8a-abf6-dd3dcfc0821c"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of warfarin may be affected </span>when co-administered with\n  Invirase/ritonavir<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "2f5cb851-cfbb-465e-89f4-0fbffc206258", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b34347cf-543e-472f-8e14-cd1542ea5392"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of warfarin may be affected </span>when co-administered with\n  Invirase/ritonavir<span lang=\"EN-GB\">.</span></p>", "ID": "5810e0d3-9d62-4f83-856c-92c17998c3ae", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "when co-administered with   Invirase/ritonavir", "ParentId": "2f5cb851-cfbb-465e-89f4-0fbffc206258"}, {"Element": "<span lang=\"EN-GB\">Concentrations\n  of warfarin may be affected </span>", "ID": "672d3316-3dfe-4903-ba49-8dc0f6f8e670", "Styles": "None", "Classes": "None", "Text": "Concentrations   of warfarin may be affected ", "ParentId": "5810e0d3-9d62-4f83-856c-92c17998c3ae"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "ad4030e1-e5ba-4da7-ac5a-0c7eb47a8ab6", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "5810e0d3-9d62-4f83-856c-92c17998c3ae"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">INR\n  (international normalised ratio) monitoring recommended.</span></p>\n</td>", "ID": "98eda3ce-4bec-4bd6-b982-3ed3212e3eb6", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b34347cf-543e-472f-8e14-cd1542ea5392"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">INR\n  (international normalised ratio) monitoring recommended.</span></p>", "ID": "015f937d-84d3-42b3-a5fd-55623e1f98f5", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "98eda3ce-4bec-4bd6-b982-3ed3212e3eb6"}, {"Element": "<span lang=\"EN-GB\">INR\n  (international normalised ratio) monitoring recommended.</span>", "ID": "c1b5715c-505d-4afd-a3c6-d3e896a04786", "Styles": "None", "Classes": "None", "Text": "INR   (international normalised ratio) monitoring recommended.", "ParentId": "015f937d-84d3-42b3-a5fd-55623e1f98f5"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Anticonvulsants</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "17bff2b5-19e5-484b-ae23-30db59d09f42", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Anticonvulsants</span></i></b></p>\n</td>", "ID": "8a7db30d-a328-4be9-99f7-e16c82dddb0c", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "17bff2b5-19e5-484b-ae23-30db59d09f42"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Anticonvulsants</span></i></b></p>", "ID": "819d1d3d-1094-4e32-b648-d337aa721eeb", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "8a7db30d-a328-4be9-99f7-e16c82dddb0c"}, {"Element": "<b><i><span lang=\"EN-GB\">Anticonvulsants</span></i></b>", "ID": "95cdd40c-eb70-4c07-8e96-3a6a880b8601", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "819d1d3d-1094-4e32-b648-d337aa721eeb"}, {"Element": "<i><span lang=\"EN-GB\">Anticonvulsants</span></i>", "ID": "fff0c45f-7e2c-4904-a734-cd46c615a210", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "95cdd40c-eb70-4c07-8e96-3a6a880b8601"}, {"Element": "<span lang=\"EN-GB\">Anticonvulsants</span>", "ID": "5be9c034-0b4d-4d8b-aac8-03432ecd2bfd", "Styles": "None", "Classes": "None", "Text": "Anticonvulsants", "ParentId": "fff0c45f-7e2c-4904-a734-cd46c615a210"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "52ccd684-282a-4cb0-a91e-653868e7bbc6", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "17bff2b5-19e5-484b-ae23-30db59d09f42"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "5915607b-7c9b-477d-bd6f-b314d795f63a", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "52ccd684-282a-4cb0-a91e-653868e7bbc6"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "eedb2f57-c314-416c-aafc-d505b495fbcd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5915607b-7c9b-477d-bd6f-b314d795f63a"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "c3354281-7724-4f6f-98cc-5f186f171354", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "17bff2b5-19e5-484b-ae23-30db59d09f42"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "a840cc8c-4b21-46ff-89c3-4fdf730fea56", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "c3354281-7724-4f6f-98cc-5f186f171354"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "e70b1829-32ef-4d67-90d5-21149ae05fcb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a840cc8c-4b21-46ff-89c3-4fdf730fea56"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\"><span lang=\"IT\">-\u00a0 Carbamazepine Phenobarbital<br/>\n  Phenytoin<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">These\n  medicinal products will induce CYP3A4 and may therefore decrease saquinavir\n  concentrations</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution.</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Monitoring of saquinavir\n  plasma concentration is recommended (see section 4.4)</p>\n</td>\n</tr>", "ID": "49012128-0626-4b2a-98cd-78b036526739", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\"><span lang=\"IT\">-\u00a0 Carbamazepine Phenobarbital<br/>\n  Phenytoin<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>", "ID": "6d18f259-71c8-4e64-b931-811280fa803b", "Styles": "width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "49012128-0626-4b2a-98cd-78b036526739"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\"><span lang=\"IT\">-\u00a0 Carbamazepine Phenobarbital<br/>\n  Phenytoin<br/>\n  (saquinavir/ritonavir)</span></p>", "ID": "26b08fbc-06c5-4ada-baa6-ac923f21262e", "Styles": "margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "6d18f259-71c8-4e64-b931-811280fa803b"}, {"Element": "<span lang=\"IT\">-\u00a0 Carbamazepine Phenobarbital<br/>\n  Phenytoin<br/>\n  (saquinavir/ritonavir)</span>", "ID": "33fa7015-eab8-476d-bb7e-948215ff4ab6", "Styles": "None", "Classes": "None", "Text": "-\u00a0 Carbamazepine Phenobarbital   Phenytoin   (saquinavir/ritonavir)", "ParentId": "26b08fbc-06c5-4ada-baa6-ac923f21262e"}, {"Element": "<br/>", "ID": "cb821e10-dc5f-4b57-9473-d50c445529d9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "33fa7015-eab8-476d-bb7e-948215ff4ab6"}, {"Element": "<br/>", "ID": "17836fea-a8b2-4312-8563-bfcf9fd0d55d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "33fa7015-eab8-476d-bb7e-948215ff4ab6"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">These\n  medicinal products will induce CYP3A4 and may therefore decrease saquinavir\n  concentrations</span></p>\n</td>", "ID": "39dfe626-7a73-4d14-9d78-4b2eeed672b4", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "49012128-0626-4b2a-98cd-78b036526739"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>", "ID": "126e0bcd-76f2-4876-932a-ac70a79bd5d4", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "39dfe626-7a73-4d14-9d78-4b2eeed672b4"}, {"Element": "<span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span>", "ID": "924815ce-43af-43b5-9df1-a6e0818d2790", "Styles": "None", "Classes": "None", "Text": "Interaction   with Invirase/ritonavir not studied.", "ParentId": "126e0bcd-76f2-4876-932a-ac70a79bd5d4"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">These\n  medicinal products will induce CYP3A4 and may therefore decrease saquinavir\n  concentrations</span></p>", "ID": "5ccc3c1e-b19b-4f06-b414-9c48b7011e55", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "39dfe626-7a73-4d14-9d78-4b2eeed672b4"}, {"Element": "<span lang=\"EN-GB\">These\n  medicinal products will induce CYP3A4 and may therefore decrease saquinavir\n  concentrations</span>", "ID": "3f62864c-44a5-49fa-9cae-1141caefb442", "Styles": "None", "Classes": "None", "Text": "These   medicinal products will induce CYP3A4 and may therefore decrease saquinavir   concentrations", "ParentId": "5ccc3c1e-b19b-4f06-b414-9c48b7011e55"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution.</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Monitoring of saquinavir\n  plasma concentration is recommended (see section 4.4)</p>\n</td>", "ID": "eed7990a-c16d-4f4d-9c4e-171813d6bee4", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "49012128-0626-4b2a-98cd-78b036526739"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution.</p>", "ID": "6a07c212-fce3-4ebe-b599-25720dfefa62", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Use with caution.", "ParentId": "eed7990a-c16d-4f4d-9c4e-171813d6bee4"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "588b7469-3a38-4484-8255-d65138f0a9d9", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "eed7990a-c16d-4f4d-9c4e-171813d6bee4"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Monitoring of saquinavir\n  plasma concentration is recommended (see section 4.4)</p>", "ID": "26b2cc8f-231d-4d5f-b41d-ac5dff1a16ce", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Monitoring of saquinavir   plasma concentration is recommended (see section 4.4)", "ParentId": "eed7990a-c16d-4f4d-9c4e-171813d6bee4"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Antidepressants</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "e9a19bb4-5ef9-4bdf-a57a-8b7b5a73b78d", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Antidepressants</span></i></b></p>\n</td>", "ID": "bafffb6b-9950-47d0-a72c-a02daf165ae4", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e9a19bb4-5ef9-4bdf-a57a-8b7b5a73b78d"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Antidepressants</span></i></b></p>", "ID": "708c8c1a-f6bc-4279-875e-841aa44107f0", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "bafffb6b-9950-47d0-a72c-a02daf165ae4"}, {"Element": "<b><i><span lang=\"EN-GB\">Antidepressants</span></i></b>", "ID": "c50b05f7-4b04-4bd7-8df3-e11a0b2480f3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "708c8c1a-f6bc-4279-875e-841aa44107f0"}, {"Element": "<i><span lang=\"EN-GB\">Antidepressants</span></i>", "ID": "7770b356-2344-44a0-a4ae-ec75e99d263a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c50b05f7-4b04-4bd7-8df3-e11a0b2480f3"}, {"Element": "<span lang=\"EN-GB\">Antidepressants</span>", "ID": "3bc9b48b-0e9d-45a3-aa32-d2f9af41617a", "Styles": "None", "Classes": "None", "Text": "Antidepressants", "ParentId": "7770b356-2344-44a0-a4ae-ec75e99d263a"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "b6c14edb-fda9-48ef-bca2-be48ff2eb1a1", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e9a19bb4-5ef9-4bdf-a57a-8b7b5a73b78d"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "57ea6e3e-bcdd-4cc5-bbef-a437679d1d2f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "b6c14edb-fda9-48ef-bca2-be48ff2eb1a1"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "b16efbd7-b0e2-433b-9eec-4cf5b89682f4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "57ea6e3e-bcdd-4cc5-bbef-a437679d1d2f"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "f30f8a4d-978e-4486-9976-b8aedebc00e6", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e9a19bb4-5ef9-4bdf-a57a-8b7b5a73b78d"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "5b7e8382-41a6-4ffa-b537-2b235d1a735b", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "f30f8a4d-978e-4486-9976-b8aedebc00e6"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "8545d907-e66b-4350-9d64-3f87eb597a4d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5b7e8382-41a6-4ffa-b537-2b235d1a735b"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Tricyclic\n  antidepressants <br/>\n  (e.g. amitriptyline, imipramine, clomipramine) (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase/ritonavir</span>\n  may increase concentrations of tricyclic antidepressants.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "51b3731f-0216-45b9-98ec-b155f7c30157", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Tricyclic\n  antidepressants <br/>\n  (e.g. amitriptyline, imipramine, clomipramine) (saquinavir/ritonavir)</span></p>\n</td>", "ID": "2b26bdae-0475-48a0-bf11-63927a98e55a", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51b3731f-0216-45b9-98ec-b155f7c30157"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Tricyclic\n  antidepressants <br/>\n  (e.g. amitriptyline, imipramine, clomipramine) (saquinavir/ritonavir)</span></p>", "ID": "88379547-51f8-4c06-b8f0-22976cf671b4", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "2b26bdae-0475-48a0-bf11-63927a98e55a"}, {"Element": "<span lang=\"IT\">Tricyclic\n  antidepressants <br/>\n  (e.g. amitriptyline, imipramine, clomipramine) (saquinavir/ritonavir)</span>", "ID": "d6ac24bb-d63f-4099-8fab-c20527385103", "Styles": "None", "Classes": "None", "Text": "Tricyclic   antidepressants    (e.g. amitriptyline, imipramine, clomipramine) (saquinavir/ritonavir)", "ParentId": "88379547-51f8-4c06-b8f0-22976cf671b4"}, {"Element": "<br/>", "ID": "4da82e2b-1fd2-44df-b633-370c120c8df2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d6ac24bb-d63f-4099-8fab-c20527385103"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase/ritonavir</span>\n  may increase concentrations of tricyclic antidepressants.</p>\n</td>", "ID": "b26da637-aa9c-4c88-9642-096ee7e738dc", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51b3731f-0216-45b9-98ec-b155f7c30157"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase/ritonavir</span>\n  may increase concentrations of tricyclic antidepressants.</p>", "ID": "6da4341e-a784-4b62-b5ee-580f8658857d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "   may increase concentrations of tricyclic antidepressants.", "ParentId": "b26da637-aa9c-4c88-9642-096ee7e738dc"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "523aac1e-03f8-4971-9e6e-08ab3f88e8fa", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "6da4341e-a784-4b62-b5ee-580f8658857d"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "29379169-a48b-49d6-80ab-e91c490ff782", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51b3731f-0216-45b9-98ec-b155f7c30157"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "769c824c-9f2f-4e0c-8790-2cff8c9fd8b3", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated in   combination with  due to   potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)", "ParentId": "29379169-a48b-49d6-80ab-e91c490ff782"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "0a350e6d-f223-4cd8-8849-a7509de1a792", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "769c824c-9f2f-4e0c-8790-2cff8c9fd8b3"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "f035070b-2159-41c3-8484-d6ae799f55aa", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "769c824c-9f2f-4e0c-8790-2cff8c9fd8b3"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Maprotiline</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Maprotiline\u2019s\n  metabolism appears to involve the cytochrome P450 isozymes CYP2D6 and CYP 1A2</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Associated\n  with a prolongation of QTc intervals.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with Invirase/ritonavir due to potentially life threatening\n  cardiac arrhythmia (see sections 4.3 and 4.4).</p>\n</td>\n</tr>", "ID": "a8e9d39d-b046-46ea-9021-5ce6f0705d38", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Maprotiline</span></p>\n</td>", "ID": "dfac9620-37fe-46eb-8b7d-96aa66c12f0b", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a8e9d39d-b046-46ea-9021-5ce6f0705d38"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Maprotiline</span></p>", "ID": "74ab36ab-b825-4433-a3ee-2f3cf771fc52", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "dfac9620-37fe-46eb-8b7d-96aa66c12f0b"}, {"Element": "<span lang=\"IT\">Maprotiline</span>", "ID": "c3a9c46b-ca4b-4d21-a540-49d01ddc9d8a", "Styles": "None", "Classes": "None", "Text": "Maprotiline", "ParentId": "74ab36ab-b825-4433-a3ee-2f3cf771fc52"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Maprotiline\u2019s\n  metabolism appears to involve the cytochrome P450 isozymes CYP2D6 and CYP 1A2</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Associated\n  with a prolongation of QTc intervals.</span></p>\n</td>", "ID": "497530f8-369c-415d-9541-f12f90bb00ec", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "a8e9d39d-b046-46ea-9021-5ce6f0705d38"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Maprotiline\u2019s\n  metabolism appears to involve the cytochrome P450 isozymes CYP2D6 and CYP 1A2</span></p>", "ID": "abe1cde9-680b-4abe-82c7-ed46f0b24f4f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "497530f8-369c-415d-9541-f12f90bb00ec"}, {"Element": "<span lang=\"EN-GB\">Maprotiline\u2019s\n  metabolism appears to involve the cytochrome P450 isozymes CYP2D6 and CYP 1A2</span>", "ID": "23978073-5165-4e55-a4cc-9b9421a4a639", "Styles": "None", "Classes": "None", "Text": "Maprotiline\u2019s   metabolism appears to involve the cytochrome P450 isozymes CYP2D6 and CYP 1A2", "ParentId": "abe1cde9-680b-4abe-82c7-ed46f0b24f4f"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Associated\n  with a prolongation of QTc intervals.</span></p>", "ID": "e41908ec-c998-4c2c-95b0-711b4cbe9dfc", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "497530f8-369c-415d-9541-f12f90bb00ec"}, {"Element": "<span lang=\"EN-GB\">Associated\n  with a prolongation of QTc intervals.</span>", "ID": "1222f42e-379e-4d4e-989e-83c7a08bc2ca", "Styles": "None", "Classes": "None", "Text": "Associated   with a prolongation of QTc intervals.", "ParentId": "e41908ec-c998-4c2c-95b0-711b4cbe9dfc"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with Invirase/ritonavir due to potentially life threatening\n  cardiac arrhythmia (see sections 4.3 and 4.4).</p>\n</td>", "ID": "5cf406fb-d208-4059-8979-6ac34f3d122d", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a8e9d39d-b046-46ea-9021-5ce6f0705d38"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with Invirase/ritonavir due to potentially life threatening\n  cardiac arrhythmia (see sections 4.3 and 4.4).</p>", "ID": "f6597d1d-305f-471a-b516-10e5356240a7", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated in   combination with Invirase/ritonavir due to potentially life threatening   cardiac arrhythmia (see sections 4.3 and 4.4).", "ParentId": "5cf406fb-d208-4059-8979-6ac34f3d122d"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Nefazodone<u><br/>\n</u></span><span lang=\"IT\">(saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with saquinavir/ritonavir not evaluated.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nefazodone\n  inhibits CYP3A4. Saquinavir concentrations may be increased.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Combination not\n  recommended. Use with caution due to possible cardiac arrhythmias. Monitoring\n  for saquinavir toxicity recommended (see section 4.4).</p>\n</td>\n</tr>", "ID": "f64cfc6a-025a-4776-b3c5-afc1f2331065", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Nefazodone<u><br/>\n</u></span><span lang=\"IT\">(saquinavir/ritonavir)</span></p>\n</td>", "ID": "86c01b59-6237-41d7-a18f-f1b3cac190a4", "Styles": "width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f64cfc6a-025a-4776-b3c5-afc1f2331065"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Nefazodone<u><br/>\n</u></span><span lang=\"IT\">(saquinavir/ritonavir)</span></p>", "ID": "57c89515-60fa-4f4c-a5bd-ab27a7d52b49", "Styles": "margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 ", "ParentId": "86c01b59-6237-41d7-a18f-f1b3cac190a4"}, {"Element": "<span lang=\"EN-GB\">Nefazodone<u><br/>\n</u></span>", "ID": "9d9e9b42-9beb-41e7-b28a-713ae33e2c37", "Styles": "None", "Classes": "None", "Text": "Nefazodone", "ParentId": "57c89515-60fa-4f4c-a5bd-ab27a7d52b49"}, {"Element": "<u><br/>\n</u>", "ID": "a2e000d4-010e-4386-8ed9-da21445e6ee9", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "9d9e9b42-9beb-41e7-b28a-713ae33e2c37"}, {"Element": "<br/>", "ID": "be2a7123-8773-41dd-9da1-1b609e3b17f0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a2e000d4-010e-4386-8ed9-da21445e6ee9"}, {"Element": "<span lang=\"IT\">(saquinavir/ritonavir)</span>", "ID": "06c503c4-64b6-45dc-9c57-1c7dc028fe20", "Styles": "None", "Classes": "None", "Text": "(saquinavir/ritonavir)", "ParentId": "57c89515-60fa-4f4c-a5bd-ab27a7d52b49"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with saquinavir/ritonavir not evaluated.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nefazodone\n  inhibits CYP3A4. Saquinavir concentrations may be increased.</span></p>\n</td>", "ID": "066a09cb-aa66-41bc-ad2a-e04b18bf27f3", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "f64cfc6a-025a-4776-b3c5-afc1f2331065"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with saquinavir/ritonavir not evaluated.</span></p>", "ID": "da538133-ae8a-4d19-803c-45529fee3f47", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "066a09cb-aa66-41bc-ad2a-e04b18bf27f3"}, {"Element": "<span lang=\"EN-GB\">Interaction\n  with saquinavir/ritonavir not evaluated.</span>", "ID": "30abb737-5964-4808-bc9f-d085ec498040", "Styles": "None", "Classes": "None", "Text": "Interaction   with saquinavir/ritonavir not evaluated.", "ParentId": "da538133-ae8a-4d19-803c-45529fee3f47"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nefazodone\n  inhibits CYP3A4. Saquinavir concentrations may be increased.</span></p>", "ID": "39df8f06-a297-44b3-b298-39ef6d2aa85d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "066a09cb-aa66-41bc-ad2a-e04b18bf27f3"}, {"Element": "<span lang=\"EN-GB\">Nefazodone\n  inhibits CYP3A4. Saquinavir concentrations may be increased.</span>", "ID": "6220e2b9-a6ac-4c08-a74a-b749ce090aa1", "Styles": "None", "Classes": "None", "Text": "Nefazodone   inhibits CYP3A4. Saquinavir concentrations may be increased.", "ParentId": "39df8f06-a297-44b3-b298-39ef6d2aa85d"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Combination not\n  recommended. Use with caution due to possible cardiac arrhythmias. Monitoring\n  for saquinavir toxicity recommended (see section 4.4).</p>\n</td>", "ID": "1ab7e0a3-edf7-4089-996b-342eb8c2517f", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f64cfc6a-025a-4776-b3c5-afc1f2331065"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Combination not\n  recommended. Use with caution due to possible cardiac arrhythmias. Monitoring\n  for saquinavir toxicity recommended (see section 4.4).</p>", "ID": "3fb3eb63-94f3-4b88-a512-0f8097db52ea", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Combination not   recommended. Use with caution due to possible cardiac arrhythmias. Monitoring   for saquinavir toxicity recommended (see section 4.4).", "ParentId": "1ab7e0a3-edf7-4089-996b-342eb8c2517f"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Trazodone<br/>\n</span><span lang=\"IT\">(saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Plasma concentrations of\n  trazodone may increase.<br/>\n  Adverse events of nausea, dizziness, hypotension and syncope have been\n  observed following coadministration of trazodone and ritonavir.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "25f15870-0314-49cb-9ba5-f92ffd54d7f7", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Trazodone<br/>\n</span><span lang=\"IT\">(saquinavir/ritonavir)</span></p>\n</td>", "ID": "488bd0b6-bb93-4488-9966-830b77455d47", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "25f15870-0314-49cb-9ba5-f92ffd54d7f7"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Trazodone<br/>\n</span><span lang=\"IT\">(saquinavir/ritonavir)</span></p>", "ID": "d6340912-cf73-4565-980c-72eacf3cfa0a", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "488bd0b6-bb93-4488-9966-830b77455d47"}, {"Element": "<span lang=\"EN-GB\">Trazodone<br/>\n</span>", "ID": "55d52452-fb21-49f5-996f-a8f275972971", "Styles": "None", "Classes": "None", "Text": "Trazodone ", "ParentId": "d6340912-cf73-4565-980c-72eacf3cfa0a"}, {"Element": "<br/>", "ID": "8a363b87-8c4a-4dde-986f-388e6e2f2219", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "55d52452-fb21-49f5-996f-a8f275972971"}, {"Element": "<span lang=\"IT\">(saquinavir/ritonavir)</span>", "ID": "4f43fee3-93e5-428b-b9fd-e5c5b1d5b424", "Styles": "None", "Classes": "None", "Text": "(saquinavir/ritonavir)", "ParentId": "d6340912-cf73-4565-980c-72eacf3cfa0a"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Plasma concentrations of\n  trazodone may increase.<br/>\n  Adverse events of nausea, dizziness, hypotension and syncope have been\n  observed following coadministration of trazodone and ritonavir.</p>\n</td>", "ID": "0d26b7c8-fe8a-4a7f-a1ea-bc30269180b3", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "25f15870-0314-49cb-9ba5-f92ffd54d7f7"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Plasma concentrations of\n  trazodone may increase.<br/>\n  Adverse events of nausea, dizziness, hypotension and syncope have been\n  observed following coadministration of trazodone and ritonavir.</p>", "ID": "3fa27e37-a65e-44cf-a56c-39abfc568e49", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Plasma concentrations of   trazodone may increase.   Adverse events of nausea, dizziness, hypotension and syncope have been   observed following coadministration of trazodone and ritonavir.", "ParentId": "0d26b7c8-fe8a-4a7f-a1ea-bc30269180b3"}, {"Element": "<br/>", "ID": "14fbb2b6-85b5-4f59-834a-4b80563b9fc3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3fa27e37-a65e-44cf-a56c-39abfc568e49"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "86f681ac-307b-4551-a4ce-da5f13931bdf", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "25f15870-0314-49cb-9ba5-f92ffd54d7f7"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "553c85ff-19ec-40f0-9b3f-bd35c2976639", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated in   combination with  due to   potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)", "ParentId": "86f681ac-307b-4551-a4ce-da5f13931bdf"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "88646ece-d837-4ff4-8653-a00098df61ff", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "553c85ff-19ec-40f0-9b3f-bd35c2976639"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "4376d8ea-1b5a-4ab1-9ddb-467c32d6c708", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "553c85ff-19ec-40f0-9b3f-bd35c2976639"}, {"Element": "<tr style=\"height:12.9pt\">\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Anti-gout\n  preparation</span></i></b></p>\n</td>\n</tr>", "ID": "2117e847-8b57-48bc-9fc4-e850d9c4f7c5", "Styles": "height:12.9pt", "Classes": "None", "Text": "  ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Anti-gout\n  preparation</span></i></b></p>\n</td>", "ID": "ee131616-2d11-43f9-860f-4ab95451f1ba", "Styles": "width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt", "Classes": "None", "Text": "  ", "ParentId": "2117e847-8b57-48bc-9fc4-e850d9c4f7c5"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Anti-gout\n  preparation</span></i></b></p>", "ID": "39c6a975-d865-4a92-8553-fa86fa1a63c8", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "ee131616-2d11-43f9-860f-4ab95451f1ba"}, {"Element": "<b><i><span lang=\"IT\">Anti-gout\n  preparation</span></i></b>", "ID": "6912a211-8fbd-4227-b7d7-c390c17069af", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "39c6a975-d865-4a92-8553-fa86fa1a63c8"}, {"Element": "<i><span lang=\"IT\">Anti-gout\n  preparation</span></i>", "ID": "c8a3573a-711a-4852-af6b-717a4679257d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6912a211-8fbd-4227-b7d7-c390c17069af"}, {"Element": "<span lang=\"IT\">Anti-gout\n  preparation</span>", "ID": "20348181-bbeb-4d23-b3a3-c083bd48ba42", "Styles": "None", "Classes": "None", "Text": "Anti-gout   preparation", "ParentId": "c8a3573a-711a-4852-af6b-717a4679257d"}, {"Element": "<tr style=\"height:53.1pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.1pt\" valign=\"top\" width=\"177\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Colchicine</p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.1pt\" valign=\"top\" width=\"236\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Concomitant use of\n  colchicine and saquinavir/ritonavir is expected to increase plasma levels of\n  colchicine due to P-gp and/or CYP3A4 inhibition by the protease inhibitor.</p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.1pt\" valign=\"top\" width=\"237\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Because of a potential increase\n  of colchicine-related toxicity (neuromuscular events including\n  rhabdomyolysis), its concomitant use with saquinavir/ritonavir is not\n  recommended, especially in the case of renal or hepatic impairment (see\n  section 4.4).</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "d32e0547-b95d-4105-a072-f0dd0308ec6a", "Styles": "height:53.1pt", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.1pt\" valign=\"top\" width=\"177\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Colchicine</p>\n</td>", "ID": "e5f88983-98fe-4683-a05e-d51f888fbc09", "Styles": "width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.1pt", "Classes": "None", "Text": "  ", "ParentId": "d32e0547-b95d-4105-a072-f0dd0308ec6a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Colchicine</p>", "ID": "0fcb93b6-4e2f-4177-8e18-b034148e78d8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Colchicine", "ParentId": "e5f88983-98fe-4683-a05e-d51f888fbc09"}, {"Element": "<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.1pt\" valign=\"top\" width=\"236\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Concomitant use of\n  colchicine and saquinavir/ritonavir is expected to increase plasma levels of\n  colchicine due to P-gp and/or CYP3A4 inhibition by the protease inhibitor.</p>\n</td>", "ID": "b1508f5f-f034-4d05-a3e6-8abb859f7a00", "Styles": "width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.1pt", "Classes": "None", "Text": "  ", "ParentId": "d32e0547-b95d-4105-a072-f0dd0308ec6a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Concomitant use of\n  colchicine and saquinavir/ritonavir is expected to increase plasma levels of\n  colchicine due to P-gp and/or CYP3A4 inhibition by the protease inhibitor.</p>", "ID": "2c44ca2a-57cf-44a5-bdb4-17d6163dddfa", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Concomitant use of   colchicine and saquinavir/ritonavir is expected to increase plasma levels of   colchicine due to P-gp and/or CYP3A4 inhibition by the protease inhibitor.", "ParentId": "b1508f5f-f034-4d05-a3e6-8abb859f7a00"}, {"Element": "<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.1pt\" valign=\"top\" width=\"237\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Because of a potential increase\n  of colchicine-related toxicity (neuromuscular events including\n  rhabdomyolysis), its concomitant use with saquinavir/ritonavir is not\n  recommended, especially in the case of renal or hepatic impairment (see\n  section 4.4).</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "5400ae0d-6ad2-45a7-8f84-5e6894dbe168", "Styles": "width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:53.1pt", "Classes": "None", "Text": "   ", "ParentId": "d32e0547-b95d-4105-a072-f0dd0308ec6a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Because of a potential increase\n  of colchicine-related toxicity (neuromuscular events including\n  rhabdomyolysis), its concomitant use with saquinavir/ritonavir is not\n  recommended, especially in the case of renal or hepatic impairment (see\n  section 4.4).</p>", "ID": "a738eff5-7dcf-49f3-8a6d-ec0bbb1b1af8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Because of a potential increase   of colchicine-related toxicity (neuromuscular events including   rhabdomyolysis), its concomitant use with saquinavir/ritonavir is not   recommended, especially in the case of renal or hepatic impairment (see   section 4.4).", "ParentId": "5400ae0d-6ad2-45a7-8f84-5e6894dbe168"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "d3452579-619e-4777-a1b4-c2bc76702486", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "5400ae0d-6ad2-45a7-8f84-5e6894dbe168"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Antihistamines</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "b52f5a04-61a3-4f43-98af-875ac7c27d7f", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Antihistamines</span></i></b></p>\n</td>", "ID": "2a5de5dc-06cb-498b-ac76-7a580022fcfb", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b52f5a04-61a3-4f43-98af-875ac7c27d7f"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Antihistamines</span></i></b></p>", "ID": "962c6f5b-b5ef-4ee7-b839-457356169e58", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "2a5de5dc-06cb-498b-ac76-7a580022fcfb"}, {"Element": "<b><i><span lang=\"EN-GB\">Antihistamines</span></i></b>", "ID": "a21a8870-2550-4f4e-ad0e-48192bb831b3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "962c6f5b-b5ef-4ee7-b839-457356169e58"}, {"Element": "<i><span lang=\"EN-GB\">Antihistamines</span></i>", "ID": "d09e55da-3f7d-420e-a04e-29065336ee0c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a21a8870-2550-4f4e-ad0e-48192bb831b3"}, {"Element": "<span lang=\"EN-GB\">Antihistamines</span>", "ID": "f17a42ce-d425-42ce-bd7f-c9be25a606e4", "Styles": "None", "Classes": "None", "Text": "Antihistamines", "ParentId": "d09e55da-3f7d-420e-a04e-29065336ee0c"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "6e266429-4323-46fe-bf71-2dd8213e7de8", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b52f5a04-61a3-4f43-98af-875ac7c27d7f"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "c5fb13a7-1715-46dc-b4e1-ed207ab28a7e", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "6e266429-4323-46fe-bf71-2dd8213e7de8"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "9ae66cfb-9667-4198-b03a-7478aa1a405a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c5fb13a7-1715-46dc-b4e1-ed207ab28a7e"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "dba53193-700a-4e5d-8e11-d049f889b6e6", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b52f5a04-61a3-4f43-98af-875ac7c27d7f"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "305ad42b-7fa9-46d2-b207-61d3449d94a4", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "dba53193-700a-4e5d-8e11-d049f889b6e6"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "d85aa962-9f4a-421b-99e1-67208518b9b6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "305ad42b-7fa9-46d2-b207-61d3449d94a4"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Terfenadine<br/>\n  Astemizole<u><br/>\n</u></span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Terfenadine AUC </span>\u2191, <span lang=\"EN-GB\">associated with a prolongation of QTc intervals.<br/>\n  A similar interaction with astemizole is likely.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with Invirase/ritonavir\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4).</p>\n</td>\n</tr>", "ID": "05d92280-31a1-4347-b7ad-3631ac0afed4", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Terfenadine<br/>\n  Astemizole<u><br/>\n</u></span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>", "ID": "d95f9814-9ae3-4629-ac3b-fe706d038af6", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "05d92280-31a1-4347-b7ad-3631ac0afed4"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Terfenadine<br/>\n  Astemizole<u><br/>\n</u></span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>", "ID": "5919136d-464c-4a4e-8839-7dbd88b2bd6c", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "d95f9814-9ae3-4629-ac3b-fe706d038af6"}, {"Element": "<span lang=\"EN-GB\">Terfenadine<br/>\n  Astemizole<u><br/>\n</u></span>", "ID": "024d7d42-fef9-484f-9d16-e98604dd04d1", "Styles": "None", "Classes": "None", "Text": "Terfenadine   Astemizole", "ParentId": "5919136d-464c-4a4e-8839-7dbd88b2bd6c"}, {"Element": "<br/>", "ID": "20f991f5-67ea-469a-9844-6b556e023382", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "024d7d42-fef9-484f-9d16-e98604dd04d1"}, {"Element": "<u><br/>\n</u>", "ID": "72906c73-6385-40e4-9124-a0ef8ec8087f", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "024d7d42-fef9-484f-9d16-e98604dd04d1"}, {"Element": "<br/>", "ID": "f8090c93-910f-459a-96c6-09f4257ea8cc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "72906c73-6385-40e4-9124-a0ef8ec8087f"}, {"Element": "<span lang=\"IT\">(</span>", "ID": "3b06e13a-6f53-4dbc-aae0-16ed52b9a529", "Styles": "None", "Classes": "None", "Text": "(", "ParentId": "5919136d-464c-4a4e-8839-7dbd88b2bd6c"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "5c84230a-66e0-4a59-aba5-09622449eef6", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "5919136d-464c-4a4e-8839-7dbd88b2bd6c"}, {"Element": "<span lang=\"IT\">)</span>", "ID": "96be4e01-3fcd-48f2-846c-91f0e5d6daf4", "Styles": "None", "Classes": "None", "Text": ")", "ParentId": "5919136d-464c-4a4e-8839-7dbd88b2bd6c"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Terfenadine AUC </span>\u2191, <span lang=\"EN-GB\">associated with a prolongation of QTc intervals.<br/>\n  A similar interaction with astemizole is likely.</span></p>\n</td>", "ID": "fc594695-74ae-4c36-9209-990c490f8f1b", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "05d92280-31a1-4347-b7ad-3631ac0afed4"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Terfenadine AUC </span>\u2191, <span lang=\"EN-GB\">associated with a prolongation of QTc intervals.<br/>\n  A similar interaction with astemizole is likely.</span></p>", "ID": "a44c6f6a-4aed-44ed-9e1b-57d3b84573ad", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "\u2191, ", "ParentId": "fc594695-74ae-4c36-9209-990c490f8f1b"}, {"Element": "<span lang=\"EN-GB\">Terfenadine AUC </span>", "ID": "e25dae67-c13e-4a5b-bc1b-2a9a64d769a8", "Styles": "None", "Classes": "None", "Text": "Terfenadine AUC ", "ParentId": "a44c6f6a-4aed-44ed-9e1b-57d3b84573ad"}, {"Element": "<span lang=\"EN-GB\">associated with a prolongation of QTc intervals.<br/>\n  A similar interaction with astemizole is likely.</span>", "ID": "ff8beaf9-82d4-44aa-aabd-ceca9f25bc49", "Styles": "None", "Classes": "None", "Text": "associated with a prolongation of QTc intervals.   A similar interaction with astemizole is likely.", "ParentId": "a44c6f6a-4aed-44ed-9e1b-57d3b84573ad"}, {"Element": "<br/>", "ID": "e7abc5ac-7fc4-4783-9286-45224c98bc63", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ff8beaf9-82d4-44aa-aabd-ceca9f25bc49"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with Invirase/ritonavir\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4).</p>\n</td>", "ID": "77d9f53e-f44d-430f-a8c6-1c495434350e", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "05d92280-31a1-4347-b7ad-3631ac0afed4"}, {"Element": "<p class=\"Normal11pt0\">Contraindicated in combination with Invirase/ritonavir\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4).</p>", "ID": "4d8a5e42-3ecd-45c5-91c9-e103852b7d78", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Contraindicated in combination with Invirase/ritonavir   due to the potential for life threatening cardiac arrhythmia (see sections   4.3 and 4.4).", "ParentId": "77d9f53e-f44d-430f-a8c6-1c495434350e"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Mizolastine<br/>\n  (</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "7a35b20f-e3bd-4641-ad7d-bd7a8f88c655", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Mizolastine<br/>\n  (</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>", "ID": "f7b33a4a-7859-41d8-ade0-4615ffa554f7", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7a35b20f-e3bd-4641-ad7d-bd7a8f88c655"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">Mizolastine<br/>\n  (</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>", "ID": "077b99e9-3da6-40b1-8fcf-30f97697ea85", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "f7b33a4a-7859-41d8-ade0-4615ffa554f7"}, {"Element": "<span lang=\"IT\">Mizolastine<br/>\n  (</span>", "ID": "05b80a4e-fef1-4e17-9a0e-6613be6365fd", "Styles": "None", "Classes": "None", "Text": "Mizolastine   (", "ParentId": "077b99e9-3da6-40b1-8fcf-30f97697ea85"}, {"Element": "<br/>", "ID": "19efaafd-a0db-4214-be59-d776728469f4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "05b80a4e-fef1-4e17-9a0e-6613be6365fd"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "c68d5b3b-c2f9-429c-9738-46fb83c1f467", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "077b99e9-3da6-40b1-8fcf-30f97697ea85"}, {"Element": "<span lang=\"IT\">)</span>", "ID": "1e882330-94bb-4e34-81f0-a465526c6edf", "Styles": "None", "Classes": "None", "Text": ")", "ParentId": "077b99e9-3da6-40b1-8fcf-30f97697ea85"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "1845621c-f257-4f7d-82e5-a5dafeb757ff", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7a35b20f-e3bd-4641-ad7d-bd7a8f88c655"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "505ecd51-b770-40f3-93fc-2d6f8f34c2b5", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "1845621c-f257-4f7d-82e5-a5dafeb757ff"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e4347d43-0c81-4f6a-8485-9d3293e271c0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "505ecd51-b770-40f3-93fc-2d6f8f34c2b5"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "59ee591b-2363-49e0-be5a-2196e8abf44f", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7a35b20f-e3bd-4641-ad7d-bd7a8f88c655"}, {"Element": "<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "4f376d63-1274-4f04-a88d-26284d69a1a6", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Contraindicated in combination with    due to the potential for life threatening cardiac arrhythmia (see sections   4.3 and 4.4)", "ParentId": "59ee591b-2363-49e0-be5a-2196e8abf44f"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "ff83d4ff-e1bf-4ed8-b630-a2ccb97f45c7", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "4f376d63-1274-4f04-a88d-26284d69a1a6"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "90c23a35-e26a-4a08-9169-f24d5fee5d05", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "4f376d63-1274-4f04-a88d-26284d69a1a6"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Anti-infectives</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "90f7fbe9-50c6-4667-817f-46b359f04557", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Anti-infectives</span></i></b></p>\n</td>", "ID": "a0638e4f-96b8-4949-8ff6-3ae6f68fa521", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "90f7fbe9-50c6-4667-817f-46b359f04557"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Anti-infectives</span></i></b></p>", "ID": "af0fcb41-f007-4446-a9b9-d76716a7239e", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "a0638e4f-96b8-4949-8ff6-3ae6f68fa521"}, {"Element": "<b><i><span lang=\"EN-GB\">Anti-infectives</span></i></b>", "ID": "54589829-320b-4f5e-a074-f88417896df8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "af0fcb41-f007-4446-a9b9-d76716a7239e"}, {"Element": "<i><span lang=\"EN-GB\">Anti-infectives</span></i>", "ID": "eb7db578-8893-4204-946f-ce0b513d95d4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "54589829-320b-4f5e-a074-f88417896df8"}, {"Element": "<span lang=\"EN-GB\">Anti-infectives</span>", "ID": "8a50dfde-454a-4ce8-8929-1230892babcf", "Styles": "None", "Classes": "None", "Text": "Anti-infectives", "ParentId": "eb7db578-8893-4204-946f-ce0b513d95d4"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "af71dfbf-5d98-4028-8799-f2f1345d4e1a", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "90f7fbe9-50c6-4667-817f-46b359f04557"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "bd171986-316e-4a23-9c20-2f77b3551757", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "af71dfbf-5d98-4028-8799-f2f1345d4e1a"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "26d6a7c0-c72f-4c55-a0c1-64598807de1e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bd171986-316e-4a23-9c20-2f77b3551757"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "c52b067d-e741-4e14-895b-3ba09980e29a", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "90f7fbe9-50c6-4667-817f-46b359f04557"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "2ff54c56-c862-47bc-9d95-f2fe8150aab6", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "c52b067d-e741-4e14-895b-3ba09980e29a"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "c85f44de-b18b-4a3c-a56d-41065cf58dcc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2ff54c56-c862-47bc-9d95-f2fe8150aab6"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Clarithromycin<u><br/>\n</u></span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Interaction with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Clarithromycin is a\n  CYP3A4 substrate and is associated with QT prolongation.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Contraindicated\n  in combination with Invirase/ritonavir due to the potential for life\n  threatening cardiac arrhythmia (see sections 4.3 and 4.4).</span></p>\n</td>\n</tr>", "ID": "68e2ca00-7c31-448d-b2c3-568816009246", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Clarithromycin<u><br/>\n</u></span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>", "ID": "5b882114-c19a-4eb4-92a2-4d6c1781114b", "Styles": "width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "68e2ca00-7c31-448d-b2c3-568816009246"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Clarithromycin<u><br/>\n</u></span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>", "ID": "8fba9dbe-f49f-49dc-9d99-043655af08d8", "Styles": "text-indent:-9.35pt;page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 ", "ParentId": "5b882114-c19a-4eb4-92a2-4d6c1781114b"}, {"Element": "<span lang=\"EN-GB\">Clarithromycin<u><br/>\n</u></span>", "ID": "e7ebc3d4-03b8-4746-827c-db05cc728d79", "Styles": "None", "Classes": "None", "Text": "Clarithromycin", "ParentId": "8fba9dbe-f49f-49dc-9d99-043655af08d8"}, {"Element": "<u><br/>\n</u>", "ID": "e9627f66-88e8-4c40-9a79-049992d21e51", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "e7ebc3d4-03b8-4746-827c-db05cc728d79"}, {"Element": "<br/>", "ID": "635a93ef-93e9-4d54-bdb5-dd63a0129222", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e9627f66-88e8-4c40-9a79-049992d21e51"}, {"Element": "<span lang=\"IT\">(</span>", "ID": "bbd5094f-d215-4c8d-8f9b-531d782493e0", "Styles": "None", "Classes": "None", "Text": "(", "ParentId": "8fba9dbe-f49f-49dc-9d99-043655af08d8"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "00109f87-f47f-4c4f-9259-a9ca9029ff61", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "8fba9dbe-f49f-49dc-9d99-043655af08d8"}, {"Element": "<span lang=\"IT\">)</span>", "ID": "19a207d6-e10b-4587-986c-ec5334705a6c", "Styles": "None", "Classes": "None", "Text": ")", "ParentId": "8fba9dbe-f49f-49dc-9d99-043655af08d8"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Interaction with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Clarithromycin is a\n  CYP3A4 substrate and is associated with QT prolongation.</p>\n</td>", "ID": "68a7d772-2c56-4a79-a122-8784bfefd683", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "68e2ca00-7c31-448d-b2c3-568816009246"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Interaction with Invirase/ritonavir not studied.</span></p>", "ID": "2d856528-21d6-463a-b452-2ea66681e1cb", "Styles": "text-indent:-9.35pt;page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 ", "ParentId": "68a7d772-2c56-4a79-a122-8784bfefd683"}, {"Element": "<span lang=\"EN-GB\">Interaction with Invirase/ritonavir not studied.</span>", "ID": "ff4c0fff-0697-404a-aad3-61c9b560faf5", "Styles": "None", "Classes": "None", "Text": "Interaction with Invirase/ritonavir not studied.", "ParentId": "2d856528-21d6-463a-b452-2ea66681e1cb"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Clarithromycin is a\n  CYP3A4 substrate and is associated with QT prolongation.</p>", "ID": "08936388-75fa-49dc-a83a-ec888b066f8a", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Clarithromycin is a   CYP3A4 substrate and is associated with QT prolongation.", "ParentId": "68a7d772-2c56-4a79-a122-8784bfefd683"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Contraindicated\n  in combination with Invirase/ritonavir due to the potential for life\n  threatening cardiac arrhythmia (see sections 4.3 and 4.4).</span></p>\n</td>", "ID": "8154ab74-127a-4d97-a353-5d9ee290ca1e", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "68e2ca00-7c31-448d-b2c3-568816009246"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Contraindicated\n  in combination with Invirase/ritonavir due to the potential for life\n  threatening cardiac arrhythmia (see sections 4.3 and 4.4).</span></p>", "ID": "9776a630-d84f-4fc6-8d23-a1b9d7a4b4f3", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "8154ab74-127a-4d97-a353-5d9ee290ca1e"}, {"Element": "<span lang=\"EN-GB\">Contraindicated\n  in combination with Invirase/ritonavir due to the potential for life\n  threatening cardiac arrhythmia (see sections 4.3 and 4.4).</span>", "ID": "a1da84a2-f0fc-4582-a63b-5003bf8f08a4", "Styles": "None", "Classes": "None", "Text": "Contraindicated   in combination with Invirase/ritonavir due to the potential for life   threatening cardiac arrhythmia (see sections 4.3 and 4.4).", "ParentId": "9776a630-d84f-4fc6-8d23-a1b9d7a4b4f3"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Clarithromycin<br/>\n  500\u00a0mg bid<u><br/>\n</u></span>(unboosted saquinavir <span lang=\"EN-GB\">1200\u00a0mg tid</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Saquinavir\n  AUC </span>\u2191 <span lang=\"EN-GB\">177 %<br/>\n  Saquinavir C<sub>max </sub></span>\u2191 <span lang=\"EN-GB\">187</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">%<br/>\n  Clarithromycin AUC </span>\u2191 <span lang=\"EN-GB\">40 %<br/>\n  Clarithromycin C<sub>max</sub> </span>\u2191 <span lang=\"EN-GB\">40 %</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "c8effb79-e412-4ce9-9d1a-0a1eaad6531a", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Clarithromycin<br/>\n  500\u00a0mg bid<u><br/>\n</u></span>(unboosted saquinavir <span lang=\"EN-GB\">1200\u00a0mg tid</span>)</p>\n</td>", "ID": "0d38f94d-9d30-410c-bfac-1d493cc2129d", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c8effb79-e412-4ce9-9d1a-0a1eaad6531a"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Clarithromycin<br/>\n  500\u00a0mg bid<u><br/>\n</u></span>(unboosted saquinavir <span lang=\"EN-GB\">1200\u00a0mg tid</span>)</p>", "ID": "ec679272-26b2-43c1-85a6-81a43e42b706", "Styles": "text-indent:-9.35pt", "Classes": "['Normal11pt0']", "Text": "-\u00a0 (unboosted saquinavir )", "ParentId": "0d38f94d-9d30-410c-bfac-1d493cc2129d"}, {"Element": "<span lang=\"EN-GB\">Clarithromycin<br/>\n  500\u00a0mg bid<u><br/>\n</u></span>", "ID": "6a970f08-8060-4a28-b9a4-d22caa2f8adc", "Styles": "None", "Classes": "None", "Text": "Clarithromycin   500\u00a0mg bid", "ParentId": "ec679272-26b2-43c1-85a6-81a43e42b706"}, {"Element": "<br/>", "ID": "2031e9f8-a758-4010-886e-1fa3990faf6b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6a970f08-8060-4a28-b9a4-d22caa2f8adc"}, {"Element": "<u><br/>\n</u>", "ID": "e34df518-6056-4259-a196-15d63d136f6b", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "6a970f08-8060-4a28-b9a4-d22caa2f8adc"}, {"Element": "<br/>", "ID": "fac6187e-d45e-4afb-94d6-cc6aadf8662a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e34df518-6056-4259-a196-15d63d136f6b"}, {"Element": "<span lang=\"EN-GB\">1200\u00a0mg tid</span>", "ID": "3abadef9-c972-47e4-8684-477d1455d38e", "Styles": "None", "Classes": "None", "Text": "1200\u00a0mg tid", "ParentId": "ec679272-26b2-43c1-85a6-81a43e42b706"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Saquinavir\n  AUC </span>\u2191 <span lang=\"EN-GB\">177 %<br/>\n  Saquinavir C<sub>max </sub></span>\u2191 <span lang=\"EN-GB\">187</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">%<br/>\n  Clarithromycin AUC </span>\u2191 <span lang=\"EN-GB\">40 %<br/>\n  Clarithromycin C<sub>max</sub> </span>\u2191 <span lang=\"EN-GB\">40 %</span></p>\n</td>", "ID": "78f933da-10d5-4b40-bf7b-6df6f62b2652", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c8effb79-e412-4ce9-9d1a-0a1eaad6531a"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Saquinavir\n  AUC </span>\u2191 <span lang=\"EN-GB\">177 %<br/>\n  Saquinavir C<sub>max </sub></span>\u2191 <span lang=\"EN-GB\">187</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">%<br/>\n  Clarithromycin AUC </span>\u2191 <span lang=\"EN-GB\">40 %<br/>\n  Clarithromycin C<sub>max</sub> </span>\u2191 <span lang=\"EN-GB\">40 %</span></p>", "ID": "ac35d518-1d62-45b9-b7bc-f91ec792ba7d", "Styles": "text-indent:-9.35pt", "Classes": "['Normal11pt0']", "Text": "-\u00a0 \u2191 \u2191 \u2191 \u2191 ", "ParentId": "78f933da-10d5-4b40-bf7b-6df6f62b2652"}, {"Element": "<span lang=\"EN-GB\">Saquinavir\n  AUC </span>", "ID": "d7efa6ae-2784-4c8f-926b-276ce50b9c0f", "Styles": "None", "Classes": "None", "Text": "Saquinavir   AUC ", "ParentId": "ac35d518-1d62-45b9-b7bc-f91ec792ba7d"}, {"Element": "<span lang=\"EN-GB\">177 %<br/>\n  Saquinavir C<sub>max </sub></span>", "ID": "487888cf-f9b4-4d32-af11-92e53553293e", "Styles": "None", "Classes": "None", "Text": "177 %   Saquinavir C", "ParentId": "ac35d518-1d62-45b9-b7bc-f91ec792ba7d"}, {"Element": "<br/>", "ID": "b3f2415b-a558-43fc-b3a5-2055cbfb8310", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "487888cf-f9b4-4d32-af11-92e53553293e"}, {"Element": "<sub>max </sub>", "ID": "268a385b-df46-4d0d-8d82-ee4c2a471fa8", "Styles": "None", "Classes": "None", "Text": "max ", "ParentId": "487888cf-f9b4-4d32-af11-92e53553293e"}, {"Element": "<span lang=\"EN-GB\">187</span>", "ID": "861b488e-f89c-456e-b277-8b98ae07073c", "Styles": "None", "Classes": "None", "Text": "187", "ParentId": "ac35d518-1d62-45b9-b7bc-f91ec792ba7d"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "41d67a66-1d55-45f7-9dd2-e5d92d0587d6", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "ac35d518-1d62-45b9-b7bc-f91ec792ba7d"}, {"Element": "<span lang=\"EN-GB\">%<br/>\n  Clarithromycin AUC </span>", "ID": "8d37fd10-453b-47ef-aa87-99fb6d1b8289", "Styles": "None", "Classes": "None", "Text": "%   Clarithromycin AUC ", "ParentId": "ac35d518-1d62-45b9-b7bc-f91ec792ba7d"}, {"Element": "<br/>", "ID": "37c1aa3f-416b-4b49-bc93-069089ba60ac", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8d37fd10-453b-47ef-aa87-99fb6d1b8289"}, {"Element": "<span lang=\"EN-GB\">40 %<br/>\n  Clarithromycin C<sub>max</sub> </span>", "ID": "02a5e624-5cd6-4cb3-8ec2-98ce10700932", "Styles": "None", "Classes": "None", "Text": "40 %   Clarithromycin C ", "ParentId": "ac35d518-1d62-45b9-b7bc-f91ec792ba7d"}, {"Element": "<br/>", "ID": "a8c089fd-34be-4589-b02c-26afffe0f584", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "02a5e624-5cd6-4cb3-8ec2-98ce10700932"}, {"Element": "<sub>max</sub>", "ID": "5c2e4ef2-16cc-4111-ad6d-dd3282a80ff8", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "02a5e624-5cd6-4cb3-8ec2-98ce10700932"}, {"Element": "<span lang=\"EN-GB\">40 %</span>", "ID": "a8556ebd-cc27-43e6-a028-718888792419", "Styles": "None", "Classes": "None", "Text": "40 %", "ParentId": "ac35d518-1d62-45b9-b7bc-f91ec792ba7d"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "d3496bdf-8ce1-4555-9f28-68d6abceb117", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c8effb79-e412-4ce9-9d1a-0a1eaad6531a"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "8418fd1d-8a79-4713-a035-de4a374b0cf3", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated in   combination with  due to the   potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)", "ParentId": "d3496bdf-8ce1-4555-9f28-68d6abceb117"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "2a7e5fe7-421a-42d4-8c44-c923b4f8eaa3", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "8418fd1d-8a79-4713-a035-de4a374b0cf3"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "abda9b48-13b4-4c62-be06-c4a7d4c5b951", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "8418fd1d-8a79-4713-a035-de4a374b0cf3"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Erythromycin<u><br/>\n</u></span><span lang=\"IT\">(saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\">Erythromycin is a CYP3A4 substrate and is associated\n  with QT prolongation.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "1192f9ae-cca1-443a-a641-7b0e3aebcbfc", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Erythromycin<u><br/>\n</u></span><span lang=\"IT\">(saquinavir/ritonavir)</span></p>\n</td>", "ID": "b0d6e921-6ab3-4773-8c63-6a8d6f8dca12", "Styles": "width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1192f9ae-cca1-443a-a641-7b0e3aebcbfc"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Erythromycin<u><br/>\n</u></span><span lang=\"IT\">(saquinavir/ritonavir)</span></p>", "ID": "83453408-204f-4032-bfd4-95a039d5f89a", "Styles": "text-indent:-9.35pt", "Classes": "['Normal11pt0']", "Text": "-\u00a0 ", "ParentId": "b0d6e921-6ab3-4773-8c63-6a8d6f8dca12"}, {"Element": "<span lang=\"EN-GB\">Erythromycin<u><br/>\n</u></span>", "ID": "e8bcfde0-84cb-40bd-9d0d-54a600566ee4", "Styles": "None", "Classes": "None", "Text": "Erythromycin", "ParentId": "83453408-204f-4032-bfd4-95a039d5f89a"}, {"Element": "<u><br/>\n</u>", "ID": "c9e15140-e1f4-42f3-bca2-8871af507e59", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "e8bcfde0-84cb-40bd-9d0d-54a600566ee4"}, {"Element": "<br/>", "ID": "6f106180-e60d-4e5b-a874-5fb18ef624d9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c9e15140-e1f4-42f3-bca2-8871af507e59"}, {"Element": "<span lang=\"IT\">(saquinavir/ritonavir)</span>", "ID": "45fdfc14-9a48-49c2-8099-c1894926ce53", "Styles": "None", "Classes": "None", "Text": "(saquinavir/ritonavir)", "ParentId": "83453408-204f-4032-bfd4-95a039d5f89a"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\">Erythromycin is a CYP3A4 substrate and is associated\n  with QT prolongation.</p>\n</td>", "ID": "4255859d-ff98-475a-88b5-87bad50f7fff", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "1192f9ae-cca1-443a-a641-7b0e3aebcbfc"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>", "ID": "06385802-d46f-487f-897a-fa79b7d1de29", "Styles": "text-indent:-9.35pt", "Classes": "['Normal11pt0']", "Text": "-\u00a0 ", "ParentId": "4255859d-ff98-475a-88b5-87bad50f7fff"}, {"Element": "<span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span>", "ID": "f363938b-8972-49cf-b997-911df4e838c5", "Styles": "None", "Classes": "None", "Text": "Interaction   with Invirase/ritonavir not studied.", "ParentId": "06385802-d46f-487f-897a-fa79b7d1de29"}, {"Element": "<p class=\"Normal11pt0\">Erythromycin is a CYP3A4 substrate and is associated\n  with QT prolongation.</p>", "ID": "22199d18-4e7e-4011-9a80-ae2394472d26", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Erythromycin is a CYP3A4 substrate and is associated   with QT prolongation.", "ParentId": "4255859d-ff98-475a-88b5-87bad50f7fff"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "6530e102-117c-4ecf-99e7-67dec231a888", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1192f9ae-cca1-443a-a641-7b0e3aebcbfc"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "35bb0d4a-fd38-4a8b-8132-9228917946b7", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated in   combination with  due to the   potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)", "ParentId": "6530e102-117c-4ecf-99e7-67dec231a888"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "e00350f2-6b5d-44c5-8dbb-1b0ea003ea38", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "35bb0d4a-fd38-4a8b-8132-9228917946b7"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "3f059d02-fde5-45fb-a20f-6b24a692027b", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "35bb0d4a-fd38-4a8b-8132-9228917946b7"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Erythromycin<br/>\n  250\u00a0mg qid<br/>\n</span>(unboosted saquinavir <span lang=\"EN-GB\">1200\u00a0mg tid</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Saquinavir\n  AUC </span>\u2191 <span lang=\"EN-GB\">99 %<br/>\n  Saquinavir C<sub>max </sub></span>\u2191 <span lang=\"EN-GB\">106</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">%<br/>\n<br/>\n</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "d086c63a-13a8-40ae-806b-95c7f616ddf3", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Erythromycin<br/>\n  250\u00a0mg qid<br/>\n</span>(unboosted saquinavir <span lang=\"EN-GB\">1200\u00a0mg tid</span>)</p>\n</td>", "ID": "ada4ba0a-fc32-43ff-bf39-35b40fb2dcb0", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d086c63a-13a8-40ae-806b-95c7f616ddf3"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Erythromycin<br/>\n  250\u00a0mg qid<br/>\n</span>(unboosted saquinavir <span lang=\"EN-GB\">1200\u00a0mg tid</span>)</p>", "ID": "b9dd3e1f-c182-4447-8139-aee0bcb49d0c", "Styles": "text-indent:-9.35pt", "Classes": "['Normal11pt0']", "Text": "-\u00a0 (unboosted saquinavir )", "ParentId": "ada4ba0a-fc32-43ff-bf39-35b40fb2dcb0"}, {"Element": "<span lang=\"EN-GB\">Erythromycin<br/>\n  250\u00a0mg qid<br/>\n</span>", "ID": "dd273f90-bb96-4a29-8b0b-2507c18fe404", "Styles": "None", "Classes": "None", "Text": "Erythromycin   250\u00a0mg qid ", "ParentId": "b9dd3e1f-c182-4447-8139-aee0bcb49d0c"}, {"Element": "<br/>", "ID": "5f8c9217-0640-4b67-928c-99b3c1fe5286", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dd273f90-bb96-4a29-8b0b-2507c18fe404"}, {"Element": "<br/>", "ID": "f0a51717-2719-4c61-9001-54d1c918c4fa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dd273f90-bb96-4a29-8b0b-2507c18fe404"}, {"Element": "<span lang=\"EN-GB\">1200\u00a0mg tid</span>", "ID": "bde70f28-bb92-4417-a74f-b691b1c0b013", "Styles": "None", "Classes": "None", "Text": "1200\u00a0mg tid", "ParentId": "b9dd3e1f-c182-4447-8139-aee0bcb49d0c"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Saquinavir\n  AUC </span>\u2191 <span lang=\"EN-GB\">99 %<br/>\n  Saquinavir C<sub>max </sub></span>\u2191 <span lang=\"EN-GB\">106</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">%<br/>\n<br/>\n</span></p>\n</td>", "ID": "4259ebac-4476-4339-8b1e-5b5ec93399ff", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d086c63a-13a8-40ae-806b-95c7f616ddf3"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt\">-\u00a0 <span lang=\"EN-GB\">Saquinavir\n  AUC </span>\u2191 <span lang=\"EN-GB\">99 %<br/>\n  Saquinavir C<sub>max </sub></span>\u2191 <span lang=\"EN-GB\">106</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">%<br/>\n<br/>\n</span></p>", "ID": "19ae9e91-cb8c-49f8-bd83-afc47a57a74b", "Styles": "text-indent:-9.35pt", "Classes": "['Normal11pt0']", "Text": "-\u00a0 \u2191 \u2191 ", "ParentId": "4259ebac-4476-4339-8b1e-5b5ec93399ff"}, {"Element": "<span lang=\"EN-GB\">Saquinavir\n  AUC </span>", "ID": "fd671f0f-bb05-4ca4-8113-18ea74aeb99d", "Styles": "None", "Classes": "None", "Text": "Saquinavir   AUC ", "ParentId": "19ae9e91-cb8c-49f8-bd83-afc47a57a74b"}, {"Element": "<span lang=\"EN-GB\">99 %<br/>\n  Saquinavir C<sub>max </sub></span>", "ID": "b3012049-88bd-449e-af96-8bd7d62f1552", "Styles": "None", "Classes": "None", "Text": "99 %   Saquinavir C", "ParentId": "19ae9e91-cb8c-49f8-bd83-afc47a57a74b"}, {"Element": "<br/>", "ID": "c861cb0d-69b4-4c4e-b7a8-8183ff9848bf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b3012049-88bd-449e-af96-8bd7d62f1552"}, {"Element": "<sub>max </sub>", "ID": "0f27aa51-84ab-4bd7-ae62-ae9fe512567d", "Styles": "None", "Classes": "None", "Text": "max ", "ParentId": "b3012049-88bd-449e-af96-8bd7d62f1552"}, {"Element": "<span lang=\"EN-GB\">106</span>", "ID": "40208733-3b38-4275-a880-8c21c3388455", "Styles": "None", "Classes": "None", "Text": "106", "ParentId": "19ae9e91-cb8c-49f8-bd83-afc47a57a74b"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "8d67f0fd-7a04-4bc9-a0ad-a9842fda3d9a", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "19ae9e91-cb8c-49f8-bd83-afc47a57a74b"}, {"Element": "<span lang=\"EN-GB\">%<br/>\n<br/>\n</span>", "ID": "96ce3623-41b9-41ce-88aa-8cf37fbd1af6", "Styles": "None", "Classes": "None", "Text": "%  ", "ParentId": "19ae9e91-cb8c-49f8-bd83-afc47a57a74b"}, {"Element": "<br/>", "ID": "f76ee84a-0c1b-4a98-a739-c906749286eb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "96ce3623-41b9-41ce-88aa-8cf37fbd1af6"}, {"Element": "<br/>", "ID": "30ceec03-1537-4c5f-8059-474218f5bfce", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "96ce3623-41b9-41ce-88aa-8cf37fbd1af6"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "0e87a75a-9427-442f-936f-214c640cab15", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d086c63a-13a8-40ae-806b-95c7f616ddf3"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "71f79ed6-1efa-4441-b6ab-416319861b67", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated in   combination with  due to the   potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)", "ParentId": "0e87a75a-9427-442f-936f-214c640cab15"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "47fa9df1-a237-40b0-b268-ec3b5775d323", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "71f79ed6-1efa-4441-b6ab-416319861b67"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "e6021f91-c1f6-4142-a8c9-9565195f8507", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "71f79ed6-1efa-4441-b6ab-416319861b67"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\"><span lang=\"IT\">Fusidic acid</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\"><span lang=\"IT\">(saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Not studied. Co-administration of\n  fusidic acid and Invirase/ritonavir can cause increased plasma concentration\n  of both fusidic acid and saquinavir/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "65ae65b2-bb19-4d2f-9c54-de6d4dfe2be2", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\"><span lang=\"IT\">Fusidic acid</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\"><span lang=\"IT\">(saquinavir/ritonavir)</span></p>\n</td>", "ID": "d9063fe1-95fd-40c6-8628-599be3f49133", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "65ae65b2-bb19-4d2f-9c54-de6d4dfe2be2"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\"><span lang=\"IT\">Fusidic acid</span></p>", "ID": "77fe6fdd-d676-40e1-93e4-477799ad1757", "Styles": "margin-left:9.35pt;text-indent:-9.35pt", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "d9063fe1-95fd-40c6-8628-599be3f49133"}, {"Element": "<span lang=\"IT\">Fusidic acid</span>", "ID": "f0bcf745-3d25-485e-811f-7fa5ec23caba", "Styles": "None", "Classes": "None", "Text": "Fusidic acid", "ParentId": "77fe6fdd-d676-40e1-93e4-477799ad1757"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\"><span lang=\"IT\">(saquinavir/ritonavir)</span></p>", "ID": "3ad38be1-4615-402b-ba7d-0342eb58bb2b", "Styles": "margin-left:9.35pt;text-indent:-9.35pt", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "d9063fe1-95fd-40c6-8628-599be3f49133"}, {"Element": "<span lang=\"IT\">(saquinavir/ritonavir)</span>", "ID": "8869be0a-3fdf-4ef2-b2b9-564fbdad5d9e", "Styles": "None", "Classes": "None", "Text": "(saquinavir/ritonavir)", "ParentId": "3ad38be1-4615-402b-ba7d-0342eb58bb2b"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Not studied. Co-administration of\n  fusidic acid and Invirase/ritonavir can cause increased plasma concentration\n  of both fusidic acid and saquinavir/ritonavir.</span></p>\n</td>", "ID": "d8ee03bb-bf13-4af5-b06c-685602da292d", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "65ae65b2-bb19-4d2f-9c54-de6d4dfe2be2"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Not studied. Co-administration of\n  fusidic acid and Invirase/ritonavir can cause increased plasma concentration\n  of both fusidic acid and saquinavir/ritonavir.</span></p>", "ID": "82e98247-0e97-4fdb-a995-7887362279ec", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "d8ee03bb-bf13-4af5-b06c-685602da292d"}, {"Element": "<span lang=\"EN-GB\">Not studied. Co-administration of\n  fusidic acid and Invirase/ritonavir can cause increased plasma concentration\n  of both fusidic acid and saquinavir/ritonavir.</span>", "ID": "c7e76c9c-d5e3-4604-981b-ec2a7cd9434b", "Styles": "None", "Classes": "None", "Text": "Not studied. Co-administration of   fusidic acid and Invirase/ritonavir can cause increased plasma concentration   of both fusidic acid and saquinavir/ritonavir.", "ParentId": "82e98247-0e97-4fdb-a995-7887362279ec"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "3c5d7a72-09ba-4c21-94fc-f550c9023eb7", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "65ae65b2-bb19-4d2f-9c54-de6d4dfe2be2"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt\"><span lang=\"IT\">\u00a0</span></p>", "ID": "0b6b7814-30a8-4372-bf7b-a5474f7fb85a", "Styles": "margin-left:.45pt;text-indent:-.45pt", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "3c5d7a72-09ba-4c21-94fc-f550c9023eb7"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "61f35bff-f878-4d03-81cd-d2f7579fa77f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0b6b7814-30a8-4372-bf7b-a5474f7fb85a"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Streptogramin antibiotics<u><br/>\n</u></span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Streptogramin\n  antibiotics such as quinupristin/dalfopristin inhibit CYP3A4. </span><span lang=\"IT\">Saquinavir concentrations may be increased.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution due to\n  possible cardiac arrhythmias. <span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "d12dc094-234f-4755-80b6-0c9d8f64af28", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Streptogramin antibiotics<u><br/>\n</u></span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>", "ID": "009c5d05-2d17-4204-85a4-cbd5435a9e51", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d12dc094-234f-4755-80b6-0c9d8f64af28"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Streptogramin antibiotics<u><br/>\n</u></span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>", "ID": "552373a3-f8f6-4ef3-a115-b4bd55f84de6", "Styles": "text-indent:-9.35pt;page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 ", "ParentId": "009c5d05-2d17-4204-85a4-cbd5435a9e51"}, {"Element": "<span lang=\"EN-GB\">Streptogramin antibiotics<u><br/>\n</u></span>", "ID": "f6d74dc5-a36e-41c9-9a38-9338ee1a29b6", "Styles": "None", "Classes": "None", "Text": "Streptogramin antibiotics", "ParentId": "552373a3-f8f6-4ef3-a115-b4bd55f84de6"}, {"Element": "<u><br/>\n</u>", "ID": "d414a15c-2dc8-43f1-9ed6-ee6e597bbd6f", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "f6d74dc5-a36e-41c9-9a38-9338ee1a29b6"}, {"Element": "<br/>", "ID": "ab0b400f-e8ce-4e3c-a762-002a2f40941f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d414a15c-2dc8-43f1-9ed6-ee6e597bbd6f"}, {"Element": "<span lang=\"IT\">(</span>", "ID": "33a5d327-e224-4a83-9611-de7434fa33ed", "Styles": "None", "Classes": "None", "Text": "(", "ParentId": "552373a3-f8f6-4ef3-a115-b4bd55f84de6"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "2a1b7077-b9d0-4ba0-837c-dbe0c0c6c469", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "552373a3-f8f6-4ef3-a115-b4bd55f84de6"}, {"Element": "<span lang=\"IT\">)</span>", "ID": "c10fea89-e971-4549-af07-43da3e0937b2", "Styles": "None", "Classes": "None", "Text": ")", "ParentId": "552373a3-f8f6-4ef3-a115-b4bd55f84de6"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Streptogramin\n  antibiotics such as quinupristin/dalfopristin inhibit CYP3A4. </span><span lang=\"IT\">Saquinavir concentrations may be increased.</span></p>\n</td>", "ID": "5a076412-3e9c-49ff-ac02-cbc82bd41009", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "d12dc094-234f-4755-80b6-0c9d8f64af28"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>", "ID": "c110af87-e160-4793-87c8-e46d08f076ce", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "5a076412-3e9c-49ff-ac02-cbc82bd41009"}, {"Element": "<span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span>", "ID": "4b8652c0-ac36-4283-99b7-e8382a00bf0b", "Styles": "None", "Classes": "None", "Text": "Interaction   with Invirase/ritonavir not studied.", "ParentId": "c110af87-e160-4793-87c8-e46d08f076ce"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Streptogramin\n  antibiotics such as quinupristin/dalfopristin inhibit CYP3A4. </span><span lang=\"IT\">Saquinavir concentrations may be increased.</span></p>", "ID": "c7391fae-aa56-45d8-b4db-225a69ea454e", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "5a076412-3e9c-49ff-ac02-cbc82bd41009"}, {"Element": "<span lang=\"EN-GB\">Streptogramin\n  antibiotics such as quinupristin/dalfopristin inhibit CYP3A4. </span>", "ID": "db0f8f3d-354c-4002-932c-9c17721bef51", "Styles": "None", "Classes": "None", "Text": "Streptogramin   antibiotics such as quinupristin/dalfopristin inhibit CYP3A4. ", "ParentId": "c7391fae-aa56-45d8-b4db-225a69ea454e"}, {"Element": "<span lang=\"IT\">Saquinavir concentrations may be increased.</span>", "ID": "a55e032b-54b1-48bb-a8f8-932097072f5c", "Styles": "None", "Classes": "None", "Text": "Saquinavir concentrations may be increased.", "ParentId": "c7391fae-aa56-45d8-b4db-225a69ea454e"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution due to\n  possible cardiac arrhythmias. <span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "17de3fce-44ae-47a0-8136-34b008dc7af7", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "d12dc094-234f-4755-80b6-0c9d8f64af28"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution due to\n  possible cardiac arrhythmias. <span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span></p>", "ID": "0647ee03-c4dd-484f-87bb-3c6b39eddaf9", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Use with caution due to   possible cardiac arrhythmias. ", "ParentId": "17de3fce-44ae-47a0-8136-34b008dc7af7"}, {"Element": "<span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span>", "ID": "3240c9d0-9f67-4a4e-9ea7-73b4ee6f62df", "Styles": "None", "Classes": "None", "Text": "Monitoring for saquinavir   toxicity recommended (see section 4.4).", "ParentId": "0647ee03-c4dd-484f-87bb-3c6b39eddaf9"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "c6f092e7-1730-4ae1-8a8b-3907a94251f9", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "17de3fce-44ae-47a0-8136-34b008dc7af7"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\"><span lang=\"FR-CH\">-\u00a0 Halofantrine<br/>\n  Pentamidine<br/>\n  Sparfloxacin<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\"><span lang=\"FR-CH\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"text-indent:.45pt;page-break-after:avoid\">Contraindicated\n  in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "86b1257b-d99c-44bb-9bd8-755ece293aa5", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\"><span lang=\"FR-CH\">-\u00a0 Halofantrine<br/>\n  Pentamidine<br/>\n  Sparfloxacin<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>", "ID": "970bcacc-bad9-4d11-8be0-0a37a3073de9", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "86b1257b-d99c-44bb-9bd8-755ece293aa5"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\"><span lang=\"FR-CH\">-\u00a0 Halofantrine<br/>\n  Pentamidine<br/>\n  Sparfloxacin<br/>\n  (saquinavir/ritonavir)</span></p>", "ID": "0b78a6eb-a028-448b-b481-6dc07a1b8270", "Styles": "text-indent:-9.35pt;page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "970bcacc-bad9-4d11-8be0-0a37a3073de9"}, {"Element": "<span lang=\"FR-CH\">-\u00a0 Halofantrine<br/>\n  Pentamidine<br/>\n  Sparfloxacin<br/>\n  (saquinavir/ritonavir)</span>", "ID": "2959244e-4e38-40eb-bde4-03d91772a160", "Styles": "None", "Classes": "None", "Text": "-\u00a0 Halofantrine   Pentamidine   Sparfloxacin   (saquinavir/ritonavir)", "ParentId": "0b78a6eb-a028-448b-b481-6dc07a1b8270"}, {"Element": "<br/>", "ID": "94b18f4a-e1be-40a9-907b-3a8dae4fef32", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2959244e-4e38-40eb-bde4-03d91772a160"}, {"Element": "<br/>", "ID": "91afdbf8-7166-4135-8e16-db625c2d1a03", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2959244e-4e38-40eb-bde4-03d91772a160"}, {"Element": "<br/>", "ID": "2d5ecb1c-6a21-47ba-aca0-5a7d964d95c4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2959244e-4e38-40eb-bde4-03d91772a160"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\"><span lang=\"FR-CH\">\u00a0</span></p>\n</td>", "ID": "6086ca6b-49b8-4230-bf32-fb17baebb731", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "86b1257b-d99c-44bb-9bd8-755ece293aa5"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\"><span lang=\"FR-CH\">\u00a0</span></p>", "ID": "5d20a2ce-89e8-44c8-a787-9330f848e536", "Styles": "text-indent:-9.35pt;page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "6086ca6b-49b8-4230-bf32-fb17baebb731"}, {"Element": "<span lang=\"FR-CH\">\u00a0</span>", "ID": "a8b4a03c-c097-4948-868f-32c022daa528", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5d20a2ce-89e8-44c8-a787-9330f848e536"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"text-indent:.45pt;page-break-after:avoid\">Contraindicated\n  in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "b271fb32-fe30-4aaa-9295-b5cd52a4666b", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "86b1257b-d99c-44bb-9bd8-755ece293aa5"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:.45pt;page-break-after:avoid\">Contraindicated\n  in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "17392d27-5f8c-424c-bce7-e85284e132b0", "Styles": "text-indent:.45pt;page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated   in combination with  due to the   potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)", "ParentId": "b271fb32-fe30-4aaa-9295-b5cd52a4666b"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "191bd302-bdfb-4daf-8b65-9dcd46467eda", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "17392d27-5f8c-424c-bce7-e85284e132b0"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "dfc17d60-790d-4e75-8e3c-d4a59725c3c1", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "17392d27-5f8c-424c-bce7-e85284e132b0"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Antifungals</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "d989b665-66c2-4ed0-81a0-841d3900c01f", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Antifungals</span></i></b></p>\n</td>", "ID": "6ddc3a5b-949c-4af7-bad1-7a9469a5c29c", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d989b665-66c2-4ed0-81a0-841d3900c01f"}, {"Element": "<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Antifungals</span></i></b></p>", "ID": "4133a9ac-bdc0-455c-a523-ab6e98270724", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "6ddc3a5b-949c-4af7-bad1-7a9469a5c29c"}, {"Element": "<b><i><span lang=\"EN-GB\">Antifungals</span></i></b>", "ID": "e32f164c-9ec6-44ac-b62e-59777ad14397", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4133a9ac-bdc0-455c-a523-ab6e98270724"}, {"Element": "<i><span lang=\"EN-GB\">Antifungals</span></i>", "ID": "73c88861-b943-4786-87e9-7c62d56103cf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e32f164c-9ec6-44ac-b62e-59777ad14397"}, {"Element": "<span lang=\"EN-GB\">Antifungals</span>", "ID": "0b923946-e747-46ce-9fbe-3bf7891a16b4", "Styles": "None", "Classes": "None", "Text": "Antifungals", "ParentId": "73c88861-b943-4786-87e9-7c62d56103cf"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "2e4a53cd-74b2-44cc-8ff2-339df49bb3e4", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d989b665-66c2-4ed0-81a0-841d3900c01f"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "fc68a54d-0667-4424-b441-e511a6fc77b0", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "2e4a53cd-74b2-44cc-8ff2-339df49bb3e4"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "b6c08f06-550a-4073-a9df-78deae5f34cb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fc68a54d-0667-4424-b441-e511a6fc77b0"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "807c6b6d-a15e-4f09-82d6-1f0c885ffd36", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d989b665-66c2-4ed0-81a0-841d3900c01f"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "20604146-7e2e-49a9-8c1e-544aa48d6fac", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "807c6b6d-a15e-4f09-82d6-1f0c885ffd36"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "894d0c09-160a-4840-9624-c10f123789b6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "20604146-7e2e-49a9-8c1e-544aa48d6fac"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Ketoconazole 200\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Saquinavir C<sub>max </sub></span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Ritonavir AUC </span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Ritonavir C<sub>max </sub></span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Ketoconazole AUC \u2191 168%<br/>\n  (90% CI 146%-193%)<br/>\n  Ketoconazole C<sub>max </sub>\u2191 45%<br/>\n  (90% CI 32%-59%)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required when\n  saquinavir/ritonavir combined with </span><span style=\"font-family:Symbol\">\u00a3</span>\u00a0200\u00a0mg/day\n  ketoconazole<span lang=\"EN-GB\">. </span>High doses of ketoconazole<br/>\n  (&gt; 200\u00a0mg/day) are not recommended.</p>\n</td>\n</tr>", "ID": "5aebfa24-f173-452f-aab7-cc7815f1e173", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Ketoconazole 200\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n</td>", "ID": "c8b88238-be7e-4a09-8e8d-d2d0ca45364a", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5aebfa24-f173-452f-aab7-cc7815f1e173"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">Ketoconazole 200\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>", "ID": "e24afd91-42ef-4c97-a05a-48008c4fc8be", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "c8b88238-be7e-4a09-8e8d-d2d0ca45364a"}, {"Element": "<span lang=\"IT\">Ketoconazole 200\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span>", "ID": "1414e6d6-8684-4aa1-af89-456c1e4441e4", "Styles": "None", "Classes": "None", "Text": "Ketoconazole 200\u00a0mg qd(saquinavir/ritonavir 1000/100\u00a0mg bid)", "ParentId": "e24afd91-42ef-4c97-a05a-48008c4fc8be"}, {"Element": "<u><br/>\n</u>", "ID": "b1e528bd-bfde-481e-969b-90b7ee9a69af", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "1414e6d6-8684-4aa1-af89-456c1e4441e4"}, {"Element": "<br/>", "ID": "a66f8393-9977-4805-9b80-9217acdf997a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b1e528bd-bfde-481e-969b-90b7ee9a69af"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Saquinavir C<sub>max </sub></span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Ritonavir AUC </span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Ritonavir C<sub>max </sub></span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Ketoconazole AUC \u2191 168%<br/>\n  (90% CI 146%-193%)<br/>\n  Ketoconazole C<sub>max </sub>\u2191 45%<br/>\n  (90% CI 32%-59%)</span></p>\n</td>", "ID": "44a3b3d0-7206-4120-9f56-687fa3d64ef4", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5aebfa24-f173-452f-aab7-cc7815f1e173"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Saquinavir C<sub>max </sub></span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Ritonavir AUC </span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Ritonavir C<sub>max </sub></span><span style=\"font-family:Symbol\">\u00ab</span><span lang=\"IT\"><br/>\n  Ketoconazole AUC \u2191 168%<br/>\n  (90% CI 146%-193%)<br/>\n  Ketoconazole C<sub>max </sub>\u2191 45%<br/>\n  (90% CI 32%-59%)</span></p>", "ID": "6d36f984-f81f-4c0c-8a12-0d4b20f98f38", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "44a3b3d0-7206-4120-9f56-687fa3d64ef4"}, {"Element": "<span lang=\"IT\">Saquinavir AUC </span>", "ID": "e80c652b-dc1d-4a85-9a07-b634aec142c0", "Styles": "None", "Classes": "None", "Text": "Saquinavir AUC ", "ParentId": "6d36f984-f81f-4c0c-8a12-0d4b20f98f38"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "8a59ef80-7e0d-4dd2-bcac-f2dfe9fefe87", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "6d36f984-f81f-4c0c-8a12-0d4b20f98f38"}, {"Element": "<span lang=\"IT\"><br/>\n  Saquinavir C<sub>max </sub></span>", "ID": "5d5fb1fb-bc55-4174-abeb-8dd5d3fb6d21", "Styles": "None", "Classes": "None", "Text": "   Saquinavir C", "ParentId": "6d36f984-f81f-4c0c-8a12-0d4b20f98f38"}, {"Element": "<br/>", "ID": "8a343fae-f34a-4a5b-9f7d-a06253c7777e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5d5fb1fb-bc55-4174-abeb-8dd5d3fb6d21"}, {"Element": "<sub>max </sub>", "ID": "8885c0fe-70d7-4e50-9f27-3de66c680585", "Styles": "None", "Classes": "None", "Text": "max ", "ParentId": "5d5fb1fb-bc55-4174-abeb-8dd5d3fb6d21"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "d56d706c-5e13-47fd-af64-da7881753c4e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "6d36f984-f81f-4c0c-8a12-0d4b20f98f38"}, {"Element": "<span lang=\"IT\"><br/>\n  Ritonavir AUC </span>", "ID": "73c8aaef-22cb-4f22-aca7-5f36dfccbecd", "Styles": "None", "Classes": "None", "Text": "   Ritonavir AUC ", "ParentId": "6d36f984-f81f-4c0c-8a12-0d4b20f98f38"}, {"Element": "<br/>", "ID": "9ef791aa-34ca-49de-a551-cbf809643a9b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "73c8aaef-22cb-4f22-aca7-5f36dfccbecd"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "f11ec092-5474-46e4-99c1-2cba34a8da56", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "6d36f984-f81f-4c0c-8a12-0d4b20f98f38"}, {"Element": "<span lang=\"IT\"><br/>\n  Ritonavir C<sub>max </sub></span>", "ID": "40947199-2339-4a7f-8ab5-8675d3e929b7", "Styles": "None", "Classes": "None", "Text": "   Ritonavir C", "ParentId": "6d36f984-f81f-4c0c-8a12-0d4b20f98f38"}, {"Element": "<br/>", "ID": "a7d2bff8-d6b2-4a31-8f0a-cb2db3217466", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "40947199-2339-4a7f-8ab5-8675d3e929b7"}, {"Element": "<sub>max </sub>", "ID": "f5b2d1de-8d99-4ef8-b072-0421f6fc0786", "Styles": "None", "Classes": "None", "Text": "max ", "ParentId": "40947199-2339-4a7f-8ab5-8675d3e929b7"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "2d60fb5a-55ea-49bf-977d-c1a5383dc507", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "6d36f984-f81f-4c0c-8a12-0d4b20f98f38"}, {"Element": "<span lang=\"IT\"><br/>\n  Ketoconazole AUC \u2191 168%<br/>\n  (90% CI 146%-193%)<br/>\n  Ketoconazole C<sub>max </sub>\u2191 45%<br/>\n  (90% CI 32%-59%)</span>", "ID": "3d4fed11-6f77-420f-8f4e-bed96db93a39", "Styles": "None", "Classes": "None", "Text": "   Ketoconazole AUC \u2191 168%   (90% CI 146%-193%)   Ketoconazole C\u2191 45%   (90% CI 32%-59%)", "ParentId": "6d36f984-f81f-4c0c-8a12-0d4b20f98f38"}, {"Element": "<br/>", "ID": "ba384578-54b3-485a-a68d-b298e178daa1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3d4fed11-6f77-420f-8f4e-bed96db93a39"}, {"Element": "<br/>", "ID": "7ae276b5-5bd1-4e76-b9b6-f7fc6cdd4d65", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3d4fed11-6f77-420f-8f4e-bed96db93a39"}, {"Element": "<br/>", "ID": "32e69213-9fab-4f82-80da-dce9400b4f38", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3d4fed11-6f77-420f-8f4e-bed96db93a39"}, {"Element": "<sub>max </sub>", "ID": "4adc8f3d-003b-49f3-95da-363b2d918976", "Styles": "None", "Classes": "None", "Text": "max ", "ParentId": "3d4fed11-6f77-420f-8f4e-bed96db93a39"}, {"Element": "<br/>", "ID": "94f8ba5e-999f-4b85-aec6-ea40cd8e2dba", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3d4fed11-6f77-420f-8f4e-bed96db93a39"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required when\n  saquinavir/ritonavir combined with </span><span style=\"font-family:Symbol\">\u00a3</span>\u00a0200\u00a0mg/day\n  ketoconazole<span lang=\"EN-GB\">. </span>High doses of ketoconazole<br/>\n  (&gt; 200\u00a0mg/day) are not recommended.</p>\n</td>", "ID": "dc129ff8-b87d-4e19-a967-80623076ed98", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5aebfa24-f173-452f-aab7-cc7815f1e173"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">No dose adjustment required when\n  saquinavir/ritonavir combined with </span><span style=\"font-family:Symbol\">\u00a3</span>\u00a0200\u00a0mg/day\n  ketoconazole<span lang=\"EN-GB\">. </span>High doses of ketoconazole<br/>\n  (&gt; 200\u00a0mg/day) are not recommended.</p>", "ID": "c818d0ee-9e2d-442b-a84a-713ce26bc843", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "\u00a0200\u00a0mg/day   ketoconazoleHigh doses of ketoconazole   (> 200\u00a0mg/day) are not recommended.", "ParentId": "dc129ff8-b87d-4e19-a967-80623076ed98"}, {"Element": "<span lang=\"EN-GB\">No dose adjustment required when\n  saquinavir/ritonavir combined with </span>", "ID": "1056d982-5d89-4f03-8788-df546c387914", "Styles": "None", "Classes": "None", "Text": "No dose adjustment required when   saquinavir/ritonavir combined with ", "ParentId": "c818d0ee-9e2d-442b-a84a-713ce26bc843"}, {"Element": "<span style=\"font-family:Symbol\">\u00a3</span>", "ID": "f05157e8-0a78-4608-84b0-b52c58d2a2f2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00a3", "ParentId": "c818d0ee-9e2d-442b-a84a-713ce26bc843"}, {"Element": "<span lang=\"EN-GB\">. </span>", "ID": "c989dd6a-91e4-4dd2-93c7-6c21878dd203", "Styles": "None", "Classes": "None", "Text": ". ", "ParentId": "c818d0ee-9e2d-442b-a84a-713ce26bc843"}, {"Element": "<br/>", "ID": "e4e1eb04-013d-400a-8498-26e2dced031e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c818d0ee-9e2d-442b-a84a-713ce26bc843"}, {"Element": "<tr style=\"height:76.4pt\">\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 Itraconazole<br/>\n  (saquinavir/ritonavir)</p>\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 </p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 Interaction\n  with Invirase/ritonavir not studied.</p>\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 Itraconazole\n  is a moderately potent inhibitor of CYP3A4. An interaction is possible.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution due to\n  possible cardiac arrhythmias. <span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span></p>\n</td>\n</tr>", "ID": "52252f9e-581a-476f-aa9f-5a8b2047b36b", "Styles": "height:76.4pt", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 Itraconazole<br/>\n  (saquinavir/ritonavir)</p>\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 </p>\n</td>", "ID": "3199bbd0-1086-426b-9a48-c715ea163000", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:76.4pt", "Classes": "None", "Text": "   ", "ParentId": "52252f9e-581a-476f-aa9f-5a8b2047b36b"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 Itraconazole<br/>\n  (saquinavir/ritonavir)</p>", "ID": "cd7c757c-db2b-4e15-9fff-457ed503c90f", "Styles": "text-indent:-9.35pt;page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 Itraconazole   (saquinavir/ritonavir)", "ParentId": "3199bbd0-1086-426b-9a48-c715ea163000"}, {"Element": "<br/>", "ID": "94653910-9aea-41e5-9250-cd1073c95f16", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cd7c757c-db2b-4e15-9fff-457ed503c90f"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 </p>", "ID": "9619034c-84ca-4527-8efb-04157ae9f681", "Styles": "text-indent:-9.35pt;page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 ", "ParentId": "3199bbd0-1086-426b-9a48-c715ea163000"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 Interaction\n  with Invirase/ritonavir not studied.</p>\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 Itraconazole\n  is a moderately potent inhibitor of CYP3A4. An interaction is possible.</p>\n</td>", "ID": "f2145a5f-b4f7-4bd5-a0eb-abe5351670b2", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt", "Classes": "None", "Text": "   ", "ParentId": "52252f9e-581a-476f-aa9f-5a8b2047b36b"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 Interaction\n  with Invirase/ritonavir not studied.</p>", "ID": "933248f4-c701-487e-913a-151030011a8e", "Styles": "text-indent:-9.35pt;page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 Interaction   with Invirase/ritonavir not studied.", "ParentId": "f2145a5f-b4f7-4bd5-a0eb-abe5351670b2"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 Itraconazole\n  is a moderately potent inhibitor of CYP3A4. An interaction is possible.</p>", "ID": "0352212a-1723-4130-971d-649458c7aa5b", "Styles": "text-indent:-9.35pt;page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 Itraconazole   is a moderately potent inhibitor of CYP3A4. An interaction is possible.", "ParentId": "f2145a5f-b4f7-4bd5-a0eb-abe5351670b2"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution due to\n  possible cardiac arrhythmias. <span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span></p>\n</td>", "ID": "b4fe38db-53a2-4e7e-ba9c-429b5178263d", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt", "Classes": "None", "Text": "  ", "ParentId": "52252f9e-581a-476f-aa9f-5a8b2047b36b"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution due to\n  possible cardiac arrhythmias. <span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span></p>", "ID": "f325f617-7522-4a1d-9644-83a44d1e888e", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Use with caution due to   possible cardiac arrhythmias. ", "ParentId": "b4fe38db-53a2-4e7e-ba9c-429b5178263d"}, {"Element": "<span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span>", "ID": "1971fcfe-1ed8-4eca-b4e9-4208f2680b05", "Styles": "None", "Classes": "None", "Text": "Monitoring for saquinavir   toxicity recommended (see section 4.4).", "ParentId": "f325f617-7522-4a1d-9644-83a44d1e888e"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Fluconazole/miconazole</span><u><br/>\n</u>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied. Both drugs are CYP3A4 inhibitors and may\n  increase the plasma concentration of saquinavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution due to\n  possible cardiac arrhythmias. <span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span></p>\n</td>\n</tr>", "ID": "7faf2906-73fd-4eac-851a-6fa402894260", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Fluconazole/miconazole</span><u><br/>\n</u>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>", "ID": "3cd16384-25b8-4ac9-a38f-b3e4c84f1230", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7faf2906-73fd-4eac-851a-6fa402894260"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Fluconazole/miconazole</span><u><br/>\n</u>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>", "ID": "8ff030dc-dea6-4b96-9ede-fa1a5673af3f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "()", "ParentId": "3cd16384-25b8-4ac9-a38f-b3e4c84f1230"}, {"Element": "<span lang=\"EN-GB\">Fluconazole/miconazole</span>", "ID": "91a2f9be-179d-4fca-b83f-e4f22fa80e53", "Styles": "None", "Classes": "None", "Text": "Fluconazole/miconazole", "ParentId": "8ff030dc-dea6-4b96-9ede-fa1a5673af3f"}, {"Element": "<u><br/>\n</u>", "ID": "a4203ce6-6f75-495e-8f13-b5ec12b27347", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "8ff030dc-dea6-4b96-9ede-fa1a5673af3f"}, {"Element": "<br/>", "ID": "f6c53705-0598-4f3e-a0b3-11a50d95aaa4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a4203ce6-6f75-495e-8f13-b5ec12b27347"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "00a67f42-0195-42fe-84f8-50b6e51978c6", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "8ff030dc-dea6-4b96-9ede-fa1a5673af3f"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied. Both drugs are CYP3A4 inhibitors and may\n  increase the plasma concentration of saquinavir.</span></p>\n</td>", "ID": "b5a4774e-2071-4388-a8f1-9c910e544558", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7faf2906-73fd-4eac-851a-6fa402894260"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied. Both drugs are CYP3A4 inhibitors and may\n  increase the plasma concentration of saquinavir.</span></p>", "ID": "b0640325-6200-414c-a8b1-479b466a4556", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "b5a4774e-2071-4388-a8f1-9c910e544558"}, {"Element": "<span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied. Both drugs are CYP3A4 inhibitors and may\n  increase the plasma concentration of saquinavir.</span>", "ID": "b7a57e52-68ca-4a35-88b2-cec91b080e8e", "Styles": "None", "Classes": "None", "Text": "Interaction   with Invirase/ritonavir not studied. Both drugs are CYP3A4 inhibitors and may   increase the plasma concentration of saquinavir.", "ParentId": "b0640325-6200-414c-a8b1-479b466a4556"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution due to\n  possible cardiac arrhythmias. <span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span></p>\n</td>", "ID": "4d948864-1bd5-45de-9cfa-19f6817681eb", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7faf2906-73fd-4eac-851a-6fa402894260"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Use with caution due to\n  possible cardiac arrhythmias. <span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span></p>", "ID": "fc051b69-1817-4b5d-8115-16531ff869a9", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Use with caution due to   possible cardiac arrhythmias. ", "ParentId": "4d948864-1bd5-45de-9cfa-19f6817681eb"}, {"Element": "<span lang=\"EN-GB\">Monitoring for saquinavir\n  toxicity recommended (see section 4.4).</span>", "ID": "14963bb6-dc9b-45d8-9f0c-62e10296c29b", "Styles": "None", "Classes": "None", "Text": "Monitoring for saquinavir   toxicity recommended (see section 4.4).", "ParentId": "fc051b69-1817-4b5d-8115-16531ff869a9"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Antimycobacterials</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "487bc451-70c0-426d-b0f4-3a1775cf3f4c", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Antimycobacterials</span></i></b></p>\n</td>", "ID": "babd3a27-bf30-4926-a5df-7722b9131409", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "487bc451-70c0-426d-b0f4-3a1775cf3f4c"}, {"Element": "<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Antimycobacterials</span></i></b></p>", "ID": "ea2a5ff5-8a7a-44b3-8c2d-2a4555cec0b7", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "babd3a27-bf30-4926-a5df-7722b9131409"}, {"Element": "<b><i><span lang=\"EN-GB\">Antimycobacterials</span></i></b>", "ID": "ff656d9e-b801-4f17-88da-c3570bbc82d8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ea2a5ff5-8a7a-44b3-8c2d-2a4555cec0b7"}, {"Element": "<i><span lang=\"EN-GB\">Antimycobacterials</span></i>", "ID": "b644d3d1-b93e-49b1-b9a2-2bcf02cf4573", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ff656d9e-b801-4f17-88da-c3570bbc82d8"}, {"Element": "<span lang=\"EN-GB\">Antimycobacterials</span>", "ID": "24cf1e55-1178-498d-94a0-e03c200247bf", "Styles": "None", "Classes": "None", "Text": "Antimycobacterials", "ParentId": "b644d3d1-b93e-49b1-b9a2-2bcf02cf4573"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "65256d5a-993a-4356-aedd-d44257dce4ce", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "487bc451-70c0-426d-b0f4-3a1775cf3f4c"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "ab88a4f0-b710-4f69-b61c-5a4873697d5e", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "65256d5a-993a-4356-aedd-d44257dce4ce"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "cc111e3e-1dd9-4e6c-86fe-7a01d8eb54b7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ab88a4f0-b710-4f69-b61c-5a4873697d5e"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "00ee3d29-e6ba-450e-824e-b62a7ee24807", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "487bc451-70c0-426d-b0f4-3a1775cf3f4c"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "a834212c-0e6c-42cc-923b-77713c9b1e12", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "00ee3d29-e6ba-450e-824e-b62a7ee24807"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "50db23ac-d5a1-4424-980d-72d108e1a14f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a834212c-0e6c-42cc-923b-77713c9b1e12"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Rifampicin 600\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">In a clinical study 11 of\n  17 (65\u00a0%) healthy volunteers developed severe hepatocellular toxicity\n  with transaminase elevations up to &gt;\u00a020-fold the upper limit of\n  normal after 1 to 5 days of co-administration.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Rifampicin is\n  contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span><br/>\n  (see section 4.3).</p>\n</td>\n</tr>", "ID": "8f32dd4d-07a3-452b-8d03-63384905b432", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Rifampicin 600\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n</td>", "ID": "b2076f12-88ae-4c99-b45e-e6a985bf76de", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f32dd4d-07a3-452b-8d03-63384905b432"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">Rifampicin 600\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>", "ID": "5341b851-f070-4c96-b4ef-4c8f79ba6453", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "b2076f12-88ae-4c99-b45e-e6a985bf76de"}, {"Element": "<span lang=\"IT\">Rifampicin 600\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span>", "ID": "08359a37-623f-463c-a700-ea00eb2404d3", "Styles": "None", "Classes": "None", "Text": "Rifampicin 600\u00a0mg qd(saquinavir/ritonavir 1000/100\u00a0mg bid)", "ParentId": "5341b851-f070-4c96-b4ef-4c8f79ba6453"}, {"Element": "<u><br/>\n</u>", "ID": "3eb60723-ec2d-43ef-9da5-ca1c84f5f34e", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "08359a37-623f-463c-a700-ea00eb2404d3"}, {"Element": "<br/>", "ID": "6a32c03b-3759-4f63-871e-f7917ecee688", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3eb60723-ec2d-43ef-9da5-ca1c84f5f34e"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">In a clinical study 11 of\n  17 (65\u00a0%) healthy volunteers developed severe hepatocellular toxicity\n  with transaminase elevations up to &gt;\u00a020-fold the upper limit of\n  normal after 1 to 5 days of co-administration.</p>\n</td>", "ID": "b1bb4a9e-535f-4f6e-a6fa-f310a1e44f20", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f32dd4d-07a3-452b-8d03-63384905b432"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">In a clinical study 11 of\n  17 (65\u00a0%) healthy volunteers developed severe hepatocellular toxicity\n  with transaminase elevations up to &gt;\u00a020-fold the upper limit of\n  normal after 1 to 5 days of co-administration.</p>", "ID": "89a630c6-2272-4c3a-8a53-85b695cf823b", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "In a clinical study 11 of   17 (65\u00a0%) healthy volunteers developed severe hepatocellular toxicity   with transaminase elevations up to >\u00a020-fold the upper limit of   normal after 1 to 5 days of co-administration.", "ParentId": "b1bb4a9e-535f-4f6e-a6fa-f310a1e44f20"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Rifampicin is\n  contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span><br/>\n  (see section 4.3).</p>\n</td>", "ID": "dd21ec2b-5e2d-4445-a324-dafff9356de3", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f32dd4d-07a3-452b-8d03-63384905b432"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Rifampicin is\n  contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span><br/>\n  (see section 4.3).</p>", "ID": "55f5a2b8-3a7c-4335-b277-70f325ee8e92", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Rifampicin is   contraindicated in combination with    (see section 4.3).", "ParentId": "dd21ec2b-5e2d-4445-a324-dafff9356de3"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "9fe7f014-eb05-4e50-a912-3877e273b29c", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "55f5a2b8-3a7c-4335-b277-70f325ee8e92"}, {"Element": "<br/>", "ID": "86103721-28c3-4cfe-93c3-b9883287f23c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "55f5a2b8-3a7c-4335-b277-70f325ee8e92"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Rifabutin <span lang=\"IT\">150\u00a0mg\n  q3d<br/>\n</span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span> 1000/100\u00a0mg bid) in\n  healthy volunteers</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC<sub>0-12</sub>\n<span style=\"font-family:Symbol\">\u00af</span> 13%<br/>\n  (90% CI: 31<span style=\"font-family:Symbol\">\u00af</span> - 9\u2191)<br/>\n  Saquinavir C<sub>max </sub><span style=\"font-family:Symbol\">\u00af</span> 15%<br/>\n  (90% CI: 32<span style=\"font-family:Symbol\">\u00af</span> - 7\u2191)<br/>\n  Ritonavir AUC<sub>0-12</sub> <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  (90% CI: 10<span style=\"font-family:Symbol\">\u00af</span> - 9\u2191)<br/>\n  Ritonavir C<sub>max </sub><span style=\"font-family:Symbol\">\u00ab</span><br/>\n  (90% CI: 8<span style=\"font-family:Symbol\">\u00af</span> - 7\u2191)<br/>\n<br/>\n  Rifabutin active moiety*<br/>\n  AUC<sub>0-72</sub> \u2191 134%<br/>\n  (90% CI 109%-162%)<br/>\n  Rifabutin active moiety*<br/>\n  C<sub>max </sub>\u2191 130%<br/>\n  (90% CI 98%-167%)</p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">Rifabutin AUC<sub>0-72</sub> \u2191\n  53%</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">(90% CI 36%-73%)</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">Rifabutin C<sub>max </sub>\u2191\n  86%</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\">(90% CI 57%-119%)</p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\">\u00a0</p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\">*\u00a0 Sum of rifabutin + 25-O-desacetyl rifabutin\n  metabolite </p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">To prevent possible\n  development of rifabutin resistance in TB and HIV co-infected patients, the\n  recommended dose of rifabutin is 150\u00a0mg every other day or three times\n  per week, with the dose of saquinavir/ritonavir unchanged (1000/100\u00a0mg\n  bid). </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Monitoring of neutropenia\n  and liver enzyme levels is recommended due to an expected increase in\n  exposure to rifabutin.</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "55f90068-6a71-41a3-8dd1-0f670ab9f4c2", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Rifabutin <span lang=\"IT\">150\u00a0mg\n  q3d<br/>\n</span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span> 1000/100\u00a0mg bid) in\n  healthy volunteers</p>\n</td>", "ID": "7a36c6e1-ee98-493e-b69f-970d5d80ffc7", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "55f90068-6a71-41a3-8dd1-0f670ab9f4c2"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Rifabutin <span lang=\"IT\">150\u00a0mg\n  q3d<br/>\n</span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span> 1000/100\u00a0mg bid) in\n  healthy volunteers</p>", "ID": "b5e2440e-370e-482a-ae86-ac4160abc4b7", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Rifabutin ( 1000/100\u00a0mg bid) in   healthy volunteers", "ParentId": "7a36c6e1-ee98-493e-b69f-970d5d80ffc7"}, {"Element": "<span lang=\"IT\">150\u00a0mg\n  q3d<br/>\n</span>", "ID": "8920d706-ab1f-423b-91b7-bed338812f2a", "Styles": "None", "Classes": "None", "Text": "150\u00a0mg   q3d ", "ParentId": "b5e2440e-370e-482a-ae86-ac4160abc4b7"}, {"Element": "<br/>", "ID": "d61016b7-a611-4d21-9508-0117e523d177", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8920d706-ab1f-423b-91b7-bed338812f2a"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "6beda68e-cfb8-44e0-b370-5f4c694642c3", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "b5e2440e-370e-482a-ae86-ac4160abc4b7"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC<sub>0-12</sub>\n<span style=\"font-family:Symbol\">\u00af</span> 13%<br/>\n  (90% CI: 31<span style=\"font-family:Symbol\">\u00af</span> - 9\u2191)<br/>\n  Saquinavir C<sub>max </sub><span style=\"font-family:Symbol\">\u00af</span> 15%<br/>\n  (90% CI: 32<span style=\"font-family:Symbol\">\u00af</span> - 7\u2191)<br/>\n  Ritonavir AUC<sub>0-12</sub> <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  (90% CI: 10<span style=\"font-family:Symbol\">\u00af</span> - 9\u2191)<br/>\n  Ritonavir C<sub>max </sub><span style=\"font-family:Symbol\">\u00ab</span><br/>\n  (90% CI: 8<span style=\"font-family:Symbol\">\u00af</span> - 7\u2191)<br/>\n<br/>\n  Rifabutin active moiety*<br/>\n  AUC<sub>0-72</sub> \u2191 134%<br/>\n  (90% CI 109%-162%)<br/>\n  Rifabutin active moiety*<br/>\n  C<sub>max </sub>\u2191 130%<br/>\n  (90% CI 98%-167%)</p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">Rifabutin AUC<sub>0-72</sub> \u2191\n  53%</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">(90% CI 36%-73%)</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">Rifabutin C<sub>max </sub>\u2191\n  86%</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\">(90% CI 57%-119%)</p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\">\u00a0</p>\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\">*\u00a0 Sum of rifabutin + 25-O-desacetyl rifabutin\n  metabolite </p>\n</td>", "ID": "7c90aec3-38cd-469d-bacf-08d1fa1daa78", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "        ", "ParentId": "55f90068-6a71-41a3-8dd1-0f670ab9f4c2"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Saquinavir AUC<sub>0-12</sub>\n<span style=\"font-family:Symbol\">\u00af</span> 13%<br/>\n  (90% CI: 31<span style=\"font-family:Symbol\">\u00af</span> - 9\u2191)<br/>\n  Saquinavir C<sub>max </sub><span style=\"font-family:Symbol\">\u00af</span> 15%<br/>\n  (90% CI: 32<span style=\"font-family:Symbol\">\u00af</span> - 7\u2191)<br/>\n  Ritonavir AUC<sub>0-12</sub> <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  (90% CI: 10<span style=\"font-family:Symbol\">\u00af</span> - 9\u2191)<br/>\n  Ritonavir C<sub>max </sub><span style=\"font-family:Symbol\">\u00ab</span><br/>\n  (90% CI: 8<span style=\"font-family:Symbol\">\u00af</span> - 7\u2191)<br/>\n<br/>\n  Rifabutin active moiety*<br/>\n  AUC<sub>0-72</sub> \u2191 134%<br/>\n  (90% CI 109%-162%)<br/>\n  Rifabutin active moiety*<br/>\n  C<sub>max </sub>\u2191 130%<br/>\n  (90% CI 98%-167%)</p>", "ID": "77169e15-a805-41c4-a2c2-a07bb761a217", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Saquinavir AUC  13%   (90% CI: 31 - 9\u2191)   Saquinavir C 15%   (90% CI: 32 - 7\u2191)   Ritonavir AUC    (90% CI: 10 - 9\u2191)   Ritonavir C   (90% CI: 8 - 7\u2191)    Rifabutin active moiety*   AUC \u2191 134%   (90% CI 109%-162%)   Rifabutin active moiety*   C\u2191 130%   (90% CI 98%-167%)", "ParentId": "7c90aec3-38cd-469d-bacf-08d1fa1daa78"}, {"Element": "<sub>0-12</sub>", "ID": "f05a4e69-1005-44b9-8cff-fb1c2b7a1805", "Styles": "None", "Classes": "None", "Text": "0-12", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "037d34aa-796c-4650-ac35-0f53b2bab719", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<br/>", "ID": "815a4fa7-5334-4271-b1b4-57e0746032cf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "18fae30f-1f8d-478e-9d54-6107b6af931b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<br/>", "ID": "df8cf5f2-8b1d-4648-be47-f9498c618b07", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<sub>max </sub>", "ID": "fc4f894d-05da-4df0-85cf-81bac9cde786", "Styles": "None", "Classes": "None", "Text": "max ", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "53e72e3c-d7b5-45b6-8739-62d762695c86", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<br/>", "ID": "47e76f24-7d17-4aaf-b5e8-22341bd471d2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "efdeb95c-3b3d-47e0-946a-359cee116098", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<br/>", "ID": "3c71f48e-ef4b-4b30-9284-a5be88193aad", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<sub>0-12</sub>", "ID": "a017f808-a82a-4388-a707-f7719f4dd0fa", "Styles": "None", "Classes": "None", "Text": "0-12", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "3d85e2d6-effb-4ec2-89af-9ab07395d6a1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<br/>", "ID": "0ed1331e-a39c-41bd-853b-81a03ed81fee", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "081f816c-f618-4931-8a89-20f68dd5693b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<br/>", "ID": "b571f8ee-7373-471f-8dd7-c769e32dc896", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<sub>max </sub>", "ID": "9f44d3d3-989b-4622-898a-788bbed63f3a", "Styles": "None", "Classes": "None", "Text": "max ", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "3260d2e0-ce67-41fa-b006-f728861d8e15", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<br/>", "ID": "18008641-9d04-48c9-98f5-b1bcb14ba8e3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "80a13c89-9a54-450e-b759-06da0c09807b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<br/>", "ID": "bae7f23f-94a8-4ef5-920f-7e05fc7fc9ad", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<br/>", "ID": "858f32d0-1d15-46b8-86a3-93f318f1afbb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<br/>", "ID": "f233ec23-7dc1-4be8-9450-9d99aa24417d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<sub>0-72</sub>", "ID": "426c38b3-abcd-4bb7-a66d-25d5350386ce", "Styles": "None", "Classes": "None", "Text": "0-72", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<br/>", "ID": "593b9f8a-c9b3-4bea-b297-7b78a66ab029", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<br/>", "ID": "65f5425b-3fa1-4057-b347-4b7eae39dde3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<br/>", "ID": "b3e3fed5-d481-4875-bc0d-e73e8c97a74f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<sub>max </sub>", "ID": "7b82ed54-ecf6-4a29-84b3-d13006eb83a6", "Styles": "None", "Classes": "None", "Text": "max ", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<br/>", "ID": "4d856695-f2ff-405d-96d3-287eaf23d16b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77169e15-a805-41c4-a2c2-a07bb761a217"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">Rifabutin AUC<sub>0-72</sub> \u2191\n  53%</span></p>", "ID": "732af147-c783-4854-8733-510c1335a22f", "Styles": "margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "7c90aec3-38cd-469d-bacf-08d1fa1daa78"}, {"Element": "<span lang=\"FR-CH\">Rifabutin AUC<sub>0-72</sub> \u2191\n  53%</span>", "ID": "2a736bda-a153-44ab-9fb3-61e04bb332c0", "Styles": "None", "Classes": "None", "Text": "Rifabutin AUC \u2191   53%", "ParentId": "732af147-c783-4854-8733-510c1335a22f"}, {"Element": "<sub>0-72</sub>", "ID": "16930e94-b397-4af5-8a3f-a9b594f86be2", "Styles": "None", "Classes": "None", "Text": "0-72", "ParentId": "2a736bda-a153-44ab-9fb3-61e04bb332c0"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">(90% CI 36%-73%)</span></p>", "ID": "680b5921-72f4-46f5-b7df-33426c59af12", "Styles": "margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "7c90aec3-38cd-469d-bacf-08d1fa1daa78"}, {"Element": "<span lang=\"FR-CH\">(90% CI 36%-73%)</span>", "ID": "18bab800-5c8a-4efc-a8e2-079147023d50", "Styles": "None", "Classes": "None", "Text": "(90% CI 36%-73%)", "ParentId": "680b5921-72f4-46f5-b7df-33426c59af12"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">Rifabutin C<sub>max </sub>\u2191\n  86%</span></p>", "ID": "f9311468-db2f-4ff9-8cee-917e3a33d1ed", "Styles": "margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "7c90aec3-38cd-469d-bacf-08d1fa1daa78"}, {"Element": "<span lang=\"FR-CH\">Rifabutin C<sub>max </sub>\u2191\n  86%</span>", "ID": "f0cfd091-b269-4800-996f-369f5eb037c1", "Styles": "None", "Classes": "None", "Text": "Rifabutin C\u2191   86%", "ParentId": "f9311468-db2f-4ff9-8cee-917e3a33d1ed"}, {"Element": "<sub>max </sub>", "ID": "dda21fff-a2a3-48c8-b268-d98d1cca0f6a", "Styles": "None", "Classes": "None", "Text": "max ", "ParentId": "f0cfd091-b269-4800-996f-369f5eb037c1"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\">(90% CI 57%-119%)</p>", "ID": "c1097265-4b0f-4a8a-a10d-6722ba6cf808", "Styles": "margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "(90% CI 57%-119%)", "ParentId": "7c90aec3-38cd-469d-bacf-08d1fa1daa78"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\">\u00a0</p>", "ID": "3e81b75f-59d0-4cf9-aa8e-fb03d600bc71", "Styles": "margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "7c90aec3-38cd-469d-bacf-08d1fa1daa78"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid\">*\u00a0 Sum of rifabutin + 25-O-desacetyl rifabutin\n  metabolite </p>", "ID": "fab10d3f-8bfd-4089-b424-6ddcf1dd3b42", "Styles": "margin-left:10.35pt;text-indent:-10.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "*\u00a0 Sum of rifabutin + 25-O-desacetyl rifabutin   metabolite ", "ParentId": "7c90aec3-38cd-469d-bacf-08d1fa1daa78"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">To prevent possible\n  development of rifabutin resistance in TB and HIV co-infected patients, the\n  recommended dose of rifabutin is 150\u00a0mg every other day or three times\n  per week, with the dose of saquinavir/ritonavir unchanged (1000/100\u00a0mg\n  bid). </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Monitoring of neutropenia\n  and liver enzyme levels is recommended due to an expected increase in\n  exposure to rifabutin.</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "1ec0ee2c-1fc2-46fe-b1d0-34114548a5fb", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "55f90068-6a71-41a3-8dd1-0f670ab9f4c2"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c3b5ff3e-5457-4ea5-bc98-0f39dfc7af0d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "1ec0ee2c-1fc2-46fe-b1d0-34114548a5fb"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e2e7fb17-5a66-4a71-a651-00bfbf6233ec", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c3b5ff3e-5457-4ea5-bc98-0f39dfc7af0d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">To prevent possible\n  development of rifabutin resistance in TB and HIV co-infected patients, the\n  recommended dose of rifabutin is 150\u00a0mg every other day or three times\n  per week, with the dose of saquinavir/ritonavir unchanged (1000/100\u00a0mg\n  bid). </p>", "ID": "7e157b9c-93a3-4ea4-be7b-fb249d6af5e9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "To prevent possible   development of rifabutin resistance in TB and HIV co-infected patients, the   recommended dose of rifabutin is 150\u00a0mg every other day or three times   per week, with the dose of saquinavir/ritonavir unchanged (1000/100\u00a0mg   bid). ", "ParentId": "1ec0ee2c-1fc2-46fe-b1d0-34114548a5fb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "9cd0dcb7-91af-46b9-8e9b-e7ec04e72668", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "1ec0ee2c-1fc2-46fe-b1d0-34114548a5fb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Monitoring of neutropenia\n  and liver enzyme levels is recommended due to an expected increase in\n  exposure to rifabutin.</p>", "ID": "f333b186-1c90-483d-a681-aa6a1250dfb8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Monitoring of neutropenia   and liver enzyme levels is recommended due to an expected increase in   exposure to rifabutin.", "ParentId": "1ec0ee2c-1fc2-46fe-b1d0-34114548a5fb"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "5daa05a1-7a71-4601-b4a5-348b24f874cf", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "1ec0ee2c-1fc2-46fe-b1d0-34114548a5fb"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><b><i>Antipsychotics</i></b></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt\">\u00a0</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n</tr>", "ID": "2b2fe06a-1d1c-4beb-a002-638ad8e84e79", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><b><i>Antipsychotics</i></b></p>\n</td>", "ID": "395db7b3-f9f8-4961-a5ee-8039b4bd19f4", "Styles": "width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2b2fe06a-1d1c-4beb-a002-638ad8e84e79"}, {"Element": "<p class=\"Normal11pt0\"><b><i>Antipsychotics</i></b></p>", "ID": "3377a156-8799-472e-8927-9ae354c0ffbf", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "395db7b3-f9f8-4961-a5ee-8039b4bd19f4"}, {"Element": "<b><i>Antipsychotics</i></b>", "ID": "9a32f62d-8012-4b66-b554-20d5307ba4a7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3377a156-8799-472e-8927-9ae354c0ffbf"}, {"Element": "<i>Antipsychotics</i>", "ID": "6c8a3a81-7d3f-45e4-ac14-a8529032c5d3", "Styles": "None", "Classes": "None", "Text": "Antipsychotics", "ParentId": "9a32f62d-8012-4b66-b554-20d5307ba4a7"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt\">\u00a0</p>\n</td>", "ID": "bf3ace7a-5060-467b-a20f-74e2438bad70", "Styles": "width:2.5in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2b2fe06a-1d1c-4beb-a002-638ad8e84e79"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:10.35pt;text-indent:-10.35pt\">\u00a0</p>", "ID": "4c0f1a70-fffe-4ec0-8f0b-3f3149fbf3fc", "Styles": "margin-left:10.35pt;text-indent:-10.35pt", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "bf3ace7a-5060-467b-a20f-74e2438bad70"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>", "ID": "db931204-6a74-4d6a-ac8e-7b4d38310b23", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2b2fe06a-1d1c-4beb-a002-638ad8e84e79"}, {"Element": "<p class=\"Normal11pt0\">\u00a0</p>", "ID": "a5cc1d11-b0d9-434f-9f0e-31151abda54e", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "db931204-6a74-4d6a-ac8e-7b4d38310b23"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Lurasidone</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Due to CYP3A inhibition by saquinavir/ritonavir,\n  concentrations of lurasidone are expected to increase.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Concomitant administration of Invirase and lurasidone is\n  contra-indicated as it may increase lurasidone-related toxicity (see section\n  4.3).</p>\n</td>\n</tr>", "ID": "e76ace32-df02-46e8-92cc-078534f40ccf", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Lurasidone</p>\n</td>", "ID": "6f25b832-14be-4466-b2ff-4423b44f632e", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e76ace32-df02-46e8-92cc-078534f40ccf"}, {"Element": "<p class=\"Normal11pt0\">Lurasidone</p>", "ID": "9bd5ad56-7324-4e69-873b-7d7d69d041f7", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Lurasidone", "ParentId": "6f25b832-14be-4466-b2ff-4423b44f632e"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Due to CYP3A inhibition by saquinavir/ritonavir,\n  concentrations of lurasidone are expected to increase.</p>\n</td>", "ID": "1929d521-11f5-4fb6-9d47-b9838fe56bf8", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e76ace32-df02-46e8-92cc-078534f40ccf"}, {"Element": "<p class=\"Normal11pt0\">Due to CYP3A inhibition by saquinavir/ritonavir,\n  concentrations of lurasidone are expected to increase.</p>", "ID": "2fe2336e-9561-4b65-8d8d-c2cbebf345fc", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Due to CYP3A inhibition by saquinavir/ritonavir,   concentrations of lurasidone are expected to increase.", "ParentId": "1929d521-11f5-4fb6-9d47-b9838fe56bf8"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Concomitant administration of Invirase and lurasidone is\n  contra-indicated as it may increase lurasidone-related toxicity (see section\n  4.3).</p>\n</td>", "ID": "4b57f3de-2599-40cb-a27f-5d227fd8d6c6", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e76ace32-df02-46e8-92cc-078534f40ccf"}, {"Element": "<p class=\"Normal11pt0\">Concomitant administration of Invirase and lurasidone is\n  contra-indicated as it may increase lurasidone-related toxicity (see section\n  4.3).</p>", "ID": "a1c3700c-394a-4d4d-a3d9-b27577775504", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Concomitant administration of Invirase and lurasidone is   contra-indicated as it may increase lurasidone-related toxicity (see section   4.3).", "ParentId": "4b57f3de-2599-40cb-a27f-5d227fd8d6c6"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Quetiapine</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Due to CYP3A inhibition by saquinavir/ritonavir,\n  concentrations of quetiapine are expected to increase.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Concomitant administration of Invirase and quetiapine is\n  contra-indicated as it may increase quetiapine-related toxicity. Increased\n  plasma concentrations of quetiapine may lead to coma (see sectin 4.3).</p>\n</td>\n</tr>", "ID": "78f39c57-94ca-46a6-b703-2b5ce8d370a2", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Quetiapine</p>\n</td>", "ID": "20a361e2-b3ef-4a76-a2a3-8daa4157d7f5", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "78f39c57-94ca-46a6-b703-2b5ce8d370a2"}, {"Element": "<p class=\"Normal11pt0\">Quetiapine</p>", "ID": "b514eec4-fbed-48cf-b849-0b01c713d8b3", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Quetiapine", "ParentId": "20a361e2-b3ef-4a76-a2a3-8daa4157d7f5"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Due to CYP3A inhibition by saquinavir/ritonavir,\n  concentrations of quetiapine are expected to increase.</p>\n</td>", "ID": "d3546d03-3bc3-4373-8a70-05fae45e8bcd", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "78f39c57-94ca-46a6-b703-2b5ce8d370a2"}, {"Element": "<p class=\"Normal11pt0\">Due to CYP3A inhibition by saquinavir/ritonavir,\n  concentrations of quetiapine are expected to increase.</p>", "ID": "4773099a-05fb-4c4c-a8d6-41f2220abf7e", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Due to CYP3A inhibition by saquinavir/ritonavir,   concentrations of quetiapine are expected to increase.", "ParentId": "d3546d03-3bc3-4373-8a70-05fae45e8bcd"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Concomitant administration of Invirase and quetiapine is\n  contra-indicated as it may increase quetiapine-related toxicity. Increased\n  plasma concentrations of quetiapine may lead to coma (see sectin 4.3).</p>\n</td>", "ID": "da01335a-a74c-40fc-8e6d-86aa3a7a8d28", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "78f39c57-94ca-46a6-b703-2b5ce8d370a2"}, {"Element": "<p class=\"Normal11pt0\">Concomitant administration of Invirase and quetiapine is\n  contra-indicated as it may increase quetiapine-related toxicity. Increased\n  plasma concentrations of quetiapine may lead to coma (see sectin 4.3).</p>", "ID": "b7275aa9-1870-4ea1-899d-58bdb4c4522a", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Concomitant administration of Invirase and quetiapine is   contra-indicated as it may increase quetiapine-related toxicity. Increased   plasma concentrations of quetiapine may lead to coma (see sectin 4.3).", "ParentId": "da01335a-a74c-40fc-8e6d-86aa3a7a8d28"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Pimozide<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Concentrations of\n  pimozide may be increased when co-administered with Invirase/ritonavir.</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Pimozide is a CYP3A4\n  substrate and is associated with QT prolongation,</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with Invirase/ritonavir due to the potential for life threatening\n  cardiac arrhythmia (see sections 4.3 and 4.4).</p>\n</td>\n</tr>", "ID": "850f2d04-7d74-4a8f-8ba3-1c4df7b00a2b", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Pimozide<br/>\n  (saquinavir/ritonavir)</p>\n</td>", "ID": "96afcaa7-e94f-49e6-9770-1a036c70abbc", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "850f2d04-7d74-4a8f-8ba3-1c4df7b00a2b"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Pimozide<br/>\n  (saquinavir/ritonavir)</p>", "ID": "49961230-347e-46ea-be32-437fced9561a", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Pimozide   (saquinavir/ritonavir)", "ParentId": "96afcaa7-e94f-49e6-9770-1a036c70abbc"}, {"Element": "<br/>", "ID": "ac6aa4a6-c93f-4ca1-aadd-19911fe88bc4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "49961230-347e-46ea-be32-437fced9561a"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Concentrations of\n  pimozide may be increased when co-administered with Invirase/ritonavir.</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Pimozide is a CYP3A4\n  substrate and is associated with QT prolongation,</p>\n</td>", "ID": "1f8d5d6b-7ce4-428d-b71c-e7c4baedfd6b", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "850f2d04-7d74-4a8f-8ba3-1c4df7b00a2b"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Concentrations of\n  pimozide may be increased when co-administered with Invirase/ritonavir.</p>", "ID": "647bfc31-cfda-4aa6-918e-07e9949571f8", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Concentrations of   pimozide may be increased when co-administered with Invirase/ritonavir.", "ParentId": "1f8d5d6b-7ce4-428d-b71c-e7c4baedfd6b"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Pimozide is a CYP3A4\n  substrate and is associated with QT prolongation,</p>", "ID": "a6841839-5adb-4b2a-af5b-d945b9a3a2bb", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Pimozide is a CYP3A4   substrate and is associated with QT prolongation,", "ParentId": "1f8d5d6b-7ce4-428d-b71c-e7c4baedfd6b"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with Invirase/ritonavir due to the potential for life threatening\n  cardiac arrhythmia (see sections 4.3 and 4.4).</p>\n</td>", "ID": "bf9d06d9-89b1-4883-a239-aa46e82e935e", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "850f2d04-7d74-4a8f-8ba3-1c4df7b00a2b"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with Invirase/ritonavir due to the potential for life threatening\n  cardiac arrhythmia (see sections 4.3 and 4.4).</p>", "ID": "3f446a16-6581-4fe2-8d11-8541b61fab97", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated in   combination with Invirase/ritonavir due to the potential for life threatening   cardiac arrhythmia (see sections 4.3 and 4.4).", "ParentId": "bf9d06d9-89b1-4883-a239-aa46e82e935e"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Clozapine<br/>\n  Haloperidol</p>\n<p class=\"Normal11pt0\">Chlorpromazine<br/>\n  Mesoridazine<br/>\n  Phenothiazines<br/>\n  Sertindole<br/>\n  Sultopride<br/>\n  Thioridazine<br/>\n  Ziprasidone<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with Invirase/ritonavir\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4).</p>\n</td>\n</tr>", "ID": "8d45c79e-f273-4bd4-9247-41a2cc926432", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Clozapine<br/>\n  Haloperidol</p>\n<p class=\"Normal11pt0\">Chlorpromazine<br/>\n  Mesoridazine<br/>\n  Phenothiazines<br/>\n  Sertindole<br/>\n  Sultopride<br/>\n  Thioridazine<br/>\n  Ziprasidone<br/>\n  (saquinavir/ritonavir)</p>\n</td>", "ID": "96f5f26b-53f8-426d-8591-4ca121b0aec4", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "8d45c79e-f273-4bd4-9247-41a2cc926432"}, {"Element": "<p class=\"Normal11pt0\">Clozapine<br/>\n  Haloperidol</p>", "ID": "28506b74-50b9-4c39-9954-f393729485cb", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Clozapine   Haloperidol", "ParentId": "96f5f26b-53f8-426d-8591-4ca121b0aec4"}, {"Element": "<br/>", "ID": "461aa900-b639-4c12-98b9-076c5cf64bb3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "28506b74-50b9-4c39-9954-f393729485cb"}, {"Element": "<p class=\"Normal11pt0\">Chlorpromazine<br/>\n  Mesoridazine<br/>\n  Phenothiazines<br/>\n  Sertindole<br/>\n  Sultopride<br/>\n  Thioridazine<br/>\n  Ziprasidone<br/>\n  (saquinavir/ritonavir)</p>", "ID": "e03ece57-5d92-474f-b1ec-0ef72e134318", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Chlorpromazine   Mesoridazine   Phenothiazines   Sertindole   Sultopride   Thioridazine   Ziprasidone   (saquinavir/ritonavir)", "ParentId": "96f5f26b-53f8-426d-8591-4ca121b0aec4"}, {"Element": "<br/>", "ID": "40e9927b-6035-4080-8925-3fb46ef66790", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e03ece57-5d92-474f-b1ec-0ef72e134318"}, {"Element": "<br/>", "ID": "373143d2-16c1-4dd2-ba43-a0d7cfdf49cd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e03ece57-5d92-474f-b1ec-0ef72e134318"}, {"Element": "<br/>", "ID": "411c0ff7-216f-44c7-afe9-8dbb48fde816", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e03ece57-5d92-474f-b1ec-0ef72e134318"}, {"Element": "<br/>", "ID": "715dbb2c-3f92-47a3-a9f7-ab4a9c664c3e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e03ece57-5d92-474f-b1ec-0ef72e134318"}, {"Element": "<br/>", "ID": "cecc6bd3-0108-400e-810e-6ef895dbdc65", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e03ece57-5d92-474f-b1ec-0ef72e134318"}, {"Element": "<br/>", "ID": "0724750e-a567-44d4-929f-fc07638da04d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e03ece57-5d92-474f-b1ec-0ef72e134318"}, {"Element": "<br/>", "ID": "f4452bc3-fd46-41d4-8fe7-475d391d7168", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e03ece57-5d92-474f-b1ec-0ef72e134318"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>", "ID": "2083b7a1-3d9b-4a82-af02-a54758bbca0f", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8d45c79e-f273-4bd4-9247-41a2cc926432"}, {"Element": "<p class=\"Normal11pt0\">\u00a0</p>", "ID": "6a77fd20-7e9f-4a6a-9f99-d366086fd3d9", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "2083b7a1-3d9b-4a82-af02-a54758bbca0f"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with Invirase/ritonavir\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4).</p>\n</td>", "ID": "f40db9f2-3159-4758-a8cd-678b0e67809d", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8d45c79e-f273-4bd4-9247-41a2cc926432"}, {"Element": "<p class=\"Normal11pt0\">Contraindicated in combination with Invirase/ritonavir\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4).</p>", "ID": "929f48ba-9814-4f61-bfce-b28a539233ac", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Contraindicated in combination with Invirase/ritonavir   due to the potential for life threatening cardiac arrhythmia (see sections   4.3 and 4.4).", "ParentId": "f40db9f2-3159-4758-a8cd-678b0e67809d"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Benzodiazepines</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "ddfbe4ba-6521-485f-9507-b24ce0b6b7f6", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Benzodiazepines</span></i></b></p>\n</td>", "ID": "854f83ce-65d3-4086-a90f-0439773550cf", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ddfbe4ba-6521-485f-9507-b24ce0b6b7f6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Benzodiazepines</span></i></b></p>", "ID": "9c3eccc8-8e1c-4921-9a3c-3b1861200581", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "854f83ce-65d3-4086-a90f-0439773550cf"}, {"Element": "<b><i><span lang=\"EN-GB\">Benzodiazepines</span></i></b>", "ID": "eac4ac7b-8b4f-4a90-aef3-41b9b291f788", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9c3eccc8-8e1c-4921-9a3c-3b1861200581"}, {"Element": "<i><span lang=\"EN-GB\">Benzodiazepines</span></i>", "ID": "e73a6c94-2e0c-4ba8-9998-8802b0fa465a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "eac4ac7b-8b4f-4a90-aef3-41b9b291f788"}, {"Element": "<span lang=\"EN-GB\">Benzodiazepines</span>", "ID": "3489a403-c60f-4e46-b336-fbe418e271d5", "Styles": "None", "Classes": "None", "Text": "Benzodiazepines", "ParentId": "e73a6c94-2e0c-4ba8-9998-8802b0fa465a"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "f1e00346-c093-4454-b595-8c66995de71e", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ddfbe4ba-6521-485f-9507-b24ce0b6b7f6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "f34309ff-e08a-4138-ab64-2bf500e98c26", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "f1e00346-c093-4454-b595-8c66995de71e"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "ab24a37b-5d0d-4e3f-b0de-d26bb93794ce", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f34309ff-e08a-4138-ab64-2bf500e98c26"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "f0d993fb-b154-48d6-a338-3f0ed6a85f5b", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ddfbe4ba-6521-485f-9507-b24ce0b6b7f6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "9c4c372f-074d-4c87-a06b-e204287a221b", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "f0d993fb-b154-48d6-a338-3f0ed6a85f5b"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "31a14e97-6688-4e91-93f8-8a64624e31b2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9c4c372f-074d-4c87-a06b-e204287a221b"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Midazolam\n  7.5\u00a0mg<br/>\n  single dose (oral)<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Midazolam\n  AUC \u2191 12.4 fold<br/>\n  Midazolam C<sub>max </sub>\u2191 4.3 fold</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Midazolam t<sub>1/2 </sub>\u2191\n  from 4.7 h to 14.9\u00a0h<br/>\n  No data are available on concomitant use of ritonavir boosted saquinavir with\n  intravenous midazolam. <span style=\"font-size:12.0pt\">Studies of other CYP3A\n  modulators and i.v. midazolam</span> suggest a possible 3-4 fold increase in\n  midazolam plasma levels.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Co-administration of\n  Invirase/ritonavir with orally administered<b> </b>midazolam is\n  contraindicated (see section 4.3). <span style=\"color:black\">Caution should\n  be used with co-administration of Invirase and parenteral midazolam.<br/>\n</span><span lang=\"EN-GB\">If Invirase is co-administered with parenteral\n  midazolam it should be done in an intensive care unit (ICU) or similar\n  setting which ensures close clinical monitoring and appropriate medical management\n  in case of respiratory depression and/or prolonged sedation. Dosage\n  adjustment should be considered, especially if more than a single dose of\n  midazolam is administered.</span></p>\n</td>\n</tr>", "ID": "7547ea73-53b3-483b-be1c-b7ff028b80f2", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Midazolam\n  7.5\u00a0mg<br/>\n  single dose (oral)<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n</td>", "ID": "14be1948-600b-4d26-a415-adaeda647c73", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7547ea73-53b3-483b-be1c-b7ff028b80f2"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Midazolam\n  7.5\u00a0mg<br/>\n  single dose (oral)<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>", "ID": "57e3846d-77fe-41d5-ab75-b38419a96e49", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "14be1948-600b-4d26-a415-adaeda647c73"}, {"Element": "<span lang=\"PT-BR\">Midazolam\n  7.5\u00a0mg<br/>\n  single dose (oral)<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span>", "ID": "2ec48e24-4863-4b8b-a510-89e8e7902eec", "Styles": "None", "Classes": "None", "Text": "Midazolam   7.5\u00a0mg   single dose (oral)(saquinavir/ritonavir 1000/100\u00a0mg bid)", "ParentId": "57e3846d-77fe-41d5-ab75-b38419a96e49"}, {"Element": "<br/>", "ID": "c696c239-6556-4716-b3d6-1d59995b7c7d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2ec48e24-4863-4b8b-a510-89e8e7902eec"}, {"Element": "<u><br/>\n</u>", "ID": "258e4eba-dd36-4716-ba76-5f7885c01892", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "2ec48e24-4863-4b8b-a510-89e8e7902eec"}, {"Element": "<br/>", "ID": "31c5491c-f6a0-4ea4-acce-584c40678805", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "258e4eba-dd36-4716-ba76-5f7885c01892"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Midazolam\n  AUC \u2191 12.4 fold<br/>\n  Midazolam C<sub>max </sub>\u2191 4.3 fold</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Midazolam t<sub>1/2 </sub>\u2191\n  from 4.7 h to 14.9\u00a0h<br/>\n  No data are available on concomitant use of ritonavir boosted saquinavir with\n  intravenous midazolam. <span style=\"font-size:12.0pt\">Studies of other CYP3A\n  modulators and i.v. midazolam</span> suggest a possible 3-4 fold increase in\n  midazolam plasma levels.</p>\n</td>", "ID": "b571c967-15de-41b0-a40f-981f4a69cf33", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "7547ea73-53b3-483b-be1c-b7ff028b80f2"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Midazolam\n  AUC \u2191 12.4 fold<br/>\n  Midazolam C<sub>max </sub>\u2191 4.3 fold</span></p>", "ID": "5e850357-2eac-465d-a76b-abdf048b5b17", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "b571c967-15de-41b0-a40f-981f4a69cf33"}, {"Element": "<span lang=\"PT-BR\">Midazolam\n  AUC \u2191 12.4 fold<br/>\n  Midazolam C<sub>max </sub>\u2191 4.3 fold</span>", "ID": "77d47d1a-254a-45a8-ae9b-515b8505a93b", "Styles": "None", "Classes": "None", "Text": "Midazolam   AUC \u2191 12.4 fold   Midazolam C\u2191 4.3 fold", "ParentId": "5e850357-2eac-465d-a76b-abdf048b5b17"}, {"Element": "<br/>", "ID": "3caf5086-1b06-40e8-b449-8a9b61dc4041", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77d47d1a-254a-45a8-ae9b-515b8505a93b"}, {"Element": "<sub>max </sub>", "ID": "707d2519-51f6-4d7d-ad63-6dcf0096ce78", "Styles": "None", "Classes": "None", "Text": "max ", "ParentId": "77d47d1a-254a-45a8-ae9b-515b8505a93b"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Midazolam t<sub>1/2 </sub>\u2191\n  from 4.7 h to 14.9\u00a0h<br/>\n  No data are available on concomitant use of ritonavir boosted saquinavir with\n  intravenous midazolam. <span style=\"font-size:12.0pt\">Studies of other CYP3A\n  modulators and i.v. midazolam</span> suggest a possible 3-4 fold increase in\n  midazolam plasma levels.</p>", "ID": "fc582b72-e5d0-4001-897d-5c6d84a0ee22", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Midazolam t\u2191   from 4.7 h to 14.9\u00a0h   No data are available on concomitant use of ritonavir boosted saquinavir with   intravenous midazolam.  suggest a possible 3-4 fold increase in   midazolam plasma levels.", "ParentId": "b571c967-15de-41b0-a40f-981f4a69cf33"}, {"Element": "<sub>1/2 </sub>", "ID": "32c10613-d24b-4c29-8ecc-e9f9122f4dfe", "Styles": "None", "Classes": "None", "Text": "1/2 ", "ParentId": "fc582b72-e5d0-4001-897d-5c6d84a0ee22"}, {"Element": "<br/>", "ID": "c51ee0df-23cb-4cee-922a-de092d6973fa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fc582b72-e5d0-4001-897d-5c6d84a0ee22"}, {"Element": "<span style=\"font-size:12.0pt\">Studies of other CYP3A\n  modulators and i.v. midazolam</span>", "ID": "41fd963d-da73-401a-9aa5-2c381e9337f9", "Styles": "font-size:12.0pt", "Classes": "None", "Text": "Studies of other CYP3A   modulators and i.v. midazolam", "ParentId": "fc582b72-e5d0-4001-897d-5c6d84a0ee22"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Co-administration of\n  Invirase/ritonavir with orally administered<b> </b>midazolam is\n  contraindicated (see section 4.3). <span style=\"color:black\">Caution should\n  be used with co-administration of Invirase and parenteral midazolam.<br/>\n</span><span lang=\"EN-GB\">If Invirase is co-administered with parenteral\n  midazolam it should be done in an intensive care unit (ICU) or similar\n  setting which ensures close clinical monitoring and appropriate medical management\n  in case of respiratory depression and/or prolonged sedation. Dosage\n  adjustment should be considered, especially if more than a single dose of\n  midazolam is administered.</span></p>\n</td>", "ID": "a0557ffc-d8f0-43ff-bc0d-cdcfb6180790", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7547ea73-53b3-483b-be1c-b7ff028b80f2"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Co-administration of\n  Invirase/ritonavir with orally administered<b> </b>midazolam is\n  contraindicated (see section 4.3). <span style=\"color:black\">Caution should\n  be used with co-administration of Invirase and parenteral midazolam.<br/>\n</span><span lang=\"EN-GB\">If Invirase is co-administered with parenteral\n  midazolam it should be done in an intensive care unit (ICU) or similar\n  setting which ensures close clinical monitoring and appropriate medical management\n  in case of respiratory depression and/or prolonged sedation. Dosage\n  adjustment should be considered, especially if more than a single dose of\n  midazolam is administered.</span></p>", "ID": "9393a24e-b373-4ace-8048-5f3a2ea1db11", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Co-administration of   Invirase/ritonavir with orally administeredmidazolam is   contraindicated (see section 4.3). ", "ParentId": "a0557ffc-d8f0-43ff-bc0d-cdcfb6180790"}, {"Element": "<b> </b>", "ID": "f6f98353-6961-4045-b470-0d4454249adc", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "9393a24e-b373-4ace-8048-5f3a2ea1db11"}, {"Element": "<span style=\"color:black\">Caution should\n  be used with co-administration of Invirase and parenteral midazolam.<br/>\n</span>", "ID": "b2b378b4-d530-4723-9d14-1cd44d0a6c41", "Styles": "color:black", "Classes": "None", "Text": "Caution should   be used with co-administration of Invirase and parenteral midazolam. ", "ParentId": "9393a24e-b373-4ace-8048-5f3a2ea1db11"}, {"Element": "<br/>", "ID": "f10bcf5f-a77e-4a18-9e2a-6bb97a9eef8c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b2b378b4-d530-4723-9d14-1cd44d0a6c41"}, {"Element": "<span lang=\"EN-GB\">If Invirase is co-administered with parenteral\n  midazolam it should be done in an intensive care unit (ICU) or similar\n  setting which ensures close clinical monitoring and appropriate medical management\n  in case of respiratory depression and/or prolonged sedation. Dosage\n  adjustment should be considered, especially if more than a single dose of\n  midazolam is administered.</span>", "ID": "5bb7aef9-1dc4-40bd-9de2-345d1e649d5e", "Styles": "None", "Classes": "None", "Text": "If Invirase is co-administered with parenteral   midazolam it should be done in an intensive care unit (ICU) or similar   setting which ensures close clinical monitoring and appropriate medical management   in case of respiratory depression and/or prolonged sedation. Dosage   adjustment should be considered, especially if more than a single dose of   midazolam is administered.", "ParentId": "9393a24e-b373-4ace-8048-5f3a2ea1db11"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Alprazolam<br/>\n  Clorazepate<br/>\n  Diazepam<br/>\n  Flurazepam<u><br/>\n</u>(saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of these medicinal products may be increased when co-administered with\n  Invirase/ritonavir. </span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Careful\n  monitoring of patients with regard to sedative effects is warranted. A\n  decrease in the dose of the benzodiazepine may be required.</span></p>\n</td>\n</tr>", "ID": "c4b0b2ab-4666-47c9-a56b-e3f240e6f4db", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Alprazolam<br/>\n  Clorazepate<br/>\n  Diazepam<br/>\n  Flurazepam<u><br/>\n</u>(saquinavir/ritonavir)</span></p>\n</td>", "ID": "93a2ffcd-1f33-47d7-be4b-c526ecfff4e0", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c4b0b2ab-4666-47c9-a56b-e3f240e6f4db"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Alprazolam<br/>\n  Clorazepate<br/>\n  Diazepam<br/>\n  Flurazepam<u><br/>\n</u>(saquinavir/ritonavir)</span></p>", "ID": "823032de-d9de-4c14-92f0-9459602b3f26", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "93a2ffcd-1f33-47d7-be4b-c526ecfff4e0"}, {"Element": "<span lang=\"PT-BR\">Alprazolam<br/>\n  Clorazepate<br/>\n  Diazepam<br/>\n  Flurazepam<u><br/>\n</u>(saquinavir/ritonavir)</span>", "ID": "850eda1f-f80e-4784-821b-38f694f192de", "Styles": "None", "Classes": "None", "Text": "Alprazolam   Clorazepate   Diazepam   Flurazepam(saquinavir/ritonavir)", "ParentId": "823032de-d9de-4c14-92f0-9459602b3f26"}, {"Element": "<br/>", "ID": "933c754a-0dee-4077-9eac-86e97ae30f84", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "850eda1f-f80e-4784-821b-38f694f192de"}, {"Element": "<br/>", "ID": "b86a955b-d817-4b76-8493-757b2044fbf0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "850eda1f-f80e-4784-821b-38f694f192de"}, {"Element": "<br/>", "ID": "90854e06-6f98-46bf-ba72-a86b5fdf0be7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "850eda1f-f80e-4784-821b-38f694f192de"}, {"Element": "<u><br/>\n</u>", "ID": "c2cf28be-256b-4033-8821-112591580245", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "850eda1f-f80e-4784-821b-38f694f192de"}, {"Element": "<br/>", "ID": "31a5f70f-f44a-425f-8684-afa8d7929b29", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c2cf28be-256b-4033-8821-112591580245"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of these medicinal products may be increased when co-administered with\n  Invirase/ritonavir. </span></p>\n</td>", "ID": "ef076886-ffe5-4014-8ba1-285daa2b47ef", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c4b0b2ab-4666-47c9-a56b-e3f240e6f4db"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of these medicinal products may be increased when co-administered with\n  Invirase/ritonavir. </span></p>", "ID": "aae5a3a2-4b0b-4f17-9732-5e06c82970c8", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "ef076886-ffe5-4014-8ba1-285daa2b47ef"}, {"Element": "<span lang=\"EN-GB\">Concentrations\n  of these medicinal products may be increased when co-administered with\n  Invirase/ritonavir. </span>", "ID": "a7b6350d-c81d-4570-96ad-ba529fb5ff20", "Styles": "None", "Classes": "None", "Text": "Concentrations   of these medicinal products may be increased when co-administered with   Invirase/ritonavir. ", "ParentId": "aae5a3a2-4b0b-4f17-9732-5e06c82970c8"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Careful\n  monitoring of patients with regard to sedative effects is warranted. A\n  decrease in the dose of the benzodiazepine may be required.</span></p>\n</td>", "ID": "692367c7-b4f4-4fe0-82e3-bcab6ebcefb1", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c4b0b2ab-4666-47c9-a56b-e3f240e6f4db"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Careful\n  monitoring of patients with regard to sedative effects is warranted. A\n  decrease in the dose of the benzodiazepine may be required.</span></p>", "ID": "fd128080-8b42-4331-8c97-03d8b5c39af0", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "692367c7-b4f4-4fe0-82e3-bcab6ebcefb1"}, {"Element": "<span lang=\"EN-GB\">Careful\n  monitoring of patients with regard to sedative effects is warranted. A\n  decrease in the dose of the benzodiazepine may be required.</span>", "ID": "955f52eb-6bb5-4226-ad73-13c857ef5272", "Styles": "None", "Classes": "None", "Text": "Careful   monitoring of patients with regard to sedative effects is warranted. A   decrease in the dose of the benzodiazepine may be required.", "ParentId": "fd128080-8b42-4331-8c97-03d8b5c39af0"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Triazolam<u><br/>\n</u><span lang=\"PT-BR\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"PT-BR\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Concentrations of triazolam may be increased when\n  co-administered with <span lang=\"EN-GB\">Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">saquinavir/ritonavir</span>,\n  due to the risk of potentially prolonged or increased sedation and\n  respiratory depression (see section 4.3).</p>\n</td>\n</tr>", "ID": "969effc9-136c-4ab1-abea-cba2c6c2665d", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\">Triazolam<u><br/>\n</u><span lang=\"PT-BR\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"PT-BR\">)</span></p>\n</td>", "ID": "be18c626-abf1-44d4-9ed3-03f3ed675c32", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "969effc9-136c-4ab1-abea-cba2c6c2665d"}, {"Element": "<p class=\"Normal11pt0\">Triazolam<u><br/>\n</u><span lang=\"PT-BR\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"PT-BR\">)</span></p>", "ID": "c1e9855d-fe57-4083-95b5-87a48da47fa2", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Triazolam", "ParentId": "be18c626-abf1-44d4-9ed3-03f3ed675c32"}, {"Element": "<u><br/>\n</u>", "ID": "aa0efc30-4dc9-49f5-9aa7-ff8df9b3c93d", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "c1e9855d-fe57-4083-95b5-87a48da47fa2"}, {"Element": "<br/>", "ID": "36033f48-8b29-4882-bb12-5e774d1594f3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "aa0efc30-4dc9-49f5-9aa7-ff8df9b3c93d"}, {"Element": "<span lang=\"PT-BR\">(</span>", "ID": "6f7e2410-04ca-47ea-8c5e-a51fb07bb969", "Styles": "None", "Classes": "None", "Text": "(", "ParentId": "c1e9855d-fe57-4083-95b5-87a48da47fa2"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "aa850413-4f77-4cbc-a2b7-501066e00c9f", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "c1e9855d-fe57-4083-95b5-87a48da47fa2"}, {"Element": "<span lang=\"PT-BR\">)</span>", "ID": "c52f2a0d-bcf1-4146-8813-167d3c6d402f", "Styles": "None", "Classes": "None", "Text": ")", "ParentId": "c1e9855d-fe57-4083-95b5-87a48da47fa2"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Concentrations of triazolam may be increased when\n  co-administered with <span lang=\"EN-GB\">Invirase/ritonavir.</span></p>\n</td>", "ID": "766b9146-8613-4762-8061-56a82e962e18", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "969effc9-136c-4ab1-abea-cba2c6c2665d"}, {"Element": "<p class=\"Normal11pt0\">Concentrations of triazolam may be increased when\n  co-administered with <span lang=\"EN-GB\">Invirase/ritonavir.</span></p>", "ID": "0d0c0a6c-fe2e-4859-8e5b-e4edd4c1b241", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Concentrations of triazolam may be increased when   co-administered with ", "ParentId": "766b9146-8613-4762-8061-56a82e962e18"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir.</span>", "ID": "3543dbb6-c6ae-4abf-937e-13cd7530f6c5", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir.", "ParentId": "0d0c0a6c-fe2e-4859-8e5b-e4edd4c1b241"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">saquinavir/ritonavir</span>,\n  due to the risk of potentially prolonged or increased sedation and\n  respiratory depression (see section 4.3).</p>\n</td>", "ID": "fa9ad57b-7a15-4b13-a321-c5ec0e6a85e7", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "969effc9-136c-4ab1-abea-cba2c6c2665d"}, {"Element": "<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">saquinavir/ritonavir</span>,\n  due to the risk of potentially prolonged or increased sedation and\n  respiratory depression (see section 4.3).</p>", "ID": "5b3718c8-7da0-4570-93a4-90df256a0ece", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Contraindicated in combination with ,   due to the risk of potentially prolonged or increased sedation and   respiratory depression (see section 4.3).", "ParentId": "fa9ad57b-7a15-4b13-a321-c5ec0e6a85e7"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "55d6bcaa-18a3-4f63-9a00-eddcfa7e4ccd", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "5b3718c8-7da0-4570-93a4-90df256a0ece"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Calcium\n  channel blockers</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "88f3d912-e23f-4eef-8f62-8c74abff6fea", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Calcium\n  channel blockers</span></i></b></p>\n</td>", "ID": "63a2c516-cbd0-488a-8517-2c1dbe5207c7", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "88f3d912-e23f-4eef-8f62-8c74abff6fea"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Calcium\n  channel blockers</span></i></b></p>", "ID": "0f6cf5c9-c6d4-4139-a1a6-561d13d93978", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "63a2c516-cbd0-488a-8517-2c1dbe5207c7"}, {"Element": "<b><i><span lang=\"EN-GB\">Calcium\n  channel blockers</span></i></b>", "ID": "2e950bd9-99a3-4182-99e9-13cba3a67f44", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0f6cf5c9-c6d4-4139-a1a6-561d13d93978"}, {"Element": "<i><span lang=\"EN-GB\">Calcium\n  channel blockers</span></i>", "ID": "2443d747-9155-4a2b-b397-8f562991e8ad", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2e950bd9-99a3-4182-99e9-13cba3a67f44"}, {"Element": "<span lang=\"EN-GB\">Calcium\n  channel blockers</span>", "ID": "7145c8a5-178a-48ed-90a5-a52e6e399f58", "Styles": "None", "Classes": "None", "Text": "Calcium   channel blockers", "ParentId": "2443d747-9155-4a2b-b397-8f562991e8ad"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "aef6cb48-b124-4fa0-adbe-787c92f17c30", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "88f3d912-e23f-4eef-8f62-8c74abff6fea"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "9bd16bb9-6c32-41a0-8f87-fed3fa824ccb", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "aef6cb48-b124-4fa0-adbe-787c92f17c30"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "144a82ca-6bf0-4f88-8081-336b723850b3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9bd16bb9-6c32-41a0-8f87-fed3fa824ccb"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "8517c545-8058-4ff2-9b68-e2a1f59ea673", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "88f3d912-e23f-4eef-8f62-8c74abff6fea"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "3a689c77-b416-407a-85c4-b24b9948f1e7", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "8517c545-8058-4ff2-9b68-e2a1f59ea673"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "e14b3d30-45cd-4d6d-a693-513b7d722c6e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3a689c77-b416-407a-85c4-b24b9948f1e7"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Felodipine, nifedipine, nicardipine,\n  diltiazem, nimodipine, verapamil, amlodipine, nisoldipine, isradipine<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of these medicinal\n  products may be increased when co-administered with Invirase/ritonavir. </span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Caution is warranted and clinical\n  monitoring of patients is recommended.</span></p>\n</td>\n</tr>", "ID": "df679025-7cbf-41de-9cfb-92a1a7666051", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Felodipine, nifedipine, nicardipine,\n  diltiazem, nimodipine, verapamil, amlodipine, nisoldipine, isradipine<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>", "ID": "acde8376-6b8b-4285-ae6c-d5f832bc5a26", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "df679025-7cbf-41de-9cfb-92a1a7666051"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">Felodipine, nifedipine, nicardipine,\n  diltiazem, nimodipine, verapamil, amlodipine, nisoldipine, isradipine<br/>\n  (saquinavir/ritonavir)</span></p>", "ID": "115f2b5a-7ccb-475d-a2d0-465884ccb8bf", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "acde8376-6b8b-4285-ae6c-d5f832bc5a26"}, {"Element": "<span lang=\"IT\">Felodipine, nifedipine, nicardipine,\n  diltiazem, nimodipine, verapamil, amlodipine, nisoldipine, isradipine<br/>\n  (saquinavir/ritonavir)</span>", "ID": "57b00a74-9a27-4f45-85d0-56077ecff860", "Styles": "None", "Classes": "None", "Text": "Felodipine, nifedipine, nicardipine,   diltiazem, nimodipine, verapamil, amlodipine, nisoldipine, isradipine   (saquinavir/ritonavir)", "ParentId": "115f2b5a-7ccb-475d-a2d0-465884ccb8bf"}, {"Element": "<br/>", "ID": "2eaf15a9-34c5-4dc1-ad9b-7f92d4964b01", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "57b00a74-9a27-4f45-85d0-56077ecff860"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of these medicinal\n  products may be increased when co-administered with Invirase/ritonavir. </span></p>\n</td>", "ID": "497a9ff5-b5c6-4e7c-b9a0-4acf5dab922f", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "df679025-7cbf-41de-9cfb-92a1a7666051"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of these medicinal\n  products may be increased when co-administered with Invirase/ritonavir. </span></p>", "ID": "dd7d444f-0b29-4cf5-9d7e-5abb724bf17b", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "497a9ff5-b5c6-4e7c-b9a0-4acf5dab922f"}, {"Element": "<span lang=\"EN-GB\">Concentrations of these medicinal\n  products may be increased when co-administered with Invirase/ritonavir. </span>", "ID": "1d94a197-d5c7-486e-a17c-9b29928501a8", "Styles": "None", "Classes": "None", "Text": "Concentrations of these medicinal   products may be increased when co-administered with Invirase/ritonavir. ", "ParentId": "dd7d444f-0b29-4cf5-9d7e-5abb724bf17b"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Caution is warranted and clinical\n  monitoring of patients is recommended.</span></p>\n</td>", "ID": "4d543961-c0bd-4d5e-b510-bef09f29d138", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "df679025-7cbf-41de-9cfb-92a1a7666051"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Caution is warranted and clinical\n  monitoring of patients is recommended.</span></p>", "ID": "d4f39e04-19ad-4b22-a28e-b6c847fc2bbc", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "4d543961-c0bd-4d5e-b510-bef09f29d138"}, {"Element": "<span lang=\"EN-GB\">Caution is warranted and clinical\n  monitoring of patients is recommended.</span>", "ID": "2bd7b4a4-1c32-4593-9b75-d35e2d740cff", "Styles": "None", "Classes": "None", "Text": "Caution is warranted and clinical   monitoring of patients is recommended.", "ParentId": "d4f39e04-19ad-4b22-a28e-b6c847fc2bbc"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Corticosteroids</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "02305ea3-8916-4303-bb29-f087852bcb9e", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Corticosteroids</span></i></b></p>\n</td>", "ID": "dd884b07-cc5c-4d00-8baa-ca332c68ee0a", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02305ea3-8916-4303-bb29-f087852bcb9e"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Corticosteroids</span></i></b></p>", "ID": "bf3f4743-7c49-4d7e-85ef-ec754417dade", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "dd884b07-cc5c-4d00-8baa-ca332c68ee0a"}, {"Element": "<b><i><span lang=\"EN-GB\">Corticosteroids</span></i></b>", "ID": "0ae92b29-b77d-49e8-88b4-a688e4460657", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bf3f4743-7c49-4d7e-85ef-ec754417dade"}, {"Element": "<i><span lang=\"EN-GB\">Corticosteroids</span></i>", "ID": "3afa83c3-f6fb-4627-9b53-729c6787ee63", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0ae92b29-b77d-49e8-88b4-a688e4460657"}, {"Element": "<span lang=\"EN-GB\">Corticosteroids</span>", "ID": "db9ea0b9-96bb-410f-b8ac-b1e4a2ca993b", "Styles": "None", "Classes": "None", "Text": "Corticosteroids", "ParentId": "3afa83c3-f6fb-4627-9b53-729c6787ee63"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "6e77ca23-f577-427b-866f-86d48f1be56e", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02305ea3-8916-4303-bb29-f087852bcb9e"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "c5bf8c68-0b47-479c-bb59-c66a545f3bc1", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "6e77ca23-f577-427b-866f-86d48f1be56e"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "91c5d739-7499-4d10-88c1-e329da2de253", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c5bf8c68-0b47-479c-bb59-c66a545f3bc1"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "ebfdbe11-5731-4e81-8539-2752d92a597d", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02305ea3-8916-4303-bb29-f087852bcb9e"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "32a27c84-d64c-4945-a1fa-ee8de0245ede", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "ebfdbe11-5731-4e81-8539-2752d92a597d"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "3125fe84-b506-48ea-8682-455679100e51", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "32a27c84-d64c-4945-a1fa-ee8de0245ede"}, {"Element": "<tr style=\"height:76.4pt\">\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Dexamethasone<br/>\n</span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Dexamethasone\n  induces CYP3A4 and may </span>decrease<span lang=\"EN-GB\"> saquinavir\n  concentrations.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Use with caution. Monitoring of saquinavir plasma\n  concentration is recommended (see section 4.4).</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "d5b50d77-5962-4b90-a5f4-7cec7ff7b86c", "Styles": "height:76.4pt", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Dexamethasone<br/>\n</span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>\n</td>", "ID": "089d4b31-0a32-4262-82dc-06dd8cd04977", "Styles": "width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:76.4pt", "Classes": "None", "Text": "  ", "ParentId": "d5b50d77-5962-4b90-a5f4-7cec7ff7b86c"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">Dexamethasone<br/>\n</span><span lang=\"IT\">(</span><span lang=\"EN-GB\">saquinavir/ritonavir</span><span lang=\"IT\">)</span></p>", "ID": "30460579-d34d-4c50-af35-ba0115fcef83", "Styles": "margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 ", "ParentId": "089d4b31-0a32-4262-82dc-06dd8cd04977"}, {"Element": "<span lang=\"EN-GB\">Dexamethasone<br/>\n</span>", "ID": "ea6efc6f-6da3-4df4-8410-8ce60582f9f6", "Styles": "None", "Classes": "None", "Text": "Dexamethasone ", "ParentId": "30460579-d34d-4c50-af35-ba0115fcef83"}, {"Element": "<br/>", "ID": "85becf66-1855-4418-9323-a15166eaaadb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ea6efc6f-6da3-4df4-8410-8ce60582f9f6"}, {"Element": "<span lang=\"IT\">(</span>", "ID": "bda1c62a-aafe-47ed-bce6-782deb8760df", "Styles": "None", "Classes": "None", "Text": "(", "ParentId": "30460579-d34d-4c50-af35-ba0115fcef83"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "c67b42ca-b106-42c6-9e9d-5c6b887f8167", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "30460579-d34d-4c50-af35-ba0115fcef83"}, {"Element": "<span lang=\"IT\">)</span>", "ID": "794f373b-b9cf-4481-8d72-b1bc6039e63d", "Styles": "None", "Classes": "None", "Text": ")", "ParentId": "30460579-d34d-4c50-af35-ba0115fcef83"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Dexamethasone\n  induces CYP3A4 and may </span>decrease<span lang=\"EN-GB\"> saquinavir\n  concentrations.</span></p>\n</td>", "ID": "faa5194f-1ab0-46ae-aa20-12c1ce6e1213", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt", "Classes": "None", "Text": "   ", "ParentId": "d5b50d77-5962-4b90-a5f4-7cec7ff7b86c"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>", "ID": "3df958e5-adac-452e-b604-53e4b8eba4ab", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "faa5194f-1ab0-46ae-aa20-12c1ce6e1213"}, {"Element": "<span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span>", "ID": "9415a739-92dc-428a-9412-2f86557eef55", "Styles": "None", "Classes": "None", "Text": "Interaction   with Invirase/ritonavir not studied.", "ParentId": "3df958e5-adac-452e-b604-53e4b8eba4ab"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Dexamethasone\n  induces CYP3A4 and may </span>decrease<span lang=\"EN-GB\"> saquinavir\n  concentrations.</span></p>", "ID": "5bb235fd-a1d9-47b4-b597-3dfca5ace066", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "decrease", "ParentId": "faa5194f-1ab0-46ae-aa20-12c1ce6e1213"}, {"Element": "<span lang=\"EN-GB\">Dexamethasone\n  induces CYP3A4 and may </span>", "ID": "727082ed-5d7a-4eed-b07e-072d6b31e4dc", "Styles": "None", "Classes": "None", "Text": "Dexamethasone   induces CYP3A4 and may ", "ParentId": "5bb235fd-a1d9-47b4-b597-3dfca5ace066"}, {"Element": "<span lang=\"EN-GB\"> saquinavir\n  concentrations.</span>", "ID": "27dad2b9-e1e9-4bf2-9c5f-b3c844830a08", "Styles": "None", "Classes": "None", "Text": " saquinavir   concentrations.", "ParentId": "5bb235fd-a1d9-47b4-b597-3dfca5ace066"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Use with caution. Monitoring of saquinavir plasma\n  concentration is recommended (see section 4.4).</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>", "ID": "dc8272b3-40ee-4449-8521-954db16f6bfa", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt", "Classes": "None", "Text": "   ", "ParentId": "d5b50d77-5962-4b90-a5f4-7cec7ff7b86c"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Use with caution. Monitoring of saquinavir plasma\n  concentration is recommended (see section 4.4).</span></p>", "ID": "50f12cba-a132-4dc0-97ab-477219268aa9", "Styles": "margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "dc8272b3-40ee-4449-8521-954db16f6bfa"}, {"Element": "<span lang=\"EN-GB\">Use with caution. Monitoring of saquinavir plasma\n  concentration is recommended (see section 4.4).</span>", "ID": "7d9e8eef-a2eb-4e0b-82f5-846d711893e6", "Styles": "None", "Classes": "None", "Text": "Use with caution. Monitoring of saquinavir plasma   concentration is recommended (see section 4.4).", "ParentId": "50f12cba-a132-4dc0-97ab-477219268aa9"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\">\u00a0</p>", "ID": "cb8755fe-40de-4503-985a-e1d4af586424", "Styles": "margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "dc8272b3-40ee-4449-8521-954db16f6bfa"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Fluticasone\n  propionate<br/>\n  50 mcg qid, intranasal<br/>\n  (ritonavir 100\u00a0mg bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Fluticasone <span lang=\"EN-GB\">propionate</span> \u2191</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Intrinsic cortisol <span style=\"font-family:Symbol\">\u00af</span> 86%<br/>\n  (90% CI 82%-89%)<br/>\n<span lang=\"EN-GB\">Greater effects may be expected when fluticasone propionate\n  is inhaled. Systemic corticosteroid effects including Cushing\u2019s\n  syndrome and adrenal suppression have been reported in patients receiving\n  ritonavir and inhaled or intranasally administered fluticasone propionate;\n  this could also occur with other corticosteroids metabolised via the P450 3A\n  pathway e.g. budesonide.<br/>\n<br/>\n  Effects of high fluticasone systemic exposure on ritonavir plasma levels yet\n  unknown.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concomitant\n  administration of boosted saquinavir and fluticasone propionate and other\n  corticosteroids metabolised via the P450 3A pathway (e.g. budesonide) is not\n  recommended unless the potential benefit of treatment outweighs the risk of\n  systemic corticosteroid effects (see section 4.4).<br/>\n  Dose reduction of the glucocorticoid should be considered with close\n  monitoring of local and systemic effects or a switch to a glucocorticoid,\n  which is not a substrate for CYP3A4 (e.g. beclomethasone).<br/>\n  In case of withdrawal of glucocorticoids progressive dose reduction may have\n  to be performed over a longer period.</span></p>\n</td>\n</tr>", "ID": "e34ff1a8-62d7-42df-b962-0757ed8f371f", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Fluticasone\n  propionate<br/>\n  50 mcg qid, intranasal<br/>\n  (ritonavir 100\u00a0mg bid)</span></p>\n</td>", "ID": "77657ddc-c42b-417d-88df-895fe74c9e15", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e34ff1a8-62d7-42df-b962-0757ed8f371f"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Fluticasone\n  propionate<br/>\n  50 mcg qid, intranasal<br/>\n  (ritonavir 100\u00a0mg bid)</span></p>", "ID": "2612cd8b-1163-41aa-96e8-d39d945aa3c0", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "77657ddc-c42b-417d-88df-895fe74c9e15"}, {"Element": "<span lang=\"EN-GB\">Fluticasone\n  propionate<br/>\n  50 mcg qid, intranasal<br/>\n  (ritonavir 100\u00a0mg bid)</span>", "ID": "f6230749-fe2f-4b0f-a8e4-ae6880d42dcc", "Styles": "None", "Classes": "None", "Text": "Fluticasone   propionate   50 mcg qid, intranasal   (ritonavir 100\u00a0mg bid)", "ParentId": "2612cd8b-1163-41aa-96e8-d39d945aa3c0"}, {"Element": "<br/>", "ID": "e4f1f16e-1b8d-44b6-b551-5dcbea298645", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f6230749-fe2f-4b0f-a8e4-ae6880d42dcc"}, {"Element": "<br/>", "ID": "b1d28654-f92e-4927-a9c6-89433e0ea04a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f6230749-fe2f-4b0f-a8e4-ae6880d42dcc"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Fluticasone <span lang=\"EN-GB\">propionate</span> \u2191</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Intrinsic cortisol <span style=\"font-family:Symbol\">\u00af</span> 86%<br/>\n  (90% CI 82%-89%)<br/>\n<span lang=\"EN-GB\">Greater effects may be expected when fluticasone propionate\n  is inhaled. Systemic corticosteroid effects including Cushing\u2019s\n  syndrome and adrenal suppression have been reported in patients receiving\n  ritonavir and inhaled or intranasally administered fluticasone propionate;\n  this could also occur with other corticosteroids metabolised via the P450 3A\n  pathway e.g. budesonide.<br/>\n<br/>\n  Effects of high fluticasone systemic exposure on ritonavir plasma levels yet\n  unknown.</span></p>\n</td>", "ID": "0bc795e1-dc83-4d18-8006-df85580b3c7a", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "e34ff1a8-62d7-42df-b962-0757ed8f371f"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Fluticasone <span lang=\"EN-GB\">propionate</span> \u2191</p>", "ID": "bd67c458-f61f-4cde-9103-15811b6dc106", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Fluticasone  \u2191", "ParentId": "0bc795e1-dc83-4d18-8006-df85580b3c7a"}, {"Element": "<span lang=\"EN-GB\">propionate</span>", "ID": "88387c67-e0a8-4605-865a-cce7dec651d9", "Styles": "None", "Classes": "None", "Text": "propionate", "ParentId": "bd67c458-f61f-4cde-9103-15811b6dc106"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Intrinsic cortisol <span style=\"font-family:Symbol\">\u00af</span> 86%<br/>\n  (90% CI 82%-89%)<br/>\n<span lang=\"EN-GB\">Greater effects may be expected when fluticasone propionate\n  is inhaled. Systemic corticosteroid effects including Cushing\u2019s\n  syndrome and adrenal suppression have been reported in patients receiving\n  ritonavir and inhaled or intranasally administered fluticasone propionate;\n  this could also occur with other corticosteroids metabolised via the P450 3A\n  pathway e.g. budesonide.<br/>\n<br/>\n  Effects of high fluticasone systemic exposure on ritonavir plasma levels yet\n  unknown.</span></p>", "ID": "40c6123f-b426-494b-920a-88be1a2acf4d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Intrinsic cortisol  86%   (90% CI 82%-89%) ", "ParentId": "0bc795e1-dc83-4d18-8006-df85580b3c7a"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "ed8cd104-90fe-4ea3-9eae-79ed6b91a9fe", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "40c6123f-b426-494b-920a-88be1a2acf4d"}, {"Element": "<br/>", "ID": "18a78e93-1174-4336-91cf-8ac0fc0eff88", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "40c6123f-b426-494b-920a-88be1a2acf4d"}, {"Element": "<br/>", "ID": "2b91c441-b984-4b0f-9c7e-723d8c551a3a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "40c6123f-b426-494b-920a-88be1a2acf4d"}, {"Element": "<span lang=\"EN-GB\">Greater effects may be expected when fluticasone propionate\n  is inhaled. Systemic corticosteroid effects including Cushing\u2019s\n  syndrome and adrenal suppression have been reported in patients receiving\n  ritonavir and inhaled or intranasally administered fluticasone propionate;\n  this could also occur with other corticosteroids metabolised via the P450 3A\n  pathway e.g. budesonide.<br/>\n<br/>\n  Effects of high fluticasone systemic exposure on ritonavir plasma levels yet\n  unknown.</span>", "ID": "b9044f79-fac1-43bb-aab0-145290c1d1ff", "Styles": "None", "Classes": "None", "Text": "Greater effects may be expected when fluticasone propionate   is inhaled. Systemic corticosteroid effects including Cushing\u2019s   syndrome and adrenal suppression have been reported in patients receiving   ritonavir and inhaled or intranasally administered fluticasone propionate;   this could also occur with other corticosteroids metabolised via the P450 3A   pathway e.g. budesonide.    Effects of high fluticasone systemic exposure on ritonavir plasma levels yet   unknown.", "ParentId": "40c6123f-b426-494b-920a-88be1a2acf4d"}, {"Element": "<br/>", "ID": "9ed9159b-9dd5-4292-9f05-0bdd204169a5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b9044f79-fac1-43bb-aab0-145290c1d1ff"}, {"Element": "<br/>", "ID": "040449b0-bb56-42cb-9d14-8b0259ef270a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b9044f79-fac1-43bb-aab0-145290c1d1ff"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concomitant\n  administration of boosted saquinavir and fluticasone propionate and other\n  corticosteroids metabolised via the P450 3A pathway (e.g. budesonide) is not\n  recommended unless the potential benefit of treatment outweighs the risk of\n  systemic corticosteroid effects (see section 4.4).<br/>\n  Dose reduction of the glucocorticoid should be considered with close\n  monitoring of local and systemic effects or a switch to a glucocorticoid,\n  which is not a substrate for CYP3A4 (e.g. beclomethasone).<br/>\n  In case of withdrawal of glucocorticoids progressive dose reduction may have\n  to be performed over a longer period.</span></p>\n</td>", "ID": "354a8e14-68e9-4871-a1ef-d0467f6cb82d", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e34ff1a8-62d7-42df-b962-0757ed8f371f"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concomitant\n  administration of boosted saquinavir and fluticasone propionate and other\n  corticosteroids metabolised via the P450 3A pathway (e.g. budesonide) is not\n  recommended unless the potential benefit of treatment outweighs the risk of\n  systemic corticosteroid effects (see section 4.4).<br/>\n  Dose reduction of the glucocorticoid should be considered with close\n  monitoring of local and systemic effects or a switch to a glucocorticoid,\n  which is not a substrate for CYP3A4 (e.g. beclomethasone).<br/>\n  In case of withdrawal of glucocorticoids progressive dose reduction may have\n  to be performed over a longer period.</span></p>", "ID": "33ebc2e6-79b7-4b1b-a97e-a87c6127f036", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "354a8e14-68e9-4871-a1ef-d0467f6cb82d"}, {"Element": "<span lang=\"EN-GB\">Concomitant\n  administration of boosted saquinavir and fluticasone propionate and other\n  corticosteroids metabolised via the P450 3A pathway (e.g. budesonide) is not\n  recommended unless the potential benefit of treatment outweighs the risk of\n  systemic corticosteroid effects (see section 4.4).<br/>\n  Dose reduction of the glucocorticoid should be considered with close\n  monitoring of local and systemic effects or a switch to a glucocorticoid,\n  which is not a substrate for CYP3A4 (e.g. beclomethasone).<br/>\n  In case of withdrawal of glucocorticoids progressive dose reduction may have\n  to be performed over a longer period.</span>", "ID": "ae8f4cf8-ac40-42b1-88d4-741d43174120", "Styles": "None", "Classes": "None", "Text": "Concomitant   administration of boosted saquinavir and fluticasone propionate and other   corticosteroids metabolised via the P450 3A pathway (e.g. budesonide) is not   recommended unless the potential benefit of treatment outweighs the risk of   systemic corticosteroid effects (see section 4.4).   Dose reduction of the glucocorticoid should be considered with close   monitoring of local and systemic effects or a switch to a glucocorticoid,   which is not a substrate for CYP3A4 (e.g. beclomethasone).   In case of withdrawal of glucocorticoids progressive dose reduction may have   to be performed over a longer period.", "ParentId": "33ebc2e6-79b7-4b1b-a97e-a87c6127f036"}, {"Element": "<br/>", "ID": "377fa582-1932-410e-9272-1147ccf3f451", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ae8f4cf8-ac40-42b1-88d4-741d43174120"}, {"Element": "<br/>", "ID": "312b22dc-2c57-4e18-bca6-81a441bd0a45", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ae8f4cf8-ac40-42b1-88d4-741d43174120"}, {"Element": "<tr style=\"height:12.9pt\">\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Endothelin\n  receptor antagonist</span></i></b></p>\n</td>\n</tr>", "ID": "24486935-f2ae-454a-b326-2346adc526a2", "Styles": "height:12.9pt", "Classes": "None", "Text": "  ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Endothelin\n  receptor antagonist</span></i></b></p>\n</td>", "ID": "1df3d748-d6ec-4994-b6a0-a7a59fcd4e11", "Styles": "width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt", "Classes": "None", "Text": "  ", "ParentId": "24486935-f2ae-454a-b326-2346adc526a2"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Endothelin\n  receptor antagonist</span></i></b></p>", "ID": "6041cdab-eaf7-4f9f-83f4-3eef91914e7b", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "1df3d748-d6ec-4994-b6a0-a7a59fcd4e11"}, {"Element": "<b><i><span lang=\"IT\">Endothelin\n  receptor antagonist</span></i></b>", "ID": "aca6dab4-89bc-48e1-9545-29785e262ecd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6041cdab-eaf7-4f9f-83f4-3eef91914e7b"}, {"Element": "<i><span lang=\"IT\">Endothelin\n  receptor antagonist</span></i>", "ID": "051204be-6871-49cd-aada-c06576a6ff0d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "aca6dab4-89bc-48e1-9545-29785e262ecd"}, {"Element": "<span lang=\"IT\">Endothelin\n  receptor antagonist</span>", "ID": "ec6b3012-f412-40d4-aa34-720238694c0b", "Styles": "None", "Classes": "None", "Text": "Endothelin   receptor antagonist", "ParentId": "051204be-6871-49cd-aada-c06576a6ff0d"}, {"Element": "<tr style=\"height:46.2pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:46.2pt\" valign=\"top\" width=\"177\">\n<p class=\"Paragraph\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Bosentan\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:46.2pt\" valign=\"top\" width=\"236\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Not studied.\n  Concomitant use of bosentan and saquinavir/ritonavir may increase plasma\n  levels of bosentan and may decrease plasma levels of saquinavir/ritonavir.</span></p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:46.2pt\" valign=\"top\" width=\"237\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Dose adjustment\n  of bosentan may be required. When bosentan is administered concomitantly with\n  saquinavir/ritonavir, the patient\u2019s tolerability of bosentan should be\n  monitored. Monitoring of the patient\u2019s HIV therapy is also recommended.</span></p>\n</td>\n</tr>", "ID": "197dd672-1a1a-4837-9158-2bd9babfb6fb", "Styles": "height:46.2pt", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:46.2pt\" valign=\"top\" width=\"177\">\n<p class=\"Paragraph\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Bosentan\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>\n</td>", "ID": "ddd8e823-322e-4b9d-93d7-a9024e3ac0b0", "Styles": "width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:46.2pt", "Classes": "None", "Text": "  ", "ParentId": "197dd672-1a1a-4837-9158-2bd9babfb6fb"}, {"Element": "<p class=\"Paragraph\" style=\"page-break-after:avoid\"><span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Bosentan\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></p>", "ID": "e1296e77-8545-4348-9f23-a7395ee739e2", "Styles": "page-break-after:avoid", "Classes": "['Paragraph']", "Text": "", "ParentId": "ddd8e823-322e-4b9d-93d7-a9024e3ac0b0"}, {"Element": "<span style='font-size:\n  11.0pt;font-family:\"Times New Roman\",serif'>Bosentan\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "bdd1dabb-20cb-4faf-b30f-327276d3e69d", "Styles": "font-size:\n  11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Bosentan\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "e1296e77-8545-4348-9f23-a7395ee739e2"}, {"Element": "<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:46.2pt\" valign=\"top\" width=\"236\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Not studied.\n  Concomitant use of bosentan and saquinavir/ritonavir may increase plasma\n  levels of bosentan and may decrease plasma levels of saquinavir/ritonavir.</span></p>\n</td>", "ID": "7cb2c65c-c780-4824-934b-d5c51a22af4a", "Styles": "width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:46.2pt", "Classes": "None", "Text": "  ", "ParentId": "197dd672-1a1a-4837-9158-2bd9babfb6fb"}, {"Element": "<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Not studied.\n  Concomitant use of bosentan and saquinavir/ritonavir may increase plasma\n  levels of bosentan and may decrease plasma levels of saquinavir/ritonavir.</span></p>", "ID": "d4cbdd55-b7bd-4346-b37a-67012f06f519", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['Paragraph']", "Text": "", "ParentId": "7cb2c65c-c780-4824-934b-d5c51a22af4a"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Not studied.\n  Concomitant use of bosentan and saquinavir/ritonavir may increase plasma\n  levels of bosentan and may decrease plasma levels of saquinavir/ritonavir.</span>", "ID": "9eb55828-8084-40da-9a8f-035ec8aed487", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Not studied.   Concomitant use of bosentan and saquinavir/ritonavir may increase plasma   levels of bosentan and may decrease plasma levels of saquinavir/ritonavir.", "ParentId": "d4cbdd55-b7bd-4346-b37a-67012f06f519"}, {"Element": "<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:46.2pt\" valign=\"top\" width=\"237\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Dose adjustment\n  of bosentan may be required. When bosentan is administered concomitantly with\n  saquinavir/ritonavir, the patient\u2019s tolerability of bosentan should be\n  monitored. Monitoring of the patient\u2019s HIV therapy is also recommended.</span></p>\n</td>", "ID": "06db6b19-d3c9-43a3-a91a-8b86b4c12311", "Styles": "width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:46.2pt", "Classes": "None", "Text": "  ", "ParentId": "197dd672-1a1a-4837-9158-2bd9babfb6fb"}, {"Element": "<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Dose adjustment\n  of bosentan may be required. When bosentan is administered concomitantly with\n  saquinavir/ritonavir, the patient\u2019s tolerability of bosentan should be\n  monitored. Monitoring of the patient\u2019s HIV therapy is also recommended.</span></p>", "ID": "e33c37ea-d3b5-4a79-8ddd-02dd16473c22", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['Paragraph']", "Text": "", "ParentId": "06db6b19-d3c9-43a3-a91a-8b86b4c12311"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Dose adjustment\n  of bosentan may be required. When bosentan is administered concomitantly with\n  saquinavir/ritonavir, the patient\u2019s tolerability of bosentan should be\n  monitored. Monitoring of the patient\u2019s HIV therapy is also recommended.</span>", "ID": "8dbf4837-df77-4e6b-8e63-9b271425dfdb", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Dose adjustment   of bosentan may be required. When bosentan is administered concomitantly with   saquinavir/ritonavir, the patient\u2019s tolerability of bosentan should be   monitored. Monitoring of the patient\u2019s HIV therapy is also recommended.", "ParentId": "e33c37ea-d3b5-4a79-8ddd-02dd16473c22"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"MsoNormal\"><b><i><u>Medicinal products that are substrates of\n  P-glycoprotein</u></i></b></p>\n<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Digitalis glycosides</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "eea4de98-db6e-4090-8626-b3362a8c09bd", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"MsoNormal\"><b><i><u>Medicinal products that are substrates of\n  P-glycoprotein</u></i></b></p>\n<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Digitalis glycosides</span></i></b></p>\n</td>", "ID": "aacfc809-f665-4df3-b36a-0cea31305f65", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "eea4de98-db6e-4090-8626-b3362a8c09bd"}, {"Element": "<p class=\"MsoNormal\"><b><i><u>Medicinal products that are substrates of\n  P-glycoprotein</u></i></b></p>", "ID": "bd826319-b449-4dc3-80ff-71c7611e3a64", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aacfc809-f665-4df3-b36a-0cea31305f65"}, {"Element": "<b><i><u>Medicinal products that are substrates of\n  P-glycoprotein</u></i></b>", "ID": "673be365-5e8f-4e44-9164-89d74d767da7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bd826319-b449-4dc3-80ff-71c7611e3a64"}, {"Element": "<i><u>Medicinal products that are substrates of\n  P-glycoprotein</u></i>", "ID": "37d1de5c-77f7-480e-ab2c-a571ec837dec", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "673be365-5e8f-4e44-9164-89d74d767da7"}, {"Element": "<u>Medicinal products that are substrates of\n  P-glycoprotein</u>", "ID": "6cb161ac-b772-4246-8582-003fb7488417", "Styles": "None", "Classes": "None", "Text": "Medicinal products that are substrates of   P-glycoprotein", "ParentId": "37d1de5c-77f7-480e-ab2c-a571ec837dec"}, {"Element": "<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Digitalis glycosides</span></i></b></p>", "ID": "da86cbdc-73f4-4ea4-b092-c0c1d54fea67", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "aacfc809-f665-4df3-b36a-0cea31305f65"}, {"Element": "<b><i><span lang=\"EN-GB\">Digitalis glycosides</span></i></b>", "ID": "8d30d05e-ee5e-47fb-aa9b-a328e21a4039", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "da86cbdc-73f4-4ea4-b092-c0c1d54fea67"}, {"Element": "<i><span lang=\"EN-GB\">Digitalis glycosides</span></i>", "ID": "1f6bc3ec-5b55-45e9-92a2-14913327910b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8d30d05e-ee5e-47fb-aa9b-a328e21a4039"}, {"Element": "<span lang=\"EN-GB\">Digitalis glycosides</span>", "ID": "5d7ac60e-7566-419e-b636-7a8648990e42", "Styles": "None", "Classes": "None", "Text": "Digitalis glycosides", "ParentId": "1f6bc3ec-5b55-45e9-92a2-14913327910b"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "2fe0e818-920b-44d2-9788-bafa61e4e6c6", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eea4de98-db6e-4090-8626-b3362a8c09bd"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "f513b050-ecdb-428c-84f6-da5f5f1601e3", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "2fe0e818-920b-44d2-9788-bafa61e4e6c6"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "405daace-b2be-4e9b-a872-e3128568fbea", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f513b050-ecdb-428c-84f6-da5f5f1601e3"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "de2e7118-1a61-4cdf-b5e1-1be38a0df788", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eea4de98-db6e-4090-8626-b3362a8c09bd"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "1a422f22-9a1e-4380-8054-460256cc62f9", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "de2e7118-1a61-4cdf-b5e1-1be38a0df788"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "9e5655c3-bc0a-493d-a73b-88b2469aed7b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1a422f22-9a1e-4380-8054-460256cc62f9"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Digoxin 0.5\u00a0mg<br/>\n  single dose</span></p>\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">(saquinavir/ritonavir 1000/100\u00a0mg\n  bid)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Digoxin AUC<sub>0-72</sub> \u2191 49%</p>\n<p class=\"Normal11pt0\">Digoxin C<sub>max </sub>\u2191 27%<br/>\n<span style=\"color:black\">Digoxin levels may differ over time. Large\n  increments of digoxin may be expected when saquinavir/ritonavir is introduced\n  in patients already treated with digoxin.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Caution should be exercised when\n  Invirase/ritonavir and digoxin are co-administered. The serum concentration\n  of digoxin should be monitored and a dose reduction of digoxin should be\n  considered if necessary.</span></p>\n</td>\n</tr>", "ID": "99227895-ea0f-4f8f-b993-dd679a6d35fd", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Digoxin 0.5\u00a0mg<br/>\n  single dose</span></p>\n<p class=\"Normal11pt0\"><span lang=\"PT-BR\">(saquinavir/ritonavir 1000/100\u00a0mg\n  bid)</span></p>\n</td>", "ID": "d0176d1b-8632-4a12-9704-3fcaf3b88f69", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "99227895-ea0f-4f8f-b993-dd679a6d35fd"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"PT-BR\">Digoxin 0.5\u00a0mg<br/>\n  single dose</span></p>", "ID": "afdfb6e6-66b7-471c-a8fb-e3a2dbd0b7ed", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "d0176d1b-8632-4a12-9704-3fcaf3b88f69"}, {"Element": "<span lang=\"PT-BR\">Digoxin 0.5\u00a0mg<br/>\n  single dose</span>", "ID": "c7763e80-1228-4341-85a7-b14d1ec470b5", "Styles": "None", "Classes": "None", "Text": "Digoxin 0.5\u00a0mg   single dose", "ParentId": "afdfb6e6-66b7-471c-a8fb-e3a2dbd0b7ed"}, {"Element": "<br/>", "ID": "2fd749ab-eeeb-48de-aea3-5cfe429f89ef", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c7763e80-1228-4341-85a7-b14d1ec470b5"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"PT-BR\">(saquinavir/ritonavir 1000/100\u00a0mg\n  bid)</span></p>", "ID": "9581ccf8-0258-4dcb-b030-cacc8144abe0", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "d0176d1b-8632-4a12-9704-3fcaf3b88f69"}, {"Element": "<span lang=\"PT-BR\">(saquinavir/ritonavir 1000/100\u00a0mg\n  bid)</span>", "ID": "48ae2834-fd0e-42b1-8b1e-47f25872b60f", "Styles": "None", "Classes": "None", "Text": "(saquinavir/ritonavir 1000/100\u00a0mg   bid)", "ParentId": "9581ccf8-0258-4dcb-b030-cacc8144abe0"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Digoxin AUC<sub>0-72</sub> \u2191 49%</p>\n<p class=\"Normal11pt0\">Digoxin C<sub>max </sub>\u2191 27%<br/>\n<span style=\"color:black\">Digoxin levels may differ over time. Large\n  increments of digoxin may be expected when saquinavir/ritonavir is introduced\n  in patients already treated with digoxin.</span></p>\n</td>", "ID": "1202e08b-a872-4523-aec4-6dee7735494e", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "99227895-ea0f-4f8f-b993-dd679a6d35fd"}, {"Element": "<p class=\"Normal11pt0\">Digoxin AUC<sub>0-72</sub> \u2191 49%</p>", "ID": "f5a2cc76-94b4-4819-8faa-39ad5534a701", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Digoxin AUC \u2191 49%", "ParentId": "1202e08b-a872-4523-aec4-6dee7735494e"}, {"Element": "<sub>0-72</sub>", "ID": "5b385960-a856-4af5-9f86-40994fd67d7d", "Styles": "None", "Classes": "None", "Text": "0-72", "ParentId": "f5a2cc76-94b4-4819-8faa-39ad5534a701"}, {"Element": "<p class=\"Normal11pt0\">Digoxin C<sub>max </sub>\u2191 27%<br/>\n<span style=\"color:black\">Digoxin levels may differ over time. Large\n  increments of digoxin may be expected when saquinavir/ritonavir is introduced\n  in patients already treated with digoxin.</span></p>", "ID": "cbc6b03c-df07-4f36-811e-960c3de3003b", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Digoxin C\u2191 27% ", "ParentId": "1202e08b-a872-4523-aec4-6dee7735494e"}, {"Element": "<sub>max </sub>", "ID": "78af9b36-82c0-4b2a-9bf7-5ca671a8c0b8", "Styles": "None", "Classes": "None", "Text": "max ", "ParentId": "cbc6b03c-df07-4f36-811e-960c3de3003b"}, {"Element": "<br/>", "ID": "751d9e27-a913-4a38-95ca-40ac099ce7cb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cbc6b03c-df07-4f36-811e-960c3de3003b"}, {"Element": "<span style=\"color:black\">Digoxin levels may differ over time. Large\n  increments of digoxin may be expected when saquinavir/ritonavir is introduced\n  in patients already treated with digoxin.</span>", "ID": "191d6acd-81f9-4def-ae24-d853d4a4fff9", "Styles": "color:black", "Classes": "None", "Text": "Digoxin levels may differ over time. Large   increments of digoxin may be expected when saquinavir/ritonavir is introduced   in patients already treated with digoxin.", "ParentId": "cbc6b03c-df07-4f36-811e-960c3de3003b"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Caution should be exercised when\n  Invirase/ritonavir and digoxin are co-administered. The serum concentration\n  of digoxin should be monitored and a dose reduction of digoxin should be\n  considered if necessary.</span></p>\n</td>", "ID": "a83177a6-1b87-48e9-a43c-01aae8d3a5a8", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "99227895-ea0f-4f8f-b993-dd679a6d35fd"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Caution should be exercised when\n  Invirase/ritonavir and digoxin are co-administered. The serum concentration\n  of digoxin should be monitored and a dose reduction of digoxin should be\n  considered if necessary.</span></p>", "ID": "75664824-8cae-4d28-8af4-590b6236f12a", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "a83177a6-1b87-48e9-a43c-01aae8d3a5a8"}, {"Element": "<span lang=\"EN-GB\">Caution should be exercised when\n  Invirase/ritonavir and digoxin are co-administered. The serum concentration\n  of digoxin should be monitored and a dose reduction of digoxin should be\n  considered if necessary.</span>", "ID": "c0dc4825-5c5c-47f4-b0df-c89333697696", "Styles": "None", "Classes": "None", "Text": "Caution should be exercised when   Invirase/ritonavir and digoxin are co-administered. The serum concentration   of digoxin should be monitored and a dose reduction of digoxin should be   considered if necessary.", "ParentId": "75664824-8cae-4d28-8af4-590b6236f12a"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Histamine\n  H<sub>2</sub>-receptor antagonist</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "59a8def9-d4f7-4571-8a8b-8b7641af9fa6", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Histamine\n  H<sub>2</sub>-receptor antagonist</span></i></b></p>\n</td>", "ID": "afc62c8b-000e-43c9-b126-2307f6bddffa", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "59a8def9-d4f7-4571-8a8b-8b7641af9fa6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Histamine\n  H<sub>2</sub>-receptor antagonist</span></i></b></p>", "ID": "bf90132f-adc2-48fc-9733-37b68c1fcb1d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "afc62c8b-000e-43c9-b126-2307f6bddffa"}, {"Element": "<b><i><span lang=\"EN-GB\">Histamine\n  H<sub>2</sub>-receptor antagonist</span></i></b>", "ID": "4c422eac-1a1c-4ea3-90cd-b25fbbeb971b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bf90132f-adc2-48fc-9733-37b68c1fcb1d"}, {"Element": "<i><span lang=\"EN-GB\">Histamine\n  H<sub>2</sub>-receptor antagonist</span></i>", "ID": "27c05153-5ac1-46e1-a890-c3bcf2b3b77b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4c422eac-1a1c-4ea3-90cd-b25fbbeb971b"}, {"Element": "<span lang=\"EN-GB\">Histamine\n  H<sub>2</sub>-receptor antagonist</span>", "ID": "cd8fbeb9-94c3-4620-b51e-89ef0023566d", "Styles": "None", "Classes": "None", "Text": "Histamine   H-receptor antagonist", "ParentId": "27c05153-5ac1-46e1-a890-c3bcf2b3b77b"}, {"Element": "<sub>2</sub>", "ID": "8761e655-64f1-4e04-860f-1cce9f6123f4", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "cd8fbeb9-94c3-4620-b51e-89ef0023566d"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "d125b362-27e7-4762-a611-870c9682dbf9", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "59a8def9-d4f7-4571-8a8b-8b7641af9fa6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "7c569b84-ca3c-453a-a2e5-3c3273e03bd4", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "d125b362-27e7-4762-a611-870c9682dbf9"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "92bada2d-3658-422b-8174-d4b77989af9d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7c569b84-ca3c-453a-a2e5-3c3273e03bd4"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "4dba090c-e2de-484d-b9bb-9273c5b6d871", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "59a8def9-d4f7-4571-8a8b-8b7641af9fa6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "eae681a0-6d59-40f0-89a6-49e0ce4ee5d6", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "4dba090c-e2de-484d-b9bb-9273c5b6d871"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "5e06a4ed-63d1-4ac5-bc29-6fcabd4d9611", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eae681a0-6d59-40f0-89a6-49e0ce4ee5d6"}, {"Element": "<tr style=\"height:76.4pt\">\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">-\u00a0 Ranitidine<u><br/>\n</u></span><span lang=\"PT-BR\">(</span><span lang=\"FR-CH\">saquinavir/ritonavir</span><span lang=\"PT-BR\">)</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">-\u00a0 Ranitidine<u><br/>\n</u></span><span lang=\"PT-BR\">(</span><span lang=\"FR-CH\">unboosted saquinavir</span><span lang=\"PT-BR\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Saquinavir\n  AUC </span>\u2191 <span lang=\"EN-GB\">67\u00a0% </span><span lang=\"PT-BR\"><br/>\n<br/>\n</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Increase not thought to be clinically relevant. No\n  dose adjustment of saquinavir recommended.</span></p>\n</td>\n</tr>", "ID": "861fb107-b89a-411a-adfc-814e10b36a9f", "Styles": "height:76.4pt", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">-\u00a0 Ranitidine<u><br/>\n</u></span><span lang=\"PT-BR\">(</span><span lang=\"FR-CH\">saquinavir/ritonavir</span><span lang=\"PT-BR\">)</span></p>\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">-\u00a0 Ranitidine<u><br/>\n</u></span><span lang=\"PT-BR\">(</span><span lang=\"FR-CH\">unboosted saquinavir</span><span lang=\"PT-BR\">)</span></p>\n</td>", "ID": "a5391f10-c3bd-4c89-98f5-a4c2ca510f15", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:76.4pt", "Classes": "None", "Text": "   ", "ParentId": "861fb107-b89a-411a-adfc-814e10b36a9f"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">-\u00a0 Ranitidine<u><br/>\n</u></span><span lang=\"PT-BR\">(</span><span lang=\"FR-CH\">saquinavir/ritonavir</span><span lang=\"PT-BR\">)</span></p>", "ID": "562403e9-3a4c-4a1f-bb30-362e26e257ff", "Styles": "margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "a5391f10-c3bd-4c89-98f5-a4c2ca510f15"}, {"Element": "<span lang=\"FR-CH\">-\u00a0 Ranitidine<u><br/>\n</u></span>", "ID": "8676da55-ae20-4aca-ad59-8f4c4af7b89e", "Styles": "None", "Classes": "None", "Text": "-\u00a0 Ranitidine", "ParentId": "562403e9-3a4c-4a1f-bb30-362e26e257ff"}, {"Element": "<u><br/>\n</u>", "ID": "6e139cc9-0aa6-436c-b1b2-b1030f1a9fa3", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "8676da55-ae20-4aca-ad59-8f4c4af7b89e"}, {"Element": "<br/>", "ID": "2cf0ac92-7ec6-4b1d-b6cb-d4d8451f4fb8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6e139cc9-0aa6-436c-b1b2-b1030f1a9fa3"}, {"Element": "<span lang=\"PT-BR\">(</span>", "ID": "10e2950a-3efb-47f1-881e-3b8dd132c47b", "Styles": "None", "Classes": "None", "Text": "(", "ParentId": "562403e9-3a4c-4a1f-bb30-362e26e257ff"}, {"Element": "<span lang=\"FR-CH\">saquinavir/ritonavir</span>", "ID": "62075d3f-e06f-4706-8957-48ae1144f8d2", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "562403e9-3a4c-4a1f-bb30-362e26e257ff"}, {"Element": "<span lang=\"PT-BR\">)</span>", "ID": "3044a8d4-7ee6-4d16-a1dd-fad5e531a3e5", "Styles": "None", "Classes": "None", "Text": ")", "ParentId": "562403e9-3a4c-4a1f-bb30-362e26e257ff"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid\"><span lang=\"FR-CH\">-\u00a0 Ranitidine<u><br/>\n</u></span><span lang=\"PT-BR\">(</span><span lang=\"FR-CH\">unboosted saquinavir</span><span lang=\"PT-BR\">)</span></p>", "ID": "af47627a-fe48-46ef-afd3-ada078ba5b27", "Styles": "margin-left:9.35pt;text-indent:-9.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "a5391f10-c3bd-4c89-98f5-a4c2ca510f15"}, {"Element": "<span lang=\"FR-CH\">-\u00a0 Ranitidine<u><br/>\n</u></span>", "ID": "e8ff5f91-0809-4653-8401-9b607953797d", "Styles": "None", "Classes": "None", "Text": "-\u00a0 Ranitidine", "ParentId": "af47627a-fe48-46ef-afd3-ada078ba5b27"}, {"Element": "<u><br/>\n</u>", "ID": "c8439f9f-c9c4-4215-a1d3-0efe825882da", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "e8ff5f91-0809-4653-8401-9b607953797d"}, {"Element": "<br/>", "ID": "8d97c355-10d5-4aa7-900d-93399523f1d9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c8439f9f-c9c4-4215-a1d3-0efe825882da"}, {"Element": "<span lang=\"PT-BR\">(</span>", "ID": "f41af902-cfbf-4c76-a33c-ef2830d8678c", "Styles": "None", "Classes": "None", "Text": "(", "ParentId": "af47627a-fe48-46ef-afd3-ada078ba5b27"}, {"Element": "<span lang=\"FR-CH\">unboosted saquinavir</span>", "ID": "60171496-ae34-41c1-9245-953efefb224c", "Styles": "None", "Classes": "None", "Text": "unboosted saquinavir", "ParentId": "af47627a-fe48-46ef-afd3-ada078ba5b27"}, {"Element": "<span lang=\"PT-BR\">)</span>", "ID": "fedfdcee-2bc4-4d51-a4be-03197f27cf0e", "Styles": "None", "Classes": "None", "Text": ")", "ParentId": "af47627a-fe48-46ef-afd3-ada078ba5b27"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Saquinavir\n  AUC </span>\u2191 <span lang=\"EN-GB\">67\u00a0% </span><span lang=\"PT-BR\"><br/>\n<br/>\n</span></p>\n</td>", "ID": "14e0a795-747e-44bb-8984-27161798916e", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt", "Classes": "None", "Text": "   ", "ParentId": "861fb107-b89a-411a-adfc-814e10b36a9f"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span></p>", "ID": "c456b697-2e71-4d3f-92b4-0d18e611214a", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "14e0a795-747e-44bb-8984-27161798916e"}, {"Element": "<span lang=\"EN-GB\">Interaction\n  with Invirase/ritonavir not studied.</span>", "ID": "0da384ed-413d-4966-9732-0b0daaa9fbc3", "Styles": "None", "Classes": "None", "Text": "Interaction   with Invirase/ritonavir not studied.", "ParentId": "c456b697-2e71-4d3f-92b4-0d18e611214a"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">Saquinavir\n  AUC </span>\u2191 <span lang=\"EN-GB\">67\u00a0% </span><span lang=\"PT-BR\"><br/>\n<br/>\n</span></p>", "ID": "44814698-1870-453b-863f-0eaa9a32740d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u2191 ", "ParentId": "14e0a795-747e-44bb-8984-27161798916e"}, {"Element": "<span lang=\"PT-BR\">Saquinavir\n  AUC </span>", "ID": "83f9bcd1-f124-429b-bd70-1b6b836f7eb2", "Styles": "None", "Classes": "None", "Text": "Saquinavir   AUC ", "ParentId": "44814698-1870-453b-863f-0eaa9a32740d"}, {"Element": "<span lang=\"EN-GB\">67\u00a0% </span>", "ID": "4866816a-ae22-4306-a824-9e7797a6465a", "Styles": "None", "Classes": "None", "Text": "67\u00a0% ", "ParentId": "44814698-1870-453b-863f-0eaa9a32740d"}, {"Element": "<span lang=\"PT-BR\"><br/>\n<br/>\n</span>", "ID": "4c218c60-0823-4d3c-b58a-b63045337400", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "44814698-1870-453b-863f-0eaa9a32740d"}, {"Element": "<br/>", "ID": "1e5ad979-f1c1-44d2-98ca-2a5ee5c6d6d5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4c218c60-0823-4d3c-b58a-b63045337400"}, {"Element": "<br/>", "ID": "d8540a0d-ba30-475f-8e34-532174f16cf6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4c218c60-0823-4d3c-b58a-b63045337400"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Increase not thought to be clinically relevant. No\n  dose adjustment of saquinavir recommended.</span></p>\n</td>", "ID": "ec1eb262-d4cc-4411-ad31-c394f94b9b72", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:76.4pt", "Classes": "None", "Text": "  ", "ParentId": "861fb107-b89a-411a-adfc-814e10b36a9f"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Increase not thought to be clinically relevant. No\n  dose adjustment of saquinavir recommended.</span></p>", "ID": "fced5cec-980b-4b38-b993-419f3e364859", "Styles": "margin-left:.45pt;text-indent:-.45pt;page-break-after:\n  avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "ec1eb262-d4cc-4411-ad31-c394f94b9b72"}, {"Element": "<span lang=\"EN-GB\">Increase not thought to be clinically relevant. No\n  dose adjustment of saquinavir recommended.</span>", "ID": "1fe866ce-65da-479e-a46a-f3c0cc007f54", "Styles": "None", "Classes": "None", "Text": "Increase not thought to be clinically relevant. No   dose adjustment of saquinavir recommended.", "ParentId": "fced5cec-980b-4b38-b993-419f3e364859"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">HMG-CoA\n  reductase inhibitors</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "30265e4f-0b72-4772-98b9-e5641c3d48bb", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">HMG-CoA\n  reductase inhibitors</span></i></b></p>\n</td>", "ID": "0af9434f-46dc-40fb-aeb6-535852f7120f", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "30265e4f-0b72-4772-98b9-e5641c3d48bb"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">HMG-CoA\n  reductase inhibitors</span></i></b></p>", "ID": "96e36b97-55c5-4f95-8354-2f80d93f8966", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "0af9434f-46dc-40fb-aeb6-535852f7120f"}, {"Element": "<b><i><span lang=\"EN-GB\">HMG-CoA\n  reductase inhibitors</span></i></b>", "ID": "a869a1a9-343c-4f66-b617-ec749d7f7940", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "96e36b97-55c5-4f95-8354-2f80d93f8966"}, {"Element": "<i><span lang=\"EN-GB\">HMG-CoA\n  reductase inhibitors</span></i>", "ID": "b1992f6e-c55b-436f-bd52-bcf52896e8c2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a869a1a9-343c-4f66-b617-ec749d7f7940"}, {"Element": "<span lang=\"EN-GB\">HMG-CoA\n  reductase inhibitors</span>", "ID": "122841af-8de3-440f-95d5-edaaab96c45c", "Styles": "None", "Classes": "None", "Text": "HMG-CoA   reductase inhibitors", "ParentId": "b1992f6e-c55b-436f-bd52-bcf52896e8c2"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "648b9807-e1c2-416f-bc44-9d4f8e591030", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "30265e4f-0b72-4772-98b9-e5641c3d48bb"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "005d3a3a-2912-4643-9ae3-51abdb3f9318", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "648b9807-e1c2-416f-bc44-9d4f8e591030"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "ac3b3dac-273a-43e6-8da5-780f67d83702", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "005d3a3a-2912-4643-9ae3-51abdb3f9318"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "a83181e5-f939-48b4-9992-085d85553ae3", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "30265e4f-0b72-4772-98b9-e5641c3d48bb"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "2ad5078c-4edd-411d-aac3-90b0bb63fbbe", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "a83181e5-f939-48b4-9992-085d85553ae3"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "f4495a8e-b68f-402c-a168-4f80e840dfe4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2ad5078c-4edd-411d-aac3-90b0bb63fbbe"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pravastatin<br/>\n  Fluvastatin<br/>\n  (</span><span lang=\"EN-GB\">saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Interaction not studied. Metabolism of\n  pravastatin and fluvastatin is not dependent on CYP3A4. </span>Interaction\n  via effects on transport proteins cannot be excluded.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Interaction unknown. If no alternative\n  treatment is available, use with careful monitoring (see section 4.4).</span></p>\n</td>\n</tr>", "ID": "33c106c0-e886-49c9-94f5-f405e4783d09", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pravastatin<br/>\n  Fluvastatin<br/>\n  (</span><span lang=\"EN-GB\">saquinavir/ritonavir)</span></p>\n</td>", "ID": "4a1a1251-f427-42f6-ace0-494577dad230", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "33c106c0-e886-49c9-94f5-f405e4783d09"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pravastatin<br/>\n  Fluvastatin<br/>\n  (</span><span lang=\"EN-GB\">saquinavir/ritonavir)</span></p>", "ID": "84abbae8-0c40-4fc5-872f-afed66518d36", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "4a1a1251-f427-42f6-ace0-494577dad230"}, {"Element": "<span lang=\"EN-GB\">Pravastatin<br/>\n  Fluvastatin<br/>\n  (</span>", "ID": "cecfe26b-f423-405e-a403-148a553d5ffb", "Styles": "None", "Classes": "None", "Text": "Pravastatin   Fluvastatin   (", "ParentId": "84abbae8-0c40-4fc5-872f-afed66518d36"}, {"Element": "<br/>", "ID": "051afd4a-68f1-4576-a37d-4de4bfea9b1c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cecfe26b-f423-405e-a403-148a553d5ffb"}, {"Element": "<br/>", "ID": "9a1b3665-34d2-44e2-9f21-a1497e336d85", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cecfe26b-f423-405e-a403-148a553d5ffb"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir)</span>", "ID": "ba412915-153c-493b-8c4e-1f6ea182c547", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir)", "ParentId": "84abbae8-0c40-4fc5-872f-afed66518d36"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Interaction not studied. Metabolism of\n  pravastatin and fluvastatin is not dependent on CYP3A4. </span>Interaction\n  via effects on transport proteins cannot be excluded.</p>\n</td>", "ID": "3945ff67-b68e-4996-a19d-1b85480c2e44", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "33c106c0-e886-49c9-94f5-f405e4783d09"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Interaction not studied. Metabolism of\n  pravastatin and fluvastatin is not dependent on CYP3A4. </span>Interaction\n  via effects on transport proteins cannot be excluded.</p>", "ID": "46be836a-61c4-4249-9fc5-53a6db85a1fd", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Interaction   via effects on transport proteins cannot be excluded.", "ParentId": "3945ff67-b68e-4996-a19d-1b85480c2e44"}, {"Element": "<span lang=\"EN-GB\">Interaction not studied. Metabolism of\n  pravastatin and fluvastatin is not dependent on CYP3A4. </span>", "ID": "d25847af-db3d-46ec-9944-a5a65ce813e0", "Styles": "None", "Classes": "None", "Text": "Interaction not studied. Metabolism of   pravastatin and fluvastatin is not dependent on CYP3A4. ", "ParentId": "46be836a-61c4-4249-9fc5-53a6db85a1fd"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Interaction unknown. If no alternative\n  treatment is available, use with careful monitoring (see section 4.4).</span></p>\n</td>", "ID": "6784e722-e89c-44c3-b077-c7b11ca90ae7", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "33c106c0-e886-49c9-94f5-f405e4783d09"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Interaction unknown. If no alternative\n  treatment is available, use with careful monitoring (see section 4.4).</span></p>", "ID": "9847b910-f4aa-415c-bbab-5e3aad0965b4", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "6784e722-e89c-44c3-b077-c7b11ca90ae7"}, {"Element": "<span lang=\"EN-GB\">Interaction unknown. If no alternative\n  treatment is available, use with careful monitoring (see section 4.4).</span>", "ID": "6a119d04-d545-4187-806e-8c7298613da1", "Styles": "None", "Classes": "None", "Text": "Interaction unknown. If no alternative   treatment is available, use with careful monitoring (see section 4.4).", "ParentId": "9847b910-f4aa-415c-bbab-5e3aad0965b4"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Simvastatin<br/>\n  Lovastatin<u><br/>\n</u>(</span><span lang=\"EN-GB\">saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Simvastatin</span> \u2191\u2191</p>\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Lovastatin </span>\u2191\u2191</p>\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Plasma concentrations highly dependent\n  on CYP3A4 metabolism. </span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Increased concentrations of simvastatin\n  and lovastatin have been associated with rhabdomyolysis. These medicinal\n  products are contraindicated for use with Invirase/ritonavir (see section\n  4.3).</span></p>\n</td>\n</tr>", "ID": "a2c646b5-0f1b-40a5-9378-7b6d9c5da36d", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Simvastatin<br/>\n  Lovastatin<u><br/>\n</u>(</span><span lang=\"EN-GB\">saquinavir/ritonavir)</span></p>\n</td>", "ID": "36050e2f-cb60-41ff-b7a1-a8f86ff1bbee", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a2c646b5-0f1b-40a5-9378-7b6d9c5da36d"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Simvastatin<br/>\n  Lovastatin<u><br/>\n</u>(</span><span lang=\"EN-GB\">saquinavir/ritonavir)</span></p>", "ID": "901040e0-5764-4b1c-bebf-b68dad998f59", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "36050e2f-cb60-41ff-b7a1-a8f86ff1bbee"}, {"Element": "<span lang=\"EN-GB\">Simvastatin<br/>\n  Lovastatin<u><br/>\n</u>(</span>", "ID": "78058eac-926c-41a4-a93d-da5ef7df2116", "Styles": "None", "Classes": "None", "Text": "Simvastatin   Lovastatin(", "ParentId": "901040e0-5764-4b1c-bebf-b68dad998f59"}, {"Element": "<br/>", "ID": "281af2f7-85bd-4f02-a7b8-12a64fd6e9a9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "78058eac-926c-41a4-a93d-da5ef7df2116"}, {"Element": "<u><br/>\n</u>", "ID": "0f7eb83d-0570-4a43-9b58-a6e1fa9c25a4", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "78058eac-926c-41a4-a93d-da5ef7df2116"}, {"Element": "<br/>", "ID": "3a109569-242e-4a0d-bb20-6e4d7d9de4b0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0f7eb83d-0570-4a43-9b58-a6e1fa9c25a4"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir)</span>", "ID": "f5e0048a-d237-43bc-883d-ca7cd60eddc7", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir)", "ParentId": "901040e0-5764-4b1c-bebf-b68dad998f59"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Simvastatin</span> \u2191\u2191</p>\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Lovastatin </span>\u2191\u2191</p>\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Plasma concentrations highly dependent\n  on CYP3A4 metabolism. </span></p>\n</td>", "ID": "2e15574b-6c49-43ac-b3c4-2aeada128187", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "a2c646b5-0f1b-40a5-9378-7b6d9c5da36d"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Simvastatin</span> \u2191\u2191</p>", "ID": "18117ae6-06f3-41c2-8925-e763e9f916f9", "Styles": "None", "Classes": "['Normal11pt0']", "Text": " \u2191\u2191", "ParentId": "2e15574b-6c49-43ac-b3c4-2aeada128187"}, {"Element": "<span lang=\"EN-GB\">Simvastatin</span>", "ID": "04518b6e-64de-4c8c-9864-c79ea1e0eb2b", "Styles": "None", "Classes": "None", "Text": "Simvastatin", "ParentId": "18117ae6-06f3-41c2-8925-e763e9f916f9"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Lovastatin </span>\u2191\u2191</p>", "ID": "7f448d6e-c41c-4576-b5bf-ca0429a5fb37", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "\u2191\u2191", "ParentId": "2e15574b-6c49-43ac-b3c4-2aeada128187"}, {"Element": "<span lang=\"EN-GB\">Lovastatin </span>", "ID": "629f8b6d-8e2b-4244-91b5-fb300c79441b", "Styles": "None", "Classes": "None", "Text": "Lovastatin ", "ParentId": "7f448d6e-c41c-4576-b5bf-ca0429a5fb37"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Plasma concentrations highly dependent\n  on CYP3A4 metabolism. </span></p>", "ID": "2a5475bf-6fde-4408-b6ec-93bd57b7d79b", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "2e15574b-6c49-43ac-b3c4-2aeada128187"}, {"Element": "<span lang=\"EN-GB\">Plasma concentrations highly dependent\n  on CYP3A4 metabolism. </span>", "ID": "786427c3-970f-4eaf-b3a2-0e6723adeb63", "Styles": "None", "Classes": "None", "Text": "Plasma concentrations highly dependent   on CYP3A4 metabolism. ", "ParentId": "2a5475bf-6fde-4408-b6ec-93bd57b7d79b"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Increased concentrations of simvastatin\n  and lovastatin have been associated with rhabdomyolysis. These medicinal\n  products are contraindicated for use with Invirase/ritonavir (see section\n  4.3).</span></p>\n</td>", "ID": "8249d4b0-755d-4638-a508-82dcd7f7b303", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a2c646b5-0f1b-40a5-9378-7b6d9c5da36d"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Increased concentrations of simvastatin\n  and lovastatin have been associated with rhabdomyolysis. These medicinal\n  products are contraindicated for use with Invirase/ritonavir (see section\n  4.3).</span></p>", "ID": "6ed6cdfb-c693-410e-92a8-391d1facc2d8", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "8249d4b0-755d-4638-a508-82dcd7f7b303"}, {"Element": "<span lang=\"EN-GB\">Increased concentrations of simvastatin\n  and lovastatin have been associated with rhabdomyolysis. These medicinal\n  products are contraindicated for use with Invirase/ritonavir (see section\n  4.3).</span>", "ID": "d2680a51-37cd-4d34-a0d9-5f2d0389722c", "Styles": "None", "Classes": "None", "Text": "Increased concentrations of simvastatin   and lovastatin have been associated with rhabdomyolysis. These medicinal   products are contraindicated for use with Invirase/ritonavir (see section   4.3).", "ParentId": "6ed6cdfb-c693-410e-92a8-391d1facc2d8"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Atorvastatin</span><span lang=\"EN-GB\"><br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Atorvastatin</span><span lang=\"EN-GB\"> is\n  less dependent on CYP3A4 for metabolism.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">When used with Invirase/ritonavir, the\n  lowest possible dose of atorvastatin should be administered and the patient\n  should be carefully monitored for signs/symptoms of myopathy (muscle\n  weakness, muscle pain, rising plasma creatinine kinase, see section 4.4).</span></p>\n</td>\n</tr>", "ID": "46b109fb-5fb5-42f3-acc0-72726d9c4381", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Atorvastatin</span><span lang=\"EN-GB\"><br/>\n  (saquinavir/ritonavir)</span></p>\n</td>", "ID": "099e8d5b-e83f-4a4a-86ff-f9258ee37fab", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "46b109fb-5fb5-42f3-acc0-72726d9c4381"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Atorvastatin</span><span lang=\"EN-GB\"><br/>\n  (saquinavir/ritonavir)</span></p>", "ID": "708bb9dc-8b03-4acf-b6cf-c22d6e9eaebe", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "099e8d5b-e83f-4a4a-86ff-f9258ee37fab"}, {"Element": "<span lang=\"EN-GB\">Atorvastatin</span>", "ID": "07458e7f-fbd0-4851-a420-e98ad5a510ef", "Styles": "None", "Classes": "None", "Text": "Atorvastatin", "ParentId": "708bb9dc-8b03-4acf-b6cf-c22d6e9eaebe"}, {"Element": "<span lang=\"EN-GB\"><br/>\n  (saquinavir/ritonavir)</span>", "ID": "a8ef4489-d454-4938-bfe0-acf885d942c3", "Styles": "None", "Classes": "None", "Text": "   (saquinavir/ritonavir)", "ParentId": "708bb9dc-8b03-4acf-b6cf-c22d6e9eaebe"}, {"Element": "<br/>", "ID": "11fa7664-8c7b-4e61-a79d-f00a1692eba5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a8ef4489-d454-4938-bfe0-acf885d942c3"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Atorvastatin</span><span lang=\"EN-GB\"> is\n  less dependent on CYP3A4 for metabolism.</span></p>\n</td>", "ID": "83b05582-012c-421a-8c9f-a29c5eb97b7a", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "46b109fb-5fb5-42f3-acc0-72726d9c4381"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Atorvastatin</span><span lang=\"EN-GB\"> is\n  less dependent on CYP3A4 for metabolism.</span></p>", "ID": "a4e481aa-e950-4049-a208-075363e92421", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "83b05582-012c-421a-8c9f-a29c5eb97b7a"}, {"Element": "<span lang=\"EN-GB\">Atorvastatin</span>", "ID": "1a5e6f44-e41a-4756-bf3d-309fef7e1c87", "Styles": "None", "Classes": "None", "Text": "Atorvastatin", "ParentId": "a4e481aa-e950-4049-a208-075363e92421"}, {"Element": "<span lang=\"EN-GB\"> is\n  less dependent on CYP3A4 for metabolism.</span>", "ID": "0fcfb422-3e14-471c-b7a4-dfd0bc4f61d2", "Styles": "None", "Classes": "None", "Text": " is   less dependent on CYP3A4 for metabolism.", "ParentId": "a4e481aa-e950-4049-a208-075363e92421"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">When used with Invirase/ritonavir, the\n  lowest possible dose of atorvastatin should be administered and the patient\n  should be carefully monitored for signs/symptoms of myopathy (muscle\n  weakness, muscle pain, rising plasma creatinine kinase, see section 4.4).</span></p>\n</td>", "ID": "b65f3b1e-685f-4785-8465-9c48f9397856", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "46b109fb-5fb5-42f3-acc0-72726d9c4381"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">When used with Invirase/ritonavir, the\n  lowest possible dose of atorvastatin should be administered and the patient\n  should be carefully monitored for signs/symptoms of myopathy (muscle\n  weakness, muscle pain, rising plasma creatinine kinase, see section 4.4).</span></p>", "ID": "2f5e161e-6c59-4026-a64d-72be7dd38b72", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "b65f3b1e-685f-4785-8465-9c48f9397856"}, {"Element": "<span lang=\"EN-GB\">When used with Invirase/ritonavir, the\n  lowest possible dose of atorvastatin should be administered and the patient\n  should be carefully monitored for signs/symptoms of myopathy (muscle\n  weakness, muscle pain, rising plasma creatinine kinase, see section 4.4).</span>", "ID": "7c9134dd-8e4f-4006-be76-f94262263d29", "Styles": "None", "Classes": "None", "Text": "When used with Invirase/ritonavir, the   lowest possible dose of atorvastatin should be administered and the patient   should be carefully monitored for signs/symptoms of myopathy (muscle   weakness, muscle pain, rising plasma creatinine kinase, see section 4.4).", "ParentId": "2f5e161e-6c59-4026-a64d-72be7dd38b72"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Immunosuppressants</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "1eada64b-b048-487c-a824-98360907bc5d", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Immunosuppressants</span></i></b></p>\n</td>", "ID": "de8c2ea9-c34f-410e-af7d-b4726bedb586", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1eada64b-b048-487c-a824-98360907bc5d"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Immunosuppressants</span></i></b></p>", "ID": "d6371c8a-c923-40fd-920c-ba7b3dc80af8", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "de8c2ea9-c34f-410e-af7d-b4726bedb586"}, {"Element": "<b><i><span lang=\"EN-GB\">Immunosuppressants</span></i></b>", "ID": "147330f4-0043-4fd1-b03f-a617ac7b0eae", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d6371c8a-c923-40fd-920c-ba7b3dc80af8"}, {"Element": "<i><span lang=\"EN-GB\">Immunosuppressants</span></i>", "ID": "3887193c-ed3f-4230-a757-0d936f05b171", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "147330f4-0043-4fd1-b03f-a617ac7b0eae"}, {"Element": "<span lang=\"EN-GB\">Immunosuppressants</span>", "ID": "99a6239a-cf9c-4adc-a4c5-403a37404135", "Styles": "None", "Classes": "None", "Text": "Immunosuppressants", "ParentId": "3887193c-ed3f-4230-a757-0d936f05b171"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "dc7f7c03-649f-46fd-9fe5-67d9cbf01d17", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1eada64b-b048-487c-a824-98360907bc5d"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "24e0674a-ab77-47d6-9f03-30e1eb37c186", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "dc7f7c03-649f-46fd-9fe5-67d9cbf01d17"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "26fce742-ab22-4044-8639-32c3336612ae", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "24e0674a-ab77-47d6-9f03-30e1eb37c186"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "8fb0eae9-7887-4979-ad24-c52e7f55df32", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1eada64b-b048-487c-a824-98360907bc5d"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "a7dc96c1-8e24-410d-bdbf-9ee279a3e81e", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "8fb0eae9-7887-4979-ad24-c52e7f55df32"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "f3c77411-a6b7-4d6c-8a56-950b5af8930a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a7dc96c1-8e24-410d-bdbf-9ee279a3e81e"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT\">Tacrolimus</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Tacrolimus is a substrate of CYP3A4 and P-glycoprotein.\n  Concomitant use of tacrolimus and saquinavir/ritonavir is expected to\n  increase plasma levels of tacrolimus.</p>\n<p class=\"Normal11pt0\">Tacrolimus may be associated with torsades de pointes<span lang=\"EN-GB\">.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Contraindicated in combination with\n  Invirase/ritonavir due to the potential for life threatening cardiac\n  arrhythmia (see sections 4.3 and 4.4).</span></p>\n</td>\n</tr>", "ID": "4334eeec-d0ee-471e-8d4b-c58ec077290b", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"PT\">Tacrolimus</span></p>\n</td>", "ID": "5bf1695c-87cd-4731-9255-e30e8140ae57", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4334eeec-d0ee-471e-8d4b-c58ec077290b"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"PT\">Tacrolimus</span></p>", "ID": "6323e88e-0408-4d61-9c8b-04f4a3942b3e", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "5bf1695c-87cd-4731-9255-e30e8140ae57"}, {"Element": "<span lang=\"PT\">Tacrolimus</span>", "ID": "88a41bae-aec0-48f5-837e-1bd756196dfd", "Styles": "None", "Classes": "None", "Text": "Tacrolimus", "ParentId": "6323e88e-0408-4d61-9c8b-04f4a3942b3e"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Tacrolimus is a substrate of CYP3A4 and P-glycoprotein.\n  Concomitant use of tacrolimus and saquinavir/ritonavir is expected to\n  increase plasma levels of tacrolimus.</p>\n<p class=\"Normal11pt0\">Tacrolimus may be associated with torsades de pointes<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "e4f9cd45-9617-4308-912c-b7df02f4ac91", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "4334eeec-d0ee-471e-8d4b-c58ec077290b"}, {"Element": "<p class=\"Normal11pt0\">Tacrolimus is a substrate of CYP3A4 and P-glycoprotein.\n  Concomitant use of tacrolimus and saquinavir/ritonavir is expected to\n  increase plasma levels of tacrolimus.</p>", "ID": "14f2c269-1988-4084-a4b2-216e11643260", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Tacrolimus is a substrate of CYP3A4 and P-glycoprotein.   Concomitant use of tacrolimus and saquinavir/ritonavir is expected to   increase plasma levels of tacrolimus.", "ParentId": "e4f9cd45-9617-4308-912c-b7df02f4ac91"}, {"Element": "<p class=\"Normal11pt0\">Tacrolimus may be associated with torsades de pointes<span lang=\"EN-GB\">.</span></p>", "ID": "bfd9bc6e-3f53-4f4f-ad38-8e23f7f03bbb", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Tacrolimus may be associated with torsades de pointes", "ParentId": "e4f9cd45-9617-4308-912c-b7df02f4ac91"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "73f83597-3084-4ab4-bb1b-c6beb7f00541", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "bfd9bc6e-3f53-4f4f-ad38-8e23f7f03bbb"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Contraindicated in combination with\n  Invirase/ritonavir due to the potential for life threatening cardiac\n  arrhythmia (see sections 4.3 and 4.4).</span></p>\n</td>", "ID": "988d31ff-254c-4344-bc18-8d67401e44d0", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4334eeec-d0ee-471e-8d4b-c58ec077290b"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Contraindicated in combination with\n  Invirase/ritonavir due to the potential for life threatening cardiac\n  arrhythmia (see sections 4.3 and 4.4).</span></p>", "ID": "976979eb-da9b-4a87-9d4e-db142b3faba3", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "988d31ff-254c-4344-bc18-8d67401e44d0"}, {"Element": "<span lang=\"EN-GB\">Contraindicated in combination with\n  Invirase/ritonavir due to the potential for life threatening cardiac\n  arrhythmia (see sections 4.3 and 4.4).</span>", "ID": "43a270ac-2781-4028-9483-bb65cd01dd09", "Styles": "None", "Classes": "None", "Text": "Contraindicated in combination with   Invirase/ritonavir due to the potential for life threatening cardiac   arrhythmia (see sections 4.3 and 4.4).", "ParentId": "976979eb-da9b-4a87-9d4e-db142b3faba3"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Ciclosporin<br/>\n<br/>\n  Rapamycin<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of these medicinal\n  products increase several fold when co-administered with Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Careful therapeutic drug monitoring is\n  necessary for these immunosuppressants when co-administered with\n  Invirase/ritonavir.</span></p>\n</td>\n</tr>", "ID": "426510a5-bf44-49f3-84a5-8985db2f8a58", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Ciclosporin<br/>\n<br/>\n  Rapamycin<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>", "ID": "cbdaef54-e227-48f6-b1eb-322d879d4f6a", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "426510a5-bf44-49f3-84a5-8985db2f8a58"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">Ciclosporin<br/>\n<br/>\n  Rapamycin<br/>\n  (saquinavir/ritonavir)</span></p>", "ID": "6e08f764-7e21-4a81-bbba-c204f9b2676d", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "cbdaef54-e227-48f6-b1eb-322d879d4f6a"}, {"Element": "<span lang=\"IT\">Ciclosporin<br/>\n<br/>\n  Rapamycin<br/>\n  (saquinavir/ritonavir)</span>", "ID": "4674f7a8-0cd2-415b-bdcf-08e1b76a2a5b", "Styles": "None", "Classes": "None", "Text": "Ciclosporin    Rapamycin   (saquinavir/ritonavir)", "ParentId": "6e08f764-7e21-4a81-bbba-c204f9b2676d"}, {"Element": "<br/>", "ID": "ea50830f-9df4-4586-982c-611e8bee99b9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4674f7a8-0cd2-415b-bdcf-08e1b76a2a5b"}, {"Element": "<br/>", "ID": "14af8d5a-ddf5-4f87-8dc7-e0301050190d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4674f7a8-0cd2-415b-bdcf-08e1b76a2a5b"}, {"Element": "<br/>", "ID": "3c68c196-b3d0-4691-974d-cb0b739339f0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4674f7a8-0cd2-415b-bdcf-08e1b76a2a5b"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of these medicinal\n  products increase several fold when co-administered with Invirase/ritonavir.</span></p>\n</td>", "ID": "313cdea1-5df3-47d4-b7f7-122c4172260b", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "426510a5-bf44-49f3-84a5-8985db2f8a58"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of these medicinal\n  products increase several fold when co-administered with Invirase/ritonavir.</span></p>", "ID": "d08733d2-d2fd-4a60-9616-bfecd5517ba8", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "313cdea1-5df3-47d4-b7f7-122c4172260b"}, {"Element": "<span lang=\"EN-GB\">Concentrations of these medicinal\n  products increase several fold when co-administered with Invirase/ritonavir.</span>", "ID": "54d9018f-6055-4433-b086-414acdc29239", "Styles": "None", "Classes": "None", "Text": "Concentrations of these medicinal   products increase several fold when co-administered with Invirase/ritonavir.", "ParentId": "d08733d2-d2fd-4a60-9616-bfecd5517ba8"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Careful therapeutic drug monitoring is\n  necessary for these immunosuppressants when co-administered with\n  Invirase/ritonavir.</span></p>\n</td>", "ID": "9507016c-3b0f-42af-86c2-2ee402ed9c3b", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "426510a5-bf44-49f3-84a5-8985db2f8a58"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Careful therapeutic drug monitoring is\n  necessary for these immunosuppressants when co-administered with\n  Invirase/ritonavir.</span></p>", "ID": "04ccc27c-58ad-4b7f-b01a-bd6d9c3d62fc", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "9507016c-3b0f-42af-86c2-2ee402ed9c3b"}, {"Element": "<span lang=\"EN-GB\">Careful therapeutic drug monitoring is\n  necessary for these immunosuppressants when co-administered with\n  Invirase/ritonavir.</span>", "ID": "5852998f-ea34-4b8e-b122-e2f0e7cc85c2", "Styles": "None", "Classes": "None", "Text": "Careful therapeutic drug monitoring is   necessary for these immunosuppressants when co-administered with   Invirase/ritonavir.", "ParentId": "04ccc27c-58ad-4b7f-b01a-bd6d9c3d62fc"}, {"Element": "<tr style=\"height:12.9pt\">\n<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Long-acting\n  beta2-adrenergic agonist</span></i></b></p>\n</td>\n</tr>", "ID": "55b42a5c-d7e8-473f-bdff-24ded51cd728", "Styles": "height:12.9pt", "Classes": "None", "Text": "  ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"7\" style=\"width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt\" valign=\"top\" width=\"650\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Long-acting\n  beta2-adrenergic agonist</span></i></b></p>\n</td>", "ID": "e9f8a632-a7fa-42d0-9c08-e30c01b0ad05", "Styles": "width:487.6pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt", "Classes": "None", "Text": "  ", "ParentId": "55b42a5c-d7e8-473f-bdff-24ded51cd728"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Long-acting\n  beta2-adrenergic agonist</span></i></b></p>", "ID": "71e2db3b-569e-4e8b-920a-6e4bbcfe49f2", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "e9f8a632-a7fa-42d0-9c08-e30c01b0ad05"}, {"Element": "<b><i><span lang=\"EN-GB\">Long-acting\n  beta2-adrenergic agonist</span></i></b>", "ID": "f622a1e0-a0c0-416a-a3dc-db80780b5439", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "71e2db3b-569e-4e8b-920a-6e4bbcfe49f2"}, {"Element": "<i><span lang=\"EN-GB\">Long-acting\n  beta2-adrenergic agonist</span></i>", "ID": "d9817f4d-c991-4502-9f90-2b378226df14", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f622a1e0-a0c0-416a-a3dc-db80780b5439"}, {"Element": "<span lang=\"EN-GB\">Long-acting\n  beta2-adrenergic agonist</span>", "ID": "92001839-bef7-4f45-96c7-159c2e61426d", "Styles": "None", "Classes": "None", "Text": "Long-acting   beta2-adrenergic agonist", "ParentId": "d9817f4d-c991-4502-9f90-2b378226df14"}, {"Element": "<tr style=\"height:89.85pt\">\n<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:89.85pt\" valign=\"top\" width=\"177\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Salmeterol</span></p>\n</td>\n<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:89.85pt\" valign=\"top\" width=\"236\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Concomitant use\n  of salmeterol and saquinavir/ritonavir is expected to increase plasma levels\n  of salmeterol.</span></p>\n</td>\n<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:89.85pt\" valign=\"top\" width=\"237\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Combination not\n  recommended as may result in increased risk of cardiovascular adverse events\n  associated with salmeterol, including QT prolongation, palpitations, and\n  sinus tachycardia (see section 4,4). </span></p>\n</td>\n</tr>", "ID": "69436d6d-73af-4797-84e8-13ce49675690", "Styles": "height:89.85pt", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"2\" style=\"width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:89.85pt\" valign=\"top\" width=\"177\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Salmeterol</span></p>\n</td>", "ID": "a956280b-d475-4232-ba71-5694502e4401", "Styles": "width:133.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:89.85pt", "Classes": "None", "Text": "  ", "ParentId": "69436d6d-73af-4797-84e8-13ce49675690"}, {"Element": "<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Salmeterol</span></p>", "ID": "62a0ef84-7f4a-4cfe-b7b8-565a3c284d79", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['Paragraph']", "Text": "", "ParentId": "a956280b-d475-4232-ba71-5694502e4401"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Salmeterol</span>", "ID": "cd223038-5634-4313-baa0-9b6ee0ff020c", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Salmeterol", "ParentId": "62a0ef84-7f4a-4cfe-b7b8-565a3c284d79"}, {"Element": "<td style=\"width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:89.85pt\" valign=\"top\" width=\"236\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Concomitant use\n  of salmeterol and saquinavir/ritonavir is expected to increase plasma levels\n  of salmeterol.</span></p>\n</td>", "ID": "f5f76983-1895-4569-b8c3-4099871cc885", "Styles": "width:177.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:89.85pt", "Classes": "None", "Text": "  ", "ParentId": "69436d6d-73af-4797-84e8-13ce49675690"}, {"Element": "<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Concomitant use\n  of salmeterol and saquinavir/ritonavir is expected to increase plasma levels\n  of salmeterol.</span></p>", "ID": "8bf0c08e-0873-4076-849a-6f860cb16256", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['Paragraph']", "Text": "", "ParentId": "f5f76983-1895-4569-b8c3-4099871cc885"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Concomitant use\n  of salmeterol and saquinavir/ritonavir is expected to increase plasma levels\n  of salmeterol.</span>", "ID": "641523f5-37c2-40a0-8420-25928a50c99f", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Concomitant use   of salmeterol and saquinavir/ritonavir is expected to increase plasma levels   of salmeterol.", "ParentId": "8bf0c08e-0873-4076-849a-6f860cb16256"}, {"Element": "<td colspan=\"4\" style=\"width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:89.85pt\" valign=\"top\" width=\"237\">\n<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Combination not\n  recommended as may result in increased risk of cardiovascular adverse events\n  associated with salmeterol, including QT prolongation, palpitations, and\n  sinus tachycardia (see section 4,4). </span></p>\n</td>", "ID": "7e3e5351-83ed-4773-93ca-e6b7e4db58a6", "Styles": "width:177.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:89.85pt", "Classes": "None", "Text": "  ", "ParentId": "69436d6d-73af-4797-84e8-13ce49675690"}, {"Element": "<p class=\"Paragraph\" style=\"line-height:normal;page-break-after:avoid\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Combination not\n  recommended as may result in increased risk of cardiovascular adverse events\n  associated with salmeterol, including QT prolongation, palpitations, and\n  sinus tachycardia (see section 4,4). </span></p>", "ID": "635975b5-121b-4907-9bc3-b63420527981", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['Paragraph']", "Text": "", "ParentId": "7e3e5351-83ed-4773-93ca-e6b7e4db58a6"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Combination not\n  recommended as may result in increased risk of cardiovascular adverse events\n  associated with salmeterol, including QT prolongation, palpitations, and\n  sinus tachycardia (see section 4,4). </span>", "ID": "b905bafe-6f27-4dc9-af2b-5a079a1c6c65", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Combination not   recommended as may result in increased risk of cardiovascular adverse events   associated with salmeterol, including QT prolongation, palpitations, and   sinus tachycardia (see section 4,4). ", "ParentId": "635975b5-121b-4907-9bc3-b63420527981"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Narcotic\n  analgesics</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "a52deb51-8388-4bad-a408-0fc501e86013", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Narcotic\n  analgesics</span></i></b></p>\n</td>", "ID": "7d62c027-1f7a-4757-8b49-e2efe1e25fba", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a52deb51-8388-4bad-a408-0fc501e86013"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Narcotic\n  analgesics</span></i></b></p>", "ID": "ddc73056-904c-4444-8b08-c00f88047d96", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "7d62c027-1f7a-4757-8b49-e2efe1e25fba"}, {"Element": "<b><i><span lang=\"EN-GB\">Narcotic\n  analgesics</span></i></b>", "ID": "905b4097-c82d-438e-b305-78b56ab79e9b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ddc73056-904c-4444-8b08-c00f88047d96"}, {"Element": "<i><span lang=\"EN-GB\">Narcotic\n  analgesics</span></i>", "ID": "69ebdb54-0590-4dbe-8dd6-3bfbdfac5a46", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "905b4097-c82d-438e-b305-78b56ab79e9b"}, {"Element": "<span lang=\"EN-GB\">Narcotic\n  analgesics</span>", "ID": "4ef1eff9-c792-44ad-9ce5-a83eaaf375a4", "Styles": "None", "Classes": "None", "Text": "Narcotic   analgesics", "ParentId": "69ebdb54-0590-4dbe-8dd6-3bfbdfac5a46"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "3d6e3afe-6029-4cef-b1c8-1a1fd32aabf0", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a52deb51-8388-4bad-a408-0fc501e86013"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "2fea1335-5382-4b42-b8db-528f95d3ca02", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "3d6e3afe-6029-4cef-b1c8-1a1fd32aabf0"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "e467ad5f-e7e6-4df9-9c57-ce2b7870f364", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2fea1335-5382-4b42-b8db-528f95d3ca02"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "e5044ab8-76ba-46b3-bd0c-191bf9323510", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a52deb51-8388-4bad-a408-0fc501e86013"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "bfe6541c-db63-4a9a-9054-8dd478cb0f90", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "e5044ab8-76ba-46b3-bd0c-191bf9323510"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "6b091149-8fce-4a92-945e-6643fe3060ba", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bfe6541c-db63-4a9a-9054-8dd478cb0f90"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Methadone </span><span lang=\"IT\">60-120\u00a0mg qd</span><span lang=\"IT\"><br/>\n  (saquinavir/ritonavir </span><span lang=\"IT\">1000/100\u00a0mg bid</span><span lang=\"IT\">)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Methadone AUC <span style=\"font-family:Symbol\">\u00af</span> <span lang=\"EN-GB\">19\u00a0%<br/>\n  (90\u00a0% CI 9\u00a0% to 29\u00a0%)<br/>\n  None of the 12 patients experienced withdrawal symptoms.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "a0bd2501-bcf4-44dc-8d3a-70804573ac0b", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Methadone </span><span lang=\"IT\">60-120\u00a0mg qd</span><span lang=\"IT\"><br/>\n  (saquinavir/ritonavir </span><span lang=\"IT\">1000/100\u00a0mg bid</span><span lang=\"IT\">)</span></p>\n</td>", "ID": "992e6e66-1b74-4738-9129-41ebb5d2d2a5", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a0bd2501-bcf4-44dc-8d3a-70804573ac0b"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Methadone </span><span lang=\"IT\">60-120\u00a0mg qd</span><span lang=\"IT\"><br/>\n  (saquinavir/ritonavir </span><span lang=\"IT\">1000/100\u00a0mg bid</span><span lang=\"IT\">)</span></p>", "ID": "806f61cf-cc1a-4c0b-8881-6bcb07e708a5", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "992e6e66-1b74-4738-9129-41ebb5d2d2a5"}, {"Element": "<span lang=\"IT\">Methadone </span>", "ID": "ea18dec5-8e4a-465d-8953-600f53f0e75f", "Styles": "None", "Classes": "None", "Text": "Methadone ", "ParentId": "806f61cf-cc1a-4c0b-8881-6bcb07e708a5"}, {"Element": "<span lang=\"IT\">60-120\u00a0mg qd</span>", "ID": "420b6b1a-dc2d-48ed-a577-e34064b0f6c1", "Styles": "None", "Classes": "None", "Text": "60-120\u00a0mg qd", "ParentId": "806f61cf-cc1a-4c0b-8881-6bcb07e708a5"}, {"Element": "<span lang=\"IT\"><br/>\n  (saquinavir/ritonavir </span>", "ID": "8dd19cb5-a133-4c62-b776-0a7dc2c485b1", "Styles": "None", "Classes": "None", "Text": "   (saquinavir/ritonavir ", "ParentId": "806f61cf-cc1a-4c0b-8881-6bcb07e708a5"}, {"Element": "<br/>", "ID": "0cd01540-5bbf-4d39-bc4d-c1fadc764316", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8dd19cb5-a133-4c62-b776-0a7dc2c485b1"}, {"Element": "<span lang=\"IT\">1000/100\u00a0mg bid</span>", "ID": "2830ee60-9eb0-4b82-a01a-2f95ec9e9da6", "Styles": "None", "Classes": "None", "Text": "1000/100\u00a0mg bid", "ParentId": "806f61cf-cc1a-4c0b-8881-6bcb07e708a5"}, {"Element": "<span lang=\"IT\">)</span>", "ID": "3b9b2df6-8393-4995-a457-85564f3d66e2", "Styles": "None", "Classes": "None", "Text": ")", "ParentId": "806f61cf-cc1a-4c0b-8881-6bcb07e708a5"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Methadone AUC <span style=\"font-family:Symbol\">\u00af</span> <span lang=\"EN-GB\">19\u00a0%<br/>\n  (90\u00a0% CI 9\u00a0% to 29\u00a0%)<br/>\n  None of the 12 patients experienced withdrawal symptoms.</span></p>\n</td>", "ID": "542602a5-3fcf-4f65-b5f8-6839e331c423", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a0bd2501-bcf4-44dc-8d3a-70804573ac0b"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Methadone AUC <span style=\"font-family:Symbol\">\u00af</span> <span lang=\"EN-GB\">19\u00a0%<br/>\n  (90\u00a0% CI 9\u00a0% to 29\u00a0%)<br/>\n  None of the 12 patients experienced withdrawal symptoms.</span></p>", "ID": "ab63a969-f7bb-4a4c-8f89-2312d0e53b3f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Methadone AUC  ", "ParentId": "542602a5-3fcf-4f65-b5f8-6839e331c423"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "37542af1-c363-45d3-adf8-01a039736dce", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "ab63a969-f7bb-4a4c-8f89-2312d0e53b3f"}, {"Element": "<span lang=\"EN-GB\">19\u00a0%<br/>\n  (90\u00a0% CI 9\u00a0% to 29\u00a0%)<br/>\n  None of the 12 patients experienced withdrawal symptoms.</span>", "ID": "53333462-25e2-4051-83e4-c184c7ec8b55", "Styles": "None", "Classes": "None", "Text": "19\u00a0%   (90\u00a0% CI 9\u00a0% to 29\u00a0%)   None of the 12 patients experienced withdrawal symptoms.", "ParentId": "ab63a969-f7bb-4a4c-8f89-2312d0e53b3f"}, {"Element": "<br/>", "ID": "8716d457-f36d-42fe-bcfd-c9c84c9894c7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "53333462-25e2-4051-83e4-c184c7ec8b55"}, {"Element": "<br/>", "ID": "f561fd10-29ca-43c8-86d5-c9ce994ebf68", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "53333462-25e2-4051-83e4-c184c7ec8b55"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "3094166f-ef34-4410-8d28-0686885068b1", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a0bd2501-bcf4-44dc-8d3a-70804573ac0b"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "ddeffc71-1105-4d1a-8f94-428abd8039bc", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated in   combination with  due to the   potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)", "ParentId": "3094166f-ef34-4410-8d28-0686885068b1"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "b0161523-a2ed-411a-ac01-cd093b7d604a", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "ddeffc71-1105-4d1a-8f94-428abd8039bc"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "40f90451-4200-43f9-9501-ab2529ff14bf", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "ddeffc71-1105-4d1a-8f94-428abd8039bc"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Oral\n  contraceptives</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "7c222b46-f6ba-4122-a5b1-337b6f8c2296", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Oral\n  contraceptives</span></i></b></p>\n</td>", "ID": "d8d32a64-cd73-4dfd-9d53-3fd587c1eccf", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7c222b46-f6ba-4122-a5b1-337b6f8c2296"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Oral\n  contraceptives</span></i></b></p>", "ID": "6267765d-358f-46d0-982a-15561f3d5d26", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "d8d32a64-cd73-4dfd-9d53-3fd587c1eccf"}, {"Element": "<b><i><span lang=\"EN-GB\">Oral\n  contraceptives</span></i></b>", "ID": "43e18195-30e0-414d-b09d-a71775862df8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6267765d-358f-46d0-982a-15561f3d5d26"}, {"Element": "<i><span lang=\"EN-GB\">Oral\n  contraceptives</span></i>", "ID": "189d58a6-c9cb-4e6d-be78-a6e97f9c26a4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "43e18195-30e0-414d-b09d-a71775862df8"}, {"Element": "<span lang=\"EN-GB\">Oral\n  contraceptives</span>", "ID": "c0435245-dc46-4de6-89d6-cf054a3ebb2a", "Styles": "None", "Classes": "None", "Text": "Oral   contraceptives", "ParentId": "189d58a6-c9cb-4e6d-be78-a6e97f9c26a4"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "dc3d2c23-77bc-459b-ad58-b0cf49c1e895", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7c222b46-f6ba-4122-a5b1-337b6f8c2296"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "cf77bf07-a569-4ab2-9aab-1ffeb2987e5d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "dc3d2c23-77bc-459b-ad58-b0cf49c1e895"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "4bf0f98a-d59a-4719-ac29-36dd335f02db", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cf77bf07-a569-4ab2-9aab-1ffeb2987e5d"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "5e9337d0-6f67-4253-b509-e38977c5062e", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7c222b46-f6ba-4122-a5b1-337b6f8c2296"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "55cd6e6b-edae-4655-8652-266cbfd99e4f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "5e9337d0-6f67-4253-b509-e38977c5062e"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "0baa96d4-2641-4324-bc18-223c0db8d9bb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "55cd6e6b-edae-4655-8652-266cbfd99e4f"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Ethinyl estradiol<br/>\n</span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentration of ethinyl estradiol may\n  be decreased when co-administered with Invirase/ritonavir. </span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Alternative or additional contraceptive\n  measures should be used when oestrogen-based oral contraceptives are\n  co-administered (see section 4.4).</span></p>\n</td>\n</tr>", "ID": "c0ad4041-56ff-4a06-b289-efd0a25224d0", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Ethinyl estradiol<br/>\n</span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>", "ID": "7173d66e-f6a1-4d99-987e-4e04de7978a0", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c0ad4041-56ff-4a06-b289-efd0a25224d0"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Ethinyl estradiol<br/>\n</span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>", "ID": "ac57351b-23f0-43aa-b77d-37293adcbf3f", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "()", "ParentId": "7173d66e-f6a1-4d99-987e-4e04de7978a0"}, {"Element": "<span lang=\"EN-GB\">Ethinyl estradiol<br/>\n</span>", "ID": "9d9c3007-c8ec-46fd-bb7a-832d891eb721", "Styles": "None", "Classes": "None", "Text": "Ethinyl estradiol ", "ParentId": "ac57351b-23f0-43aa-b77d-37293adcbf3f"}, {"Element": "<br/>", "ID": "2f4ea4b4-025e-409e-8ae5-621f94688ff7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9d9c3007-c8ec-46fd-bb7a-832d891eb721"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "d8584ba7-d510-4f78-ad5e-a305d9a1a87b", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "ac57351b-23f0-43aa-b77d-37293adcbf3f"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentration of ethinyl estradiol may\n  be decreased when co-administered with Invirase/ritonavir. </span></p>\n</td>", "ID": "aef00ae3-55c9-44eb-bfe2-e1f3bb25358f", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c0ad4041-56ff-4a06-b289-efd0a25224d0"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentration of ethinyl estradiol may\n  be decreased when co-administered with Invirase/ritonavir. </span></p>", "ID": "cffea985-b05b-4c23-990a-36874505563b", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "aef00ae3-55c9-44eb-bfe2-e1f3bb25358f"}, {"Element": "<span lang=\"EN-GB\">Concentration of ethinyl estradiol may\n  be decreased when co-administered with Invirase/ritonavir. </span>", "ID": "a1692e2a-682c-44fa-82ed-22759cbf9420", "Styles": "None", "Classes": "None", "Text": "Concentration of ethinyl estradiol may   be decreased when co-administered with Invirase/ritonavir. ", "ParentId": "cffea985-b05b-4c23-990a-36874505563b"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Alternative or additional contraceptive\n  measures should be used when oestrogen-based oral contraceptives are\n  co-administered (see section 4.4).</span></p>\n</td>", "ID": "36affea5-9119-46c0-93f6-3b2a04078d01", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c0ad4041-56ff-4a06-b289-efd0a25224d0"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Alternative or additional contraceptive\n  measures should be used when oestrogen-based oral contraceptives are\n  co-administered (see section 4.4).</span></p>", "ID": "d2e27ec4-52a1-464f-a348-143e5cf34b77", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "36affea5-9119-46c0-93f6-3b2a04078d01"}, {"Element": "<span lang=\"EN-GB\">Alternative or additional contraceptive\n  measures should be used when oestrogen-based oral contraceptives are\n  co-administered (see section 4.4).</span>", "ID": "2ab35af1-524c-4790-b542-c47cc4853699", "Styles": "None", "Classes": "None", "Text": "Alternative or additional contraceptive   measures should be used when oestrogen-based oral contraceptives are   co-administered (see section 4.4).", "ParentId": "d2e27ec4-52a1-464f-a348-143e5cf34b77"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Phosphodiesterase type 5 (PDE5)\n  inhibitors</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "ba58f09b-02bf-4bb0-a06c-97eb23701418", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Phosphodiesterase type 5 (PDE5)\n  inhibitors</span></i></b></p>\n</td>", "ID": "0fe1a64f-540c-41ea-8362-6f4b94324b52", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ba58f09b-02bf-4bb0-a06c-97eb23701418"}, {"Element": "<p class=\"Normal11pt0\"><b><i><span lang=\"EN-GB\">Phosphodiesterase type 5 (PDE5)\n  inhibitors</span></i></b></p>", "ID": "90880d33-0e39-47b1-82ae-89976d559f6e", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "0fe1a64f-540c-41ea-8362-6f4b94324b52"}, {"Element": "<b><i><span lang=\"EN-GB\">Phosphodiesterase type 5 (PDE5)\n  inhibitors</span></i></b>", "ID": "853542d9-67bb-4a0e-9418-480a400814f9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "90880d33-0e39-47b1-82ae-89976d559f6e"}, {"Element": "<i><span lang=\"EN-GB\">Phosphodiesterase type 5 (PDE5)\n  inhibitors</span></i>", "ID": "a61fdf51-e06f-48fa-94cf-56e4feed6fe8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "853542d9-67bb-4a0e-9418-480a400814f9"}, {"Element": "<span lang=\"EN-GB\">Phosphodiesterase type 5 (PDE5)\n  inhibitors</span>", "ID": "c5e29fa2-51ee-4f60-b699-2389485ed3f5", "Styles": "None", "Classes": "None", "Text": "Phosphodiesterase type 5 (PDE5)   inhibitors", "ParentId": "a61fdf51-e06f-48fa-94cf-56e4feed6fe8"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "0d4c69ae-6490-449b-905d-8e7c10249e69", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ba58f09b-02bf-4bb0-a06c-97eb23701418"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "927b22c4-a8a8-4a8e-80ba-bb9884491db5", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "0d4c69ae-6490-449b-905d-8e7c10249e69"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "dfe0b3d8-02a5-462e-922c-784fa86080cd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "927b22c4-a8a8-4a8e-80ba-bb9884491db5"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "dea38ee0-bc86-4549-9a93-6d8ca7e9ec3c", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ba58f09b-02bf-4bb0-a06c-97eb23701418"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">\u00a0</span></p>", "ID": "fabfad95-a760-44ee-a2fb-240b235df7a0", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "dea38ee0-bc86-4549-9a93-6d8ca7e9ec3c"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "1d0445a8-0eb5-4a24-bc3d-28afdef5abb5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fabfad95-a760-44ee-a2fb-240b235df7a0"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">\u00a0Sildenafil</p>\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">(saquinavir/ritonavir)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sildenafil\n  100\u00a0mg<br/>\n  (single dose)<br/>\n  (unboosted saquinavir 1200\u00a0mg tid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt\">Interaction with\n  Invirase/ritonavir not studied.</p>\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt\">Saquinavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  Sildenafil Cmax \u2191 140\u00a0%<br/>\n  Sildenafil AUC \u2191 210\u00a0%</p>\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt\">-Sildenafil is a substrate of\n  CYP3A4.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt\">Contraindicated\n  in combination with Invirase/ritonavir due to the potential for life\n  threatening cardiac arrhythmia (see sections 4.3 and 4.4).</p>\n</td>\n</tr>", "ID": "7aea7c0b-65db-4450-a0b4-8c6cba467a20", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">\u00a0Sildenafil</p>\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">(saquinavir/ritonavir)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sildenafil\n  100\u00a0mg<br/>\n  (single dose)<br/>\n  (unboosted saquinavir 1200\u00a0mg tid)</p>\n</td>", "ID": "7891c86d-a400-4375-af8d-842d2484232a", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "7aea7c0b-65db-4450-a0b4-8c6cba467a20"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">\u00a0Sildenafil</p>", "ID": "4c1d816a-98b6-47c3-bab6-904ce20a4ba4", "Styles": "margin-left:9.35pt;text-indent:-9.35pt", "Classes": "['Normal11pt0']", "Text": "\u00a0Sildenafil", "ParentId": "7891c86d-a400-4375-af8d-842d2484232a"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">(saquinavir/ritonavir)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sildenafil\n  100\u00a0mg<br/>\n  (single dose)<br/>\n  (unboosted saquinavir 1200\u00a0mg tid)</p>", "ID": "895a5922-86a6-4f00-8802-ba5ed475c226", "Styles": "margin-left:9.35pt;text-indent:-9.35pt", "Classes": "['Normal11pt0']", "Text": "(saquinavir/ritonavir)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sildenafil   100\u00a0mg   (single dose)   (unboosted saquinavir 1200\u00a0mg tid)", "ParentId": "7891c86d-a400-4375-af8d-842d2484232a"}, {"Element": "<br/>", "ID": "a0f4efa0-2c27-4db1-8fb0-b5be773d3b8d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "895a5922-86a6-4f00-8802-ba5ed475c226"}, {"Element": "<br/>", "ID": "ffbdf38e-8f59-4b4b-9dc2-9fb752d7eccc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "895a5922-86a6-4f00-8802-ba5ed475c226"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt\">Interaction with\n  Invirase/ritonavir not studied.</p>\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt\">Saquinavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  Sildenafil Cmax \u2191 140\u00a0%<br/>\n  Sildenafil AUC \u2191 210\u00a0%</p>\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt\">-Sildenafil is a substrate of\n  CYP3A4.</p>\n</td>", "ID": "5c304e40-b0da-41bb-9bcd-1c2d8b84ebe4", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "7aea7c0b-65db-4450-a0b4-8c6cba467a20"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:3.3pt\">Interaction with\n  Invirase/ritonavir not studied.</p>", "ID": "7fd849f1-b611-4d4c-88ba-8b4163851e9b", "Styles": "margin-left:3.3pt", "Classes": "['Normal11pt0']", "Text": "Interaction with   Invirase/ritonavir not studied.", "ParentId": "5c304e40-b0da-41bb-9bcd-1c2d8b84ebe4"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:3.3pt\">Saquinavir <span style=\"font-family:Symbol\">\u00ab</span><br/>\n  Sildenafil Cmax \u2191 140\u00a0%<br/>\n  Sildenafil AUC \u2191 210\u00a0%</p>", "ID": "c8528499-02dd-4ae2-8a2a-3e286838ab19", "Styles": "margin-left:3.3pt", "Classes": "['Normal11pt0']", "Text": "Saquinavir    Sildenafil Cmax \u2191 140\u00a0%   Sildenafil AUC \u2191 210\u00a0%", "ParentId": "5c304e40-b0da-41bb-9bcd-1c2d8b84ebe4"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "b35ec860-07c5-4e84-a049-ef5113927410", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "c8528499-02dd-4ae2-8a2a-3e286838ab19"}, {"Element": "<br/>", "ID": "1231033a-5269-437b-8f74-118b4dda6e8f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c8528499-02dd-4ae2-8a2a-3e286838ab19"}, {"Element": "<br/>", "ID": "69757fee-e98e-4c5c-9ca4-294658ca0dfe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c8528499-02dd-4ae2-8a2a-3e286838ab19"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:3.3pt\">-Sildenafil is a substrate of\n  CYP3A4.</p>", "ID": "338dbc7e-cdce-4850-910b-f7f7c570aa85", "Styles": "margin-left:3.3pt", "Classes": "['Normal11pt0']", "Text": "-Sildenafil is a substrate of   CYP3A4.", "ParentId": "5c304e40-b0da-41bb-9bcd-1c2d8b84ebe4"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt\">Contraindicated\n  in combination with Invirase/ritonavir due to the potential for life\n  threatening cardiac arrhythmia (see sections 4.3 and 4.4).</p>\n</td>", "ID": "625312f2-46f0-44da-930b-cbd7616f8b4b", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7aea7c0b-65db-4450-a0b4-8c6cba467a20"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:.45pt;text-indent:-.45pt\">Contraindicated\n  in combination with Invirase/ritonavir due to the potential for life\n  threatening cardiac arrhythmia (see sections 4.3 and 4.4).</p>", "ID": "7e689e82-1d97-4a73-a337-54e2dc00025d", "Styles": "margin-left:.45pt;text-indent:-.45pt", "Classes": "['Normal11pt0']", "Text": "Contraindicated   in combination with Invirase/ritonavir due to the potential for life   threatening cardiac arrhythmia (see sections 4.3 and 4.4).", "ParentId": "625312f2-46f0-44da-930b-cbd7616f8b4b"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vardenafil<u><br/>\n</u></span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of vardenafil may be increased when co-administered with Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "9053f2ae-5ff7-4c9d-a5d0-f7c3adb917d9", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vardenafil<u><br/>\n</u></span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>", "ID": "7c91f554-abb5-4758-b297-fd2773926e65", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9053f2ae-5ff7-4c9d-a5d0-f7c3adb917d9"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vardenafil<u><br/>\n</u></span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>", "ID": "d5763425-c970-48e7-9e34-bb720d9395f7", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "()", "ParentId": "7c91f554-abb5-4758-b297-fd2773926e65"}, {"Element": "<span lang=\"EN-GB\">Vardenafil<u><br/>\n</u></span>", "ID": "a02a83f5-2b55-4576-9baf-1b696335a699", "Styles": "None", "Classes": "None", "Text": "Vardenafil", "ParentId": "d5763425-c970-48e7-9e34-bb720d9395f7"}, {"Element": "<u><br/>\n</u>", "ID": "d97f6281-a999-4179-aaed-7b3ac3b770d4", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "a02a83f5-2b55-4576-9baf-1b696335a699"}, {"Element": "<br/>", "ID": "600c38ea-c4f1-46eb-9d0f-01056ba2e067", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d97f6281-a999-4179-aaed-7b3ac3b770d4"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "5b80d4aa-1c9d-406d-8a5a-a3f8f502a5d9", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "d5763425-c970-48e7-9e34-bb720d9395f7"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of vardenafil may be increased when co-administered with Invirase/ritonavir.</span></p>\n</td>", "ID": "a975bae2-7b53-4fde-a237-67e8320a2bfb", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9053f2ae-5ff7-4c9d-a5d0-f7c3adb917d9"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Concentrations\n  of vardenafil may be increased when co-administered with Invirase/ritonavir.</span></p>", "ID": "79f43aaf-8616-49cc-97a0-6588364966b1", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "a975bae2-7b53-4fde-a237-67e8320a2bfb"}, {"Element": "<span lang=\"EN-GB\">Concentrations\n  of vardenafil may be increased when co-administered with Invirase/ritonavir.</span>", "ID": "0c286a35-2064-42d5-aa6c-2f0ccfd9d8ed", "Styles": "None", "Classes": "None", "Text": "Concentrations   of vardenafil may be increased when co-administered with Invirase/ritonavir.", "ParentId": "79f43aaf-8616-49cc-97a0-6588364966b1"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "df79ab5c-e046-4c2c-a334-87a24f5bf3d0", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9053f2ae-5ff7-4c9d-a5d0-f7c3adb917d9"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "1720e51d-1dcc-43fb-bcb2-c90d5f9acd2d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated in   combination with  due to the   potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)", "ParentId": "df79ab5c-e046-4c2c-a334-87a24f5bf3d0"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "42264657-c4bb-41d8-83a1-bd578dafbd41", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "1720e51d-1dcc-43fb-bcb2-c90d5f9acd2d"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "f5ccd7e2-3f88-4730-87ff-0635453b7b92", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "1720e51d-1dcc-43fb-bcb2-c90d5f9acd2d"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Tadalafil<u><br/>\n</u></span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of tadalafil may be\n  increased when co-administered with Invirase/ritonavir.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "9f24f51b-aa7f-4695-ab11-61c9f57167c6", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Tadalafil<u><br/>\n</u></span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>\n</td>", "ID": "f62f1e7c-2685-4273-8a52-4a48933bef3c", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9f24f51b-aa7f-4695-ab11-61c9f57167c6"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Tadalafil<u><br/>\n</u></span>(<span lang=\"EN-GB\">saquinavir/ritonavir</span>)</p>", "ID": "7f043c3c-d09c-4b04-bcf1-c3e732c1495c", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "()", "ParentId": "f62f1e7c-2685-4273-8a52-4a48933bef3c"}, {"Element": "<span lang=\"EN-GB\">Tadalafil<u><br/>\n</u></span>", "ID": "259eaae6-4903-45b6-afa8-a353600d5a76", "Styles": "None", "Classes": "None", "Text": "Tadalafil", "ParentId": "7f043c3c-d09c-4b04-bcf1-c3e732c1495c"}, {"Element": "<u><br/>\n</u>", "ID": "6837afe8-431c-4d08-a4fd-549b62fd1688", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "259eaae6-4903-45b6-afa8-a353600d5a76"}, {"Element": "<br/>", "ID": "857eeade-50cb-45af-a9f3-f51ed9b8d70c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6837afe8-431c-4d08-a4fd-549b62fd1688"}, {"Element": "<span lang=\"EN-GB\">saquinavir/ritonavir</span>", "ID": "9ae796ca-84f6-485f-8624-103b022d1486", "Styles": "None", "Classes": "None", "Text": "saquinavir/ritonavir", "ParentId": "7f043c3c-d09c-4b04-bcf1-c3e732c1495c"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of tadalafil may be\n  increased when co-administered with Invirase/ritonavir.</span></p>\n</td>", "ID": "6a976737-9467-44dd-9d3f-98b14d0109d8", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9f24f51b-aa7f-4695-ab11-61c9f57167c6"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Concentrations of tadalafil may be\n  increased when co-administered with Invirase/ritonavir.</span></p>", "ID": "5987b503-beb4-4784-96ac-20386b6e969e", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "6a976737-9467-44dd-9d3f-98b14d0109d8"}, {"Element": "<span lang=\"EN-GB\">Concentrations of tadalafil may be\n  increased when co-administered with Invirase/ritonavir.</span>", "ID": "12853503-0dd8-48a6-b323-3e7e828cc47f", "Styles": "None", "Classes": "None", "Text": "Concentrations of tadalafil may be   increased when co-administered with Invirase/ritonavir.", "ParentId": "5987b503-beb4-4784-96ac-20386b6e969e"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "52450523-3457-4317-b479-c4020e0a2353", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9f24f51b-aa7f-4695-ab11-61c9f57167c6"}, {"Element": "<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to the potential for life threatening cardiac arrhythmia (see sections\n  4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "25e81cce-57cf-4a62-a95f-ee1b7a69b56a", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Contraindicated in combination with    due to the potential for life threatening cardiac arrhythmia (see sections   4.3 and 4.4)", "ParentId": "52450523-3457-4317-b479-c4020e0a2353"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "abd75be6-5070-48b4-abdd-bfb30fe62eca", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "25e81cce-57cf-4a62-a95f-ee1b7a69b56a"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "38c25104-3380-47c9-a609-6e9154c4c524", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "25e81cce-57cf-4a62-a95f-ee1b7a69b56a"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Proton pump\n  inhibitors</i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "69f31e12-53ff-45e4-a0de-de28146e9bd2", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Proton pump\n  inhibitors</i></b></p>\n</td>", "ID": "67f26506-3a35-4be1-bd6c-0a8cfd931572", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "69f31e12-53ff-45e4-a0de-de28146e9bd2"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Proton pump\n  inhibitors</i></b></p>", "ID": "9ab642e3-a421-4fe5-9aae-17cfe6f32b02", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "67f26506-3a35-4be1-bd6c-0a8cfd931572"}, {"Element": "<b><i>Proton pump\n  inhibitors</i></b>", "ID": "42110915-0e86-4d51-a594-2d92be8af68b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9ab642e3-a421-4fe5-9aae-17cfe6f32b02"}, {"Element": "<i>Proton pump\n  inhibitors</i>", "ID": "8f08d2f6-72af-4b0e-a950-3cfeb626a82b", "Styles": "None", "Classes": "None", "Text": "Proton pump   inhibitors", "ParentId": "42110915-0e86-4d51-a594-2d92be8af68b"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "3c754775-0fe5-4b4c-baf3-48f4d1775490", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "69f31e12-53ff-45e4-a0de-de28146e9bd2"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "bb2e84a2-4f21-43cd-ade9-11356428a5c1", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "3c754775-0fe5-4b4c-baf3-48f4d1775490"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "0a1f4023-7e3f-448e-b591-640ada99995f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bb2e84a2-4f21-43cd-ade9-11356428a5c1"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "24da1699-39ff-4ada-9fa0-c5c554df8fad", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "69f31e12-53ff-45e4-a0de-de28146e9bd2"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "3024d65a-a5af-44b6-8326-4e187a5ef4c0", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "24da1699-39ff-4ada-9fa0-c5c554df8fad"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "c19b1334-5404-4558-a6a0-b2d3fcd4cb69", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3024d65a-a5af-44b6-8326-4e187a5ef4c0"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Omeprazole\n  40\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Saquinavir\n  AUC \u2191 82%<br/>\n  (90\u00a0% CI 44-131\u00a0%)</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Saquinavir\n  C<sub>max</sub> \u2191 75%<br/>\n  (90\u00a0% CI 38-123\u00a0%)<br/>\n  Ritonavir </span><span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Combination not\n  recommended.</p>\n</td>\n</tr>", "ID": "7b59b810-a439-48ee-9ce1-e436bfdf9b40", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Omeprazole\n  40\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "ded740a0-f530-4d68-9b7e-b99881ba48f2", "Styles": "width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "7b59b810-a439-48ee-9ce1-e436bfdf9b40"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Omeprazole\n  40\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span></p>", "ID": "d3bf784d-fc3c-4165-9a36-413f41fca52d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "ded740a0-f530-4d68-9b7e-b99881ba48f2"}, {"Element": "<span lang=\"IT\">Omeprazole\n  40\u00a0mg qd<u><br/>\n</u>(saquinavir/ritonavir 1000/100\u00a0mg bid)</span>", "ID": "fa3bc7ff-0644-4da7-a7b4-c0b8dc1082da", "Styles": "None", "Classes": "None", "Text": "Omeprazole   40\u00a0mg qd(saquinavir/ritonavir 1000/100\u00a0mg bid)", "ParentId": "d3bf784d-fc3c-4165-9a36-413f41fca52d"}, {"Element": "<u><br/>\n</u>", "ID": "28c76316-9eb4-4ffc-b45a-b6bb4d02256f", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "fa3bc7ff-0644-4da7-a7b4-c0b8dc1082da"}, {"Element": "<br/>", "ID": "701becda-44df-484d-aec2-a507af6b244f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "28c76316-9eb4-4ffc-b45a-b6bb4d02256f"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "2e013c89-423e-4297-a127-2cdc6eb9fed9", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "ded740a0-f530-4d68-9b7e-b99881ba48f2"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "2b4f06cd-d5c4-4dd5-a7ab-0f7eac28f058", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2e013c89-423e-4297-a127-2cdc6eb9fed9"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Saquinavir\n  AUC \u2191 82%<br/>\n  (90\u00a0% CI 44-131\u00a0%)</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Saquinavir\n  C<sub>max</sub> \u2191 75%<br/>\n  (90\u00a0% CI 38-123\u00a0%)<br/>\n  Ritonavir </span><span style=\"font-family:Symbol\">\u00ab</span></p>\n</td>", "ID": "824a7598-1ffa-4847-bad3-2f4218aa3a02", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "7b59b810-a439-48ee-9ce1-e436bfdf9b40"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Saquinavir\n  AUC \u2191 82%<br/>\n  (90\u00a0% CI 44-131\u00a0%)</span></p>", "ID": "0f2d3050-e2e2-4f7e-8f65-5ea3be4115e3", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "824a7598-1ffa-4847-bad3-2f4218aa3a02"}, {"Element": "<span lang=\"IT\">Saquinavir\n  AUC \u2191 82%<br/>\n  (90\u00a0% CI 44-131\u00a0%)</span>", "ID": "02776fc8-d5d8-4d28-85f9-095dffe07ce5", "Styles": "None", "Classes": "None", "Text": "Saquinavir   AUC \u2191 82%   (90\u00a0% CI 44-131\u00a0%)", "ParentId": "0f2d3050-e2e2-4f7e-8f65-5ea3be4115e3"}, {"Element": "<br/>", "ID": "20466224-7a79-48ed-bcbf-cd5d6d74f144", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "02776fc8-d5d8-4d28-85f9-095dffe07ce5"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Saquinavir\n  C<sub>max</sub> \u2191 75%<br/>\n  (90\u00a0% CI 38-123\u00a0%)<br/>\n  Ritonavir </span><span style=\"font-family:Symbol\">\u00ab</span></p>", "ID": "d7190356-4d4e-41e1-8d2b-2c0594f2ce0e", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "824a7598-1ffa-4847-bad3-2f4218aa3a02"}, {"Element": "<span lang=\"IT\">Saquinavir\n  C<sub>max</sub> \u2191 75%<br/>\n  (90\u00a0% CI 38-123\u00a0%)<br/>\n  Ritonavir </span>", "ID": "c8cfd949-70bb-4b07-8f15-2c67556bd4c8", "Styles": "None", "Classes": "None", "Text": "Saquinavir   C \u2191 75%   (90\u00a0% CI 38-123\u00a0%)   Ritonavir ", "ParentId": "d7190356-4d4e-41e1-8d2b-2c0594f2ce0e"}, {"Element": "<sub>max</sub>", "ID": "7ac03346-b241-4761-bd41-8bbff7a19c0f", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "c8cfd949-70bb-4b07-8f15-2c67556bd4c8"}, {"Element": "<br/>", "ID": "2300a896-52e1-4c7d-9f10-5a796b5540a4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c8cfd949-70bb-4b07-8f15-2c67556bd4c8"}, {"Element": "<br/>", "ID": "aa09b8fc-c80d-455b-8c89-7c4e4f9efa03", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c8cfd949-70bb-4b07-8f15-2c67556bd4c8"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "214e620f-95b2-4816-8ac6-6c2cb00b4cb4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "d7190356-4d4e-41e1-8d2b-2c0594f2ce0e"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Combination not\n  recommended.</p>\n</td>", "ID": "95b2593a-72aa-4dbf-9752-441248b13657", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7b59b810-a439-48ee-9ce1-e436bfdf9b40"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Combination not\n  recommended.</p>", "ID": "004defc0-24fb-45e1-a692-f70f54f454bd", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Combination not   recommended.", "ParentId": "95b2593a-72aa-4dbf-9752-441248b13657"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Other proton pump\n  inhibitors (saquinavir/ritonavir 1000/100\u00a0mg bid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">No data are available on\n  the concomitant administration of Invirase/ritonavir and other proton pump\n  inhibitors.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Combination not\n  recommended.</p>\n</td>\n</tr>", "ID": "e3e1c481-b1b9-44a3-8afe-5fc2036c9922", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Other proton pump\n  inhibitors (saquinavir/ritonavir 1000/100\u00a0mg bid)</p>\n</td>", "ID": "ef80f957-33ea-45dd-b820-a771e5353f65", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e3e1c481-b1b9-44a3-8afe-5fc2036c9922"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Other proton pump\n  inhibitors (saquinavir/ritonavir 1000/100\u00a0mg bid)</p>", "ID": "42ab442d-6103-4021-a3f6-dbec87ceeca9", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Other proton pump   inhibitors (saquinavir/ritonavir 1000/100\u00a0mg bid)", "ParentId": "ef80f957-33ea-45dd-b820-a771e5353f65"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">No data are available on\n  the concomitant administration of Invirase/ritonavir and other proton pump\n  inhibitors.</p>\n</td>", "ID": "dffdc1e9-48b8-4d9f-ac7d-9f4b4b304493", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e3e1c481-b1b9-44a3-8afe-5fc2036c9922"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">No data are available on\n  the concomitant administration of Invirase/ritonavir and other proton pump\n  inhibitors.</p>", "ID": "b1550b17-7b40-4bc6-8aab-23bf1c0f2a77", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "No data are available on   the concomitant administration of Invirase/ritonavir and other proton pump   inhibitors.", "ParentId": "dffdc1e9-48b8-4d9f-ac7d-9f4b4b304493"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Combination not\n  recommended.</p>\n</td>", "ID": "e2ab2838-9ad6-4d45-8252-cc8182e89fee", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e3e1c481-b1b9-44a3-8afe-5fc2036c9922"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Combination not\n  recommended.</p>", "ID": "02c58307-d9ef-47aa-91ea-1119ad64a287", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Combination not   recommended.", "ParentId": "e2ab2838-9ad6-4d45-8252-cc8182e89fee"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Tyrosine kinase\n  inhibitors</i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "14f3d742-c932-4363-a018-39b728339d5d", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Tyrosine kinase\n  inhibitors</i></b></p>\n</td>", "ID": "134ccc68-5859-44b9-94fe-8aa3c6d2adcd", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "14f3d742-c932-4363-a018-39b728339d5d"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Tyrosine kinase\n  inhibitors</i></b></p>", "ID": "a77b6336-015c-4232-b005-7c3f2cd61bac", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "134ccc68-5859-44b9-94fe-8aa3c6d2adcd"}, {"Element": "<b><i>Tyrosine kinase\n  inhibitors</i></b>", "ID": "0ca57648-ff29-4e37-a3c7-b879eba34891", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a77b6336-015c-4232-b005-7c3f2cd61bac"}, {"Element": "<i>Tyrosine kinase\n  inhibitors</i>", "ID": "462d355b-09ec-4c50-8cb4-75cf829a8103", "Styles": "None", "Classes": "None", "Text": "Tyrosine kinase   inhibitors", "ParentId": "0ca57648-ff29-4e37-a3c7-b879eba34891"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "e065938b-a156-442e-814c-e94648b3dece", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "14f3d742-c932-4363-a018-39b728339d5d"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "387c292c-9a54-4fa8-a6b0-aca7494ebe04", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "e065938b-a156-442e-814c-e94648b3dece"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "74ae348f-26f8-470d-9922-a8745573d22c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "387c292c-9a54-4fa8-a6b0-aca7494ebe04"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "ff83b675-3ca2-4474-b4e6-5cc9f0054131", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "14f3d742-c932-4363-a018-39b728339d5d"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "00b06103-641f-4e21-84c6-5c5567726b11", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "ff83b675-3ca2-4474-b4e6-5cc9f0054131"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "d528eb9b-8e2f-45f1-856c-68fe8c695ba2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "00b06103-641f-4e21-84c6-5c5567726b11"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">All tyrosine kinase\n  inhibitors with a risk of QT prolongation </p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">e.g. dasatinib,\n  </span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">sunitinib</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with Invirase/ritonavir due to the potential for life threatening\n  cardiac arrhythmia (see sections 4.3 and 4.4).</p>\n</td>\n</tr>", "ID": "dde0f558-4b18-4433-beb3-8ae3717f4175", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">All tyrosine kinase\n  inhibitors with a risk of QT prolongation </p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">e.g. dasatinib,\n  </span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">sunitinib</span></p>\n</td>", "ID": "30434aba-00dd-4a66-8947-b35920372282", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "dde0f558-4b18-4433-beb3-8ae3717f4175"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">All tyrosine kinase\n  inhibitors with a risk of QT prolongation </p>", "ID": "24429027-1fd8-4189-af67-d5e3fa4ccf97", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "All tyrosine kinase   inhibitors with a risk of QT prolongation ", "ParentId": "30434aba-00dd-4a66-8947-b35920372282"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">e.g. dasatinib,\n  </span></p>", "ID": "1d6db074-c79f-442b-ade4-3b6f74e27825", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "30434aba-00dd-4a66-8947-b35920372282"}, {"Element": "<span lang=\"IT\">e.g. dasatinib,\n  </span>", "ID": "809ed709-5bde-447b-a9fb-418d3f4d734b", "Styles": "None", "Classes": "None", "Text": "e.g. dasatinib,   ", "ParentId": "1d6db074-c79f-442b-ade4-3b6f74e27825"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">sunitinib</span></p>", "ID": "8fd57796-448c-4fdb-97d6-277c8b975c9d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "30434aba-00dd-4a66-8947-b35920372282"}, {"Element": "<span lang=\"IT\">sunitinib</span>", "ID": "866d6918-7524-49d8-8f41-8c6d832abb37", "Styles": "None", "Classes": "None", "Text": "sunitinib", "ParentId": "8fd57796-448c-4fdb-97d6-277c8b975c9d"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied</p>\n</td>", "ID": "3a5dd4c0-58b0-46c6-80c4-85d828c716fb", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "dde0f558-4b18-4433-beb3-8ae3717f4175"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Interaction with\n  Invirase/ritonavir not studied</p>", "ID": "15a50c8b-d565-4bab-a519-722fa1c7e991", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Interaction with   Invirase/ritonavir not studied", "ParentId": "3a5dd4c0-58b0-46c6-80c4-85d828c716fb"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with Invirase/ritonavir due to the potential for life threatening\n  cardiac arrhythmia (see sections 4.3 and 4.4).</p>\n</td>", "ID": "f01c595a-ac9d-40d5-9362-5c71e2429831", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "dde0f558-4b18-4433-beb3-8ae3717f4175"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with Invirase/ritonavir due to the potential for life threatening\n  cardiac arrhythmia (see sections 4.3 and 4.4).</p>", "ID": "8de4ae4e-6e29-4d14-befa-4545171dbf24", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated in   combination with Invirase/ritonavir due to the potential for life threatening   cardiac arrhythmia (see sections 4.3 and 4.4).", "ParentId": "f01c595a-ac9d-40d5-9362-5c71e2429831"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Others</i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "5a5e52cd-a160-477e-978a-1a7e45ae3a5c", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Others</i></b></p>\n</td>", "ID": "c4e7a466-2d16-484e-b182-f57ae98d884a", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5a5e52cd-a160-477e-978a-1a7e45ae3a5c"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i>Others</i></b></p>", "ID": "ad83a826-1e74-4a49-8c8c-deed25d6a661", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "c4e7a466-2d16-484e-b182-f57ae98d884a"}, {"Element": "<b><i>Others</i></b>", "ID": "3c33fa60-2fe8-42bb-8179-d89c923dab21", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ad83a826-1e74-4a49-8c8c-deed25d6a661"}, {"Element": "<i>Others</i>", "ID": "a8775768-4b86-446f-863b-f3558ba0da08", "Styles": "None", "Classes": "None", "Text": "Others", "ParentId": "3c33fa60-2fe8-42bb-8179-d89c923dab21"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "30775662-df14-4e3d-b661-ccb7ba2f6f4d", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5a5e52cd-a160-477e-978a-1a7e45ae3a5c"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "b792b087-2c8f-457d-9ac7-51a840d4167c", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "30775662-df14-4e3d-b661-ccb7ba2f6f4d"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "4f706915-f383-4cff-8d2e-f18c3d08b0c4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b792b087-2c8f-457d-9ac7-51a840d4167c"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "59bc065b-69a2-409a-b808-71ea9588e556", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5a5e52cd-a160-477e-978a-1a7e45ae3a5c"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">\u00a0</span></p>", "ID": "0d1da9e7-9eb1-48d7-8615-3e989236e50b", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "59bc065b-69a2-409a-b808-71ea9588e556"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "c5510f1d-9cd8-494b-9430-e01dce8e57f9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0d1da9e7-9eb1-48d7-8615-3e989236e50b"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Ergot\n  alkaloids (e.g. ergotamine, dihydroergotamine, ergonovine, and\n  methylergonovine)<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Invirase/ritonavir may\n  increase ergot alkaloids exposure, and consequently, increase the potential\n  for acute ergot toxicity.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">The concomitant use of\n  Invirase/ritonavir and ergot alkaloids is contra-indicated (see section 4.3).</p>\n</td>\n</tr>", "ID": "13de64d0-709d-4221-a528-0f4a25ad5e55", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Ergot\n  alkaloids (e.g. ergotamine, dihydroergotamine, ergonovine, and\n  methylergonovine)<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>", "ID": "ccdb6d2e-3466-4faf-8a0c-e63029caadba", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "13de64d0-709d-4221-a528-0f4a25ad5e55"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Ergot\n  alkaloids (e.g. ergotamine, dihydroergotamine, ergonovine, and\n  methylergonovine)<br/>\n  (saquinavir/ritonavir)</span></p>", "ID": "261e1adc-5bbc-4e86-b44d-3f5fa8c46a20", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "ccdb6d2e-3466-4faf-8a0c-e63029caadba"}, {"Element": "<span lang=\"IT\">Ergot\n  alkaloids (e.g. ergotamine, dihydroergotamine, ergonovine, and\n  methylergonovine)<br/>\n  (saquinavir/ritonavir)</span>", "ID": "df970726-677c-46b4-a356-c92ff4f59172", "Styles": "None", "Classes": "None", "Text": "Ergot   alkaloids (e.g. ergotamine, dihydroergotamine, ergonovine, and   methylergonovine)   (saquinavir/ritonavir)", "ParentId": "261e1adc-5bbc-4e86-b44d-3f5fa8c46a20"}, {"Element": "<br/>", "ID": "ba199e35-b30e-4723-a453-258c5b68dcf5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "df970726-677c-46b4-a356-c92ff4f59172"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Invirase/ritonavir may\n  increase ergot alkaloids exposure, and consequently, increase the potential\n  for acute ergot toxicity.</p>\n</td>", "ID": "2aac13ca-31a2-4d0c-b8f9-fed67b93c156", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "13de64d0-709d-4221-a528-0f4a25ad5e55"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Invirase/ritonavir may\n  increase ergot alkaloids exposure, and consequently, increase the potential\n  for acute ergot toxicity.</p>", "ID": "af212b4b-b3cf-45b4-8a18-55be423ae8b0", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Invirase/ritonavir may   increase ergot alkaloids exposure, and consequently, increase the potential   for acute ergot toxicity.", "ParentId": "2aac13ca-31a2-4d0c-b8f9-fed67b93c156"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">The concomitant use of\n  Invirase/ritonavir and ergot alkaloids is contra-indicated (see section 4.3).</p>\n</td>", "ID": "a87c1f0f-81ef-4ede-8d32-4777bdb9a263", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "13de64d0-709d-4221-a528-0f4a25ad5e55"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">The concomitant use of\n  Invirase/ritonavir and ergot alkaloids is contra-indicated (see section 4.3).</p>", "ID": "a39ef5eb-836e-4f56-b0a4-3906b694d6fa", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "The concomitant use of   Invirase/ritonavir and ergot alkaloids is contra-indicated (see section 4.3).", "ParentId": "a87c1f0f-81ef-4ede-8d32-4777bdb9a263"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Grapefruit\n  juice<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Interaction with Invirase/ritonavir not studied.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">\u00a0</p>\n</td>\n</tr>", "ID": "3dae0e7b-d907-434a-9ea3-c3bd1a7e630b", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Grapefruit\n  juice<br/>\n  (saquinavir/ritonavir)</p>\n</td>", "ID": "e0352e5c-6330-461d-af72-53593836dee9", "Styles": "width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3dae0e7b-d907-434a-9ea3-c3bd1a7e630b"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Grapefruit\n  juice<br/>\n  (saquinavir/ritonavir)</p>", "ID": "5c9fa073-021a-410f-a2c2-a3b4c13878de", "Styles": "margin-left:9.35pt;text-indent:-9.35pt", "Classes": "['Normal11pt0']", "Text": "-\u00a0 Grapefruit   juice   (saquinavir/ritonavir)", "ParentId": "e0352e5c-6330-461d-af72-53593836dee9"}, {"Element": "<br/>", "ID": "57d6dd38-49cf-4f73-a276-851da97d22e9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5c9fa073-021a-410f-a2c2-a3b4c13878de"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Interaction with Invirase/ritonavir not studied.</p>\n</td>", "ID": "a4b3064e-c9ca-4882-9a67-b62827853f70", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3dae0e7b-d907-434a-9ea3-c3bd1a7e630b"}, {"Element": "<p class=\"Normal11pt0\">Interaction with Invirase/ritonavir not studied.</p>", "ID": "d8bb126d-6ead-48e1-ba55-5efb074ece1a", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Interaction with Invirase/ritonavir not studied.", "ParentId": "a4b3064e-c9ca-4882-9a67-b62827853f70"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">\u00a0</p>\n</td>", "ID": "2d1de158-47e0-4d4e-96b5-cad99c2028d8", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3dae0e7b-d907-434a-9ea3-c3bd1a7e630b"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">\u00a0</p>", "ID": "d7a2681b-1ee0-42f3-ad84-14a92d8c543d", "Styles": "margin-left:9.35pt;text-indent:-9.35pt", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "2d1de158-47e0-4d4e-96b5-cad99c2028d8"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Grapefruit\n  juice<br/>\n  (single dose)<br/>\n  (unboosted saquinavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Saquinavir \u2191 50% (normal strength grapefruit\n  juice)</p>\n<p class=\"Normal11pt0\">Saquinavir \u2191 100% (double strength grapefruit\n  juice)</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt\">Increase not thought to be\n  clinically relevant. No dose adjustment required.</p>\n</td>\n</tr>", "ID": "26780510-b78e-4032-9bdd-c6cbd37b2851", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Grapefruit\n  juice<br/>\n  (single dose)<br/>\n  (unboosted saquinavir)</p>\n</td>", "ID": "123f23ef-5d82-4a2a-816a-dfc084e1ebee", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "26780510-b78e-4032-9bdd-c6cbd37b2851"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Grapefruit\n  juice<br/>\n  (single dose)<br/>\n  (unboosted saquinavir)</p>", "ID": "02a33846-053c-4afa-80b9-b79bafe983a5", "Styles": "margin-left:9.35pt;text-indent:-9.35pt", "Classes": "['Normal11pt0']", "Text": "-\u00a0 Grapefruit   juice   (single dose)   (unboosted saquinavir)", "ParentId": "123f23ef-5d82-4a2a-816a-dfc084e1ebee"}, {"Element": "<br/>", "ID": "71516899-8433-4f6b-9c91-2d32aad8c121", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "02a33846-053c-4afa-80b9-b79bafe983a5"}, {"Element": "<br/>", "ID": "0e939acd-65f5-4503-979f-2138b5867a96", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "02a33846-053c-4afa-80b9-b79bafe983a5"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Saquinavir \u2191 50% (normal strength grapefruit\n  juice)</p>\n<p class=\"Normal11pt0\">Saquinavir \u2191 100% (double strength grapefruit\n  juice)</p>\n</td>", "ID": "9e2ba057-093d-4008-9c7f-0259d9d870aa", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "26780510-b78e-4032-9bdd-c6cbd37b2851"}, {"Element": "<p class=\"Normal11pt0\">Saquinavir \u2191 50% (normal strength grapefruit\n  juice)</p>", "ID": "3bde519c-0b9f-4c4e-9ac6-2bdd7b5bc97f", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Saquinavir \u2191 50% (normal strength grapefruit   juice)", "ParentId": "9e2ba057-093d-4008-9c7f-0259d9d870aa"}, {"Element": "<p class=\"Normal11pt0\">Saquinavir \u2191 100% (double strength grapefruit\n  juice)</p>", "ID": "71e7e406-e0c7-4d0c-ad5a-3fe25ecaabd1", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Saquinavir \u2191 100% (double strength grapefruit   juice)", "ParentId": "9e2ba057-093d-4008-9c7f-0259d9d870aa"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:.45pt\">Increase not thought to be\n  clinically relevant. No dose adjustment required.</p>\n</td>", "ID": "bd3b5724-9cbe-4183-ae05-d55d0e905e16", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "26780510-b78e-4032-9bdd-c6cbd37b2851"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:.45pt\">Increase not thought to be\n  clinically relevant. No dose adjustment required.</p>", "ID": "4f5abd21-e1de-41a2-99ae-7589d8035ad8", "Styles": "margin-left:.45pt", "Classes": "['Normal11pt0']", "Text": "Increase not thought to be   clinically relevant. No dose adjustment required.", "ParentId": "bd3b5724-9cbe-4183-ae05-d55d0e905e16"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Garlic\n  capsules<br/>\n  (saquinavir/ritonavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Interaction with Invirase/ritonavir not studied.</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">\u00a0</p>\n</td>\n</tr>", "ID": "c9771206-cc25-4a19-b2e2-81f30fdcf884", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Garlic\n  capsules<br/>\n  (saquinavir/ritonavir)</p>\n</td>", "ID": "f5c656e5-d69a-4e13-842b-4b81ae5e3f16", "Styles": "width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c9771206-cc25-4a19-b2e2-81f30fdcf884"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Garlic\n  capsules<br/>\n  (saquinavir/ritonavir)</p>", "ID": "3ffbabb0-3a9e-46d5-8a76-b7380d0de386", "Styles": "margin-left:9.35pt;text-indent:-9.35pt", "Classes": "['Normal11pt0']", "Text": "-\u00a0 Garlic   capsules   (saquinavir/ritonavir)", "ParentId": "f5c656e5-d69a-4e13-842b-4b81ae5e3f16"}, {"Element": "<br/>", "ID": "1b1cc039-eae9-437c-a99c-ed9d97109f99", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3ffbabb0-3a9e-46d5-8a76-b7380d0de386"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\">Interaction with Invirase/ritonavir not studied.</p>\n</td>", "ID": "d8a43a39-1565-463b-924f-d20749836b3d", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c9771206-cc25-4a19-b2e2-81f30fdcf884"}, {"Element": "<p class=\"Normal11pt0\">Interaction with Invirase/ritonavir not studied.</p>", "ID": "fe2dc904-e2bb-4cb0-a1c8-15d716b33083", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Interaction with Invirase/ritonavir not studied.", "ParentId": "d8a43a39-1565-463b-924f-d20749836b3d"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">\u00a0</p>\n</td>", "ID": "1d9e11ab-7c9a-4b7a-99b6-5c99c921e743", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c9771206-cc25-4a19-b2e2-81f30fdcf884"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">\u00a0</p>", "ID": "4eca5171-5b3a-4893-9a4d-3c12850cb7d7", "Styles": "margin-left:9.35pt;text-indent:-9.35pt", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "1d9e11ab-7c9a-4b7a-99b6-5c99c921e743"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Garlic\n  capsules<br/>\n  (dose approx. equivalent to two 4\u00a0g cloves of garlic daily)<br/>\n  (unboosted saquinavir 1200\u00a0mg tid)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"FR-CH\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"FR-CH\"> 51\u00a0%<br/>\n  Saquinavir Ctrough </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"FR-CH\"> 49\u00a0% (8 hours post dose)<br/>\n  Saquinavir Cmax </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"FR-CH\"> 54\u00a0%.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt\">Patients on saquinavir\n  treatment must not take garlic capsules due to the risk of decreased plasma\n  concentrations and loss of virological response and possible resistance to\n  one or more components of the antiretroviral regimen.</p>\n</td>\n</tr>", "ID": "17b1efdc-4c49-4ddf-aa9c-62e3aedfe72a", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Garlic\n  capsules<br/>\n  (dose approx. equivalent to two 4\u00a0g cloves of garlic daily)<br/>\n  (unboosted saquinavir 1200\u00a0mg tid)</p>\n</td>", "ID": "4ec465fe-acb1-42f9-baf3-8b3d3546ea0f", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "17b1efdc-4c49-4ddf-aa9c-62e3aedfe72a"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt;text-indent:-9.35pt\">-\u00a0 Garlic\n  capsules<br/>\n  (dose approx. equivalent to two 4\u00a0g cloves of garlic daily)<br/>\n  (unboosted saquinavir 1200\u00a0mg tid)</p>", "ID": "a9521b60-2fb7-4ad4-85fb-d2570627d1a5", "Styles": "margin-left:9.35pt;text-indent:-9.35pt", "Classes": "['Normal11pt0']", "Text": "-\u00a0 Garlic   capsules   (dose approx. equivalent to two 4\u00a0g cloves of garlic daily)   (unboosted saquinavir 1200\u00a0mg tid)", "ParentId": "4ec465fe-acb1-42f9-baf3-8b3d3546ea0f"}, {"Element": "<br/>", "ID": "5c16a5e0-a5d5-4691-bcee-81bf3e557046", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a9521b60-2fb7-4ad4-85fb-d2570627d1a5"}, {"Element": "<br/>", "ID": "78538a7a-4b1b-417e-bab9-4deea6769aeb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a9521b60-2fb7-4ad4-85fb-d2570627d1a5"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"FR-CH\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"FR-CH\"> 51\u00a0%<br/>\n  Saquinavir Ctrough </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"FR-CH\"> 49\u00a0% (8 hours post dose)<br/>\n  Saquinavir Cmax </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"FR-CH\"> 54\u00a0%.</span></p>\n</td>", "ID": "ab5590ad-d9dd-4dfb-b85a-dfe01f818533", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "17b1efdc-4c49-4ddf-aa9c-62e3aedfe72a"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"FR-CH\">Saquinavir AUC </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"FR-CH\"> 51\u00a0%<br/>\n  Saquinavir Ctrough </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"FR-CH\"> 49\u00a0% (8 hours post dose)<br/>\n  Saquinavir Cmax </span><span style=\"font-family:Symbol\">\u00af</span><span lang=\"FR-CH\"> 54\u00a0%.</span></p>", "ID": "15bb74f0-b523-4038-a2aa-ade19a40036d", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "ab5590ad-d9dd-4dfb-b85a-dfe01f818533"}, {"Element": "<span lang=\"FR-CH\">Saquinavir AUC </span>", "ID": "2e706249-569a-4371-ae34-37fa830a6a0d", "Styles": "None", "Classes": "None", "Text": "Saquinavir AUC ", "ParentId": "15bb74f0-b523-4038-a2aa-ade19a40036d"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "4206dd37-7f9a-4af7-9524-b9d94e202ac9", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "15bb74f0-b523-4038-a2aa-ade19a40036d"}, {"Element": "<span lang=\"FR-CH\"> 51\u00a0%<br/>\n  Saquinavir Ctrough </span>", "ID": "82fe850d-147a-4c53-8c2d-864eb8d24d11", "Styles": "None", "Classes": "None", "Text": " 51\u00a0%   Saquinavir Ctrough ", "ParentId": "15bb74f0-b523-4038-a2aa-ade19a40036d"}, {"Element": "<br/>", "ID": "00cb9d5c-b173-4e4d-b4c8-5bf3b99e70e7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "82fe850d-147a-4c53-8c2d-864eb8d24d11"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "b146f299-a0e2-49f7-848b-0be14862e0c3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "15bb74f0-b523-4038-a2aa-ade19a40036d"}, {"Element": "<span lang=\"FR-CH\"> 49\u00a0% (8 hours post dose)<br/>\n  Saquinavir Cmax </span>", "ID": "5d7f3c27-e3b2-44a5-8923-ef9926b8eff5", "Styles": "None", "Classes": "None", "Text": " 49\u00a0% (8 hours post dose)   Saquinavir Cmax ", "ParentId": "15bb74f0-b523-4038-a2aa-ade19a40036d"}, {"Element": "<br/>", "ID": "9c800b78-72c5-4700-89fe-7837cf716e07", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5d7f3c27-e3b2-44a5-8923-ef9926b8eff5"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "576cff71-4a61-424b-99f2-0f9bbfce4c48", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "15bb74f0-b523-4038-a2aa-ade19a40036d"}, {"Element": "<span lang=\"FR-CH\"> 54\u00a0%.</span>", "ID": "a1f38506-b702-4980-bb5c-fb2bddfd857c", "Styles": "None", "Classes": "None", "Text": " 54\u00a0%.", "ParentId": "15bb74f0-b523-4038-a2aa-ade19a40036d"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:9.35pt\">Patients on saquinavir\n  treatment must not take garlic capsules due to the risk of decreased plasma\n  concentrations and loss of virological response and possible resistance to\n  one or more components of the antiretroviral regimen.</p>\n</td>", "ID": "50691172-ede6-46d5-8382-f161f4fc86f6", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "17b1efdc-4c49-4ddf-aa9c-62e3aedfe72a"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:9.35pt\">Patients on saquinavir\n  treatment must not take garlic capsules due to the risk of decreased plasma\n  concentrations and loss of virological response and possible resistance to\n  one or more components of the antiretroviral regimen.</p>", "ID": "283a3be7-5114-4cdd-8262-13e125971df6", "Styles": "margin-left:9.35pt", "Classes": "['Normal11pt0']", "Text": "Patients on saquinavir   treatment must not take garlic capsules due to the risk of decreased plasma   concentrations and loss of virological response and possible resistance to   one or more components of the antiretroviral regimen.", "ParentId": "50691172-ede6-46d5-8382-f161f4fc86f6"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">St. John\u2019s wort <br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt;page-break-after:avoid\"><span lang=\"EN-GB\">Interaction with Invirase/ritonavir not studied.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:12.6pt;text-indent:-9.35pt;\n  page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "a4deb7ea-0dca-4cec-b4b3-bbbb7958039e", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">St. John\u2019s wort <br/>\n  (saquinavir/ritonavir)</span></p>\n</td>", "ID": "3d0a600b-800f-49f7-a916-639ddc5fe9fa", "Styles": "width:131.4pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a4deb7ea-0dca-4cec-b4b3-bbbb7958039e"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">St. John\u2019s wort <br/>\n  (saquinavir/ritonavir)</span></p>", "ID": "20029808-9fe2-4a8b-9739-d2bf5b668716", "Styles": "text-indent:-9.35pt;page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0 ", "ParentId": "3d0a600b-800f-49f7-a916-639ddc5fe9fa"}, {"Element": "<span lang=\"EN-GB\">St. John\u2019s wort <br/>\n  (saquinavir/ritonavir)</span>", "ID": "48918b4f-22e2-43a9-abf0-8226fc0ffbfa", "Styles": "None", "Classes": "None", "Text": "St. John\u2019s wort    (saquinavir/ritonavir)", "ParentId": "20029808-9fe2-4a8b-9739-d2bf5b668716"}, {"Element": "<br/>", "ID": "291e51e8-7168-4154-af38-1c0e3e573199", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "48918b4f-22e2-43a9-abf0-8226fc0ffbfa"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt;page-break-after:avoid\"><span lang=\"EN-GB\">Interaction with Invirase/ritonavir not studied.</span></p>\n</td>", "ID": "97885318-3567-4b58-b9ce-4fb452bf338b", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a4deb7ea-0dca-4cec-b4b3-bbbb7958039e"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:3.3pt;page-break-after:avoid\"><span lang=\"EN-GB\">Interaction with Invirase/ritonavir not studied.</span></p>", "ID": "24aefe43-f395-4200-ae9b-f85606424048", "Styles": "margin-left:3.3pt;page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "97885318-3567-4b58-b9ce-4fb452bf338b"}, {"Element": "<span lang=\"EN-GB\">Interaction with Invirase/ritonavir not studied.</span>", "ID": "be079ca0-9284-47c4-982d-19940fa55d31", "Styles": "None", "Classes": "None", "Text": "Interaction with Invirase/ritonavir not studied.", "ParentId": "24aefe43-f395-4200-ae9b-f85606424048"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"margin-left:12.6pt;text-indent:-9.35pt;\n  page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "cc38e2ab-d891-45f4-9fe8-994356dfd1c9", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a4deb7ea-0dca-4cec-b4b3-bbbb7958039e"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:12.6pt;text-indent:-9.35pt;\n  page-break-after:avoid\">\u00a0</p>", "ID": "00b77285-569d-4dad-8185-0a67789923a6", "Styles": "margin-left:12.6pt;text-indent:-9.35pt;\n  page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "cc38e2ab-d891-45f4-9fe8-994356dfd1c9"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">St. John\u2019s wort </span><br/>\n  (unboosted saquinavir)</p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt;page-break-after:avoid\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <span lang=\"EN-GB\">Plasma levels of unboosted saquinavir can be reduced by\n  concomitant use of the herbal preparation St. John\u2019s wort <i>(Hypericum\n  perforatum)</i>. This is due to induction of drug metabolising enzymes and/or\n  transport proteins by St. John\u2019s wort.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Herbal\n  preparations containing St. John\u2019s wort must not be used concomitantly\n  with Invirase. If a patient is already taking St. John\u2019s wort, stop St.\n  John\u2019s wort, check viral levels and if possible saquinavir levels.\n  Saquinavir levels may increase on stopping St. John\u2019s wort, and the\n  dose of saquinavir may need adjusting. The inducing effect of St.\n  John\u2019s wort may persist for at least 2 weeks after cessation of\n  treatment.</span></p>\n</td>\n</tr>", "ID": "e1962d9c-5f2e-4daa-9c37-65eef4474cc5", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">St. John\u2019s wort </span><br/>\n  (unboosted saquinavir)</p>\n</td>", "ID": "b9b93387-b3ac-4e7e-bcf4-89e3a1131b04", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e1962d9c-5f2e-4daa-9c37-65eef4474cc5"}, {"Element": "<p class=\"Normal11pt0\" style=\"text-indent:-9.35pt;page-break-after:avoid\">-\u00a0 <span lang=\"EN-GB\">St. John\u2019s wort </span><br/>\n  (unboosted saquinavir)</p>", "ID": "98386a98-9625-4b94-aa63-91c15a927034", "Styles": "text-indent:-9.35pt;page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "-\u00a0    (unboosted saquinavir)", "ParentId": "b9b93387-b3ac-4e7e-bcf4-89e3a1131b04"}, {"Element": "<span lang=\"EN-GB\">St. John\u2019s wort </span>", "ID": "8c506183-5f6f-4733-8e5b-f224d2472b8e", "Styles": "None", "Classes": "None", "Text": "St. John\u2019s wort ", "ParentId": "98386a98-9625-4b94-aa63-91c15a927034"}, {"Element": "<br/>", "ID": "db455318-dee9-404a-b70f-bb4c034bc7ee", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "98386a98-9625-4b94-aa63-91c15a927034"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"margin-left:3.3pt;page-break-after:avoid\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <span lang=\"EN-GB\">Plasma levels of unboosted saquinavir can be reduced by\n  concomitant use of the herbal preparation St. John\u2019s wort <i>(Hypericum\n  perforatum)</i>. This is due to induction of drug metabolising enzymes and/or\n  transport proteins by St. John\u2019s wort.</span></p>\n</td>", "ID": "7ebf3fce-e5c5-4ef7-8b91-0289a1c7248b", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e1962d9c-5f2e-4daa-9c37-65eef4474cc5"}, {"Element": "<p class=\"Normal11pt0\" style=\"margin-left:3.3pt;page-break-after:avoid\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <span lang=\"EN-GB\">Plasma levels of unboosted saquinavir can be reduced by\n  concomitant use of the herbal preparation St. John\u2019s wort <i>(Hypericum\n  perforatum)</i>. This is due to induction of drug metabolising enzymes and/or\n  transport proteins by St. John\u2019s wort.</span></p>", "ID": "d7558a75-aa64-41f6-a5f1-6bccf8a60e9f", "Styles": "margin-left:3.3pt;page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7ebf3fce-e5c5-4ef7-8b91-0289a1c7248b"}, {"Element": "<span lang=\"EN-GB\">Plasma levels of unboosted saquinavir can be reduced by\n  concomitant use of the herbal preparation St. John\u2019s wort <i>(Hypericum\n  perforatum)</i>. This is due to induction of drug metabolising enzymes and/or\n  transport proteins by St. John\u2019s wort.</span>", "ID": "80a13576-457e-4f32-b663-a16f8c8678ef", "Styles": "None", "Classes": "None", "Text": "Plasma levels of unboosted saquinavir can be reduced by   concomitant use of the herbal preparation St. John\u2019s wort . This is due to induction of drug metabolising enzymes and/or   transport proteins by St. John\u2019s wort.", "ParentId": "d7558a75-aa64-41f6-a5f1-6bccf8a60e9f"}, {"Element": "<i>(Hypericum\n  perforatum)</i>", "ID": "31bcd90d-3ede-4aad-9279-a1394f5de908", "Styles": "None", "Classes": "None", "Text": "(Hypericum   perforatum)", "ParentId": "80a13576-457e-4f32-b663-a16f8c8678ef"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Herbal\n  preparations containing St. John\u2019s wort must not be used concomitantly\n  with Invirase. If a patient is already taking St. John\u2019s wort, stop St.\n  John\u2019s wort, check viral levels and if possible saquinavir levels.\n  Saquinavir levels may increase on stopping St. John\u2019s wort, and the\n  dose of saquinavir may need adjusting. The inducing effect of St.\n  John\u2019s wort may persist for at least 2 weeks after cessation of\n  treatment.</span></p>\n</td>", "ID": "d5b70145-092c-435c-8deb-5dcb8ad69f06", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e1962d9c-5f2e-4daa-9c37-65eef4474cc5"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Herbal\n  preparations containing St. John\u2019s wort must not be used concomitantly\n  with Invirase. If a patient is already taking St. John\u2019s wort, stop St.\n  John\u2019s wort, check viral levels and if possible saquinavir levels.\n  Saquinavir levels may increase on stopping St. John\u2019s wort, and the\n  dose of saquinavir may need adjusting. The inducing effect of St.\n  John\u2019s wort may persist for at least 2 weeks after cessation of\n  treatment.</span></p>", "ID": "ad05daee-5f9d-4570-bc34-fb7628c5e2fa", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "d5b70145-092c-435c-8deb-5dcb8ad69f06"}, {"Element": "<span lang=\"EN-GB\">Herbal\n  preparations containing St. John\u2019s wort must not be used concomitantly\n  with Invirase. If a patient is already taking St. John\u2019s wort, stop St.\n  John\u2019s wort, check viral levels and if possible saquinavir levels.\n  Saquinavir levels may increase on stopping St. John\u2019s wort, and the\n  dose of saquinavir may need adjusting. The inducing effect of St.\n  John\u2019s wort may persist for at least 2 weeks after cessation of\n  treatment.</span>", "ID": "d00651e3-f53d-41e9-9cf4-b317e465e40a", "Styles": "None", "Classes": "None", "Text": "Herbal   preparations containing St. John\u2019s wort must not be used concomitantly   with Invirase. If a patient is already taking St. John\u2019s wort, stop St.   John\u2019s wort, check viral levels and if possible saquinavir levels.   Saquinavir levels may increase on stopping St. John\u2019s wort, and the   dose of saquinavir may need adjusting. The inducing effect of St.   John\u2019s wort may persist for at least 2 weeks after cessation of   treatment.", "ParentId": "ad05daee-5f9d-4570-bc34-fb7628c5e2fa"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><u><span lang=\"EN-GB\">Other\n  potential interactions</span></u></i></b></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Medicinal\n  products that are substrates of CYP3A4</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "1dc16d56-858c-4a26-8948-8da737aa7bee", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><u><span lang=\"EN-GB\">Other\n  potential interactions</span></u></i></b></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Medicinal\n  products that are substrates of CYP3A4</span></i></b></p>\n</td>", "ID": "de495f08-2bce-4bed-b8ae-18aaaa53ddbd", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "1dc16d56-858c-4a26-8948-8da737aa7bee"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><u><span lang=\"EN-GB\">Other\n  potential interactions</span></u></i></b></p>", "ID": "c5753835-268b-4379-b575-ca7952defa6b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "de495f08-2bce-4bed-b8ae-18aaaa53ddbd"}, {"Element": "<b><i><u><span lang=\"EN-GB\">Other\n  potential interactions</span></u></i></b>", "ID": "4a8c82ce-4f19-439c-b228-4aceb1513958", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c5753835-268b-4379-b575-ca7952defa6b"}, {"Element": "<i><u><span lang=\"EN-GB\">Other\n  potential interactions</span></u></i>", "ID": "a0ebe677-d6f1-455d-ac26-4d17329e5d18", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4a8c82ce-4f19-439c-b228-4aceb1513958"}, {"Element": "<u><span lang=\"EN-GB\">Other\n  potential interactions</span></u>", "ID": "b4cb6ada-7bf7-4cea-a3e8-c166fa4c39fa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a0ebe677-d6f1-455d-ac26-4d17329e5d18"}, {"Element": "<span lang=\"EN-GB\">Other\n  potential interactions</span>", "ID": "f5d74466-60ce-42cc-bcee-f77893f10d89", "Styles": "None", "Classes": "None", "Text": "Other   potential interactions", "ParentId": "b4cb6ada-7bf7-4cea-a3e8-c166fa4c39fa"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Medicinal\n  products that are substrates of CYP3A4</span></i></b></p>", "ID": "7300a415-226d-486c-bdb9-6707e6e54c30", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "de495f08-2bce-4bed-b8ae-18aaaa53ddbd"}, {"Element": "<b><i><span lang=\"EN-GB\">Medicinal\n  products that are substrates of CYP3A4</span></i></b>", "ID": "0e317f52-27f9-49ad-9767-ce76fdd51584", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7300a415-226d-486c-bdb9-6707e6e54c30"}, {"Element": "<i><span lang=\"EN-GB\">Medicinal\n  products that are substrates of CYP3A4</span></i>", "ID": "2f5f497b-461b-4547-b5dd-f6bc2fd0d9f6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0e317f52-27f9-49ad-9767-ce76fdd51584"}, {"Element": "<span lang=\"EN-GB\">Medicinal\n  products that are substrates of CYP3A4</span>", "ID": "c084617f-19bb-4c5d-84e8-bea415616ad0", "Styles": "None", "Classes": "None", "Text": "Medicinal   products that are substrates of CYP3A4", "ParentId": "2f5f497b-461b-4547-b5dd-f6bc2fd0d9f6"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "5136fb1f-a32f-4375-82fc-9500602cf619", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1dc16d56-858c-4a26-8948-8da737aa7bee"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "1854e632-693f-4667-b674-66f081522537", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "5136fb1f-a32f-4375-82fc-9500602cf619"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "b5651ec1-71d9-4caa-bda5-dfe2417fb91d", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1dc16d56-858c-4a26-8948-8da737aa7bee"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "33f52ae5-5408-4738-8124-6e508c944857", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "b5651ec1-71d9-4caa-bda5-dfe2417fb91d"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">e.g.\n  dapsone, disopyramide, quinine, fentanyl, and alfentanyl</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "e2b1532a-0bd8-44ab-8c15-35eb6a1fb1b1", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">e.g.\n  dapsone, disopyramide, quinine, fentanyl, and alfentanyl</span></p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n</td>", "ID": "dc8921e5-4e87-457d-b27d-f49e63d31d58", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "e2b1532a-0bd8-44ab-8c15-35eb6a1fb1b1"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">e.g.\n  dapsone, disopyramide, quinine, fentanyl, and alfentanyl</span></p>", "ID": "0f0e23a6-0e1b-4d01-acef-545b00fbd9c4", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "dc8921e5-4e87-457d-b27d-f49e63d31d58"}, {"Element": "<span lang=\"EN-GB\">e.g.\n  dapsone, disopyramide, quinine, fentanyl, and alfentanyl</span>", "ID": "8481a857-b137-4337-b493-e7d020407179", "Styles": "None", "Classes": "None", "Text": "e.g.   dapsone, disopyramide, quinine, fentanyl, and alfentanyl", "ParentId": "0f0e23a6-0e1b-4d01-acef-545b00fbd9c4"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "3203f347-0657-4262-a0c7-951fa21daca9", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "dc8921e5-4e87-457d-b27d-f49e63d31d58"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "2da1c3fb-0af4-4b79-b920-09d0931d2e10", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3203f347-0657-4262-a0c7-951fa21daca9"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "63a6fcec-6e23-4944-aeb9-673366ca45cd", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "2da1c3fb-0af4-4b79-b920-09d0931d2e10"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span></p>\n</td>", "ID": "9b3928d0-114b-49fc-8e8d-78a563b2e52f", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e2b1532a-0bd8-44ab-8c15-35eb6a1fb1b1"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span></p>", "ID": "66a51825-b7dc-4ef6-ad69-93f88cd1eef9", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "9b3928d0-114b-49fc-8e8d-78a563b2e52f"}, {"Element": "<span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span>", "ID": "5962c2ea-6f0e-45fd-b86d-2d6346d3c418", "Styles": "None", "Classes": "None", "Text": "Although   specific studies have not been performed, co-administration of   Invirase/ritonavir with medicinal products that are mainly metabolised by   CYP3A4 pathway may result in elevated plasma concentrations of these   medicinal products.", "ParentId": "66a51825-b7dc-4ef6-ad69-93f88cd1eef9"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "099f402e-61ea-40f9-9a5f-8921863895e8", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e2b1532a-0bd8-44ab-8c15-35eb6a1fb1b1"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to\n  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "795a8bbb-c69b-4a33-b74e-f7c2f19fb6c0", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated in   combination with  due to   potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)", "ParentId": "099f402e-61ea-40f9-9a5f-8921863895e8"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "3f9e1bcf-bae6-4da6-a781-7f1ac5ba429f", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "795a8bbb-c69b-4a33-b74e-f7c2f19fb6c0"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "f50b156d-8e2c-45fe-bd32-9e06acea6b10", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "795a8bbb-c69b-4a33-b74e-f7c2f19fb6c0"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"IT\">Gastroenterological medicinal\n  products</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n</tr>", "ID": "4d0f3225-c07b-4235-b466-3d704c9ec9c6", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\"><b><i><span lang=\"IT\">Gastroenterological medicinal\n  products</span></i></b></p>\n</td>", "ID": "be6feaa5-7d2d-43b7-b568-7248693bccc5", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4d0f3225-c07b-4235-b466-3d704c9ec9c6"}, {"Element": "<p class=\"Normal11pt0\"><b><i><span lang=\"IT\">Gastroenterological medicinal\n  products</span></i></b></p>", "ID": "16917b8a-397a-4d4e-9b31-424408b46078", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "be6feaa5-7d2d-43b7-b568-7248693bccc5"}, {"Element": "<b><i><span lang=\"IT\">Gastroenterological medicinal\n  products</span></i></b>", "ID": "3ad8d067-3fbd-4f0c-97ac-aaca3f82e737", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "16917b8a-397a-4d4e-9b31-424408b46078"}, {"Element": "<i><span lang=\"IT\">Gastroenterological medicinal\n  products</span></i>", "ID": "de762d5e-78d0-4265-a2c0-4cc5beeba6f1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3ad8d067-3fbd-4f0c-97ac-aaca3f82e737"}, {"Element": "<span lang=\"IT\">Gastroenterological medicinal\n  products</span>", "ID": "35c753fc-ef90-4f95-a8e1-d9f9dece6fde", "Styles": "None", "Classes": "None", "Text": "Gastroenterological medicinal   products", "ParentId": "de762d5e-78d0-4265-a2c0-4cc5beeba6f1"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>", "ID": "9d1b5ae9-7a13-4698-b5c7-d83e62a2ccad", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4d0f3225-c07b-4235-b466-3d704c9ec9c6"}, {"Element": "<p class=\"Normal11pt0\">\u00a0</p>", "ID": "1aac4d84-ac24-4d60-bf9c-ad4621f38918", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "9d1b5ae9-7a13-4698-b5c7-d83e62a2ccad"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>", "ID": "0afff653-ecad-4ab0-8637-f1b0d7a37b28", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4d0f3225-c07b-4235-b466-3d704c9ec9c6"}, {"Element": "<p class=\"Normal11pt0\">\u00a0</p>", "ID": "8b837b65-86d4-43dd-9b22-4975abb09e51", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "0afff653-ecad-4ab0-8637-f1b0d7a37b28"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Metoclopramide</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">It is unknown whether medicinal\n  products which reduce the gastrointestinal transit time could lead to lower\n  saquinavir plasma concentrations.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>\n</tr>", "ID": "df439d2d-212d-4ad4-b916-5bd9c19697a6", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Metoclopramide</span></p>\n</td>", "ID": "4410a886-6f9b-456d-a344-26a8b157e188", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "df439d2d-212d-4ad4-b916-5bd9c19697a6"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">Metoclopramide</span></p>", "ID": "f4d87b3c-8131-4324-a870-f610810d2bfe", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "4410a886-6f9b-456d-a344-26a8b157e188"}, {"Element": "<span lang=\"EN-GB\">Metoclopramide</span>", "ID": "b8e731f6-4851-408e-a75c-b3b2c5f678a3", "Styles": "None", "Classes": "None", "Text": "Metoclopramide", "ParentId": "f4d87b3c-8131-4324-a870-f610810d2bfe"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">It is unknown whether medicinal\n  products which reduce the gastrointestinal transit time could lead to lower\n  saquinavir plasma concentrations.</span></p>\n</td>", "ID": "39298228-7976-4261-841d-7a72369a409f", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "df439d2d-212d-4ad4-b916-5bd9c19697a6"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">It is unknown whether medicinal\n  products which reduce the gastrointestinal transit time could lead to lower\n  saquinavir plasma concentrations.</span></p>", "ID": "658ee9ab-4349-4702-96ef-a4b498701952", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "39298228-7976-4261-841d-7a72369a409f"}, {"Element": "<span lang=\"EN-GB\">It is unknown whether medicinal\n  products which reduce the gastrointestinal transit time could lead to lower\n  saquinavir plasma concentrations.</span>", "ID": "8fa9754e-f280-47a6-846a-2d7417d3fa08", "Styles": "None", "Classes": "None", "Text": "It is unknown whether medicinal   products which reduce the gastrointestinal transit time could lead to lower   saquinavir plasma concentrations.", "ParentId": "658ee9ab-4349-4702-96ef-a4b498701952"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">\u00a0</p>\n</td>", "ID": "09bf9c85-34f3-46bf-a4d5-6e94060e55b4", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "df439d2d-212d-4ad4-b916-5bd9c19697a6"}, {"Element": "<p class=\"Normal11pt0\">\u00a0</p>", "ID": "c1daa199-d5f7-4edb-93c2-f8be43e38e12", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "09bf9c85-34f3-46bf-a4d5-6e94060e55b4"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Cisapride<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to potentially\n  life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "c4cb1b03-fdcb-4d02-80f1-77eeae321b54", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Cisapride<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>", "ID": "d910404b-65b0-46fb-993e-bfb92af6a75e", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c4cb1b03-fdcb-4d02-80f1-77eeae321b54"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"IT\">Cisapride<br/>\n  (saquinavir/ritonavir)</span></p>", "ID": "c1d88d3c-db45-4834-8463-310895c4c061", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "d910404b-65b0-46fb-993e-bfb92af6a75e"}, {"Element": "<span lang=\"IT\">Cisapride<br/>\n  (saquinavir/ritonavir)</span>", "ID": "53584f9c-ba17-4bac-84d9-81e1759b55d8", "Styles": "None", "Classes": "None", "Text": "Cisapride   (saquinavir/ritonavir)", "ParentId": "c1d88d3c-db45-4834-8463-310895c4c061"}, {"Element": "<br/>", "ID": "2b39f30e-52fb-493d-bc1c-a5de48f55b79", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "53584f9c-ba17-4bac-84d9-81e1759b55d8"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span></p>\n</td>", "ID": "e711338c-2a81-48c4-8f70-1567962e096a", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c4cb1b03-fdcb-4d02-80f1-77eeae321b54"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span></p>", "ID": "78f86f5b-330b-4437-a92d-a7229b765c91", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "e711338c-2a81-48c4-8f70-1567962e096a"}, {"Element": "<span lang=\"EN-GB\">Although\n  specific studies have not been performed, co-administration of\n  Invirase/ritonavir with medicinal products that are mainly metabolised by\n  CYP3A4 pathway may result in elevated plasma concentrations of these\n  medicinal products.</span>", "ID": "bad2a2ea-84b4-4830-ab34-3cd772399647", "Styles": "None", "Classes": "None", "Text": "Although   specific studies have not been performed, co-administration of   Invirase/ritonavir with medicinal products that are mainly metabolised by   CYP3A4 pathway may result in elevated plasma concentrations of these   medicinal products.", "ParentId": "78f86f5b-330b-4437-a92d-a7229b765c91"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to potentially\n  life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "14bc1778-ac79-40dc-ad7f-304eb301ffbc", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c4cb1b03-fdcb-4d02-80f1-77eeae321b54"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to potentially\n  life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "35dc21d7-cf3d-4a20-b5c7-042dca30d8f0", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated in   combination with  due to potentially   life threatening cardiac arrhythmia (see sections 4.3 and 4.4)", "ParentId": "14bc1778-ac79-40dc-ad7f-304eb301ffbc"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "2120a38c-327c-45e7-83f6-5e8cc17ccd1a", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "35dc21d7-cf3d-4a20-b5c7-042dca30d8f0"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "4f713435-1658-45d2-aacd-cd8628fd9af6", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "35dc21d7-cf3d-4a20-b5c7-042dca30d8f0"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Diphemanil<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to potentially life threatening cardiac arrhythmia (see sections 4.3 and\n  4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "795c886b-0f5e-4489-9f94-61fe57c32ce2", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\"><span lang=\"IT\">Diphemanil<br/>\n  (saquinavir/ritonavir)</span></p>\n</td>", "ID": "63276539-1a5d-4983-be29-9a58e5fb7795", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "795c886b-0f5e-4489-9f94-61fe57c32ce2"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"IT\">Diphemanil<br/>\n  (saquinavir/ritonavir)</span></p>", "ID": "9f5d7e8a-f1d9-43aa-ac1d-f712612c8c03", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "63276539-1a5d-4983-be29-9a58e5fb7795"}, {"Element": "<span lang=\"IT\">Diphemanil<br/>\n  (saquinavir/ritonavir)</span>", "ID": "473179a7-379f-4adf-9e27-858b7d96da80", "Styles": "None", "Classes": "None", "Text": "Diphemanil   (saquinavir/ritonavir)", "ParentId": "9f5d7e8a-f1d9-43aa-ac1d-f712612c8c03"}, {"Element": "<br/>", "ID": "386586ef-c4f9-42a6-9420-c2d500cbbdfb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "473179a7-379f-4adf-9e27-858b7d96da80"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "f95b726f-2500-45be-b37e-f92691125752", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "795c886b-0f5e-4489-9f94-61fe57c32ce2"}, {"Element": "<p class=\"Normal11pt0\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ed5ec0ac-07ae-475c-bcb4-998a92be0730", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "f95b726f-2500-45be-b37e-f92691125752"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ced693af-e7f8-464e-a511-da63810c0e19", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ed5ec0ac-07ae-475c-bcb4-998a92be0730"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to potentially life threatening cardiac arrhythmia (see sections 4.3 and\n  4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "fab9df8d-c18f-4913-add9-58f43f1033aa", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "795c886b-0f5e-4489-9f94-61fe57c32ce2"}, {"Element": "<p class=\"Normal11pt0\">Contraindicated in combination with <span lang=\"EN-GB\">Invirase/ritonavir</span>\n  due to potentially life threatening cardiac arrhythmia (see sections 4.3 and\n  4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "14f48071-bf27-451f-b054-6e980d81ee0a", "Styles": "None", "Classes": "['Normal11pt0']", "Text": "Contraindicated in combination with    due to potentially life threatening cardiac arrhythmia (see sections 4.3 and   4.4)", "ParentId": "fab9df8d-c18f-4913-add9-58f43f1033aa"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "3b830cb9-5ff1-4588-8a70-6767d85ee4c0", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "14f48071-bf27-451f-b054-6e980d81ee0a"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "051577bf-ec7c-47eb-b4d4-84841f0adc5b", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "14f48071-bf27-451f-b054-6e980d81ee0a"}, {"Element": "<tr>\n<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Vasodilators\n  (peripheral)</span></i></b></p>\n</td>\n<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "a1698b0a-3e90-4a32-a190-fc3420f10961", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td colspan=\"5\" style=\"width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"615\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Vasodilators\n  (peripheral)</span></i></b></p>\n</td>", "ID": "295043fb-3fb2-4ede-b8f3-656c1a39e799", "Styles": "width:461.6pt;border-top:none;\n  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\n  border-right:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a1698b0a-3e90-4a32-a190-fc3420f10961"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b><i><span lang=\"IT\">Vasodilators\n  (peripheral)</span></i></b></p>", "ID": "94862a9e-0c2b-4dc6-8965-4c37251e5a4d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "295043fb-3fb2-4ede-b8f3-656c1a39e799"}, {"Element": "<b><i><span lang=\"IT\">Vasodilators\n  (peripheral)</span></i></b>", "ID": "c413b10e-3732-48b5-925c-d7e91a6f8a4d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "94862a9e-0c2b-4dc6-8965-4c37251e5a4d"}, {"Element": "<i><span lang=\"IT\">Vasodilators\n  (peripheral)</span></i>", "ID": "1fb846f9-f20c-4b1d-a592-0c0f17b27eb9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c413b10e-3732-48b5-925c-d7e91a6f8a4d"}, {"Element": "<span lang=\"IT\">Vasodilators\n  (peripheral)</span>", "ID": "d5f5d5fc-5576-4155-9f16-0d76dbdf65c1", "Styles": "None", "Classes": "None", "Text": "Vasodilators   (peripheral)", "ParentId": "1fb846f9-f20c-4b1d-a592-0c0f17b27eb9"}, {"Element": "<td style=\"width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"16\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "841d72f3-4c22-49f0-b0a9-f2ade8be8b16", "Styles": "width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a1698b0a-3e90-4a32-a190-fc3420f10961"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "d5407e25-6bd9-43dd-a64b-63496c70cc6c", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "841d72f3-4c22-49f0-b0a9-f2ade8be8b16"}, {"Element": "<td style=\"width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"19\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "7b40a225-eedd-483e-811a-c4f1d9771eb4", "Styles": "width:14.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a1698b0a-3e90-4a32-a190-fc3420f10961"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "6f1d11f1-6b5e-4e4c-bf2c-33246a8ce447", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "7b40a225-eedd-483e-811a-c4f1d9771eb4"}, {"Element": "<tr>\n<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vincamine\n  i.v.</span></p>\n</td>\n<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "6db70174-1de0-4180-b2a6-77265c9e12c4", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"175\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vincamine\n  i.v.</span></p>\n</td>", "ID": "c1ee9dc5-8805-4ac5-84d7-d2df7c5d62dd", "Styles": "width:131.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6db70174-1de0-4180-b2a6-77265c9e12c4"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vincamine\n  i.v.</span></p>", "ID": "e0aefffe-6e4f-4cdc-b903-32e463fddb23", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "c1ee9dc5-8805-4ac5-84d7-d2df7c5d62dd"}, {"Element": "<span lang=\"EN-GB\">Vincamine\n  i.v.</span>", "ID": "2877208c-1de1-40b7-a1e3-6eeeb7699076", "Styles": "None", "Classes": "None", "Text": "Vincamine   i.v.", "ParentId": "e0aefffe-6e4f-4cdc-b903-32e463fddb23"}, {"Element": "<td colspan=\"3\" style=\"width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"240\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "5246f964-0002-4867-9f81-66376ca4e7ab", "Styles": "width:2.5in;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6db70174-1de0-4180-b2a6-77265c9e12c4"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "0993b227-c0e1-4179-9782-981b1d59888b", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "5246f964-0002-4867-9f81-66376ca4e7ab"}, {"Element": "<td colspan=\"3\" style=\"width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"235\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "b4be4940-7732-4deb-8a6d-a08ed1224ea6", "Styles": "width:176.2pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6db70174-1de0-4180-b2a6-77265c9e12c4"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Contraindicated in\n  combination with <span lang=\"EN-GB\">Invirase/ritonavir</span> due to the\n  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=\"EN-GB\">.</span></p>", "ID": "b7c553c2-ba84-43fa-86e1-95a5280ff497", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Contraindicated in   combination with  due to the   potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)", "ParentId": "b4be4940-7732-4deb-8a6d-a08ed1224ea6"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir</span>", "ID": "e9dd5602-7628-4750-9ffd-1445d3c9d05b", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "b7c553c2-ba84-43fa-86e1-95a5280ff497"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "2e417ce4-da5f-4357-a749-b3d20304d76d", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "b7c553c2-ba84-43fa-86e1-95a5280ff497"}, {"Element": "<tr height=\"0\">\n<td style=\"border:none\" width=\"175\"></td>\n<td style=\"border:none\" width=\"2\"></td>\n<td style=\"border:none\" width=\"236\"></td>\n<td style=\"border:none\" width=\"2\"></td>\n<td style=\"border:none\" width=\"200\"></td>\n<td style=\"border:none\" width=\"16\"></td>\n<td style=\"border:none\" width=\"19\"></td>\n</tr>", "ID": "32d5010b-170f-4e1b-9346-d7148078f816", "Styles": "None", "Classes": "None", "Text": "        ", "ParentId": "ec4aa98f-873a-41b4-8ff4-6d875320e4f2"}, {"Element": "<td style=\"border:none\" width=\"175\"></td>", "ID": "acb7dcae-1fc5-419d-b349-9a533a9b07a2", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "32d5010b-170f-4e1b-9346-d7148078f816"}, {"Element": "<td style=\"border:none\" width=\"2\"></td>", "ID": "6743ff6a-029e-430c-bc12-3d46d9ae32b8", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "32d5010b-170f-4e1b-9346-d7148078f816"}, {"Element": "<td style=\"border:none\" width=\"236\"></td>", "ID": "6e3c6e14-2b7b-4a5a-8e97-7ff549101fc5", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "32d5010b-170f-4e1b-9346-d7148078f816"}, {"Element": "<td style=\"border:none\" width=\"2\"></td>", "ID": "e2a536a1-03e3-44b8-b0df-d0fee3499631", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "32d5010b-170f-4e1b-9346-d7148078f816"}, {"Element": "<td style=\"border:none\" width=\"200\"></td>", "ID": "50e37b25-98f8-45a0-8a2b-c1063ced7517", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "32d5010b-170f-4e1b-9346-d7148078f816"}, {"Element": "<td style=\"border:none\" width=\"16\"></td>", "ID": "3bd4fd1f-2d50-465a-8f43-64a4404e8a45", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "32d5010b-170f-4e1b-9346-d7148078f816"}, {"Element": "<td style=\"border:none\" width=\"19\"></td>", "ID": "20ae4ae6-2cff-42d0-89d1-743a62550843", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "32d5010b-170f-4e1b-9346-d7148078f816"}, {"Element": "<p class=\"MsoNormal\"><i><u>Key:</u></i> <span style=\"font-family:Symbol\">\u00af</span>\nreduced, \u2191 increased, <span style=\"font-family:Symbol\">\u00ab</span>\nunchanged, \u2191\u2191 markedly increased</p>", "ID": "e281022f-9e56-421a-9612-8815b4b425b7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "  reduced, \u2191 increased,  unchanged, \u2191\u2191 markedly increased", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<i><u>Key:</u></i>", "ID": "8063530c-b0c7-4e20-a0ab-29a610bd7a1e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e281022f-9e56-421a-9612-8815b4b425b7"}, {"Element": "<u>Key:</u>", "ID": "df6151f9-0f04-4262-964f-406b50696a93", "Styles": "None", "Classes": "None", "Text": "Key:", "ParentId": "8063530c-b0c7-4e20-a0ab-29a610bd7a1e"}, {"Element": "<span style=\"font-family:Symbol\">\u00af</span>", "ID": "8839fab9-22fc-4bfb-b7fe-847bfb662553", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00af", "ParentId": "e281022f-9e56-421a-9612-8815b4b425b7"}, {"Element": "<span style=\"font-family:Symbol\">\u00ab</span>", "ID": "8e5fdc12-e447-46f6-9edc-223ffde154d2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00ab", "ParentId": "e281022f-9e56-421a-9612-8815b4b425b7"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "5055f36f-8389-41fb-ba41-a085b06e2cfb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy and\nlactation</span></b></p>", "ID": "dc5c3ef8-1c17-4f23-9aea-1f28f6ae9ff5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy and\nlactation</span></b>", "ID": "24f5bd59-bb33-42fc-91af-3033f5138b4c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dc5c3ef8-1c17-4f23-9aea-1f28f6ae9ff5"}, {"Element": "<span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy and\nlactation</span>", "ID": "d555b593-511d-4c0f-a86a-aba069f3904c", "Styles": "None", "Classes": "None", "Text": "4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy and lactation", "ParentId": "24f5bd59-bb33-42fc-91af-3033f5138b4c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "754d394a-3baa-44be-9408-72107b7827f1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "45fffc04-0492-44ec-83eb-1d6d047eaed2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "754d394a-3baa-44be-9408-72107b7827f1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6cec36e8-92d4-401c-adb3-a722b5e21b44", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "45fffc04-0492-44ec-83eb-1d6d047eaed2"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Pregnancy</span></i></b><b><span lang=\"EN-GB\">: </span></b><span lang=\"EN-GB\">Evaluation of experimental animal\nstudies does not indicate direct or indirect harmful effects with respect to\nthe development of the embryo or foetus, the course of gestation and peri- and\npost-natal development. Clinical experience in pregnant women is limited:\nCongenital malformations, birth defects and other disorders (without a\ncongenital malformation) have been reported rarely in pregnant women who had\nreceived saquinavir in combination with other antiretroviral agents. However,\nso far the available data are insufficient and do not identify specific risks\nfor the unborn child. Saquinavir should be used during pregnancy only if the\npotential benefit justifies the potential risk to the foetus (see section 5.3).</span></p>", "ID": "06432ca2-f893-4489-a3e3-a1360ac02d26", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Pregnancy</span></i></b>", "ID": "160f5e88-4bbc-491b-b8f3-28df926b54fc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "06432ca2-f893-4489-a3e3-a1360ac02d26"}, {"Element": "<i><span lang=\"EN-GB\">Pregnancy</span></i>", "ID": "16b8a9cc-fd34-4742-8a47-446a6485c8f8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "160f5e88-4bbc-491b-b8f3-28df926b54fc"}, {"Element": "<span lang=\"EN-GB\">Pregnancy</span>", "ID": "b60735fe-5f2b-4387-8088-783ff84384b8", "Styles": "None", "Classes": "None", "Text": "Pregnancy", "ParentId": "16b8a9cc-fd34-4742-8a47-446a6485c8f8"}, {"Element": "<b><span lang=\"EN-GB\">: </span></b>", "ID": "3eac6cb7-79f7-4cf4-bee2-932722a7fb8a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "06432ca2-f893-4489-a3e3-a1360ac02d26"}, {"Element": "<span lang=\"EN-GB\">: </span>", "ID": "9e61b23e-3182-4b86-abf0-002a1fe36c12", "Styles": "None", "Classes": "None", "Text": ": ", "ParentId": "3eac6cb7-79f7-4cf4-bee2-932722a7fb8a"}, {"Element": "<span lang=\"EN-GB\">Evaluation of experimental animal\nstudies does not indicate direct or indirect harmful effects with respect to\nthe development of the embryo or foetus, the course of gestation and peri- and\npost-natal development. Clinical experience in pregnant women is limited:\nCongenital malformations, birth defects and other disorders (without a\ncongenital malformation) have been reported rarely in pregnant women who had\nreceived saquinavir in combination with other antiretroviral agents. However,\nso far the available data are insufficient and do not identify specific risks\nfor the unborn child. Saquinavir should be used during pregnancy only if the\npotential benefit justifies the potential risk to the foetus (see section 5.3).</span>", "ID": "aa24d8ee-22bc-493c-b643-8ef497446b6a", "Styles": "None", "Classes": "None", "Text": "Evaluation of experimental animal studies does not indicate direct or indirect harmful effects with respect to the development of the embryo or foetus, the course of gestation and peri- and post-natal development. Clinical experience in pregnant women is limited: Congenital malformations, birth defects and other disorders (without a congenital malformation) have been reported rarely in pregnant women who had received saquinavir in combination with other antiretroviral agents. However, so far the available data are insufficient and do not identify specific risks for the unborn child. Saquinavir should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus (see section 5.3).", "ParentId": "06432ca2-f893-4489-a3e3-a1360ac02d26"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "fbefb343-65f7-46a5-9655-b634d36bf77b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "90899a5c-142f-447c-803d-d9e05463d41e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fbefb343-65f7-46a5-9655-b634d36bf77b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8ecf87ce-7e7a-43a0-92e8-d0e023680253", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "90899a5c-142f-447c-803d-d9e05463d41e"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Breast-feeding</span></i></b><b><span lang=\"EN-GB\">: </span></b><span lang=\"EN-GB\">There are no laboratory animal or\nhuman data available on secretion of saquinavir in breast milk. The potential\nfor adverse reactions to saquinavir in nursing infants cannot be assessed, and\ntherefore, breast-feeding should be discontinued prior to receiving saquinavir.\nIt is recommended that HIV-infected women do not breast feed their infants\nunder any circumstances in order to avoid transmission of HIV.</span></p>", "ID": "957c390d-16cb-49da-9c1e-aea4fd1264bc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Breast-feeding</span></i></b>", "ID": "f1d6145d-f245-4527-b067-b9f999047857", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "957c390d-16cb-49da-9c1e-aea4fd1264bc"}, {"Element": "<i><span lang=\"EN-GB\">Breast-feeding</span></i>", "ID": "4e199506-e385-4e03-9ee6-49d2a3754d00", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f1d6145d-f245-4527-b067-b9f999047857"}, {"Element": "<span lang=\"EN-GB\">Breast-feeding</span>", "ID": "ef308981-9152-425d-9b71-48d6664250b1", "Styles": "None", "Classes": "None", "Text": "Breast-feeding", "ParentId": "4e199506-e385-4e03-9ee6-49d2a3754d00"}, {"Element": "<b><span lang=\"EN-GB\">: </span></b>", "ID": "e4171c30-8d4d-42cd-9d72-283cacdf44a4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "957c390d-16cb-49da-9c1e-aea4fd1264bc"}, {"Element": "<span lang=\"EN-GB\">: </span>", "ID": "6b7f8350-52e7-4dca-a358-4e6aa982af3a", "Styles": "None", "Classes": "None", "Text": ": ", "ParentId": "e4171c30-8d4d-42cd-9d72-283cacdf44a4"}, {"Element": "<span lang=\"EN-GB\">There are no laboratory animal or\nhuman data available on secretion of saquinavir in breast milk. The potential\nfor adverse reactions to saquinavir in nursing infants cannot be assessed, and\ntherefore, breast-feeding should be discontinued prior to receiving saquinavir.\nIt is recommended that HIV-infected women do not breast feed their infants\nunder any circumstances in order to avoid transmission of HIV.</span>", "ID": "6630617a-d0ae-4969-a360-cfe5343ce9ad", "Styles": "None", "Classes": "None", "Text": "There are no laboratory animal or human data available on secretion of saquinavir in breast milk. The potential for adverse reactions to saquinavir in nursing infants cannot be assessed, and therefore, breast-feeding should be discontinued prior to receiving saquinavir. It is recommended that HIV-infected women do not breast feed their infants under any circumstances in order to avoid transmission of HIV.", "ParentId": "957c390d-16cb-49da-9c1e-aea4fd1264bc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "81ab9dde-7ec4-4912-9ea9-0723949ac980", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9d92b6a4-efc9-40f9-8e07-da69cef0fb4d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "81ab9dde-7ec4-4912-9ea9-0723949ac980"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to\ndrive and use machines</span></b></p>", "ID": "7a70fffe-01b1-48d8-bd27-9cbf4dec2701", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to\ndrive and use machines</span></b>", "ID": "2e84b843-3ad9-4074-bb56-e8d0f832e5fa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7a70fffe-01b1-48d8-bd27-9cbf4dec2701"}, {"Element": "<span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to\ndrive and use machines</span>", "ID": "c762e3c4-f251-4fe9-ba2c-39db6b115bd0", "Styles": "None", "Classes": "None", "Text": "4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use machines", "ParentId": "2e84b843-3ad9-4074-bb56-e8d0f832e5fa"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0bc9b523-4731-4273-8e33-af8cf383ab0e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4ac71354-f47c-435e-982d-56381b0fe91a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0bc9b523-4731-4273-8e33-af8cf383ab0e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase may\nhave a minor influence on the ability to drive and use machines. Dizziness,\nfatigue and visual impairment have been reported during treatment with\nInvirase.</span><span lang=\"EN-GB\"> No studies on the effects on the ability to\ndrive and use machines have been performed.</span></p>", "ID": "a126099b-2c3d-4eac-adb0-b57de8880fd8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Invirase may\nhave a minor influence on the ability to drive and use machines. Dizziness,\nfatigue and visual impairment have been reported during treatment with\nInvirase.</span>", "ID": "49399201-bbff-42bc-ab27-22c9df9642aa", "Styles": "None", "Classes": "None", "Text": "Invirase may have a minor influence on the ability to drive and use machines. Dizziness, fatigue and visual impairment have been reported during treatment with Invirase.", "ParentId": "a126099b-2c3d-4eac-adb0-b57de8880fd8"}, {"Element": "<span lang=\"EN-GB\"> No studies on the effects on the ability to\ndrive and use machines have been performed.</span>", "ID": "354cbf12-17d7-4c94-914d-fe1a69358393", "Styles": "None", "Classes": "None", "Text": " No studies on the effects on the ability to drive and use machines have been performed.", "ParentId": "a126099b-2c3d-4eac-adb0-b57de8880fd8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cf8cd25d-3bfb-48e3-9f76-44f3803ee589", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "75d27f4c-79cf-416d-a577-10fd50323c14", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cf8cd25d-3bfb-48e3-9f76-44f3803ee589"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span></b></p>", "ID": "f3f054b2-55ea-4bb5-85ba-0f99947268df", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span></b>", "ID": "8889b07d-c1ac-45d2-be9f-4f9920bcfecb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f3f054b2-55ea-4bb5-85ba-0f99947268df"}, {"Element": "<span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span>", "ID": "d42e866b-de7e-4f53-afc8-b61e087e681d", "Styles": "None", "Classes": "None", "Text": "4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects", "ParentId": "8889b07d-c1ac-45d2-be9f-4f9920bcfecb"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "333bd192-cf7a-4b08-b06d-bd83e71f34c2", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "2ea1da47-f61a-4e19-a2b2-bbe55129c27b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "333bd192-cf7a-4b08-b06d-bd83e71f34c2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2ffaa891-4e1c-4469-ad22-5f3846aa8491", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2ea1da47-f61a-4e19-a2b2-bbe55129c27b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><i>a.\nSummary of the safety profile</i></b></p>", "ID": "ce0e0322-d2d5-4814-996a-e0018ac38ee3", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i>a.\nSummary of the safety profile</i></b>", "ID": "e995976b-449b-4cf8-b52e-834a63ef22f1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ce0e0322-d2d5-4814-996a-e0018ac38ee3"}, {"Element": "<i>a.\nSummary of the safety profile</i>", "ID": "1c624bfe-1635-4476-9642-b9b00c03e31e", "Styles": "None", "Classes": "None", "Text": "a. Summary of the safety profile", "ParentId": "e995976b-449b-4cf8-b52e-834a63ef22f1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4a5d8c56-d87a-40f5-8de1-d25081617725", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "41e3e205-598a-4704-a794-70b59c6c15a0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4a5d8c56-d87a-40f5-8de1-d25081617725"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Limited data is available from two clinical\nstudies where the safety of saquinavir soft capsule (1000\u00a0mg twice daily)\nused in combination with low dose ritonavir (100\u00a0mg twice daily) for at\nleast 48 weeks was studied in 311 patients. </span></p>", "ID": "5ca39906-d41e-4d2a-ae2b-2037e41b27b7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Limited data is available from two clinical\nstudies where the safety of saquinavir soft capsule (1000\u00a0mg twice daily)\nused in combination with low dose ritonavir (100\u00a0mg twice daily) for at\nleast 48 weeks was studied in 311 patients. </span>", "ID": "b51ab200-7fad-4148-98cc-cdef4f68e2a5", "Styles": "None", "Classes": "None", "Text": "Limited data is available from two clinical studies where the safety of saquinavir soft capsule (1000\u00a0mg twice daily) used in combination with low dose ritonavir (100\u00a0mg twice daily) for at least 48 weeks was studied in 311 patients. ", "ParentId": "5ca39906-d41e-4d2a-ae2b-2037e41b27b7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "88dc430d-a6bf-48fe-ab89-0056ac5985f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d45be628-890f-49b4-bfac-94b7dde1a0aa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "88dc430d-a6bf-48fe-ab89-0056ac5985f6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The following adverse events with an at\nleast possible relationship to ritonavir boosted saquinavir (i.e. adverse\nreactions) were reported most frequently: nausea, diarrhoea, fatigue, vomiting,\nflatulence, and abdominal pain.</span></p>", "ID": "6120e770-7d66-428e-be9e-99d09db8d703", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">The following adverse events with an at\nleast possible relationship to ritonavir boosted saquinavir (i.e. adverse\nreactions) were reported most frequently: nausea, diarrhoea, fatigue, vomiting,\nflatulence, and abdominal pain.</span>", "ID": "b6ec79fa-c56f-4c56-8846-ddce584e7a66", "Styles": "None", "Classes": "None", "Text": "The following adverse events with an at least possible relationship to ritonavir boosted saquinavir (i.e. adverse reactions) were reported most frequently: nausea, diarrhoea, fatigue, vomiting, flatulence, and abdominal pain.", "ParentId": "6120e770-7d66-428e-be9e-99d09db8d703"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c5d4a3cf-ee31-4b09-a47d-1510ebc98750", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "77dc1c67-c5cd-445b-8d7f-069c12a8962c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c5d4a3cf-ee31-4b09-a47d-1510ebc98750"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The following adverse events were reported\nwith the highest severity (grades 3 and 4): anaemia, diabetes mellitus,\ndiarrhoea, nausea, vomiting and fatigue. </span></p>", "ID": "c0870d70-7f6c-46f7-9d89-3dd9411cda25", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">The following adverse events were reported\nwith the highest severity (grades 3 and 4): anaemia, diabetes mellitus,\ndiarrhoea, nausea, vomiting and fatigue. </span>", "ID": "db154a62-7c23-4f3f-8d78-dd4d30fd3948", "Styles": "None", "Classes": "None", "Text": "The following adverse events were reported with the highest severity (grades 3 and 4): anaemia, diabetes mellitus, diarrhoea, nausea, vomiting and fatigue. ", "ParentId": "c0870d70-7f6c-46f7-9d89-3dd9411cda25"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "aa9ae78a-4cd0-4933-9ad0-446e42f1808d", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "2ea45261-4822-4c0b-b436-3ae7af17c9ec", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "aa9ae78a-4cd0-4933-9ad0-446e42f1808d"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "8af7dd88-2013-493f-85ce-ce1b86251eb2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2ea45261-4822-4c0b-b436-3ae7af17c9ec"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "67828e48-e76c-4433-beef-59fcfabb6af0", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "8af7dd88-2013-493f-85ce-ce1b86251eb2"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">For comprehensive dose adjustment recommendations and\ndrug-associated adverse reactions for ritonavir and other medicinal products\nused in combination with saquinavir, physicians should refer to the Summary of\nProduct Characteristics for each of these medicinal products.</span></p>", "ID": "eb146912-9dd0-4154-842f-0c72fc0e3108", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">For comprehensive dose adjustment recommendations and\ndrug-associated adverse reactions for ritonavir and other medicinal products\nused in combination with saquinavir, physicians should refer to the Summary of\nProduct Characteristics for each of these medicinal products.</span>", "ID": "90d950e8-9d48-479a-bab1-258a0fe9d71a", "Styles": "None", "Classes": "None", "Text": "For comprehensive dose adjustment recommendations and drug-associated adverse reactions for ritonavir and other medicinal products used in combination with saquinavir, physicians should refer to the Summary of Product Characteristics for each of these medicinal products.", "ParentId": "eb146912-9dd0-4154-842f-0c72fc0e3108"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2e5b5d21-f5a1-4299-8089-cdbc2f6f269c", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4c5b8027-03a1-4c28-9eac-dd4af41a40cd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2e5b5d21-f5a1-4299-8089-cdbc2f6f269c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><i>b.\nTabulated list of adverse reactions</i></b></p>", "ID": "04922553-8761-4e45-b4b7-bb2ca0844628", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i>b.\nTabulated list of adverse reactions</i></b>", "ID": "1cead195-aebd-44f0-94d0-49e45967e53b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "04922553-8761-4e45-b4b7-bb2ca0844628"}, {"Element": "<i>b.\nTabulated list of adverse reactions</i>", "ID": "5da2d805-836a-4c24-840a-25e3c8eb3456", "Styles": "None", "Classes": "None", "Text": "b. Tabulated list of adverse reactions", "ParentId": "1cead195-aebd-44f0-94d0-49e45967e53b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>", "ID": "c3cb0419-34d9-4c1e-9d58-5d4d78340f22", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Adverse reactions from two pivotal studies\nof saquinavir soft capsule (1000\u00a0mg twice daily) used in combination with\nlow dose ritonavir (100\u00a0mg twice daily) for at least 48 weeks are\nsummarised in Table 2.\u00a0 Also included are serious and non-serious adverse\nreactions from post-marketing spontaneous reports for which a causal\nrelationship to saquinavir cannot be excluded. </span></p>", "ID": "b0d91a18-0a5a-47f6-822c-8e7cd792a6f1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Adverse reactions from two pivotal studies\nof saquinavir soft capsule (1000\u00a0mg twice daily) used in combination with\nlow dose ritonavir (100\u00a0mg twice daily) for at least 48 weeks are\nsummarised in Table 2.\u00a0 Also included are serious and non-serious adverse\nreactions from post-marketing spontaneous reports for which a causal\nrelationship to saquinavir cannot be excluded. </span>", "ID": "5fa8e3c0-ad03-4bac-ad60-72d74a3d127a", "Styles": "None", "Classes": "None", "Text": "Adverse reactions from two pivotal studies of saquinavir soft capsule (1000\u00a0mg twice daily) used in combination with low dose ritonavir (100\u00a0mg twice daily) for at least 48 weeks are summarised in Table 2.\u00a0 Also included are serious and non-serious adverse reactions from post-marketing spontaneous reports for which a causal relationship to saquinavir cannot be excluded. ", "ParentId": "b0d91a18-0a5a-47f6-822c-8e7cd792a6f1"}, {"Element": "<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">Adverse reactions are\npresented according to the MedDRA system organ classification. The frequency\ngroupings according to MedDRA convention are: Very common (\u2265 1/10);\ncommon (\u2265 1/100 to &lt;1/10); uncommon (\u2265 1/1,000 to &lt;1/100);\nrare (\u2265 1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known\n(frequency cannot be estimated from the available data).</span></p>", "ID": "8204ffb3-1173-4c44-8753-ed390a8755ff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"layout-grid-mode:line\">Adverse reactions are\npresented according to the MedDRA system organ classification. The frequency\ngroupings according to MedDRA convention are: Very common (\u2265 1/10);\ncommon (\u2265 1/100 to &lt;1/10); uncommon (\u2265 1/1,000 to &lt;1/100);\nrare (\u2265 1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known\n(frequency cannot be estimated from the available data).</span>", "ID": "b4b892e5-4a2f-4387-9c7e-db525b4f3e71", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Adverse reactions are presented according to the MedDRA system organ classification. The frequency groupings according to MedDRA convention are: Very common (\u2265 1/10); common (\u2265 1/100 to <1/10); uncommon (\u2265 1/1,000 to <1/100); rare (\u2265 1/10,000 to <1/1,000); very rare (<1/10,000); not known (frequency cannot be estimated from the available data).", "ParentId": "8204ffb3-1173-4c44-8753-ed390a8755ff"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "0629a87c-13d0-4b30-a6d2-3a2a0f649101", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "f25dfc84-05c2-4608-85f9-f6ee5831b685", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "0629a87c-13d0-4b30-a6d2-3a2a0f649101"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:42.55pt;text-indent:-41.15pt;page-break-after:\navoid\"><span lang=\"EN-GB\">Table 2: Incidences of Adverse Reactions and marked\nlaboratory abnormalities in </span><span lang=\"EN-GB\">clinical studies and\npost-marketing experience in adult patients</span><span lang=\"EN-GB\">. </span></p>", "ID": "be00b660-da3d-4872-bc97-648c3c3d366e", "Styles": "margin-left:42.55pt;text-indent:-41.15pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Table 2: Incidences of Adverse Reactions and marked\nlaboratory abnormalities in </span>", "ID": "d65a6a32-e3d6-4195-9846-7529da2c9364", "Styles": "None", "Classes": "None", "Text": "Table 2: Incidences of Adverse Reactions and marked laboratory abnormalities in ", "ParentId": "be00b660-da3d-4872-bc97-648c3c3d366e"}, {"Element": "<span lang=\"EN-GB\">clinical studies and\npost-marketing experience in adult patients</span>", "ID": "d63fac12-398c-41e6-b133-0a0234f05eef", "Styles": "None", "Classes": "None", "Text": "clinical studies and post-marketing experience in adult patients", "ParentId": "be00b660-da3d-4872-bc97-648c3c3d366e"}, {"Element": "<span lang=\"EN-GB\">. </span>", "ID": "4024dc22-d897-44c9-915a-e27b9f58dfc7", "Styles": "None", "Classes": "None", "Text": ". ", "ParentId": "be00b660-da3d-4872-bc97-648c3c3d366e"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<thead>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><i><span lang=\"EN-GB\">Body System</span></i></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Frequency of reaction</span></b></p>\n</td>\n<td style=\"width:231.1pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Adverse reactions</span></b></p>\n</td>\n</tr>\n</thead>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Blood and the lymphatic system disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Decreased platelet count</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Anaemia, decreased haemoglobin, decreased lymphocyte count,\n  decreased white blood cell count</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Neutropenia</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Eye Disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Visual impairment</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Immune System Disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Hypersensitivity\u00a0 </span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Metabolism and nutrition disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Increased blood cholesterol, increased blood triglycerides</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Diabetes mellitus, anorexia, increased appetite</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Decreased appetite</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Psychiatric Disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Decreased libido, sleep disorder</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Nervous System Disorder</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Paraesthesia, peripheral neuropathy, dizziness, dysgeusia,\n  headache</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Somnolence, convulsions</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Dyspnoea</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Gastrointestinal disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Diarrhoea, nausea</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Vomiting, abdominal distension, abdominal pain, upper abdominal\n  pain, constipation, dry mouth, dyspepsia, eructation, flatulence, lip dry,\n  loose stools</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Pancreatitis</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Hepato-biliary disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\">Increased\n  alanine aminotransferase, increased aspartate aminotransferase, increased low\n  density lipoprotein</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\">Increased\n  blood bilirubin, increased blood amylase</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\">Hepatitis,\n  jaundice</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Renal and urinary disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Increased blood creatinine</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Renal impairment</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Alopecia, dry skin, eczema, lipoatrophy, pruritus, rash</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"FR-CH\">Stevens Johnson syndrome, dermatitis bullous</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Musculoskeletal and connective tissue disorders</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Muscle spasms</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">General disorders and administration site conditions</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Asthenia, fatigue, increased fat tissue, malaise</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Mucosal ulceration</span></p>\n</td>\n</tr>\n</table>", "ID": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "                                        ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<thead>\n<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><i><span lang=\"EN-GB\">Body System</span></i></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Frequency of reaction</span></b></p>\n</td>\n<td style=\"width:231.1pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Adverse reactions</span></b></p>\n</td>\n</tr>\n</thead>", "ID": "6bbaaee3-1cca-40ab-ac29-771dc0d70e9f", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><i><span lang=\"EN-GB\">Body System</span></i></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Frequency of reaction</span></b></p>\n</td>\n<td style=\"width:231.1pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Adverse reactions</span></b></p>\n</td>\n</tr>", "ID": "c44851f0-902f-4040-aac9-b7e2fd5c68d1", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "6bbaaee3-1cca-40ab-ac29-771dc0d70e9f"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><i><span lang=\"EN-GB\">Body System</span></i></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Frequency of reaction</span></b></p>\n</td>", "ID": "0a5b06f3-6186-4a82-929c-89f44bdcaf75", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n   padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "c44851f0-902f-4040-aac9-b7e2fd5c68d1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><i><span lang=\"EN-GB\">Body System</span></i></b></p>", "ID": "72db1b54-6c73-440d-9fd7-4a1d6ff5b4dc", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a5b06f3-6186-4a82-929c-89f44bdcaf75"}, {"Element": "<b><i><span lang=\"EN-GB\">Body System</span></i></b>", "ID": "ab090c6e-157c-4a75-89c2-b2c2224e6a50", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "72db1b54-6c73-440d-9fd7-4a1d6ff5b4dc"}, {"Element": "<i><span lang=\"EN-GB\">Body System</span></i>", "ID": "b8372356-4756-4aec-8071-190a5da66b35", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ab090c6e-157c-4a75-89c2-b2c2224e6a50"}, {"Element": "<span lang=\"EN-GB\">Body System</span>", "ID": "e04464c8-fbb3-42c5-8258-c8223e524a30", "Styles": "None", "Classes": "None", "Text": "Body System", "ParentId": "b8372356-4756-4aec-8071-190a5da66b35"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Frequency of reaction</span></b></p>", "ID": "74e9e7ac-70f6-4cc3-961f-c2f460460f3a", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a5b06f3-6186-4a82-929c-89f44bdcaf75"}, {"Element": "<b><span lang=\"EN-GB\">Frequency of reaction</span></b>", "ID": "99a02633-5d3e-42a5-aff3-d950cd72ba00", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "74e9e7ac-70f6-4cc3-961f-c2f460460f3a"}, {"Element": "<span lang=\"EN-GB\">Frequency of reaction</span>", "ID": "4183aef2-7935-48f5-b6b7-afd4e9007b75", "Styles": "None", "Classes": "None", "Text": "Frequency of reaction", "ParentId": "99a02633-5d3e-42a5-aff3-d950cd72ba00"}, {"Element": "<td style=\"width:231.1pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Adverse reactions</span></b></p>\n</td>", "ID": "a9292431-58e9-4539-bc13-4c0af8e8cbb6", "Styles": "width:231.1pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c44851f0-902f-4040-aac9-b7e2fd5c68d1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Adverse reactions</span></b></p>", "ID": "1c94ff64-2fa6-4707-83f0-07ce66026f51", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a9292431-58e9-4539-bc13-4c0af8e8cbb6"}, {"Element": "<b><span lang=\"EN-GB\">Adverse reactions</span></b>", "ID": "9daf1103-a8df-48b1-89ca-6eaf881cea96", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1c94ff64-2fa6-4707-83f0-07ce66026f51"}, {"Element": "<span lang=\"EN-GB\">Adverse reactions</span>", "ID": "048e8faa-11a8-42f9-865c-bde4d6ef1ce1", "Styles": "None", "Classes": "None", "Text": "Adverse reactions", "ParentId": "9daf1103-a8df-48b1-89ca-6eaf881cea96"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Blood and the lymphatic system disorders</span></i></p>\n</td>\n</tr>", "ID": "72e60592-5709-4a2b-9a22-110264d53ba0", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Blood and the lymphatic system disorders</span></i></p>\n</td>", "ID": "9790411e-8b55-4cfd-9086-ba849a327dc8", "Styles": "width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "72e60592-5709-4a2b-9a22-110264d53ba0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Blood and the lymphatic system disorders</span></i></p>", "ID": "b9f6d9cb-6e62-4854-b3f4-479abc0fccde", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9790411e-8b55-4cfd-9086-ba849a327dc8"}, {"Element": "<i><span lang=\"EN-GB\">Blood and the lymphatic system disorders</span></i>", "ID": "aa01b1b5-0e79-4209-970c-7697483116c9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b9f6d9cb-6e62-4854-b3f4-479abc0fccde"}, {"Element": "<span lang=\"EN-GB\">Blood and the lymphatic system disorders</span>", "ID": "f4362d8a-c6c2-4392-8d4c-1ccdf47ce7aa", "Styles": "None", "Classes": "None", "Text": "Blood and the lymphatic system disorders", "ParentId": "aa01b1b5-0e79-4209-970c-7697483116c9"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Decreased platelet count</span></p>\n</td>\n</tr>", "ID": "9165d636-c897-4611-9129-5599100cf2e3", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>\n</td>", "ID": "46e2daa3-b86d-4eb6-8887-0dd565fc9548", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9165d636-c897-4611-9129-5599100cf2e3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>", "ID": "06779d24-0a99-4a00-96ee-75b8da8ba4ee", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "46e2daa3-b86d-4eb6-8887-0dd565fc9548"}, {"Element": "<span lang=\"EN-GB\">Very common</span>", "ID": "a3f38b28-7f5d-4828-8f78-e277bdea2380", "Styles": "None", "Classes": "None", "Text": "Very common", "ParentId": "06779d24-0a99-4a00-96ee-75b8da8ba4ee"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Decreased platelet count</span></p>\n</td>", "ID": "16ded04e-8856-4220-afd3-ac9beb454b72", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9165d636-c897-4611-9129-5599100cf2e3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Decreased platelet count</span></p>", "ID": "10e499a5-00d7-46e5-9594-5c244566531c", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "16ded04e-8856-4220-afd3-ac9beb454b72"}, {"Element": "<span lang=\"EN-GB\">Decreased platelet count</span>", "ID": "9c6c03cb-7c3b-47fd-adfd-41192e569d8b", "Styles": "None", "Classes": "None", "Text": "Decreased platelet count", "ParentId": "10e499a5-00d7-46e5-9594-5c244566531c"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Anaemia, decreased haemoglobin, decreased lymphocyte count,\n  decreased white blood cell count</span></p>\n</td>\n</tr>", "ID": "30ad78d5-3350-4059-8f7f-0e25665b8342", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>", "ID": "0853c1e9-b4c6-47c0-9c64-2cd86ece4677", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "30ad78d5-3350-4059-8f7f-0e25665b8342"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>", "ID": "3fccdad8-cee1-4503-9563-4e638320cf76", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0853c1e9-b4c6-47c0-9c64-2cd86ece4677"}, {"Element": "<span lang=\"EN-GB\">Common</span>", "ID": "a8be456e-d641-422e-9735-f0f085dc4cec", "Styles": "None", "Classes": "None", "Text": "Common", "ParentId": "3fccdad8-cee1-4503-9563-4e638320cf76"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Anaemia, decreased haemoglobin, decreased lymphocyte count,\n  decreased white blood cell count</span></p>\n</td>", "ID": "24e33bb6-5a62-4fdc-b90b-eef7d2883e37", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "30ad78d5-3350-4059-8f7f-0e25665b8342"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Anaemia, decreased haemoglobin, decreased lymphocyte count,\n  decreased white blood cell count</span></p>", "ID": "a48e476c-4eea-4e47-839a-c2525cd56bfb", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "24e33bb6-5a62-4fdc-b90b-eef7d2883e37"}, {"Element": "<span lang=\"EN-GB\">Anaemia, decreased haemoglobin, decreased lymphocyte count,\n  decreased white blood cell count</span>", "ID": "2ad2c55a-b82a-4e59-bfd1-8d522759d68a", "Styles": "None", "Classes": "None", "Text": "Anaemia, decreased haemoglobin, decreased lymphocyte count,   decreased white blood cell count", "ParentId": "a48e476c-4eea-4e47-839a-c2525cd56bfb"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Neutropenia</span></p>\n</td>\n</tr>", "ID": "24ae70fd-e9a7-4993-9627-754c5be00c7c", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>", "ID": "8342716d-a588-4dee-91c4-9fba4bf0c953", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "24ae70fd-e9a7-4993-9627-754c5be00c7c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>", "ID": "d6008931-6500-40a2-ada3-9a6a9f4caebf", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8342716d-a588-4dee-91c4-9fba4bf0c953"}, {"Element": "<span lang=\"EN-GB\">Uncommon</span>", "ID": "c8579eb4-93f5-485b-a3c7-144e2dd5085e", "Styles": "None", "Classes": "None", "Text": "Uncommon", "ParentId": "d6008931-6500-40a2-ada3-9a6a9f4caebf"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Neutropenia</span></p>\n</td>", "ID": "38b28dec-66cb-4be5-8225-c5b04f247d16", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "24ae70fd-e9a7-4993-9627-754c5be00c7c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Neutropenia</span></p>", "ID": "c15a0a7b-7728-46fd-800f-50bd3e7d5ef9", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "38b28dec-66cb-4be5-8225-c5b04f247d16"}, {"Element": "<span lang=\"EN-GB\">Neutropenia</span>", "ID": "5682c860-9fe9-4aef-983b-903f96b346eb", "Styles": "None", "Classes": "None", "Text": "Neutropenia", "ParentId": "c15a0a7b-7728-46fd-800f-50bd3e7d5ef9"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Eye Disorders</span></i></p>\n</td>\n</tr>", "ID": "c0f1c77f-5b04-4eb9-a3b3-41d91a50859f", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Eye Disorders</span></i></p>\n</td>", "ID": "c98ab56c-ba2a-4a8e-a198-0de8d7d380fb", "Styles": "width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c0f1c77f-5b04-4eb9-a3b3-41d91a50859f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Eye Disorders</span></i></p>", "ID": "7b8f5be2-3991-4000-8fea-2a5086a23ef2", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c98ab56c-ba2a-4a8e-a198-0de8d7d380fb"}, {"Element": "<i><span lang=\"EN-GB\">Eye Disorders</span></i>", "ID": "a234bfb7-64ac-49de-924e-e2a943919d65", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7b8f5be2-3991-4000-8fea-2a5086a23ef2"}, {"Element": "<span lang=\"EN-GB\">Eye Disorders</span>", "ID": "6028f25d-6253-49fc-9b92-fb6439bc84bc", "Styles": "None", "Classes": "None", "Text": "Eye Disorders", "ParentId": "a234bfb7-64ac-49de-924e-e2a943919d65"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Visual impairment</span></p>\n</td>\n</tr>", "ID": "45fd75ac-5b68-41d9-ab9f-8090602adc1f", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>", "ID": "ddb3701a-928c-463e-8160-a5e1eb9f665d", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "45fd75ac-5b68-41d9-ab9f-8090602adc1f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>", "ID": "d07627b3-321f-4a61-96a3-ce6a74c79f29", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ddb3701a-928c-463e-8160-a5e1eb9f665d"}, {"Element": "<span lang=\"EN-GB\">Uncommon</span>", "ID": "0cbc19d4-f896-4628-b7c2-324362319f8e", "Styles": "None", "Classes": "None", "Text": "Uncommon", "ParentId": "d07627b3-321f-4a61-96a3-ce6a74c79f29"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Visual impairment</span></p>\n</td>", "ID": "69e5db9e-c566-463e-a1b5-5b19084fdfbf", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "45fd75ac-5b68-41d9-ab9f-8090602adc1f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Visual impairment</span></p>", "ID": "e6d51314-6cfe-4b4c-8460-5642fa8ba9fd", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "69e5db9e-c566-463e-a1b5-5b19084fdfbf"}, {"Element": "<span lang=\"EN-GB\">Visual impairment</span>", "ID": "5f1e03f8-d85c-4331-961c-716f0a6db168", "Styles": "None", "Classes": "None", "Text": "Visual impairment", "ParentId": "e6d51314-6cfe-4b4c-8460-5642fa8ba9fd"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Immune System Disorders</span></i></p>\n</td>\n</tr>", "ID": "4ffc9ddd-6a61-4faa-942e-94100806670d", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Immune System Disorders</span></i></p>\n</td>", "ID": "559a2b31-369c-497f-a7a7-471ffbec658c", "Styles": "width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4ffc9ddd-6a61-4faa-942e-94100806670d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Immune System Disorders</span></i></p>", "ID": "395b85c6-c172-4ca6-84a5-be760bfdd04b", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "559a2b31-369c-497f-a7a7-471ffbec658c"}, {"Element": "<i><span lang=\"EN-GB\">Immune System Disorders</span></i>", "ID": "9f7ede83-ad34-497d-b05b-1d233088978b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "395b85c6-c172-4ca6-84a5-be760bfdd04b"}, {"Element": "<span lang=\"EN-GB\">Immune System Disorders</span>", "ID": "fc6894ea-5e3d-4234-91cb-76b3a406d9b3", "Styles": "None", "Classes": "None", "Text": "Immune System Disorders", "ParentId": "9f7ede83-ad34-497d-b05b-1d233088978b"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Hypersensitivity\u00a0 </span></p>\n</td>\n</tr>", "ID": "8a28a0e7-555d-4aaa-9159-9fec69541cd3", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>", "ID": "9a7d3b08-0bf2-46d9-b05d-577d103908ac", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8a28a0e7-555d-4aaa-9159-9fec69541cd3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>", "ID": "414fd0bb-59f2-402f-820f-20826b504ceb", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9a7d3b08-0bf2-46d9-b05d-577d103908ac"}, {"Element": "<span lang=\"EN-GB\">Common</span>", "ID": "b48718b3-effd-44ef-a461-662f7f69d0fd", "Styles": "None", "Classes": "None", "Text": "Common", "ParentId": "414fd0bb-59f2-402f-820f-20826b504ceb"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Hypersensitivity\u00a0 </span></p>\n</td>", "ID": "f38ac162-d09b-4e54-b196-a380ec656c92", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8a28a0e7-555d-4aaa-9159-9fec69541cd3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Hypersensitivity\u00a0 </span></p>", "ID": "811ed534-2b6a-402b-89cd-dbec7ef0561c", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f38ac162-d09b-4e54-b196-a380ec656c92"}, {"Element": "<span lang=\"EN-GB\">Hypersensitivity\u00a0 </span>", "ID": "50a44eb1-dbb5-49ed-a613-c353d0b86a04", "Styles": "None", "Classes": "None", "Text": "Hypersensitivity\u00a0 ", "ParentId": "811ed534-2b6a-402b-89cd-dbec7ef0561c"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Metabolism and nutrition disorders</span></i></p>\n</td>\n</tr>", "ID": "e22b222e-0929-4d7f-8122-9c1dbf96597a", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Metabolism and nutrition disorders</span></i></p>\n</td>", "ID": "6c894f93-02ce-433b-893a-e30d723b37ad", "Styles": "width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e22b222e-0929-4d7f-8122-9c1dbf96597a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Metabolism and nutrition disorders</span></i></p>", "ID": "ac92ca64-036d-4bb2-911b-2b2dec08e775", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6c894f93-02ce-433b-893a-e30d723b37ad"}, {"Element": "<i><span lang=\"EN-GB\">Metabolism and nutrition disorders</span></i>", "ID": "421f97fb-fb7b-4fb4-bae1-c6a2edec4979", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ac92ca64-036d-4bb2-911b-2b2dec08e775"}, {"Element": "<span lang=\"EN-GB\">Metabolism and nutrition disorders</span>", "ID": "683418d4-b053-43c8-b2fb-b65e4973a225", "Styles": "None", "Classes": "None", "Text": "Metabolism and nutrition disorders", "ParentId": "421f97fb-fb7b-4fb4-bae1-c6a2edec4979"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Increased blood cholesterol, increased blood triglycerides</span></p>\n</td>\n</tr>", "ID": "d0ae5925-c91d-4143-a888-3cb3f331f3c2", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>\n</td>", "ID": "ef39b531-23e6-4456-ba11-77f0e4f036c1", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d0ae5925-c91d-4143-a888-3cb3f331f3c2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>", "ID": "e8e99b90-9325-4087-9e2c-463c81a0af10", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ef39b531-23e6-4456-ba11-77f0e4f036c1"}, {"Element": "<span lang=\"EN-GB\">Very common</span>", "ID": "bc66f9a9-a0d2-477d-a118-dae54ff7cb43", "Styles": "None", "Classes": "None", "Text": "Very common", "ParentId": "e8e99b90-9325-4087-9e2c-463c81a0af10"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Increased blood cholesterol, increased blood triglycerides</span></p>\n</td>", "ID": "bb66a687-4a4a-479f-bb02-c8b00512efba", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d0ae5925-c91d-4143-a888-3cb3f331f3c2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Increased blood cholesterol, increased blood triglycerides</span></p>", "ID": "8b45b2f0-7996-4254-bbff-5331ab92da2c", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bb66a687-4a4a-479f-bb02-c8b00512efba"}, {"Element": "<span lang=\"EN-GB\">Increased blood cholesterol, increased blood triglycerides</span>", "ID": "1bb13986-e854-45a8-ae7a-7fecb135e3c9", "Styles": "None", "Classes": "None", "Text": "Increased blood cholesterol, increased blood triglycerides", "ParentId": "8b45b2f0-7996-4254-bbff-5331ab92da2c"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Diabetes mellitus, anorexia, increased appetite</span></p>\n</td>\n</tr>", "ID": "c2c2ae35-27ec-4976-a5eb-4827d9220a8b", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>", "ID": "b02b323d-fd24-4192-b00a-2fcdd6a53b9b", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c2c2ae35-27ec-4976-a5eb-4827d9220a8b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>", "ID": "bea16971-83cf-406d-9aae-a163d7272484", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b02b323d-fd24-4192-b00a-2fcdd6a53b9b"}, {"Element": "<span lang=\"EN-GB\">Common</span>", "ID": "e1c7713f-c2e0-4648-ab81-12ca527b4fa0", "Styles": "None", "Classes": "None", "Text": "Common", "ParentId": "bea16971-83cf-406d-9aae-a163d7272484"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Diabetes mellitus, anorexia, increased appetite</span></p>\n</td>", "ID": "f9fe8f16-fd6e-4ca9-b92a-9d06019f76df", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c2c2ae35-27ec-4976-a5eb-4827d9220a8b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Diabetes mellitus, anorexia, increased appetite</span></p>", "ID": "974c642a-e483-4da6-92c3-821c4780b564", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f9fe8f16-fd6e-4ca9-b92a-9d06019f76df"}, {"Element": "<span lang=\"EN-GB\">Diabetes mellitus, anorexia, increased appetite</span>", "ID": "43d84495-1b8a-47d2-9a40-801dc5efe1be", "Styles": "None", "Classes": "None", "Text": "Diabetes mellitus, anorexia, increased appetite", "ParentId": "974c642a-e483-4da6-92c3-821c4780b564"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Decreased appetite</span></p>\n</td>\n</tr>", "ID": "e845c54c-91bd-43c6-ba79-7d0351e35c2b", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>", "ID": "916a783b-305e-4e76-8c8f-28d097d9036c", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e845c54c-91bd-43c6-ba79-7d0351e35c2b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>", "ID": "b7593cac-0774-4bc8-8c84-3ace46b783cb", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "916a783b-305e-4e76-8c8f-28d097d9036c"}, {"Element": "<span lang=\"EN-GB\">Uncommon</span>", "ID": "5124b9b5-a36b-46cf-b7e6-287171af1626", "Styles": "None", "Classes": "None", "Text": "Uncommon", "ParentId": "b7593cac-0774-4bc8-8c84-3ace46b783cb"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Decreased appetite</span></p>\n</td>", "ID": "7b643b2a-beba-40fb-a2e4-72f2dd5a92aa", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e845c54c-91bd-43c6-ba79-7d0351e35c2b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Decreased appetite</span></p>", "ID": "80b37948-1e50-424a-b4a6-2a5cc8c63941", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7b643b2a-beba-40fb-a2e4-72f2dd5a92aa"}, {"Element": "<span lang=\"EN-GB\">Decreased appetite</span>", "ID": "0aafeee6-23fd-40ee-920a-827b32e76f08", "Styles": "None", "Classes": "None", "Text": "Decreased appetite", "ParentId": "80b37948-1e50-424a-b4a6-2a5cc8c63941"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Psychiatric Disorders</span></i></p>\n</td>\n</tr>", "ID": "f830fcfa-d98a-446b-8f85-76df2cdf238a", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Psychiatric Disorders</span></i></p>\n</td>", "ID": "cabdf286-89cb-4764-ac04-94f4ebbd41d2", "Styles": "width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f830fcfa-d98a-446b-8f85-76df2cdf238a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Psychiatric Disorders</span></i></p>", "ID": "2ddceca0-f7f1-4e60-96ab-25e1b0a1782b", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cabdf286-89cb-4764-ac04-94f4ebbd41d2"}, {"Element": "<i><span lang=\"EN-GB\">Psychiatric Disorders</span></i>", "ID": "baea3669-237e-457c-b253-eb9a51095a76", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2ddceca0-f7f1-4e60-96ab-25e1b0a1782b"}, {"Element": "<span lang=\"EN-GB\">Psychiatric Disorders</span>", "ID": "50440933-a4ec-4c71-9e05-aa04794ba7dd", "Styles": "None", "Classes": "None", "Text": "Psychiatric Disorders", "ParentId": "baea3669-237e-457c-b253-eb9a51095a76"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Decreased libido, sleep disorder</span></p>\n</td>\n</tr>", "ID": "5ef6b4fb-7651-42e0-965a-7ccbb80494c9", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>", "ID": "4d902b5b-d43e-4736-ab7d-da703e2a4a8b", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5ef6b4fb-7651-42e0-965a-7ccbb80494c9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>", "ID": "a2ff32c9-0c4a-4e10-824b-ce02f3d855ae", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d902b5b-d43e-4736-ab7d-da703e2a4a8b"}, {"Element": "<span lang=\"EN-GB\">Common</span>", "ID": "b68125ff-25c5-4295-823d-5248b10c5783", "Styles": "None", "Classes": "None", "Text": "Common", "ParentId": "a2ff32c9-0c4a-4e10-824b-ce02f3d855ae"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Decreased libido, sleep disorder</span></p>\n</td>", "ID": "049c29bc-603c-4a87-8b60-af9b2156cb44", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5ef6b4fb-7651-42e0-965a-7ccbb80494c9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Decreased libido, sleep disorder</span></p>", "ID": "bdcbb480-132b-44a3-b8be-28cf55b80711", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "049c29bc-603c-4a87-8b60-af9b2156cb44"}, {"Element": "<span lang=\"EN-GB\">Decreased libido, sleep disorder</span>", "ID": "c1fb3c1d-3af1-4c43-acc9-1c3e6e20b665", "Styles": "None", "Classes": "None", "Text": "Decreased libido, sleep disorder", "ParentId": "bdcbb480-132b-44a3-b8be-28cf55b80711"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Nervous System Disorder</span></i></p>\n</td>\n</tr>", "ID": "d62faacf-3872-4f38-96c7-32b12603ac86", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Nervous System Disorder</span></i></p>\n</td>", "ID": "b57cc0ae-b037-4d79-b437-02556f2e1489", "Styles": "width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d62faacf-3872-4f38-96c7-32b12603ac86"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Nervous System Disorder</span></i></p>", "ID": "8006db44-85ff-453e-a0ec-366013c3d48c", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b57cc0ae-b037-4d79-b437-02556f2e1489"}, {"Element": "<i><span lang=\"EN-GB\">Nervous System Disorder</span></i>", "ID": "786e4108-8e05-4ae0-af15-d16344fdba14", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8006db44-85ff-453e-a0ec-366013c3d48c"}, {"Element": "<span lang=\"EN-GB\">Nervous System Disorder</span>", "ID": "d5a9a9a6-6b46-4b82-bf84-b1a56512f273", "Styles": "None", "Classes": "None", "Text": "Nervous System Disorder", "ParentId": "786e4108-8e05-4ae0-af15-d16344fdba14"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Paraesthesia, peripheral neuropathy, dizziness, dysgeusia,\n  headache</span></p>\n</td>\n</tr>", "ID": "ca39adf6-3af5-41ca-b41c-8ab8396bd8e4", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>", "ID": "5cd9137e-16d5-44d3-87cc-fdbb741c4401", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ca39adf6-3af5-41ca-b41c-8ab8396bd8e4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>", "ID": "f1991914-3f0c-4713-b1e4-01cbf028dc59", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5cd9137e-16d5-44d3-87cc-fdbb741c4401"}, {"Element": "<span lang=\"EN-GB\">Common</span>", "ID": "510644bf-271e-43b5-b1f0-e64e56601b98", "Styles": "None", "Classes": "None", "Text": "Common", "ParentId": "f1991914-3f0c-4713-b1e4-01cbf028dc59"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Paraesthesia, peripheral neuropathy, dizziness, dysgeusia,\n  headache</span></p>\n</td>", "ID": "b3924fbe-85fd-47bc-8519-277f6bb35916", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ca39adf6-3af5-41ca-b41c-8ab8396bd8e4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Paraesthesia, peripheral neuropathy, dizziness, dysgeusia,\n  headache</span></p>", "ID": "4d22287d-4da1-4dec-88b8-a1ce2a5fe90e", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b3924fbe-85fd-47bc-8519-277f6bb35916"}, {"Element": "<span lang=\"EN-GB\">Paraesthesia, peripheral neuropathy, dizziness, dysgeusia,\n  headache</span>", "ID": "301a3a33-c3a1-4f78-a9f3-e51289df0c7d", "Styles": "None", "Classes": "None", "Text": "Paraesthesia, peripheral neuropathy, dizziness, dysgeusia,   headache", "ParentId": "4d22287d-4da1-4dec-88b8-a1ce2a5fe90e"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Somnolence, convulsions</span></p>\n</td>\n</tr>", "ID": "30623bd4-79cc-4912-88c2-f220a159ce0d", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>", "ID": "bc05e84f-055c-4ed2-9895-129b4574d47b", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "30623bd4-79cc-4912-88c2-f220a159ce0d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>", "ID": "470248d6-5069-4c73-800d-7335c7cdd67a", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bc05e84f-055c-4ed2-9895-129b4574d47b"}, {"Element": "<span lang=\"EN-GB\">Uncommon</span>", "ID": "dc92371b-60ff-4b88-83e4-400e4961becd", "Styles": "None", "Classes": "None", "Text": "Uncommon", "ParentId": "470248d6-5069-4c73-800d-7335c7cdd67a"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Somnolence, convulsions</span></p>\n</td>", "ID": "8fd56990-f802-40b6-abee-722e151b3970", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "30623bd4-79cc-4912-88c2-f220a159ce0d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Somnolence, convulsions</span></p>", "ID": "fcb2e105-2c9e-4720-8b7b-940bd4f5d361", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8fd56990-f802-40b6-abee-722e151b3970"}, {"Element": "<span lang=\"EN-GB\">Somnolence, convulsions</span>", "ID": "2bc48ee1-3ebe-4bfc-8510-0031dc898ef9", "Styles": "None", "Classes": "None", "Text": "Somnolence, convulsions", "ParentId": "fcb2e105-2c9e-4720-8b7b-940bd4f5d361"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal disorders</span></i></p>\n</td>\n</tr>", "ID": "4e61e79c-adb0-4483-a21c-58509294fc99", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal disorders</span></i></p>\n</td>", "ID": "309cc26b-0384-41b0-af3d-6b00121abe39", "Styles": "width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4e61e79c-adb0-4483-a21c-58509294fc99"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal disorders</span></i></p>", "ID": "9cb5e255-bba2-4d7e-a132-5ede4f3491e1", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "309cc26b-0384-41b0-af3d-6b00121abe39"}, {"Element": "<i><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal disorders</span></i>", "ID": "715b6ab7-93b5-4203-8665-833d16ff635d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9cb5e255-bba2-4d7e-a132-5ede4f3491e1"}, {"Element": "<span lang=\"EN-GB\">Respiratory, thoracic and mediastinal disorders</span>", "ID": "8be4daca-2d96-4d85-87e0-c75454e0d341", "Styles": "None", "Classes": "None", "Text": "Respiratory, thoracic and mediastinal disorders", "ParentId": "715b6ab7-93b5-4203-8665-833d16ff635d"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Dyspnoea</span></p>\n</td>\n</tr>", "ID": "9ac2a078-6d78-4079-be8f-a2876dafe3b8", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>", "ID": "e2a306a9-5849-47b7-8c7e-1f31814b43a3", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9ac2a078-6d78-4079-be8f-a2876dafe3b8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>", "ID": "173a4467-3531-483a-80aa-8c4f234bb51c", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e2a306a9-5849-47b7-8c7e-1f31814b43a3"}, {"Element": "<span lang=\"EN-GB\">Common</span>", "ID": "0f32e8b2-a696-49f8-b956-5ed443abcfd1", "Styles": "None", "Classes": "None", "Text": "Common", "ParentId": "173a4467-3531-483a-80aa-8c4f234bb51c"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Dyspnoea</span></p>\n</td>", "ID": "fdf373b6-84c4-4eb3-862f-c98f1fd7dbd5", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9ac2a078-6d78-4079-be8f-a2876dafe3b8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Dyspnoea</span></p>", "ID": "c0df0869-f9f1-4f7c-8f8b-0088ee8e2e2e", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fdf373b6-84c4-4eb3-862f-c98f1fd7dbd5"}, {"Element": "<span lang=\"EN-GB\">Dyspnoea</span>", "ID": "462e3d84-5ea7-4a03-a9ac-b64cbdbe95b8", "Styles": "None", "Classes": "None", "Text": "Dyspnoea", "ParentId": "c0df0869-f9f1-4f7c-8f8b-0088ee8e2e2e"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Gastrointestinal disorders</span></i></p>\n</td>\n</tr>", "ID": "d2f63236-9a39-4a53-86f7-eae6f9f785ae", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Gastrointestinal disorders</span></i></p>\n</td>", "ID": "d5dbeb77-ddc9-45cc-b90a-8de714dec19a", "Styles": "width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d2f63236-9a39-4a53-86f7-eae6f9f785ae"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Gastrointestinal disorders</span></i></p>", "ID": "40cda42f-0471-436e-adaf-b4121a49f314", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d5dbeb77-ddc9-45cc-b90a-8de714dec19a"}, {"Element": "<i><span lang=\"EN-GB\">Gastrointestinal disorders</span></i>", "ID": "3795fdfa-2077-4a8a-8252-2c666632a233", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "40cda42f-0471-436e-adaf-b4121a49f314"}, {"Element": "<span lang=\"EN-GB\">Gastrointestinal disorders</span>", "ID": "b3b43aa3-4edc-40b7-9ad1-c1a79c0d37e6", "Styles": "None", "Classes": "None", "Text": "Gastrointestinal disorders", "ParentId": "3795fdfa-2077-4a8a-8252-2c666632a233"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Diarrhoea, nausea</span></p>\n</td>\n</tr>", "ID": "c4d1edef-85a0-44c8-a9ba-f0690eb2918f", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>\n</td>", "ID": "3a3b0c79-3e11-4ba9-8227-861cbd3c3db8", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c4d1edef-85a0-44c8-a9ba-f0690eb2918f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>", "ID": "755100fa-480f-4878-80ac-b21d9b644f16", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3a3b0c79-3e11-4ba9-8227-861cbd3c3db8"}, {"Element": "<span lang=\"EN-GB\">Very common</span>", "ID": "abed658c-a169-47c5-a598-738ce672733a", "Styles": "None", "Classes": "None", "Text": "Very common", "ParentId": "755100fa-480f-4878-80ac-b21d9b644f16"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Diarrhoea, nausea</span></p>\n</td>", "ID": "18bef95f-e1a7-424b-8ae3-7fcc63afc781", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c4d1edef-85a0-44c8-a9ba-f0690eb2918f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Diarrhoea, nausea</span></p>", "ID": "591bff66-4da8-4c03-b9b7-c64fb74ed573", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18bef95f-e1a7-424b-8ae3-7fcc63afc781"}, {"Element": "<span lang=\"EN-GB\">Diarrhoea, nausea</span>", "ID": "8901614e-791c-4894-b502-f23dc0c40f74", "Styles": "None", "Classes": "None", "Text": "Diarrhoea, nausea", "ParentId": "591bff66-4da8-4c03-b9b7-c64fb74ed573"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Vomiting, abdominal distension, abdominal pain, upper abdominal\n  pain, constipation, dry mouth, dyspepsia, eructation, flatulence, lip dry,\n  loose stools</span></p>\n</td>\n</tr>", "ID": "e9998273-9401-48b5-9afd-781715e77e1f", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>", "ID": "a2782de0-5f67-4afb-959b-16fbc065b7e0", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e9998273-9401-48b5-9afd-781715e77e1f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>", "ID": "188d0314-1862-41b2-aae6-0267cf605702", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a2782de0-5f67-4afb-959b-16fbc065b7e0"}, {"Element": "<span lang=\"EN-GB\">Common</span>", "ID": "c6fe88f7-cd09-4b69-b9d9-b4c81ed7d69c", "Styles": "None", "Classes": "None", "Text": "Common", "ParentId": "188d0314-1862-41b2-aae6-0267cf605702"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Vomiting, abdominal distension, abdominal pain, upper abdominal\n  pain, constipation, dry mouth, dyspepsia, eructation, flatulence, lip dry,\n  loose stools</span></p>\n</td>", "ID": "da141d7c-d103-48a3-a47e-f12b70d1a7bb", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e9998273-9401-48b5-9afd-781715e77e1f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Vomiting, abdominal distension, abdominal pain, upper abdominal\n  pain, constipation, dry mouth, dyspepsia, eructation, flatulence, lip dry,\n  loose stools</span></p>", "ID": "711e785f-ca0c-47db-8bd6-6fdcc2409ec3", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "da141d7c-d103-48a3-a47e-f12b70d1a7bb"}, {"Element": "<span lang=\"EN-GB\">Vomiting, abdominal distension, abdominal pain, upper abdominal\n  pain, constipation, dry mouth, dyspepsia, eructation, flatulence, lip dry,\n  loose stools</span>", "ID": "50b18bd1-65bf-4d2d-9790-d6dbd46a4417", "Styles": "None", "Classes": "None", "Text": "Vomiting, abdominal distension, abdominal pain, upper abdominal   pain, constipation, dry mouth, dyspepsia, eructation, flatulence, lip dry,   loose stools", "ParentId": "711e785f-ca0c-47db-8bd6-6fdcc2409ec3"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Pancreatitis</span></p>\n</td>\n</tr>", "ID": "14f9fafd-8a0b-4740-a85d-ee2300f0e624", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>", "ID": "a554c48d-d59d-4b31-ad1d-cec3cde232de", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "14f9fafd-8a0b-4740-a85d-ee2300f0e624"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>", "ID": "0ba9796a-dc66-4b3a-bddd-22c5a551eaf0", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a554c48d-d59d-4b31-ad1d-cec3cde232de"}, {"Element": "<span lang=\"EN-GB\">Uncommon</span>", "ID": "ae621498-d1c3-472b-bb20-fcdaf6a727f4", "Styles": "None", "Classes": "None", "Text": "Uncommon", "ParentId": "0ba9796a-dc66-4b3a-bddd-22c5a551eaf0"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Pancreatitis</span></p>\n</td>", "ID": "9fc7bc15-e4f4-4cae-9039-2926d3cb7c2b", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "14f9fafd-8a0b-4740-a85d-ee2300f0e624"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Pancreatitis</span></p>", "ID": "1009d7c5-8a8d-458c-93a0-44dbae586dfd", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9fc7bc15-e4f4-4cae-9039-2926d3cb7c2b"}, {"Element": "<span lang=\"EN-GB\">Pancreatitis</span>", "ID": "a184ef6a-269f-445a-8953-264de8f7b58e", "Styles": "None", "Classes": "None", "Text": "Pancreatitis", "ParentId": "1009d7c5-8a8d-458c-93a0-44dbae586dfd"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Hepato-biliary disorders</span></i></p>\n</td>\n</tr>", "ID": "f0d221b2-f028-4238-8c2b-b5ae819bdaac", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Hepato-biliary disorders</span></i></p>\n</td>", "ID": "57d1087d-fa78-4c15-af2b-20b96591c576", "Styles": "width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f0d221b2-f028-4238-8c2b-b5ae819bdaac"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Hepato-biliary disorders</span></i></p>", "ID": "f94d3501-c57f-42ad-b188-1a1a53cb245b", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "57d1087d-fa78-4c15-af2b-20b96591c576"}, {"Element": "<i><span lang=\"EN-GB\">Hepato-biliary disorders</span></i>", "ID": "e70afe0f-432c-466a-8f5c-4049ea038242", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f94d3501-c57f-42ad-b188-1a1a53cb245b"}, {"Element": "<span lang=\"EN-GB\">Hepato-biliary disorders</span>", "ID": "75790f1c-1f73-4659-b77f-3df3736b60b6", "Styles": "None", "Classes": "None", "Text": "Hepato-biliary disorders", "ParentId": "e70afe0f-432c-466a-8f5c-4049ea038242"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\">Increased\n  alanine aminotransferase, increased aspartate aminotransferase, increased low\n  density lipoprotein</p>\n</td>\n</tr>", "ID": "12cc708d-1a5a-4e7a-8396-078c89eb048b", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>\n</td>", "ID": "0a949d68-4769-4f98-8ec8-d619396efc92", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "12cc708d-1a5a-4e7a-8396-078c89eb048b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Very common</span></p>", "ID": "ea5f89e7-8a11-441f-943f-4d3c98d6db44", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a949d68-4769-4f98-8ec8-d619396efc92"}, {"Element": "<span lang=\"EN-GB\">Very common</span>", "ID": "01b17220-90db-4a60-8189-006306b4f012", "Styles": "None", "Classes": "None", "Text": "Very common", "ParentId": "ea5f89e7-8a11-441f-943f-4d3c98d6db44"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\">Increased\n  alanine aminotransferase, increased aspartate aminotransferase, increased low\n  density lipoprotein</p>\n</td>", "ID": "588ce0d9-5de5-4506-9c16-4ee77a86a3cc", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "12cc708d-1a5a-4e7a-8396-078c89eb048b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\">Increased\n  alanine aminotransferase, increased aspartate aminotransferase, increased low\n  density lipoprotein</p>", "ID": "24bb38df-cd7d-4248-879d-1b095a2ae71c", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "Increased   alanine aminotransferase, increased aspartate aminotransferase, increased low   density lipoprotein", "ParentId": "588ce0d9-5de5-4506-9c16-4ee77a86a3cc"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\">Increased\n  blood bilirubin, increased blood amylase</p>\n</td>\n</tr>", "ID": "5d4e840a-dc37-421b-84b9-a77678d9cbb3", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>", "ID": "33b92cdb-7442-4bf6-9a3f-97438062f261", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5d4e840a-dc37-421b-84b9-a77678d9cbb3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>", "ID": "ee5f9a5b-e769-4a82-b760-252f892ee799", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "33b92cdb-7442-4bf6-9a3f-97438062f261"}, {"Element": "<span lang=\"EN-GB\">Common</span>", "ID": "b6077eeb-0f8a-444c-8530-e5a2826fd22e", "Styles": "None", "Classes": "None", "Text": "Common", "ParentId": "ee5f9a5b-e769-4a82-b760-252f892ee799"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\">Increased\n  blood bilirubin, increased blood amylase</p>\n</td>", "ID": "240a65f6-cbb2-49ac-b264-7ccaedeee8e6", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5d4e840a-dc37-421b-84b9-a77678d9cbb3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\">Increased\n  blood bilirubin, increased blood amylase</p>", "ID": "97411a9d-d793-45a9-83a9-b93b7daf4567", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "Increased   blood bilirubin, increased blood amylase", "ParentId": "240a65f6-cbb2-49ac-b264-7ccaedeee8e6"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\">Hepatitis,\n  jaundice</p>\n</td>\n</tr>", "ID": "bcf48dda-547e-4a75-ad56-7668fcdaf5e8", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>", "ID": "4e0eeb6b-c389-478f-bd0e-b4d959b1334d", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "bcf48dda-547e-4a75-ad56-7668fcdaf5e8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>", "ID": "85edff30-4454-41df-84f7-ae7f5512018b", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4e0eeb6b-c389-478f-bd0e-b4d959b1334d"}, {"Element": "<span lang=\"EN-GB\">Uncommon</span>", "ID": "fd97097a-08b8-4766-bbfa-39bf5ca13297", "Styles": "None", "Classes": "None", "Text": "Uncommon", "ParentId": "85edff30-4454-41df-84f7-ae7f5512018b"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\">Hepatitis,\n  jaundice</p>\n</td>", "ID": "549f9735-6315-4121-9739-3fbfdf39f608", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "bcf48dda-547e-4a75-ad56-7668fcdaf5e8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\">Hepatitis,\n  jaundice</p>", "ID": "f7b731e6-6119-4689-971e-b3f2cecfaf38", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "Hepatitis,   jaundice", "ParentId": "549f9735-6315-4121-9739-3fbfdf39f608"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Renal and urinary disorders</span></i></p>\n</td>\n</tr>", "ID": "5dadf7a1-8377-4c8e-8f84-b632994ebcee", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Renal and urinary disorders</span></i></p>\n</td>", "ID": "4f0bc8fe-0e29-4938-af2a-c7a1fd6d0e77", "Styles": "width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5dadf7a1-8377-4c8e-8f84-b632994ebcee"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Renal and urinary disorders</span></i></p>", "ID": "2ce21a75-8a00-4259-bbd9-36ad047bafb3", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4f0bc8fe-0e29-4938-af2a-c7a1fd6d0e77"}, {"Element": "<i><span lang=\"EN-GB\">Renal and urinary disorders</span></i>", "ID": "b934761a-17ed-4a1f-ad07-7d7dcac3bddd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2ce21a75-8a00-4259-bbd9-36ad047bafb3"}, {"Element": "<span lang=\"EN-GB\">Renal and urinary disorders</span>", "ID": "e8428c7b-b89a-43ef-9fb7-03d7da92143a", "Styles": "None", "Classes": "None", "Text": "Renal and urinary disorders", "ParentId": "b934761a-17ed-4a1f-ad07-7d7dcac3bddd"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Increased blood creatinine</span></p>\n</td>\n</tr>", "ID": "93b7f453-56b8-49df-b5b5-431ba740fe10", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>", "ID": "ac30d701-9f31-4ad2-a1b3-e16a93e71cbf", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "93b7f453-56b8-49df-b5b5-431ba740fe10"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>", "ID": "fc8df35f-8fc0-4a0a-aed6-d2490abb3e6e", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ac30d701-9f31-4ad2-a1b3-e16a93e71cbf"}, {"Element": "<span lang=\"EN-GB\">Common</span>", "ID": "03e8a33c-e8fe-4bf3-9427-6b5df44e6f3c", "Styles": "None", "Classes": "None", "Text": "Common", "ParentId": "fc8df35f-8fc0-4a0a-aed6-d2490abb3e6e"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Increased blood creatinine</span></p>\n</td>", "ID": "00116467-f277-4947-bb61-e3740949023f", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "93b7f453-56b8-49df-b5b5-431ba740fe10"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Increased blood creatinine</span></p>", "ID": "12b70b4b-203d-4a93-a599-7d717b4df953", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "00116467-f277-4947-bb61-e3740949023f"}, {"Element": "<span lang=\"EN-GB\">Increased blood creatinine</span>", "ID": "8fa52cc5-b6dd-4c06-a4d6-11119979a2cb", "Styles": "None", "Classes": "None", "Text": "Increased blood creatinine", "ParentId": "12b70b4b-203d-4a93-a599-7d717b4df953"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Renal impairment</span></p>\n</td>\n</tr>", "ID": "ec7a9edf-a21e-43e7-b039-0dc329af529a", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>", "ID": "ee419865-fb11-423f-9a13-7a623735d040", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ec7a9edf-a21e-43e7-b039-0dc329af529a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>", "ID": "39d5926d-aae0-461e-af50-cca5090f85ee", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ee419865-fb11-423f-9a13-7a623735d040"}, {"Element": "<span lang=\"EN-GB\">Uncommon</span>", "ID": "5057ea62-c8f4-430b-9f29-296c760ac90a", "Styles": "None", "Classes": "None", "Text": "Uncommon", "ParentId": "39d5926d-aae0-461e-af50-cca5090f85ee"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Renal impairment</span></p>\n</td>", "ID": "20e8b5d9-1bdc-4db5-8125-666807f67384", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ec7a9edf-a21e-43e7-b039-0dc329af529a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Renal impairment</span></p>", "ID": "95f4acd3-5fa2-4621-b73a-c2a4bc28ddf9", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "20e8b5d9-1bdc-4db5-8125-666807f67384"}, {"Element": "<span lang=\"EN-GB\">Renal impairment</span>", "ID": "9ac62dee-d978-409a-9680-85c078ba1cb6", "Styles": "None", "Classes": "None", "Text": "Renal impairment", "ParentId": "95f4acd3-5fa2-4621-b73a-c2a4bc28ddf9"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders</span></i></p>\n</td>\n</tr>", "ID": "19e7b4c1-236e-4aa2-a3ed-e8872bc6e4a6", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders</span></i></p>\n</td>", "ID": "718341d1-d249-4e56-a6d9-3b15f8826b31", "Styles": "width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "19e7b4c1-236e-4aa2-a3ed-e8872bc6e4a6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders</span></i></p>", "ID": "b3eb1a92-7610-41de-95ea-a5c692601532", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "718341d1-d249-4e56-a6d9-3b15f8826b31"}, {"Element": "<i><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders</span></i>", "ID": "e73a6355-f3a4-47c6-8be5-1b9e291bc8e2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b3eb1a92-7610-41de-95ea-a5c692601532"}, {"Element": "<span lang=\"EN-GB\">Skin and subcutaneous tissue disorders</span>", "ID": "e9a615ad-1699-4fe2-8df6-e22e01c4ec2f", "Styles": "None", "Classes": "None", "Text": "Skin and subcutaneous tissue disorders", "ParentId": "e73a6355-f3a4-47c6-8be5-1b9e291bc8e2"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Alopecia, dry skin, eczema, lipoatrophy, pruritus, rash</span></p>\n</td>\n</tr>", "ID": "8e12609c-c3ae-4f27-957e-4dfb7f36e7ca", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>", "ID": "b8ae69ab-67e8-4e90-8fb7-42909e8b5663", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8e12609c-c3ae-4f27-957e-4dfb7f36e7ca"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>", "ID": "31fd4485-b71a-428b-ad55-a6ce0e9f2874", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b8ae69ab-67e8-4e90-8fb7-42909e8b5663"}, {"Element": "<span lang=\"EN-GB\">Common</span>", "ID": "9f41696f-5295-4ab8-9a56-30812647cb44", "Styles": "None", "Classes": "None", "Text": "Common", "ParentId": "31fd4485-b71a-428b-ad55-a6ce0e9f2874"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Alopecia, dry skin, eczema, lipoatrophy, pruritus, rash</span></p>\n</td>", "ID": "ded60e88-36d4-4b4d-93e8-b01d9bf1c952", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8e12609c-c3ae-4f27-957e-4dfb7f36e7ca"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Alopecia, dry skin, eczema, lipoatrophy, pruritus, rash</span></p>", "ID": "5e3d82cb-d628-4e1f-ad1e-aee17cb5a1ff", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ded60e88-36d4-4b4d-93e8-b01d9bf1c952"}, {"Element": "<span lang=\"EN-GB\">Alopecia, dry skin, eczema, lipoatrophy, pruritus, rash</span>", "ID": "14733faf-760a-4986-b98b-ac5a6b9e5cfb", "Styles": "None", "Classes": "None", "Text": "Alopecia, dry skin, eczema, lipoatrophy, pruritus, rash", "ParentId": "5e3d82cb-d628-4e1f-ad1e-aee17cb5a1ff"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"FR-CH\">Stevens Johnson syndrome, dermatitis bullous</span></p>\n</td>\n</tr>", "ID": "7c5d5657-b3c2-459c-9ab1-113a9bb92f18", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>", "ID": "29848698-da61-4b90-b9a7-99404b7d3854", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7c5d5657-b3c2-459c-9ab1-113a9bb92f18"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>", "ID": "b5334d22-0e61-4ad4-9ba4-2dad2a6d7b84", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "29848698-da61-4b90-b9a7-99404b7d3854"}, {"Element": "<span lang=\"EN-GB\">Uncommon</span>", "ID": "915f1447-78d6-4e5f-85a5-e2b19db25d32", "Styles": "None", "Classes": "None", "Text": "Uncommon", "ParentId": "b5334d22-0e61-4ad4-9ba4-2dad2a6d7b84"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"FR-CH\">Stevens Johnson syndrome, dermatitis bullous</span></p>\n</td>", "ID": "847864ba-0bcc-463b-a825-9ad86fa3b966", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7c5d5657-b3c2-459c-9ab1-113a9bb92f18"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"FR-CH\">Stevens Johnson syndrome, dermatitis bullous</span></p>", "ID": "a325659f-76b0-4adb-90c9-83c333eadcdf", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "847864ba-0bcc-463b-a825-9ad86fa3b966"}, {"Element": "<span lang=\"FR-CH\">Stevens Johnson syndrome, dermatitis bullous</span>", "ID": "d690b22d-78e6-4959-9b83-45b017e117b9", "Styles": "None", "Classes": "None", "Text": "Stevens Johnson syndrome, dermatitis bullous", "ParentId": "a325659f-76b0-4adb-90c9-83c333eadcdf"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Musculoskeletal and connective tissue disorders</span></i></p>\n</td>\n</tr>", "ID": "685a8b2c-187e-40ee-821a-883bc2fd8f44", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Musculoskeletal and connective tissue disorders</span></i></p>\n</td>", "ID": "17ec6f77-c257-4380-a8f8-5f418420b297", "Styles": "width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "685a8b2c-187e-40ee-821a-883bc2fd8f44"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Musculoskeletal and connective tissue disorders</span></i></p>", "ID": "49c7d6a4-da4c-4a17-8f63-f901e7b7d7e3", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "17ec6f77-c257-4380-a8f8-5f418420b297"}, {"Element": "<i><span lang=\"EN-GB\">Musculoskeletal and connective tissue disorders</span></i>", "ID": "22439136-9f5b-4f29-b51d-27c1c68b6927", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "49c7d6a4-da4c-4a17-8f63-f901e7b7d7e3"}, {"Element": "<span lang=\"EN-GB\">Musculoskeletal and connective tissue disorders</span>", "ID": "62af6859-d5d8-4567-bb6f-2f8b462a3a6c", "Styles": "None", "Classes": "None", "Text": "Musculoskeletal and connective tissue disorders", "ParentId": "22439136-9f5b-4f29-b51d-27c1c68b6927"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Muscle spasms</span></p>\n</td>\n</tr>", "ID": "cd0613e0-d7ac-4cb7-9b19-4f3487089205", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>", "ID": "57906c23-ce2a-4f3b-a491-f9a4b6a887d6", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cd0613e0-d7ac-4cb7-9b19-4f3487089205"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>", "ID": "84b37dd4-2598-4bda-9043-bb981a2277b0", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "57906c23-ce2a-4f3b-a491-f9a4b6a887d6"}, {"Element": "<span lang=\"EN-GB\">Common</span>", "ID": "4b67f56f-1fec-48cf-80d9-e075b178dec7", "Styles": "None", "Classes": "None", "Text": "Common", "ParentId": "84b37dd4-2598-4bda-9043-bb981a2277b0"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Muscle spasms</span></p>\n</td>", "ID": "9049213c-a9bf-4723-992e-6427f609583f", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cd0613e0-d7ac-4cb7-9b19-4f3487089205"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Muscle spasms</span></p>", "ID": "9bd5ebd6-656d-4a1a-a3bc-bbd551a04dd9", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9049213c-a9bf-4723-992e-6427f609583f"}, {"Element": "<span lang=\"EN-GB\">Muscle spasms</span>", "ID": "5a9a6038-c411-4374-a833-8cc93f426914", "Styles": "None", "Classes": "None", "Text": "Muscle spasms", "ParentId": "9bd5ebd6-656d-4a1a-a3bc-bbd551a04dd9"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">General disorders and administration site conditions</span></i></p>\n</td>\n</tr>", "ID": "aa3c8346-5fb5-4cd5-bca1-df73bd69cf38", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td colspan=\"2\" style=\"width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"616\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">General disorders and administration site conditions</span></i></p>\n</td>", "ID": "9eeeab24-0882-43f8-800d-2b52946dae54", "Styles": "width:462.15pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "aa3c8346-5fb5-4cd5-bca1-df73bd69cf38"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">General disorders and administration site conditions</span></i></p>", "ID": "3cb6cb12-b71e-4dbd-b584-67469d533b7e", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9eeeab24-0882-43f8-800d-2b52946dae54"}, {"Element": "<i><span lang=\"EN-GB\">General disorders and administration site conditions</span></i>", "ID": "c18eeb06-80ac-442b-8091-eb0c8497fb9c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3cb6cb12-b71e-4dbd-b584-67469d533b7e"}, {"Element": "<span lang=\"EN-GB\">General disorders and administration site conditions</span>", "ID": "22ae7ad3-7ee3-4a68-b203-6b38558a19fb", "Styles": "None", "Classes": "None", "Text": "General disorders and administration site conditions", "ParentId": "c18eeb06-80ac-442b-8091-eb0c8497fb9c"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Asthenia, fatigue, increased fat tissue, malaise</span></p>\n</td>\n</tr>", "ID": "1e4a9d80-99b8-413b-8b4e-36184593d5c5", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>\n</td>", "ID": "b77cc997-3ead-4c99-97cf-6dc79290a34c", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1e4a9d80-99b8-413b-8b4e-36184593d5c5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Common</span></p>", "ID": "f96472ae-36ab-42de-b4b1-dfac679a8a7f", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b77cc997-3ead-4c99-97cf-6dc79290a34c"}, {"Element": "<span lang=\"EN-GB\">Common</span>", "ID": "6befeff2-9f1c-458a-bd14-483cb1e2f5d6", "Styles": "None", "Classes": "None", "Text": "Common", "ParentId": "f96472ae-36ab-42de-b4b1-dfac679a8a7f"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Asthenia, fatigue, increased fat tissue, malaise</span></p>\n</td>", "ID": "0e96e930-72e5-4ec3-85e9-4fb4f2e89750", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1e4a9d80-99b8-413b-8b4e-36184593d5c5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Asthenia, fatigue, increased fat tissue, malaise</span></p>", "ID": "764f65c4-bd63-4a11-8a62-37ba3b8bfc1f", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0e96e930-72e5-4ec3-85e9-4fb4f2e89750"}, {"Element": "<span lang=\"EN-GB\">Asthenia, fatigue, increased fat tissue, malaise</span>", "ID": "edd9637c-b634-468e-894c-4cc678b4bfcf", "Styles": "None", "Classes": "None", "Text": "Asthenia, fatigue, increased fat tissue, malaise", "ParentId": "764f65c4-bd63-4a11-8a62-37ba3b8bfc1f"}, {"Element": "<tr>\n<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>\n<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Mucosal ulceration</span></p>\n</td>\n</tr>", "ID": "d7e20e7c-dfdc-4ff9-8a23-83b18c2f38cb", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "e49b7d1d-c5a5-4758-9ccc-eef7eb6b99d2"}, {"Element": "<td style=\"width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>\n</td>", "ID": "98abcf5d-df77-437f-b85e-ce45082f0cc4", "Styles": "width:231.05pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d7e20e7c-dfdc-4ff9-8a23-83b18c2f38cb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Uncommon</span></p>", "ID": "b561f07f-4f1b-4bb9-89a5-2bc7c6c98610", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "98abcf5d-df77-437f-b85e-ce45082f0cc4"}, {"Element": "<span lang=\"EN-GB\">Uncommon</span>", "ID": "f19e08ad-dcb8-4aa6-ac82-a9d251cdfb0f", "Styles": "None", "Classes": "None", "Text": "Uncommon", "ParentId": "b561f07f-4f1b-4bb9-89a5-2bc7c6c98610"}, {"Element": "<td style=\"width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"308\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Mucosal ulceration</span></p>\n</td>", "ID": "6105dd85-9da4-469a-b082-1fb5654caab9", "Styles": "width:231.1pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d7e20e7c-dfdc-4ff9-8a23-83b18c2f38cb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Mucosal ulceration</span></p>", "ID": "e47a8c49-24b3-407c-9298-023d7b7fc6b8", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6105dd85-9da4-469a-b082-1fb5654caab9"}, {"Element": "<span lang=\"EN-GB\">Mucosal ulceration</span>", "ID": "4552011a-1840-4e51-a881-11d20d4ccdec", "Styles": "None", "Classes": "None", "Text": "Mucosal ulceration", "ParentId": "e47a8c49-24b3-407c-9298-023d7b7fc6b8"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "daab0416-ede6-4552-b58b-041baed8d645", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9401bec0-de39-49b2-8586-24221670c9f2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "daab0416-ede6-4552-b58b-041baed8d645"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i>c. Description of\nselected adverse reactions</i></b></p>", "ID": "49858cba-93e1-40bb-aef2-9cb9b0b43412", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i>c. Description of\nselected adverse reactions</i></b>", "ID": "7b6100fd-4887-4927-93d3-b641cddf5333", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "49858cba-93e1-40bb-aef2-9cb9b0b43412"}, {"Element": "<i>c. Description of\nselected adverse reactions</i>", "ID": "80a17918-0353-4918-8a54-542260e62854", "Styles": "None", "Classes": "None", "Text": "c. Description of selected adverse reactions", "ParentId": "7b6100fd-4887-4927-93d3-b641cddf5333"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "964122dd-4611-4381-ac26-cd9a6e455aa4", "Styles": "text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c1fb7f71-2ec4-49d5-bb2e-6dbb238709ba", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "964122dd-4611-4381-ac26-cd9a6e455aa4"}, {"Element": "<p class=\"MsoNormal\"><i>Metabolic parameters</i></p>", "ID": "9dbb810c-379b-48d7-946e-2f254891afa5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<i>Metabolic parameters</i>", "ID": "6139343b-a2a4-412b-bfbd-5a4cc3955d49", "Styles": "None", "Classes": "None", "Text": "Metabolic parameters", "ParentId": "9dbb810c-379b-48d7-946e-2f254891afa5"}, {"Element": "<p class=\"MsoNormal\">Weight and levels of blood lipids and glucose may increase\nduring antiretroviral therapy (see section 4.4).</p>", "ID": "902e10c7-a5bf-4574-9d8d-2a2d459cbe59", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4).", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b95486dd-6390-4ec9-9b62-16d4fafd114a", "Styles": "margin-left:.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8c79fc74-63f1-4481-a00e-583e24b468c4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b95486dd-6390-4ec9-9b62-16d4fafd114a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.1pt\"><span lang=\"EN-GB\">There have been\nreports of increased bleeding, including spontaneous skin haematomas and\nhaemarthroses, in haemophilic patients type A and B treated with protease\ninhibitors (see section 4.4).</span></p>", "ID": "5d0bd25f-5c11-4183-a75b-018629df31af", "Styles": "margin-left:.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">There have been\nreports of increased bleeding, including spontaneous skin haematomas and\nhaemarthroses, in haemophilic patients type A and B treated with protease\ninhibitors (see section 4.4).</span>", "ID": "40defe83-bc91-4067-bb1f-844265e8caef", "Styles": "None", "Classes": "None", "Text": "There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in haemophilic patients type A and B treated with protease inhibitors (see section 4.4).", "ParentId": "5d0bd25f-5c11-4183-a75b-018629df31af"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "46a73431-28ba-4127-8f45-c1f5592106d4", "Styles": "margin-left:.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e4cc2e39-ab6f-41ee-a34a-8d611b4e7a51", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "46a73431-28ba-4127-8f45-c1f5592106d4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.1pt;text-autospace:none\"><span lang=\"EN-GB\">Increased CPK, myalgia, myositis and rarely, rhabdomyolysis have\nbeen reported with protease inhibitors, particularly in combination with\nnucleoside analogues. </span><span lang=\"EN-GB\">Cases of osteonecrosis have been\nreported, particularly in patients with generally acknowledged risk factors,\nadvanced HIV disease or long-term exposure to combination antiretroviral\ntherapy (CART). The frequency of this is unknown (see section 4.4).</span><span lang=\"EN-GB\"> </span></p>", "ID": "9704c35c-e32a-46c4-9496-ede1710878c2", "Styles": "margin-left:.1pt;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Increased CPK, myalgia, myositis and rarely, rhabdomyolysis have\nbeen reported with protease inhibitors, particularly in combination with\nnucleoside analogues. </span>", "ID": "ad8aa46f-891e-45c6-bcee-44794142fb1e", "Styles": "None", "Classes": "None", "Text": "Increased CPK, myalgia, myositis and rarely, rhabdomyolysis have been reported with protease inhibitors, particularly in combination with nucleoside analogues. ", "ParentId": "9704c35c-e32a-46c4-9496-ede1710878c2"}, {"Element": "<span lang=\"EN-GB\">Cases of osteonecrosis have been\nreported, particularly in patients with generally acknowledged risk factors,\nadvanced HIV disease or long-term exposure to combination antiretroviral\ntherapy (CART). The frequency of this is unknown (see section 4.4).</span>", "ID": "c8b0faf1-1f6a-40d3-8e62-dd8b9e525ca0", "Styles": "None", "Classes": "None", "Text": "Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy (CART). The frequency of this is unknown (see section 4.4).", "ParentId": "9704c35c-e32a-46c4-9496-ede1710878c2"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "dd6ad388-033a-4ac5-835b-475bea7950bf", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "9704c35c-e32a-46c4-9496-ede1710878c2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.1pt;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8c086cb0-5cee-4dc0-b78d-c757ef5fa60e", "Styles": "margin-left:.1pt;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5c274ae2-38e4-421d-83d4-e7013b3c78ab", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8c086cb0-5cee-4dc0-b78d-c757ef5fa60e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.1pt;text-autospace:none\"><span lang=\"EN-GB\">In HIV-infected patients with severe immune deficiency at the time\nof initiation of combination antiretroviral therapy (CART), an inflammatory\nreaction to asymptomatic or residual opportunistic infections may arise.</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">Autoimmune disorders (such as\nGraves\u2019disease and autoimmune hepatitis) have also been reported;\nhowever, the reported time to onset is more variable and these events can occur\nmany months after initiation of treatment (see section 4.4).</span></p>", "ID": "b11a5586-3b76-48ed-9715-0027ba127cf1", "Styles": "margin-left:.1pt;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">In HIV-infected patients with severe immune deficiency at the time\nof initiation of combination antiretroviral therapy (CART), an inflammatory\nreaction to asymptomatic or residual opportunistic infections may arise.</span>", "ID": "d3774941-9e68-4d01-bfb2-85f772a535b8", "Styles": "None", "Classes": "None", "Text": "In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.", "ParentId": "b11a5586-3b76-48ed-9715-0027ba127cf1"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "8dd4e4cd-5639-409a-a597-b966d288dd01", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "b11a5586-3b76-48ed-9715-0027ba127cf1"}, {"Element": "<span lang=\"EN-GB\">Autoimmune disorders (such as\nGraves\u2019disease and autoimmune hepatitis) have also been reported;\nhowever, the reported time to onset is more variable and these events can occur\nmany months after initiation of treatment (see section 4.4).</span>", "ID": "ae85289d-011c-4a54-b1a8-9040defbc4e9", "Styles": "None", "Classes": "None", "Text": "Autoimmune disorders (such as Graves\u2019disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).", "ParentId": "b11a5586-3b76-48ed-9715-0027ba127cf1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1f172471-fcf9-430f-8feb-53b5e6aa65b4", "Styles": "margin-left:.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2e2935d5-c69b-4882-90de-31ca202e714c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1f172471-fcf9-430f-8feb-53b5e6aa65b4"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><i><span lang=\"EN-GB\">d.\nPaediatric population</span></i></b></p>", "ID": "c341104b-bb92-4320-862a-e29981f459a7", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">d.\nPaediatric population</span></i></b>", "ID": "29da4e43-caf8-4013-8eb9-9a356d6372f2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c341104b-bb92-4320-862a-e29981f459a7"}, {"Element": "<i><span lang=\"EN-GB\">d.\nPaediatric population</span></i>", "ID": "752c6069-ba59-4452-ba79-95cf2916e5db", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "29da4e43-caf8-4013-8eb9-9a356d6372f2"}, {"Element": "<span lang=\"EN-GB\">d.\nPaediatric population</span>", "ID": "18337595-30ec-49b7-92c6-e01ede5caa7d", "Styles": "None", "Classes": "None", "Text": "d. Paediatric population", "ParentId": "752c6069-ba59-4452-ba79-95cf2916e5db"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "065d3d4b-8ea7-4cec-a87b-9d794c754786", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f978f7b5-f369-4c3b-ac14-f0e0db40a6fd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "065d3d4b-8ea7-4cec-a87b-9d794c754786"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Limited safety\ndata are available from a paediatric study (NV20911, n=18) in which the safety\nof saquinavir hard capsules (50\u00a0mg/kg bid, not to exceed 1000\u00a0mg bid)\nused in combination with low dose ritonavir oral solution (3\u00a0mg/kg bid for\nbody weight from 5 to &lt;15\u00a0kg, 2.5\u00a0mg/kg bid for body weight from\n15 to 40\u00a0kg and 100\u00a0mg bid for body weight &gt;40\u00a0kg) has been\nstudied in paediatric patients aged 4 months to 6 years old.</span></p>", "ID": "b4551d8e-d06f-4786-89d0-832156c76f0e", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Limited safety\ndata are available from a paediatric study (NV20911, n=18) in which the safety\nof saquinavir hard capsules (50\u00a0mg/kg bid, not to exceed 1000\u00a0mg bid)\nused in combination with low dose ritonavir oral solution (3\u00a0mg/kg bid for\nbody weight from 5 to &lt;15\u00a0kg, 2.5\u00a0mg/kg bid for body weight from\n15 to 40\u00a0kg and 100\u00a0mg bid for body weight &gt;40\u00a0kg) has been\nstudied in paediatric patients aged 4 months to 6 years old.</span>", "ID": "8c2898b7-a5e1-4ddd-a9ef-00132b106ed3", "Styles": "None", "Classes": "None", "Text": "Limited safety data are available from a paediatric study (NV20911, n=18) in which the safety of saquinavir hard capsules (50\u00a0mg/kg bid, not to exceed 1000\u00a0mg bid) used in combination with low dose ritonavir oral solution (3\u00a0mg/kg bid for body weight from 5 to <15\u00a0kg, 2.5\u00a0mg/kg bid for body weight from 15 to 40\u00a0kg and 100\u00a0mg bid for body weight >40\u00a0kg) has been studied in paediatric patients aged 4 months to 6 years old.", "ParentId": "b4551d8e-d06f-4786-89d0-832156c76f0e"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9e5c194a-0b50-4ae9-9cc1-aef527a65595", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cab306fa-b69c-4267-b2e9-88f40b87662d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9e5c194a-0b50-4ae9-9cc1-aef527a65595"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Four patients\nin the study experienced five adverse events that were considered related to\ntrial treatment. These events were vomiting (3 patients), abdominal pain (1\npatient) and diarrhoea (1 patient). </span>No unexpected adverse events were\nobserved in this study.</p>", "ID": "044634f5-e097-46af-b267-5c17ab0ac669", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "No unexpected adverse events were observed in this study.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Four patients\nin the study experienced five adverse events that were considered related to\ntrial treatment. These events were vomiting (3 patients), abdominal pain (1\npatient) and diarrhoea (1 patient). </span>", "ID": "f89b58b6-7524-4d60-92fc-7187f279b909", "Styles": "None", "Classes": "None", "Text": "Four patients in the study experienced five adverse events that were considered related to trial treatment. These events were vomiting (3 patients), abdominal pain (1 patient) and diarrhoea (1 patient). ", "ParentId": "044634f5-e097-46af-b267-5c17ab0ac669"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "85067960-8ec7-40c8-8125-7d1131087ef3", "Styles": "margin-left:.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "744d8338-c701-4e50-ada7-65f188c2377e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "85067960-8ec7-40c8-8125-7d1131087ef3"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u></p>", "ID": "fb497710-2c3a-4023-a6e3-83e3d69fb53e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u>", "ID": "674aaa34-0610-43e4-ac8c-19b5ec50a72c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fb497710-2c3a-4023-a6e3-83e3d69fb53e"}, {"Element": "<span lang=\"EN-GB\">Reporting of suspected adverse reactions</span>", "ID": "d5148ad8-fd1d-4f7f-b723-acd51cc33bdf", "Styles": "None", "Classes": "None", "Text": "Reporting of suspected adverse reactions", "ParentId": "674aaa34-0610-43e4-ac8c-19b5ec50a72c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after\nauthorisation of the medicinal product is important. It allows continued\nmonitoring of the benefit/risk balance of the medicinal product. </span>Healthcare\nprofessionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in </span><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:silver\">Appendix V</span></a><span lang=\"EN-GB\" style=\"background:silver\">.</span></p>", "ID": "498979fb-a51b-4ad7-8d28-df5eb2bf19b6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Healthcare professionals are asked to report any suspected adverse reactions via ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Reporting suspected adverse reactions after\nauthorisation of the medicinal product is important. It allows continued\nmonitoring of the benefit/risk balance of the medicinal product. </span>", "ID": "0815e555-61ef-4a54-9394-f3dfbdf9bfa5", "Styles": "None", "Classes": "None", "Text": "Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. ", "ParentId": "498979fb-a51b-4ad7-8d28-df5eb2bf19b6"}, {"Element": "<span style=\"background:silver\">the national reporting system listed in </span>", "ID": "7b819365-98ad-46bf-b55d-10cbde144083", "Styles": "background:silver", "Classes": "None", "Text": "the national reporting system listed in ", "ParentId": "498979fb-a51b-4ad7-8d28-df5eb2bf19b6"}, {"Element": "<a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:silver\">Appendix V</span></a>", "ID": "7162ad56-6f90-49e4-a421-bc0d3ca425b4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "498979fb-a51b-4ad7-8d28-df5eb2bf19b6"}, {"Element": "<span style=\"background:silver\">Appendix V</span>", "ID": "1350383e-c4f6-4c35-b093-ad70f4a12de3", "Styles": "background:silver", "Classes": "None", "Text": "Appendix V", "ParentId": "7162ad56-6f90-49e4-a421-bc0d3ca425b4"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">.</span>", "ID": "4417acad-c97a-403f-9adc-db25de3bc6b2", "Styles": "background:silver", "Classes": "None", "Text": ".", "ParentId": "498979fb-a51b-4ad7-8d28-df5eb2bf19b6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "46bd895c-7ad7-4da0-857b-b6f174a4dcba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "739f5c67-ddd4-473a-9438-3bf430a6c347", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "46bd895c-7ad7-4da0-857b-b6f174a4dcba"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span></b></p>", "ID": "3ba00424-ebdf-48a6-9a84-2ba98845fb8c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span></b>", "ID": "2f92c101-931d-47af-b7c4-e537f662785c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3ba00424-ebdf-48a6-9a84-2ba98845fb8c"}, {"Element": "<span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span>", "ID": "21893534-6e7b-4aff-94db-768ba856e277", "Styles": "None", "Classes": "None", "Text": "4.9\u00a0\u00a0\u00a0\u00a0 Overdose", "ParentId": "2f92c101-931d-47af-b7c4-e537f662785c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3f6b8b16-408e-4e72-be52-cac7ce6e3ecf", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "464efa2e-5833-4505-8b48-f6ab8a11b545", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3f6b8b16-408e-4e72-be52-cac7ce6e3ecf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There is limited experience of overdose\nwith saquinavir. Whereas acute or chronic overdose of saquinavir alone did not\nresult in major complications, in combination with other protease inhibitors,\noverdose symptoms and signs such as general weakness, fatigue, diarrhoea,\nnausea, vomiting, hair loss, dry mouth, hyponatraemia, weight loss and\northostatic hypotension have been observed. There is no specific antidote for\noverdose with saquinavir. Treatment of overdose with saquinavir should consist\nof general supportive measures, including monitoring of vital signs and ECG,\nand observations of the patient\u2019s clinical status. If indicated,\nprevention of further absorption can be considered. Since saquinavir is highly\nprotein bound, dialysis is unlikely to be beneficial in significant removal of\nthe active substance.</span></p>", "ID": "2278062e-b7d9-465b-816b-9fecf726af30", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">There is limited experience of overdose\nwith saquinavir. Whereas acute or chronic overdose of saquinavir alone did not\nresult in major complications, in combination with other protease inhibitors,\noverdose symptoms and signs such as general weakness, fatigue, diarrhoea,\nnausea, vomiting, hair loss, dry mouth, hyponatraemia, weight loss and\northostatic hypotension have been observed. There is no specific antidote for\noverdose with saquinavir. Treatment of overdose with saquinavir should consist\nof general supportive measures, including monitoring of vital signs and ECG,\nand observations of the patient\u2019s clinical status. If indicated,\nprevention of further absorption can be considered. Since saquinavir is highly\nprotein bound, dialysis is unlikely to be beneficial in significant removal of\nthe active substance.</span>", "ID": "0ae986ce-cf87-434b-a309-9afa9cbea302", "Styles": "None", "Classes": "None", "Text": "There is limited experience of overdose with saquinavir. Whereas acute or chronic overdose of saquinavir alone did not result in major complications, in combination with other protease inhibitors, overdose symptoms and signs such as general weakness, fatigue, diarrhoea, nausea, vomiting, hair loss, dry mouth, hyponatraemia, weight loss and orthostatic hypotension have been observed. There is no specific antidote for overdose with saquinavir. Treatment of overdose with saquinavir should consist of general supportive measures, including monitoring of vital signs and ECG, and observations of the patient\u2019s clinical status. If indicated, prevention of further absorption can be considered. Since saquinavir is highly protein bound, dialysis is unlikely to be beneficial in significant removal of the active substance.", "ParentId": "2278062e-b7d9-465b-816b-9fecf726af30"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cfb53361-d523-401f-97f3-fe214a5a4fe5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "228fca42-2997-4cfe-9e43-447661f08c6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cfb53361-d523-401f-97f3-fe214a5a4fe5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "15a6c359-cd04-400c-a8b1-53057003d0c4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9000d049-89dc-4d82-9d58-9294f80061cd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "15a6c359-cd04-400c-a8b1-53057003d0c4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></b><b><span lang=\"EN-GB\">PHARMACOLOGICAL PROPERTIES</span></b></p>", "ID": "9655416b-8e48-4615-835e-df2bd20e8ee8", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></b>", "ID": "a90b2771-c2dc-4e3f-a7b6-8583151b8909", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9655416b-8e48-4615-835e-df2bd20e8ee8"}, {"Element": "<span lang=\"EN-GB\" style=\"text-transform:uppercase\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "9f2dae4f-b676-400a-9e2f-4c9b46b28167", "Styles": "text-transform:uppercase", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "a90b2771-c2dc-4e3f-a7b6-8583151b8909"}, {"Element": "<b><span lang=\"EN-GB\">PHARMACOLOGICAL PROPERTIES</span></b>", "ID": "d0f4d4ad-6e71-458a-8e69-872e1580b30c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9655416b-8e48-4615-835e-df2bd20e8ee8"}, {"Element": "<span lang=\"EN-GB\">PHARMACOLOGICAL PROPERTIES</span>", "ID": "f8213d42-e508-4914-86c4-b1ea537f9a0d", "Styles": "None", "Classes": "None", "Text": "PHARMACOLOGICAL PROPERTIES", "ParentId": "d0f4d4ad-6e71-458a-8e69-872e1580b30c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4074607c-9a47-4888-a65a-1b917b3eeeb1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9a63ac2b-ef6a-4f07-856e-d24e81398b21", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4074607c-9a47-4888-a65a-1b917b3eeeb1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span></b></p>", "ID": "91921b59-078f-4673-8728-cec3ec52849a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span></b>", "ID": "d639b594-5570-4377-aa20-1e8e66321f15", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "91921b59-078f-4673-8728-cec3ec52849a"}, {"Element": "<span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span>", "ID": "81ff080b-30d0-49f7-bcac-48721982fa41", "Styles": "None", "Classes": "None", "Text": "5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic properties", "ParentId": "d639b594-5570-4377-aa20-1e8e66321f15"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>", "ID": "5186a87c-4051-4f35-9e43-b3cb972e9e76", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">\u00a0</span></i></b>", "ID": "161b5599-767e-4ec6-a520-0ed1806b29f1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5186a87c-4051-4f35-9e43-b3cb972e9e76"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "4f2c801c-b19c-4b32-9b1f-0220c827a8dd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "161b5599-767e-4ec6-a520-0ed1806b29f1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "61570964-2583-4246-95d6-3067c2ddfb16", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4f2c801c-b19c-4b32-9b1f-0220c827a8dd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pharmaco-therapeutic\ngroup: Antiviral agent, ATC code J05A E01</span></p>", "ID": "95529d2c-9b40-4560-aa06-50ed4cb03a6e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Pharmaco-therapeutic\ngroup: Antiviral agent, ATC code J05A E01</span>", "ID": "78bc1107-b66f-4e02-b725-0636745b7f69", "Styles": "None", "Classes": "None", "Text": "Pharmaco-therapeutic group: Antiviral agent, ATC code J05A E01", "ParentId": "95529d2c-9b40-4560-aa06-50ed4cb03a6e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>", "ID": "9019af6d-b51a-4c7c-86d2-e619a772c012", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">\u00a0</span></i></b>", "ID": "5489588a-efe6-4549-8929-8cefb89ed9ac", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9019af6d-b51a-4c7c-86d2-e619a772c012"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "a1b9fe96-172f-4d3a-bcca-b186c96251ad", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5489588a-efe6-4549-8929-8cefb89ed9ac"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0222521f-b274-4223-986d-a6605579280f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a1b9fe96-172f-4d3a-bcca-b186c96251ad"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Mechanism of action:</span></i></b><i><span lang=\"EN-GB\"> </span></i><span lang=\"EN-GB\" style=\"color:black\">The HIV\nprotease\u00a0is an essential viral enzyme required for\u00a0the specific\ncleavage of viral\u00a0gag and gag-pol polyproteins.\nSaquinavir\u00a0selectively\u00a0inhibits the HIV protease, thereby preventing\nthe creation of\u00a0mature infectious virus particles<strong><span style=\"font-weight:normal\">.</span></strong></span></p>", "ID": "f79d1fea-adee-46f5-a125-8eb37bfe791c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Mechanism of action:</span></i></b>", "ID": "35df78d7-0bdb-45a3-aac7-4a9d0ae1fc75", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f79d1fea-adee-46f5-a125-8eb37bfe791c"}, {"Element": "<i><span lang=\"EN-GB\">Mechanism of action:</span></i>", "ID": "630d506c-21a8-4907-861e-2ce2cdab1b38", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "35df78d7-0bdb-45a3-aac7-4a9d0ae1fc75"}, {"Element": "<span lang=\"EN-GB\">Mechanism of action:</span>", "ID": "923dcf84-91f4-412d-a945-e5340ed419e3", "Styles": "None", "Classes": "None", "Text": "Mechanism of action:", "ParentId": "630d506c-21a8-4907-861e-2ce2cdab1b38"}, {"Element": "<i><span lang=\"EN-GB\"> </span></i>", "ID": "c797384b-acdb-4e7c-9e06-686d90a69cd0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f79d1fea-adee-46f5-a125-8eb37bfe791c"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "8dd22778-d238-40b9-966c-5a00b9269aa8", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "c797384b-acdb-4e7c-9e06-686d90a69cd0"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">The HIV\nprotease\u00a0is an essential viral enzyme required for\u00a0the specific\ncleavage of viral\u00a0gag and gag-pol polyproteins.\nSaquinavir\u00a0selectively\u00a0inhibits the HIV protease, thereby preventing\nthe creation of\u00a0mature infectious virus particles<strong><span style=\"font-weight:normal\">.</span></strong></span>", "ID": "effcd5d4-9529-4cbe-baf0-bb204ff8b04b", "Styles": "color:black", "Classes": "None", "Text": "The HIV protease\u00a0is an essential viral enzyme required for\u00a0the specific cleavage of viral\u00a0gag and gag-pol polyproteins. Saquinavir\u00a0selectively\u00a0inhibits the HIV protease, thereby preventing the creation of\u00a0mature infectious virus particles", "ParentId": "f79d1fea-adee-46f5-a125-8eb37bfe791c"}, {"Element": "<strong><span style=\"font-weight:normal\">.</span></strong>", "ID": "df406f04-ae35-433f-974c-f191c63e74ba", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "effcd5d4-9529-4cbe-baf0-bb204ff8b04b"}, {"Element": "<span style=\"font-weight:normal\">.</span>", "ID": "d05b9c68-428e-4579-8d26-5bcc624e7a25", "Styles": "font-weight:normal", "Classes": "None", "Text": ".", "ParentId": "df406f04-ae35-433f-974c-f191c63e74ba"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "15b408ec-6db3-445f-be60-4fd6ae4cb6e0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d9b0a0fc-deb0-4bb4-9ec8-50aa9949355f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "15b408ec-6db3-445f-be60-4fd6ae4cb6e0"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">QT and PR prolongation on\nelectrocardiogram:</span></i></b><i><span lang=\"EN-GB\"> </span></i>The effects of\ntherapeutic (1000/100\u00a0mg twice daily) and supra-therapeutic\n(1500/100\u00a0mg twice daily) doses of Invirase/ritonavir on the QT interval\nwere evaluated in a 4-way crossover, double-blind, placebo- and active-controlled\n(moxifloxacin 400\u00a0mg) study in healthy male and female volunteers aged 18\nto 55 years old (N=59). On Day 3 of dosing, ECG measurements were done over a\nperiod of 20\u00a0hours. The Day 3 timepoint was chosen since the pharmacokinetic\nexposure was maximum on that day in a previous 14-day multiple dose\npharmacokinetic study. On Day 3, mean C<sub>max </sub>values were approximately\n3\u2011fold and 4\u2011fold higher with the therapeutic and supra-therapeutic\ndoses, respectively, relative to the mean C<sub>max </sub>observed at steady\nstate with the therapeutic dose administered to HIV patients. On Day\u00a03,\nthe upper 1-sided 95% confidence interval of the maximum mean difference in\npre-dose baseline-corrected QTcS (study specific heart rate corrected QT)\nbetween the active drug and placebo arms was &gt; 10 msec for the two\nritonavir-boosted Invirase treatment groups (see results in Table 3). While the\nsupra-therapeutic dose of Invirase/ritonavir appeared to have a greater effect\non the QT interval than the therapeutic dose of Invirase/ritonavir, it is not\nsure if maximum effect for both doses has been observed. In the therapeutic and\nthe supra-therapeutic arm 11% and 18% of subjects, respectively, had a QTcS\nbetween 450 and 480 msec. There was no QT prolongation &gt; 500 msec and no\ntorsade de pointes in the study (see also section 4.4).</p>", "ID": "9ff0727a-4f33-45b8-9880-40dcb1319614", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The effects of therapeutic (1000/100\u00a0mg twice daily) and supra-therapeutic (1500/100\u00a0mg twice daily) doses of Invirase/ritonavir on the QT interval were evaluated in a 4-way crossover, double-blind, placebo- and active-controlled (moxifloxacin 400\u00a0mg) study in healthy male and female volunteers aged 18 to 55 years old (N=59). On Day 3 of dosing, ECG measurements were done over a period of 20\u00a0hours. The Day 3 timepoint was chosen since the pharmacokinetic exposure was maximum on that day in a previous 14-day multiple dose pharmacokinetic study. On Day 3, mean Cvalues were approximately 3\u2011fold and 4\u2011fold higher with the therapeutic and supra-therapeutic doses, respectively, relative to the mean Cobserved at steady state with the therapeutic dose administered to HIV patients. On Day\u00a03, the upper 1-sided 95% confidence interval of the maximum mean difference in pre-dose baseline-corrected QTcS (study specific heart rate corrected QT) between the active drug and placebo arms was > 10 msec for the two ritonavir-boosted Invirase treatment groups (see results in Table 3). While the supra-therapeutic dose of Invirase/ritonavir appeared to have a greater effect on the QT interval than the therapeutic dose of Invirase/ritonavir, it is not sure if maximum effect for both doses has been observed. In the therapeutic and the supra-therapeutic arm 11% and 18% of subjects, respectively, had a QTcS between 450 and 480 msec. There was no QT prolongation > 500 msec and no torsade de pointes in the study (see also section 4.4).", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">QT and PR prolongation on\nelectrocardiogram:</span></i></b>", "ID": "4cd7735a-b3ed-4f70-9cc9-770f238c42bd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9ff0727a-4f33-45b8-9880-40dcb1319614"}, {"Element": "<i><span lang=\"EN-GB\">QT and PR prolongation on\nelectrocardiogram:</span></i>", "ID": "0c36c64f-66c8-4a3c-af6a-ebf9df22989c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4cd7735a-b3ed-4f70-9cc9-770f238c42bd"}, {"Element": "<span lang=\"EN-GB\">QT and PR prolongation on\nelectrocardiogram:</span>", "ID": "b4af2b49-4037-4d59-9f67-7bbe8c1a670d", "Styles": "None", "Classes": "None", "Text": "QT and PR prolongation on electrocardiogram:", "ParentId": "0c36c64f-66c8-4a3c-af6a-ebf9df22989c"}, {"Element": "<i><span lang=\"EN-GB\"> </span></i>", "ID": "5f941019-3c4c-4106-a66a-aef60d48291c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9ff0727a-4f33-45b8-9880-40dcb1319614"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "01deab0a-62fe-430a-af43-01b0aff9bc58", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "5f941019-3c4c-4106-a66a-aef60d48291c"}, {"Element": "<sub>max </sub>", "ID": "8384c262-d804-494b-b0de-33719431fa4b", "Styles": "None", "Classes": "None", "Text": "max ", "ParentId": "9ff0727a-4f33-45b8-9880-40dcb1319614"}, {"Element": "<sub>max </sub>", "ID": "35d71392-2bea-4420-90af-fd3fbfbbca0a", "Styles": "None", "Classes": "None", "Text": "max ", "ParentId": "9ff0727a-4f33-45b8-9880-40dcb1319614"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a582d54f-68c5-4057-8b06-f79085196dee", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:42.55pt;text-indent:-42.55pt\">Table 3:\nMaximum mean of ddQTcS<sup>\u2020</sup> (msec) on day 3 for therapeutic dose\nof Invirase/ritonavir, supra-therapeutic dose of Invirase/ritonavir and active\ncontrol moxifloxacin in healthy volunteers in Thorough QT (TQT) Study</p>", "ID": "807c36a7-ee4b-4029-b7c0-81decec61a44", "Styles": "margin-left:42.55pt;text-indent:-42.55pt", "Classes": "['MsoNormal']", "Text": "Table 3: Maximum mean of ddQTcS (msec) on day 3 for therapeutic dose of Invirase/ritonavir, supra-therapeutic dose of Invirase/ritonavir and active control moxifloxacin in healthy volunteers in Thorough QT (TQT) Study", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<sup>\u2020</sup>", "ID": "460aa18b-32f0-4130-a83f-13173150d2cf", "Styles": "None", "Classes": "None", "Text": "\u2020", "ParentId": "807c36a7-ee4b-4029-b7c0-81decec61a44"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "9d6a7189-f2f3-4ff1-abdc-f13d8c8ee49b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:453.4pt;border-collapse:collapse;border:none\" width=\"605\">\n<tr>\n<td style=\"width:102.35pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"136\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Treatment</span></b></p>\n</td>\n<td style=\"width:89.6pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Post-Dose</span></b></p>\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Time Point</span></b></p>\n</td>\n<td style=\"width:98.25pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Mean </span></b></p>\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">ddQTcS</span></b></p>\n</td>\n<td style=\"width:1.0in;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"96\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Standard Error</span></b></p>\n</td>\n<td style=\"width:91.2pt;border-top:solid black 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:none;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Upper 95%-CI of\n  ddQTcS</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:102.35pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"136\">\n<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Invirase/ritonavir\n  1000/100\u00a0mg BID</span></p>\n</td>\n<td style=\"width:89.6pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span style=\"font-size:11.0pt\">12 hours</span></p>\n</td>\n<td style=\"width:98.25pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">18.86</span></p>\n</td>\n<td style=\"width:1.0in;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"96\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">1.91</span></p>\n</td>\n<td style=\"width:91.2pt;border:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">22.01</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:102.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"136\">\n<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Invirase/ritonavir</span></p>\n<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">1500/100\u00a0mg\n  BID</span></p>\n</td>\n<td style=\"width:89.6pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span style=\"font-size:11.0pt\">20 hours</span></p>\n</td>\n<td style=\"width:98.25pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">30.22</span></p>\n</td>\n<td style=\"width:1.0in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"96\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">1.91</span></p>\n</td>\n<td style=\"width:91.2pt;border:none;border-top:solid windowtext 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">33.36</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:102.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"136\">\n<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Moxifloxacin^</span></p>\n</td>\n<td style=\"width:89.6pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span style=\"font-size:11.0pt\">4 hours</span></p>\n</td>\n<td style=\"width:98.25pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">12.18</span></p>\n</td>\n<td style=\"width:1.0in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"96\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">1.93</span></p>\n</td>\n<td style=\"width:91.2pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:none;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">15.36</span></p>\n</td>\n</tr>\n</table>", "ID": "206720bf-6bd5-4e01-9504-e18fc549f5f9", "Styles": "width:453.4pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "     ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<tr>\n<td style=\"width:102.35pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"136\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Treatment</span></b></p>\n</td>\n<td style=\"width:89.6pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Post-Dose</span></b></p>\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Time Point</span></b></p>\n</td>\n<td style=\"width:98.25pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Mean </span></b></p>\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">ddQTcS</span></b></p>\n</td>\n<td style=\"width:1.0in;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"96\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Standard Error</span></b></p>\n</td>\n<td style=\"width:91.2pt;border-top:solid black 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:none;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Upper 95%-CI of\n  ddQTcS</span></b></p>\n</td>\n</tr>", "ID": "689673a7-1d46-4892-9e4a-c33e6939b040", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "206720bf-6bd5-4e01-9504-e18fc549f5f9"}, {"Element": "<td style=\"width:102.35pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"136\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Treatment</span></b></p>\n</td>", "ID": "57b15866-ba93-43de-8083-44ae7417ba63", "Styles": "width:102.35pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "689673a7-1d46-4892-9e4a-c33e6939b040"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Treatment</span></b></p>", "ID": "8a26bd7f-9fe8-4a99-91de-9b19dbee2bd7", "Styles": "text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['TableText10']", "Text": "", "ParentId": "57b15866-ba93-43de-8083-44ae7417ba63"}, {"Element": "<b><span style=\"font-size:11.0pt\">Treatment</span></b>", "ID": "debbcef0-91dc-4494-a6b6-c6aa0b936801", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8a26bd7f-9fe8-4a99-91de-9b19dbee2bd7"}, {"Element": "<span style=\"font-size:11.0pt\">Treatment</span>", "ID": "f40dc46c-953b-495f-a3cf-1fd81bfac277", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Treatment", "ParentId": "debbcef0-91dc-4494-a6b6-c6aa0b936801"}, {"Element": "<td style=\"width:89.6pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Post-Dose</span></b></p>\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Time Point</span></b></p>\n</td>", "ID": "6eb1e1f1-8d02-4bfc-b269-6fbdafe56553", "Styles": "width:89.6pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "   ", "ParentId": "689673a7-1d46-4892-9e4a-c33e6939b040"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Post-Dose</span></b></p>", "ID": "a6fb5c08-897d-4785-b07d-4ddcce02015c", "Styles": "text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['TableText10']", "Text": "", "ParentId": "6eb1e1f1-8d02-4bfc-b269-6fbdafe56553"}, {"Element": "<b><span style=\"font-size:11.0pt\">Post-Dose</span></b>", "ID": "f3db2484-9810-4b06-b622-cc0fd667c894", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a6fb5c08-897d-4785-b07d-4ddcce02015c"}, {"Element": "<span style=\"font-size:11.0pt\">Post-Dose</span>", "ID": "a7814ce1-6d47-4249-9442-43125190d3c7", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Post-Dose", "ParentId": "f3db2484-9810-4b06-b622-cc0fd667c894"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Time Point</span></b></p>", "ID": "33020dbe-9c19-4ae3-8a1a-151e43458e02", "Styles": "text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['TableText10']", "Text": "", "ParentId": "6eb1e1f1-8d02-4bfc-b269-6fbdafe56553"}, {"Element": "<b><span style=\"font-size:11.0pt\">Time Point</span></b>", "ID": "b28e7a88-abbc-426d-8019-b2ebd11b5433", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "33020dbe-9c19-4ae3-8a1a-151e43458e02"}, {"Element": "<span style=\"font-size:11.0pt\">Time Point</span>", "ID": "877eec97-9677-4eba-815a-e3cd1299aef7", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Time Point", "ParentId": "b28e7a88-abbc-426d-8019-b2ebd11b5433"}, {"Element": "<td style=\"width:98.25pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Mean </span></b></p>\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">ddQTcS</span></b></p>\n</td>", "ID": "8362db9b-48b6-49dd-b294-ed3394551199", "Styles": "width:98.25pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "   ", "ParentId": "689673a7-1d46-4892-9e4a-c33e6939b040"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Mean </span></b></p>", "ID": "4d3adb3d-4c42-4c8e-b71c-150c8cd8276e", "Styles": "text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['TableText10']", "Text": "", "ParentId": "8362db9b-48b6-49dd-b294-ed3394551199"}, {"Element": "<b><span style=\"font-size:11.0pt\">Mean </span></b>", "ID": "70c8eec0-ff71-40e5-97e5-0c8ed3f6d571", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4d3adb3d-4c42-4c8e-b71c-150c8cd8276e"}, {"Element": "<span style=\"font-size:11.0pt\">Mean </span>", "ID": "ff420bac-7443-40da-b54b-4cfe1e244a3c", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Mean ", "ParentId": "70c8eec0-ff71-40e5-97e5-0c8ed3f6d571"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">ddQTcS</span></b></p>", "ID": "155c35ee-7ba3-49c9-9a50-cf2c5fb4a226", "Styles": "text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['TableText10']", "Text": "", "ParentId": "8362db9b-48b6-49dd-b294-ed3394551199"}, {"Element": "<b><span style=\"font-size:11.0pt\">ddQTcS</span></b>", "ID": "f2268d92-ecf5-4d78-beb4-476c7431efd2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "155c35ee-7ba3-49c9-9a50-cf2c5fb4a226"}, {"Element": "<span style=\"font-size:11.0pt\">ddQTcS</span>", "ID": "03ff2757-20d8-4dbc-a4e5-981fdbe1cdb7", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "ddQTcS", "ParentId": "f2268d92-ecf5-4d78-beb4-476c7431efd2"}, {"Element": "<td style=\"width:1.0in;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"96\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Standard Error</span></b></p>\n</td>", "ID": "eaef3716-575b-4a1f-9008-25fe553c9af1", "Styles": "width:1.0in;border:solid black 1.0pt;\n  border-left:none;padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "689673a7-1d46-4892-9e4a-c33e6939b040"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Standard Error</span></b></p>", "ID": "96ab4e72-64cf-463f-a8d0-f5ba03ff66dd", "Styles": "text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['TableText10']", "Text": "", "ParentId": "eaef3716-575b-4a1f-9008-25fe553c9af1"}, {"Element": "<b><span style=\"font-size:11.0pt\">Standard Error</span></b>", "ID": "955cc9f8-e76f-4748-a571-c1c06b48178c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "96ab4e72-64cf-463f-a8d0-f5ba03ff66dd"}, {"Element": "<span style=\"font-size:11.0pt\">Standard Error</span>", "ID": "cb1e220e-ab0b-4b37-9036-7abbfd2bdb9d", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Standard Error", "ParentId": "955cc9f8-e76f-4748-a571-c1c06b48178c"}, {"Element": "<td style=\"width:91.2pt;border-top:solid black 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:none;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Upper 95%-CI of\n  ddQTcS</span></b></p>\n</td>", "ID": "f67008b5-682a-46a0-9562-8eb38e234ad0", "Styles": "width:91.2pt;border-top:solid black 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:none;\n  padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "689673a7-1d46-4892-9e4a-c33e6939b040"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Upper 95%-CI of\n  ddQTcS</span></b></p>", "ID": "74f2e37c-932b-47ff-a5b2-723d5309f598", "Styles": "text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['TableText10']", "Text": "", "ParentId": "f67008b5-682a-46a0-9562-8eb38e234ad0"}, {"Element": "<b><span style=\"font-size:11.0pt\">Upper 95%-CI of\n  ddQTcS</span></b>", "ID": "3dd44586-c8e6-4bcb-b4f1-ab77acef059b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "74f2e37c-932b-47ff-a5b2-723d5309f598"}, {"Element": "<span style=\"font-size:11.0pt\">Upper 95%-CI of\n  ddQTcS</span>", "ID": "deeecb1b-344c-48af-8ae0-803aa2540d7d", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Upper 95%-CI of   ddQTcS", "ParentId": "3dd44586-c8e6-4bcb-b4f1-ab77acef059b"}, {"Element": "<tr>\n<td style=\"width:102.35pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"136\">\n<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Invirase/ritonavir\n  1000/100\u00a0mg BID</span></p>\n</td>\n<td style=\"width:89.6pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span style=\"font-size:11.0pt\">12 hours</span></p>\n</td>\n<td style=\"width:98.25pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">18.86</span></p>\n</td>\n<td style=\"width:1.0in;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"96\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">1.91</span></p>\n</td>\n<td style=\"width:91.2pt;border:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">22.01</span></p>\n</td>\n</tr>", "ID": "8f5d79de-7da0-472f-845b-58d4b42859a8", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "206720bf-6bd5-4e01-9504-e18fc549f5f9"}, {"Element": "<td style=\"width:102.35pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"136\">\n<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Invirase/ritonavir\n  1000/100\u00a0mg BID</span></p>\n</td>", "ID": "a9fe4be8-1c72-4acd-8b52-be4ab5a56635", "Styles": "width:102.35pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f5d79de-7da0-472f-845b-58d4b42859a8"}, {"Element": "<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Invirase/ritonavir\n  1000/100\u00a0mg BID</span></p>", "ID": "a61ec47e-68c5-4a10-9e85-ba2eaf090400", "Styles": "text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid", "Classes": "['TableText10']", "Text": "", "ParentId": "a9fe4be8-1c72-4acd-8b52-be4ab5a56635"}, {"Element": "<span style=\"font-size:11.0pt\">Invirase/ritonavir\n  1000/100\u00a0mg BID</span>", "ID": "7e615846-fe40-433d-979f-5d0165ac7ffc", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Invirase/ritonavir   1000/100\u00a0mg BID", "ParentId": "a61ec47e-68c5-4a10-9e85-ba2eaf090400"}, {"Element": "<td style=\"width:89.6pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span style=\"font-size:11.0pt\">12 hours</span></p>\n</td>", "ID": "634e70af-7c90-4342-b3ee-38a5757d59b6", "Styles": "width:89.6pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f5d79de-7da0-472f-845b-58d4b42859a8"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span style=\"font-size:11.0pt\">12 hours</span></p>", "ID": "054cc041-ef24-478e-9316-8aeb6741b19b", "Styles": "text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['TableText10']", "Text": "", "ParentId": "634e70af-7c90-4342-b3ee-38a5757d59b6"}, {"Element": "<span style=\"font-size:11.0pt\">12 hours</span>", "ID": "72eda7fb-2c0b-4e7c-9525-9b17e57e7f7a", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "12 hours", "ParentId": "054cc041-ef24-478e-9316-8aeb6741b19b"}, {"Element": "<td style=\"width:98.25pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">18.86</span></p>\n</td>", "ID": "2ab0c528-2adc-4798-8e8b-637d1a7bb6e9", "Styles": "width:98.25pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f5d79de-7da0-472f-845b-58d4b42859a8"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">18.86</span></p>", "ID": "35e18698-a05a-4f3a-b70f-07839f2bc78c", "Styles": "text-align:center;line-height:14.0pt", "Classes": "['TableText10']", "Text": "", "ParentId": "2ab0c528-2adc-4798-8e8b-637d1a7bb6e9"}, {"Element": "<span style=\"font-size:11.0pt\">18.86</span>", "ID": "7b30e9cb-6a66-437b-9f1c-210821a95927", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "18.86", "ParentId": "35e18698-a05a-4f3a-b70f-07839f2bc78c"}, {"Element": "<td style=\"width:1.0in;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"96\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">1.91</span></p>\n</td>", "ID": "591ffb5b-b3a7-4125-8ee7-d6342216b12e", "Styles": "width:1.0in;border:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f5d79de-7da0-472f-845b-58d4b42859a8"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">1.91</span></p>", "ID": "ec7f6d95-212d-46a4-a703-32080f2c3790", "Styles": "text-align:center;line-height:14.0pt", "Classes": "['TableText10']", "Text": "", "ParentId": "591ffb5b-b3a7-4125-8ee7-d6342216b12e"}, {"Element": "<span style=\"font-size:11.0pt\">1.91</span>", "ID": "5ed3c4c6-c84b-4947-b17d-dbb8bef2ca47", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "1.91", "ParentId": "ec7f6d95-212d-46a4-a703-32080f2c3790"}, {"Element": "<td style=\"width:91.2pt;border:none;padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">22.01</span></p>\n</td>", "ID": "3db88d8a-461c-4df1-add2-5875c744d8c9", "Styles": "width:91.2pt;border:none;padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f5d79de-7da0-472f-845b-58d4b42859a8"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">22.01</span></p>", "ID": "1f4ad7f6-9857-4e78-a314-3a7aa672d2cb", "Styles": "text-align:center;line-height:14.0pt", "Classes": "['TableText10']", "Text": "", "ParentId": "3db88d8a-461c-4df1-add2-5875c744d8c9"}, {"Element": "<span style=\"font-size:11.0pt\">22.01</span>", "ID": "ea715d2f-452a-472a-a8c9-89fe96000b6a", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "22.01", "ParentId": "1f4ad7f6-9857-4e78-a314-3a7aa672d2cb"}, {"Element": "<tr>\n<td style=\"width:102.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"136\">\n<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Invirase/ritonavir</span></p>\n<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">1500/100\u00a0mg\n  BID</span></p>\n</td>\n<td style=\"width:89.6pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span style=\"font-size:11.0pt\">20 hours</span></p>\n</td>\n<td style=\"width:98.25pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">30.22</span></p>\n</td>\n<td style=\"width:1.0in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"96\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">1.91</span></p>\n</td>\n<td style=\"width:91.2pt;border:none;border-top:solid windowtext 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">33.36</span></p>\n</td>\n</tr>", "ID": "c1cf8d45-9955-43a2-a82e-06b3569b1689", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "206720bf-6bd5-4e01-9504-e18fc549f5f9"}, {"Element": "<td style=\"width:102.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"136\">\n<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Invirase/ritonavir</span></p>\n<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">1500/100\u00a0mg\n  BID</span></p>\n</td>", "ID": "9e40e6ec-a660-48f8-8e55-e57278eace7f", "Styles": "width:102.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "   ", "ParentId": "c1cf8d45-9955-43a2-a82e-06b3569b1689"}, {"Element": "<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Invirase/ritonavir</span></p>", "ID": "4d66b89d-733d-4868-a57b-0742711ad82e", "Styles": "text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid", "Classes": "['TableText10']", "Text": "", "ParentId": "9e40e6ec-a660-48f8-8e55-e57278eace7f"}, {"Element": "<span style=\"font-size:11.0pt\">Invirase/ritonavir</span>", "ID": "9c9edd8c-f7f1-4d65-ac8b-79f379dd3270", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Invirase/ritonavir", "ParentId": "4d66b89d-733d-4868-a57b-0742711ad82e"}, {"Element": "<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">1500/100\u00a0mg\n  BID</span></p>", "ID": "d6949876-4910-41a8-a278-6d26dbc1d664", "Styles": "text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid", "Classes": "['TableText10']", "Text": "", "ParentId": "9e40e6ec-a660-48f8-8e55-e57278eace7f"}, {"Element": "<span style=\"font-size:11.0pt\">1500/100\u00a0mg\n  BID</span>", "ID": "f65fbcfd-3925-4703-96da-5146c8577447", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "1500/100\u00a0mg   BID", "ParentId": "d6949876-4910-41a8-a278-6d26dbc1d664"}, {"Element": "<td style=\"width:89.6pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span style=\"font-size:11.0pt\">20 hours</span></p>\n</td>", "ID": "76b42098-fdb8-465f-bcbf-b197d703300a", "Styles": "width:89.6pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "c1cf8d45-9955-43a2-a82e-06b3569b1689"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span style=\"font-size:11.0pt\">20 hours</span></p>", "ID": "8161b60b-c0f9-4b61-b37f-cf6f612c0089", "Styles": "text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['TableText10']", "Text": "", "ParentId": "76b42098-fdb8-465f-bcbf-b197d703300a"}, {"Element": "<span style=\"font-size:11.0pt\">20 hours</span>", "ID": "bc8bdefe-e163-47cc-8fce-38cfedf3abbd", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "20 hours", "ParentId": "8161b60b-c0f9-4b61-b37f-cf6f612c0089"}, {"Element": "<td style=\"width:98.25pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">30.22</span></p>\n</td>", "ID": "95b1f1d1-d79f-4d6e-9935-2a76e6e48ecc", "Styles": "width:98.25pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "c1cf8d45-9955-43a2-a82e-06b3569b1689"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">30.22</span></p>", "ID": "97f7aeb0-b3d7-4095-8ff1-652b6766d65f", "Styles": "text-align:center;line-height:14.0pt", "Classes": "['TableText10']", "Text": "", "ParentId": "95b1f1d1-d79f-4d6e-9935-2a76e6e48ecc"}, {"Element": "<span style=\"font-size:11.0pt\">30.22</span>", "ID": "426e1e1c-e022-4bd8-a5df-22c8f7a35ae5", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "30.22", "ParentId": "97f7aeb0-b3d7-4095-8ff1-652b6766d65f"}, {"Element": "<td style=\"width:1.0in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"96\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">1.91</span></p>\n</td>", "ID": "c4baed5f-dfe4-40ff-bd3b-698d82e3331f", "Styles": "width:1.0in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "c1cf8d45-9955-43a2-a82e-06b3569b1689"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">1.91</span></p>", "ID": "f48a53f3-6bb8-4f98-8940-7851fa650da3", "Styles": "text-align:center;line-height:14.0pt", "Classes": "['TableText10']", "Text": "", "ParentId": "c4baed5f-dfe4-40ff-bd3b-698d82e3331f"}, {"Element": "<span style=\"font-size:11.0pt\">1.91</span>", "ID": "5a0c0114-97fb-4519-9ba0-1e21abe7983b", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "1.91", "ParentId": "f48a53f3-6bb8-4f98-8940-7851fa650da3"}, {"Element": "<td style=\"width:91.2pt;border:none;border-top:solid windowtext 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">33.36</span></p>\n</td>", "ID": "20474899-da23-4ed4-a7cf-299b7d71e97f", "Styles": "width:91.2pt;border:none;border-top:solid windowtext 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "c1cf8d45-9955-43a2-a82e-06b3569b1689"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">33.36</span></p>", "ID": "b06d8150-b91b-4141-b44c-a76bfdc8ff16", "Styles": "text-align:center;line-height:14.0pt", "Classes": "['TableText10']", "Text": "", "ParentId": "20474899-da23-4ed4-a7cf-299b7d71e97f"}, {"Element": "<span style=\"font-size:11.0pt\">33.36</span>", "ID": "2f1bb39f-7250-4e71-a963-1f68a4347569", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "33.36", "ParentId": "b06d8150-b91b-4141-b44c-a76bfdc8ff16"}, {"Element": "<tr>\n<td style=\"width:102.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"136\">\n<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Moxifloxacin^</span></p>\n</td>\n<td style=\"width:89.6pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span style=\"font-size:11.0pt\">4 hours</span></p>\n</td>\n<td style=\"width:98.25pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">12.18</span></p>\n</td>\n<td style=\"width:1.0in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"96\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">1.93</span></p>\n</td>\n<td style=\"width:91.2pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:none;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">15.36</span></p>\n</td>\n</tr>", "ID": "e15030a6-cd84-44fd-a05b-a10e84d6bfab", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "206720bf-6bd5-4e01-9504-e18fc549f5f9"}, {"Element": "<td style=\"width:102.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"136\">\n<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Moxifloxacin^</span></p>\n</td>", "ID": "249431c4-e01f-4e07-8b29-b85956187914", "Styles": "width:102.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "e15030a6-cd84-44fd-a05b-a10e84d6bfab"}, {"Element": "<p class=\"TableText10\" style=\"text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Moxifloxacin^</span></p>", "ID": "c817fd5f-5086-4a57-b824-09dd90a7ac3f", "Styles": "text-align:justify;text-justify:inter-ideograph;\n  line-height:14.0pt;page-break-after:avoid", "Classes": "['TableText10']", "Text": "", "ParentId": "249431c4-e01f-4e07-8b29-b85956187914"}, {"Element": "<span style=\"font-size:11.0pt\">Moxifloxacin^</span>", "ID": "48210439-6fb2-4504-8a0b-79f7f67edafe", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Moxifloxacin^", "ParentId": "c817fd5f-5086-4a57-b824-09dd90a7ac3f"}, {"Element": "<td style=\"width:89.6pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"119\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span style=\"font-size:11.0pt\">4 hours</span></p>\n</td>", "ID": "48a600bd-c980-40ed-a426-55e46f4f65d5", "Styles": "width:89.6pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "e15030a6-cd84-44fd-a05b-a10e84d6bfab"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt;\n  page-break-after:avoid\"><span style=\"font-size:11.0pt\">4 hours</span></p>", "ID": "81b529ef-ffe0-4ff9-b345-659cf4faea73", "Styles": "text-align:center;line-height:14.0pt;\n  page-break-after:avoid", "Classes": "['TableText10']", "Text": "", "ParentId": "48a600bd-c980-40ed-a426-55e46f4f65d5"}, {"Element": "<span style=\"font-size:11.0pt\">4 hours</span>", "ID": "8671d7b9-1bfc-4efb-8027-55618088c664", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "4 hours", "ParentId": "81b529ef-ffe0-4ff9-b345-659cf4faea73"}, {"Element": "<td style=\"width:98.25pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">12.18</span></p>\n</td>", "ID": "79e12bc5-9aed-4146-8099-7d2587cec2b3", "Styles": "width:98.25pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "e15030a6-cd84-44fd-a05b-a10e84d6bfab"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">12.18</span></p>", "ID": "2d5cea6c-b9e2-4a80-9b89-94daf021f19e", "Styles": "text-align:center;line-height:14.0pt", "Classes": "['TableText10']", "Text": "", "ParentId": "79e12bc5-9aed-4146-8099-7d2587cec2b3"}, {"Element": "<span style=\"font-size:11.0pt\">12.18</span>", "ID": "0355bb95-6667-41aa-b27f-5ca6c664f4e0", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "12.18", "ParentId": "2d5cea6c-b9e2-4a80-9b89-94daf021f19e"}, {"Element": "<td style=\"width:1.0in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"96\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">1.93</span></p>\n</td>", "ID": "61c7be87-c9d4-4360-89a2-e5ba88bb7d52", "Styles": "width:1.0in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "e15030a6-cd84-44fd-a05b-a10e84d6bfab"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">1.93</span></p>", "ID": "f922eb6f-132c-4c9a-ae75-bb95bb0e3f3d", "Styles": "text-align:center;line-height:14.0pt", "Classes": "['TableText10']", "Text": "", "ParentId": "61c7be87-c9d4-4360-89a2-e5ba88bb7d52"}, {"Element": "<span style=\"font-size:11.0pt\">1.93</span>", "ID": "c6e14a67-da76-497e-b135-5242319e3a8f", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "1.93", "ParentId": "f922eb6f-132c-4c9a-ae75-bb95bb0e3f3d"}, {"Element": "<td style=\"width:91.2pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:none;\n  padding:0in 3.4pt 0in 3.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">15.36</span></p>\n</td>", "ID": "1a1ee62c-38c1-436f-b8d3-d7913ef8e6f8", "Styles": "width:91.2pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid black 1.0pt;border-right:none;\n  padding:0in 3.4pt 0in 3.4pt", "Classes": "None", "Text": "  ", "ParentId": "e15030a6-cd84-44fd-a05b-a10e84d6bfab"}, {"Element": "<p align=\"center\" class=\"TableText10\" style=\"text-align:center;line-height:14.0pt\"><span style=\"font-size:11.0pt\">15.36</span></p>", "ID": "cc24bab7-fb91-407a-9b49-ec0bcc445b15", "Styles": "text-align:center;line-height:14.0pt", "Classes": "['TableText10']", "Text": "", "ParentId": "1a1ee62c-38c1-436f-b8d3-d7913ef8e6f8"}, {"Element": "<span style=\"font-size:11.0pt\">15.36</span>", "ID": "c9ae2f7c-f714-4be7-a8ee-166ce825ebc0", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "15.36", "ParentId": "cc24bab7-fb91-407a-9b49-ec0bcc445b15"}, {"Element": "<p class=\"MsoNormal\"><b><sup>\u2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </sup></b>Derived\ndifference of pre-dose baseline corrected QTcS between active treatment and\nplacebo arms</p>", "ID": "72c403e1-85a4-4418-b50c-e9700fee91a4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Derived difference of pre-dose baseline corrected QTcS between active treatment and placebo arms", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><sup>\u2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </sup></b>", "ID": "ff9736de-d44c-4e3f-aa9c-f3ea58c0b1c0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "72c403e1-85a4-4418-b50c-e9700fee91a4"}, {"Element": "<sup>\u2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </sup>", "ID": "2b961466-d66e-463b-a0a9-7fd5ae1a1ce2", "Styles": "None", "Classes": "None", "Text": "\u2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ff9736de-d44c-4e3f-aa9c-f3ea58c0b1c0"}, {"Element": "<p class=\"MsoNormal\">^\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 400\u00a0mg\nwas administered only on Day 3</p>", "ID": "1f433e6f-abe0-44ac-8c1d-6bfda41580cc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "^\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 400\u00a0mg was administered only on Day 3", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">Note: QTcS in this study was QT/RR<sup>0.319</sup> for males\nand QT/RR<sup>0.337</sup> for females, which are similar to Fridericia\u2019s correction\n(QTcF=QT/RR<sup>0.333</sup>).</p>", "ID": "eb9203b5-7ff0-4f88-add6-2347640367b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Note: QTcS in this study was QT/RR for males and QT/RR for females, which are similar to Fridericia\u2019s correction (QTcF=QT/RR).", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<sup>0.319</sup>", "ID": "4b1d5446-f3c2-4998-87d1-1636e32982f6", "Styles": "None", "Classes": "None", "Text": "0.319", "ParentId": "eb9203b5-7ff0-4f88-add6-2347640367b4"}, {"Element": "<sup>0.337</sup>", "ID": "09f436ec-745b-4a08-9279-0554d0fcbd9f", "Styles": "None", "Classes": "None", "Text": "0.337", "ParentId": "eb9203b5-7ff0-4f88-add6-2347640367b4"}, {"Element": "<sup>0.333</sup>", "ID": "c2552ebd-7b3d-4687-91ee-da1887fa1ef5", "Styles": "None", "Classes": "None", "Text": "0.333", "ParentId": "eb9203b5-7ff0-4f88-add6-2347640367b4"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "501e96c4-7966-4803-b868-ab8a230e4c32", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">In this study, PR interval of &gt; 200 msec was also\nobserved in 40% and 47% of subjects receiving Invirase/ritonavir\n1000/100\u00a0mg twice daily and 1500/100\u00a0mg twice daily, respectively, on\nDay 3. PR intervals of &gt; 200\u00a0msec were seen in 3% of subjects in the\nactive control group (moxifloxacin) and 5% in the placebo arm. The maximum mean\nPR interval changes relative to the pre-dose baseline value were 25 msec and 34\nmsec in the two ritonavir-boosted Invirase treatment groups, 1000/100\u00a0mg\ntwice daily and 1500/100\u00a0mg twice daily, respectively (also see section\n4.4).</p>", "ID": "3f8eaf89-ede0-4ab0-8360-7070fc4965f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In this study, PR interval of > 200 msec was also observed in 40% and 47% of subjects receiving Invirase/ritonavir 1000/100\u00a0mg twice daily and 1500/100\u00a0mg twice daily, respectively, on Day 3. PR intervals of > 200\u00a0msec were seen in 3% of subjects in the active control group (moxifloxacin) and 5% in the placebo arm. The maximum mean PR interval changes relative to the pre-dose baseline value were 25 msec and 34 msec in the two ritonavir-boosted Invirase treatment groups, 1000/100\u00a0mg twice daily and 1500/100\u00a0mg twice daily, respectively (also see section 4.4).", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "bb844903-bfb9-4471-ad35-918566236f99", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">Events of syncope/presyncope occurred at a higher than\nexpected rate and were seen more frequently under treatment with saquinavir (11\nof 13). The clinical relevance of these findings from this study in healthy\nvolunteers to the use of Invirase/ritonavir in HIV-infected patients is unclear,\nbut doses exceeding Invirase/ritonavir 1000/100\u00a0mg twice daily should be\navoided.</p>", "ID": "0afe999b-0c35-4024-a634-f45571245eb7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Events of syncope/presyncope occurred at a higher than expected rate and were seen more frequently under treatment with saquinavir (11 of 13). The clinical relevance of these findings from this study in healthy volunteers to the use of Invirase/ritonavir in HIV-infected patients is unclear, but doses exceeding Invirase/ritonavir 1000/100\u00a0mg twice daily should be avoided.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "cc40048c-2d66-4d76-9feb-b1d8a0399fcc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">The effect of treatment initiation with a dosing regimen of\nInvirase/ritonavir 500\u00a0/100 mg twice daily in combination with 2 NRTIs for\nthe first 7 days of treatment followed by Invirase/ritonavir 1000\u00a0/ 100 mg\ntwice daily in combination with 2 NRTIs in the subsequent 7 days on QTc\ninterval, PK, and viral load was evaluated in an open-label 2-week\nobservational study in 23 HIV-1 infected, treatment-na\u00efve patients\ninitiating Invirase/ritonavir therapy. ECG and PK measurements were collected\non Days 3, 4, 7, 10, and 14 of treatment with the modified Invirase/ritonavir\ntreatment. The primary study variable was maximal change from dense predose\nbaseline in QTcF (\u0394QTcFdense). The modified Invirase/ritonavir regimen\nreduced mean maximum \u0394QTcF<sub>dense</sub> in the first week of treatment\ncompared with the same value in healthy volunteers receiving the standard\nInvirase/ritonavir dosing regimen in the TQT study on Day 3, (Table 4) based on\ncross-study comparison in a different population. Only 2/21 (9%) patients\nacross all study days had maximum QTcF change from dense predose baseline\n\u2265 30 ms following administration of the modified Invirase/ritonavir\nregimen in the treatment-na\u00efve HIV-1 infected patient population; and the\nmaximum mean change from dense predose baseline in QTcF was &lt; 10 ms across\nall study days. These results suggest that the QTc liability is reduced with\nthe modified Invirase/ritonavir dosing regimen, based on a cross-study\ncomparison in a different population (Table 4). The proportion of patients with\na reported PR interval prolongation &gt; 200 ms in this study ranged from 3/22\n(14%) (day 3) to 8/21 (38%) (day14).</p>", "ID": "1fa4ac65-507e-4e9f-83d7-966c632c9d2a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The effect of treatment initiation with a dosing regimen of Invirase/ritonavir 500\u00a0/100 mg twice daily in combination with 2 NRTIs for the first 7 days of treatment followed by Invirase/ritonavir 1000\u00a0/ 100 mg twice daily in combination with 2 NRTIs in the subsequent 7 days on QTc interval, PK, and viral load was evaluated in an open-label 2-week observational study in 23 HIV-1 infected, treatment-na\u00efve patients initiating Invirase/ritonavir therapy. ECG and PK measurements were collected on Days 3, 4, 7, 10, and 14 of treatment with the modified Invirase/ritonavir treatment. The primary study variable was maximal change from dense predose baseline in QTcF (\u0394QTcFdense). The modified Invirase/ritonavir regimen reduced mean maximum \u0394QTcF in the first week of treatment compared with the same value in healthy volunteers receiving the standard Invirase/ritonavir dosing regimen in the TQT study on Day 3, (Table 4) based on cross-study comparison in a different population. Only 2/21 (9%) patients across all study days had maximum QTcF change from dense predose baseline \u2265 30 ms following administration of the modified Invirase/ritonavir regimen in the treatment-na\u00efve HIV-1 infected patient population; and the maximum mean change from dense predose baseline in QTcF was < 10 ms across all study days. These results suggest that the QTc liability is reduced with the modified Invirase/ritonavir dosing regimen, based on a cross-study comparison in a different population (Table 4). The proportion of patients with a reported PR interval prolongation > 200 ms in this study ranged from 3/22 (14%) (day 3) to 8/21 (38%) (day14).", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<sub>dense</sub>", "ID": "17d7290a-d2a9-4eb8-a45f-6d4e3199830e", "Styles": "None", "Classes": "None", "Text": "dense", "ParentId": "1fa4ac65-507e-4e9f-83d7-966c632c9d2a"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "03098f77-70a1-4dd5-b77f-eec8a8e91d2d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">Following the modified Invirase/ritonavir regimen,\nsaquinavir exposure during the first week peaked on Day 3 and declined to the\nlowest exposure on Day 7 with ritonavir induction effects, while Day 14\nsaquinavir PK parameters (following full doses of Invirase/ritonavir in the\nsecond week) approached the range of historical mean values for saquinavir\nsteady-state values in HIV-1 infected patients (Table 9). Mean Invirase C<sub>max</sub>\nwith the modified Invirase/ritonavir regimen was approximately 53-83% lower\nacross study days in the HIV-1 infected patients relative to the mean C<sub>max</sub>\nachieved in healthy volunteers in the TQT study on Day 3. Continuous declines\nin HIV-RNA were observed in all treatment-na\u00efve patients receiving the\nmodified Invirase/ritonavir dosing regimen over the 2-week treatment period,\nsuggesting HIV viral suppression during the time of the study. No long-term\nefficacy was evaluated with the modified regimen. </p>", "ID": "1c8d28b6-0401-48e3-98e4-e51b401b0f6b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Following the modified Invirase/ritonavir regimen, saquinavir exposure during the first week peaked on Day 3 and declined to the lowest exposure on Day 7 with ritonavir induction effects, while Day 14 saquinavir PK parameters (following full doses of Invirase/ritonavir in the second week) approached the range of historical mean values for saquinavir steady-state values in HIV-1 infected patients (Table 9). Mean Invirase C with the modified Invirase/ritonavir regimen was approximately 53-83% lower across study days in the HIV-1 infected patients relative to the mean C achieved in healthy volunteers in the TQT study on Day 3. Continuous declines in HIV-RNA were observed in all treatment-na\u00efve patients receiving the modified Invirase/ritonavir dosing regimen over the 2-week treatment period, suggesting HIV viral suppression during the time of the study. No long-term efficacy was evaluated with the modified regimen. ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<sub>max</sub>", "ID": "535afa15-79c2-4a05-9d4a-606daabb924b", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "1c8d28b6-0401-48e3-98e4-e51b401b0f6b"}, {"Element": "<sub>max</sub>", "ID": "23b8a1ae-aef0-401e-9382-66f7637b02ce", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "1c8d28b6-0401-48e3-98e4-e51b401b0f6b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "79ff6d63-8b3c-46dd-979c-1c6b4ea7bc5c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">Table 4: Summary of Electrocardiogram Parameters following administration\nof the Modified Invirase/ritonavir Regimen in Treatment Na\u00efve HIV-1\ninfected Patients initiating treatment with Invirase/ritonavir</p>", "ID": "6525788d-2e17-4e92-a59b-c2076a662bce", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Table 4: Summary of Electrocardiogram Parameters following administration of the Modified Invirase/ritonavir Regimen in Treatment Na\u00efve HIV-1 infected Patients initiating treatment with Invirase/ritonavir", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<div align=\"right\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:472.7pt;border-collapse:collapse\" width=\"630\">\n<tr style=\"height:31.9pt\">\n<td style=\"width:122.9pt;border:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"164\">\n<p class=\"MsoNormal\"><b>Parameter</b></p>\n</td>\n<td style=\"width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><b>Day 3</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=22)</b></p>\n</td>\n<td style=\"width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><b>Day 4</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><b>Day 7</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:63.0pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"84\">\n<p class=\"MsoNormal\"><b>Day 10</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:58.5pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"78\">\n<p class=\"MsoNormal\"><b>Day 14</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:66.3pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"88\">\n<p class=\"MsoNormal\"><b>TQT Study </b></p>\n<p class=\"MsoNormal\"><b>Day 3*</b></p>\n<p class=\"MsoNormal\"><b>(n=57)</b></p>\n</td>\n</tr>\n<tr style=\"height:19.95pt\">\n<td style=\"width:122.9pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:19.95pt\" valign=\"top\" width=\"164\">\n<p class=\"MsoNormal\"><span style=\"color:black\">Mean Maximal \u0394QTcF<sub><span style=\"position:relative;top:3.5pt\">dense</span></sub>\u00a0ms (SD)</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">3.26 \u00b1 7.01</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0.52 \u00b1 9.25 </span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">7.13 \u00b1 7.36</span></p>\n</td>\n<td style=\"width:63.0pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"84\">\n<p class=\"MsoNormal\"><span style=\"color:black\">11.97 \u00b1 11.55</span></p>\n</td>\n<td style=\"width:58.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"78\">\n<p class=\"MsoNormal\"><span style=\"color:black\">7.48 \u00b1 8.46</span></p>\n</td>\n<td style=\"width:66.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"88\">\n<p class=\"MsoNormal\"><span style=\"color:black\">32.2 \u00b1 13.4</span></p>\n</td>\n</tr>\n<tr style=\"height:11.5pt\">\n<td style=\"width:122.9pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:11.5pt\" valign=\"top\" width=\"164\">\n<p class=\"MsoNormal\"><span style=\"color:black\">Patients with maximal \u0394QTcF<sub><span style=\"position:relative;top:3.5pt\">dense</span></sub>\u00a0\u2265 30 ms (%)</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>\n<td style=\"width:63.0pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"84\">\n<p class=\"MsoNormal\"><span style=\"color:black\">2/21 (9%)</span></p>\n</td>\n<td style=\"width:58.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"78\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>\n<td style=\"width:66.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"88\">\n<p class=\"MsoNormal\"><span style=\"color:black\">29/57 (51%)</span></p>\n</td>\n</tr>\n</table>\n</div>", "ID": "7d7c9fee-6882-4778-971f-a98a905c7f56", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:472.7pt;border-collapse:collapse\" width=\"630\">\n<tr style=\"height:31.9pt\">\n<td style=\"width:122.9pt;border:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"164\">\n<p class=\"MsoNormal\"><b>Parameter</b></p>\n</td>\n<td style=\"width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><b>Day 3</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=22)</b></p>\n</td>\n<td style=\"width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><b>Day 4</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><b>Day 7</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:63.0pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"84\">\n<p class=\"MsoNormal\"><b>Day 10</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:58.5pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"78\">\n<p class=\"MsoNormal\"><b>Day 14</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:66.3pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"88\">\n<p class=\"MsoNormal\"><b>TQT Study </b></p>\n<p class=\"MsoNormal\"><b>Day 3*</b></p>\n<p class=\"MsoNormal\"><b>(n=57)</b></p>\n</td>\n</tr>\n<tr style=\"height:19.95pt\">\n<td style=\"width:122.9pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:19.95pt\" valign=\"top\" width=\"164\">\n<p class=\"MsoNormal\"><span style=\"color:black\">Mean Maximal \u0394QTcF<sub><span style=\"position:relative;top:3.5pt\">dense</span></sub>\u00a0ms (SD)</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">3.26 \u00b1 7.01</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0.52 \u00b1 9.25 </span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">7.13 \u00b1 7.36</span></p>\n</td>\n<td style=\"width:63.0pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"84\">\n<p class=\"MsoNormal\"><span style=\"color:black\">11.97 \u00b1 11.55</span></p>\n</td>\n<td style=\"width:58.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"78\">\n<p class=\"MsoNormal\"><span style=\"color:black\">7.48 \u00b1 8.46</span></p>\n</td>\n<td style=\"width:66.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"88\">\n<p class=\"MsoNormal\"><span style=\"color:black\">32.2 \u00b1 13.4</span></p>\n</td>\n</tr>\n<tr style=\"height:11.5pt\">\n<td style=\"width:122.9pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:11.5pt\" valign=\"top\" width=\"164\">\n<p class=\"MsoNormal\"><span style=\"color:black\">Patients with maximal \u0394QTcF<sub><span style=\"position:relative;top:3.5pt\">dense</span></sub>\u00a0\u2265 30 ms (%)</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>\n<td style=\"width:63.0pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"84\">\n<p class=\"MsoNormal\"><span style=\"color:black\">2/21 (9%)</span></p>\n</td>\n<td style=\"width:58.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"78\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>\n<td style=\"width:66.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"88\">\n<p class=\"MsoNormal\"><span style=\"color:black\">29/57 (51%)</span></p>\n</td>\n</tr>\n</table>", "ID": "4af16a78-aca3-4e55-b3d1-c1058b6f057d", "Styles": "width:472.7pt;border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "    ", "ParentId": "7d7c9fee-6882-4778-971f-a98a905c7f56"}, {"Element": "<tr style=\"height:31.9pt\">\n<td style=\"width:122.9pt;border:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"164\">\n<p class=\"MsoNormal\"><b>Parameter</b></p>\n</td>\n<td style=\"width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><b>Day 3</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=22)</b></p>\n</td>\n<td style=\"width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><b>Day 4</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><b>Day 7</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:63.0pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"84\">\n<p class=\"MsoNormal\"><b>Day 10</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:58.5pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"78\">\n<p class=\"MsoNormal\"><b>Day 14</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:66.3pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"88\">\n<p class=\"MsoNormal\"><b>TQT Study </b></p>\n<p class=\"MsoNormal\"><b>Day 3*</b></p>\n<p class=\"MsoNormal\"><b>(n=57)</b></p>\n</td>\n</tr>", "ID": "061bb075-7f7f-44d8-8fd3-13a8f4780849", "Styles": "height:31.9pt", "Classes": "None", "Text": "        ", "ParentId": "4af16a78-aca3-4e55-b3d1-c1058b6f057d"}, {"Element": "<td style=\"width:122.9pt;border:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"164\">\n<p class=\"MsoNormal\"><b>Parameter</b></p>\n</td>", "ID": "644c0e5b-a747-47a9-a153-46a8cb43cf79", "Styles": "width:122.9pt;border:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:31.9pt", "Classes": "None", "Text": "  ", "ParentId": "061bb075-7f7f-44d8-8fd3-13a8f4780849"}, {"Element": "<p class=\"MsoNormal\"><b>Parameter</b></p>", "ID": "48133347-3037-463c-9403-487f7558d531", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "644c0e5b-a747-47a9-a153-46a8cb43cf79"}, {"Element": "<b>Parameter</b>", "ID": "bc889ef6-33ef-450b-91c9-6f86be7b3809", "Styles": "None", "Classes": "None", "Text": "Parameter", "ParentId": "48133347-3037-463c-9403-487f7558d531"}, {"Element": "<td style=\"width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><b>Day 3</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=22)</b></p>\n</td>", "ID": "2719fe24-5c31-4bb9-88f1-5ede93048a9d", "Styles": "width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt", "Classes": "None", "Text": "    ", "ParentId": "061bb075-7f7f-44d8-8fd3-13a8f4780849"}, {"Element": "<p class=\"MsoNormal\"><b>Day 3</b></p>", "ID": "3cf2a74d-252b-49f7-bdc7-eaf28fec2eaf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2719fe24-5c31-4bb9-88f1-5ede93048a9d"}, {"Element": "<b>Day 3</b>", "ID": "685d76b5-e437-45d5-8df8-0299db4f18b1", "Styles": "None", "Classes": "None", "Text": "Day 3", "ParentId": "3cf2a74d-252b-49f7-bdc7-eaf28fec2eaf"}, {"Element": "<p class=\"MsoNormal\"><b>500/100 mg</b></p>", "ID": "8cb1aec0-d0af-4fed-8727-617454d3b134", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2719fe24-5c31-4bb9-88f1-5ede93048a9d"}, {"Element": "<b>500/100 mg</b>", "ID": "1681b0ac-4c27-4353-bf2f-0a5400c0842d", "Styles": "None", "Classes": "None", "Text": "500/100 mg", "ParentId": "8cb1aec0-d0af-4fed-8727-617454d3b134"}, {"Element": "<p class=\"MsoNormal\"><b>(n=22)</b></p>", "ID": "8e42c41b-21e8-4ae2-b51d-29254305ea3b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2719fe24-5c31-4bb9-88f1-5ede93048a9d"}, {"Element": "<b>(n=22)</b>", "ID": "0016e3de-4686-4e97-a86d-655bc22b7789", "Styles": "None", "Classes": "None", "Text": "(n=22)", "ParentId": "8e42c41b-21e8-4ae2-b51d-29254305ea3b"}, {"Element": "<td style=\"width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><b>Day 4</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>", "ID": "d6de99a4-7915-44ee-9f24-8af8ff4d63b6", "Styles": "width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt", "Classes": "None", "Text": "    ", "ParentId": "061bb075-7f7f-44d8-8fd3-13a8f4780849"}, {"Element": "<p class=\"MsoNormal\"><b>Day 4</b></p>", "ID": "316e038a-d43a-4fec-a362-6e3280b5aa3b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d6de99a4-7915-44ee-9f24-8af8ff4d63b6"}, {"Element": "<b>Day 4</b>", "ID": "2294afb0-e530-4ba0-a11f-68e728af2597", "Styles": "None", "Classes": "None", "Text": "Day 4", "ParentId": "316e038a-d43a-4fec-a362-6e3280b5aa3b"}, {"Element": "<p class=\"MsoNormal\"><b>500/100 mg</b></p>", "ID": "2ba59a4d-85b2-4407-80ff-39caca012cc9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d6de99a4-7915-44ee-9f24-8af8ff4d63b6"}, {"Element": "<b>500/100 mg</b>", "ID": "9c7e0335-8988-4b7c-a42a-fb49234af2b8", "Styles": "None", "Classes": "None", "Text": "500/100 mg", "ParentId": "2ba59a4d-85b2-4407-80ff-39caca012cc9"}, {"Element": "<p class=\"MsoNormal\"><b>(n=21)</b></p>", "ID": "30af4f14-65c6-4de4-bfe1-8d573181d34b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d6de99a4-7915-44ee-9f24-8af8ff4d63b6"}, {"Element": "<b>(n=21)</b>", "ID": "0f757f28-084e-4d9a-a9b2-a5520895c578", "Styles": "None", "Classes": "None", "Text": "(n=21)", "ParentId": "30af4f14-65c6-4de4-bfe1-8d573181d34b"}, {"Element": "<td style=\"width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><b>Day 7</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>", "ID": "1d5e80f9-bd34-4516-afb8-45d2fd22a8a0", "Styles": "width:.75in;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt", "Classes": "None", "Text": "    ", "ParentId": "061bb075-7f7f-44d8-8fd3-13a8f4780849"}, {"Element": "<p class=\"MsoNormal\"><b>Day 7</b></p>", "ID": "e59c2d64-ff0a-4bda-81f3-7a5fd29aac25", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1d5e80f9-bd34-4516-afb8-45d2fd22a8a0"}, {"Element": "<b>Day 7</b>", "ID": "30f8499e-076f-4224-8940-2de581ef08e0", "Styles": "None", "Classes": "None", "Text": "Day 7", "ParentId": "e59c2d64-ff0a-4bda-81f3-7a5fd29aac25"}, {"Element": "<p class=\"MsoNormal\"><b>500/100 mg</b></p>", "ID": "ccb7eeca-3671-481e-9949-edb3207484e9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1d5e80f9-bd34-4516-afb8-45d2fd22a8a0"}, {"Element": "<b>500/100 mg</b>", "ID": "adb2ec93-cd54-4583-9b6e-b3cc18becd0e", "Styles": "None", "Classes": "None", "Text": "500/100 mg", "ParentId": "ccb7eeca-3671-481e-9949-edb3207484e9"}, {"Element": "<p class=\"MsoNormal\"><b>(n=21)</b></p>", "ID": "04cfe93e-d2c5-47b9-9f81-e82983c0f799", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1d5e80f9-bd34-4516-afb8-45d2fd22a8a0"}, {"Element": "<b>(n=21)</b>", "ID": "fd04ff64-ef49-405a-921a-e3ea8ea359a7", "Styles": "None", "Classes": "None", "Text": "(n=21)", "ParentId": "04cfe93e-d2c5-47b9-9f81-e82983c0f799"}, {"Element": "<td style=\"width:63.0pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"84\">\n<p class=\"MsoNormal\"><b>Day 10</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>", "ID": "d96d2bbd-511e-49f5-b792-d92d48283f80", "Styles": "width:63.0pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt", "Classes": "None", "Text": "    ", "ParentId": "061bb075-7f7f-44d8-8fd3-13a8f4780849"}, {"Element": "<p class=\"MsoNormal\"><b>Day 10</b></p>", "ID": "c0b198ae-e64f-42c1-98a1-e988b02cb621", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d96d2bbd-511e-49f5-b792-d92d48283f80"}, {"Element": "<b>Day 10</b>", "ID": "a380d6de-7479-4dda-ad96-ee525f78024b", "Styles": "None", "Classes": "None", "Text": "Day 10", "ParentId": "c0b198ae-e64f-42c1-98a1-e988b02cb621"}, {"Element": "<p class=\"MsoNormal\"><b>1000/100 mg</b></p>", "ID": "15cfd1ab-76fd-437b-be32-24784d70035e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d96d2bbd-511e-49f5-b792-d92d48283f80"}, {"Element": "<b>1000/100 mg</b>", "ID": "25340d32-8c24-40fc-9c1a-a715bb7b35c0", "Styles": "None", "Classes": "None", "Text": "1000/100 mg", "ParentId": "15cfd1ab-76fd-437b-be32-24784d70035e"}, {"Element": "<p class=\"MsoNormal\"><b>(n=21)</b></p>", "ID": "a028b1d1-f54f-42e4-b281-77da125b041a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d96d2bbd-511e-49f5-b792-d92d48283f80"}, {"Element": "<b>(n=21)</b>", "ID": "72f50430-f1ab-4d4a-9ec2-f9f978bea4b4", "Styles": "None", "Classes": "None", "Text": "(n=21)", "ParentId": "a028b1d1-f54f-42e4-b281-77da125b041a"}, {"Element": "<td style=\"width:58.5pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"78\">\n<p class=\"MsoNormal\"><b>Day 14</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>", "ID": "5cca996c-10d4-4fa7-a55d-15161e23bf3a", "Styles": "width:58.5pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt", "Classes": "None", "Text": "    ", "ParentId": "061bb075-7f7f-44d8-8fd3-13a8f4780849"}, {"Element": "<p class=\"MsoNormal\"><b>Day 14</b></p>", "ID": "92a542a0-75ac-4a4c-aabb-951653ef9cf7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5cca996c-10d4-4fa7-a55d-15161e23bf3a"}, {"Element": "<b>Day 14</b>", "ID": "e0774381-e596-406b-b91a-577adc92ab29", "Styles": "None", "Classes": "None", "Text": "Day 14", "ParentId": "92a542a0-75ac-4a4c-aabb-951653ef9cf7"}, {"Element": "<p class=\"MsoNormal\"><b>1000/100 mg</b></p>", "ID": "b0346462-4d55-4c94-9e7d-c0eb24c80aae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5cca996c-10d4-4fa7-a55d-15161e23bf3a"}, {"Element": "<b>1000/100 mg</b>", "ID": "63330d96-eb1d-4378-b178-b6cc164f384f", "Styles": "None", "Classes": "None", "Text": "1000/100 mg", "ParentId": "b0346462-4d55-4c94-9e7d-c0eb24c80aae"}, {"Element": "<p class=\"MsoNormal\"><b>(n=21)</b></p>", "ID": "7420e9e9-d2c2-4850-961b-1be7eb75c907", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5cca996c-10d4-4fa7-a55d-15161e23bf3a"}, {"Element": "<b>(n=21)</b>", "ID": "d929875f-494e-48ed-bc40-2845e14ddb2f", "Styles": "None", "Classes": "None", "Text": "(n=21)", "ParentId": "7420e9e9-d2c2-4850-961b-1be7eb75c907"}, {"Element": "<td style=\"width:66.3pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt\" valign=\"top\" width=\"88\">\n<p class=\"MsoNormal\"><b>TQT Study </b></p>\n<p class=\"MsoNormal\"><b>Day 3*</b></p>\n<p class=\"MsoNormal\"><b>(n=57)</b></p>\n</td>", "ID": "ae40af0a-d3d1-4361-9ede-9c76b3ba453b", "Styles": "width:66.3pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt", "Classes": "None", "Text": "    ", "ParentId": "061bb075-7f7f-44d8-8fd3-13a8f4780849"}, {"Element": "<p class=\"MsoNormal\"><b>TQT Study </b></p>", "ID": "252266f0-816f-41aa-9764-42d2ed5d11d9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ae40af0a-d3d1-4361-9ede-9c76b3ba453b"}, {"Element": "<b>TQT Study </b>", "ID": "9769b8ad-c35a-4376-88f5-9e012c933335", "Styles": "None", "Classes": "None", "Text": "TQT Study ", "ParentId": "252266f0-816f-41aa-9764-42d2ed5d11d9"}, {"Element": "<p class=\"MsoNormal\"><b>Day 3*</b></p>", "ID": "ceee6039-2102-4bb5-b8bc-2f0a6c5323ee", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ae40af0a-d3d1-4361-9ede-9c76b3ba453b"}, {"Element": "<b>Day 3*</b>", "ID": "0f193cb6-b3a3-436a-9475-05aa1969e5d4", "Styles": "None", "Classes": "None", "Text": "Day 3*", "ParentId": "ceee6039-2102-4bb5-b8bc-2f0a6c5323ee"}, {"Element": "<p class=\"MsoNormal\"><b>(n=57)</b></p>", "ID": "a52175f8-9ca6-44be-a214-f01dd1eea158", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ae40af0a-d3d1-4361-9ede-9c76b3ba453b"}, {"Element": "<b>(n=57)</b>", "ID": "aff1f2ca-1f4f-4115-9229-c21741b557a4", "Styles": "None", "Classes": "None", "Text": "(n=57)", "ParentId": "a52175f8-9ca6-44be-a214-f01dd1eea158"}, {"Element": "<tr style=\"height:19.95pt\">\n<td style=\"width:122.9pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:19.95pt\" valign=\"top\" width=\"164\">\n<p class=\"MsoNormal\"><span style=\"color:black\">Mean Maximal \u0394QTcF<sub><span style=\"position:relative;top:3.5pt\">dense</span></sub>\u00a0ms (SD)</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">3.26 \u00b1 7.01</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0.52 \u00b1 9.25 </span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">7.13 \u00b1 7.36</span></p>\n</td>\n<td style=\"width:63.0pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"84\">\n<p class=\"MsoNormal\"><span style=\"color:black\">11.97 \u00b1 11.55</span></p>\n</td>\n<td style=\"width:58.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"78\">\n<p class=\"MsoNormal\"><span style=\"color:black\">7.48 \u00b1 8.46</span></p>\n</td>\n<td style=\"width:66.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"88\">\n<p class=\"MsoNormal\"><span style=\"color:black\">32.2 \u00b1 13.4</span></p>\n</td>\n</tr>", "ID": "21481cc1-1a85-484b-bd3a-44d1db449a43", "Styles": "height:19.95pt", "Classes": "None", "Text": "        ", "ParentId": "4af16a78-aca3-4e55-b3d1-c1058b6f057d"}, {"Element": "<td style=\"width:122.9pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:19.95pt\" valign=\"top\" width=\"164\">\n<p class=\"MsoNormal\"><span style=\"color:black\">Mean Maximal \u0394QTcF<sub><span style=\"position:relative;top:3.5pt\">dense</span></sub>\u00a0ms (SD)</span></p>\n</td>", "ID": "0d0c8a6a-972b-4be0-a022-f28cbfbc1244", "Styles": "width:122.9pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:19.95pt", "Classes": "None", "Text": "  ", "ParentId": "21481cc1-1a85-484b-bd3a-44d1db449a43"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">Mean Maximal \u0394QTcF<sub><span style=\"position:relative;top:3.5pt\">dense</span></sub>\u00a0ms (SD)</span></p>", "ID": "85a80fdd-cd72-4d8e-b9b9-b55c446841f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0d0c8a6a-972b-4be0-a022-f28cbfbc1244"}, {"Element": "<span style=\"color:black\">Mean Maximal \u0394QTcF<sub><span style=\"position:relative;top:3.5pt\">dense</span></sub>\u00a0ms (SD)</span>", "ID": "1656b2ff-057b-4efc-94fb-bfd0e022e338", "Styles": "color:black", "Classes": "None", "Text": "Mean Maximal \u0394QTcF\u00a0ms (SD)", "ParentId": "85a80fdd-cd72-4d8e-b9b9-b55c446841f6"}, {"Element": "<sub><span style=\"position:relative;top:3.5pt\">dense</span></sub>", "ID": "89f7790d-3a7e-4767-905f-260d6e639077", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1656b2ff-057b-4efc-94fb-bfd0e022e338"}, {"Element": "<span style=\"position:relative;top:3.5pt\">dense</span>", "ID": "55ea5c5d-cf01-43b1-80e0-f1798aeff559", "Styles": "position:relative;top:3.5pt", "Classes": "None", "Text": "dense", "ParentId": "89f7790d-3a7e-4767-905f-260d6e639077"}, {"Element": "<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">3.26 \u00b1 7.01</span></p>\n</td>", "ID": "8b00241e-289f-49b8-85ff-1994ad3b9734", "Styles": "width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt", "Classes": "None", "Text": "  ", "ParentId": "21481cc1-1a85-484b-bd3a-44d1db449a43"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">3.26 \u00b1 7.01</span></p>", "ID": "c8a72f82-62af-48d8-8e27-f95a024e09f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b00241e-289f-49b8-85ff-1994ad3b9734"}, {"Element": "<span style=\"color:black\">3.26 \u00b1 7.01</span>", "ID": "7c879085-8725-4577-988c-a63fef0adcaa", "Styles": "color:black", "Classes": "None", "Text": "3.26 \u00b1 7.01", "ParentId": "c8a72f82-62af-48d8-8e27-f95a024e09f2"}, {"Element": "<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0.52 \u00b1 9.25 </span></p>\n</td>", "ID": "b9787754-d0ac-4ad9-b6a5-8b91ec5f8fb8", "Styles": "width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt", "Classes": "None", "Text": "  ", "ParentId": "21481cc1-1a85-484b-bd3a-44d1db449a43"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">0.52 \u00b1 9.25 </span></p>", "ID": "7336f8c4-a114-4394-9122-12ac68dd6041", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b9787754-d0ac-4ad9-b6a5-8b91ec5f8fb8"}, {"Element": "<span style=\"color:black\">0.52 \u00b1 9.25 </span>", "ID": "4a7fe003-5b13-41d8-ac74-5d7c8c0eb77d", "Styles": "color:black", "Classes": "None", "Text": "0.52 \u00b1 9.25 ", "ParentId": "7336f8c4-a114-4394-9122-12ac68dd6041"}, {"Element": "<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">7.13 \u00b1 7.36</span></p>\n</td>", "ID": "04a994cb-4a54-46f1-ba60-d21502ac73da", "Styles": "width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt", "Classes": "None", "Text": "  ", "ParentId": "21481cc1-1a85-484b-bd3a-44d1db449a43"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">7.13 \u00b1 7.36</span></p>", "ID": "a5942c73-4f3e-4e72-81a6-cdabc7510c0d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04a994cb-4a54-46f1-ba60-d21502ac73da"}, {"Element": "<span style=\"color:black\">7.13 \u00b1 7.36</span>", "ID": "84f5718e-010a-4bf8-998a-0d195fa4e175", "Styles": "color:black", "Classes": "None", "Text": "7.13 \u00b1 7.36", "ParentId": "a5942c73-4f3e-4e72-81a6-cdabc7510c0d"}, {"Element": "<td style=\"width:63.0pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"84\">\n<p class=\"MsoNormal\"><span style=\"color:black\">11.97 \u00b1 11.55</span></p>\n</td>", "ID": "7074737f-add6-4497-a19e-6e54f3794e64", "Styles": "width:63.0pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt", "Classes": "None", "Text": "  ", "ParentId": "21481cc1-1a85-484b-bd3a-44d1db449a43"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">11.97 \u00b1 11.55</span></p>", "ID": "c84ce9a5-0d50-498d-a872-24a4757fefd1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7074737f-add6-4497-a19e-6e54f3794e64"}, {"Element": "<span style=\"color:black\">11.97 \u00b1 11.55</span>", "ID": "2c86c75f-1f0c-43e6-b7bd-713b3e93705a", "Styles": "color:black", "Classes": "None", "Text": "11.97 \u00b1 11.55", "ParentId": "c84ce9a5-0d50-498d-a872-24a4757fefd1"}, {"Element": "<td style=\"width:58.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"78\">\n<p class=\"MsoNormal\"><span style=\"color:black\">7.48 \u00b1 8.46</span></p>\n</td>", "ID": "38d2272e-dd3b-4f7b-8f91-af77d013fd62", "Styles": "width:58.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt", "Classes": "None", "Text": "  ", "ParentId": "21481cc1-1a85-484b-bd3a-44d1db449a43"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">7.48 \u00b1 8.46</span></p>", "ID": "51c17bc8-5b8f-4736-b240-c85a24a762d4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "38d2272e-dd3b-4f7b-8f91-af77d013fd62"}, {"Element": "<span style=\"color:black\">7.48 \u00b1 8.46</span>", "ID": "42aeeb04-3661-4897-b39d-2406f7cd1349", "Styles": "color:black", "Classes": "None", "Text": "7.48 \u00b1 8.46", "ParentId": "51c17bc8-5b8f-4736-b240-c85a24a762d4"}, {"Element": "<td style=\"width:66.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt\" valign=\"top\" width=\"88\">\n<p class=\"MsoNormal\"><span style=\"color:black\">32.2 \u00b1 13.4</span></p>\n</td>", "ID": "cffa763a-e2d0-40a8-a8d0-cc07673f2934", "Styles": "width:66.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:19.95pt", "Classes": "None", "Text": "  ", "ParentId": "21481cc1-1a85-484b-bd3a-44d1db449a43"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">32.2 \u00b1 13.4</span></p>", "ID": "12395205-564b-4208-aad8-bbf525e38e89", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cffa763a-e2d0-40a8-a8d0-cc07673f2934"}, {"Element": "<span style=\"color:black\">32.2 \u00b1 13.4</span>", "ID": "5f5638d2-7c88-4a15-8eff-742f37f96a53", "Styles": "color:black", "Classes": "None", "Text": "32.2 \u00b1 13.4", "ParentId": "12395205-564b-4208-aad8-bbf525e38e89"}, {"Element": "<tr style=\"height:11.5pt\">\n<td style=\"width:122.9pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:11.5pt\" valign=\"top\" width=\"164\">\n<p class=\"MsoNormal\"><span style=\"color:black\">Patients with maximal \u0394QTcF<sub><span style=\"position:relative;top:3.5pt\">dense</span></sub>\u00a0\u2265 30 ms (%)</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>\n<td style=\"width:63.0pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"84\">\n<p class=\"MsoNormal\"><span style=\"color:black\">2/21 (9%)</span></p>\n</td>\n<td style=\"width:58.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"78\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>\n<td style=\"width:66.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"88\">\n<p class=\"MsoNormal\"><span style=\"color:black\">29/57 (51%)</span></p>\n</td>\n</tr>", "ID": "2caae11b-1f91-4e0f-a6ed-8e28f7cb6d47", "Styles": "height:11.5pt", "Classes": "None", "Text": "        ", "ParentId": "4af16a78-aca3-4e55-b3d1-c1058b6f057d"}, {"Element": "<td style=\"width:122.9pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:11.5pt\" valign=\"top\" width=\"164\">\n<p class=\"MsoNormal\"><span style=\"color:black\">Patients with maximal \u0394QTcF<sub><span style=\"position:relative;top:3.5pt\">dense</span></sub>\u00a0\u2265 30 ms (%)</span></p>\n</td>", "ID": "4b3a2c41-a1cb-4d55-a888-bd18eb657da5", "Styles": "width:122.9pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:11.5pt", "Classes": "None", "Text": "  ", "ParentId": "2caae11b-1f91-4e0f-a6ed-8e28f7cb6d47"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">Patients with maximal \u0394QTcF<sub><span style=\"position:relative;top:3.5pt\">dense</span></sub>\u00a0\u2265 30 ms (%)</span></p>", "ID": "b82cd90b-6ae6-4193-bce1-ffd2d9971b24", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4b3a2c41-a1cb-4d55-a888-bd18eb657da5"}, {"Element": "<span style=\"color:black\">Patients with maximal \u0394QTcF<sub><span style=\"position:relative;top:3.5pt\">dense</span></sub>\u00a0\u2265 30 ms (%)</span>", "ID": "63dd9909-d0ae-4b6d-b86e-118fe050598f", "Styles": "color:black", "Classes": "None", "Text": "Patients with maximal \u0394QTcF\u00a0\u2265 30 ms (%)", "ParentId": "b82cd90b-6ae6-4193-bce1-ffd2d9971b24"}, {"Element": "<sub><span style=\"position:relative;top:3.5pt\">dense</span></sub>", "ID": "2aa443a7-83a2-4576-b68d-0d3a90368fcb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "63dd9909-d0ae-4b6d-b86e-118fe050598f"}, {"Element": "<span style=\"position:relative;top:3.5pt\">dense</span>", "ID": "82fe30ff-f19e-4abd-91a3-a10cca3fa44e", "Styles": "position:relative;top:3.5pt", "Classes": "None", "Text": "dense", "ParentId": "2aa443a7-83a2-4576-b68d-0d3a90368fcb"}, {"Element": "<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>", "ID": "a16119be-5504-4dde-8ee3-5b0a803cb690", "Styles": "width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt", "Classes": "None", "Text": "  ", "ParentId": "2caae11b-1f91-4e0f-a6ed-8e28f7cb6d47"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>", "ID": "76e77825-057c-43ad-8161-46cbbca15bb5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a16119be-5504-4dde-8ee3-5b0a803cb690"}, {"Element": "<span style=\"color:black\">0</span>", "ID": "c9155b08-39c3-4661-937d-c7b97fcfac8c", "Styles": "color:black", "Classes": "None", "Text": "0", "ParentId": "76e77825-057c-43ad-8161-46cbbca15bb5"}, {"Element": "<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>", "ID": "ff758fab-fdb5-4efd-8ea9-2ad1080614cb", "Styles": "width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt", "Classes": "None", "Text": "  ", "ParentId": "2caae11b-1f91-4e0f-a6ed-8e28f7cb6d47"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>", "ID": "fa75dfc4-47ca-4378-87c3-46827d02fdc9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ff758fab-fdb5-4efd-8ea9-2ad1080614cb"}, {"Element": "<span style=\"color:black\">0</span>", "ID": "52398cb9-d026-4204-95e7-436cc116abe2", "Styles": "color:black", "Classes": "None", "Text": "0", "ParentId": "fa75dfc4-47ca-4378-87c3-46827d02fdc9"}, {"Element": "<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"72\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>", "ID": "e69dbcf8-1095-455b-b129-c4234f2f0066", "Styles": "width:.75in;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt", "Classes": "None", "Text": "  ", "ParentId": "2caae11b-1f91-4e0f-a6ed-8e28f7cb6d47"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>", "ID": "4b9f4735-9965-42bf-a187-32eaa179d95d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e69dbcf8-1095-455b-b129-c4234f2f0066"}, {"Element": "<span style=\"color:black\">0</span>", "ID": "b6d62be2-21f9-4435-8bd8-7790718357f2", "Styles": "color:black", "Classes": "None", "Text": "0", "ParentId": "4b9f4735-9965-42bf-a187-32eaa179d95d"}, {"Element": "<td style=\"width:63.0pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"84\">\n<p class=\"MsoNormal\"><span style=\"color:black\">2/21 (9%)</span></p>\n</td>", "ID": "ee0acc14-beb1-4d54-a20e-51dac55e55ff", "Styles": "width:63.0pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt", "Classes": "None", "Text": "  ", "ParentId": "2caae11b-1f91-4e0f-a6ed-8e28f7cb6d47"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">2/21 (9%)</span></p>", "ID": "4b612436-3327-4329-a8fe-e315e68aa10a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ee0acc14-beb1-4d54-a20e-51dac55e55ff"}, {"Element": "<span style=\"color:black\">2/21 (9%)</span>", "ID": "a266f978-3a8d-4eed-9b24-c1c1adea5179", "Styles": "color:black", "Classes": "None", "Text": "2/21 (9%)", "ParentId": "4b612436-3327-4329-a8fe-e315e68aa10a"}, {"Element": "<td style=\"width:58.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"78\">\n<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>\n</td>", "ID": "218cc8c9-3dad-47c1-a6f5-2180d2440908", "Styles": "width:58.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt", "Classes": "None", "Text": "  ", "ParentId": "2caae11b-1f91-4e0f-a6ed-8e28f7cb6d47"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">0</span></p>", "ID": "75ffa773-d000-42b8-aca7-52bb0a174d1a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "218cc8c9-3dad-47c1-a6f5-2180d2440908"}, {"Element": "<span style=\"color:black\">0</span>", "ID": "fc9226f3-3557-4446-ab21-bc9f21f23539", "Styles": "color:black", "Classes": "None", "Text": "0", "ParentId": "75ffa773-d000-42b8-aca7-52bb0a174d1a"}, {"Element": "<td style=\"width:66.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt\" valign=\"top\" width=\"88\">\n<p class=\"MsoNormal\"><span style=\"color:black\">29/57 (51%)</span></p>\n</td>", "ID": "98356418-02cf-44dc-89d0-c5ec0a158ea5", "Styles": "width:66.3pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:11.5pt", "Classes": "None", "Text": "  ", "ParentId": "2caae11b-1f91-4e0f-a6ed-8e28f7cb6d47"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">29/57 (51%)</span></p>", "ID": "c5839f09-6de4-42ee-bdd3-2f421980d1ef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "98356418-02cf-44dc-89d0-c5ec0a158ea5"}, {"Element": "<span style=\"color:black\">29/57 (51%)</span>", "ID": "6175006b-de19-4865-9e31-0ce2b993832d", "Styles": "color:black", "Classes": "None", "Text": "29/57 (51%)", "ParentId": "c5839f09-6de4-42ee-bdd3-2f421980d1ef"}, {"Element": "<p class=\"MsoNormal\">*Historical data from the thorough QT study conducted in\nhealthy volunteers</p>", "ID": "16c9da26-f8f4-4a86-b475-d3023e5cf0a1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "*Historical data from the thorough QT study conducted in healthy volunteers", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ac9a6d3a-9a60-48bb-8987-f91a76cf73cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Antiviral activity in vitro:</span></i></b><span lang=\"EN-GB\"> </span><span style=\"color:black\">Saquinavir\u00a0demonstrates\nantiviral activity against a panel of laboratory strains and clinical isolates\nof HIV-1 with typical EC<sub>50</sub> and\u00a0EC<sub>90</sub> values in the\nrange 1-10 nM and 5-50 nM, respectively, </span><span lang=\"EN-GB\" style=\"color:black\">with no apparent difference between subtype B and non-B\nclades. The corresponding serum (50% human serum) adjusted EC<sub>50</sub>\nranged from 25-250 nM. Clinical isolates of HIV-2 demonstrated EC<sub>50</sub>\nvalues in the range of 0.3-2.4 nM.</span></p>", "ID": "f791f7a8-4b6a-4479-86ee-3b14c444756b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Antiviral activity in vitro:</span></i></b>", "ID": "62ada85a-859d-4f6a-be4d-37431bf8cb55", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f791f7a8-4b6a-4479-86ee-3b14c444756b"}, {"Element": "<i><span lang=\"EN-GB\">Antiviral activity in vitro:</span></i>", "ID": "51d83a69-1663-4bc7-b23b-8be93ad399e5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "62ada85a-859d-4f6a-be4d-37431bf8cb55"}, {"Element": "<span lang=\"EN-GB\">Antiviral activity in vitro:</span>", "ID": "d6df3584-a252-4eca-85be-c7cc34d6293c", "Styles": "None", "Classes": "None", "Text": "Antiviral activity in vitro:", "ParentId": "51d83a69-1663-4bc7-b23b-8be93ad399e5"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "c7ac9ac3-df12-4edd-b300-d7763140ee5a", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "f791f7a8-4b6a-4479-86ee-3b14c444756b"}, {"Element": "<span style=\"color:black\">Saquinavir\u00a0demonstrates\nantiviral activity against a panel of laboratory strains and clinical isolates\nof HIV-1 with typical EC<sub>50</sub> and\u00a0EC<sub>90</sub> values in the\nrange 1-10 nM and 5-50 nM, respectively, </span>", "ID": "b5851228-f9d6-4462-add7-fe553a1a1604", "Styles": "color:black", "Classes": "None", "Text": "Saquinavir\u00a0demonstrates antiviral activity against a panel of laboratory strains and clinical isolates of HIV-1 with typical EC and\u00a0EC values in the range 1-10 nM and 5-50 nM, respectively, ", "ParentId": "f791f7a8-4b6a-4479-86ee-3b14c444756b"}, {"Element": "<sub>50</sub>", "ID": "02f71350-b74e-42b0-a184-24b1075378f8", "Styles": "None", "Classes": "None", "Text": "50", "ParentId": "b5851228-f9d6-4462-add7-fe553a1a1604"}, {"Element": "<sub>90</sub>", "ID": "cc8120cb-fd40-4b37-9498-dad35ee6382d", "Styles": "None", "Classes": "None", "Text": "90", "ParentId": "b5851228-f9d6-4462-add7-fe553a1a1604"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">with no apparent difference between subtype B and non-B\nclades. The corresponding serum (50% human serum) adjusted EC<sub>50</sub>\nranged from 25-250 nM. Clinical isolates of HIV-2 demonstrated EC<sub>50</sub>\nvalues in the range of 0.3-2.4 nM.</span>", "ID": "e79048d4-8239-4a9b-9f9d-6c47ec4604b8", "Styles": "color:black", "Classes": "None", "Text": "with no apparent difference between subtype B and non-B clades. The corresponding serum (50% human serum) adjusted EC ranged from 25-250 nM. Clinical isolates of HIV-2 demonstrated EC values in the range of 0.3-2.4 nM.", "ParentId": "f791f7a8-4b6a-4479-86ee-3b14c444756b"}, {"Element": "<sub>50</sub>", "ID": "8c2ed138-a80a-40ff-9a55-8770a1b9d406", "Styles": "None", "Classes": "None", "Text": "50", "ParentId": "e79048d4-8239-4a9b-9f9d-6c47ec4604b8"}, {"Element": "<sub>50</sub>", "ID": "a60cc501-b623-47ae-8d15-d6ca54939d0b", "Styles": "None", "Classes": "None", "Text": "50", "ParentId": "e79048d4-8239-4a9b-9f9d-6c47ec4604b8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f4b5f6c1-bc57-43da-95a1-4a674807e89e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "386667b7-090f-44b3-92c8-b1654188f886", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f4b5f6c1-bc57-43da-95a1-4a674807e89e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i>Resistance</i></b></p>", "ID": "d032489d-4b1d-41ed-8471-a1902ecf644f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i>Resistance</i></b>", "ID": "cb872b27-b105-4188-ba3f-99dcadefd3ae", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d032489d-4b1d-41ed-8471-a1902ecf644f"}, {"Element": "<i>Resistance</i>", "ID": "ce33db21-b7cf-4c78-93cb-9fd6256a3bbe", "Styles": "None", "Classes": "None", "Text": "Resistance", "ParentId": "cb872b27-b105-4188-ba3f-99dcadefd3ae"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>\u00a0</i></p>", "ID": "3f0496a1-0bd9-428b-8e23-f514493878c4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<i>\u00a0</i>", "ID": "b0f1c9d6-8a37-4f17-9910-f2378b41498d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3f0496a1-0bd9-428b-8e23-f514493878c4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Antiviral activity\naccording to baseline genotype and phenotype:</i></p>", "ID": "1f34660a-e382-465b-99a9-c539f66c9d7b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<i>Antiviral activity\naccording to baseline genotype and phenotype:</i>", "ID": "84f37106-7dc0-4440-8209-0e9426eaebf7", "Styles": "None", "Classes": "None", "Text": "Antiviral activity according to baseline genotype and phenotype:", "ParentId": "1f34660a-e382-465b-99a9-c539f66c9d7b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em>\u00a0</em></p>", "ID": "9922962e-2def-4d69-9fb7-e72be947941e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<em>\u00a0</em>", "ID": "f01d68c6-1b4e-4c59-b6aa-0986c2ab3861", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9922962e-2def-4d69-9fb7-e72be947941e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><span style=\"font-style:\nnormal\">Genotypic and phenotypic clinical cut-offs predicting the clinical\nefficacy of ritonavir boosted saquinavir have been derived from retrospective\nanalyses of the RESIST 1 and 2 clinical studies and analysis of a large\nhospital cohort (Marcelin et al 2007). </span></em></p>", "ID": "6124d6f4-fbbd-4c4f-9557-7baa12ca0e86", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<em><span style=\"font-style:\nnormal\">Genotypic and phenotypic clinical cut-offs predicting the clinical\nefficacy of ritonavir boosted saquinavir have been derived from retrospective\nanalyses of the RESIST 1 and 2 clinical studies and analysis of a large\nhospital cohort (Marcelin et al 2007). </span></em>", "ID": "01400e51-d870-466a-a588-4a6635054b88", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6124d6f4-fbbd-4c4f-9557-7baa12ca0e86"}, {"Element": "<span style=\"font-style:\nnormal\">Genotypic and phenotypic clinical cut-offs predicting the clinical\nefficacy of ritonavir boosted saquinavir have been derived from retrospective\nanalyses of the RESIST 1 and 2 clinical studies and analysis of a large\nhospital cohort (Marcelin et al 2007). </span>", "ID": "2f940de0-444d-4cca-bf6b-6266e26eeb7f", "Styles": "font-style:\nnormal", "Classes": "None", "Text": "Genotypic and phenotypic clinical cut-offs predicting the clinical efficacy of ritonavir boosted saquinavir have been derived from retrospective analyses of the RESIST 1 and 2 clinical studies and analysis of a large hospital cohort (Marcelin et al 2007). ", "ParentId": "01400e51-d870-466a-a588-4a6635054b88"}, {"Element": "<p class=\"MsoNormal\"><em><span style=\"font-style:normal\">\u00a0</span></em></p>", "ID": "570167e3-b655-4dae-ba3a-2b08eb959787", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<em><span style=\"font-style:normal\">\u00a0</span></em>", "ID": "a010181f-c234-4687-acc8-2296889617cf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "570167e3-b655-4dae-ba3a-2b08eb959787"}, {"Element": "<span style=\"font-style:normal\">\u00a0</span>", "ID": "3b6495a0-cd56-4b60-9470-04c683b111f7", "Styles": "font-style:normal", "Classes": "None", "Text": "\u00a0", "ParentId": "a010181f-c234-4687-acc8-2296889617cf"}, {"Element": "<p class=\"MsoNormal\"><em><span style=\"font-style:normal\">Baseline saquinavir\nphenotype (shift in susceptibility relative to reference, PhenoSense Assay) was\nshown to be a predictive factor of virological outcome. Virological response\nwas first observed to decrease when the fold shift exceeded 2.3-fold; whereas\nvirological benefit was not observed when the fold shift exceeded 12-fold.</span></em></p>", "ID": "2628af3b-2895-4818-9c90-2075225d45ad", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<em><span style=\"font-style:normal\">Baseline saquinavir\nphenotype (shift in susceptibility relative to reference, PhenoSense Assay) was\nshown to be a predictive factor of virological outcome. Virological response\nwas first observed to decrease when the fold shift exceeded 2.3-fold; whereas\nvirological benefit was not observed when the fold shift exceeded 12-fold.</span></em>", "ID": "9ee3fe0e-0daa-4beb-b453-85e488975d58", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2628af3b-2895-4818-9c90-2075225d45ad"}, {"Element": "<span style=\"font-style:normal\">Baseline saquinavir\nphenotype (shift in susceptibility relative to reference, PhenoSense Assay) was\nshown to be a predictive factor of virological outcome. Virological response\nwas first observed to decrease when the fold shift exceeded 2.3-fold; whereas\nvirological benefit was not observed when the fold shift exceeded 12-fold.</span>", "ID": "1b0c3104-e79b-4d06-9d0f-8704c4c56aec", "Styles": "font-style:normal", "Classes": "None", "Text": "Baseline saquinavir phenotype (shift in susceptibility relative to reference, PhenoSense Assay) was shown to be a predictive factor of virological outcome. Virological response was first observed to decrease when the fold shift exceeded 2.3-fold; whereas virological benefit was not observed when the fold shift exceeded 12-fold.", "ParentId": "9ee3fe0e-0daa-4beb-b453-85e488975d58"}, {"Element": "<p class=\"MsoNormal\"><em><span style=\"font-style:normal\">\u00a0</span></em></p>", "ID": "35c236f5-a7d3-4181-a4f6-addc8bc25cc8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<em><span style=\"font-style:normal\">\u00a0</span></em>", "ID": "3ff3a765-bdbb-436e-bce6-aee5c75d66bf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "35c236f5-a7d3-4181-a4f6-addc8bc25cc8"}, {"Element": "<span style=\"font-style:normal\">\u00a0</span>", "ID": "c64bfa32-3d31-46ea-91c2-738b3b30a85c", "Styles": "font-style:normal", "Classes": "None", "Text": "\u00a0", "ParentId": "3ff3a765-bdbb-436e-bce6-aee5c75d66bf"}, {"Element": "<p class=\"MsoNormal\"><em><span style=\"font-style:normal\">Marcelin et al (2007)\nidentified nine protease codons (L10F/I/M/R/V, I15A/V, K20I/M/R/T, L24I, I62V,\nG73S/T, V82A/F/S/T, I84V, L90M) that were associated with decreased virological\nresponse to saquinavir/ritonavir (1000/100\u00a0mg twice daily) in 138\nsaquinavir naive patients. The presence of 3 or more mutations was associated\nwith reduced response to saquinavir/ritonavir.</span></em><em><span style=\"font-style:normal\"> </span></em><em><span style=\"font-style:normal\">The\nassociation between the number of these saquinavir-associated resistance\nmutations and virological response was confirmed in an independent clinical\nstudy (RESIST 1 and 2) involving a more heavily treatment experienced patient\npopulation, including 54% who had received prior saquinavir (p=0.0133, see\nTable\u00a05). The G48V mutation, previously identified </span></em><em>in\nvitro</em><em><span style=\"font-style:normal\"> as a saquinavir signature\nmutation, was present at baseline in virus from three patients, none of whom\nresponded to therapy.</span></em></p>", "ID": "7f4606ce-70c9-485f-b09d-f167a3a54417", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<em><span style=\"font-style:normal\">Marcelin et al (2007)\nidentified nine protease codons (L10F/I/M/R/V, I15A/V, K20I/M/R/T, L24I, I62V,\nG73S/T, V82A/F/S/T, I84V, L90M) that were associated with decreased virological\nresponse to saquinavir/ritonavir (1000/100\u00a0mg twice daily) in 138\nsaquinavir naive patients. The presence of 3 or more mutations was associated\nwith reduced response to saquinavir/ritonavir.</span></em>", "ID": "068cde60-8fec-4932-9b46-ba8162713824", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7f4606ce-70c9-485f-b09d-f167a3a54417"}, {"Element": "<span style=\"font-style:normal\">Marcelin et al (2007)\nidentified nine protease codons (L10F/I/M/R/V, I15A/V, K20I/M/R/T, L24I, I62V,\nG73S/T, V82A/F/S/T, I84V, L90M) that were associated with decreased virological\nresponse to saquinavir/ritonavir (1000/100\u00a0mg twice daily) in 138\nsaquinavir naive patients. The presence of 3 or more mutations was associated\nwith reduced response to saquinavir/ritonavir.</span>", "ID": "3ed977be-ec0a-49f1-82e4-6320471aca67", "Styles": "font-style:normal", "Classes": "None", "Text": "Marcelin et al (2007) identified nine protease codons (L10F/I/M/R/V, I15A/V, K20I/M/R/T, L24I, I62V, G73S/T, V82A/F/S/T, I84V, L90M) that were associated with decreased virological response to saquinavir/ritonavir (1000/100\u00a0mg twice daily) in 138 saquinavir naive patients. The presence of 3 or more mutations was associated with reduced response to saquinavir/ritonavir.", "ParentId": "068cde60-8fec-4932-9b46-ba8162713824"}, {"Element": "<em><span style=\"font-style:normal\"> </span></em>", "ID": "6339d860-223a-47e4-afd3-a1810a93111e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7f4606ce-70c9-485f-b09d-f167a3a54417"}, {"Element": "<span style=\"font-style:normal\"> </span>", "ID": "5ce0430f-9518-4a86-a028-210b714e2c0f", "Styles": "font-style:normal", "Classes": "None", "Text": " ", "ParentId": "6339d860-223a-47e4-afd3-a1810a93111e"}, {"Element": "<em><span style=\"font-style:normal\">The\nassociation between the number of these saquinavir-associated resistance\nmutations and virological response was confirmed in an independent clinical\nstudy (RESIST 1 and 2) involving a more heavily treatment experienced patient\npopulation, including 54% who had received prior saquinavir (p=0.0133, see\nTable\u00a05). The G48V mutation, previously identified </span></em>", "ID": "5965acf9-c1bf-443e-a686-472526982fed", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7f4606ce-70c9-485f-b09d-f167a3a54417"}, {"Element": "<span style=\"font-style:normal\">The\nassociation between the number of these saquinavir-associated resistance\nmutations and virological response was confirmed in an independent clinical\nstudy (RESIST 1 and 2) involving a more heavily treatment experienced patient\npopulation, including 54% who had received prior saquinavir (p=0.0133, see\nTable\u00a05). The G48V mutation, previously identified </span>", "ID": "01a7e65e-86be-4bdc-8ede-98a2b3b7b360", "Styles": "font-style:normal", "Classes": "None", "Text": "The association between the number of these saquinavir-associated resistance mutations and virological response was confirmed in an independent clinical study (RESIST 1 and 2) involving a more heavily treatment experienced patient population, including 54% who had received prior saquinavir (p=0.0133, see Table\u00a05). The G48V mutation, previously identified ", "ParentId": "5965acf9-c1bf-443e-a686-472526982fed"}, {"Element": "<em>in\nvitro</em>", "ID": "1d632c7b-bd82-4adf-b02a-0b81a89fa7d8", "Styles": "None", "Classes": "None", "Text": "in vitro", "ParentId": "7f4606ce-70c9-485f-b09d-f167a3a54417"}, {"Element": "<em><span style=\"font-style:normal\"> as a saquinavir signature\nmutation, was present at baseline in virus from three patients, none of whom\nresponded to therapy.</span></em>", "ID": "5e21d580-1d0e-493a-9787-bd5303a7df4e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7f4606ce-70c9-485f-b09d-f167a3a54417"}, {"Element": "<span style=\"font-style:normal\"> as a saquinavir signature\nmutation, was present at baseline in virus from three patients, none of whom\nresponded to therapy.</span>", "ID": "d033bb77-c96e-4a04-96c8-5710adc6ed60", "Styles": "font-style:normal", "Classes": "None", "Text": " as a saquinavir signature mutation, was present at baseline in virus from three patients, none of whom responded to therapy.", "ParentId": "5e21d580-1d0e-493a-9787-bd5303a7df4e"}, {"Element": "<p class=\"MsoNormal\"><em><span style=\"font-style:normal\">\u00a0</span></em></p>", "ID": "215ae2d1-6bb5-45b6-aed9-36549c696b24", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<em><span style=\"font-style:normal\">\u00a0</span></em>", "ID": "091eaff5-ae8b-4511-bf7f-84c6e16c2c7b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "215ae2d1-6bb5-45b6-aed9-36549c696b24"}, {"Element": "<span style=\"font-style:normal\">\u00a0</span>", "ID": "e3c06840-503a-486e-8873-5a92bf14fdce", "Styles": "font-style:normal", "Classes": "None", "Text": "\u00a0", "ParentId": "091eaff5-ae8b-4511-bf7f-84c6e16c2c7b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:39.15pt;text-indent:-39.15pt;page-break-after:\navoid\"><em><span style=\"font-style:normal\">Table 5: Virological response to\nsaquinavir/ritonavir stratified by the number of baseline saquinavir-associated\nresistance mutations</span></em></p>", "ID": "2a8b1d76-5418-45b9-9307-cab0d9159299", "Styles": "margin-left:39.15pt;text-indent:-39.15pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<em><span style=\"font-style:normal\">Table 5: Virological response to\nsaquinavir/ritonavir stratified by the number of baseline saquinavir-associated\nresistance mutations</span></em>", "ID": "33946e36-e273-43cb-967c-c50005ca3e09", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2a8b1d76-5418-45b9-9307-cab0d9159299"}, {"Element": "<span style=\"font-style:normal\">Table 5: Virological response to\nsaquinavir/ritonavir stratified by the number of baseline saquinavir-associated\nresistance mutations</span>", "ID": "1fb8a3fb-b58f-4c89-918d-e20cc833ca98", "Styles": "font-style:normal", "Classes": "None", "Text": "Table 5: Virological response to saquinavir/ritonavir stratified by the number of baseline saquinavir-associated resistance mutations", "ParentId": "33946e36-e273-43cb-967c-c50005ca3e09"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><em><span lang=\"EN-GB\" style=\"font-style:normal\">\u00a0</span></em></p>", "ID": "602e6fde-478e-4475-b54d-9a692110e2d5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<em><span lang=\"EN-GB\" style=\"font-style:normal\">\u00a0</span></em>", "ID": "5eabfddd-864f-4694-ae19-a6cdb3cb9b68", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "602e6fde-478e-4475-b54d-9a692110e2d5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-style:normal\">\u00a0</span>", "ID": "9437bb82-dcfd-4393-bb1b-f6beebb4d016", "Styles": "font-style:normal", "Classes": "None", "Text": "\u00a0", "ParentId": "5eabfddd-864f-4694-ae19-a6cdb3cb9b68"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td rowspan=\"3\" style=\"width:70.0pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Number of Saquinavir Associated Resistance Mutations\n  at Baseline*</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:2.45in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"235\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Marcelin et al (2007)</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:181.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"242\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">RESIST 1 &amp; 2</span></b></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:2.45in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"235\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">SQV Naive Population</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:181.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"242\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">SQV Naive/Experienced Population</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">N=138</span></b></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Change in Baseline Plasma HIV-1 RNA at<br/>\n<u>Weeks 12-20</u></span></b></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">N=114</span></b></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Change in Baseline Plasma HIV-1 RNA at<br/>\n<u>Week 4</u></span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">35</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-2.24</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">2</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-2.04</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">1</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">29</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.88</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">3</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.69</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">2</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">24</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.43</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">14</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.57</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">3</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">30</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.52</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">28</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.41</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">4</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">9</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.18</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">40</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.75</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">5</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">6</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.11</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">17</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.44</span></p>\n</td>\n</tr>\n<tr style=\"height:16.15pt\">\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">6</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">5</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.30</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">9</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0.08</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">7</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">1</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0.24</span></p>\n</td>\n</tr>\n</table>", "ID": "723a432f-f5da-42ec-844b-f16dd4950ba4", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "            ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<tr>\n<td rowspan=\"3\" style=\"width:70.0pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Number of Saquinavir Associated Resistance Mutations\n  at Baseline*</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:2.45in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"235\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Marcelin et al (2007)</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:181.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"242\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">RESIST 1 &amp; 2</span></b></p>\n</td>\n</tr>", "ID": "ccf9f0c7-3f4a-4733-8caf-c890bdbc333e", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "723a432f-f5da-42ec-844b-f16dd4950ba4"}, {"Element": "<td rowspan=\"3\" style=\"width:70.0pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Number of Saquinavir Associated Resistance Mutations\n  at Baseline*</span></b></p>\n</td>", "ID": "b95d14cf-5a2d-4afe-9b9c-585cd249453d", "Styles": "width:70.0pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ccf9f0c7-3f4a-4733-8caf-c890bdbc333e"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Number of Saquinavir Associated Resistance Mutations\n  at Baseline*</span></b></p>", "ID": "997536cc-7c56-4017-b6fe-998037e3ac65", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "b95d14cf-5a2d-4afe-9b9c-585cd249453d"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Number of Saquinavir Associated Resistance Mutations\n  at Baseline*</span></b>", "ID": "d675bb88-3e1b-4b6e-8077-e9b6ad62ae81", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "997536cc-7c56-4017-b6fe-998037e3ac65"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">Number of Saquinavir Associated Resistance Mutations\n  at Baseline*</span>", "ID": "66d11c3f-7c91-49f2-86fc-3c8394fd6944", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Number of Saquinavir Associated Resistance Mutations   at Baseline*", "ParentId": "d675bb88-3e1b-4b6e-8077-e9b6ad62ae81"}, {"Element": "<td colspan=\"2\" style=\"width:2.45in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"235\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Marcelin et al (2007)</span></b></p>\n</td>", "ID": "932e3de3-8a6f-4a06-a12e-55fb4ae1537c", "Styles": "width:2.45in;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ccf9f0c7-3f4a-4733-8caf-c890bdbc333e"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Marcelin et al (2007)</span></b></p>", "ID": "3e059d9e-befb-4dba-bbb5-5eed8bd82cec", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "932e3de3-8a6f-4a06-a12e-55fb4ae1537c"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Marcelin et al (2007)</span></b>", "ID": "c7e56011-6534-4a80-8365-c2f8e0181769", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3e059d9e-befb-4dba-bbb5-5eed8bd82cec"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">Marcelin et al (2007)</span>", "ID": "26ccd433-5eb6-47dd-bdc5-dc09734039fe", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Marcelin et al (2007)", "ParentId": "c7e56011-6534-4a80-8365-c2f8e0181769"}, {"Element": "<td colspan=\"2\" style=\"width:181.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"242\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">RESIST 1 &amp; 2</span></b></p>\n</td>", "ID": "85de69d4-04e2-49f1-9655-c16f825175e4", "Styles": "width:181.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ccf9f0c7-3f4a-4733-8caf-c890bdbc333e"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">RESIST 1 &amp; 2</span></b></p>", "ID": "41b90cf6-5938-4890-9ac3-b8f8325f236d", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "85de69d4-04e2-49f1-9655-c16f825175e4"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">RESIST 1 &amp; 2</span></b>", "ID": "00f8450d-08de-4d68-b81a-82b2956cea77", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "41b90cf6-5938-4890-9ac3-b8f8325f236d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">RESIST 1 &amp; 2</span>", "ID": "c52d3771-b518-4210-b325-dd0b932eb27b", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "RESIST 1 & 2", "ParentId": "00f8450d-08de-4d68-b81a-82b2956cea77"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:2.45in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"235\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">SQV Naive Population</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:181.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"242\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">SQV Naive/Experienced Population</span></b></p>\n</td>\n</tr>", "ID": "6fd50245-957d-41cb-b061-d0e7de194c57", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "723a432f-f5da-42ec-844b-f16dd4950ba4"}, {"Element": "<td colspan=\"2\" style=\"width:2.45in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"235\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">SQV Naive Population</span></b></p>\n</td>", "ID": "986eb11a-c2bf-43f1-9402-037a39c980d2", "Styles": "width:2.45in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6fd50245-957d-41cb-b061-d0e7de194c57"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">SQV Naive Population</span></b></p>", "ID": "020efd65-50c4-4ea5-b51b-6a1ac4325d8c", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "986eb11a-c2bf-43f1-9402-037a39c980d2"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">SQV Naive Population</span></b>", "ID": "3d3b196f-f4db-4877-be9f-7ec3f6ddc931", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "020efd65-50c4-4ea5-b51b-6a1ac4325d8c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">SQV Naive Population</span>", "ID": "d88ded4c-66b8-4ff3-9b78-9791513e04f8", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "SQV Naive Population", "ParentId": "3d3b196f-f4db-4877-be9f-7ec3f6ddc931"}, {"Element": "<td colspan=\"2\" style=\"width:181.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"242\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">SQV Naive/Experienced Population</span></b></p>\n</td>", "ID": "99a650b7-d844-4b2b-8db5-8170465bf14b", "Styles": "width:181.75pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6fd50245-957d-41cb-b061-d0e7de194c57"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">SQV Naive/Experienced Population</span></b></p>", "ID": "17a12562-390e-4560-8110-3e5d840123fd", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "99a650b7-d844-4b2b-8db5-8170465bf14b"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">SQV Naive/Experienced Population</span></b>", "ID": "458d1375-fc98-4bff-83e1-e3b97487d7cf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "17a12562-390e-4560-8110-3e5d840123fd"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">SQV Naive/Experienced Population</span>", "ID": "6b7c79f9-d28f-4501-8956-c8f79fa0a8b9", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "SQV Naive/Experienced Population", "ParentId": "458d1375-fc98-4bff-83e1-e3b97487d7cf"}, {"Element": "<tr>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">N=138</span></b></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Change in Baseline Plasma HIV-1 RNA at<br/>\n<u>Weeks 12-20</u></span></b></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">N=114</span></b></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Change in Baseline Plasma HIV-1 RNA at<br/>\n<u>Week 4</u></span></b></p>\n</td>\n</tr>", "ID": "63fd8b97-8d9d-47bd-b4bd-af497ffe7b31", "Styles": "None", "Classes": "None", "Text": "     ", "ParentId": "723a432f-f5da-42ec-844b-f16dd4950ba4"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">N=138</span></b></p>\n</td>", "ID": "5e4d0121-7131-4457-a331-a1b03614e9b1", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "63fd8b97-8d9d-47bd-b4bd-af497ffe7b31"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">N=138</span></b></p>", "ID": "6a224789-f094-4ebf-b6e3-664d562e83bd", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "5e4d0121-7131-4457-a331-a1b03614e9b1"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">N=138</span></b>", "ID": "e8c3555d-180e-496e-8afb-7c34e4ecc34d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6a224789-f094-4ebf-b6e3-664d562e83bd"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">N=138</span>", "ID": "71d439da-57e1-4ada-85fc-23100c0ab8e7", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "N=138", "ParentId": "e8c3555d-180e-496e-8afb-7c34e4ecc34d"}, {"Element": "<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Change in Baseline Plasma HIV-1 RNA at<br/>\n<u>Weeks 12-20</u></span></b></p>\n</td>", "ID": "9fbbbcf7-d905-49a0-8c00-ea4099b7e6be", "Styles": "width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "63fd8b97-8d9d-47bd-b4bd-af497ffe7b31"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Change in Baseline Plasma HIV-1 RNA at<br/>\n<u>Weeks 12-20</u></span></b></p>", "ID": "71d10a81-495c-465e-b7c0-b49387f3ac68", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "9fbbbcf7-d905-49a0-8c00-ea4099b7e6be"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Change in Baseline Plasma HIV-1 RNA at<br/>\n<u>Weeks 12-20</u></span></b>", "ID": "89e0b3aa-f39b-4882-a45d-50cb381e4cdd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "71d10a81-495c-465e-b7c0-b49387f3ac68"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">Change in Baseline Plasma HIV-1 RNA at<br/>\n<u>Weeks 12-20</u></span>", "ID": "871dadb9-e93b-440a-9906-4bc5c6b0fd1e", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Change in Baseline Plasma HIV-1 RNA at ", "ParentId": "89e0b3aa-f39b-4882-a45d-50cb381e4cdd"}, {"Element": "<br/>", "ID": "1e6630ab-871a-4b24-9172-c49b053f9511", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "871dadb9-e93b-440a-9906-4bc5c6b0fd1e"}, {"Element": "<u>Weeks 12-20</u>", "ID": "35bedf1c-bf71-4aca-8669-ab85269f477c", "Styles": "None", "Classes": "None", "Text": "Weeks 12-20", "ParentId": "871dadb9-e93b-440a-9906-4bc5c6b0fd1e"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">N=114</span></b></p>\n</td>", "ID": "ad366243-ae91-4a9b-87d8-e30e83d537d8", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "63fd8b97-8d9d-47bd-b4bd-af497ffe7b31"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">N=114</span></b></p>", "ID": "91b25f82-84dc-4133-9aca-b79fbd6fdd95", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "ad366243-ae91-4a9b-87d8-e30e83d537d8"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">N=114</span></b>", "ID": "2e59adf1-5fdb-41fd-8c25-52289a6ebe4d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "91b25f82-84dc-4133-9aca-b79fbd6fdd95"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">N=114</span>", "ID": "fe87209b-cdb6-4592-a9cb-e1e7fabed49e", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "N=114", "ParentId": "2e59adf1-5fdb-41fd-8c25-52289a6ebe4d"}, {"Element": "<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Change in Baseline Plasma HIV-1 RNA at<br/>\n<u>Week 4</u></span></b></p>\n</td>", "ID": "bdbb3c56-f693-4ba9-b9be-f8e3c6d91bb0", "Styles": "width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "63fd8b97-8d9d-47bd-b4bd-af497ffe7b31"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Change in Baseline Plasma HIV-1 RNA at<br/>\n<u>Week 4</u></span></b></p>", "ID": "a06828f5-d080-4cde-87e6-3e996538fbb8", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "bdbb3c56-f693-4ba9-b9be-f8e3c6d91bb0"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Change in Baseline Plasma HIV-1 RNA at<br/>\n<u>Week 4</u></span></b>", "ID": "17f701bf-b198-422f-b8b5-6a5f32a07315", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a06828f5-d080-4cde-87e6-3e996538fbb8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt\">Change in Baseline Plasma HIV-1 RNA at<br/>\n<u>Week 4</u></span>", "ID": "b66b5f37-4866-45a2-91cf-2a46892dfcbe", "Styles": "font-size:11.0pt", "Classes": "None", "Text": "Change in Baseline Plasma HIV-1 RNA at ", "ParentId": "17f701bf-b198-422f-b8b5-6a5f32a07315"}, {"Element": "<br/>", "ID": "9c0d41c3-48cb-495e-9a27-d5d82833e8e5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b66b5f37-4866-45a2-91cf-2a46892dfcbe"}, {"Element": "<u>Week 4</u>", "ID": "3894d427-4657-469c-98f6-3c4784d423a2", "Styles": "None", "Classes": "None", "Text": "Week 4", "ParentId": "b66b5f37-4866-45a2-91cf-2a46892dfcbe"}, {"Element": "<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">35</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-2.24</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">2</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-2.04</span></p>\n</td>\n</tr>", "ID": "e8fb240e-b2cd-4abd-87c3-16969142f440", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "723a432f-f5da-42ec-844b-f16dd4950ba4"}, {"Element": "<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0</span></p>\n</td>", "ID": "f68dc2ec-20b2-4fce-9d9e-86b98c8d1ea1", "Styles": "width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e8fb240e-b2cd-4abd-87c3-16969142f440"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0</span></p>", "ID": "5b219568-656e-4f0f-ac22-67dd65660b26", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "f68dc2ec-20b2-4fce-9d9e-86b98c8d1ea1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0</span>", "ID": "9620c894-d502-468b-8754-8a4cbdfb5026", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "0", "ParentId": "5b219568-656e-4f0f-ac22-67dd65660b26"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">35</span></p>\n</td>", "ID": "508ba542-5de2-49c5-9e7f-5a2e75fb859d", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e8fb240e-b2cd-4abd-87c3-16969142f440"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">35</span></p>", "ID": "6ebc2306-0d57-44a1-b174-cd1724dfb8bf", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "508ba542-5de2-49c5-9e7f-5a2e75fb859d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">35</span>", "ID": "16c83583-434e-4bed-83ab-7c26da4e1e8d", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "35", "ParentId": "6ebc2306-0d57-44a1-b174-cd1724dfb8bf"}, {"Element": "<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-2.24</span></p>\n</td>", "ID": "617989ba-1e53-4825-bfc7-4e6d9cf9cf7b", "Styles": "width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e8fb240e-b2cd-4abd-87c3-16969142f440"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-2.24</span></p>", "ID": "db0aae28-e903-41e0-9e3a-94d715a3b073", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "617989ba-1e53-4825-bfc7-4e6d9cf9cf7b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-2.24</span>", "ID": "af7f8739-6d53-4649-9167-117ae2e35ac9", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "-2.24", "ParentId": "db0aae28-e903-41e0-9e3a-94d715a3b073"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">2</span></p>\n</td>", "ID": "2deca31a-dba1-4b51-a1ab-127c3c6e4413", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e8fb240e-b2cd-4abd-87c3-16969142f440"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">2</span></p>", "ID": "994b2703-0b40-4a1b-b4a0-e729143df2f2", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "2deca31a-dba1-4b51-a1ab-127c3c6e4413"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">2</span>", "ID": "6a302705-ee7b-4654-b520-c550a1cc68d0", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "2", "ParentId": "994b2703-0b40-4a1b-b4a0-e729143df2f2"}, {"Element": "<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-2.04</span></p>\n</td>", "ID": "dd6c49af-befa-4028-8905-471296b77639", "Styles": "width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e8fb240e-b2cd-4abd-87c3-16969142f440"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-2.04</span></p>", "ID": "f8ad68ff-040a-4030-bb65-3450c2e7141f", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "dd6c49af-befa-4028-8905-471296b77639"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-2.04</span>", "ID": "b2fec5c9-8369-44ef-8857-501e0a754bab", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "-2.04", "ParentId": "f8ad68ff-040a-4030-bb65-3450c2e7141f"}, {"Element": "<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">1</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">29</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.88</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">3</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.69</span></p>\n</td>\n</tr>", "ID": "6c6e7c9a-8d77-490b-b297-66157454a2b9", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "723a432f-f5da-42ec-844b-f16dd4950ba4"}, {"Element": "<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">1</span></p>\n</td>", "ID": "3c79509f-83c3-4e6a-9b8a-915b7dd42b74", "Styles": "width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6c6e7c9a-8d77-490b-b297-66157454a2b9"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">1</span></p>", "ID": "93d511c3-1e6a-4aa0-8bd8-73f1af247bde", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "3c79509f-83c3-4e6a-9b8a-915b7dd42b74"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">1</span>", "ID": "a087ce79-879e-4a5a-96c0-dd64384a3d12", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "1", "ParentId": "93d511c3-1e6a-4aa0-8bd8-73f1af247bde"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">29</span></p>\n</td>", "ID": "6fb57738-2997-4ad3-b1fc-f82af585ad48", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6c6e7c9a-8d77-490b-b297-66157454a2b9"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">29</span></p>", "ID": "234299b8-67c3-4096-a6d6-ca77f95fe9fd", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "6fb57738-2997-4ad3-b1fc-f82af585ad48"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">29</span>", "ID": "c8fc75a3-70d2-4bd6-a008-f536a322a9e0", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "29", "ParentId": "234299b8-67c3-4096-a6d6-ca77f95fe9fd"}, {"Element": "<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.88</span></p>\n</td>", "ID": "b3454952-77ff-4df4-b671-a7b7e2602f3e", "Styles": "width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6c6e7c9a-8d77-490b-b297-66157454a2b9"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.88</span></p>", "ID": "75e642c3-4933-48de-9264-107965447a20", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "b3454952-77ff-4df4-b671-a7b7e2602f3e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.88</span>", "ID": "64fee420-dd93-4a4f-92c3-7cbe80978100", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "-1.88", "ParentId": "75e642c3-4933-48de-9264-107965447a20"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">3</span></p>\n</td>", "ID": "5e10a0fe-030d-4978-81a0-12f753517a73", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6c6e7c9a-8d77-490b-b297-66157454a2b9"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">3</span></p>", "ID": "dc180a71-2fb2-43f7-bac5-3ab73d29deef", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "5e10a0fe-030d-4978-81a0-12f753517a73"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">3</span>", "ID": "b9c8a6c7-d48c-4974-9c1e-1d33033c6ee5", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "3", "ParentId": "dc180a71-2fb2-43f7-bac5-3ab73d29deef"}, {"Element": "<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.69</span></p>\n</td>", "ID": "12187f92-46fb-41b0-8de2-6f95bb423bb9", "Styles": "width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6c6e7c9a-8d77-490b-b297-66157454a2b9"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.69</span></p>", "ID": "4b2ad2a8-530c-4a50-bcd5-798797131bf4", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "12187f92-46fb-41b0-8de2-6f95bb423bb9"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.69</span>", "ID": "8112c4b0-47f1-4cc0-a329-544d64d04be9", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "-1.69", "ParentId": "4b2ad2a8-530c-4a50-bcd5-798797131bf4"}, {"Element": "<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">2</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">24</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.43</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">14</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.57</span></p>\n</td>\n</tr>", "ID": "7dc70bdf-6d26-4b2f-922e-09bce0861e41", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "723a432f-f5da-42ec-844b-f16dd4950ba4"}, {"Element": "<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">2</span></p>\n</td>", "ID": "59af397b-3f66-48cf-bcf3-fe797a8efa81", "Styles": "width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7dc70bdf-6d26-4b2f-922e-09bce0861e41"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">2</span></p>", "ID": "14766626-a98a-488e-b3dc-1d7dba81a39b", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "59af397b-3f66-48cf-bcf3-fe797a8efa81"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">2</span>", "ID": "b632eca5-a7c4-40a4-930a-454a4821503e", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "2", "ParentId": "14766626-a98a-488e-b3dc-1d7dba81a39b"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">24</span></p>\n</td>", "ID": "439caf66-d5c1-434c-9dc1-ee152fb5646c", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7dc70bdf-6d26-4b2f-922e-09bce0861e41"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">24</span></p>", "ID": "75256677-544a-4d75-8f15-0b22a128d99b", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "439caf66-d5c1-434c-9dc1-ee152fb5646c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">24</span>", "ID": "84a616a1-a117-4d45-bb5e-d1141da351d7", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "24", "ParentId": "75256677-544a-4d75-8f15-0b22a128d99b"}, {"Element": "<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.43</span></p>\n</td>", "ID": "d9c84e43-a658-4208-b7b8-77a28219ca01", "Styles": "width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7dc70bdf-6d26-4b2f-922e-09bce0861e41"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.43</span></p>", "ID": "8072f428-1eb8-487a-a9d7-9a9b97153ca1", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "d9c84e43-a658-4208-b7b8-77a28219ca01"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.43</span>", "ID": "d555221e-88fb-4dbc-8728-e74a3d1eb9f3", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "-1.43", "ParentId": "8072f428-1eb8-487a-a9d7-9a9b97153ca1"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">14</span></p>\n</td>", "ID": "71e576cc-68a6-4549-9733-cf3d06c4f0c8", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7dc70bdf-6d26-4b2f-922e-09bce0861e41"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">14</span></p>", "ID": "fcdd083c-a7ee-4d7b-84b7-1c58bde35a70", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "71e576cc-68a6-4549-9733-cf3d06c4f0c8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">14</span>", "ID": "e0103122-a437-49d4-8524-b21ea75e4a1f", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "14", "ParentId": "fcdd083c-a7ee-4d7b-84b7-1c58bde35a70"}, {"Element": "<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.57</span></p>\n</td>", "ID": "3998ae35-2aa0-4e3e-a7c7-3fd1392ba21a", "Styles": "width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7dc70bdf-6d26-4b2f-922e-09bce0861e41"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.57</span></p>", "ID": "de3b28f2-d639-4845-94a4-1c7ab7f24a87", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "3998ae35-2aa0-4e3e-a7c7-3fd1392ba21a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.57</span>", "ID": "ad913c48-e9a6-4d60-9a7a-a3c11bb86195", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "-1.57", "ParentId": "de3b28f2-d639-4845-94a4-1c7ab7f24a87"}, {"Element": "<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">3</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">30</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.52</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">28</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.41</span></p>\n</td>\n</tr>", "ID": "eb31ab49-92ba-4480-aa4f-77e3fe71d9c4", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "723a432f-f5da-42ec-844b-f16dd4950ba4"}, {"Element": "<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">3</span></p>\n</td>", "ID": "7be0a9eb-3bf1-41d5-8c2b-a7c129e68bcd", "Styles": "width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eb31ab49-92ba-4480-aa4f-77e3fe71d9c4"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">3</span></p>", "ID": "8c2b5f08-10ee-4879-a774-9b7f00190ad6", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "7be0a9eb-3bf1-41d5-8c2b-a7c129e68bcd"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">3</span>", "ID": "f7717b36-1574-47c9-8109-beed570b5742", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "3", "ParentId": "8c2b5f08-10ee-4879-a774-9b7f00190ad6"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">30</span></p>\n</td>", "ID": "c65f92b9-58f4-46c0-be4d-152317ac4beb", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eb31ab49-92ba-4480-aa4f-77e3fe71d9c4"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">30</span></p>", "ID": "6b68ca28-c423-4e01-a6d3-8433517cb955", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "c65f92b9-58f4-46c0-be4d-152317ac4beb"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">30</span>", "ID": "0b2f549f-5c85-41ef-8e0f-20cd6f42c09d", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "30", "ParentId": "6b68ca28-c423-4e01-a6d3-8433517cb955"}, {"Element": "<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.52</span></p>\n</td>", "ID": "88182e7e-609a-48e2-9963-6d5e2dbdc9e2", "Styles": "width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eb31ab49-92ba-4480-aa4f-77e3fe71d9c4"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.52</span></p>", "ID": "fb537d3d-1f99-4655-a73e-c95b0d20fdbd", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "88182e7e-609a-48e2-9963-6d5e2dbdc9e2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.52</span>", "ID": "beaf7f34-5189-4a93-8073-ddf805604800", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "-0.52", "ParentId": "fb537d3d-1f99-4655-a73e-c95b0d20fdbd"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">28</span></p>\n</td>", "ID": "87bec889-b940-4604-b32d-19898eaee751", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eb31ab49-92ba-4480-aa4f-77e3fe71d9c4"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">28</span></p>", "ID": "bb122ef8-1139-45c1-8ffa-82f0f906b15a", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "87bec889-b940-4604-b32d-19898eaee751"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">28</span>", "ID": "5662ad7b-0de0-4abb-ac32-e452fffb82a6", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "28", "ParentId": "bb122ef8-1139-45c1-8ffa-82f0f906b15a"}, {"Element": "<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.41</span></p>\n</td>", "ID": "6f6c7e63-ad7a-471b-adc5-9f9a07535a32", "Styles": "width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eb31ab49-92ba-4480-aa4f-77e3fe71d9c4"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.41</span></p>", "ID": "c77e2161-c66f-4777-bbd0-fe7601e289cc", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "6f6c7e63-ad7a-471b-adc5-9f9a07535a32"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-1.41</span>", "ID": "3803f30f-1c4d-4e33-a8ca-748b1975d66b", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "-1.41", "ParentId": "c77e2161-c66f-4777-bbd0-fe7601e289cc"}, {"Element": "<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">4</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">9</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.18</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">40</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.75</span></p>\n</td>\n</tr>", "ID": "d34c5333-ccb5-448e-9e11-b3655228f271", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "723a432f-f5da-42ec-844b-f16dd4950ba4"}, {"Element": "<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">4</span></p>\n</td>", "ID": "df02cece-fc66-450d-9ef8-4fd10897481a", "Styles": "width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d34c5333-ccb5-448e-9e11-b3655228f271"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">4</span></p>", "ID": "47b7208a-b3b9-4ac6-b9ed-35ad62c64c49", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "df02cece-fc66-450d-9ef8-4fd10897481a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">4</span>", "ID": "e3900c50-be60-485c-ae29-12a4fb0752b5", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "4", "ParentId": "47b7208a-b3b9-4ac6-b9ed-35ad62c64c49"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">9</span></p>\n</td>", "ID": "f5597ce3-49f3-465d-b87c-84ec1cfca141", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d34c5333-ccb5-448e-9e11-b3655228f271"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">9</span></p>", "ID": "98b6f89b-6a00-4e40-ae18-9bd3731e38b9", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "f5597ce3-49f3-465d-b87c-84ec1cfca141"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">9</span>", "ID": "8aaa001e-2bb9-4b8f-b817-3dad9c7681ae", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "9", "ParentId": "98b6f89b-6a00-4e40-ae18-9bd3731e38b9"}, {"Element": "<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.18</span></p>\n</td>", "ID": "01f0032c-1a92-4657-954f-a72b3125e2e2", "Styles": "width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d34c5333-ccb5-448e-9e11-b3655228f271"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.18</span></p>", "ID": "63274443-6411-4b5f-bc22-6abc386df20e", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "01f0032c-1a92-4657-954f-a72b3125e2e2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.18</span>", "ID": "bdffd9ab-9133-43e7-8947-706ec0c2b9db", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "-0.18", "ParentId": "63274443-6411-4b5f-bc22-6abc386df20e"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">40</span></p>\n</td>", "ID": "f501616e-fab6-4030-8f2b-a532041f6092", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d34c5333-ccb5-448e-9e11-b3655228f271"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">40</span></p>", "ID": "9bb65b29-a924-45fe-a327-9de704831cd2", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "f501616e-fab6-4030-8f2b-a532041f6092"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">40</span>", "ID": "d161055a-555d-4f8e-a460-7f7daa76afda", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "40", "ParentId": "9bb65b29-a924-45fe-a327-9de704831cd2"}, {"Element": "<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.75</span></p>\n</td>", "ID": "87b2f63c-6d09-42b9-beb0-b1fdcb4de8b1", "Styles": "width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d34c5333-ccb5-448e-9e11-b3655228f271"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.75</span></p>", "ID": "0c019a9c-763e-43c3-a56b-c03f690fd0bc", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "87b2f63c-6d09-42b9-beb0-b1fdcb4de8b1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.75</span>", "ID": "0136789e-b417-4f8c-9c21-ff5910a19be5", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "-0.75", "ParentId": "0c019a9c-763e-43c3-a56b-c03f690fd0bc"}, {"Element": "<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">5</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">6</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.11</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">17</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.44</span></p>\n</td>\n</tr>", "ID": "968a84a3-b000-439b-bfe6-6ee231ca7029", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "723a432f-f5da-42ec-844b-f16dd4950ba4"}, {"Element": "<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">5</span></p>\n</td>", "ID": "24bf0e9c-c16a-4c93-aae4-4a264f5c0ca7", "Styles": "width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "968a84a3-b000-439b-bfe6-6ee231ca7029"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">5</span></p>", "ID": "d548fc9e-e53d-4863-a82f-2c884213c9cf", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "24bf0e9c-c16a-4c93-aae4-4a264f5c0ca7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">5</span>", "ID": "6cf8bcd3-3a0d-47a3-8a89-e385ea08eec7", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "5", "ParentId": "d548fc9e-e53d-4863-a82f-2c884213c9cf"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">6</span></p>\n</td>", "ID": "e3179f8a-d3d3-414b-a553-d80f37094e1d", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "968a84a3-b000-439b-bfe6-6ee231ca7029"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">6</span></p>", "ID": "5094970d-b1e5-4b32-a809-8635a2be95c4", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "e3179f8a-d3d3-414b-a553-d80f37094e1d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">6</span>", "ID": "c5f29435-1299-4e39-a42a-4a4b4b5e1535", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "6", "ParentId": "5094970d-b1e5-4b32-a809-8635a2be95c4"}, {"Element": "<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.11</span></p>\n</td>", "ID": "ac7da74d-a232-40c9-ae8e-8bcd788fb277", "Styles": "width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "968a84a3-b000-439b-bfe6-6ee231ca7029"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.11</span></p>", "ID": "5931ec7a-7f43-4c79-9e00-5ef23bea67eb", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "ac7da74d-a232-40c9-ae8e-8bcd788fb277"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.11</span>", "ID": "c5b5bf31-c9a8-475a-8257-aa6bb7245222", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "-0.11", "ParentId": "5931ec7a-7f43-4c79-9e00-5ef23bea67eb"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">17</span></p>\n</td>", "ID": "ab5cbbaf-2a08-4b59-86bc-5142d6a53d5a", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "968a84a3-b000-439b-bfe6-6ee231ca7029"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">17</span></p>", "ID": "59a38f16-0fb1-42f0-8a21-ef06dcfc2a57", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "ab5cbbaf-2a08-4b59-86bc-5142d6a53d5a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">17</span>", "ID": "a39267a4-c74c-464a-b92e-c4f6852ea3ab", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "17", "ParentId": "59a38f16-0fb1-42f0-8a21-ef06dcfc2a57"}, {"Element": "<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.44</span></p>\n</td>", "ID": "f0c94389-fd8e-4a1e-b5a8-ccffc4ae7acd", "Styles": "width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "968a84a3-b000-439b-bfe6-6ee231ca7029"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.44</span></p>", "ID": "eeda4a82-dbf3-4b23-bc76-7c08236dcc7e", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "f0c94389-fd8e-4a1e-b5a8-ccffc4ae7acd"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.44</span>", "ID": "2cb55ace-78d4-428e-bad6-35dca7b8cf56", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "-0.44", "ParentId": "eeda4a82-dbf3-4b23-bc76-7c08236dcc7e"}, {"Element": "<tr style=\"height:16.15pt\">\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">6</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">5</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.30</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">9</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0.08</span></p>\n</td>\n</tr>", "ID": "cde7fa5a-baef-4fae-8af8-0d9ef260d80a", "Styles": "height:16.15pt", "Classes": "None", "Text": "      ", "ParentId": "723a432f-f5da-42ec-844b-f16dd4950ba4"}, {"Element": "<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">6</span></p>\n</td>", "ID": "9542b09a-c5ff-4197-9acf-7665377c40d2", "Styles": "width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt;height:16.15pt", "Classes": "None", "Text": "  ", "ParentId": "cde7fa5a-baef-4fae-8af8-0d9ef260d80a"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">6</span></p>", "ID": "27b8c24c-fa73-421c-a23e-dcff4069802a", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "9542b09a-c5ff-4197-9acf-7665377c40d2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">6</span>", "ID": "60d29920-32f7-4b84-a727-abe211f27819", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "6", "ParentId": "27b8c24c-fa73-421c-a23e-dcff4069802a"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">5</span></p>\n</td>", "ID": "7c8ed8d9-d620-4831-ac77-4de036e31bc4", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt", "Classes": "None", "Text": "  ", "ParentId": "cde7fa5a-baef-4fae-8af8-0d9ef260d80a"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">5</span></p>", "ID": "25805609-2210-444a-ab12-097d54a2cd1f", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "7c8ed8d9-d620-4831-ac77-4de036e31bc4"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">5</span>", "ID": "4e7868da-c0db-4e36-8b9f-d1a220f99e87", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "5", "ParentId": "25805609-2210-444a-ab12-097d54a2cd1f"}, {"Element": "<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.30</span></p>\n</td>", "ID": "e432e220-606d-46dc-8c3d-3f945e1ffebd", "Styles": "width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt", "Classes": "None", "Text": "  ", "ParentId": "cde7fa5a-baef-4fae-8af8-0d9ef260d80a"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.30</span></p>", "ID": "a291e014-4e03-4774-9e51-1abfe6d56c47", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "e432e220-606d-46dc-8c3d-3f945e1ffebd"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-0.30</span>", "ID": "5ab26acb-bea0-4b19-a68a-d3eadf70019f", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "-0.30", "ParentId": "a291e014-4e03-4774-9e51-1abfe6d56c47"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">9</span></p>\n</td>", "ID": "0c1659fb-1c03-4cd4-9412-4305368aeba3", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt", "Classes": "None", "Text": "  ", "ParentId": "cde7fa5a-baef-4fae-8af8-0d9ef260d80a"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">9</span></p>", "ID": "469f7819-1e16-4590-befa-3ecccd2a659e", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "0c1659fb-1c03-4cd4-9412-4305368aeba3"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">9</span>", "ID": "9013c691-0e1d-4dd7-99c4-dd1eedffa609", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "9", "ParentId": "469f7819-1e16-4590-befa-3ecccd2a659e"}, {"Element": "<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0.08</span></p>\n</td>", "ID": "b717f242-4402-4157-a901-5fd3d3f94653", "Styles": "width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:16.15pt", "Classes": "None", "Text": "  ", "ParentId": "cde7fa5a-baef-4fae-8af8-0d9ef260d80a"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0.08</span></p>", "ID": "9cc18270-e410-42ba-afb1-6e3abdcd3256", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "b717f242-4402-4157-a901-5fd3d3f94653"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0.08</span>", "ID": "d26490c1-e98e-47d5-b1a4-79b69ba4015e", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "0.08", "ParentId": "9cc18270-e410-42ba-afb1-6e3abdcd3256"}, {"Element": "<tr>\n<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">7</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0</span></p>\n</td>\n<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-</span></p>\n</td>\n<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">1</span></p>\n</td>\n<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0.24</span></p>\n</td>\n</tr>", "ID": "64a6167c-9016-4af6-8ae3-ac02cdee3762", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "723a432f-f5da-42ec-844b-f16dd4950ba4"}, {"Element": "<td style=\"width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"93\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">7</span></p>\n</td>", "ID": "96a41cbc-7bf1-419a-be48-11183a2db716", "Styles": "width:70.0pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "64a6167c-9016-4af6-8ae3-ac02cdee3762"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">7</span></p>", "ID": "f734a877-a8ef-4bdb-84b4-a9e5df09b19b", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "96a41cbc-7bf1-419a-be48-11183a2db716"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">7</span>", "ID": "f17fd858-0c73-4edd-9edd-93350595cc5f", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "7", "ParentId": "f734a877-a8ef-4bdb-84b4-a9e5df09b19b"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0</span></p>\n</td>", "ID": "2f3e7808-c73c-4306-b51f-61c5067e465c", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "64a6167c-9016-4af6-8ae3-ac02cdee3762"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0</span></p>", "ID": "17f49af5-53ca-4d97-bc45-c74fce18e08b", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "2f3e7808-c73c-4306-b51f-61c5067e465c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0</span>", "ID": "1ba3ff2c-a1b1-4332-ba65-737157dc3eed", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "0", "ParentId": "17f49af5-53ca-4d97-bc45-c74fce18e08b"}, {"Element": "<td style=\"width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"176\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-</span></p>\n</td>", "ID": "03292400-b47c-4c4e-a1a4-07a3410e4d0f", "Styles": "width:132.15pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "64a6167c-9016-4af6-8ae3-ac02cdee3762"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-</span></p>", "ID": "5f03d474-9a7e-4e67-ac09-3ad9fdd16e69", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "03292400-b47c-4c4e-a1a4-07a3410e4d0f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">-</span>", "ID": "5ecc2c66-08ed-4f4b-ab54-867ceaaa652e", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "-", "ParentId": "5f03d474-9a7e-4e67-ac09-3ad9fdd16e69"}, {"Element": "<td style=\"width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"59\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">1</span></p>\n</td>", "ID": "8a37199f-d4ee-4502-adc6-460728f5ad4f", "Styles": "width:44.25pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "64a6167c-9016-4af6-8ae3-ac02cdee3762"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">1</span></p>", "ID": "1401898d-0f12-4ddc-a168-484f401ba129", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "8a37199f-d4ee-4502-adc6-460728f5ad4f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">1</span>", "ID": "94f629b6-2701-4c52-9b8c-5b7df4d1b5bb", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "1", "ParentId": "1401898d-0f12-4ddc-a168-484f401ba129"}, {"Element": "<td style=\"width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"183\">\n<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0.24</span></p>\n</td>", "ID": "8501aa12-31a9-4d0b-b2ad-48250adf9a1a", "Styles": "width:137.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "64a6167c-9016-4af6-8ae3-ac02cdee3762"}, {"Element": "<p align=\"center\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0.24</span></p>", "ID": "7da9dba4-c686-471c-8172-c13d5dbf6244", "Styles": "margin-bottom:0in;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['TextTi12']", "Text": "", "ParentId": "8501aa12-31a9-4d0b-b2ad-48250adf9a1a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:\n  11.0pt\">0.24</span>", "ID": "eb319c58-f172-4979-b720-a93d752351e1", "Styles": "font-size:\n  11.0pt", "Classes": "None", "Text": "0.24", "ParentId": "7da9dba4-c686-471c-8172-c13d5dbf6244"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:24.0pt;text-indent:-24.0pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">*\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><em><span lang=\"EN-GB\">Saquinavir Mutation Score Mutations: L10F/I/M/R/V, I15A/V,\nK20I/M/R/T, L24I, I62V, G73S/T, V82A/F/S/T, I84V, L90M</span></em></p>", "ID": "63fc5e71-113a-49db-9eb7-95874146ce21", "Styles": "margin-left:24.0pt;text-indent:-24.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">*\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "fa025e22-610d-4441-9519-f5c31ae25344", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "*\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "63fc5e71-113a-49db-9eb7-95874146ce21"}, {"Element": "<em><span lang=\"EN-GB\">Saquinavir Mutation Score Mutations: L10F/I/M/R/V, I15A/V,\nK20I/M/R/T, L24I, I62V, G73S/T, V82A/F/S/T, I84V, L90M</span></em>", "ID": "1189b3ef-e1c4-48ef-b830-5fd78670c3d7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "63fc5e71-113a-49db-9eb7-95874146ce21"}, {"Element": "<span lang=\"EN-GB\">Saquinavir Mutation Score Mutations: L10F/I/M/R/V, I15A/V,\nK20I/M/R/T, L24I, I62V, G73S/T, V82A/F/S/T, I84V, L90M</span>", "ID": "df46fac8-0e8c-4c73-9817-0287a9f175f1", "Styles": "None", "Classes": "None", "Text": "Saquinavir Mutation Score Mutations: L10F/I/M/R/V, I15A/V, K20I/M/R/T, L24I, I62V, G73S/T, V82A/F/S/T, I84V, L90M", "ParentId": "1189b3ef-e1c4-48ef-b830-5fd78670c3d7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "83dd880e-6d3b-4e7f-8a36-de374f0ad97b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5e7f7884-8acf-49a9-9937-416d1e31ae6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "83dd880e-6d3b-4e7f-8a36-de374f0ad97b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt;page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Clinical results from studies with treatment na\u00efve and\nexperienced patients</span></i></b></p>", "ID": "eb80c7e1-424a-4a21-9e8e-176b5a8a9f39", "Styles": "line-height:13.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Clinical results from studies with treatment na\u00efve and\nexperienced patients</span></i></b>", "ID": "80cba48d-6ff9-4d0d-b113-251f20f1468c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "eb80c7e1-424a-4a21-9e8e-176b5a8a9f39"}, {"Element": "<i><span lang=\"EN-GB\">Clinical results from studies with treatment na\u00efve and\nexperienced patients</span></i>", "ID": "c96e55b0-907e-43fa-ac2c-3c25d4262cd1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "80cba48d-6ff9-4d0d-b113-251f20f1468c"}, {"Element": "<span lang=\"EN-GB\">Clinical results from studies with treatment na\u00efve and\nexperienced patients</span>", "ID": "570109e8-caaf-4800-af12-350f053d4f76", "Styles": "None", "Classes": "None", "Text": "Clinical results from studies with treatment na\u00efve and experienced patients", "ParentId": "c96e55b0-907e-43fa-ac2c-3c25d4262cd1"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "1b6dbfc0-77d1-4036-8e25-0921f2d11ec1", "Styles": "line-height:13.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "d17079e4-e8be-498f-ae99-a696c8caeabe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1b6dbfc0-77d1-4036-8e25-0921f2d11ec1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f4863616-67ab-4841-84ab-e5b8e5dc5937", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d17079e4-e8be-498f-ae99-a696c8caeabe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the MaxCmin1 study, the safety and\nefficacy of saquinavir soft capsules/ritonavir 1000/100\u00a0mg twice daily\nplus 2 NRTIs/<span style=\"layout-grid-mode:line\">Non-Nucleoside Reverse\nTranscriptase Inhibitors (</span>NNRTIs) was compared to indinavir/ritonavir\n800/100\u00a0mg twice daily plus 2 NRTIs/NNRTIs in over 300 (both protease\ninhibitor treatment na\u00efve and experienced) subjects. The combination of\nsaquinavir and ritonavir exhibited a superior virological activity compared\nwith the indinavir and ritonavir arm when switch from the assigned treatment\nwas counted as virological failure. </span></p>", "ID": "2a62ee5a-d114-4d88-9043-f3e6e15f0134", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">In the MaxCmin1 study, the safety and\nefficacy of saquinavir soft capsules/ritonavir 1000/100\u00a0mg twice daily\nplus 2 NRTIs/<span style=\"layout-grid-mode:line\">Non-Nucleoside Reverse\nTranscriptase Inhibitors (</span>NNRTIs) was compared to indinavir/ritonavir\n800/100\u00a0mg twice daily plus 2 NRTIs/NNRTIs in over 300 (both protease\ninhibitor treatment na\u00efve and experienced) subjects. The combination of\nsaquinavir and ritonavir exhibited a superior virological activity compared\nwith the indinavir and ritonavir arm when switch from the assigned treatment\nwas counted as virological failure. </span>", "ID": "ba0582e8-2d18-4586-b651-ef7b6ec9a7c8", "Styles": "None", "Classes": "None", "Text": "In the MaxCmin1 study, the safety and efficacy of saquinavir soft capsules/ritonavir 1000/100\u00a0mg twice daily plus 2 NRTIs/NNRTIs) was compared to indinavir/ritonavir 800/100\u00a0mg twice daily plus 2 NRTIs/NNRTIs in over 300 (both protease inhibitor treatment na\u00efve and experienced) subjects. The combination of saquinavir and ritonavir exhibited a superior virological activity compared with the indinavir and ritonavir arm when switch from the assigned treatment was counted as virological failure. ", "ParentId": "2a62ee5a-d114-4d88-9043-f3e6e15f0134"}, {"Element": "<span style=\"layout-grid-mode:line\">Non-Nucleoside Reverse\nTranscriptase Inhibitors (</span>", "ID": "f4156c66-2a9f-476d-a16e-43111e29ce5f", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Non-Nucleoside Reverse Transcriptase Inhibitors (", "ParentId": "ba0582e8-2d18-4586-b651-ef7b6ec9a7c8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fe0ecc96-d2dd-41c8-8b11-f96a28544dc5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0169c0c3-e2e6-4354-ba55-9bded2d3023a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fe0ecc96-d2dd-41c8-8b11-f96a28544dc5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the MaxCmin2 study, the safety and\nefficacy of saquinavir soft capsules/ritonavir 1000/100\u00a0mg twice daily\nplus 2\u00a0NRTIs/NNRTIs was compared with lopinavir/ritonavir 400/100\u00a0mg\ntwice daily plus 2 NRTIs/NNRTIs in 324 (both protease inhibitor treatment\nna\u00efve and experienced) subjects. None of the subjects in the\nlopinavir/ritonavir arm had been exposed to lopinavir prior to randomisation\nwhereas 16 of the subjects in the saquinavir/ritonavir arm had previously been\nexposed to saquinavir.</span></p>", "ID": "237acdb0-35df-450d-964d-0ca712e8572a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">In the MaxCmin2 study, the safety and\nefficacy of saquinavir soft capsules/ritonavir 1000/100\u00a0mg twice daily\nplus 2\u00a0NRTIs/NNRTIs was compared with lopinavir/ritonavir 400/100\u00a0mg\ntwice daily plus 2 NRTIs/NNRTIs in 324 (both protease inhibitor treatment\nna\u00efve and experienced) subjects. None of the subjects in the\nlopinavir/ritonavir arm had been exposed to lopinavir prior to randomisation\nwhereas 16 of the subjects in the saquinavir/ritonavir arm had previously been\nexposed to saquinavir.</span>", "ID": "e4e8b2d8-8a53-41ac-859c-8970b26669aa", "Styles": "None", "Classes": "None", "Text": "In the MaxCmin2 study, the safety and efficacy of saquinavir soft capsules/ritonavir 1000/100\u00a0mg twice daily plus 2\u00a0NRTIs/NNRTIs was compared with lopinavir/ritonavir 400/100\u00a0mg twice daily plus 2 NRTIs/NNRTIs in 324 (both protease inhibitor treatment na\u00efve and experienced) subjects. None of the subjects in the lopinavir/ritonavir arm had been exposed to lopinavir prior to randomisation whereas 16 of the subjects in the saquinavir/ritonavir arm had previously been exposed to saquinavir.", "ParentId": "237acdb0-35df-450d-964d-0ca712e8572a"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "4df748bd-dee1-48a8-8897-c3336901186d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Table\u00a06: Subject\nDemographics MaxCmin1 and MaxCmin2<sup>\u2020</sup></p>", "ID": "324fa8d5-dc99-4b80-aaa9-2b6cb636a40d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Table\u00a06: Subject Demographics MaxCmin1 and MaxCmin2", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<sup>\u2020</sup>", "ID": "a4bce8e6-7bbf-4d30-8e3d-5d406a7ea228", "Styles": "None", "Classes": "None", "Text": "\u2020", "ParentId": "324fa8d5-dc99-4b80-aaa9-2b6cb636a40d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "70f801a7-98ff-4573-b3e0-603108ff73da", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:135.0pt;border-top:solid black 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">MaxCmin1</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:135.0pt;border-top:solid black 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">MaxCmin2</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border-top:none;border-left:\n  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">SQV/r</span></b></p>\n</td>\n<td style=\"width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">IDV/r</span></b></p>\n</td>\n<td style=\"width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">SQV/r</span></b></p>\n</td>\n<td style=\"width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">LPV/r</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=148</span></b></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=158</span></b></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=161</span></b></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=163</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Sex</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Male</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">82%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">74%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">81%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">76%</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Race\n  (White/Black/Asian) %</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">86/9/1</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">82/12/4</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">75/19/1</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">74/19/2</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Age,\n  median, yrs</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">39</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">40</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">40</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">40</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">CDC\n  Category C (%)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">32%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">32%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">31%</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Antiretroviral\n  na\u00efve (%)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">22%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">31%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">34%</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">PI\n  na\u00efve (%)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">41%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">38%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">48%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">48%</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">Median\n  Baseline HIV-1 RNA, log<sub>10</sub> copies/ml (IQR)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">4.0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(1.7-5.1)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">3.9</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(1.7-5.2)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">4.4 </span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(3.1-5.1)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">4.6</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(3.5-5.3)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  Baseline CD4<sup>+</sup> Cell Count, cells/mm<sup>3</sup> (IQR)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">272</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(135-420)\n  </span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">280</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(139-453)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">241</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(86-400)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">239</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(95-420)</span></p>\n</td>\n</tr>\n</table>", "ID": "79ac5d4b-23f8-4fb5-9e91-36a89dcfe7dd", "Styles": "margin-left:5.4pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "            ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:135.0pt;border-top:solid black 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">MaxCmin1</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:135.0pt;border-top:solid black 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">MaxCmin2</span></b></p>\n</td>\n</tr>", "ID": "4634f154-e3d0-458f-b497-69a6825bc6da", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "79ac5d4b-23f8-4fb5-9e91-36a89dcfe7dd"}, {"Element": "<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "22e1ca73-de3f-431a-a25e-43fc678fc981", "Styles": "width:2.25in;border:solid black 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4634f154-e3d0-458f-b497-69a6825bc6da"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "5cd10f56-f7c6-48b7-8388-5c48d28a7a71", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "22e1ca73-de3f-431a-a25e-43fc678fc981"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "19a82872-68c6-478f-8ba3-8d056fea9516", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5cd10f56-f7c6-48b7-8388-5c48d28a7a71"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c1321953-7dfb-4282-8347-2677ffb67545", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "19a82872-68c6-478f-8ba3-8d056fea9516"}, {"Element": "<td colspan=\"2\" style=\"width:135.0pt;border-top:solid black 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">MaxCmin1</span></b></p>\n</td>", "ID": "cee334d8-47e0-4d14-997e-bbb5165804a2", "Styles": "width:135.0pt;border-top:solid black 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4634f154-e3d0-458f-b497-69a6825bc6da"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">MaxCmin1</span></b></p>", "ID": "c9ba65cf-a3a8-4360-b155-a208748cb5b0", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "cee334d8-47e0-4d14-997e-bbb5165804a2"}, {"Element": "<b><span lang=\"EN-GB\">MaxCmin1</span></b>", "ID": "36f79a0f-5e5f-4951-9e3b-ffefa09c1a6e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c9ba65cf-a3a8-4360-b155-a208748cb5b0"}, {"Element": "<span lang=\"EN-GB\">MaxCmin1</span>", "ID": "e710b9eb-2d43-4199-bb9d-e9d198b0c6fd", "Styles": "None", "Classes": "None", "Text": "MaxCmin1", "ParentId": "36f79a0f-5e5f-4951-9e3b-ffefa09c1a6e"}, {"Element": "<td colspan=\"2\" style=\"width:135.0pt;border-top:solid black 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"180\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">MaxCmin2</span></b></p>\n</td>", "ID": "73324deb-71c1-4850-b51c-de1fd7a84606", "Styles": "width:135.0pt;border-top:solid black 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4634f154-e3d0-458f-b497-69a6825bc6da"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">MaxCmin2</span></b></p>", "ID": "f9d58f84-7e3f-446a-94f7-3ec266f28fd2", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "73324deb-71c1-4850-b51c-de1fd7a84606"}, {"Element": "<b><span lang=\"EN-GB\">MaxCmin2</span></b>", "ID": "6d629641-c051-45dd-9783-2d9a365cd3e8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f9d58f84-7e3f-446a-94f7-3ec266f28fd2"}, {"Element": "<span lang=\"EN-GB\">MaxCmin2</span>", "ID": "034badf3-c9d0-492e-a4b6-e5cbfd91c181", "Styles": "None", "Classes": "None", "Text": "MaxCmin2", "ParentId": "6d629641-c051-45dd-9783-2d9a365cd3e8"}, {"Element": "<tr>\n<td style=\"width:2.25in;border-top:none;border-left:\n  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">SQV/r</span></b></p>\n</td>\n<td style=\"width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">IDV/r</span></b></p>\n</td>\n<td style=\"width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">SQV/r</span></b></p>\n</td>\n<td style=\"width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">LPV/r</span></b></p>\n</td>\n</tr>", "ID": "a3749521-6347-4d9b-9ead-58f72ec7d5dd", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "79ac5d4b-23f8-4fb5-9e91-36a89dcfe7dd"}, {"Element": "<td style=\"width:2.25in;border-top:none;border-left:\n  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "47ed8ff1-da0c-45b2-b58b-d2dbb7d88751", "Styles": "width:2.25in;border-top:none;border-left:\n  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a3749521-6347-4d9b-9ead-58f72ec7d5dd"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "653ca25f-728b-4f2b-aecd-18d9ba20e596", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "47ed8ff1-da0c-45b2-b58b-d2dbb7d88751"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "c8dfe0dd-8a17-4904-974f-2a68ea88ce9a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "653ca25f-728b-4f2b-aecd-18d9ba20e596"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2160ade3-d2b9-4592-bf0a-29eb62813a54", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c8dfe0dd-8a17-4904-974f-2a68ea88ce9a"}, {"Element": "<td style=\"width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">SQV/r</span></b></p>\n</td>", "ID": "c84e9c72-ff2f-4264-8ef0-cdb1313aeb7b", "Styles": "width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a3749521-6347-4d9b-9ead-58f72ec7d5dd"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">SQV/r</span></b></p>", "ID": "153b9243-f41f-4069-b2e2-59caa60e665a", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "c84e9c72-ff2f-4264-8ef0-cdb1313aeb7b"}, {"Element": "<b><span lang=\"EN-GB\">SQV/r</span></b>", "ID": "477c3a24-0a76-42d9-bb0e-373c8611e179", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "153b9243-f41f-4069-b2e2-59caa60e665a"}, {"Element": "<span lang=\"EN-GB\">SQV/r</span>", "ID": "5cef95d4-4c9c-462e-a6a2-2b02cc0f44a8", "Styles": "None", "Classes": "None", "Text": "SQV/r", "ParentId": "477c3a24-0a76-42d9-bb0e-373c8611e179"}, {"Element": "<td style=\"width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">IDV/r</span></b></p>\n</td>", "ID": "36fe20a1-df9e-41cb-8183-dab3914cf731", "Styles": "width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a3749521-6347-4d9b-9ead-58f72ec7d5dd"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">IDV/r</span></b></p>", "ID": "97f40c0c-e5d1-49df-8f32-33923a0a26f4", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "36fe20a1-df9e-41cb-8183-dab3914cf731"}, {"Element": "<b><span lang=\"EN-GB\">IDV/r</span></b>", "ID": "696cfcce-cbd1-4f92-aa44-e3dd28e84300", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "97f40c0c-e5d1-49df-8f32-33923a0a26f4"}, {"Element": "<span lang=\"EN-GB\">IDV/r</span>", "ID": "4014f70d-3e34-4a12-b926-ecd64fe5cbd6", "Styles": "None", "Classes": "None", "Text": "IDV/r", "ParentId": "696cfcce-cbd1-4f92-aa44-e3dd28e84300"}, {"Element": "<td style=\"width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">SQV/r</span></b></p>\n</td>", "ID": "1857a251-c4de-44be-8a56-6627b13dcf47", "Styles": "width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a3749521-6347-4d9b-9ead-58f72ec7d5dd"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">SQV/r</span></b></p>", "ID": "0b784380-0228-4205-be93-3df88c7550a7", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "1857a251-c4de-44be-8a56-6627b13dcf47"}, {"Element": "<b><span lang=\"EN-GB\">SQV/r</span></b>", "ID": "24c17a6d-467b-4a11-9299-dd2e9dab9d86", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0b784380-0228-4205-be93-3df88c7550a7"}, {"Element": "<span lang=\"EN-GB\">SQV/r</span>", "ID": "09b66644-71f2-4933-92fb-35e33583885e", "Styles": "None", "Classes": "None", "Text": "SQV/r", "ParentId": "24c17a6d-467b-4a11-9299-dd2e9dab9d86"}, {"Element": "<td style=\"width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">LPV/r</span></b></p>\n</td>", "ID": "9eddbca6-2701-4824-b649-88de17cf64fa", "Styles": "width:67.5pt;border:none;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a3749521-6347-4d9b-9ead-58f72ec7d5dd"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">LPV/r</span></b></p>", "ID": "9c2e7e8c-9a27-4da3-a6e6-f5258d25f4d0", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "9eddbca6-2701-4824-b649-88de17cf64fa"}, {"Element": "<b><span lang=\"EN-GB\">LPV/r</span></b>", "ID": "c3c733da-d9a7-46ca-ba89-62f14589cda6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9c2e7e8c-9a27-4da3-a6e6-f5258d25f4d0"}, {"Element": "<span lang=\"EN-GB\">LPV/r</span>", "ID": "2730a9c7-2a4b-4d3f-9659-d83f58cd0de8", "Styles": "None", "Classes": "None", "Text": "LPV/r", "ParentId": "c3c733da-d9a7-46ca-ba89-62f14589cda6"}, {"Element": "<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=148</span></b></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=158</span></b></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=161</span></b></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=163</span></b></p>\n</td>\n</tr>", "ID": "503da7c2-5171-435d-a027-183b51a940c9", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "79ac5d4b-23f8-4fb5-9e91-36a89dcfe7dd"}, {"Element": "<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "b1b1c052-8419-4f64-bc8f-5fc675b33b5c", "Styles": "width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "503da7c2-5171-435d-a027-183b51a940c9"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "f6678e1e-1de1-4dc4-a5fe-7675229ca959", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "b1b1c052-8419-4f64-bc8f-5fc675b33b5c"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "2fe9f1ed-c414-4bf2-bfec-058078ff1194", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f6678e1e-1de1-4dc4-a5fe-7675229ca959"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "afac9b6d-d5c3-41e1-93cd-a535efd90de0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2fe9f1ed-c414-4bf2-bfec-058078ff1194"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=148</span></b></p>\n</td>", "ID": "71ad080f-8c19-421d-ab64-926bf1de2fe6", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "503da7c2-5171-435d-a027-183b51a940c9"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=148</span></b></p>", "ID": "4e98e205-c8fa-4df6-b3bd-5507d7d42892", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "71ad080f-8c19-421d-ab64-926bf1de2fe6"}, {"Element": "<b><span lang=\"EN-GB\">N=148</span></b>", "ID": "9babada7-d80b-4fbc-bb21-a1ab2db849de", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4e98e205-c8fa-4df6-b3bd-5507d7d42892"}, {"Element": "<span lang=\"EN-GB\">N=148</span>", "ID": "cf5b1048-e595-4ec0-9a74-075a8f185926", "Styles": "None", "Classes": "None", "Text": "N=148", "ParentId": "9babada7-d80b-4fbc-bb21-a1ab2db849de"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=158</span></b></p>\n</td>", "ID": "853583e1-a053-4949-840f-36f53ec75db0", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "503da7c2-5171-435d-a027-183b51a940c9"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=158</span></b></p>", "ID": "ddc0f07a-c096-4193-87a2-b7c9ad3c7b96", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "853583e1-a053-4949-840f-36f53ec75db0"}, {"Element": "<b><span lang=\"EN-GB\">N=158</span></b>", "ID": "707a7481-960f-48f2-8378-d8f820de59cf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ddc0f07a-c096-4193-87a2-b7c9ad3c7b96"}, {"Element": "<span lang=\"EN-GB\">N=158</span>", "ID": "d23f5a4c-28f4-46be-9fcd-e5d3d10c738e", "Styles": "None", "Classes": "None", "Text": "N=158", "ParentId": "707a7481-960f-48f2-8378-d8f820de59cf"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=161</span></b></p>\n</td>", "ID": "123cf921-15f0-413d-859c-0a555d6c8ea1", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "503da7c2-5171-435d-a027-183b51a940c9"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=161</span></b></p>", "ID": "dc7a6308-ced8-4367-bf05-ee65c59289dd", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "123cf921-15f0-413d-859c-0a555d6c8ea1"}, {"Element": "<b><span lang=\"EN-GB\">N=161</span></b>", "ID": "92d91333-f940-4a34-9323-afd697a190b6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dc7a6308-ced8-4367-bf05-ee65c59289dd"}, {"Element": "<span lang=\"EN-GB\">N=161</span>", "ID": "9f662422-31d3-40a6-b07d-04a95b6ce872", "Styles": "None", "Classes": "None", "Text": "N=161", "ParentId": "92d91333-f940-4a34-9323-afd697a190b6"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=163</span></b></p>\n</td>", "ID": "a86e751a-eb18-4d4b-8420-07e3aaeefcd2", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "503da7c2-5171-435d-a027-183b51a940c9"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">N=163</span></b></p>", "ID": "ea6646e8-3fc0-4faf-8bfb-62838c5d84c4", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "a86e751a-eb18-4d4b-8420-07e3aaeefcd2"}, {"Element": "<b><span lang=\"EN-GB\">N=163</span></b>", "ID": "984bbaf3-7759-4456-b041-21b80b821c0d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ea6646e8-3fc0-4faf-8bfb-62838c5d84c4"}, {"Element": "<span lang=\"EN-GB\">N=163</span>", "ID": "25afc966-fbdd-4dc4-ae5c-9d1e2b804a79", "Styles": "None", "Classes": "None", "Text": "N=163", "ParentId": "984bbaf3-7759-4456-b041-21b80b821c0d"}, {"Element": "<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Sex</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Male</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">82%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">74%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">81%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">76%</span></p>\n</td>\n</tr>", "ID": "de310113-d2f8-4eca-85d9-bf693b0c481f", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "79ac5d4b-23f8-4fb5-9e91-36a89dcfe7dd"}, {"Element": "<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Sex</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Male</span></p>\n</td>", "ID": "fe3d10b0-d9a1-4806-a272-da30b3997dfd", "Styles": "width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "de310113-d2f8-4eca-85d9-bf693b0c481f"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Sex</span></p>", "ID": "d573d240-a15e-485a-a48e-f82462b49d62", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "fe3d10b0-d9a1-4806-a272-da30b3997dfd"}, {"Element": "<span lang=\"EN-GB\">Sex</span>", "ID": "1b49c169-5593-4dd0-921d-5dba246a991f", "Styles": "None", "Classes": "None", "Text": "Sex", "ParentId": "d573d240-a15e-485a-a48e-f82462b49d62"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Male</span></p>", "ID": "741b2f40-57c2-4071-97ab-22a7fb41a24a", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "fe3d10b0-d9a1-4806-a272-da30b3997dfd"}, {"Element": "<span lang=\"EN-GB\">Male</span>", "ID": "43ab7bc3-cd72-449b-aa73-ea21552f508f", "Styles": "None", "Classes": "None", "Text": "Male", "ParentId": "741b2f40-57c2-4071-97ab-22a7fb41a24a"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">82%</span></p>\n</td>", "ID": "e43bbe8b-275c-4bdc-8de3-826421a32fd5", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "de310113-d2f8-4eca-85d9-bf693b0c481f"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "12cdc7a0-0867-410b-bbdb-237edad3eacb", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "e43bbe8b-275c-4bdc-8de3-826421a32fd5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2f34b03e-cdca-45b8-a6bd-18dd7dc8403a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "12cdc7a0-0867-410b-bbdb-237edad3eacb"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">82%</span></p>", "ID": "fd0032e3-0915-48b8-ba8c-7e5e2bc902a8", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "e43bbe8b-275c-4bdc-8de3-826421a32fd5"}, {"Element": "<span lang=\"EN-GB\">82%</span>", "ID": "3f15fe96-5291-44f8-9b54-55b134d20dcd", "Styles": "None", "Classes": "None", "Text": "82%", "ParentId": "fd0032e3-0915-48b8-ba8c-7e5e2bc902a8"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">74%</span></p>\n</td>", "ID": "3cdd76ba-b3b6-454a-b6db-71a2c2b98e46", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "de310113-d2f8-4eca-85d9-bf693b0c481f"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bcfd0eb4-55b4-4d3c-a27f-412dface085e", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "3cdd76ba-b3b6-454a-b6db-71a2c2b98e46"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5d8b8728-d18b-4748-a0ce-6f77aa195dfe", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bcfd0eb4-55b4-4d3c-a27f-412dface085e"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">74%</span></p>", "ID": "46a8f811-38e5-4768-9f9d-5bb06a8b0ed3", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "3cdd76ba-b3b6-454a-b6db-71a2c2b98e46"}, {"Element": "<span lang=\"EN-GB\">74%</span>", "ID": "3ffa4918-d40a-4dd2-a9bb-bf7d4af044db", "Styles": "None", "Classes": "None", "Text": "74%", "ParentId": "46a8f811-38e5-4768-9f9d-5bb06a8b0ed3"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">81%</span></p>\n</td>", "ID": "537da9a1-6b3b-4434-933a-6fc18ea4d0f8", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "de310113-d2f8-4eca-85d9-bf693b0c481f"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eec6aa4e-f229-4b96-a916-98aaeaf43449", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "537da9a1-6b3b-4434-933a-6fc18ea4d0f8"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ca14f616-b338-499d-8606-a3bd1e04e5c2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eec6aa4e-f229-4b96-a916-98aaeaf43449"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">81%</span></p>", "ID": "3ba92380-ef3c-4364-a224-2a74d41fc87e", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "537da9a1-6b3b-4434-933a-6fc18ea4d0f8"}, {"Element": "<span lang=\"EN-GB\">81%</span>", "ID": "f1ed0377-64a5-48b3-8013-2306eff529b6", "Styles": "None", "Classes": "None", "Text": "81%", "ParentId": "3ba92380-ef3c-4364-a224-2a74d41fc87e"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">76%</span></p>\n</td>", "ID": "6b5895ab-0bef-4b11-bf68-e9c423aa6cc2", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "de310113-d2f8-4eca-85d9-bf693b0c481f"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3210a6bb-30ab-4c7c-b03a-54a742177b2f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "6b5895ab-0bef-4b11-bf68-e9c423aa6cc2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "99cdaeac-62ac-4dec-b362-4ebf82425dc5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3210a6bb-30ab-4c7c-b03a-54a742177b2f"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">76%</span></p>", "ID": "0be938ae-fabe-405f-81ba-6903c40d39ed", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "6b5895ab-0bef-4b11-bf68-e9c423aa6cc2"}, {"Element": "<span lang=\"EN-GB\">76%</span>", "ID": "0ec913fd-640a-42bb-aefd-eeebd1ab24b8", "Styles": "None", "Classes": "None", "Text": "76%", "ParentId": "0be938ae-fabe-405f-81ba-6903c40d39ed"}, {"Element": "<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Race\n  (White/Black/Asian) %</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">86/9/1</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">82/12/4</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">75/19/1</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">74/19/2</span></p>\n</td>\n</tr>", "ID": "8df5b99e-b53e-4003-8001-efa67ba0f4f3", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "79ac5d4b-23f8-4fb5-9e91-36a89dcfe7dd"}, {"Element": "<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Race\n  (White/Black/Asian) %</span></p>\n</td>", "ID": "2b5789b7-5c71-4058-b742-f9b65c26f379", "Styles": "width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8df5b99e-b53e-4003-8001-efa67ba0f4f3"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Race\n  (White/Black/Asian) %</span></p>", "ID": "020d4d1e-06f2-4da7-a1c5-86a7ef24cf73", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "2b5789b7-5c71-4058-b742-f9b65c26f379"}, {"Element": "<span lang=\"EN-GB\">Race\n  (White/Black/Asian) %</span>", "ID": "90ce4b4a-71f3-43f8-be23-2f901ea2bc20", "Styles": "None", "Classes": "None", "Text": "Race   (White/Black/Asian) %", "ParentId": "020d4d1e-06f2-4da7-a1c5-86a7ef24cf73"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">86/9/1</span></p>\n</td>", "ID": "1af5923b-5e09-4e1a-87db-c251fe8043cb", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8df5b99e-b53e-4003-8001-efa67ba0f4f3"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">86/9/1</span></p>", "ID": "cdfc48f0-48a1-4dcf-8e4f-965dec9d24e8", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "1af5923b-5e09-4e1a-87db-c251fe8043cb"}, {"Element": "<span lang=\"EN-GB\">86/9/1</span>", "ID": "772180f9-ee5e-47d8-a51c-161eebdf75c8", "Styles": "None", "Classes": "None", "Text": "86/9/1", "ParentId": "cdfc48f0-48a1-4dcf-8e4f-965dec9d24e8"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">82/12/4</span></p>\n</td>", "ID": "6f836ae1-9938-4563-bf02-28681cfa756f", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8df5b99e-b53e-4003-8001-efa67ba0f4f3"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">82/12/4</span></p>", "ID": "029e3abd-759b-4ea9-be14-234ba961d360", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "6f836ae1-9938-4563-bf02-28681cfa756f"}, {"Element": "<span lang=\"EN-GB\">82/12/4</span>", "ID": "a4b8383d-7a88-4c37-8349-8624b90b9790", "Styles": "None", "Classes": "None", "Text": "82/12/4", "ParentId": "029e3abd-759b-4ea9-be14-234ba961d360"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">75/19/1</span></p>\n</td>", "ID": "eaf5aba0-7dc3-4f92-b795-828910fd8ce6", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8df5b99e-b53e-4003-8001-efa67ba0f4f3"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">75/19/1</span></p>", "ID": "881cb8b0-238a-461d-b2cb-d283b5bb85b7", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "eaf5aba0-7dc3-4f92-b795-828910fd8ce6"}, {"Element": "<span lang=\"EN-GB\">75/19/1</span>", "ID": "fee14bfb-1574-41fe-bea9-9cbece34f40b", "Styles": "None", "Classes": "None", "Text": "75/19/1", "ParentId": "881cb8b0-238a-461d-b2cb-d283b5bb85b7"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">74/19/2</span></p>\n</td>", "ID": "7c2ded7f-2c28-49a9-a49e-e6d747debfa2", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8df5b99e-b53e-4003-8001-efa67ba0f4f3"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">74/19/2</span></p>", "ID": "459505f7-1840-44c7-b6cb-ec161a442637", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "7c2ded7f-2c28-49a9-a49e-e6d747debfa2"}, {"Element": "<span lang=\"EN-GB\">74/19/2</span>", "ID": "bcb002be-42d4-440f-944c-3b0686d44edd", "Styles": "None", "Classes": "None", "Text": "74/19/2", "ParentId": "459505f7-1840-44c7-b6cb-ec161a442637"}, {"Element": "<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Age,\n  median, yrs</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">39</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">40</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">40</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">40</span></p>\n</td>\n</tr>", "ID": "2e7a0ee0-82e6-4054-931b-176781011264", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "79ac5d4b-23f8-4fb5-9e91-36a89dcfe7dd"}, {"Element": "<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Age,\n  median, yrs</span></p>\n</td>", "ID": "f3a85c85-87b3-4c1d-8d78-e1aa1cca0257", "Styles": "width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2e7a0ee0-82e6-4054-931b-176781011264"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Age,\n  median, yrs</span></p>", "ID": "5c094578-3d6c-4d64-98c5-d9183fca507f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "f3a85c85-87b3-4c1d-8d78-e1aa1cca0257"}, {"Element": "<span lang=\"EN-GB\">Age,\n  median, yrs</span>", "ID": "5dc78229-5b66-49ed-b26c-66d8cccc3c83", "Styles": "None", "Classes": "None", "Text": "Age,   median, yrs", "ParentId": "5c094578-3d6c-4d64-98c5-d9183fca507f"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">39</span></p>\n</td>", "ID": "15ac9dcd-2448-4dc9-855f-1970626a59de", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2e7a0ee0-82e6-4054-931b-176781011264"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">39</span></p>", "ID": "f325d114-6114-4d57-8b03-d7dd7d8f8973", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "15ac9dcd-2448-4dc9-855f-1970626a59de"}, {"Element": "<span lang=\"EN-GB\">39</span>", "ID": "6aa3eb9c-0c77-4d7e-8f51-d72bae89e406", "Styles": "None", "Classes": "None", "Text": "39", "ParentId": "f325d114-6114-4d57-8b03-d7dd7d8f8973"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">40</span></p>\n</td>", "ID": "4c3a9fbc-a710-447b-a930-f031a7f37371", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2e7a0ee0-82e6-4054-931b-176781011264"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">40</span></p>", "ID": "b65a0553-986a-4f75-b862-af17ce746873", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "4c3a9fbc-a710-447b-a930-f031a7f37371"}, {"Element": "<span lang=\"EN-GB\">40</span>", "ID": "d895335d-1589-41d9-b0e0-a710b7f9a794", "Styles": "None", "Classes": "None", "Text": "40", "ParentId": "b65a0553-986a-4f75-b862-af17ce746873"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">40</span></p>\n</td>", "ID": "389da285-6d24-432d-9352-76475b77534c", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2e7a0ee0-82e6-4054-931b-176781011264"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">40</span></p>", "ID": "f8a171ac-992c-4a16-9355-a43b46ca968f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "389da285-6d24-432d-9352-76475b77534c"}, {"Element": "<span lang=\"EN-GB\">40</span>", "ID": "c5aedded-7643-44d1-b991-4b272e248107", "Styles": "None", "Classes": "None", "Text": "40", "ParentId": "f8a171ac-992c-4a16-9355-a43b46ca968f"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">40</span></p>\n</td>", "ID": "67dc63b5-d346-4e8c-b3f6-5c303eef83fc", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2e7a0ee0-82e6-4054-931b-176781011264"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">40</span></p>", "ID": "42c63634-15dc-48d1-81fd-afdd4856a492", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "67dc63b5-d346-4e8c-b3f6-5c303eef83fc"}, {"Element": "<span lang=\"EN-GB\">40</span>", "ID": "19d508f3-69df-400e-acf0-a2e4e5693d3a", "Styles": "None", "Classes": "None", "Text": "40", "ParentId": "42c63634-15dc-48d1-81fd-afdd4856a492"}, {"Element": "<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">CDC\n  Category C (%)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">32%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">32%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">31%</span></p>\n</td>\n</tr>", "ID": "7aa63c91-43d9-4639-9bea-37b8e8497d3d", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "79ac5d4b-23f8-4fb5-9e91-36a89dcfe7dd"}, {"Element": "<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">CDC\n  Category C (%)</span></p>\n</td>", "ID": "c4451a61-08b1-42f7-bd2e-5fb5e9d64d46", "Styles": "width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7aa63c91-43d9-4639-9bea-37b8e8497d3d"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">CDC\n  Category C (%)</span></p>", "ID": "a3715be0-a276-44d3-9dd7-c9b1ff9a3491", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "c4451a61-08b1-42f7-bd2e-5fb5e9d64d46"}, {"Element": "<span lang=\"EN-GB\">CDC\n  Category C (%)</span>", "ID": "d34f33f3-ca7f-4948-82ea-ce5dd5dea346", "Styles": "None", "Classes": "None", "Text": "CDC   Category C (%)", "ParentId": "a3715be0-a276-44d3-9dd7-c9b1ff9a3491"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">32%</span></p>\n</td>", "ID": "7d155be5-7ca5-4624-8a47-29905dd1ba45", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7aa63c91-43d9-4639-9bea-37b8e8497d3d"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">32%</span></p>", "ID": "f074899c-ddf0-47aa-afbd-70a93b3047f3", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "7d155be5-7ca5-4624-8a47-29905dd1ba45"}, {"Element": "<span lang=\"EN-GB\">32%</span>", "ID": "de634b74-59fa-4f2e-b057-06bacf513a86", "Styles": "None", "Classes": "None", "Text": "32%", "ParentId": "f074899c-ddf0-47aa-afbd-70a93b3047f3"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28%</span></p>\n</td>", "ID": "dc6d42e3-3a65-4fcc-ba88-41610a1ec86e", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7aa63c91-43d9-4639-9bea-37b8e8497d3d"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28%</span></p>", "ID": "fd5468bc-4b1a-4e2f-a3af-b8fd89c4a3b1", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "dc6d42e3-3a65-4fcc-ba88-41610a1ec86e"}, {"Element": "<span lang=\"EN-GB\">28%</span>", "ID": "4268e160-52da-492b-9b2a-3845fd2198be", "Styles": "None", "Classes": "None", "Text": "28%", "ParentId": "fd5468bc-4b1a-4e2f-a3af-b8fd89c4a3b1"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">32%</span></p>\n</td>", "ID": "deb517c9-0e97-4af2-be3d-7e278f8a0e84", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7aa63c91-43d9-4639-9bea-37b8e8497d3d"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">32%</span></p>", "ID": "f1524952-7137-4224-9000-92cf363e83f8", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "deb517c9-0e97-4af2-be3d-7e278f8a0e84"}, {"Element": "<span lang=\"EN-GB\">32%</span>", "ID": "326e8e22-c56d-469c-ab98-c6d8ecddb359", "Styles": "None", "Classes": "None", "Text": "32%", "ParentId": "f1524952-7137-4224-9000-92cf363e83f8"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">31%</span></p>\n</td>", "ID": "70135dee-46f6-4af2-a7b9-32e787a5f44c", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7aa63c91-43d9-4639-9bea-37b8e8497d3d"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">31%</span></p>", "ID": "d6405e6b-86ff-4a5d-b6d0-594a4f79e573", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "70135dee-46f6-4af2-a7b9-32e787a5f44c"}, {"Element": "<span lang=\"EN-GB\">31%</span>", "ID": "92534a7c-f26a-4706-814e-46b9a91816eb", "Styles": "None", "Classes": "None", "Text": "31%", "ParentId": "d6405e6b-86ff-4a5d-b6d0-594a4f79e573"}, {"Element": "<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Antiretroviral\n  na\u00efve (%)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">22%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">31%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">34%</span></p>\n</td>\n</tr>", "ID": "b2a24c76-c87a-4634-8115-84aa4be8f6d2", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "79ac5d4b-23f8-4fb5-9e91-36a89dcfe7dd"}, {"Element": "<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Antiretroviral\n  na\u00efve (%)</span></p>\n</td>", "ID": "c3fc681e-1a8a-46f9-bc38-5d74e7c33678", "Styles": "width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b2a24c76-c87a-4634-8115-84aa4be8f6d2"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Antiretroviral\n  na\u00efve (%)</span></p>", "ID": "220ab439-fcfe-4206-aee6-4f8360c294bc", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "c3fc681e-1a8a-46f9-bc38-5d74e7c33678"}, {"Element": "<span lang=\"EN-GB\">Antiretroviral\n  na\u00efve (%)</span>", "ID": "c1b8c7cd-5db6-4ac6-bbab-669821377e88", "Styles": "None", "Classes": "None", "Text": "Antiretroviral   na\u00efve (%)", "ParentId": "220ab439-fcfe-4206-aee6-4f8360c294bc"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28%</span></p>\n</td>", "ID": "29b287eb-67ee-4328-954b-079d2330f78f", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b2a24c76-c87a-4634-8115-84aa4be8f6d2"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28%</span></p>", "ID": "5d2181e3-b936-42db-ae42-a94620f7a246", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "29b287eb-67ee-4328-954b-079d2330f78f"}, {"Element": "<span lang=\"EN-GB\">28%</span>", "ID": "6efbbafa-5ee2-4f2d-b160-7dfd28e18eda", "Styles": "None", "Classes": "None", "Text": "28%", "ParentId": "5d2181e3-b936-42db-ae42-a94620f7a246"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">22%</span></p>\n</td>", "ID": "e7a5d2bc-7c7b-4c78-b63c-2e4be21b97c7", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b2a24c76-c87a-4634-8115-84aa4be8f6d2"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">22%</span></p>", "ID": "bf555293-2edc-4afb-b606-db0c9b077f47", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "e7a5d2bc-7c7b-4c78-b63c-2e4be21b97c7"}, {"Element": "<span lang=\"EN-GB\">22%</span>", "ID": "dd5dd3be-6c38-43cd-b4c4-ef07a149711e", "Styles": "None", "Classes": "None", "Text": "22%", "ParentId": "bf555293-2edc-4afb-b606-db0c9b077f47"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">31%</span></p>\n</td>", "ID": "4e1f862d-0ad4-4150-b7dc-2ec30f40fb0a", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b2a24c76-c87a-4634-8115-84aa4be8f6d2"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">31%</span></p>", "ID": "f35c58c8-f821-4cfc-9258-acc6b791f2e9", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "4e1f862d-0ad4-4150-b7dc-2ec30f40fb0a"}, {"Element": "<span lang=\"EN-GB\">31%</span>", "ID": "c1466c8b-002f-41ba-8f84-beb3c5254ffd", "Styles": "None", "Classes": "None", "Text": "31%", "ParentId": "f35c58c8-f821-4cfc-9258-acc6b791f2e9"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">34%</span></p>\n</td>", "ID": "e4b6bb31-e416-4ec1-83c0-e8cbd98dd095", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b2a24c76-c87a-4634-8115-84aa4be8f6d2"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">34%</span></p>", "ID": "f45d02ee-e672-46c2-b560-e4fe8dfbb95b", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "e4b6bb31-e416-4ec1-83c0-e8cbd98dd095"}, {"Element": "<span lang=\"EN-GB\">34%</span>", "ID": "0fedee54-46f5-44a1-9ec3-e4aba9960284", "Styles": "None", "Classes": "None", "Text": "34%", "ParentId": "f45d02ee-e672-46c2-b560-e4fe8dfbb95b"}, {"Element": "<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">PI\n  na\u00efve (%)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">41%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">38%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">48%</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">48%</span></p>\n</td>\n</tr>", "ID": "19cf62da-a1f6-4cf1-a762-9317e1029e54", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "79ac5d4b-23f8-4fb5-9e91-36a89dcfe7dd"}, {"Element": "<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">PI\n  na\u00efve (%)</span></p>\n</td>", "ID": "ad2f5dd6-a43c-4c35-b796-7437539911ef", "Styles": "width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "19cf62da-a1f6-4cf1-a762-9317e1029e54"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">PI\n  na\u00efve (%)</span></p>", "ID": "bc808518-59dd-4cc6-bbcc-33dfca5f7727", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "ad2f5dd6-a43c-4c35-b796-7437539911ef"}, {"Element": "<span lang=\"EN-GB\">PI\n  na\u00efve (%)</span>", "ID": "013d37fe-99b7-4d38-8376-b0ebcb437a2b", "Styles": "None", "Classes": "None", "Text": "PI   na\u00efve (%)", "ParentId": "bc808518-59dd-4cc6-bbcc-33dfca5f7727"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">41%</span></p>\n</td>", "ID": "215fdd69-fa3e-46a6-abaf-4ae7d6a0fe02", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "19cf62da-a1f6-4cf1-a762-9317e1029e54"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">41%</span></p>", "ID": "ead531dc-74c9-43ad-a3da-3ca464b22f10", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "215fdd69-fa3e-46a6-abaf-4ae7d6a0fe02"}, {"Element": "<span lang=\"EN-GB\">41%</span>", "ID": "32bab868-1d34-4eed-9059-76a4e7332a77", "Styles": "None", "Classes": "None", "Text": "41%", "ParentId": "ead531dc-74c9-43ad-a3da-3ca464b22f10"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">38%</span></p>\n</td>", "ID": "640f2cad-da71-4e72-9a95-39c973d11ec8", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "19cf62da-a1f6-4cf1-a762-9317e1029e54"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">38%</span></p>", "ID": "3456b406-1c28-4916-9435-d53ba7373f55", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "640f2cad-da71-4e72-9a95-39c973d11ec8"}, {"Element": "<span lang=\"EN-GB\">38%</span>", "ID": "fe900196-289d-4d7e-9beb-2ed4c16ed4cd", "Styles": "None", "Classes": "None", "Text": "38%", "ParentId": "3456b406-1c28-4916-9435-d53ba7373f55"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">48%</span></p>\n</td>", "ID": "7a657aa7-bc1e-4e53-bf63-b9364b450fd5", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "19cf62da-a1f6-4cf1-a762-9317e1029e54"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">48%</span></p>", "ID": "e6cf9144-eb7d-40f7-8f66-80da2fe9e53f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "7a657aa7-bc1e-4e53-bf63-b9364b450fd5"}, {"Element": "<span lang=\"EN-GB\">48%</span>", "ID": "e1d849da-7032-40c2-a67c-5533b7ad5876", "Styles": "None", "Classes": "None", "Text": "48%", "ParentId": "e6cf9144-eb7d-40f7-8f66-80da2fe9e53f"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">48%</span></p>\n</td>", "ID": "7073abfe-8c06-4b00-a026-e5af7ec670a4", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "19cf62da-a1f6-4cf1-a762-9317e1029e54"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">48%</span></p>", "ID": "4d943bbc-2722-469a-8dcb-c5f54499b939", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "7073abfe-8c06-4b00-a026-e5af7ec670a4"}, {"Element": "<span lang=\"EN-GB\">48%</span>", "ID": "5c683895-b1f5-47c0-83b8-a026f132b904", "Styles": "None", "Classes": "None", "Text": "48%", "ParentId": "4d943bbc-2722-469a-8dcb-c5f54499b939"}, {"Element": "<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">Median\n  Baseline HIV-1 RNA, log<sub>10</sub> copies/ml (IQR)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">4.0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(1.7-5.1)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">3.9</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(1.7-5.2)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">4.4 </span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(3.1-5.1)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">4.6</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(3.5-5.3)</span></p>\n</td>\n</tr>", "ID": "02a139b6-bb0c-42ae-9abd-5cd2d517d49f", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "79ac5d4b-23f8-4fb5-9e91-36a89dcfe7dd"}, {"Element": "<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">Median\n  Baseline HIV-1 RNA, log<sub>10</sub> copies/ml (IQR)</span></p>\n</td>", "ID": "82b895d1-17f9-48e9-9a20-47450dc491a3", "Styles": "width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02a139b6-bb0c-42ae-9abd-5cd2d517d49f"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">Median\n  Baseline HIV-1 RNA, log<sub>10</sub> copies/ml (IQR)</span></p>", "ID": "520d942f-38d1-4ebf-80d2-a26bde66dda7", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "82b895d1-17f9-48e9-9a20-47450dc491a3"}, {"Element": "<span lang=\"ES\">Median\n  Baseline HIV-1 RNA, log<sub>10</sub> copies/ml (IQR)</span>", "ID": "6d2733e1-8566-4076-b4b7-e94663a6320b", "Styles": "None", "Classes": "None", "Text": "Median   Baseline HIV-1 RNA, log copies/ml (IQR)", "ParentId": "520d942f-38d1-4ebf-80d2-a26bde66dda7"}, {"Element": "<sub>10</sub>", "ID": "1805e290-14d7-4c73-be02-2650d0dbeff3", "Styles": "None", "Classes": "None", "Text": "10", "ParentId": "6d2733e1-8566-4076-b4b7-e94663a6320b"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">4.0</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(1.7-5.1)</span></p>\n</td>", "ID": "c47334f4-7cd6-453e-8b1d-f37e20e79878", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "02a139b6-bb0c-42ae-9abd-5cd2d517d49f"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">4.0</span></p>", "ID": "48cb5fc1-d3be-46ef-bd6f-5f66c037a4cb", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "c47334f4-7cd6-453e-8b1d-f37e20e79878"}, {"Element": "<span lang=\"ES\">4.0</span>", "ID": "c352f600-538e-4e4c-a90a-4fa6e9d2cef6", "Styles": "None", "Classes": "None", "Text": "4.0", "ParentId": "48cb5fc1-d3be-46ef-bd6f-5f66c037a4cb"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(1.7-5.1)</span></p>", "ID": "ffec9970-d6a7-4590-80f9-4f7d7174093a", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "c47334f4-7cd6-453e-8b1d-f37e20e79878"}, {"Element": "<span lang=\"ES\">(1.7-5.1)</span>", "ID": "63fc19f0-511f-428d-9bc4-e45db071335a", "Styles": "None", "Classes": "None", "Text": "(1.7-5.1)", "ParentId": "ffec9970-d6a7-4590-80f9-4f7d7174093a"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">3.9</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(1.7-5.2)</span></p>\n</td>", "ID": "6848a7d5-61da-4ede-98dd-64f2474d3084", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "02a139b6-bb0c-42ae-9abd-5cd2d517d49f"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">3.9</span></p>", "ID": "8e8294a3-ecbf-4b4c-ab9b-ad0e3c553f25", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "6848a7d5-61da-4ede-98dd-64f2474d3084"}, {"Element": "<span lang=\"ES\">3.9</span>", "ID": "f478bad8-978a-4240-8fa9-6fc340325009", "Styles": "None", "Classes": "None", "Text": "3.9", "ParentId": "8e8294a3-ecbf-4b4c-ab9b-ad0e3c553f25"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(1.7-5.2)</span></p>", "ID": "7905af5c-50cf-4bca-b172-7b0199937b9b", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "6848a7d5-61da-4ede-98dd-64f2474d3084"}, {"Element": "<span lang=\"ES\">(1.7-5.2)</span>", "ID": "514f6924-ecf6-49f4-9744-b5a8ac2376d4", "Styles": "None", "Classes": "None", "Text": "(1.7-5.2)", "ParentId": "7905af5c-50cf-4bca-b172-7b0199937b9b"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">4.4 </span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(3.1-5.1)</span></p>\n</td>", "ID": "fa24873b-3b53-4a54-99a2-0b4e0dad0c1c", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "02a139b6-bb0c-42ae-9abd-5cd2d517d49f"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">4.4 </span></p>", "ID": "31775514-2f2c-4a1e-878b-74ef50e32829", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "fa24873b-3b53-4a54-99a2-0b4e0dad0c1c"}, {"Element": "<span lang=\"ES\">4.4 </span>", "ID": "87ed2698-d722-4158-bf3a-cab3e2c51c34", "Styles": "None", "Classes": "None", "Text": "4.4 ", "ParentId": "31775514-2f2c-4a1e-878b-74ef50e32829"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(3.1-5.1)</span></p>", "ID": "05e3ee91-c104-4a35-a9ee-105e514471e7", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "fa24873b-3b53-4a54-99a2-0b4e0dad0c1c"}, {"Element": "<span lang=\"ES\">(3.1-5.1)</span>", "ID": "16edd798-85e6-49e0-b18f-cfa2aed14a35", "Styles": "None", "Classes": "None", "Text": "(3.1-5.1)", "ParentId": "05e3ee91-c104-4a35-a9ee-105e514471e7"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">4.6</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(3.5-5.3)</span></p>\n</td>", "ID": "7bc92de0-a6db-4304-b642-ab028fabb9d3", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "02a139b6-bb0c-42ae-9abd-5cd2d517d49f"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">4.6</span></p>", "ID": "6bebb598-42b2-4d37-840f-964294e9d627", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "7bc92de0-a6db-4304-b642-ab028fabb9d3"}, {"Element": "<span lang=\"ES\">4.6</span>", "ID": "ce5f3598-fe93-4ed7-8c82-4e558373a3f5", "Styles": "None", "Classes": "None", "Text": "4.6", "ParentId": "6bebb598-42b2-4d37-840f-964294e9d627"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"ES\">(3.5-5.3)</span></p>", "ID": "5b113aa6-903e-45cd-9bd7-6c953ccd8ea8", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "7bc92de0-a6db-4304-b642-ab028fabb9d3"}, {"Element": "<span lang=\"ES\">(3.5-5.3)</span>", "ID": "e1f97912-c135-47ba-ac55-1afbd08bbbd6", "Styles": "None", "Classes": "None", "Text": "(3.5-5.3)", "ParentId": "5b113aa6-903e-45cd-9bd7-6c953ccd8ea8"}, {"Element": "<tr>\n<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  Baseline CD4<sup>+</sup> Cell Count, cells/mm<sup>3</sup> (IQR)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">272</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(135-420)\n  </span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">280</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(139-453)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">241</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(86-400)</span></p>\n</td>\n<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">239</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(95-420)</span></p>\n</td>\n</tr>", "ID": "dd34ad31-3228-43f4-a564-1045d4894779", "Styles": "None", "Classes": "None", "Text": "      ", "ParentId": "79ac5d4b-23f8-4fb5-9e91-36a89dcfe7dd"}, {"Element": "<td style=\"width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  Baseline CD4<sup>+</sup> Cell Count, cells/mm<sup>3</sup> (IQR)</span></p>\n</td>", "ID": "5516be79-89c1-41a4-8bf6-0b1c6d1af222", "Styles": "width:2.25in;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "dd34ad31-3228-43f4-a564-1045d4894779"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\n  Baseline CD4<sup>+</sup> Cell Count, cells/mm<sup>3</sup> (IQR)</span></p>", "ID": "0c864a1f-b103-4f24-9a22-1ac6bbe91142", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "5516be79-89c1-41a4-8bf6-0b1c6d1af222"}, {"Element": "<span lang=\"EN-GB\">Median\n  Baseline CD4<sup>+</sup> Cell Count, cells/mm<sup>3</sup> (IQR)</span>", "ID": "6ef447b6-4386-4ba4-be87-8d1ed157add7", "Styles": "None", "Classes": "None", "Text": "Median   Baseline CD4 Cell Count, cells/mm (IQR)", "ParentId": "0c864a1f-b103-4f24-9a22-1ac6bbe91142"}, {"Element": "<sup>+</sup>", "ID": "ae4df5b7-40be-4d9b-90c7-f2028e4a2536", "Styles": "None", "Classes": "None", "Text": "+", "ParentId": "6ef447b6-4386-4ba4-be87-8d1ed157add7"}, {"Element": "<sup>3</sup>", "ID": "6dcd5f69-2148-4a81-a1a6-66bda3175556", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "6ef447b6-4386-4ba4-be87-8d1ed157add7"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">272</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(135-420)\n  </span></p>\n</td>", "ID": "ddcafa34-31f7-4071-bb72-8e541b1c3769", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "dd34ad31-3228-43f4-a564-1045d4894779"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">272</span></p>", "ID": "7e61324a-c821-4991-8601-5c22d35f58b5", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "ddcafa34-31f7-4071-bb72-8e541b1c3769"}, {"Element": "<span lang=\"EN-GB\">272</span>", "ID": "892b902e-8b1d-4f1e-9eab-42145ba33df9", "Styles": "None", "Classes": "None", "Text": "272", "ParentId": "7e61324a-c821-4991-8601-5c22d35f58b5"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(135-420)\n  </span></p>", "ID": "aff0354c-41a4-4dd9-be4d-5a1114d830d1", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "ddcafa34-31f7-4071-bb72-8e541b1c3769"}, {"Element": "<span lang=\"EN-GB\">(135-420)\n  </span>", "ID": "64e4dd93-a594-431e-affa-36bbe500a109", "Styles": "None", "Classes": "None", "Text": "(135-420)   ", "ParentId": "aff0354c-41a4-4dd9-be4d-5a1114d830d1"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">280</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(139-453)</span></p>\n</td>", "ID": "c5d1c3f0-cc75-4141-a3d4-48596d09daef", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "dd34ad31-3228-43f4-a564-1045d4894779"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">280</span></p>", "ID": "9206720d-55bf-4b55-93ab-1a0e7ffdb406", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "c5d1c3f0-cc75-4141-a3d4-48596d09daef"}, {"Element": "<span lang=\"EN-GB\">280</span>", "ID": "2d0cf164-3391-4622-9af4-38f4fb66bcb7", "Styles": "None", "Classes": "None", "Text": "280", "ParentId": "9206720d-55bf-4b55-93ab-1a0e7ffdb406"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(139-453)</span></p>", "ID": "5e805efb-7d11-42a0-941b-6d3e921c0255", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "c5d1c3f0-cc75-4141-a3d4-48596d09daef"}, {"Element": "<span lang=\"EN-GB\">(139-453)</span>", "ID": "3dc2ca26-91c1-42f5-a39b-628edc6946b5", "Styles": "None", "Classes": "None", "Text": "(139-453)", "ParentId": "5e805efb-7d11-42a0-941b-6d3e921c0255"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">241</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(86-400)</span></p>\n</td>", "ID": "b3f1f9ec-50c9-4bfa-82cf-55a16c91cde9", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "dd34ad31-3228-43f4-a564-1045d4894779"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">241</span></p>", "ID": "882c6d32-1355-4186-9176-9e29b404c90a", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "b3f1f9ec-50c9-4bfa-82cf-55a16c91cde9"}, {"Element": "<span lang=\"EN-GB\">241</span>", "ID": "b51d0a21-588f-4322-ae9a-33617ca50689", "Styles": "None", "Classes": "None", "Text": "241", "ParentId": "882c6d32-1355-4186-9176-9e29b404c90a"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(86-400)</span></p>", "ID": "17560e49-24a7-4e9b-84a3-813d918fe47b", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "b3f1f9ec-50c9-4bfa-82cf-55a16c91cde9"}, {"Element": "<span lang=\"EN-GB\">(86-400)</span>", "ID": "8ef98386-6d27-4cbd-82bf-3195a3bcca4b", "Styles": "None", "Classes": "None", "Text": "(86-400)", "ParentId": "17560e49-24a7-4e9b-84a3-813d918fe47b"}, {"Element": "<td style=\"width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\">\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">239</span></p>\n<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(95-420)</span></p>\n</td>", "ID": "7b5cd7e6-d2aa-4c20-abd7-89587c485fd5", "Styles": "width:67.5pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "dd34ad31-3228-43f4-a564-1045d4894779"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">239</span></p>", "ID": "135d986a-919c-4968-8a78-7259b82b04a3", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "7b5cd7e6-d2aa-4c20-abd7-89587c485fd5"}, {"Element": "<span lang=\"EN-GB\">239</span>", "ID": "55d43341-8127-433c-8c19-132e0a65bb2a", "Styles": "None", "Classes": "None", "Text": "239", "ParentId": "135d986a-919c-4968-8a78-7259b82b04a3"}, {"Element": "<p class=\"Normal11pt\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">(95-420)</span></p>", "ID": "7ca10269-99b9-42de-8870-7cc5c8c90d12", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt']", "Text": "", "ParentId": "7b5cd7e6-d2aa-4c20-abd7-89587c485fd5"}, {"Element": "<span lang=\"EN-GB\">(95-420)</span>", "ID": "86f65772-896f-4056-81f9-f6a32ded2d4d", "Styles": "None", "Classes": "None", "Text": "(95-420)", "ParentId": "7ca10269-99b9-42de-8870-7cc5c8c90d12"}, {"Element": "<p class=\"MsoNormal\"><sup>\u2020 </sup>data from clinical study report</p>", "ID": "ce67501d-8878-4379-a33d-7bea60bcd444", "Styles": "None", "Classes": "['MsoNormal']", "Text": "data from clinical study report", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<sup>\u2020 </sup>", "ID": "9f8e7817-2b1a-45ad-9a0d-cd3c24336c16", "Styles": "None", "Classes": "None", "Text": "\u2020 ", "ParentId": "ce67501d-8878-4379-a33d-7bea60bcd444"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "db652be5-916b-4708-ada0-847e6298c84a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Table\u00a07: Outcomes at\nWeek 48 MaxCmin1 and MaxCmin2<sup>\u2020</sup></p>", "ID": "38b1b026-279d-486b-b6cf-44e9dc3c3ced", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Table\u00a07: Outcomes at Week 48 MaxCmin1 and MaxCmin2", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<sup>\u2020</sup>", "ID": "33e749df-a09e-4fdf-b7b8-1223b570f24a", "Styles": "None", "Classes": "None", "Text": "\u2020", "ParentId": "38b1b026-279d-486b-b6cf-44e9dc3c3ced"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>", "ID": "d7f40de0-0944-4799-828b-ed4c44610965", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>\u00a0</b>", "ID": "1cdaa842-873c-4970-9e0b-7dca9db78928", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d7f40de0-0944-4799-828b-ed4c44610965"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"619\">\n<tr style=\"page-break-inside:avoid;height:18.4pt\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Outcomes</b></p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>MaxCmin1</b></p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>MaxCmin2</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:14.35pt\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>SQV/r</b></p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>IDV/r</b></p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>SQV/r</b></p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>LPV/r</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Initiated assigned\n  treatment, </p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">n (%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">148</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(94%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">158</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(99%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">161</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(94%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">163</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(98%)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Discontinued assigned\n  treatment, n (%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">40</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(27%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">64</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(41%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">48</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(30%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">23</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(14%)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.01</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.001</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Virological failure\n  ITT/e*<sup>#</sup></p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">36/148 (24%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">41/158 (26%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">53/161 (33%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">29/163 (18%)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.76</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.002</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Proportion with VL &lt;\n  50 copies/ml at week 48, ITT/e<sup>#</sup></p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">97/144<br/>\n  (67%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">106/154<br/>\n  (69%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">90/158<br/>\n  (57%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">106/162<br/>\n  (65%)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:14.35pt\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P &gt;0.05<sup>\u2021</sup></p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.12</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Proportion with VL &lt;\n  50 copies/ml at week 48,</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">On Treatment</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">82/104<br/>\n  (79%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">73/93<br/>\n  (78%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">84/113<br/>\n  (74%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">97/138<br/>\n  (70%)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P&gt;0.05<sup>\u2021</sup></p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.48</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Median increase in CD4\n  cell count at week 48 (cells/mm<sup>3</sup>)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">85</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">73</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">110</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">106</p>\n</td>\n</tr>\n</table>", "ID": "8e794d9f-4fc3-4312-8c7d-7f11198b41a7", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "             ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<tr style=\"page-break-inside:avoid;height:18.4pt\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Outcomes</b></p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>MaxCmin1</b></p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>MaxCmin2</b></p>\n</td>\n</tr>", "ID": "7b53da24-3377-4939-afbf-0d05d52ca33d", "Styles": "page-break-inside:avoid;height:18.4pt", "Classes": "None", "Text": "    ", "ParentId": "8e794d9f-4fc3-4312-8c7d-7f11198b41a7"}, {"Element": "<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Outcomes</b></p>\n</td>", "ID": "2ee6ab39-f751-4c52-8c31-5f59b27d28d3", "Styles": "width:144.9pt;border:solid windowtext 1.0pt;\n  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:18.4pt", "Classes": "None", "Text": "  ", "ParentId": "7b53da24-3377-4939-afbf-0d05d52ca33d"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>Outcomes</b></p>", "ID": "5baabb62-98a5-4342-b5da-f954e8799900", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "2ee6ab39-f751-4c52-8c31-5f59b27d28d3"}, {"Element": "<b>Outcomes</b>", "ID": "b74b70b6-7fad-4737-80a5-552d5854fde5", "Styles": "None", "Classes": "None", "Text": "Outcomes", "ParentId": "5baabb62-98a5-4342-b5da-f954e8799900"}, {"Element": "<td colspan=\"2\" style=\"width:159.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>MaxCmin1</b></p>\n</td>", "ID": "8dec95aa-f7ef-47b7-bdaf-14c981d20df0", "Styles": "width:159.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:18.4pt", "Classes": "None", "Text": "  ", "ParentId": "7b53da24-3377-4939-afbf-0d05d52ca33d"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>MaxCmin1</b></p>", "ID": "12b418cd-445e-4ee0-8876-4815d897fee8", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "8dec95aa-f7ef-47b7-bdaf-14c981d20df0"}, {"Element": "<b>MaxCmin1</b>", "ID": "6e9d662d-622d-4831-bdd7-ce0a086d1781", "Styles": "None", "Classes": "None", "Text": "MaxCmin1", "ParentId": "12b418cd-445e-4ee0-8876-4815d897fee8"}, {"Element": "<td colspan=\"2\" style=\"width:159.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>MaxCmin2</b></p>\n</td>", "ID": "ecd171f4-6a74-4254-913c-cd3282e68368", "Styles": "width:159.75pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:18.4pt", "Classes": "None", "Text": "  ", "ParentId": "7b53da24-3377-4939-afbf-0d05d52ca33d"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>MaxCmin2</b></p>", "ID": "20391a30-1fb9-4b45-8dcf-d6f01f4591fb", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "ecd171f4-6a74-4254-913c-cd3282e68368"}, {"Element": "<b>MaxCmin2</b>", "ID": "1c006d7f-0b36-4773-8dfb-db2918613355", "Styles": "None", "Classes": "None", "Text": "MaxCmin2", "ParentId": "20391a30-1fb9-4b45-8dcf-d6f01f4591fb"}, {"Element": "<tr style=\"page-break-inside:avoid;height:14.35pt\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>SQV/r</b></p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>IDV/r</b></p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>SQV/r</b></p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>LPV/r</b></p>\n</td>\n</tr>", "ID": "03c8a22a-a9f0-4e8f-b1d4-ab5921ad7c43", "Styles": "page-break-inside:avoid;height:14.35pt", "Classes": "None", "Text": "      ", "ParentId": "8e794d9f-4fc3-4312-8c7d-7f11198b41a7"}, {"Element": "<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>\n</td>", "ID": "d696b7ea-3884-43a4-8691-e1ca7ffaf8c1", "Styles": "width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt", "Classes": "None", "Text": "  ", "ParentId": "03c8a22a-a9f0-4e8f-b1d4-ab5921ad7c43"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>", "ID": "d87daa72-2b8e-4ae7-85c2-c321f9260e15", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "d696b7ea-3884-43a4-8691-e1ca7ffaf8c1"}, {"Element": "<b>\u00a0</b>", "ID": "0ebcf001-de28-4f4a-86da-99b95309f502", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d87daa72-2b8e-4ae7-85c2-c321f9260e15"}, {"Element": "<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>SQV/r</b></p>\n</td>", "ID": "d2aee040-b262-4dd3-af54-e49a46ec2e94", "Styles": "width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt", "Classes": "None", "Text": "  ", "ParentId": "03c8a22a-a9f0-4e8f-b1d4-ab5921ad7c43"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>SQV/r</b></p>", "ID": "7e45f006-c4b0-4652-8743-2c6a36acace3", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "d2aee040-b262-4dd3-af54-e49a46ec2e94"}, {"Element": "<b>SQV/r</b>", "ID": "deb53255-c0af-4912-a231-1d28abd61026", "Styles": "None", "Classes": "None", "Text": "SQV/r", "ParentId": "7e45f006-c4b0-4652-8743-2c6a36acace3"}, {"Element": "<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>IDV/r</b></p>\n</td>", "ID": "757363d3-dc35-404a-977c-5cdd85d88f5d", "Styles": "width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt", "Classes": "None", "Text": "  ", "ParentId": "03c8a22a-a9f0-4e8f-b1d4-ab5921ad7c43"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>IDV/r</b></p>", "ID": "cf9cfb1e-4534-4bee-a307-e8dffe53140f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "757363d3-dc35-404a-977c-5cdd85d88f5d"}, {"Element": "<b>IDV/r</b>", "ID": "c3e04683-a2e1-49d4-9d90-b7bac48021cf", "Styles": "None", "Classes": "None", "Text": "IDV/r", "ParentId": "cf9cfb1e-4534-4bee-a307-e8dffe53140f"}, {"Element": "<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>SQV/r</b></p>\n</td>", "ID": "dd7d78bd-902b-495a-862b-55a0c3df910e", "Styles": "width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt", "Classes": "None", "Text": "  ", "ParentId": "03c8a22a-a9f0-4e8f-b1d4-ab5921ad7c43"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>SQV/r</b></p>", "ID": "4de6120c-3aaf-4151-ac63-8249df5d1a4f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "dd7d78bd-902b-495a-862b-55a0c3df910e"}, {"Element": "<b>SQV/r</b>", "ID": "ab6b9035-4eb5-49c6-be70-ed64fbbb165b", "Styles": "None", "Classes": "None", "Text": "SQV/r", "ParentId": "4de6120c-3aaf-4151-ac63-8249df5d1a4f"}, {"Element": "<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>LPV/r</b></p>\n</td>", "ID": "74aba8e5-b370-4f41-9e2b-72443c20dae7", "Styles": "width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt", "Classes": "None", "Text": "  ", "ParentId": "03c8a22a-a9f0-4e8f-b1d4-ab5921ad7c43"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\"><b>LPV/r</b></p>", "ID": "53533419-8cc9-49f7-9571-fded187e3b72", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "", "ParentId": "74aba8e5-b370-4f41-9e2b-72443c20dae7"}, {"Element": "<b>LPV/r</b>", "ID": "9e5777ce-4d90-49eb-9371-00a699d614da", "Styles": "None", "Classes": "None", "Text": "LPV/r", "ParentId": "53533419-8cc9-49f7-9571-fded187e3b72"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Initiated assigned\n  treatment, </p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">n (%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">148</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(94%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">158</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(99%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">161</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(94%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">163</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(98%)</p>\n</td>\n</tr>", "ID": "7ae22305-5232-4e73-887b-8e7b97cdeb6c", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "8e794d9f-4fc3-4312-8c7d-7f11198b41a7"}, {"Element": "<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Initiated assigned\n  treatment, </p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">n (%)</p>\n</td>", "ID": "0445c7f1-221d-481a-bf95-455f534f164f", "Styles": "width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "7ae22305-5232-4e73-887b-8e7b97cdeb6c"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Initiated assigned\n  treatment, </p>", "ID": "73061880-e094-4d05-a690-24e55ed9671a", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Initiated assigned   treatment, ", "ParentId": "0445c7f1-221d-481a-bf95-455f534f164f"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">n (%)</p>", "ID": "2364ebcf-e790-420d-8dee-68cbd91cb81d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "n (%)", "ParentId": "0445c7f1-221d-481a-bf95-455f534f164f"}, {"Element": "<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">148</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(94%)</p>\n</td>", "ID": "8d4aaf25-1bc4-49a6-bb6e-1309cd6931ae", "Styles": "width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "7ae22305-5232-4e73-887b-8e7b97cdeb6c"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">148</p>", "ID": "418c2d00-d230-4816-b309-958cfffea0d4", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "148", "ParentId": "8d4aaf25-1bc4-49a6-bb6e-1309cd6931ae"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(94%)</p>", "ID": "326ebe28-5c73-4727-90e4-fe6e1e6f1194", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "(94%)", "ParentId": "8d4aaf25-1bc4-49a6-bb6e-1309cd6931ae"}, {"Element": "<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">158</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(99%)</p>\n</td>", "ID": "1480c32c-e69e-4a30-8672-b661e5aee27a", "Styles": "width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "7ae22305-5232-4e73-887b-8e7b97cdeb6c"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">158</p>", "ID": "0b6f5b3f-a678-4994-aedb-1bc0ecd4658a", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "158", "ParentId": "1480c32c-e69e-4a30-8672-b661e5aee27a"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(99%)</p>", "ID": "44840a04-0275-4565-8a0a-fae76de5fd3b", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "(99%)", "ParentId": "1480c32c-e69e-4a30-8672-b661e5aee27a"}, {"Element": "<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">161</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(94%)</p>\n</td>", "ID": "7077606d-91cb-4e2d-a94b-16419b2943ae", "Styles": "width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "7ae22305-5232-4e73-887b-8e7b97cdeb6c"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">161</p>", "ID": "5a6ac6d5-8f69-4757-927a-5e25e16757f5", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "161", "ParentId": "7077606d-91cb-4e2d-a94b-16419b2943ae"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(94%)</p>", "ID": "a50ed0c9-4b15-4943-86c9-9d8a32977bb4", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "(94%)", "ParentId": "7077606d-91cb-4e2d-a94b-16419b2943ae"}, {"Element": "<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">163</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(98%)</p>\n</td>", "ID": "6e93e9ec-9250-48d0-be90-93e241b53863", "Styles": "width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "7ae22305-5232-4e73-887b-8e7b97cdeb6c"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">163</p>", "ID": "1b3413db-bfdb-4cc4-9655-39ff0e5de647", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "163", "ParentId": "6e93e9ec-9250-48d0-be90-93e241b53863"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(98%)</p>", "ID": "f7066ee7-d9ca-48f4-a399-7398c3a69459", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "(98%)", "ParentId": "6e93e9ec-9250-48d0-be90-93e241b53863"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Discontinued assigned\n  treatment, n (%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">40</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(27%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">64</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(41%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">48</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(30%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">23</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(14%)</p>\n</td>\n</tr>", "ID": "ccbd75c4-f335-4f95-8426-5a26b7ca8124", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "8e794d9f-4fc3-4312-8c7d-7f11198b41a7"}, {"Element": "<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Discontinued assigned\n  treatment, n (%)</p>\n</td>", "ID": "852b0251-1b53-49cb-8063-e44050c3eb68", "Styles": "width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ccbd75c4-f335-4f95-8426-5a26b7ca8124"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Discontinued assigned\n  treatment, n (%)</p>", "ID": "9599162e-da61-4e0c-816e-0d11bb18a5e3", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Discontinued assigned   treatment, n (%)", "ParentId": "852b0251-1b53-49cb-8063-e44050c3eb68"}, {"Element": "<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">40</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(27%)</p>\n</td>", "ID": "89a8be87-9978-47f5-bfc8-505047d42583", "Styles": "width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "ccbd75c4-f335-4f95-8426-5a26b7ca8124"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">40</p>", "ID": "4efd0f10-1e2f-40e2-9803-41e7ecf17c01", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "40", "ParentId": "89a8be87-9978-47f5-bfc8-505047d42583"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(27%)</p>", "ID": "d1973bf6-a36f-4ca2-8a06-9fac0da59c17", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "(27%)", "ParentId": "89a8be87-9978-47f5-bfc8-505047d42583"}, {"Element": "<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">64</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(41%)</p>\n</td>", "ID": "b116bbaf-1758-4485-8412-bf0305ec1488", "Styles": "width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "ccbd75c4-f335-4f95-8426-5a26b7ca8124"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">64</p>", "ID": "91a2cd33-fc40-49ab-abde-3b6875dc79b4", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "64", "ParentId": "b116bbaf-1758-4485-8412-bf0305ec1488"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(41%)</p>", "ID": "e18c09fc-ab50-4b2f-aa0d-43cf1d95e57b", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "(41%)", "ParentId": "b116bbaf-1758-4485-8412-bf0305ec1488"}, {"Element": "<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">48</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(30%)</p>\n</td>", "ID": "5323738f-b245-4cc5-ab64-e2cd05c523a0", "Styles": "width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "ccbd75c4-f335-4f95-8426-5a26b7ca8124"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">48</p>", "ID": "05fe6880-7bfc-4960-97ee-ca2b7537f4fe", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "48", "ParentId": "5323738f-b245-4cc5-ab64-e2cd05c523a0"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(30%)</p>", "ID": "08c1ec1c-211d-4fc4-8f93-8e20f3765cfe", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "(30%)", "ParentId": "5323738f-b245-4cc5-ab64-e2cd05c523a0"}, {"Element": "<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">23</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(14%)</p>\n</td>", "ID": "92a52242-c443-46ce-89b2-a9dd5b6c4294", "Styles": "width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "ccbd75c4-f335-4f95-8426-5a26b7ca8124"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">23</p>", "ID": "ff12a157-0f0f-4765-8dc5-d189d512e1a9", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "23", "ParentId": "92a52242-c443-46ce-89b2-a9dd5b6c4294"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">(14%)</p>", "ID": "d99dc3ac-dfc2-41f5-b35e-2f621086c5e5", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "(14%)", "ParentId": "92a52242-c443-46ce-89b2-a9dd5b6c4294"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.01</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.001</p>\n</td>\n</tr>", "ID": "a8e9a75e-be0d-4100-825c-e17b32f70efc", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "8e794d9f-4fc3-4312-8c7d-7f11198b41a7"}, {"Element": "<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "9e61310a-5ee1-4347-874c-f7f231ce7fc8", "Styles": "width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a8e9a75e-be0d-4100-825c-e17b32f70efc"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "cecd01d1-055c-4dc6-a840-56e78626d429", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "9e61310a-5ee1-4347-874c-f7f231ce7fc8"}, {"Element": "<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.01</p>\n</td>", "ID": "8a6be0d7-44cd-4a14-aaed-802e4ec1a8b5", "Styles": "width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a8e9a75e-be0d-4100-825c-e17b32f70efc"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.01</p>", "ID": "7e7df53b-6800-4865-be14-ce4a53867b4d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "P=0.01", "ParentId": "8a6be0d7-44cd-4a14-aaed-802e4ec1a8b5"}, {"Element": "<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.001</p>\n</td>", "ID": "9608ec1c-038e-4c01-add6-7388087d0f54", "Styles": "width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a8e9a75e-be0d-4100-825c-e17b32f70efc"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.001</p>", "ID": "33825c55-8fb8-4ef4-bbea-45e3f141bf96", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "P=0.001", "ParentId": "9608ec1c-038e-4c01-add6-7388087d0f54"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Virological failure\n  ITT/e*<sup>#</sup></p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">36/148 (24%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">41/158 (26%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">53/161 (33%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">29/163 (18%)</p>\n</td>\n</tr>", "ID": "92cc5673-f48f-44df-b31f-9b9acf00d981", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "8e794d9f-4fc3-4312-8c7d-7f11198b41a7"}, {"Element": "<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Virological failure\n  ITT/e*<sup>#</sup></p>\n</td>", "ID": "148bdba6-9ac3-4018-87c3-a9d968791035", "Styles": "width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "92cc5673-f48f-44df-b31f-9b9acf00d981"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Virological failure\n  ITT/e*<sup>#</sup></p>", "ID": "1292558a-1eab-43ae-a4f0-d10835d23c69", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Virological failure   ITT/e*", "ParentId": "148bdba6-9ac3-4018-87c3-a9d968791035"}, {"Element": "<sup>#</sup>", "ID": "2c0bee56-b022-4d19-9e10-6665a1344f87", "Styles": "None", "Classes": "None", "Text": "#", "ParentId": "1292558a-1eab-43ae-a4f0-d10835d23c69"}, {"Element": "<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">36/148 (24%)</p>\n</td>", "ID": "ae03d088-f61f-4b04-9eb7-3a7fccc45dc9", "Styles": "width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "92cc5673-f48f-44df-b31f-9b9acf00d981"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">36/148 (24%)</p>", "ID": "23a7b2c2-fb60-4749-b077-497ca3e0857b", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "36/148 (24%)", "ParentId": "ae03d088-f61f-4b04-9eb7-3a7fccc45dc9"}, {"Element": "<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">41/158 (26%)</p>\n</td>", "ID": "b6219f92-5aca-480e-9240-2fd501d8db4d", "Styles": "width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "92cc5673-f48f-44df-b31f-9b9acf00d981"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">41/158 (26%)</p>", "ID": "5316c6f7-85c0-4bf3-b8a9-1e947ccd4ab1", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "41/158 (26%)", "ParentId": "b6219f92-5aca-480e-9240-2fd501d8db4d"}, {"Element": "<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">53/161 (33%)</p>\n</td>", "ID": "71b163b5-dffd-4ef3-b5a4-336cd8a84a5a", "Styles": "width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "92cc5673-f48f-44df-b31f-9b9acf00d981"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">53/161 (33%)</p>", "ID": "91b5028a-88a3-4b82-9429-3c76a15005d5", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "53/161 (33%)", "ParentId": "71b163b5-dffd-4ef3-b5a4-336cd8a84a5a"}, {"Element": "<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">29/163 (18%)</p>\n</td>", "ID": "296075bd-3eef-40de-9e3f-44b07424ff88", "Styles": "width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "92cc5673-f48f-44df-b31f-9b9acf00d981"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">29/163 (18%)</p>", "ID": "557f3d57-2987-427c-b4eb-7aaeed0dc78a", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "29/163 (18%)", "ParentId": "296075bd-3eef-40de-9e3f-44b07424ff88"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.76</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.002</p>\n</td>\n</tr>", "ID": "f5dfd8ee-6a40-4de8-bea3-d3ee0a44a6bf", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "8e794d9f-4fc3-4312-8c7d-7f11198b41a7"}, {"Element": "<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "91a08d5c-bb1f-4380-8398-9ada47ec3714", "Styles": "width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f5dfd8ee-6a40-4de8-bea3-d3ee0a44a6bf"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "b1563515-755e-4f76-87c0-4930acba63fd", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "91a08d5c-bb1f-4380-8398-9ada47ec3714"}, {"Element": "<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.76</p>\n</td>", "ID": "945bc334-be06-4fd4-82f7-49106722023c", "Styles": "width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f5dfd8ee-6a40-4de8-bea3-d3ee0a44a6bf"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.76</p>", "ID": "bbfec5b8-ff60-4dd5-8c4d-8eec6488fd81", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "P=0.76", "ParentId": "945bc334-be06-4fd4-82f7-49106722023c"}, {"Element": "<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.002</p>\n</td>", "ID": "6398aa69-9863-49a9-8659-6d2fc99e1b26", "Styles": "width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f5dfd8ee-6a40-4de8-bea3-d3ee0a44a6bf"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.002</p>", "ID": "4f77c474-e8fa-4401-8973-93f7a142596f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "P=0.002", "ParentId": "6398aa69-9863-49a9-8659-6d2fc99e1b26"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Proportion with VL &lt;\n  50 copies/ml at week 48, ITT/e<sup>#</sup></p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">97/144<br/>\n  (67%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">106/154<br/>\n  (69%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">90/158<br/>\n  (57%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">106/162<br/>\n  (65%)</p>\n</td>\n</tr>", "ID": "b1e896e2-198a-4fc2-9d14-d7a02371cd65", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "8e794d9f-4fc3-4312-8c7d-7f11198b41a7"}, {"Element": "<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Proportion with VL &lt;\n  50 copies/ml at week 48, ITT/e<sup>#</sup></p>\n</td>", "ID": "b116bcc7-b7fb-46c2-822c-99eb6e4b6ad2", "Styles": "width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b1e896e2-198a-4fc2-9d14-d7a02371cd65"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Proportion with VL &lt;\n  50 copies/ml at week 48, ITT/e<sup>#</sup></p>", "ID": "e856d0fa-7e38-4648-a07e-95776e835c83", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Proportion with VL <   50 copies/ml at week 48, ITT/e", "ParentId": "b116bcc7-b7fb-46c2-822c-99eb6e4b6ad2"}, {"Element": "<sup>#</sup>", "ID": "2bc8b8ef-1d0b-4822-83df-69986ad728de", "Styles": "None", "Classes": "None", "Text": "#", "ParentId": "e856d0fa-7e38-4648-a07e-95776e835c83"}, {"Element": "<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">97/144<br/>\n  (67%)</p>\n</td>", "ID": "e1f77e84-9e3f-4fbf-81ae-353f9f5eeb5a", "Styles": "width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b1e896e2-198a-4fc2-9d14-d7a02371cd65"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">97/144<br/>\n  (67%)</p>", "ID": "d087198a-6d1e-47ae-96ed-040da4f26f1d", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "97/144   (67%)", "ParentId": "e1f77e84-9e3f-4fbf-81ae-353f9f5eeb5a"}, {"Element": "<br/>", "ID": "230fda50-4ed4-4b6f-bc6a-c60e38a72e47", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d087198a-6d1e-47ae-96ed-040da4f26f1d"}, {"Element": "<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">106/154<br/>\n  (69%)</p>\n</td>", "ID": "db0d0fe0-3a75-4b31-b452-4c00c17ea7e7", "Styles": "width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b1e896e2-198a-4fc2-9d14-d7a02371cd65"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">106/154<br/>\n  (69%)</p>", "ID": "19315e18-0df4-49f2-81e6-974d6f0e2c52", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "106/154   (69%)", "ParentId": "db0d0fe0-3a75-4b31-b452-4c00c17ea7e7"}, {"Element": "<br/>", "ID": "e230e981-f76d-46ae-984b-25b3a53c6048", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "19315e18-0df4-49f2-81e6-974d6f0e2c52"}, {"Element": "<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">90/158<br/>\n  (57%)</p>\n</td>", "ID": "d651ec81-ccc2-4dec-ad55-cf434078f698", "Styles": "width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b1e896e2-198a-4fc2-9d14-d7a02371cd65"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">90/158<br/>\n  (57%)</p>", "ID": "b8a31d87-0f76-4898-ac96-ec930eb93ede", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "90/158   (57%)", "ParentId": "d651ec81-ccc2-4dec-ad55-cf434078f698"}, {"Element": "<br/>", "ID": "fb4c58b4-e2f0-48c5-8ade-fe56f0bffa4f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b8a31d87-0f76-4898-ac96-ec930eb93ede"}, {"Element": "<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">106/162<br/>\n  (65%)</p>\n</td>", "ID": "85c36fcc-f78c-4ea3-9b30-1c819deedce3", "Styles": "width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b1e896e2-198a-4fc2-9d14-d7a02371cd65"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">106/162<br/>\n  (65%)</p>", "ID": "7ca9c7f9-5b9f-4b0d-bec6-e6d164553bcd", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "106/162   (65%)", "ParentId": "85c36fcc-f78c-4ea3-9b30-1c819deedce3"}, {"Element": "<br/>", "ID": "7fe3d284-a44f-44d7-be6d-61eceb8eac45", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7ca9c7f9-5b9f-4b0d-bec6-e6d164553bcd"}, {"Element": "<tr style=\"page-break-inside:avoid;height:14.35pt\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P &gt;0.05<sup>\u2021</sup></p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.12</p>\n</td>\n</tr>", "ID": "2f1611b4-c2b8-4853-b289-37368a9bdff6", "Styles": "page-break-inside:avoid;height:14.35pt", "Classes": "None", "Text": "    ", "ParentId": "8e794d9f-4fc3-4312-8c7d-7f11198b41a7"}, {"Element": "<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "8d6c156c-2f7d-40b7-936a-e749a90677cc", "Styles": "width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt", "Classes": "None", "Text": "  ", "ParentId": "2f1611b4-c2b8-4853-b289-37368a9bdff6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "13f0100e-238d-40e3-b5c3-51c3e10eb17f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "8d6c156c-2f7d-40b7-936a-e749a90677cc"}, {"Element": "<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P &gt;0.05<sup>\u2021</sup></p>\n</td>", "ID": "8fb8a363-b785-4262-8b1a-88afd35a84b1", "Styles": "width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt", "Classes": "None", "Text": "  ", "ParentId": "2f1611b4-c2b8-4853-b289-37368a9bdff6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P &gt;0.05<sup>\u2021</sup></p>", "ID": "3c4381b0-f9fc-471a-983c-586ca21ef0a0", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "P >0.05", "ParentId": "8fb8a363-b785-4262-8b1a-88afd35a84b1"}, {"Element": "<sup>\u2021</sup>", "ID": "907a2d6b-79fb-48a7-8324-66389e68093e", "Styles": "None", "Classes": "None", "Text": "\u2021", "ParentId": "3c4381b0-f9fc-471a-983c-586ca21ef0a0"}, {"Element": "<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.12</p>\n</td>", "ID": "17fdc6ed-1887-423d-a437-c2e794621b94", "Styles": "width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:14.35pt", "Classes": "None", "Text": "  ", "ParentId": "2f1611b4-c2b8-4853-b289-37368a9bdff6"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.12</p>", "ID": "1ab3d465-d8ed-4040-9ad0-acf7a79b0bdf", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "P=0.12", "ParentId": "17fdc6ed-1887-423d-a437-c2e794621b94"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Proportion with VL &lt;\n  50 copies/ml at week 48,</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">On Treatment</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">82/104<br/>\n  (79%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">73/93<br/>\n  (78%)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">84/113<br/>\n  (74%)</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">97/138<br/>\n  (70%)</p>\n</td>\n</tr>", "ID": "9c464af1-2c2f-4d12-b184-ca1181d7b684", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "8e794d9f-4fc3-4312-8c7d-7f11198b41a7"}, {"Element": "<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Proportion with VL &lt;\n  50 copies/ml at week 48,</p>\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">On Treatment</p>\n</td>", "ID": "fa055c9d-de7f-4ad3-82ac-a4c0a12eb828", "Styles": "width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "9c464af1-2c2f-4d12-b184-ca1181d7b684"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Proportion with VL &lt;\n  50 copies/ml at week 48,</p>", "ID": "f10b098b-5860-4064-9f21-d915b53b57aa", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Proportion with VL <   50 copies/ml at week 48,", "ParentId": "fa055c9d-de7f-4ad3-82ac-a4c0a12eb828"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">On Treatment</p>", "ID": "9f6a1a09-f97f-42d7-b135-3b8787be9267", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "On Treatment", "ParentId": "fa055c9d-de7f-4ad3-82ac-a4c0a12eb828"}, {"Element": "<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">82/104<br/>\n  (79%)</p>\n</td>", "ID": "660c6a99-cd17-4a22-beb5-e3e40fb20f69", "Styles": "width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9c464af1-2c2f-4d12-b184-ca1181d7b684"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">82/104<br/>\n  (79%)</p>", "ID": "23467d2d-5a45-44e5-86fa-a003da1188e8", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "82/104   (79%)", "ParentId": "660c6a99-cd17-4a22-beb5-e3e40fb20f69"}, {"Element": "<br/>", "ID": "002fecdb-b73d-44bd-9d7c-eb2d8045f44e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "23467d2d-5a45-44e5-86fa-a003da1188e8"}, {"Element": "<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">73/93<br/>\n  (78%)</p>\n</td>", "ID": "6c83081d-96d2-49c7-9aea-25e442be0d22", "Styles": "width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9c464af1-2c2f-4d12-b184-ca1181d7b684"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">73/93<br/>\n  (78%)</p>", "ID": "e8ebc7f7-a144-48c5-b63f-4341bd6b4b6c", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "73/93   (78%)", "ParentId": "6c83081d-96d2-49c7-9aea-25e442be0d22"}, {"Element": "<br/>", "ID": "618e9092-989a-440d-823d-1f05be5c9d15", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e8ebc7f7-a144-48c5-b63f-4341bd6b4b6c"}, {"Element": "<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">84/113<br/>\n  (74%)</p>\n</td>", "ID": "453510e7-a026-4170-ab72-21d351c3c1af", "Styles": "width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9c464af1-2c2f-4d12-b184-ca1181d7b684"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">84/113<br/>\n  (74%)</p>", "ID": "05f14934-d12e-4f10-bf5f-68c9e3a85649", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "84/113   (74%)", "ParentId": "453510e7-a026-4170-ab72-21d351c3c1af"}, {"Element": "<br/>", "ID": "30569959-539f-4524-9ab2-12c2f18bf396", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "05f14934-d12e-4f10-bf5f-68c9e3a85649"}, {"Element": "<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">97/138<br/>\n  (70%)</p>\n</td>", "ID": "21daa3d8-d71d-481d-a6ab-ca55c56afd77", "Styles": "width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9c464af1-2c2f-4d12-b184-ca1181d7b684"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">97/138<br/>\n  (70%)</p>", "ID": "0d5278bf-f7b8-4553-b60f-457aa2f8ed4b", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "97/138   (70%)", "ParentId": "21daa3d8-d71d-481d-a6ab-ca55c56afd77"}, {"Element": "<br/>", "ID": "4591cd2a-a78a-4034-9496-357f0c22da1f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0d5278bf-f7b8-4553-b60f-457aa2f8ed4b"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P&gt;0.05<sup>\u2021</sup></p>\n</td>\n<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.48</p>\n</td>\n</tr>", "ID": "4107dc4c-9c3c-4622-a8b7-b435d7051278", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "8e794d9f-4fc3-4312-8c7d-7f11198b41a7"}, {"Element": "<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "7d5e9f85-e24d-433c-9bf2-709a9833d9c2", "Styles": "width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4107dc4c-9c3c-4622-a8b7-b435d7051278"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "e2ce745c-2eaf-43b7-8161-c0439dda0516", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "\u00a0", "ParentId": "7d5e9f85-e24d-433c-9bf2-709a9833d9c2"}, {"Element": "<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P&gt;0.05<sup>\u2021</sup></p>\n</td>", "ID": "732329a7-e978-4177-ac6c-77a4bc623d5f", "Styles": "width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4107dc4c-9c3c-4622-a8b7-b435d7051278"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P&gt;0.05<sup>\u2021</sup></p>", "ID": "49ed8b68-568d-450e-b70b-33146b7f564f", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "P>0.05", "ParentId": "732329a7-e978-4177-ac6c-77a4bc623d5f"}, {"Element": "<sup>\u2021</sup>", "ID": "f86d12e0-d142-4b98-b261-9dbd939bdff0", "Styles": "None", "Classes": "None", "Text": "\u2021", "ParentId": "49ed8b68-568d-450e-b70b-33146b7f564f"}, {"Element": "<td colspan=\"2\" style=\"width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"213\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.48</p>\n</td>", "ID": "a2d4784e-0651-448c-b67a-dd30a51f6a83", "Styles": "width:159.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4107dc4c-9c3c-4622-a8b7-b435d7051278"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">P=0.48</p>", "ID": "a04a11a9-7dc6-48d6-a98a-239764f3e24a", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "P=0.48", "ParentId": "a2d4784e-0651-448c-b67a-dd30a51f6a83"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Median increase in CD4\n  cell count at week 48 (cells/mm<sup>3</sup>)</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">85</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">73</p>\n</td>\n<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">110</p>\n</td>\n<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">106</p>\n</td>\n</tr>", "ID": "2844d12c-8d0d-43bf-8d22-1d7d8a6933eb", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "8e794d9f-4fc3-4312-8c7d-7f11198b41a7"}, {"Element": "<td style=\"width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"193\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Median increase in CD4\n  cell count at week 48 (cells/mm<sup>3</sup>)</p>\n</td>", "ID": "0060d108-2982-4557-937a-bc8f89e00364", "Styles": "width:144.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2844d12c-8d0d-43bf-8d22-1d7d8a6933eb"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">Median increase in CD4\n  cell count at week 48 (cells/mm<sup>3</sup>)</p>", "ID": "48459915-2675-422d-b4cf-519e9fb65722", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "Median increase in CD4   cell count at week 48 (cells/mm)", "ParentId": "0060d108-2982-4557-937a-bc8f89e00364"}, {"Element": "<sup>3</sup>", "ID": "6b6849dd-6dc3-4d01-867b-3f4c9c3ac83f", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "48459915-2675-422d-b4cf-519e9fb65722"}, {"Element": "<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">85</p>\n</td>", "ID": "92558935-1fd7-4d67-95ff-0cf4c973f40a", "Styles": "width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2844d12c-8d0d-43bf-8d22-1d7d8a6933eb"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">85</p>", "ID": "027d2489-ea4a-4526-bd26-2848f0902682", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "85", "ParentId": "92558935-1fd7-4d67-95ff-0cf4c973f40a"}, {"Element": "<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">73</p>\n</td>", "ID": "4fca0591-6ec0-4112-9871-14f5acc7d9eb", "Styles": "width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2844d12c-8d0d-43bf-8d22-1d7d8a6933eb"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">73</p>", "ID": "94f0f09c-1955-4904-9cb6-da18ec1fae04", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "73", "ParentId": "4fca0591-6ec0-4112-9871-14f5acc7d9eb"}, {"Element": "<td style=\"width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"106\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">110</p>\n</td>", "ID": "c5f117d7-872b-4009-9f4f-45c2ae29312f", "Styles": "width:79.85pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2844d12c-8d0d-43bf-8d22-1d7d8a6933eb"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">110</p>", "ID": "5916d2bc-e39a-41d9-80b2-730796b77f71", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "110", "ParentId": "c5f117d7-872b-4009-9f4f-45c2ae29312f"}, {"Element": "<td style=\"width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"107\">\n<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">106</p>\n</td>", "ID": "4023e83e-fe04-4e30-a9b0-2c62df14566b", "Styles": "width:79.9pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2844d12c-8d0d-43bf-8d22-1d7d8a6933eb"}, {"Element": "<p class=\"Normal11pt0\" style=\"page-break-after:avoid\">106</p>", "ID": "7babef30-e5e8-479d-ae74-cae86a9f6d36", "Styles": "page-break-after:avoid", "Classes": "['Normal11pt0']", "Text": "106", "ParentId": "4023e83e-fe04-4e30-a9b0-2c62df14566b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:24.0pt;text-indent:-24.0pt;page-break-after:\navoid\">*\u00a0\u00a0\u00a0\u00a0\u00a0 For both studies: For patients entering study\nwith VL\u00a0&lt;\u00a0200\u00a0copies/ml, VF defined as <u>&gt;</u>\u00a0200\u00a0copies/ml.\nMaxCmin1: For those entering with VL\u00a0<u>&gt;</u>\u00a0200 copies/ml, VF\ndefined as any increase <u>&gt;</u>\u00a00.5\u00a0logs and/or VL\u00a0<u>&gt;\u00a0</u>50,000\ncopies/ml at week 4, <u>&gt;\u00a0</u>5,000\u00a0copies/ml at week 12, or <u>&gt;</u>\u00a0200\u00a0copies/ml\nat week 24 or thereafter. MaxCmin2: any rise <u>&gt;</u>\u00a00.5\u00a0log at a\nspecific visit; <u>&lt;</u>\u00a00.5\u00a0log reduction if VL\u00a0<u>&gt;</u>\u00a0200\u00a0copies/ml\nat week 4; <u>&lt;</u>\u00a01.0\u00a0log reduction from base line if VL\u00a0<u>&gt;</u>\u00a0200\u00a0copies/ml\nat week 12; and a VL\u00a0<u>&gt;</u>\u00a0200 copies/ml at week 24.</p>", "ID": "7da0ff70-8c0b-4336-a9df-c2a824370ad2", "Styles": "margin-left:24.0pt;text-indent:-24.0pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "*\u00a0\u00a0\u00a0\u00a0\u00a0 For both studies: For patients entering study with VL\u00a0<\u00a0200\u00a0copies/ml, VF defined as \u00a0200\u00a0copies/ml. MaxCmin1: For those entering with VL\u00a0\u00a0200 copies/ml, VF defined as any increase \u00a00.5\u00a0logs and/or VL\u00a050,000 copies/ml at week 4, 5,000\u00a0copies/ml at week 12, or \u00a0200\u00a0copies/ml at week 24 or thereafter. MaxCmin2: any rise \u00a00.5\u00a0log at a specific visit; \u00a00.5\u00a0log reduction if VL\u00a0\u00a0200\u00a0copies/ml at week 4; \u00a01.0\u00a0log reduction from base line if VL\u00a0\u00a0200\u00a0copies/ml at week 12; and a VL\u00a0\u00a0200 copies/ml at week 24.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<u>&gt;</u>", "ID": "ebedfbff-8a52-472a-9a53-b791a01481e2", "Styles": "None", "Classes": "None", "Text": ">", "ParentId": "7da0ff70-8c0b-4336-a9df-c2a824370ad2"}, {"Element": "<u>&gt;</u>", "ID": "4ce1b3cb-d704-4195-8de8-07832ec4787a", "Styles": "None", "Classes": "None", "Text": ">", "ParentId": "7da0ff70-8c0b-4336-a9df-c2a824370ad2"}, {"Element": "<u>&gt;</u>", "ID": "8766411e-0743-467d-9a62-1561b3314e86", "Styles": "None", "Classes": "None", "Text": ">", "ParentId": "7da0ff70-8c0b-4336-a9df-c2a824370ad2"}, {"Element": "<u>&gt;\u00a0</u>", "ID": "13763966-51dd-4583-9079-074c343f0992", "Styles": "None", "Classes": "None", "Text": ">\u00a0", "ParentId": "7da0ff70-8c0b-4336-a9df-c2a824370ad2"}, {"Element": "<u>&gt;\u00a0</u>", "ID": "140e3662-a263-4387-a104-234e4c90f97b", "Styles": "None", "Classes": "None", "Text": ">\u00a0", "ParentId": "7da0ff70-8c0b-4336-a9df-c2a824370ad2"}, {"Element": "<u>&gt;</u>", "ID": "7090880b-737f-4e25-9498-609a0b030730", "Styles": "None", "Classes": "None", "Text": ">", "ParentId": "7da0ff70-8c0b-4336-a9df-c2a824370ad2"}, {"Element": "<u>&gt;</u>", "ID": "9d3fc79a-7324-48a3-ab41-45b2b5f746df", "Styles": "None", "Classes": "None", "Text": ">", "ParentId": "7da0ff70-8c0b-4336-a9df-c2a824370ad2"}, {"Element": "<u>&lt;</u>", "ID": "cb616003-4c48-43b6-9dca-3dc1d46da636", "Styles": "None", "Classes": "None", "Text": "<", "ParentId": "7da0ff70-8c0b-4336-a9df-c2a824370ad2"}, {"Element": "<u>&gt;</u>", "ID": "8645ba05-1d9b-4a60-b52c-675318942211", "Styles": "None", "Classes": "None", "Text": ">", "ParentId": "7da0ff70-8c0b-4336-a9df-c2a824370ad2"}, {"Element": "<u>&lt;</u>", "ID": "7a21a0e7-7a4a-4281-bfb6-f4a6e5ed4f91", "Styles": "None", "Classes": "None", "Text": "<", "ParentId": "7da0ff70-8c0b-4336-a9df-c2a824370ad2"}, {"Element": "<u>&gt;</u>", "ID": "70fe93e2-706b-4328-91e3-743afcad71b1", "Styles": "None", "Classes": "None", "Text": ">", "ParentId": "7da0ff70-8c0b-4336-a9df-c2a824370ad2"}, {"Element": "<u>&gt;</u>", "ID": "5204488e-b6ee-4ce1-81c8-3b447fe9e231", "Styles": "None", "Classes": "None", "Text": ">", "ParentId": "7da0ff70-8c0b-4336-a9df-c2a824370ad2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:24.0pt;text-indent:-24.0pt\"><sup>#</sup>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ITT/e\n= Intent-to-treat/exposed</p>", "ID": "9f821720-f8e0-4ff8-9df5-f1497d780b66", "Styles": "margin-left:24.0pt;text-indent:-24.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ITT/e = Intent-to-treat/exposed", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<sup>#</sup>", "ID": "1b786f34-dfef-4291-9cd7-23c0573d26e3", "Styles": "None", "Classes": "None", "Text": "#", "ParentId": "9f821720-f8e0-4ff8-9df5-f1497d780b66"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:24.0pt;text-indent:-24.0pt\"><sup>\u2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </sup>Data\nfrom clinical study report</p>", "ID": "1c56226b-8bc8-4600-8926-c09b03e7a7c4", "Styles": "margin-left:24.0pt;text-indent:-24.0pt", "Classes": "['MsoNormal']", "Text": "Data from clinical study report", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<sup>\u2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </sup>", "ID": "6c5c2883-1e6d-4f35-937a-c30763a2186b", "Styles": "None", "Classes": "None", "Text": "\u2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "1c56226b-8bc8-4600-8926-c09b03e7a7c4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:24.0pt;text-indent:-24.0pt\"><sup>\u2021\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </sup>Data\nfrom<b> </b>MaxCmin1 publication</p>", "ID": "0b4417da-9c77-49bc-a5dd-ed673120c048", "Styles": "margin-left:24.0pt;text-indent:-24.0pt", "Classes": "['MsoNormal']", "Text": "Data fromMaxCmin1 publication", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<sup>\u2021\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </sup>", "ID": "45510a54-564e-4a0c-91e5-2110f831c6a9", "Styles": "None", "Classes": "None", "Text": "\u2021\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "0b4417da-9c77-49bc-a5dd-ed673120c048"}, {"Element": "<b> </b>", "ID": "3cacb963-57a4-43e4-8940-713bc8ef9cea", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "0b4417da-9c77-49bc-a5dd-ed673120c048"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>", "ID": "3d83f2c4-4519-4a67-a398-1329f7624841", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">\u00a0</span></i></b>", "ID": "7cc01ca4-67b1-49df-a3ed-29557be7562f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3d83f2c4-4519-4a67-a398-1329f7624841"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "cdde8b83-84cd-42b6-8e08-fe5aa6db18a1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7cc01ca4-67b1-49df-a3ed-29557be7562f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "04d92ba2-ca6c-4868-96f3-cc376a59a64d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cdde8b83-84cd-42b6-8e08-fe5aa6db18a1"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Clinical results from paediatric\nstudies</span></i></b></p>", "ID": "077733b4-d2d9-44d1-bf2c-6725e9540cc5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Clinical results from paediatric\nstudies</span></i></b>", "ID": "88d0c53f-ccb1-4eba-8c0f-64e68764363e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "077733b4-d2d9-44d1-bf2c-6725e9540cc5"}, {"Element": "<i><span lang=\"EN-GB\">Clinical results from paediatric\nstudies</span></i>", "ID": "874f9bde-c7bc-4afa-8c20-9ad77367998b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "88d0c53f-ccb1-4eba-8c0f-64e68764363e"}, {"Element": "<span lang=\"EN-GB\">Clinical results from paediatric\nstudies</span>", "ID": "bd0192bd-d7e6-4eb2-bc95-f66e3e472024", "Styles": "None", "Classes": "None", "Text": "Clinical results from paediatric studies", "ParentId": "874f9bde-c7bc-4afa-8c20-9ad77367998b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1c6a887b-8c86-448c-9942-5bbd915f4e32", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2ef83292-bd86-4d07-bb8f-de89562543f0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1c6a887b-8c86-448c-9942-5bbd915f4e32"}, {"Element": "<p class=\"MsoNormal\">The pharmacokinetics, safety and activity of saquinavir have\nbeen evaluated in an open label, multicenter study in 18 children aged 4 months\nto less than 6 years old in which saquinavir (50\u00a0mg/kg bid up to the adult\ndose of 1000\u00a0mg bid) was administered in combination with ritonavir oral\nsolution (3\u00a0mg/kg bid for body weight from 5 to &lt;15\u00a0kg,\n2.5\u00a0mg/kg bid for body weight from 15 to 40\u00a0kg and 100\u00a0mg bid\nfor body weight &gt;40\u00a0kg) plus \u22652 background ARVs. The infants and\nyoung children were stratified into 2 groups: Group A \u201cLow Age\nGroup\u201d 4 months to less than 2 years old (n=5) and Group B \u201cHigh\nAge Group\u201d children 2 years to less than 6 years old (n=13). </p>", "ID": "c1145fc4-3108-4734-a793-c827b160b618", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The pharmacokinetics, safety and activity of saquinavir have been evaluated in an open label, multicenter study in 18 children aged 4 months to less than 6 years old in which saquinavir (50\u00a0mg/kg bid up to the adult dose of 1000\u00a0mg bid) was administered in combination with ritonavir oral solution (3\u00a0mg/kg bid for body weight from 5 to <15\u00a0kg, 2.5\u00a0mg/kg bid for body weight from 15 to 40\u00a0kg and 100\u00a0mg bid for body weight >40\u00a0kg) plus \u22652 background ARVs. The infants and young children were stratified into 2 groups: Group A \u201cLow Age Group\u201d 4 months to less than 2 years old (n=5) and Group B \u201cHigh Age Group\u201d children 2 years to less than 6 years old (n=13). ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "4cac6f6e-4196-4373-8bf6-03eda10576dd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">In the \u201cHigh Age Group\u201d, the number of patients\nwith a viral load &lt;400 copies/mL at week 48 was 11 of 13.\u00a0 The number\nof patients with viral load &lt;50 copies/mL was 9 of 13 for the same\nperiod.\u00a0 The CD4 lymphocyte count expressed as percentage mean CD4\nincreased by a mean of 2.97% over the same 48 week period. The size of the\nstudy was too small to allow conclusions on clinical benefit.</p>", "ID": "c00259e4-daae-4200-9623-30465eaf0450", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In the \u201cHigh Age Group\u201d, the number of patients with a viral load <400 copies/mL at week 48 was 11 of 13.\u00a0 The number of patients with viral load <50 copies/mL was 9 of 13 for the same period.\u00a0 The CD4 lymphocyte count expressed as percentage mean CD4 increased by a mean of 2.97% over the same 48 week period. The size of the study was too small to allow conclusions on clinical benefit.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d294ab1f-cf96-4159-97f5-c34ce6ea28f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties</span></b></p>", "ID": "ea432b59-a30e-4505-a6bc-606763c2b72c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties</span></b>", "ID": "40ed3878-2a59-49b1-a4c0-63143142e4e9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ea432b59-a30e-4505-a6bc-606763c2b72c"}, {"Element": "<span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties</span>", "ID": "d083904a-827b-4fe0-9f81-22df88dc604e", "Styles": "None", "Classes": "None", "Text": "5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties", "ParentId": "40ed3878-2a59-49b1-a4c0-63143142e4e9"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "b88770b5-d511-4259-9d5a-16ba579d7ed1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">Saquinavir is essentially completely metabolised by CYP3A4.\nRitonavir inhibits the metabolism of saquinavir, thereby increasing\n(\"boosting\") the plasma levels of saquinavir. </p>", "ID": "06c76a9c-32da-4518-a46a-f03e5cd8ecc1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Saquinavir is essentially completely metabolised by CYP3A4. Ritonavir inhibits the metabolism of saquinavir, thereby increasing (\"boosting\") the plasma levels of saquinavir. ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "f74eb722-a8aa-4464-b020-c53d869916e3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "a02fe928-0af2-4b36-ab19-b6cea5bcf18f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f74eb722-a8aa-4464-b020-c53d869916e3"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0aa93d78-be31-48f0-bd67-b327cfdb79b8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a02fe928-0af2-4b36-ab19-b6cea5bcf18f"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Absorption:</span></i></b><span lang=\"EN-GB\"> In HIV-infected adult patients, Invirase in combination with\nritonavir at doses of 1000/100\u00a0mg twice daily provides saquinavir systemic\nexposures over a 24-hour period similar to or greater than those achieved with saquinavir\nsoft capsules 1200\u00a0mg tid (see Table 8). The pharmacokinetics of\nsaquinavir is stable during long-term treatment.</span></p>", "ID": "def63a8c-2fab-4967-b6e6-382c2d3702f0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Absorption:</span></i></b>", "ID": "6f155979-e646-44b9-ab6b-53a8bd15a1b2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "def63a8c-2fab-4967-b6e6-382c2d3702f0"}, {"Element": "<i><span lang=\"EN-GB\">Absorption:</span></i>", "ID": "e8b05f8b-fbd5-4d2a-8bc0-26e7f9cbcdeb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6f155979-e646-44b9-ab6b-53a8bd15a1b2"}, {"Element": "<span lang=\"EN-GB\">Absorption:</span>", "ID": "01faa7f9-1c2d-4a48-aa6f-4933f684a8f5", "Styles": "None", "Classes": "None", "Text": "Absorption:", "ParentId": "e8b05f8b-fbd5-4d2a-8bc0-26e7f9cbcdeb"}, {"Element": "<span lang=\"EN-GB\"> In HIV-infected adult patients, Invirase in combination with\nritonavir at doses of 1000/100\u00a0mg twice daily provides saquinavir systemic\nexposures over a 24-hour period similar to or greater than those achieved with saquinavir\nsoft capsules 1200\u00a0mg tid (see Table 8). The pharmacokinetics of\nsaquinavir is stable during long-term treatment.</span>", "ID": "db3d4ba5-3570-433d-b2c7-3203fc13befa", "Styles": "None", "Classes": "None", "Text": " In HIV-infected adult patients, Invirase in combination with ritonavir at doses of 1000/100\u00a0mg twice daily provides saquinavir systemic exposures over a 24-hour period similar to or greater than those achieved with saquinavir soft capsules 1200\u00a0mg tid (see Table 8). The pharmacokinetics of saquinavir is stable during long-term treatment.", "ParentId": "def63a8c-2fab-4967-b6e6-382c2d3702f0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "45ffb49a-0967-4044-a4d0-fdd6029898d9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0c89a715-17c6-443f-a13b-191446804680", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "45ffb49a-0967-4044-a4d0-fdd6029898d9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:42.55pt;text-indent:-42.55pt;page-break-after:\navoid\"><span lang=\"EN-GB\">Table 8: Mean (% CV) AUC, C<sub>max</sub> and C<sub>min</sub>\nof saquinavir in patients following multiple dosing of Invirase, saquinavir\nsoft capsules, Invirase/ritonavir, and saquinavir soft capsules/ritonavir</span></p>", "ID": "fabb99f3-790e-4d70-8700-a9d7b896d47e", "Styles": "margin-left:42.55pt;text-indent:-42.55pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Table 8: Mean (% CV) AUC, C<sub>max</sub> and C<sub>min</sub>\nof saquinavir in patients following multiple dosing of Invirase, saquinavir\nsoft capsules, Invirase/ritonavir, and saquinavir soft capsules/ritonavir</span>", "ID": "76e0c855-1e3d-4db4-9a79-d73c8c262092", "Styles": "None", "Classes": "None", "Text": "Table 8: Mean (% CV) AUC, C and C of saquinavir in patients following multiple dosing of Invirase, saquinavir soft capsules, Invirase/ritonavir, and saquinavir soft capsules/ritonavir", "ParentId": "fabb99f3-790e-4d70-8700-a9d7b896d47e"}, {"Element": "<sub>max</sub>", "ID": "b014ad4c-7935-4a7e-b3e8-afb0aefa98a1", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "76e0c855-1e3d-4db4-9a79-d73c8c262092"}, {"Element": "<sub>min</sub>", "ID": "08456285-afa6-4cd0-ab81-585d57fd6b6c", "Styles": "None", "Classes": "None", "Text": "min", "ParentId": "76e0c855-1e3d-4db4-9a79-d73c8c262092"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bac03316-fcce-4276-b421-d4a6108100a9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d79f0772-6530-49c7-883e-86ec9496a0ed", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bac03316-fcce-4276-b421-d4a6108100a9"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Treatment</span></b></p>\n</td>\n<td style=\"width:.4in;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">N</span></b></p>\n</td>\n<td style=\"width:91.7pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">AUC\u03c4 (ng\u00b7h/ml)</span></b></p>\n</td>\n<td style=\"width:63.8pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">AUC<sub>0-24 </sub>(ng\u00b7h/ml)</span></b><sup>\n  \u2020</sup></p>\n</td>\n<td style=\"width:76.55pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">C<sub>max</sub></span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(ng/ml)</span></b></p>\n</td>\n<td style=\"width:77.35pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">C<sub>min</sub></span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(ng/ml)</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase </span>(hard\n  capsule)<span lang=\"EN-GB\"><br/>\n  600\u00a0mg tid</span></p>\n</td>\n<td style=\"width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoEndnoteText\" style=\"text-align:center;line-height:\n  13.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">10</span></p>\n</td>\n<td style=\"width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">866 (62)</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">2,598</span></p>\n</td>\n<td style=\"width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">197 (75)</span></p>\n</td>\n<td style=\"width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">75 (82)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FR-CH\">saquinavir\n  soft capsule</span><span lang=\"FR-CH\"><br/>\n  1200\u00a0mg tid</span></p>\n</td>\n<td style=\"width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31</span></p>\n</td>\n<td style=\"width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7,249 (85)</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">21,747</span></p>\n</td>\n<td style=\"width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">2,181 (74)</span></p>\n</td>\n<td style=\"width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">216 (84)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase </span>(tablet)<br/>\n<span lang=\"EN-GB\">1000\u00a0mg bid plus ritonavir 100\u00a0mg bid*<br/>\n  (fasting condition)</span></p>\n</td>\n<td style=\"width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">22</span></p>\n</td>\n<td style=\"width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">10,320</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(2,530-30,327)</p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">20,640</p>\n</td>\n<td style=\"width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">1,509</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(355-4,101)</span></p>\n</td>\n<td style=\"width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">313</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(70-1,725)<sup> \u2020\u2020</sup></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase </span>(tablet)<br/>\n<span lang=\"EN-GB\">1000\u00a0mg bid plus ritonavir 100\u00a0mg bid*<br/>\n  (high fat meal)</span></p>\n</td>\n<td style=\"width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">22</span></p>\n</td>\n<td style=\"width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">34,926</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(11,826-105,992)</p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">69,852</p>\n</td>\n<td style=\"width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5,208</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(1,536-14,369)</span></p>\n</td>\n<td style=\"width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1,179</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(334-5,176)<sup> \u2020\u2020</sup></p>\n</td>\n</tr>\n</table>", "ID": "c1df7c36-d7a7-40f7-a536-37c0778589d8", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "      ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<tr>\n<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Treatment</span></b></p>\n</td>\n<td style=\"width:.4in;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">N</span></b></p>\n</td>\n<td style=\"width:91.7pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">AUC\u03c4 (ng\u00b7h/ml)</span></b></p>\n</td>\n<td style=\"width:63.8pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">AUC<sub>0-24 </sub>(ng\u00b7h/ml)</span></b><sup>\n  \u2020</sup></p>\n</td>\n<td style=\"width:76.55pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">C<sub>max</sub></span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(ng/ml)</span></b></p>\n</td>\n<td style=\"width:77.35pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">C<sub>min</sub></span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(ng/ml)</span></b></p>\n</td>\n</tr>", "ID": "708d4f2f-c9b6-40e1-887f-62181625fa50", "Styles": "None", "Classes": "None", "Text": "       ", "ParentId": "c1df7c36-d7a7-40f7-a536-37c0778589d8"}, {"Element": "<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Treatment</span></b></p>\n</td>", "ID": "870384f0-b789-4e00-ad01-c9b7ae390338", "Styles": "width:125.9pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "708d4f2f-c9b6-40e1-887f-62181625fa50"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Treatment</span></b></p>", "ID": "a988930e-b63e-4e29-9e24-2ee1f96c986b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "870384f0-b789-4e00-ad01-c9b7ae390338"}, {"Element": "<b><span lang=\"EN-GB\">Treatment</span></b>", "ID": "15ce5dc3-8d07-4f44-ad8b-227034ec69c0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a988930e-b63e-4e29-9e24-2ee1f96c986b"}, {"Element": "<span lang=\"EN-GB\">Treatment</span>", "ID": "e9c0aeb2-5a65-4db6-a6c9-a8ef4f31d5f7", "Styles": "None", "Classes": "None", "Text": "Treatment", "ParentId": "15ce5dc3-8d07-4f44-ad8b-227034ec69c0"}, {"Element": "<td style=\"width:.4in;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">N</span></b></p>\n</td>", "ID": "de816eb1-621e-499b-a960-504b2c5fcb55", "Styles": "width:.4in;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "708d4f2f-c9b6-40e1-887f-62181625fa50"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">N</span></b></p>", "ID": "a5b9d77a-e310-4e67-bbfc-c92bbf613e15", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "de816eb1-621e-499b-a960-504b2c5fcb55"}, {"Element": "<b><span lang=\"EN-GB\">N</span></b>", "ID": "aaf4af5f-2f86-41a2-8ad6-1aeed07704e3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a5b9d77a-e310-4e67-bbfc-c92bbf613e15"}, {"Element": "<span lang=\"EN-GB\">N</span>", "ID": "df78fdc2-2505-4f2f-9490-519392669490", "Styles": "None", "Classes": "None", "Text": "N", "ParentId": "aaf4af5f-2f86-41a2-8ad6-1aeed07704e3"}, {"Element": "<td style=\"width:91.7pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">AUC\u03c4 (ng\u00b7h/ml)</span></b></p>\n</td>", "ID": "b96607f0-4ece-4a69-850c-515db2a45aed", "Styles": "width:91.7pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "708d4f2f-c9b6-40e1-887f-62181625fa50"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">AUC\u03c4 (ng\u00b7h/ml)</span></b></p>", "ID": "13d5d809-3e3a-45a1-a126-db9fdf7ccace", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b96607f0-4ece-4a69-850c-515db2a45aed"}, {"Element": "<b><span lang=\"EN-GB\">AUC\u03c4 (ng\u00b7h/ml)</span></b>", "ID": "4234c659-8f73-4741-8c64-7f9399c936c0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "13d5d809-3e3a-45a1-a126-db9fdf7ccace"}, {"Element": "<span lang=\"EN-GB\">AUC\u03c4 (ng\u00b7h/ml)</span>", "ID": "7b0ff9dc-db22-4178-9d20-72fcfaac9c5b", "Styles": "None", "Classes": "None", "Text": "AUC\u03c4 (ng\u00b7h/ml)", "ParentId": "4234c659-8f73-4741-8c64-7f9399c936c0"}, {"Element": "<td style=\"width:63.8pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">AUC<sub>0-24 </sub>(ng\u00b7h/ml)</span></b><sup>\n  \u2020</sup></p>\n</td>", "ID": "d70c34eb-5b4a-459c-a635-d3b606f0cd63", "Styles": "width:63.8pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "708d4f2f-c9b6-40e1-887f-62181625fa50"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">AUC<sub>0-24 </sub>(ng\u00b7h/ml)</span></b><sup>\n  \u2020</sup></p>", "ID": "28a3a3e6-553b-4818-933c-da57deddcc0f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d70c34eb-5b4a-459c-a635-d3b606f0cd63"}, {"Element": "<b><span lang=\"EN-GB\">AUC<sub>0-24 </sub>(ng\u00b7h/ml)</span></b>", "ID": "33d527a0-e037-407b-8e3b-518aa189de75", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "28a3a3e6-553b-4818-933c-da57deddcc0f"}, {"Element": "<span lang=\"EN-GB\">AUC<sub>0-24 </sub>(ng\u00b7h/ml)</span>", "ID": "e86eb787-928f-4710-b6f0-08fcf8676544", "Styles": "None", "Classes": "None", "Text": "AUC(ng\u00b7h/ml)", "ParentId": "33d527a0-e037-407b-8e3b-518aa189de75"}, {"Element": "<sub>0-24 </sub>", "ID": "ae52a980-e56d-40b5-a0c0-16c8a8c6701c", "Styles": "None", "Classes": "None", "Text": "0-24 ", "ParentId": "e86eb787-928f-4710-b6f0-08fcf8676544"}, {"Element": "<sup>\n  \u2020</sup>", "ID": "46bee06f-01c2-4050-90cd-996c3667224a", "Styles": "None", "Classes": "None", "Text": "   \u2020", "ParentId": "28a3a3e6-553b-4818-933c-da57deddcc0f"}, {"Element": "<td style=\"width:76.55pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">C<sub>max</sub></span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(ng/ml)</span></b></p>\n</td>", "ID": "a56187b6-7cc6-4e52-a15d-c304fb977984", "Styles": "width:76.55pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "708d4f2f-c9b6-40e1-887f-62181625fa50"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">C<sub>max</sub></span></b></p>", "ID": "4ff56390-2239-4023-9a29-d32aa4f15f84", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a56187b6-7cc6-4e52-a15d-c304fb977984"}, {"Element": "<b><span lang=\"EN-GB\">C<sub>max</sub></span></b>", "ID": "a5554786-506b-4604-820c-4465ee861afe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4ff56390-2239-4023-9a29-d32aa4f15f84"}, {"Element": "<span lang=\"EN-GB\">C<sub>max</sub></span>", "ID": "e42cb157-3197-468d-aec4-c4f225118098", "Styles": "None", "Classes": "None", "Text": "C", "ParentId": "a5554786-506b-4604-820c-4465ee861afe"}, {"Element": "<sub>max</sub>", "ID": "c526f8f1-7072-4f8d-90af-23d213673452", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "e42cb157-3197-468d-aec4-c4f225118098"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(ng/ml)</span></b></p>", "ID": "74e4843d-59f5-4ae4-8ad4-04fd62beda20", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a56187b6-7cc6-4e52-a15d-c304fb977984"}, {"Element": "<b><span lang=\"EN-GB\">(ng/ml)</span></b>", "ID": "70a014ec-dbd9-46d4-be2f-c8c67bf35a11", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "74e4843d-59f5-4ae4-8ad4-04fd62beda20"}, {"Element": "<span lang=\"EN-GB\">(ng/ml)</span>", "ID": "368b6985-4a91-4161-84e9-08f9af37d8af", "Styles": "None", "Classes": "None", "Text": "(ng/ml)", "ParentId": "70a014ec-dbd9-46d4-be2f-c8c67bf35a11"}, {"Element": "<td style=\"width:77.35pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">C<sub>min</sub></span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(ng/ml)</span></b></p>\n</td>", "ID": "6afe2f50-6f4c-4c5c-baa9-e17f7efe9a65", "Styles": "width:77.35pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "708d4f2f-c9b6-40e1-887f-62181625fa50"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">C<sub>min</sub></span></b></p>", "ID": "ee910bc5-18a1-496a-bcbb-c2a6a68a0425", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6afe2f50-6f4c-4c5c-baa9-e17f7efe9a65"}, {"Element": "<b><span lang=\"EN-GB\">C<sub>min</sub></span></b>", "ID": "c41eb8fe-3e67-4419-a012-d482f30187e5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ee910bc5-18a1-496a-bcbb-c2a6a68a0425"}, {"Element": "<span lang=\"EN-GB\">C<sub>min</sub></span>", "ID": "cd91e69b-4c62-4d82-b7df-25362680413e", "Styles": "None", "Classes": "None", "Text": "C", "ParentId": "c41eb8fe-3e67-4419-a012-d482f30187e5"}, {"Element": "<sub>min</sub>", "ID": "44ed7c37-7022-4763-a340-b07175b15be6", "Styles": "None", "Classes": "None", "Text": "min", "ParentId": "cd91e69b-4c62-4d82-b7df-25362680413e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">(ng/ml)</span></b></p>", "ID": "a8c9876f-2727-49f5-b4e9-420f9992631b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6afe2f50-6f4c-4c5c-baa9-e17f7efe9a65"}, {"Element": "<b><span lang=\"EN-GB\">(ng/ml)</span></b>", "ID": "af3cd0a0-ad78-441c-900c-99c8f41765e0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a8c9876f-2727-49f5-b4e9-420f9992631b"}, {"Element": "<span lang=\"EN-GB\">(ng/ml)</span>", "ID": "1a9c1303-159f-434c-ba7c-0d78a602e094", "Styles": "None", "Classes": "None", "Text": "(ng/ml)", "ParentId": "af3cd0a0-ad78-441c-900c-99c8f41765e0"}, {"Element": "<tr>\n<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase </span>(hard\n  capsule)<span lang=\"EN-GB\"><br/>\n  600\u00a0mg tid</span></p>\n</td>\n<td style=\"width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoEndnoteText\" style=\"text-align:center;line-height:\n  13.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">10</span></p>\n</td>\n<td style=\"width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">866 (62)</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">2,598</span></p>\n</td>\n<td style=\"width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">197 (75)</span></p>\n</td>\n<td style=\"width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">75 (82)</span></p>\n</td>\n</tr>", "ID": "30aa442d-567b-4aac-b1f9-290565b0a0fd", "Styles": "None", "Classes": "None", "Text": "       ", "ParentId": "c1df7c36-d7a7-40f7-a536-37c0778589d8"}, {"Element": "<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase </span>(hard\n  capsule)<span lang=\"EN-GB\"><br/>\n  600\u00a0mg tid</span></p>\n</td>", "ID": "ff228951-e19b-467b-9761-bf8b0e54e98b", "Styles": "width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "30aa442d-567b-4aac-b1f9-290565b0a0fd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase </span>(hard\n  capsule)<span lang=\"EN-GB\"><br/>\n  600\u00a0mg tid</span></p>", "ID": "277c907b-67ea-4c02-bc37-614f0fb8b7b9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "(hard   capsule)", "ParentId": "ff228951-e19b-467b-9761-bf8b0e54e98b"}, {"Element": "<span lang=\"EN-GB\">Invirase </span>", "ID": "aa897868-3fad-4ead-ada2-02014d184ab9", "Styles": "None", "Classes": "None", "Text": "Invirase ", "ParentId": "277c907b-67ea-4c02-bc37-614f0fb8b7b9"}, {"Element": "<span lang=\"EN-GB\"><br/>\n  600\u00a0mg tid</span>", "ID": "b2a8b174-05ba-416f-a597-83237611fc5e", "Styles": "None", "Classes": "None", "Text": "   600\u00a0mg tid", "ParentId": "277c907b-67ea-4c02-bc37-614f0fb8b7b9"}, {"Element": "<br/>", "ID": "3ee753f3-2710-4c51-afdc-7ba9c75a05e9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b2a8b174-05ba-416f-a597-83237611fc5e"}, {"Element": "<td style=\"width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoEndnoteText\" style=\"text-align:center;line-height:\n  13.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">10</span></p>\n</td>", "ID": "f2e1e199-4489-4d7a-a76a-fe4dbb42b43a", "Styles": "width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "30aa442d-567b-4aac-b1f9-290565b0a0fd"}, {"Element": "<p align=\"center\" class=\"MsoEndnoteText\" style=\"text-align:center;line-height:\n  13.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">10</span></p>", "ID": "3cfc6598-fbde-46a4-b160-0b5b779182f0", "Styles": "text-align:center;line-height:\n  13.0pt;page-break-after:avoid", "Classes": "['MsoEndnoteText']", "Text": "", "ParentId": "f2e1e199-4489-4d7a-a76a-fe4dbb42b43a"}, {"Element": "<span lang=\"EN-GB\">10</span>", "ID": "6bd0c983-de63-4751-b6f3-86cda05e1ab5", "Styles": "None", "Classes": "None", "Text": "10", "ParentId": "3cfc6598-fbde-46a4-b160-0b5b779182f0"}, {"Element": "<td style=\"width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">866 (62)</span></p>\n</td>", "ID": "39350060-78c7-46e7-8949-3fa132aed00a", "Styles": "width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "30aa442d-567b-4aac-b1f9-290565b0a0fd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">866 (62)</span></p>", "ID": "f6fc9a07-c2a5-4ac3-8782-177e10dfdb9c", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "39350060-78c7-46e7-8949-3fa132aed00a"}, {"Element": "<span lang=\"EN-GB\">866 (62)</span>", "ID": "14351f55-b16b-404a-b4b8-2c2f08e9c0b6", "Styles": "None", "Classes": "None", "Text": "866 (62)", "ParentId": "f6fc9a07-c2a5-4ac3-8782-177e10dfdb9c"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">2,598</span></p>\n</td>", "ID": "fb3c1514-2063-4a3e-b9f5-c16092067321", "Styles": "width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "30aa442d-567b-4aac-b1f9-290565b0a0fd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">2,598</span></p>", "ID": "0cb84852-79cf-4a27-bc7e-3293a1e5019e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fb3c1514-2063-4a3e-b9f5-c16092067321"}, {"Element": "<span lang=\"EN-GB\">2,598</span>", "ID": "b830ee89-579f-4b33-ab87-8dde70a190ad", "Styles": "None", "Classes": "None", "Text": "2,598", "ParentId": "0cb84852-79cf-4a27-bc7e-3293a1e5019e"}, {"Element": "<td style=\"width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">197 (75)</span></p>\n</td>", "ID": "c9f08d24-b067-444a-a1c9-86fd8fc11561", "Styles": "width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "30aa442d-567b-4aac-b1f9-290565b0a0fd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">197 (75)</span></p>", "ID": "3bb8342f-b7a8-4b25-9af2-1597593a831b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c9f08d24-b067-444a-a1c9-86fd8fc11561"}, {"Element": "<span lang=\"EN-GB\">197 (75)</span>", "ID": "b3b7a1a4-c1f7-4a6e-8244-14d0c09207e3", "Styles": "None", "Classes": "None", "Text": "197 (75)", "ParentId": "3bb8342f-b7a8-4b25-9af2-1597593a831b"}, {"Element": "<td style=\"width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">75 (82)</span></p>\n</td>", "ID": "7f882f69-6ca7-469c-8103-65507a29624e", "Styles": "width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "30aa442d-567b-4aac-b1f9-290565b0a0fd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">75 (82)</span></p>", "ID": "9be50464-2810-492c-8670-cdd1c45b0185", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7f882f69-6ca7-469c-8103-65507a29624e"}, {"Element": "<span lang=\"EN-GB\">75 (82)</span>", "ID": "959a87cc-9bc7-4614-ba13-a532447110e7", "Styles": "None", "Classes": "None", "Text": "75 (82)", "ParentId": "9be50464-2810-492c-8670-cdd1c45b0185"}, {"Element": "<tr>\n<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FR-CH\">saquinavir\n  soft capsule</span><span lang=\"FR-CH\"><br/>\n  1200\u00a0mg tid</span></p>\n</td>\n<td style=\"width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31</span></p>\n</td>\n<td style=\"width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7,249 (85)</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">21,747</span></p>\n</td>\n<td style=\"width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">2,181 (74)</span></p>\n</td>\n<td style=\"width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">216 (84)</span></p>\n</td>\n</tr>", "ID": "b65ded70-b38c-4812-9aca-850cb7db7a7c", "Styles": "None", "Classes": "None", "Text": "       ", "ParentId": "c1df7c36-d7a7-40f7-a536-37c0778589d8"}, {"Element": "<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FR-CH\">saquinavir\n  soft capsule</span><span lang=\"FR-CH\"><br/>\n  1200\u00a0mg tid</span></p>\n</td>", "ID": "ce441259-a822-4a71-9853-b88e3ac4a155", "Styles": "width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b65ded70-b38c-4812-9aca-850cb7db7a7c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FR-CH\">saquinavir\n  soft capsule</span><span lang=\"FR-CH\"><br/>\n  1200\u00a0mg tid</span></p>", "ID": "62224f26-7ca5-4356-968d-b667b600eea9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ce441259-a822-4a71-9853-b88e3ac4a155"}, {"Element": "<span lang=\"FR-CH\">saquinavir\n  soft capsule</span>", "ID": "5e4a0814-8116-421a-b6c0-21e032409ed6", "Styles": "None", "Classes": "None", "Text": "saquinavir   soft capsule", "ParentId": "62224f26-7ca5-4356-968d-b667b600eea9"}, {"Element": "<span lang=\"FR-CH\"><br/>\n  1200\u00a0mg tid</span>", "ID": "0e92382b-6998-4ac1-b964-546fefc4874c", "Styles": "None", "Classes": "None", "Text": "   1200\u00a0mg tid", "ParentId": "62224f26-7ca5-4356-968d-b667b600eea9"}, {"Element": "<br/>", "ID": "30c04585-838e-4877-826f-04b1d3d7a176", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0e92382b-6998-4ac1-b964-546fefc4874c"}, {"Element": "<td style=\"width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31</span></p>\n</td>", "ID": "aee0c1bc-240f-4875-9998-907f6b055256", "Styles": "width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b65ded70-b38c-4812-9aca-850cb7db7a7c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">31</span></p>", "ID": "67de7830-93a6-4f67-8740-f1389ca7608a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aee0c1bc-240f-4875-9998-907f6b055256"}, {"Element": "<span lang=\"EN-GB\">31</span>", "ID": "c71cbbcf-4421-4638-b5a6-95743096cfd4", "Styles": "None", "Classes": "None", "Text": "31", "ParentId": "67de7830-93a6-4f67-8740-f1389ca7608a"}, {"Element": "<td style=\"width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7,249 (85)</span></p>\n</td>", "ID": "937a677c-1304-43ad-86b8-f0197a0efff9", "Styles": "width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b65ded70-b38c-4812-9aca-850cb7db7a7c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">7,249 (85)</span></p>", "ID": "f7ac9e0d-62d5-4996-8493-09d70a83d404", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "937a677c-1304-43ad-86b8-f0197a0efff9"}, {"Element": "<span lang=\"EN-GB\">7,249 (85)</span>", "ID": "1d715e76-e159-4cd6-8722-5be9b169b93a", "Styles": "None", "Classes": "None", "Text": "7,249 (85)", "ParentId": "f7ac9e0d-62d5-4996-8493-09d70a83d404"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">21,747</span></p>\n</td>", "ID": "45a5c1c2-8aec-4e8c-8388-7f758854e78b", "Styles": "width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b65ded70-b38c-4812-9aca-850cb7db7a7c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">21,747</span></p>", "ID": "f96e6eb7-3484-4315-ba9b-ff119ee36c89", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "45a5c1c2-8aec-4e8c-8388-7f758854e78b"}, {"Element": "<span lang=\"EN-GB\">21,747</span>", "ID": "559e8c3f-930d-4e70-8c0f-2f612b224d06", "Styles": "None", "Classes": "None", "Text": "21,747", "ParentId": "f96e6eb7-3484-4315-ba9b-ff119ee36c89"}, {"Element": "<td style=\"width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">2,181 (74)</span></p>\n</td>", "ID": "e6c9ec64-e19c-4830-a0f5-597c681186dd", "Styles": "width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b65ded70-b38c-4812-9aca-850cb7db7a7c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">2,181 (74)</span></p>", "ID": "798a4214-50f8-430c-9367-6c80a86b9db2", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e6c9ec64-e19c-4830-a0f5-597c681186dd"}, {"Element": "<span lang=\"EN-GB\">2,181 (74)</span>", "ID": "235837d6-998f-4fbc-adb3-948492867953", "Styles": "None", "Classes": "None", "Text": "2,181 (74)", "ParentId": "798a4214-50f8-430c-9367-6c80a86b9db2"}, {"Element": "<td style=\"width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">216 (84)</span></p>\n</td>", "ID": "788d3bbd-e2ad-413e-9604-7928deb40df6", "Styles": "width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b65ded70-b38c-4812-9aca-850cb7db7a7c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">216 (84)</span></p>", "ID": "8ef8a5d8-c0ea-48a4-8d73-5f4bb9ee8618", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "788d3bbd-e2ad-413e-9604-7928deb40df6"}, {"Element": "<span lang=\"EN-GB\">216 (84)</span>", "ID": "e5a421ad-5da7-43b3-b62d-661e60a69bd5", "Styles": "None", "Classes": "None", "Text": "216 (84)", "ParentId": "8ef8a5d8-c0ea-48a4-8d73-5f4bb9ee8618"}, {"Element": "<tr>\n<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase </span>(tablet)<br/>\n<span lang=\"EN-GB\">1000\u00a0mg bid plus ritonavir 100\u00a0mg bid*<br/>\n  (fasting condition)</span></p>\n</td>\n<td style=\"width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">22</span></p>\n</td>\n<td style=\"width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">10,320</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(2,530-30,327)</p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">20,640</p>\n</td>\n<td style=\"width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">1,509</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(355-4,101)</span></p>\n</td>\n<td style=\"width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">313</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(70-1,725)<sup> \u2020\u2020</sup></p>\n</td>\n</tr>", "ID": "537db23f-2e1d-474f-9736-216d1bf7b76c", "Styles": "None", "Classes": "None", "Text": "       ", "ParentId": "c1df7c36-d7a7-40f7-a536-37c0778589d8"}, {"Element": "<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase </span>(tablet)<br/>\n<span lang=\"EN-GB\">1000\u00a0mg bid plus ritonavir 100\u00a0mg bid*<br/>\n  (fasting condition)</span></p>\n</td>", "ID": "edc367e5-311c-48f5-b596-56d6f51dd63b", "Styles": "width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "537db23f-2e1d-474f-9736-216d1bf7b76c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase </span>(tablet)<br/>\n<span lang=\"EN-GB\">1000\u00a0mg bid plus ritonavir 100\u00a0mg bid*<br/>\n  (fasting condition)</span></p>", "ID": "54cb687b-193f-4123-ad18-9f7d327108cc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "(tablet) ", "ParentId": "edc367e5-311c-48f5-b596-56d6f51dd63b"}, {"Element": "<span lang=\"EN-GB\">Invirase </span>", "ID": "f1dd9217-e64d-49bf-a506-e631d8916d13", "Styles": "None", "Classes": "None", "Text": "Invirase ", "ParentId": "54cb687b-193f-4123-ad18-9f7d327108cc"}, {"Element": "<br/>", "ID": "5f8ba557-5381-4e91-8531-23a237b46c8e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "54cb687b-193f-4123-ad18-9f7d327108cc"}, {"Element": "<span lang=\"EN-GB\">1000\u00a0mg bid plus ritonavir 100\u00a0mg bid*<br/>\n  (fasting condition)</span>", "ID": "b1d20a0c-1dc9-4b8e-9acf-925db157f1bd", "Styles": "None", "Classes": "None", "Text": "1000\u00a0mg bid plus ritonavir 100\u00a0mg bid*   (fasting condition)", "ParentId": "54cb687b-193f-4123-ad18-9f7d327108cc"}, {"Element": "<br/>", "ID": "f05ba32b-3269-4759-ab65-c55dd1f80ff7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b1d20a0c-1dc9-4b8e-9acf-925db157f1bd"}, {"Element": "<td style=\"width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">22</span></p>\n</td>", "ID": "70cf73f1-eba1-4f85-aeae-c08128f4303b", "Styles": "width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "537db23f-2e1d-474f-9736-216d1bf7b76c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">22</span></p>", "ID": "7d73fd40-3a1f-48c7-8597-84d3964d2dc7", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "70cf73f1-eba1-4f85-aeae-c08128f4303b"}, {"Element": "<span lang=\"EN-GB\">22</span>", "ID": "e9ddc8a2-ea80-4ba3-b40a-47e8823fe1c2", "Styles": "None", "Classes": "None", "Text": "22", "ParentId": "7d73fd40-3a1f-48c7-8597-84d3964d2dc7"}, {"Element": "<td style=\"width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">10,320</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(2,530-30,327)</p>\n</td>", "ID": "172834ce-4dfe-4a99-b0e4-c35a41babfef", "Styles": "width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "537db23f-2e1d-474f-9736-216d1bf7b76c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">10,320</p>", "ID": "ff4305b6-fa3e-42b1-9b55-08bcb3ef951f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "10,320", "ParentId": "172834ce-4dfe-4a99-b0e4-c35a41babfef"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(2,530-30,327)</p>", "ID": "acbdc01c-3c74-4681-8eeb-59088ca232fa", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "(2,530-30,327)", "ParentId": "172834ce-4dfe-4a99-b0e4-c35a41babfef"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">20,640</p>\n</td>", "ID": "7ce1551f-9867-4c0d-8958-c2c03e707bec", "Styles": "width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "537db23f-2e1d-474f-9736-216d1bf7b76c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">20,640</p>", "ID": "383a3f4f-89d4-4f1b-80cd-011fabc49f38", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "20,640", "ParentId": "7ce1551f-9867-4c0d-8958-c2c03e707bec"}, {"Element": "<td style=\"width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">1,509</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(355-4,101)</span></p>\n</td>", "ID": "a0f3b486-ef5e-4d23-835d-656115ae0217", "Styles": "width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "537db23f-2e1d-474f-9736-216d1bf7b76c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">1,509</span></p>", "ID": "dc33ad1f-5c84-4f09-a5e3-e9e9df0bc584", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a0f3b486-ef5e-4d23-835d-656115ae0217"}, {"Element": "<span lang=\"EN-GB\">1,509</span>", "ID": "e0352550-4120-42cf-b4e9-b89544016ad8", "Styles": "None", "Classes": "None", "Text": "1,509", "ParentId": "dc33ad1f-5c84-4f09-a5e3-e9e9df0bc584"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(355-4,101)</span></p>", "ID": "75efbd7f-2b2a-4abb-b4db-d4f5705539a4", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a0f3b486-ef5e-4d23-835d-656115ae0217"}, {"Element": "<span lang=\"EN-GB\">(355-4,101)</span>", "ID": "444e3d21-e3ee-4cd1-ae17-86bf50cde0b8", "Styles": "None", "Classes": "None", "Text": "(355-4,101)", "ParentId": "75efbd7f-2b2a-4abb-b4db-d4f5705539a4"}, {"Element": "<td style=\"width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">313</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(70-1,725)<sup> \u2020\u2020</sup></p>\n</td>", "ID": "7e4d7228-93e1-4bcc-afa0-343c96a66160", "Styles": "width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "537db23f-2e1d-474f-9736-216d1bf7b76c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">313</p>", "ID": "07acb1a8-7d65-43c7-8ada-bbcd3de5cd01", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "313", "ParentId": "7e4d7228-93e1-4bcc-afa0-343c96a66160"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(70-1,725)<sup> \u2020\u2020</sup></p>", "ID": "0cfe150d-5851-49ec-913b-bbd264e7f840", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "(70-1,725)", "ParentId": "7e4d7228-93e1-4bcc-afa0-343c96a66160"}, {"Element": "<sup> \u2020\u2020</sup>", "ID": "bb2de1ee-1b08-4953-9ad5-e42e31786a2a", "Styles": "None", "Classes": "None", "Text": " \u2020\u2020", "ParentId": "0cfe150d-5851-49ec-913b-bbd264e7f840"}, {"Element": "<tr>\n<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase </span>(tablet)<br/>\n<span lang=\"EN-GB\">1000\u00a0mg bid plus ritonavir 100\u00a0mg bid*<br/>\n  (high fat meal)</span></p>\n</td>\n<td style=\"width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">22</span></p>\n</td>\n<td style=\"width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">34,926</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(11,826-105,992)</p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">69,852</p>\n</td>\n<td style=\"width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5,208</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(1,536-14,369)</span></p>\n</td>\n<td style=\"width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1,179</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(334-5,176)<sup> \u2020\u2020</sup></p>\n</td>\n</tr>", "ID": "16ae6e12-de13-47eb-a15b-4397afe23e14", "Styles": "None", "Classes": "None", "Text": "       ", "ParentId": "c1df7c36-d7a7-40f7-a536-37c0778589d8"}, {"Element": "<td style=\"width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase </span>(tablet)<br/>\n<span lang=\"EN-GB\">1000\u00a0mg bid plus ritonavir 100\u00a0mg bid*<br/>\n  (high fat meal)</span></p>\n</td>", "ID": "ca701cad-b322-4499-9c8e-9e9a613194c1", "Styles": "width:125.9pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "16ae6e12-de13-47eb-a15b-4397afe23e14"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Invirase </span>(tablet)<br/>\n<span lang=\"EN-GB\">1000\u00a0mg bid plus ritonavir 100\u00a0mg bid*<br/>\n  (high fat meal)</span></p>", "ID": "d9b08277-efdf-49b9-8100-62ac8f9f47f3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "(tablet) ", "ParentId": "ca701cad-b322-4499-9c8e-9e9a613194c1"}, {"Element": "<span lang=\"EN-GB\">Invirase </span>", "ID": "a8b576df-ff97-4d1b-ae49-c4ea47c30ee0", "Styles": "None", "Classes": "None", "Text": "Invirase ", "ParentId": "d9b08277-efdf-49b9-8100-62ac8f9f47f3"}, {"Element": "<br/>", "ID": "90d58fbc-c473-49f6-912e-636e1550bc83", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d9b08277-efdf-49b9-8100-62ac8f9f47f3"}, {"Element": "<span lang=\"EN-GB\">1000\u00a0mg bid plus ritonavir 100\u00a0mg bid*<br/>\n  (high fat meal)</span>", "ID": "880d8113-9ef8-42b8-bfdf-1ab66756f27e", "Styles": "None", "Classes": "None", "Text": "1000\u00a0mg bid plus ritonavir 100\u00a0mg bid*   (high fat meal)", "ParentId": "d9b08277-efdf-49b9-8100-62ac8f9f47f3"}, {"Element": "<br/>", "ID": "2fa8d84b-60cd-4153-8b1c-eb5b9fad738c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "880d8113-9ef8-42b8-bfdf-1ab66756f27e"}, {"Element": "<td style=\"width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">22</span></p>\n</td>", "ID": "25a214fa-53f2-490d-877d-9e8def9547bf", "Styles": "width:.4in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "16ae6e12-de13-47eb-a15b-4397afe23e14"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">22</span></p>", "ID": "e12cf681-c625-49c9-9690-e7eb8cfb27d0", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "25a214fa-53f2-490d-877d-9e8def9547bf"}, {"Element": "<span lang=\"EN-GB\">22</span>", "ID": "8cd5ec83-2d0c-47de-85c7-5ceabb75d924", "Styles": "None", "Classes": "None", "Text": "22", "ParentId": "e12cf681-c625-49c9-9690-e7eb8cfb27d0"}, {"Element": "<td style=\"width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"122\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">34,926</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(11,826-105,992)</p>\n</td>", "ID": "7eb02ebe-389c-4896-8c1d-d3097b67c634", "Styles": "width:91.7pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "16ae6e12-de13-47eb-a15b-4397afe23e14"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">34,926</p>", "ID": "14316f29-aa54-484b-8f2b-8e7a0a33ae8d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "34,926", "ParentId": "7eb02ebe-389c-4896-8c1d-d3097b67c634"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(11,826-105,992)</p>", "ID": "a84027e4-5bc0-4fb6-a9cd-b58ee1965f25", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "(11,826-105,992)", "ParentId": "7eb02ebe-389c-4896-8c1d-d3097b67c634"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">69,852</p>\n</td>", "ID": "d4953db2-826a-4ea3-b3c5-0dbe57381537", "Styles": "width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "16ae6e12-de13-47eb-a15b-4397afe23e14"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">69,852</p>", "ID": "2c235ff6-08e4-4150-b5fa-fae3fa36f8ab", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "69,852", "ParentId": "d4953db2-826a-4ea3-b3c5-0dbe57381537"}, {"Element": "<td style=\"width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5,208</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(1,536-14,369)</span></p>\n</td>", "ID": "5938562e-d365-44c9-8c10-8079e102a47c", "Styles": "width:76.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "16ae6e12-de13-47eb-a15b-4397afe23e14"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5,208</span></p>", "ID": "730fe2d7-7172-4596-88d4-12aee75a5d3f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5938562e-d365-44c9-8c10-8079e102a47c"}, {"Element": "<span lang=\"EN-GB\">5,208</span>", "ID": "55a143e4-4132-428a-958e-680a1f154066", "Styles": "None", "Classes": "None", "Text": "5,208", "ParentId": "730fe2d7-7172-4596-88d4-12aee75a5d3f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(1,536-14,369)</span></p>", "ID": "0bf65075-e0e8-4d54-868a-e4bf1255bb47", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5938562e-d365-44c9-8c10-8079e102a47c"}, {"Element": "<span lang=\"EN-GB\">(1,536-14,369)</span>", "ID": "856f777c-d170-4d9f-9fbc-e15801a5f330", "Styles": "None", "Classes": "None", "Text": "(1,536-14,369)", "ParentId": "0bf65075-e0e8-4d54-868a-e4bf1255bb47"}, {"Element": "<td style=\"width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1,179</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(334-5,176)<sup> \u2020\u2020</sup></p>\n</td>", "ID": "7268b0ad-4dea-406e-87dd-b45a48b594f4", "Styles": "width:77.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "16ae6e12-de13-47eb-a15b-4397afe23e14"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1,179</p>", "ID": "0a591b1e-d1c6-4d66-a152-9ae343723ddf", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "1,179", "ParentId": "7268b0ad-4dea-406e-87dd-b45a48b594f4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">(334-5,176)<sup> \u2020\u2020</sup></p>", "ID": "fd338be5-8dba-4993-9e62-d2357d67147d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "(334-5,176)", "ParentId": "7268b0ad-4dea-406e-87dd-b45a48b594f4"}, {"Element": "<sup> \u2020\u2020</sup>", "ID": "e4f455d8-f12b-4c7b-b139-e437d1344841", "Styles": "None", "Classes": "None", "Text": " \u2020\u2020", "ParentId": "fd338be5-8dba-4993-9e62-d2357d67147d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u03c4 =\ndosing interval, i.e. 8 hour for tid and 12 h for bid dosing.</span></p>", "ID": "89a85d3f-b6bb-4dd3-a62a-0bc38f7663f7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u03c4 =\ndosing interval, i.e. 8 hour for tid and 12 h for bid dosing.</span>", "ID": "0e7e9cbc-5fe3-45c4-b562-ab541574522d", "Styles": "None", "Classes": "None", "Text": "\u03c4 = dosing interval, i.e. 8 hour for tid and 12 h for bid dosing.", "ParentId": "89a85d3f-b6bb-4dd3-a62a-0bc38f7663f7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">C</span><sub><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>min</span></sub><span lang=\"EN-GB\">\n= the observed plasma concentration at the end of the dose interval.</span></p>", "ID": "9c082277-e101-4aa4-88fc-18f64a480402", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">C</span>", "ID": "37b1723e-990c-40c7-8181-90f141017e82", "Styles": "None", "Classes": "None", "Text": "C", "ParentId": "9c082277-e101-4aa4-88fc-18f64a480402"}, {"Element": "<sub><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>min</span></sub>", "ID": "f636428e-2599-4c98-b7b5-ded7702601a5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9c082277-e101-4aa4-88fc-18f64a480402"}, {"Element": "<span lang=\"EN-GB\" style='font-family:\"Times\",serif'>min</span>", "ID": "ed466ca9-f569-4e3b-9b91-333ab649818b", "Styles": "font-family:\"Times\",serif", "Classes": "None", "Text": "min", "ParentId": "f636428e-2599-4c98-b7b5-ded7702601a5"}, {"Element": "<span lang=\"EN-GB\">\n= the observed plasma concentration at the end of the dose interval.</span>", "ID": "331e2150-6284-47aa-808d-037db004b642", "Styles": "None", "Classes": "None", "Text": " = the observed plasma concentration at the end of the dose interval.", "ParentId": "9c082277-e101-4aa4-88fc-18f64a480402"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">bid = twice\ndaily</span></p>", "ID": "8bda0911-3cfb-41a7-9223-65ef12b996a3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">bid = twice\ndaily</span>", "ID": "3954eff2-ac47-45cb-83df-a8347bc9048f", "Styles": "None", "Classes": "None", "Text": "bid = twice daily", "ParentId": "8bda0911-3cfb-41a7-9223-65ef12b996a3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">tid = three\ntimes daily</span></p>", "ID": "f2cb8f4a-15e4-4a0a-9f20-edb3e6c07fbc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">tid = three\ntimes daily</span>", "ID": "28d1b758-b5c5-4b0d-957d-b56c282aa76b", "Styles": "None", "Classes": "None", "Text": "tid = three times daily", "ParentId": "f2cb8f4a-15e4-4a0a-9f20-edb3e6c07fbc"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">* results\nare geometric mean (min - max) </span></p>", "ID": "ab04e4fa-8f4e-43dc-8701-778d5a7fa34c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">* results\nare geometric mean (min - max) </span>", "ID": "3fbef3b9-a9a0-4039-bbcd-1789e4380b9a", "Styles": "None", "Classes": "None", "Text": "* results are geometric mean (min - max) ", "ParentId": "ab04e4fa-8f4e-43dc-8701-778d5a7fa34c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup>\u2020 </sup><span lang=\"EN-GB\">derived from tid or bid dosing schedule</span></p>", "ID": "d7dda877-7de6-4fd0-a412-faf401200226", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<sup>\u2020 </sup>", "ID": "095f29d7-5736-4e47-b402-1e1989b743c0", "Styles": "None", "Classes": "None", "Text": "\u2020 ", "ParentId": "d7dda877-7de6-4fd0-a412-faf401200226"}, {"Element": "<span lang=\"EN-GB\">derived from tid or bid dosing schedule</span>", "ID": "c5d74dd2-e102-4a34-8e1b-6b4766574268", "Styles": "None", "Classes": "None", "Text": "derived from tid or bid dosing schedule", "ParentId": "d7dda877-7de6-4fd0-a412-faf401200226"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup>\u2020\u2020 </sup><span lang=\"EN-GB\">C<sub>trough</sub></span><span lang=\"EN-GB\"> values</span></p>", "ID": "c110ee8b-461d-4f99-87e5-b34228d05b3c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<sup>\u2020\u2020 </sup>", "ID": "22510ed4-5eb6-4cdf-862e-32133e40b415", "Styles": "None", "Classes": "None", "Text": "\u2020\u2020 ", "ParentId": "c110ee8b-461d-4f99-87e5-b34228d05b3c"}, {"Element": "<span lang=\"EN-GB\">C<sub>trough</sub></span>", "ID": "5384ef97-596a-4cb6-b998-e0ff1761578c", "Styles": "None", "Classes": "None", "Text": "C", "ParentId": "c110ee8b-461d-4f99-87e5-b34228d05b3c"}, {"Element": "<sub>trough</sub>", "ID": "76945c1e-0cfc-4ef5-aae5-ee3d2d3c18a6", "Styles": "None", "Classes": "None", "Text": "trough", "ParentId": "5384ef97-596a-4cb6-b998-e0ff1761578c"}, {"Element": "<span lang=\"EN-GB\"> values</span>", "ID": "fa5f9b2b-57fb-47c5-b1fa-5dc769824485", "Styles": "None", "Classes": "None", "Text": " values", "ParentId": "c110ee8b-461d-4f99-87e5-b34228d05b3c"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8f9f3351-bfb3-4686-8d5a-f282a940b005", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Absolute bioavailability averaged 4\u00a0%\n(CV 73\u00a0%, range: 1\u00a0% to 9\u00a0%) in 8 healthy volunteers who\nreceived a single 600\u00a0mg dose (3 x 200\u00a0mg</span> hard capsule<span lang=\"EN-GB\">) of Invirase following a heavy breakfast. The low bioavailability\nis thought to be due to a combination of incomplete absorption and extensive\nfirst-pass metabolism. Gastric pH has been shown to be only a minor component\nin the large increase in bioavailability seen when given with food. The\nabsolute bioavailability of saquinavir co-administered with ritonavir has not\nbeen established in humans.</span></p>", "ID": "d36a41d4-9590-4e1f-9d4a-a5599e2478bc", "Styles": "None", "Classes": "['MsoNormal']", "Text": " hard capsule", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Absolute bioavailability averaged 4\u00a0%\n(CV 73\u00a0%, range: 1\u00a0% to 9\u00a0%) in 8 healthy volunteers who\nreceived a single 600\u00a0mg dose (3 x 200\u00a0mg</span>", "ID": "8b606980-1bf5-4a8d-be2f-c732f70de0ab", "Styles": "None", "Classes": "None", "Text": "Absolute bioavailability averaged 4\u00a0% (CV 73\u00a0%, range: 1\u00a0% to 9\u00a0%) in 8 healthy volunteers who received a single 600\u00a0mg dose (3 x 200\u00a0mg", "ParentId": "d36a41d4-9590-4e1f-9d4a-a5599e2478bc"}, {"Element": "<span lang=\"EN-GB\">) of Invirase following a heavy breakfast. The low bioavailability\nis thought to be due to a combination of incomplete absorption and extensive\nfirst-pass metabolism. Gastric pH has been shown to be only a minor component\nin the large increase in bioavailability seen when given with food. The\nabsolute bioavailability of saquinavir co-administered with ritonavir has not\nbeen established in humans.</span>", "ID": "41a42cce-f8aa-46d5-bcd6-9e933dfaf86d", "Styles": "None", "Classes": "None", "Text": ") of Invirase following a heavy breakfast. The low bioavailability is thought to be due to a combination of incomplete absorption and extensive first-pass metabolism. Gastric pH has been shown to be only a minor component in the large increase in bioavailability seen when given with food. The absolute bioavailability of saquinavir co-administered with ritonavir has not been established in humans.", "ParentId": "d36a41d4-9590-4e1f-9d4a-a5599e2478bc"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "6ca973d0-b5b3-41c1-a5ff-ce37cbd2cd07", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In combination with ritonavir,\nbioequivalence of Invirase hard capsules and film-coated tablets was\ndemonstrated under fed conditions.</span></p>", "ID": "6e6fdf06-5b8b-4232-b490-85799c2c6b98", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">In combination with ritonavir,\nbioequivalence of Invirase hard capsules and film-coated tablets was\ndemonstrated under fed conditions.</span>", "ID": "6c43f71b-4a52-49bb-b17f-cc14f7cce9ef", "Styles": "None", "Classes": "None", "Text": "In combination with ritonavir, bioequivalence of Invirase hard capsules and film-coated tablets was demonstrated under fed conditions.", "ParentId": "6e6fdf06-5b8b-4232-b490-85799c2c6b98"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "74b2d112-f7b6-4097-bf46-9ebf6824ec33", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "03146e4d-7d30-4308-8df1-ff268e943417", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "74b2d112-f7b6-4097-bf46-9ebf6824ec33"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Effective therapy in treatment na\u00efve\npatients is associated with a C<sub>min</sub> of approximately 50\u00a0ng/ml\nand an AUC<sub>0-24</sub> of about 20,000\u00a0ng\u00b7h/ml. <span style=\"layout-grid-mode:line\">Effective therapy in treatment experienced\npatients is associated with a C<sub>min</sub> of approximately 100 ng/ml and an\nAUC<sub>0-24</sub> of about 20,000\u00a0ng</span>\u00b7<span style=\"layout-grid-mode:line\">h/ml.</span></span></p>", "ID": "3f42343b-a472-4c7f-afca-f5f840737dec", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Effective therapy in treatment na\u00efve\npatients is associated with a C<sub>min</sub> of approximately 50\u00a0ng/ml\nand an AUC<sub>0-24</sub> of about 20,000\u00a0ng\u00b7h/ml. <span style=\"layout-grid-mode:line\">Effective therapy in treatment experienced\npatients is associated with a C<sub>min</sub> of approximately 100 ng/ml and an\nAUC<sub>0-24</sub> of about 20,000\u00a0ng</span>\u00b7<span style=\"layout-grid-mode:line\">h/ml.</span></span>", "ID": "e0b37b44-0417-490c-a33e-617c550791cb", "Styles": "None", "Classes": "None", "Text": "Effective therapy in treatment na\u00efve patients is associated with a C of approximately 50\u00a0ng/ml and an AUC of about 20,000\u00a0ng\u00b7h/ml. \u00b7", "ParentId": "3f42343b-a472-4c7f-afca-f5f840737dec"}, {"Element": "<sub>min</sub>", "ID": "bb683bf6-204d-4082-af8c-1198431f8f33", "Styles": "None", "Classes": "None", "Text": "min", "ParentId": "e0b37b44-0417-490c-a33e-617c550791cb"}, {"Element": "<sub>0-24</sub>", "ID": "e56f3132-06f1-44bc-95b1-cfb461d8ce15", "Styles": "None", "Classes": "None", "Text": "0-24", "ParentId": "e0b37b44-0417-490c-a33e-617c550791cb"}, {"Element": "<span style=\"layout-grid-mode:line\">Effective therapy in treatment experienced\npatients is associated with a C<sub>min</sub> of approximately 100 ng/ml and an\nAUC<sub>0-24</sub> of about 20,000\u00a0ng</span>", "ID": "1015c84b-a188-42f8-b925-9d3a59913e8c", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Effective therapy in treatment experienced patients is associated with a C of approximately 100 ng/ml and an AUC of about 20,000\u00a0ng", "ParentId": "e0b37b44-0417-490c-a33e-617c550791cb"}, {"Element": "<sub>min</sub>", "ID": "ea9b7546-7e3d-46df-af81-c936aba363d9", "Styles": "None", "Classes": "None", "Text": "min", "ParentId": "1015c84b-a188-42f8-b925-9d3a59913e8c"}, {"Element": "<sub>0-24</sub>", "ID": "00cbe8ab-8330-4e73-8594-6fbcd8e41045", "Styles": "None", "Classes": "None", "Text": "0-24", "ParentId": "1015c84b-a188-42f8-b925-9d3a59913e8c"}, {"Element": "<span style=\"layout-grid-mode:line\">h/ml.</span>", "ID": "78b08753-fb01-4305-bf7e-b6b7c74824ed", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "h/ml.", "ParentId": "e0b37b44-0417-490c-a33e-617c550791cb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "7de88ff1-b264-42e4-a789-d26e784b7d47", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "83dbf941-a077-4f41-b117-eb5654f08f75", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "7de88ff1-b264-42e4-a789-d26e784b7d47"}, {"Element": "<p class=\"MsoNormal\">In treatment-na\u00efve HIV-1 infected patients initiating\nInvirase/ritonavir treatment with a modified Invirase/ritonavir dosing regimen\nof <span lang=\"EN-GB\">Invirase 500\u00a0mg two times daily with ritonavir\n100\u00a0mg two times daily for the first 7 days of treatment and increased to\nInvirase 1000\u00a0mg two times daily with ritonavir 100\u00a0mg two times\ndaily in the subsequent 7 days, </span>saquinavir systemic exposures generally\napproached or exceeded the range of historical steady-state values with the\nstandard Invirase/ritonavir 1000\u00a0mg/100\u00a0mg bid dosing regimen across\nstudy days <span lang=\"EN-GB\">(see Tables 9 and 8)</span>. </p>", "ID": "e66910b1-e1b1-4c97-8671-21ef5551c441", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In treatment-na\u00efve HIV-1 infected patients initiating Invirase/ritonavir treatment with a modified Invirase/ritonavir dosing regimen of saquinavir systemic exposures generally approached or exceeded the range of historical steady-state values with the standard Invirase/ritonavir 1000\u00a0mg/100\u00a0mg bid dosing regimen across study days . ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Invirase 500\u00a0mg two times daily with ritonavir\n100\u00a0mg two times daily for the first 7 days of treatment and increased to\nInvirase 1000\u00a0mg two times daily with ritonavir 100\u00a0mg two times\ndaily in the subsequent 7 days, </span>", "ID": "fee9eac2-3d45-420c-a11d-1432f7cbe7ce", "Styles": "None", "Classes": "None", "Text": "Invirase 500\u00a0mg two times daily with ritonavir 100\u00a0mg two times daily for the first 7 days of treatment and increased to Invirase 1000\u00a0mg two times daily with ritonavir 100\u00a0mg two times daily in the subsequent 7 days, ", "ParentId": "e66910b1-e1b1-4c97-8671-21ef5551c441"}, {"Element": "<span lang=\"EN-GB\">(see Tables 9 and 8)</span>", "ID": "fcce5ae8-28d2-46ff-9688-1488143e9878", "Styles": "None", "Classes": "None", "Text": "(see Tables 9 and 8)", "ParentId": "e66910b1-e1b1-4c97-8671-21ef5551c441"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "0f564e3a-4cc7-4f02-a07a-abc9d53d09ef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">Table 9: Mean (CV%) PK Parameters following administration\nof the Modified Invirase/ritonavir Regimen in Treatment Na\u00efve HIV-1\ninfected Patients initiating treatment with Invirase/ritonavir</p>", "ID": "752f1d95-5788-4fa6-8eed-6a679ffcd3fe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Table 9: Mean (CV%) PK Parameters following administration of the Modified Invirase/ritonavir Regimen in Treatment Na\u00efve HIV-1 infected Patients initiating treatment with Invirase/ritonavir", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<div align=\"right\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:465.15pt;border-collapse:collapse;border:none\" width=\"620\">\n<tr style=\"height:36.95pt\">\n<td style=\"width:80.6pt;border:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\"><b>Parameter</b></p>\n</td>\n<td style=\"width:78.45pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\"><b>Day 3</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=22)</b></p>\n</td>\n<td style=\"width:73.9pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\"><b>Day 4</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:73.9pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\"><b>Day 7</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:79.15pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\"><b>Day 10</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:79.15pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\"><b>Day 14</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n</tr>\n<tr style=\"height:15.2pt\">\n<td style=\"width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\">AUC<sub>0-12</sub><b><sub> </sub></b><b><span lang=\"EN-GB\">(ng*hr/ml)</span></b></p>\n</td>\n<td style=\"width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\">27100 (35.7)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:15.2pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">20300 (39.9)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:15.2pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">12600 (54.5)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">34200 (48.4)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">31100 (49.6)</p>\n</td>\n</tr>\n<tr style=\"height:13.3pt\">\n<td style=\"width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\">C<sub>max</sub> (ng/ml)</p>\n</td>\n<td style=\"width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\">4030 (29.1)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">2960 (40.2)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">1960 (53.3)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">5300 (36.0)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">4860 (46.8)</p>\n</td>\n</tr>\n<tr style=\"height:13.3pt\">\n<td style=\"width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\">C<b><sub><span lang=\"EN-GB\">12</span></sub></b><b><span lang=\"EN-GB\"> (ng/ml)</span></b></p>\n</td>\n<td style=\"width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\">899 (64.9)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">782 (62.4)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">416 (98.5)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">1220 (91.6)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">1120 (80.9)</p>\n</td>\n</tr>\n</table>\n</div>", "ID": "7aee458e-748a-4e0d-ac73-3c3ac32a89a0", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:465.15pt;border-collapse:collapse;border:none\" width=\"620\">\n<tr style=\"height:36.95pt\">\n<td style=\"width:80.6pt;border:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\"><b>Parameter</b></p>\n</td>\n<td style=\"width:78.45pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\"><b>Day 3</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=22)</b></p>\n</td>\n<td style=\"width:73.9pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\"><b>Day 4</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:73.9pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\"><b>Day 7</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:79.15pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\"><b>Day 10</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:79.15pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\"><b>Day 14</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n</tr>\n<tr style=\"height:15.2pt\">\n<td style=\"width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\">AUC<sub>0-12</sub><b><sub> </sub></b><b><span lang=\"EN-GB\">(ng*hr/ml)</span></b></p>\n</td>\n<td style=\"width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\">27100 (35.7)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:15.2pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">20300 (39.9)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:15.2pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">12600 (54.5)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">34200 (48.4)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">31100 (49.6)</p>\n</td>\n</tr>\n<tr style=\"height:13.3pt\">\n<td style=\"width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\">C<sub>max</sub> (ng/ml)</p>\n</td>\n<td style=\"width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\">4030 (29.1)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">2960 (40.2)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">1960 (53.3)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">5300 (36.0)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">4860 (46.8)</p>\n</td>\n</tr>\n<tr style=\"height:13.3pt\">\n<td style=\"width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\">C<b><sub><span lang=\"EN-GB\">12</span></sub></b><b><span lang=\"EN-GB\"> (ng/ml)</span></b></p>\n</td>\n<td style=\"width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\">899 (64.9)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">782 (62.4)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">416 (98.5)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">1220 (91.6)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">1120 (80.9)</p>\n</td>\n</tr>\n</table>", "ID": "6251d55e-572d-4bc0-a7ac-75389542a763", "Styles": "width:465.15pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "     ", "ParentId": "7aee458e-748a-4e0d-ac73-3c3ac32a89a0"}, {"Element": "<tr style=\"height:36.95pt\">\n<td style=\"width:80.6pt;border:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\"><b>Parameter</b></p>\n</td>\n<td style=\"width:78.45pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\"><b>Day 3</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=22)</b></p>\n</td>\n<td style=\"width:73.9pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\"><b>Day 4</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:73.9pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\"><b>Day 7</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:79.15pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\"><b>Day 10</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n<td style=\"width:79.15pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\"><b>Day 14</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>\n</tr>", "ID": "0e48aedd-d1b1-4dce-8b3e-44f635aefd25", "Styles": "height:36.95pt", "Classes": "None", "Text": "       ", "ParentId": "6251d55e-572d-4bc0-a7ac-75389542a763"}, {"Element": "<td style=\"width:80.6pt;border:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\"><b>Parameter</b></p>\n</td>", "ID": "3d0335fc-22f9-4bf5-af4e-4da613263932", "Styles": "width:80.6pt;border:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:36.95pt", "Classes": "None", "Text": "  ", "ParentId": "0e48aedd-d1b1-4dce-8b3e-44f635aefd25"}, {"Element": "<p class=\"MsoNormal\"><b>Parameter</b></p>", "ID": "d0248431-319e-4ea4-93a8-e09bc20de1ff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3d0335fc-22f9-4bf5-af4e-4da613263932"}, {"Element": "<b>Parameter</b>", "ID": "fd459510-3d36-41fe-8523-5610c6c10c8e", "Styles": "None", "Classes": "None", "Text": "Parameter", "ParentId": "d0248431-319e-4ea4-93a8-e09bc20de1ff"}, {"Element": "<td style=\"width:78.45pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\"><b>Day 3</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=22)</b></p>\n</td>", "ID": "e5ad02ac-005f-46dc-ae67-d1e7645eec33", "Styles": "width:78.45pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt", "Classes": "None", "Text": "    ", "ParentId": "0e48aedd-d1b1-4dce-8b3e-44f635aefd25"}, {"Element": "<p class=\"MsoNormal\"><b>Day 3</b></p>", "ID": "55b6d875-c669-4176-b6c8-f1cddb2d8774", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e5ad02ac-005f-46dc-ae67-d1e7645eec33"}, {"Element": "<b>Day 3</b>", "ID": "2450b8fe-3f18-432c-bc6b-cc21bafbef5a", "Styles": "None", "Classes": "None", "Text": "Day 3", "ParentId": "55b6d875-c669-4176-b6c8-f1cddb2d8774"}, {"Element": "<p class=\"MsoNormal\"><b>500/100 mg</b></p>", "ID": "00cd23f4-8c42-4728-938e-45e107c02018", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e5ad02ac-005f-46dc-ae67-d1e7645eec33"}, {"Element": "<b>500/100 mg</b>", "ID": "156b2e62-3670-4a8d-81fc-1ae7fe33feda", "Styles": "None", "Classes": "None", "Text": "500/100 mg", "ParentId": "00cd23f4-8c42-4728-938e-45e107c02018"}, {"Element": "<p class=\"MsoNormal\"><b>(n=22)</b></p>", "ID": "55222e4f-cedb-4915-8814-32082f34e4b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e5ad02ac-005f-46dc-ae67-d1e7645eec33"}, {"Element": "<b>(n=22)</b>", "ID": "55e5b11d-9a98-4853-bd42-34f21dc19dae", "Styles": "None", "Classes": "None", "Text": "(n=22)", "ParentId": "55222e4f-cedb-4915-8814-32082f34e4b8"}, {"Element": "<td style=\"width:73.9pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\"><b>Day 4</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>", "ID": "52564c0d-129b-4f13-897d-55607a2ccfbb", "Styles": "width:73.9pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt", "Classes": "None", "Text": "    ", "ParentId": "0e48aedd-d1b1-4dce-8b3e-44f635aefd25"}, {"Element": "<p class=\"MsoNormal\"><b>Day 4</b></p>", "ID": "ab1dc6d3-036b-460f-84fa-c188a41b7d45", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "52564c0d-129b-4f13-897d-55607a2ccfbb"}, {"Element": "<b>Day 4</b>", "ID": "b33fe447-e3fa-4828-9771-b01f6af78fd9", "Styles": "None", "Classes": "None", "Text": "Day 4", "ParentId": "ab1dc6d3-036b-460f-84fa-c188a41b7d45"}, {"Element": "<p class=\"MsoNormal\"><b>500/100 mg</b></p>", "ID": "96305a1f-7fa2-41bd-af68-560d21ddd3ad", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "52564c0d-129b-4f13-897d-55607a2ccfbb"}, {"Element": "<b>500/100 mg</b>", "ID": "91ae2ae5-e259-4565-a626-7881249b412b", "Styles": "None", "Classes": "None", "Text": "500/100 mg", "ParentId": "96305a1f-7fa2-41bd-af68-560d21ddd3ad"}, {"Element": "<p class=\"MsoNormal\"><b>(n=21)</b></p>", "ID": "3a5f53aa-b08b-4b6f-9016-8a2efafdc7cf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "52564c0d-129b-4f13-897d-55607a2ccfbb"}, {"Element": "<b>(n=21)</b>", "ID": "59c149b7-6787-4d13-96d4-eef51c4ce301", "Styles": "None", "Classes": "None", "Text": "(n=21)", "ParentId": "3a5f53aa-b08b-4b6f-9016-8a2efafdc7cf"}, {"Element": "<td style=\"width:73.9pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\"><b>Day 7</b></p>\n<p class=\"MsoNormal\"><b>500/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>", "ID": "8268acf9-fdd7-4a7d-86bb-10ab1a71d1b5", "Styles": "width:73.9pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt", "Classes": "None", "Text": "    ", "ParentId": "0e48aedd-d1b1-4dce-8b3e-44f635aefd25"}, {"Element": "<p class=\"MsoNormal\"><b>Day 7</b></p>", "ID": "40ecfa80-2b6e-46d3-8a41-430d5675c515", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8268acf9-fdd7-4a7d-86bb-10ab1a71d1b5"}, {"Element": "<b>Day 7</b>", "ID": "53d371b2-953b-44d0-b65e-2c5c2e63d066", "Styles": "None", "Classes": "None", "Text": "Day 7", "ParentId": "40ecfa80-2b6e-46d3-8a41-430d5675c515"}, {"Element": "<p class=\"MsoNormal\"><b>500/100 mg</b></p>", "ID": "e92a89dc-3ec2-4b1f-be21-311a6a90a2c9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8268acf9-fdd7-4a7d-86bb-10ab1a71d1b5"}, {"Element": "<b>500/100 mg</b>", "ID": "0a3bbc78-f5d6-4fb5-b6d4-75b6c018d2d9", "Styles": "None", "Classes": "None", "Text": "500/100 mg", "ParentId": "e92a89dc-3ec2-4b1f-be21-311a6a90a2c9"}, {"Element": "<p class=\"MsoNormal\"><b>(n=21)</b></p>", "ID": "e1031555-daa1-4db3-a1d6-090d43e079a2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8268acf9-fdd7-4a7d-86bb-10ab1a71d1b5"}, {"Element": "<b>(n=21)</b>", "ID": "ee25f9d3-c02f-4153-8d09-fc826f4c3d7e", "Styles": "None", "Classes": "None", "Text": "(n=21)", "ParentId": "e1031555-daa1-4db3-a1d6-090d43e079a2"}, {"Element": "<td style=\"width:79.15pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\"><b>Day 10</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>", "ID": "69aea914-9915-41af-bd19-3fbc5592ff8d", "Styles": "width:79.15pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt", "Classes": "None", "Text": "    ", "ParentId": "0e48aedd-d1b1-4dce-8b3e-44f635aefd25"}, {"Element": "<p class=\"MsoNormal\"><b>Day 10</b></p>", "ID": "e2e299da-e936-4145-b136-453d4f63a732", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "69aea914-9915-41af-bd19-3fbc5592ff8d"}, {"Element": "<b>Day 10</b>", "ID": "95d3a0cb-18ca-4bef-84c4-2154f84117bf", "Styles": "None", "Classes": "None", "Text": "Day 10", "ParentId": "e2e299da-e936-4145-b136-453d4f63a732"}, {"Element": "<p class=\"MsoNormal\"><b>1000/100 mg</b></p>", "ID": "bd9165c6-246c-4e32-b658-538130a88e62", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "69aea914-9915-41af-bd19-3fbc5592ff8d"}, {"Element": "<b>1000/100 mg</b>", "ID": "d3ce37b4-f850-4800-a8a9-b8d17ef69001", "Styles": "None", "Classes": "None", "Text": "1000/100 mg", "ParentId": "bd9165c6-246c-4e32-b658-538130a88e62"}, {"Element": "<p class=\"MsoNormal\"><b>(n=21)</b></p>", "ID": "bafc1ace-3927-4e57-95bd-e1e0cdbab7c3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "69aea914-9915-41af-bd19-3fbc5592ff8d"}, {"Element": "<b>(n=21)</b>", "ID": "e8aedef4-f919-4c19-93d6-4d1f2f463aec", "Styles": "None", "Classes": "None", "Text": "(n=21)", "ParentId": "bafc1ace-3927-4e57-95bd-e1e0cdbab7c3"}, {"Element": "<td style=\"width:79.15pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\"><b>Day 14</b></p>\n<p class=\"MsoNormal\"><b>1000/100 mg</b></p>\n<p class=\"MsoNormal\"><b>(n=21)</b></p>\n</td>", "ID": "a81caed6-d6d9-40a0-9743-e982d8303431", "Styles": "width:79.15pt;border:solid black 1.0pt;\n  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt", "Classes": "None", "Text": "    ", "ParentId": "0e48aedd-d1b1-4dce-8b3e-44f635aefd25"}, {"Element": "<p class=\"MsoNormal\"><b>Day 14</b></p>", "ID": "e98311c9-0c95-4606-8f45-960c608838a5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a81caed6-d6d9-40a0-9743-e982d8303431"}, {"Element": "<b>Day 14</b>", "ID": "9a723a64-3c15-4b7e-973f-3e26fdf3e193", "Styles": "None", "Classes": "None", "Text": "Day 14", "ParentId": "e98311c9-0c95-4606-8f45-960c608838a5"}, {"Element": "<p class=\"MsoNormal\"><b>1000/100 mg</b></p>", "ID": "468fd28d-7180-4214-96b9-cb90f899c29a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a81caed6-d6d9-40a0-9743-e982d8303431"}, {"Element": "<b>1000/100 mg</b>", "ID": "1481cc9b-ee3d-458e-96e2-e769d6553c5c", "Styles": "None", "Classes": "None", "Text": "1000/100 mg", "ParentId": "468fd28d-7180-4214-96b9-cb90f899c29a"}, {"Element": "<p class=\"MsoNormal\"><b>(n=21)</b></p>", "ID": "a2083590-ed2a-4055-840f-c4672fd102cf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a81caed6-d6d9-40a0-9743-e982d8303431"}, {"Element": "<b>(n=21)</b>", "ID": "05b876fe-2b54-42d0-8794-3d35a2f30398", "Styles": "None", "Classes": "None", "Text": "(n=21)", "ParentId": "a2083590-ed2a-4055-840f-c4672fd102cf"}, {"Element": "<tr style=\"height:15.2pt\">\n<td style=\"width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\">AUC<sub>0-12</sub><b><sub> </sub></b><b><span lang=\"EN-GB\">(ng*hr/ml)</span></b></p>\n</td>\n<td style=\"width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\">27100 (35.7)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:15.2pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">20300 (39.9)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:15.2pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">12600 (54.5)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">34200 (48.4)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">31100 (49.6)</p>\n</td>\n</tr>", "ID": "3f87566d-f83a-44b4-836e-03d15a8549bf", "Styles": "height:15.2pt", "Classes": "None", "Text": "       ", "ParentId": "6251d55e-572d-4bc0-a7ac-75389542a763"}, {"Element": "<td style=\"width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\">AUC<sub>0-12</sub><b><sub> </sub></b><b><span lang=\"EN-GB\">(ng*hr/ml)</span></b></p>\n</td>", "ID": "741c2052-0fd2-43a6-a75a-911e48d58f2e", "Styles": "width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:15.2pt", "Classes": "None", "Text": "  ", "ParentId": "3f87566d-f83a-44b4-836e-03d15a8549bf"}, {"Element": "<p class=\"MsoNormal\">AUC<sub>0-12</sub><b><sub> </sub></b><b><span lang=\"EN-GB\">(ng*hr/ml)</span></b></p>", "ID": "b96c0d4e-45f5-41d7-9051-7fb3c42cc2b0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "AUC", "ParentId": "741c2052-0fd2-43a6-a75a-911e48d58f2e"}, {"Element": "<sub>0-12</sub>", "ID": "70c6496d-dc53-4be0-a73e-9c20ad31a399", "Styles": "None", "Classes": "None", "Text": "0-12", "ParentId": "b96c0d4e-45f5-41d7-9051-7fb3c42cc2b0"}, {"Element": "<b><sub> </sub></b>", "ID": "e373ae26-7992-412a-816f-df5f60883907", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b96c0d4e-45f5-41d7-9051-7fb3c42cc2b0"}, {"Element": "<sub> </sub>", "ID": "1faa65c5-3164-450e-88c9-cc16cfb9aba5", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "e373ae26-7992-412a-816f-df5f60883907"}, {"Element": "<b><span lang=\"EN-GB\">(ng*hr/ml)</span></b>", "ID": "e63a8c81-1e80-4521-a8d4-663b9565b347", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b96c0d4e-45f5-41d7-9051-7fb3c42cc2b0"}, {"Element": "<span lang=\"EN-GB\">(ng*hr/ml)</span>", "ID": "7f739013-e7da-40a1-bce9-248240758b28", "Styles": "None", "Classes": "None", "Text": "(ng*hr/ml)", "ParentId": "e63a8c81-1e80-4521-a8d4-663b9565b347"}, {"Element": "<td style=\"width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\">27100 (35.7)</p>\n</td>", "ID": "5aba2c9b-eb31-4e7e-903c-45978e298ccd", "Styles": "width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt", "Classes": "None", "Text": "  ", "ParentId": "3f87566d-f83a-44b4-836e-03d15a8549bf"}, {"Element": "<p class=\"MsoNormal\">27100 (35.7)</p>", "ID": "7df11e50-75a5-48e5-b985-3f06e51424fc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "27100 (35.7)", "ParentId": "5aba2c9b-eb31-4e7e-903c-45978e298ccd"}, {"Element": "<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:15.2pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">20300 (39.9)</p>\n</td>", "ID": "9bf2e7ae-f5b5-4989-9267-20b1f8c484d5", "Styles": "width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:15.2pt", "Classes": "None", "Text": "  ", "ParentId": "3f87566d-f83a-44b4-836e-03d15a8549bf"}, {"Element": "<p class=\"MsoNormal\">20300 (39.9)</p>", "ID": "bdd49b0c-793c-4dc6-a832-e9ddfb81f9dc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "20300 (39.9)", "ParentId": "9bf2e7ae-f5b5-4989-9267-20b1f8c484d5"}, {"Element": "<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:15.2pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">12600 (54.5)</p>\n</td>", "ID": "9e30acbf-0796-4dd8-979b-f2bafa456f66", "Styles": "width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:15.2pt", "Classes": "None", "Text": "  ", "ParentId": "3f87566d-f83a-44b4-836e-03d15a8549bf"}, {"Element": "<p class=\"MsoNormal\">12600 (54.5)</p>", "ID": "13ed18f6-1e3f-470a-841b-82d6d399dc67", "Styles": "None", "Classes": "['MsoNormal']", "Text": "12600 (54.5)", "ParentId": "9e30acbf-0796-4dd8-979b-f2bafa456f66"}, {"Element": "<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">34200 (48.4)</p>\n</td>", "ID": "8a2936e2-eb12-42ed-801a-398cbecbd92f", "Styles": "width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt", "Classes": "None", "Text": "  ", "ParentId": "3f87566d-f83a-44b4-836e-03d15a8549bf"}, {"Element": "<p class=\"MsoNormal\">34200 (48.4)</p>", "ID": "8df8dfed-1882-4de0-8a09-1d4d34e77a86", "Styles": "None", "Classes": "['MsoNormal']", "Text": "34200 (48.4)", "ParentId": "8a2936e2-eb12-42ed-801a-398cbecbd92f"}, {"Element": "<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">31100 (49.6)</p>\n</td>", "ID": "0f128590-41dd-4fe5-b0cc-699e21c4ad6e", "Styles": "width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt", "Classes": "None", "Text": "  ", "ParentId": "3f87566d-f83a-44b4-836e-03d15a8549bf"}, {"Element": "<p class=\"MsoNormal\">31100 (49.6)</p>", "ID": "6d69ebea-b2e8-4ccf-82a7-138eec7b8567", "Styles": "None", "Classes": "['MsoNormal']", "Text": "31100 (49.6)", "ParentId": "0f128590-41dd-4fe5-b0cc-699e21c4ad6e"}, {"Element": "<tr style=\"height:13.3pt\">\n<td style=\"width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\">C<sub>max</sub> (ng/ml)</p>\n</td>\n<td style=\"width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\">4030 (29.1)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">2960 (40.2)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">1960 (53.3)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">5300 (36.0)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">4860 (46.8)</p>\n</td>\n</tr>", "ID": "0caa9e55-db31-41f0-8ee0-caacaf084ff2", "Styles": "height:13.3pt", "Classes": "None", "Text": "       ", "ParentId": "6251d55e-572d-4bc0-a7ac-75389542a763"}, {"Element": "<td style=\"width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\">C<sub>max</sub> (ng/ml)</p>\n</td>", "ID": "1ceae783-74eb-451f-8c8a-87d35718a8b8", "Styles": "width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:13.3pt", "Classes": "None", "Text": "  ", "ParentId": "0caa9e55-db31-41f0-8ee0-caacaf084ff2"}, {"Element": "<p class=\"MsoNormal\">C<sub>max</sub> (ng/ml)</p>", "ID": "4db1220b-4a3d-4a3a-ba01-f1bee51cdd12", "Styles": "None", "Classes": "['MsoNormal']", "Text": "C (ng/ml)", "ParentId": "1ceae783-74eb-451f-8c8a-87d35718a8b8"}, {"Element": "<sub>max</sub>", "ID": "f10f9095-a2b1-4b09-b2c2-39b63e1440c9", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "4db1220b-4a3d-4a3a-ba01-f1bee51cdd12"}, {"Element": "<td style=\"width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\">4030 (29.1)</p>\n</td>", "ID": "9b5b7389-a43d-45e4-9b40-1fc2757ded18", "Styles": "width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt", "Classes": "None", "Text": "  ", "ParentId": "0caa9e55-db31-41f0-8ee0-caacaf084ff2"}, {"Element": "<p class=\"MsoNormal\">4030 (29.1)</p>", "ID": "0c042912-a901-4115-8add-414051b25820", "Styles": "None", "Classes": "['MsoNormal']", "Text": "4030 (29.1)", "ParentId": "9b5b7389-a43d-45e4-9b40-1fc2757ded18"}, {"Element": "<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">2960 (40.2)</p>\n</td>", "ID": "d0b33efd-eba2-487d-85d7-95a84323746f", "Styles": "width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt", "Classes": "None", "Text": "  ", "ParentId": "0caa9e55-db31-41f0-8ee0-caacaf084ff2"}, {"Element": "<p class=\"MsoNormal\">2960 (40.2)</p>", "ID": "878273e5-e7e2-4cd1-b483-f07ea27d5ad2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "2960 (40.2)", "ParentId": "d0b33efd-eba2-487d-85d7-95a84323746f"}, {"Element": "<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">1960 (53.3)</p>\n</td>", "ID": "ff63d42f-ceae-4e4e-bf83-9f8b8f394c3f", "Styles": "width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt", "Classes": "None", "Text": "  ", "ParentId": "0caa9e55-db31-41f0-8ee0-caacaf084ff2"}, {"Element": "<p class=\"MsoNormal\">1960 (53.3)</p>", "ID": "3f47e0b0-e208-43b6-88d4-568849e13b7a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "1960 (53.3)", "ParentId": "ff63d42f-ceae-4e4e-bf83-9f8b8f394c3f"}, {"Element": "<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">5300 (36.0)</p>\n</td>", "ID": "a1051583-0f8e-4891-8c9c-0b2e66c6fb36", "Styles": "width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt", "Classes": "None", "Text": "  ", "ParentId": "0caa9e55-db31-41f0-8ee0-caacaf084ff2"}, {"Element": "<p class=\"MsoNormal\">5300 (36.0)</p>", "ID": "e854cfc6-8c88-4ea4-9b4a-5773e7793ed5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "5300 (36.0)", "ParentId": "a1051583-0f8e-4891-8c9c-0b2e66c6fb36"}, {"Element": "<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">4860 (46.8)</p>\n</td>", "ID": "ba950892-4be7-4ffb-bf7f-9dc5fa143f3f", "Styles": "width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt", "Classes": "None", "Text": "  ", "ParentId": "0caa9e55-db31-41f0-8ee0-caacaf084ff2"}, {"Element": "<p class=\"MsoNormal\">4860 (46.8)</p>", "ID": "ddfc71b2-a57c-4ac9-a0f5-59ec1ab8b578", "Styles": "None", "Classes": "['MsoNormal']", "Text": "4860 (46.8)", "ParentId": "ba950892-4be7-4ffb-bf7f-9dc5fa143f3f"}, {"Element": "<tr style=\"height:13.3pt\">\n<td style=\"width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\">C<b><sub><span lang=\"EN-GB\">12</span></sub></b><b><span lang=\"EN-GB\"> (ng/ml)</span></b></p>\n</td>\n<td style=\"width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\">899 (64.9)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">782 (62.4)</p>\n</td>\n<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">416 (98.5)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">1220 (91.6)</p>\n</td>\n<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">1120 (80.9)</p>\n</td>\n</tr>", "ID": "02d83a08-50f0-4165-8ae9-2ad00e42872c", "Styles": "height:13.3pt", "Classes": "None", "Text": "       ", "ParentId": "6251d55e-572d-4bc0-a7ac-75389542a763"}, {"Element": "<td style=\"width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"107\">\n<p class=\"MsoNormal\">C<b><sub><span lang=\"EN-GB\">12</span></sub></b><b><span lang=\"EN-GB\"> (ng/ml)</span></b></p>\n</td>", "ID": "797bc713-92df-4fbe-89e5-2f20aad1b8c2", "Styles": "width:80.6pt;border:solid black 1.0pt;\n  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:13.3pt", "Classes": "None", "Text": "  ", "ParentId": "02d83a08-50f0-4165-8ae9-2ad00e42872c"}, {"Element": "<p class=\"MsoNormal\">C<b><sub><span lang=\"EN-GB\">12</span></sub></b><b><span lang=\"EN-GB\"> (ng/ml)</span></b></p>", "ID": "df0610e4-50fa-4e54-b708-13b1681fc199", "Styles": "None", "Classes": "['MsoNormal']", "Text": "C", "ParentId": "797bc713-92df-4fbe-89e5-2f20aad1b8c2"}, {"Element": "<b><sub><span lang=\"EN-GB\">12</span></sub></b>", "ID": "e61e0700-5ecf-4af8-a0ec-e84329a80ccd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "df0610e4-50fa-4e54-b708-13b1681fc199"}, {"Element": "<sub><span lang=\"EN-GB\">12</span></sub>", "ID": "a788816d-c1d2-456f-b6e3-1a038b941d6f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e61e0700-5ecf-4af8-a0ec-e84329a80ccd"}, {"Element": "<span lang=\"EN-GB\">12</span>", "ID": "5c2647ad-0beb-4b01-b207-5d9081925121", "Styles": "None", "Classes": "None", "Text": "12", "ParentId": "a788816d-c1d2-456f-b6e3-1a038b941d6f"}, {"Element": "<b><span lang=\"EN-GB\"> (ng/ml)</span></b>", "ID": "47fda228-3b47-4104-9884-754f4c6c0caa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "df0610e4-50fa-4e54-b708-13b1681fc199"}, {"Element": "<span lang=\"EN-GB\"> (ng/ml)</span>", "ID": "3774eef7-8dbc-42b9-a9d5-8efd15d250f9", "Styles": "None", "Classes": "None", "Text": " (ng/ml)", "ParentId": "47fda228-3b47-4104-9884-754f4c6c0caa"}, {"Element": "<td style=\"width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"105\">\n<p class=\"MsoNormal\">899 (64.9)</p>\n</td>", "ID": "04236678-9c07-488f-b229-8b7bc68b3bf7", "Styles": "width:78.45pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt", "Classes": "None", "Text": "  ", "ParentId": "02d83a08-50f0-4165-8ae9-2ad00e42872c"}, {"Element": "<p class=\"MsoNormal\">899 (64.9)</p>", "ID": "3cb6ec78-3f4b-4210-85c4-dc1ec3b5dbfb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "899 (64.9)", "ParentId": "04236678-9c07-488f-b229-8b7bc68b3bf7"}, {"Element": "<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">782 (62.4)</p>\n</td>", "ID": "e973d127-07f0-475a-a10d-801a2230baeb", "Styles": "width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt", "Classes": "None", "Text": "  ", "ParentId": "02d83a08-50f0-4165-8ae9-2ad00e42872c"}, {"Element": "<p class=\"MsoNormal\">782 (62.4)</p>", "ID": "0b60dd3b-cf49-4a9f-a288-12735e99ee5c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "782 (62.4)", "ParentId": "e973d127-07f0-475a-a10d-801a2230baeb"}, {"Element": "<td style=\"width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt\" valign=\"top\" width=\"99\">\n<p class=\"MsoNormal\">416 (98.5)</p>\n</td>", "ID": "d64a82dd-8bc3-416e-88c1-f34db9729d3a", "Styles": "width:73.9pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;\n  height:13.3pt", "Classes": "None", "Text": "  ", "ParentId": "02d83a08-50f0-4165-8ae9-2ad00e42872c"}, {"Element": "<p class=\"MsoNormal\">416 (98.5)</p>", "ID": "7b38673e-3cc2-4a71-a6e5-1843186244f5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "416 (98.5)", "ParentId": "d64a82dd-8bc3-416e-88c1-f34db9729d3a"}, {"Element": "<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">1220 (91.6)</p>\n</td>", "ID": "86336c1c-9ed8-4550-9e1d-7e28ae7dce00", "Styles": "width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt", "Classes": "None", "Text": "  ", "ParentId": "02d83a08-50f0-4165-8ae9-2ad00e42872c"}, {"Element": "<p class=\"MsoNormal\">1220 (91.6)</p>", "ID": "71f3742a-cc08-4ecf-8374-c7e0b75eb4ce", "Styles": "None", "Classes": "['MsoNormal']", "Text": "1220 (91.6)", "ParentId": "86336c1c-9ed8-4550-9e1d-7e28ae7dce00"}, {"Element": "<td style=\"width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt\" valign=\"top\" width=\"106\">\n<p class=\"MsoNormal\">1120 (80.9)</p>\n</td>", "ID": "42f8cb9d-9501-406b-8804-fb43d131a7c3", "Styles": "width:79.15pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt", "Classes": "None", "Text": "  ", "ParentId": "02d83a08-50f0-4165-8ae9-2ad00e42872c"}, {"Element": "<p class=\"MsoNormal\">1120 (80.9)</p>", "ID": "c4829cb2-435b-48ef-84f6-e11fb5a97035", "Styles": "None", "Classes": "['MsoNormal']", "Text": "1120 (80.9)", "ParentId": "42f8cb9d-9501-406b-8804-fb43d131a7c3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2f7c7ce4-873e-4a43-8352-f65341cf0475", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c050a7bb-20f5-4951-97e8-0e87ed6f71f8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2f7c7ce4-873e-4a43-8352-f65341cf0475"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">In vitro</span></i><span lang=\"EN-GB\">\nstudies have shown that saquinavir is a substrate for P-glycoprotein (P-gp).</span></p>", "ID": "d0eb1e1a-c12e-47f4-981a-9d384c6f2682", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<i><span lang=\"EN-GB\">In vitro</span></i>", "ID": "cc4abad1-bbfd-4df8-9bdc-00f940b9f30d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d0eb1e1a-c12e-47f4-981a-9d384c6f2682"}, {"Element": "<span lang=\"EN-GB\">In vitro</span>", "ID": "29a56cb1-bc16-4804-8ea7-c2b26eaf4410", "Styles": "None", "Classes": "None", "Text": "In vitro", "ParentId": "cc4abad1-bbfd-4df8-9bdc-00f940b9f30d"}, {"Element": "<span lang=\"EN-GB\">\nstudies have shown that saquinavir is a substrate for P-glycoprotein (P-gp).</span>", "ID": "80da6bf9-3c8d-4968-9355-2c739b4e337f", "Styles": "None", "Classes": "None", "Text": " studies have shown that saquinavir is a substrate for P-glycoprotein (P-gp).", "ParentId": "d0eb1e1a-c12e-47f4-981a-9d384c6f2682"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>", "ID": "136bc3d8-68d1-4627-95a7-61a036172c3b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">\u00a0</span></i></b>", "ID": "9364c18d-c038-42f0-8fca-b922aec64c25", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "136bc3d8-68d1-4627-95a7-61a036172c3b"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "2762401f-db0f-4308-a606-591a5e55a2a9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9364c18d-c038-42f0-8fca-b922aec64c25"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "db044627-df11-48c5-996b-ed614a2ae9e4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2762401f-db0f-4308-a606-591a5e55a2a9"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Effect of food:</span></i></b><span lang=\"EN-GB\"> </span>In a cross-over study in 22 HIV-infected patients treated\nwith Invirase/ritonavir 1000\u00a0mg/100\u00a0mg twice daily and receiving\nthree consecutive doses under fasting conditions or after a high-fat,\nhigh-calorie meal (46 g fat, 1,091 Kcal), the AUC<sub>0-12</sub>, C<sub>max</sub>\nand C<sub>trough</sub> values of saquinavir under fasting conditions were about\n70 per cent lower than with a high-fat meal. All but one of the patients\nachieved C<sub>trough</sub> values of saquinavir above the therapeutic\nthreshold (100 ng/ml) in the fasted state. There were no clinically significant\ndifferences in the pharmacokinetic profile of ritonavir in fasting and fed\nconditions but the ritonavir C<sub>trough</sub> (geometric mean 245 vs. 348\nng/ml) was lower in the fasting state compared to the administration with a\nmeal. Invirase/ritonavir should be administered with or after food.</p>", "ID": "6c0c4a6e-df89-4c45-9d59-86c7b6b10d70", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In a cross-over study in 22 HIV-infected patients treated with Invirase/ritonavir 1000\u00a0mg/100\u00a0mg twice daily and receiving three consecutive doses under fasting conditions or after a high-fat, high-calorie meal (46 g fat, 1,091 Kcal), the AUC, C and C values of saquinavir under fasting conditions were about 70 per cent lower than with a high-fat meal. All but one of the patients achieved C values of saquinavir above the therapeutic threshold (100 ng/ml) in the fasted state. There were no clinically significant differences in the pharmacokinetic profile of ritonavir in fasting and fed conditions but the ritonavir C (geometric mean 245 vs. 348 ng/ml) was lower in the fasting state compared to the administration with a meal. Invirase/ritonavir should be administered with or after food.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Effect of food:</span></i></b>", "ID": "80fd7c21-f2a6-41e8-903b-5f440a498fd2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6c0c4a6e-df89-4c45-9d59-86c7b6b10d70"}, {"Element": "<i><span lang=\"EN-GB\">Effect of food:</span></i>", "ID": "e78b99de-cbe3-4892-9ec3-36e70632e9ca", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "80fd7c21-f2a6-41e8-903b-5f440a498fd2"}, {"Element": "<span lang=\"EN-GB\">Effect of food:</span>", "ID": "ec278f4b-6d19-49c5-bab7-c7336dd48f24", "Styles": "None", "Classes": "None", "Text": "Effect of food:", "ParentId": "e78b99de-cbe3-4892-9ec3-36e70632e9ca"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "9344ea18-7e21-42ce-88df-7cc3caa61aca", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "6c0c4a6e-df89-4c45-9d59-86c7b6b10d70"}, {"Element": "<sub>0-12</sub>", "ID": "c9e9d7e2-8915-452d-a0d4-ed3b3863601f", "Styles": "None", "Classes": "None", "Text": "0-12", "ParentId": "6c0c4a6e-df89-4c45-9d59-86c7b6b10d70"}, {"Element": "<sub>max</sub>", "ID": "8c22fce5-382a-4c98-ba8e-05bedb92fc8b", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "6c0c4a6e-df89-4c45-9d59-86c7b6b10d70"}, {"Element": "<sub>trough</sub>", "ID": "afdf8dcd-ebd2-441c-8891-ab1b7ea5c220", "Styles": "None", "Classes": "None", "Text": "trough", "ParentId": "6c0c4a6e-df89-4c45-9d59-86c7b6b10d70"}, {"Element": "<sub>trough</sub>", "ID": "b076ebe8-4243-4085-a96f-fdbeaa0a9a3a", "Styles": "None", "Classes": "None", "Text": "trough", "ParentId": "6c0c4a6e-df89-4c45-9d59-86c7b6b10d70"}, {"Element": "<sub>trough</sub>", "ID": "d780f151-975c-459c-a9a3-04efdb30560e", "Styles": "None", "Classes": "None", "Text": "trough", "ParentId": "6c0c4a6e-df89-4c45-9d59-86c7b6b10d70"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ccf8ffdc-84dc-4135-a57d-4c09293081e1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ea0e1c03-3822-4162-9cc1-483f0fd7badf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ccf8ffdc-84dc-4135-a57d-4c09293081e1"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Distribution in adults:</span></i></b><span lang=\"EN-GB\"> Saquinavir partitions extensively into the tissues. The mean\nsteady-state volume of distribution following intravenous administration of a\n12\u00a0mg dose of saquinavir was 700\u00a0l (CV 39\u00a0%). It has been shown\nthat saquinavir is approximately 97\u00a0% bound to plasma proteins up to\n30\u00a0</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">m</span><span lang=\"EN-GB\">g/ml. In two patients receiving Invirase 600\u00a0mg three times\ndaily, cerebrospinal fluid concentrations of saquinavir were negligible when\ncompared to concentrations from matching plasma samples.</span></p>", "ID": "5967086a-263e-4e54-bc85-bff94a183403", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Distribution in adults:</span></i></b>", "ID": "9a995236-1d30-423c-a3dd-1b2883615003", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5967086a-263e-4e54-bc85-bff94a183403"}, {"Element": "<i><span lang=\"EN-GB\">Distribution in adults:</span></i>", "ID": "0bb4f15a-7bea-4282-a5c9-8e43ebec0a32", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9a995236-1d30-423c-a3dd-1b2883615003"}, {"Element": "<span lang=\"EN-GB\">Distribution in adults:</span>", "ID": "520b3126-bb5f-4c57-b7e0-18e21aec6ed9", "Styles": "None", "Classes": "None", "Text": "Distribution in adults:", "ParentId": "0bb4f15a-7bea-4282-a5c9-8e43ebec0a32"}, {"Element": "<span lang=\"EN-GB\"> Saquinavir partitions extensively into the tissues. The mean\nsteady-state volume of distribution following intravenous administration of a\n12\u00a0mg dose of saquinavir was 700\u00a0l (CV 39\u00a0%). It has been shown\nthat saquinavir is approximately 97\u00a0% bound to plasma proteins up to\n30\u00a0</span>", "ID": "23037054-08d1-4885-ba69-621f55004054", "Styles": "None", "Classes": "None", "Text": " Saquinavir partitions extensively into the tissues. The mean steady-state volume of distribution following intravenous administration of a 12\u00a0mg dose of saquinavir was 700\u00a0l (CV 39\u00a0%). It has been shown that saquinavir is approximately 97\u00a0% bound to plasma proteins up to 30\u00a0", "ParentId": "5967086a-263e-4e54-bc85-bff94a183403"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">m</span>", "ID": "0e2d0db9-9fe9-417d-9606-f2964c6ceb84", "Styles": "font-family:Symbol", "Classes": "None", "Text": "m", "ParentId": "5967086a-263e-4e54-bc85-bff94a183403"}, {"Element": "<span lang=\"EN-GB\">g/ml. In two patients receiving Invirase 600\u00a0mg three times\ndaily, cerebrospinal fluid concentrations of saquinavir were negligible when\ncompared to concentrations from matching plasma samples.</span>", "ID": "d74dd7b3-a156-432f-8a08-93f2c0cd5081", "Styles": "None", "Classes": "None", "Text": "g/ml. In two patients receiving Invirase 600\u00a0mg three times daily, cerebrospinal fluid concentrations of saquinavir were negligible when compared to concentrations from matching plasma samples.", "ParentId": "5967086a-263e-4e54-bc85-bff94a183403"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "414b6985-e951-49a8-836b-7c1c4eecde28", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cecd362f-e9f0-492a-8734-93a10d506979", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "414b6985-e951-49a8-836b-7c1c4eecde28"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Biotransformation and elimination in\nadults:</span></i></b><b><span lang=\"EN-GB\"> </span></b><i><span lang=\"EN-GB\">In\nvitro</span></i><span lang=\"EN-GB\"> studies using human liver microsomes have\nshown that the metabolism of saquinavir is cytochrome P450 mediated with the\nspecific isoenzyme, CYP3A4, responsible for more than 90\u00a0% of the hepatic\nmetabolism. Based on <i>in vitro</i> studies, saquinavir is rapidly metabolised\nto a range of mono- and di-hydroxylated inactive compounds. In a mass balance\nstudy using 600\u00a0mg 14C-saquinavir (n = 8), 88\u00a0% and 1\u00a0% of the\norally administered radioactivity, was recovered in faeces and urine, respectively,\nwithin 4 days of dosing. In an additional four subjects administered\n10.5\u00a0mg 14C-saquinavir intravenously, 81\u00a0% and 3\u00a0% of the\nintravenously administered radioactivity was recovered in faeces and urine,\nrespectively, within 4\u00a0days of dosing. 13\u00a0% of circulating saquinavir\nin plasma was present as unchanged compound after oral administration and the\nremainder as metabolites. Following intravenous administration 66\u00a0% of\ncirculating saquinavir was present as unchanged compound and the remainder as\nmetabolites, suggesting that saquinavir undergoes extensive first pass\nmetabolism. <i>In vitro</i> experiments have shown that the hepatic metabolism\nof saquinavir becomes saturable at concentrations above 2 </span><span lang=\"EN-GB\" style=\"font-family:Symbol\">m</span><span lang=\"EN-GB\">g/ml.</span></p>", "ID": "cc72bb92-5622-4dca-ac9e-1e3a6acb6ac1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Biotransformation and elimination in\nadults:</span></i></b>", "ID": "7dcc68c2-2051-4485-a129-c7fc72996575", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cc72bb92-5622-4dca-ac9e-1e3a6acb6ac1"}, {"Element": "<i><span lang=\"EN-GB\">Biotransformation and elimination in\nadults:</span></i>", "ID": "e6ebd6e8-5e79-4c9c-8864-ee5c7e8a7092", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7dcc68c2-2051-4485-a129-c7fc72996575"}, {"Element": "<span lang=\"EN-GB\">Biotransformation and elimination in\nadults:</span>", "ID": "e0f99b4b-a4ab-45d8-b703-745e825a9639", "Styles": "None", "Classes": "None", "Text": "Biotransformation and elimination in adults:", "ParentId": "e6ebd6e8-5e79-4c9c-8864-ee5c7e8a7092"}, {"Element": "<b><span lang=\"EN-GB\"> </span></b>", "ID": "4dab4d4f-ab05-40e7-bfed-457f6b1f133a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cc72bb92-5622-4dca-ac9e-1e3a6acb6ac1"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "9e08ff50-418f-487a-89ef-cd5a328788f1", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "4dab4d4f-ab05-40e7-bfed-457f6b1f133a"}, {"Element": "<i><span lang=\"EN-GB\">In\nvitro</span></i>", "ID": "7c2165ef-e337-4973-84fc-c5677018ccdc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cc72bb92-5622-4dca-ac9e-1e3a6acb6ac1"}, {"Element": "<span lang=\"EN-GB\">In\nvitro</span>", "ID": "7f70947d-9c93-4b22-819c-f75b0536ce76", "Styles": "None", "Classes": "None", "Text": "In vitro", "ParentId": "7c2165ef-e337-4973-84fc-c5677018ccdc"}, {"Element": "<span lang=\"EN-GB\"> studies using human liver microsomes have\nshown that the metabolism of saquinavir is cytochrome P450 mediated with the\nspecific isoenzyme, CYP3A4, responsible for more than 90\u00a0% of the hepatic\nmetabolism. Based on <i>in vitro</i> studies, saquinavir is rapidly metabolised\nto a range of mono- and di-hydroxylated inactive compounds. In a mass balance\nstudy using 600\u00a0mg 14C-saquinavir (n = 8), 88\u00a0% and 1\u00a0% of the\norally administered radioactivity, was recovered in faeces and urine, respectively,\nwithin 4 days of dosing. In an additional four subjects administered\n10.5\u00a0mg 14C-saquinavir intravenously, 81\u00a0% and 3\u00a0% of the\nintravenously administered radioactivity was recovered in faeces and urine,\nrespectively, within 4\u00a0days of dosing. 13\u00a0% of circulating saquinavir\nin plasma was present as unchanged compound after oral administration and the\nremainder as metabolites. Following intravenous administration 66\u00a0% of\ncirculating saquinavir was present as unchanged compound and the remainder as\nmetabolites, suggesting that saquinavir undergoes extensive first pass\nmetabolism. <i>In vitro</i> experiments have shown that the hepatic metabolism\nof saquinavir becomes saturable at concentrations above 2 </span>", "ID": "191d0f5c-071a-42d9-830c-623e2248870c", "Styles": "None", "Classes": "None", "Text": " studies using human liver microsomes have shown that the metabolism of saquinavir is cytochrome P450 mediated with the specific isoenzyme, CYP3A4, responsible for more than 90\u00a0% of the hepatic metabolism. Based on  studies, saquinavir is rapidly metabolised to a range of mono- and di-hydroxylated inactive compounds. In a mass balance study using 600\u00a0mg 14C-saquinavir (n = 8), 88\u00a0% and 1\u00a0% of the orally administered radioactivity, was recovered in faeces and urine, respectively, within 4 days of dosing. In an additional four subjects administered 10.5\u00a0mg 14C-saquinavir intravenously, 81\u00a0% and 3\u00a0% of the intravenously administered radioactivity was recovered in faeces and urine, respectively, within 4\u00a0days of dosing. 13\u00a0% of circulating saquinavir in plasma was present as unchanged compound after oral administration and the remainder as metabolites. Following intravenous administration 66\u00a0% of circulating saquinavir was present as unchanged compound and the remainder as metabolites, suggesting that saquinavir undergoes extensive first pass metabolism.  experiments have shown that the hepatic metabolism of saquinavir becomes saturable at concentrations above 2 ", "ParentId": "cc72bb92-5622-4dca-ac9e-1e3a6acb6ac1"}, {"Element": "<i>in vitro</i>", "ID": "bc69af6a-7605-47e1-a28b-b2d666d940d9", "Styles": "None", "Classes": "None", "Text": "in vitro", "ParentId": "191d0f5c-071a-42d9-830c-623e2248870c"}, {"Element": "<i>In vitro</i>", "ID": "b4359941-7977-42d1-a256-25d1613b5fed", "Styles": "None", "Classes": "None", "Text": "In vitro", "ParentId": "191d0f5c-071a-42d9-830c-623e2248870c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">m</span>", "ID": "a01939b6-f1a3-41d3-aec4-32e7700f77dd", "Styles": "font-family:Symbol", "Classes": "None", "Text": "m", "ParentId": "cc72bb92-5622-4dca-ac9e-1e3a6acb6ac1"}, {"Element": "<span lang=\"EN-GB\">g/ml.</span>", "ID": "ce8a8b48-f1d4-4809-9054-8f59c092f481", "Styles": "None", "Classes": "None", "Text": "g/ml.", "ParentId": "cc72bb92-5622-4dca-ac9e-1e3a6acb6ac1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Systemic clearance of saquinavir was high,\n1.14 l/h/kg (CV 12\u00a0%), slightly above the hepatic plasma flow, and\nconstant after intravenous doses of 6, 36 and 72\u00a0mg. The mean residence\ntime of saquinavir was 7 hours (n = 8).</span></p>", "ID": "3fa8794d-9669-41e0-ab5e-8655dbc44180", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Systemic clearance of saquinavir was high,\n1.14 l/h/kg (CV 12\u00a0%), slightly above the hepatic plasma flow, and\nconstant after intravenous doses of 6, 36 and 72\u00a0mg. The mean residence\ntime of saquinavir was 7 hours (n = 8).</span>", "ID": "4d4d7bba-e139-4787-bb9a-aaeb46bb3623", "Styles": "None", "Classes": "None", "Text": "Systemic clearance of saquinavir was high, 1.14 l/h/kg (CV 12\u00a0%), slightly above the hepatic plasma flow, and constant after intravenous doses of 6, 36 and 72\u00a0mg. The mean residence time of saquinavir was 7 hours (n = 8).", "ParentId": "3fa8794d-9669-41e0-ab5e-8655dbc44180"}, {"Element": "<p class=\"MsoNormal\"><b><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i></b></p>", "ID": "5ca45a10-feff-4fb0-8e64-f29e7d1df806", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i></b>", "ID": "4161e3f0-cd8e-49eb-b3c1-b49ee6ef8c22", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5ca45a10-feff-4fb0-8e64-f29e7d1df806"}, {"Element": "<i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i>", "ID": "4df83b35-2629-4f73-8cfc-868b9e0ef871", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4161e3f0-cd8e-49eb-b3c1-b49ee6ef8c22"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "6fc1dda8-2ada-4839-b47b-ee094fb33b01", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4df83b35-2629-4f73-8cfc-868b9e0ef871"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "a9686f36-684b-4d7e-bb13-63fb54686bec", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6fc1dda8-2ada-4839-b47b-ee094fb33b01"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "b8207d15-8794-439e-80e1-a486ea05acdc", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "a9686f36-684b-4d7e-bb13-63fb54686bec"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><u><span lang=\"EN-GB\">Special\npopulations</span></u></i></b></p>", "ID": "80245990-d253-4932-a989-7cc888ee39b8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><u><span lang=\"EN-GB\">Special\npopulations</span></u></i></b>", "ID": "acf21800-a8fc-48b2-afdd-ca21fccfdcae", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "80245990-d253-4932-a989-7cc888ee39b8"}, {"Element": "<i><u><span lang=\"EN-GB\">Special\npopulations</span></u></i>", "ID": "d93de0ef-8e85-44f9-b5ac-5cc4c1fe7fa0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "acf21800-a8fc-48b2-afdd-ca21fccfdcae"}, {"Element": "<u><span lang=\"EN-GB\">Special\npopulations</span></u>", "ID": "fb722b68-10b3-495f-8d34-8bc58ea84ae3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d93de0ef-8e85-44f9-b5ac-5cc4c1fe7fa0"}, {"Element": "<span lang=\"EN-GB\">Special\npopulations</span>", "ID": "3f60e5e5-ce0b-4fae-a90e-194a927ae2b7", "Styles": "None", "Classes": "None", "Text": "Special populations", "ParentId": "fb722b68-10b3-495f-8d34-8bc58ea84ae3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i>\u00a0</i></b></p>", "ID": "882112ef-8d5c-438b-8e4c-670338debdbb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i>\u00a0</i></b>", "ID": "f536d31c-1b4e-4552-80fb-19e955485fff", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "882112ef-8d5c-438b-8e4c-670338debdbb"}, {"Element": "<i>\u00a0</i>", "ID": "0e34af1d-9668-4aad-87b9-06feb003c327", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f536d31c-1b4e-4552-80fb-19e955485fff"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i>Effect of gender\nfollowing treatment with Invirase/ritonavir:</i></b> A gender difference was\nobserved with females showing higher saquinavir exposure than males (AUC on\naverage 56\u00a0% higher and C<sub>max</sub> on average 26\u00a0% higher) in\nthe bioequivalence study comparing Invirase 500\u00a0mg film coated tablets\nwith Invirase 200\u00a0mg hard capsules both in combination with ritonavir.\nThere was no evidence that age and body-weight explained the gender difference\nin this study. Limited data from controlled clinical studies with the approved\ndosage regimen do not indicate a major difference in the efficacy and safety\nprofile between men and women.</p>", "ID": "c6c54c93-a3ba-433d-a915-00949ff906f9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": " A gender difference was observed with females showing higher saquinavir exposure than males (AUC on average 56\u00a0% higher and C on average 26\u00a0% higher) in the bioequivalence study comparing Invirase 500\u00a0mg film coated tablets with Invirase 200\u00a0mg hard capsules both in combination with ritonavir. There was no evidence that age and body-weight explained the gender difference in this study. Limited data from controlled clinical studies with the approved dosage regimen do not indicate a major difference in the efficacy and safety profile between men and women.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i>Effect of gender\nfollowing treatment with Invirase/ritonavir:</i></b>", "ID": "1fba4bba-84bc-43da-b707-52537ef5f80f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c6c54c93-a3ba-433d-a915-00949ff906f9"}, {"Element": "<i>Effect of gender\nfollowing treatment with Invirase/ritonavir:</i>", "ID": "520433e3-f4ff-4151-bf65-95909b88115c", "Styles": "None", "Classes": "None", "Text": "Effect of gender following treatment with Invirase/ritonavir:", "ParentId": "1fba4bba-84bc-43da-b707-52537ef5f80f"}, {"Element": "<sub>max</sub>", "ID": "59d3f237-84f6-4912-971c-372ccf3f3069", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "c6c54c93-a3ba-433d-a915-00949ff906f9"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8da273d0-7cef-44c9-bb60-5fea0da59713", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><b><i>Patients with hepatic impairment: </i></b>The effect\nof hepatic impairment on the steady state pharmacokinetics of\nsaquinavir/ritonavir (1000\u00a0mg/100\u00a0mg twice daily for 14 days) was\ninvestigated in 7 HIV-infected patients with moderate liver impairment (Child\nPugh Grade B score 7 to 9). The study included a control group consisting of 7\nHIV-infected patients with normal hepatic function matched with the hepatically\nimpaired patients for age, gender, weight and tobacco use. The mean\n(%\u00a0coefficient of variation in parentheses) values for saquinavir AUC<sub>0-12</sub>\nand C<sub>max</sub> were 24.3 (102%)\u00a0\u00b5g\u00b7hr/ml and 3.6 (83%)\n\u00b5g/ml, respectively, for HIV-infected patients with moderate hepatic\nimpairment. The corresponding values in the control group were 28.5 (71%)\n\u00b5g\u00b7hr/ml and 4.3 (68%)\u00a0\u00b5g/ml. The geometric mean ratio\n(ratio of pharmacokinetic parameters in hepatically impaired patients to\npatients with normal liver function) (90% confidence interval) was 0.7 (0.3 to\n1.6) for both AUC<sub>0-12</sub> and C<sub>max</sub>, which suggests\napproximately 30% reduction in the pharmacokinetic exposure in patients with\nmoderate hepatic impairment. Results are based on total concentrations\n(protein-bound and unbound). Concentrations unbound at steady-state were not\nassessed. No dosage adjustment seems warranted for patients with moderate\nhepatic impairment based on limited data. Close monitoring of safety (including\nsigns of cardiac arrhythmia) and of virologic response is recommended due to\nincreased variability of the exposure in this population<i><span style='font-size:10.0pt;font-family:\"Arial\",sans-serif'> </span></i><span lang=\"EN-GB\">(see sections 4.2 and 4.4)</span>.</p>", "ID": "08940836-df21-4d7d-9aaf-d3f8c83f6c82", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The effect of hepatic impairment on the steady state pharmacokinetics of saquinavir/ritonavir (1000\u00a0mg/100\u00a0mg twice daily for 14 days) was investigated in 7 HIV-infected patients with moderate liver impairment (Child Pugh Grade B score 7 to 9). The study included a control group consisting of 7 HIV-infected patients with normal hepatic function matched with the hepatically impaired patients for age, gender, weight and tobacco use. The mean (%\u00a0coefficient of variation in parentheses) values for saquinavir AUC and C were 24.3 (102%)\u00a0\u00b5g\u00b7hr/ml and 3.6 (83%) \u00b5g/ml, respectively, for HIV-infected patients with moderate hepatic impairment. The corresponding values in the control group were 28.5 (71%) \u00b5g\u00b7hr/ml and 4.3 (68%)\u00a0\u00b5g/ml. The geometric mean ratio (ratio of pharmacokinetic parameters in hepatically impaired patients to patients with normal liver function) (90% confidence interval) was 0.7 (0.3 to 1.6) for both AUC and C, which suggests approximately 30% reduction in the pharmacokinetic exposure in patients with moderate hepatic impairment. Results are based on total concentrations (protein-bound and unbound). Concentrations unbound at steady-state were not assessed. No dosage adjustment seems warranted for patients with moderate hepatic impairment based on limited data. Close monitoring of safety (including signs of cardiac arrhythmia) and of virologic response is recommended due to increased variability of the exposure in this population.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i>Patients with hepatic impairment: </i></b>", "ID": "ade955e1-3357-4b12-a3e3-3966138e4c96", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "08940836-df21-4d7d-9aaf-d3f8c83f6c82"}, {"Element": "<i>Patients with hepatic impairment: </i>", "ID": "e278a6ef-e500-48b8-bf3d-1ef3a3c96c86", "Styles": "None", "Classes": "None", "Text": "Patients with hepatic impairment: ", "ParentId": "ade955e1-3357-4b12-a3e3-3966138e4c96"}, {"Element": "<sub>0-12</sub>", "ID": "81957c17-693c-42d3-9cb5-009e10914752", "Styles": "None", "Classes": "None", "Text": "0-12", "ParentId": "08940836-df21-4d7d-9aaf-d3f8c83f6c82"}, {"Element": "<sub>max</sub>", "ID": "c6ccba33-babc-4b37-a304-8ae7be7a1d4e", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "08940836-df21-4d7d-9aaf-d3f8c83f6c82"}, {"Element": "<sub>0-12</sub>", "ID": "3889f8a2-07d1-487b-8bf8-d627c4768a4d", "Styles": "None", "Classes": "None", "Text": "0-12", "ParentId": "08940836-df21-4d7d-9aaf-d3f8c83f6c82"}, {"Element": "<sub>max</sub>", "ID": "7909bbac-c15b-4f52-b751-af0488d6215b", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "08940836-df21-4d7d-9aaf-d3f8c83f6c82"}, {"Element": "<i><span style='font-size:10.0pt;font-family:\"Arial\",sans-serif'> </span></i>", "ID": "b0863e98-2f5f-43cf-90ee-70ca7b83224a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "08940836-df21-4d7d-9aaf-d3f8c83f6c82"}, {"Element": "<span style='font-size:10.0pt;font-family:\"Arial\",sans-serif'> </span>", "ID": "e458850b-599f-469f-ac86-df6d967ff4cc", "Styles": "font-size:10.0pt;font-family:\"Arial\",sans-serif", "Classes": "None", "Text": " ", "ParentId": "b0863e98-2f5f-43cf-90ee-70ca7b83224a"}, {"Element": "<span lang=\"EN-GB\">(see sections 4.2 and 4.4)</span>", "ID": "ae6db54c-9ef3-4653-abfb-c4f1917222ce", "Styles": "None", "Classes": "None", "Text": "(see sections 4.2 and 4.4)", "ParentId": "08940836-df21-4d7d-9aaf-d3f8c83f6c82"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "cd1b5216-1f0b-43b5-a638-6bf6494a5b2b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><i><span lang=\"EN-GB\">Paediatric\nPatients</span></i></b><span lang=\"EN-GB\">: Steady state pharmacokinetic\ninformation is available from HIV-infected paediatric patients from study\nNV20911. In this study, 5 patients were &lt;2 years and 13 between 2 to &lt;6\nyears and received 50\u00a0mg/kg saquinavir bid (not to exceed 1000\u00a0mg\nbid) boosted with ritonavir at 3\u00a0mg/kg for patients with body weight\nranging from 5 to &lt;15\u00a0kg or 2.5\u00a0mg/kg for patients with body\nweight ranging from 15 to 40\u00a0kg (not to exceed 100\u00a0mg bid).</span><span lang=\"EN-GB\"> Sixteen of 18 children could not swallow Invirase hard capsules and\nreceived medication by opening the capsules and mixing the contents with\ndifferent vehicles.</span><span lang=\"EN-GB\"> The pharmacokinetic exposure\nparameters for </span><span lang=\"EN-GB\">the \u201cHigh Age Group\u201d </span><span lang=\"EN-GB\">are listed in Table 10. </span><span lang=\"EN-GB\">Results of the\n\u201cLow Age Group\u201d are not shown as data are limited due to the small\nsize of the group.</span></p>", "ID": "d2df182d-b7b1-4c56-ab0a-6b6aee4f5934", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Paediatric\nPatients</span></i></b>", "ID": "8a4d24fc-1b7a-4d1a-8830-9a6579478608", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d2df182d-b7b1-4c56-ab0a-6b6aee4f5934"}, {"Element": "<i><span lang=\"EN-GB\">Paediatric\nPatients</span></i>", "ID": "3aff52cf-8409-4f40-a333-b8e5dc75c50f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8a4d24fc-1b7a-4d1a-8830-9a6579478608"}, {"Element": "<span lang=\"EN-GB\">Paediatric\nPatients</span>", "ID": "1356026b-8765-4905-b6d9-0b23d8259b9b", "Styles": "None", "Classes": "None", "Text": "Paediatric Patients", "ParentId": "3aff52cf-8409-4f40-a333-b8e5dc75c50f"}, {"Element": "<span lang=\"EN-GB\">: Steady state pharmacokinetic\ninformation is available from HIV-infected paediatric patients from study\nNV20911. In this study, 5 patients were &lt;2 years and 13 between 2 to &lt;6\nyears and received 50\u00a0mg/kg saquinavir bid (not to exceed 1000\u00a0mg\nbid) boosted with ritonavir at 3\u00a0mg/kg for patients with body weight\nranging from 5 to &lt;15\u00a0kg or 2.5\u00a0mg/kg for patients with body\nweight ranging from 15 to 40\u00a0kg (not to exceed 100\u00a0mg bid).</span>", "ID": "d5a610b4-a08c-40dd-bc4f-04dcdf58a9e0", "Styles": "None", "Classes": "None", "Text": ": Steady state pharmacokinetic information is available from HIV-infected paediatric patients from study NV20911. In this study, 5 patients were <2 years and 13 between 2 to <6 years and received 50\u00a0mg/kg saquinavir bid (not to exceed 1000\u00a0mg bid) boosted with ritonavir at 3\u00a0mg/kg for patients with body weight ranging from 5 to <15\u00a0kg or 2.5\u00a0mg/kg for patients with body weight ranging from 15 to 40\u00a0kg (not to exceed 100\u00a0mg bid).", "ParentId": "d2df182d-b7b1-4c56-ab0a-6b6aee4f5934"}, {"Element": "<span lang=\"EN-GB\"> Sixteen of 18 children could not swallow Invirase hard capsules and\nreceived medication by opening the capsules and mixing the contents with\ndifferent vehicles.</span>", "ID": "1034ab1d-463d-4a2f-95aa-c7580d28d0db", "Styles": "None", "Classes": "None", "Text": " Sixteen of 18 children could not swallow Invirase hard capsules and received medication by opening the capsules and mixing the contents with different vehicles.", "ParentId": "d2df182d-b7b1-4c56-ab0a-6b6aee4f5934"}, {"Element": "<span lang=\"EN-GB\"> The pharmacokinetic exposure\nparameters for </span>", "ID": "28ea2f49-298e-41c5-b783-884420ce2aa9", "Styles": "None", "Classes": "None", "Text": " The pharmacokinetic exposure parameters for ", "ParentId": "d2df182d-b7b1-4c56-ab0a-6b6aee4f5934"}, {"Element": "<span lang=\"EN-GB\">the \u201cHigh Age Group\u201d </span>", "ID": "9db36477-0d6f-4674-a590-95e6ed3a7dcf", "Styles": "None", "Classes": "None", "Text": "the \u201cHigh Age Group\u201d ", "ParentId": "d2df182d-b7b1-4c56-ab0a-6b6aee4f5934"}, {"Element": "<span lang=\"EN-GB\">are listed in Table 10. </span>", "ID": "c91e126a-ed6c-43f6-8755-d23f1c9b494f", "Styles": "None", "Classes": "None", "Text": "are listed in Table 10. ", "ParentId": "d2df182d-b7b1-4c56-ab0a-6b6aee4f5934"}, {"Element": "<span lang=\"EN-GB\">Results of the\n\u201cLow Age Group\u201d are not shown as data are limited due to the small\nsize of the group.</span>", "ID": "914b861a-14f4-4967-9223-e81013d98319", "Styles": "None", "Classes": "None", "Text": "Results of the \u201cLow Age Group\u201d are not shown as data are limited due to the small size of the group.", "ParentId": "d2df182d-b7b1-4c56-ab0a-6b6aee4f5934"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:TimesNewRomanPSMT\">\u00a0</span></p>", "ID": "460ae6a6-36df-4ca1-985c-d47024415d07", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:TimesNewRomanPSMT\">\u00a0</span>", "ID": "45933765-e864-43f4-beaf-acc81bdc48ba", "Styles": "font-family:TimesNewRomanPSMT", "Classes": "None", "Text": "\u00a0", "ParentId": "460ae6a6-36df-4ca1-985c-d47024415d07"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Table\u00a010:\nPharmacokinetic parameters of saquinavir at steady-state in HIV-infected\npediatric patients</p>", "ID": "43f6847b-e0c9-40c8-b696-b787eac03eb4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Table\u00a010: Pharmacokinetic parameters of saquinavir at steady-state in HIV-infected pediatric patients", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "60d632bf-763c-430c-8e52-917ebf317421", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td colspan=\"3\" style=\"width:221.4pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"295\">\n<p class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt\">\u00a0</p>\n</td>\n<td colspan=\"3\" style=\"width:221.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"295\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>Mean \u00b1 SD Saquinavir (%CV) Pharmacokinetic\n  Parameters*</b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:95.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt\"><b>Study</b></p>\n</td>\n<td style=\"width:78.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:14.0pt\"><b>Age</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:14.0pt\"><b>Group</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:14.0pt\">(Years)</p>\n</td>\n<td style=\"width:48.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"64\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>N</b></p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>AUC<sub>0-12h</sub> (ng\u2022h/mL)</b></p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>C<sub>trough</sub> (ng/mL)</b></p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>C<sub>max </sub>(ng/mL)</b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:95.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt\">NV20911</p>\n</td>\n<td style=\"width:78.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">2 to &lt; 6 years</p>\n</td>\n<td style=\"width:48.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"64\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">13</p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">38000 \u00b1 18100</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">(48%)</p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">1860 \u00b1 1060</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">(57%)</p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">5570 \u00b1 2780</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">(50%)</p>\n</td>\n</tr>\n</table>", "ID": "a2f42f65-5022-4653-83a7-003bf9b75272", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "    ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<tr>\n<td colspan=\"3\" style=\"width:221.4pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"295\">\n<p class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt\">\u00a0</p>\n</td>\n<td colspan=\"3\" style=\"width:221.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"295\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>Mean \u00b1 SD Saquinavir (%CV) Pharmacokinetic\n  Parameters*</b></p>\n</td>\n</tr>", "ID": "36586b26-5bfa-492a-99eb-e2176852e85a", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "a2f42f65-5022-4653-83a7-003bf9b75272"}, {"Element": "<td colspan=\"3\" style=\"width:221.4pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"295\">\n<p class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt\">\u00a0</p>\n</td>", "ID": "353c34eb-ee12-4734-9d28-c1380f579571", "Styles": "width:221.4pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "36586b26-5bfa-492a-99eb-e2176852e85a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt\">\u00a0</p>", "ID": "39d11bba-a749-4251-958e-35d6d2424733", "Styles": "margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "353c34eb-ee12-4734-9d28-c1380f579571"}, {"Element": "<td colspan=\"3\" style=\"width:221.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"295\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>Mean \u00b1 SD Saquinavir (%CV) Pharmacokinetic\n  Parameters*</b></p>\n</td>", "ID": "b7a0f6a8-6fcf-4351-90e4-b2e732451004", "Styles": "width:221.4pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "36586b26-5bfa-492a-99eb-e2176852e85a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>Mean \u00b1 SD Saquinavir (%CV) Pharmacokinetic\n  Parameters*</b></p>", "ID": "a822bfdf-43f4-4eea-95f2-c760b6aeb40c", "Styles": "margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b7a0f6a8-6fcf-4351-90e4-b2e732451004"}, {"Element": "<b>Mean \u00b1 SD Saquinavir (%CV) Pharmacokinetic\n  Parameters*</b>", "ID": "3d76e575-697b-4309-85e7-93677941970a", "Styles": "None", "Classes": "None", "Text": "Mean \u00b1 SD Saquinavir (%CV) Pharmacokinetic   Parameters*", "ParentId": "a822bfdf-43f4-4eea-95f2-c760b6aeb40c"}, {"Element": "<tr>\n<td style=\"width:95.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt\"><b>Study</b></p>\n</td>\n<td style=\"width:78.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:14.0pt\"><b>Age</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:14.0pt\"><b>Group</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:14.0pt\">(Years)</p>\n</td>\n<td style=\"width:48.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"64\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>N</b></p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>AUC<sub>0-12h</sub> (ng\u2022h/mL)</b></p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>C<sub>trough</sub> (ng/mL)</b></p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>C<sub>max </sub>(ng/mL)</b></p>\n</td>\n</tr>", "ID": "ee84bcb4-93f7-4901-866f-372b8719050e", "Styles": "None", "Classes": "None", "Text": "       ", "ParentId": "a2f42f65-5022-4653-83a7-003bf9b75272"}, {"Element": "<td style=\"width:95.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt\"><b>Study</b></p>\n</td>", "ID": "4d5ee5de-adfb-468c-a8ce-284dfc7ab569", "Styles": "width:95.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee84bcb4-93f7-4901-866f-372b8719050e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt\"><b>Study</b></p>", "ID": "fbe54390-de02-486d-acef-862f7ad5fd50", "Styles": "margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d5ee5de-adfb-468c-a8ce-284dfc7ab569"}, {"Element": "<b>Study</b>", "ID": "68f1d635-abe2-419e-ae12-d33f66503ee6", "Styles": "None", "Classes": "None", "Text": "Study", "ParentId": "fbe54390-de02-486d-acef-862f7ad5fd50"}, {"Element": "<td style=\"width:78.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:14.0pt\"><b>Age</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:14.0pt\"><b>Group</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:14.0pt\">(Years)</p>\n</td>", "ID": "17db3d59-2b8c-488e-8513-5f95d0daf689", "Styles": "width:78.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "ee84bcb4-93f7-4901-866f-372b8719050e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:14.0pt\"><b>Age</b></p>", "ID": "16994b5b-dc5f-4ca4-aed7-a8d1e67a607b", "Styles": "text-align:center;line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "17db3d59-2b8c-488e-8513-5f95d0daf689"}, {"Element": "<b>Age</b>", "ID": "645f54f2-6942-4d9f-9743-aee08ef276de", "Styles": "None", "Classes": "None", "Text": "Age", "ParentId": "16994b5b-dc5f-4ca4-aed7-a8d1e67a607b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:14.0pt\"><b>Group</b></p>", "ID": "c0c253a0-2076-4398-91dc-d947fd75e2f2", "Styles": "text-align:center;line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "17db3d59-2b8c-488e-8513-5f95d0daf689"}, {"Element": "<b>Group</b>", "ID": "0d817d0a-1764-403e-8638-779c10e620a9", "Styles": "None", "Classes": "None", "Text": "Group", "ParentId": "c0c253a0-2076-4398-91dc-d947fd75e2f2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:14.0pt\">(Years)</p>", "ID": "29bcd370-4ec9-4739-b9f3-2043719f45b8", "Styles": "text-align:center;line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "(Years)", "ParentId": "17db3d59-2b8c-488e-8513-5f95d0daf689"}, {"Element": "<td style=\"width:48.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"64\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>N</b></p>\n</td>", "ID": "dfc64c57-8492-47a7-a596-660e4e0274a0", "Styles": "width:48.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee84bcb4-93f7-4901-866f-372b8719050e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>N</b></p>", "ID": "29a85d59-a4f3-421e-8f7e-2d4e5305a8e8", "Styles": "margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dfc64c57-8492-47a7-a596-660e4e0274a0"}, {"Element": "<b>N</b>", "ID": "d77e795d-414b-4639-a21c-9f25e5b7170e", "Styles": "None", "Classes": "None", "Text": "N", "ParentId": "29a85d59-a4f3-421e-8f7e-2d4e5305a8e8"}, {"Element": "<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>AUC<sub>0-12h</sub> (ng\u2022h/mL)</b></p>\n</td>", "ID": "a803062b-6bc2-4830-8aa3-bcca06f6d28b", "Styles": "width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee84bcb4-93f7-4901-866f-372b8719050e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>AUC<sub>0-12h</sub> (ng\u2022h/mL)</b></p>", "ID": "f9127dfa-45db-4003-88cf-51179b73b760", "Styles": "margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a803062b-6bc2-4830-8aa3-bcca06f6d28b"}, {"Element": "<b>AUC<sub>0-12h</sub> (ng\u2022h/mL)</b>", "ID": "d05a85fe-0a38-433f-880f-5970bc249db1", "Styles": "None", "Classes": "None", "Text": "AUC (ng\u2022h/mL)", "ParentId": "f9127dfa-45db-4003-88cf-51179b73b760"}, {"Element": "<sub>0-12h</sub>", "ID": "15a75c79-1dd9-45a3-a28d-8d373dc2240e", "Styles": "None", "Classes": "None", "Text": "0-12h", "ParentId": "d05a85fe-0a38-433f-880f-5970bc249db1"}, {"Element": "<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>C<sub>trough</sub> (ng/mL)</b></p>\n</td>", "ID": "f89ad422-15b3-47d3-b4c7-71bec23fb501", "Styles": "width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee84bcb4-93f7-4901-866f-372b8719050e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>C<sub>trough</sub> (ng/mL)</b></p>", "ID": "e15b53b5-8eee-4d39-a87f-80970f763157", "Styles": "margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f89ad422-15b3-47d3-b4c7-71bec23fb501"}, {"Element": "<b>C<sub>trough</sub> (ng/mL)</b>", "ID": "fa1fe8d1-c611-4c0c-9dfc-5fae193999d4", "Styles": "None", "Classes": "None", "Text": "C (ng/mL)", "ParentId": "e15b53b5-8eee-4d39-a87f-80970f763157"}, {"Element": "<sub>trough</sub>", "ID": "863294c7-ef52-4a44-b3de-a992b5a317bd", "Styles": "None", "Classes": "None", "Text": "trough", "ParentId": "fa1fe8d1-c611-4c0c-9dfc-5fae193999d4"}, {"Element": "<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>C<sub>max </sub>(ng/mL)</b></p>\n</td>", "ID": "8355e8fb-594f-4fd2-8481-71deb1d69e10", "Styles": "width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee84bcb4-93f7-4901-866f-372b8719050e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\"><b>C<sub>max </sub>(ng/mL)</b></p>", "ID": "f0291cd3-4b85-44dc-b610-3afe36121cc1", "Styles": "margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8355e8fb-594f-4fd2-8481-71deb1d69e10"}, {"Element": "<b>C<sub>max </sub>(ng/mL)</b>", "ID": "1641d8cb-7f9d-4b34-8f7b-e3666b6a365d", "Styles": "None", "Classes": "None", "Text": "C(ng/mL)", "ParentId": "f0291cd3-4b85-44dc-b610-3afe36121cc1"}, {"Element": "<sub>max </sub>", "ID": "36afb726-b07d-463b-aefb-adf1542e0cea", "Styles": "None", "Classes": "None", "Text": "max ", "ParentId": "1641d8cb-7f9d-4b34-8f7b-e3666b6a365d"}, {"Element": "<tr>\n<td style=\"width:95.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt\">NV20911</p>\n</td>\n<td style=\"width:78.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">2 to &lt; 6 years</p>\n</td>\n<td style=\"width:48.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"64\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">13</p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">38000 \u00b1 18100</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">(48%)</p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">1860 \u00b1 1060</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">(57%)</p>\n</td>\n<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">5570 \u00b1 2780</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">(50%)</p>\n</td>\n</tr>", "ID": "35d274ab-0e82-4986-948f-f89336c60efc", "Styles": "None", "Classes": "None", "Text": "       ", "ParentId": "a2f42f65-5022-4653-83a7-003bf9b75272"}, {"Element": "<td style=\"width:95.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt\">NV20911</p>\n</td>", "ID": "dbaae6f8-cdaf-4c20-b80e-0b469c2cd4da", "Styles": "width:95.4pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "35d274ab-0e82-4986-948f-f89336c60efc"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt\">NV20911</p>", "ID": "21f60d74-2b17-4971-811b-cc69288021bd", "Styles": "margin-bottom:8.5pt;text-align:justify;text-justify:\n  inter-ideograph;line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "NV20911", "ParentId": "dbaae6f8-cdaf-4c20-b80e-0b469c2cd4da"}, {"Element": "<td style=\"width:78.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"104\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">2 to &lt; 6 years</p>\n</td>", "ID": "adb37ae5-429a-4a9e-b4c5-ead4e43112ca", "Styles": "width:78.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "35d274ab-0e82-4986-948f-f89336c60efc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">2 to &lt; 6 years</p>", "ID": "be49d988-3045-433e-b74d-8f9fecbb717d", "Styles": "margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "2 to < 6 years", "ParentId": "adb37ae5-429a-4a9e-b4c5-ead4e43112ca"}, {"Element": "<td style=\"width:48.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"64\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">13</p>\n</td>", "ID": "3b810586-6737-4f80-8719-9cab928f022d", "Styles": "width:48.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "35d274ab-0e82-4986-948f-f89336c60efc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">13</p>", "ID": "81ff92f5-ea08-4f2c-bd97-1acee83bf3ac", "Styles": "margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "13", "ParentId": "3b810586-6737-4f80-8719-9cab928f022d"}, {"Element": "<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">38000 \u00b1 18100</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">(48%)</p>\n</td>", "ID": "544c182f-5ca2-4568-86b9-a620277aaab8", "Styles": "width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "35d274ab-0e82-4986-948f-f89336c60efc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">38000 \u00b1 18100</p>", "ID": "dffe7435-96f9-4c80-9aa6-ea8bc5e394a9", "Styles": "margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "38000 \u00b1 18100", "ParentId": "544c182f-5ca2-4568-86b9-a620277aaab8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">(48%)</p>", "ID": "dae1127b-398c-4513-85d5-ccfe81601236", "Styles": "margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "(48%)", "ParentId": "544c182f-5ca2-4568-86b9-a620277aaab8"}, {"Element": "<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">1860 \u00b1 1060</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">(57%)</p>\n</td>", "ID": "3a113a4e-582b-48b3-bc61-a49cd18f49f9", "Styles": "width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "35d274ab-0e82-4986-948f-f89336c60efc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">1860 \u00b1 1060</p>", "ID": "0c51a886-2b32-4bb9-a39a-0a3f382c7060", "Styles": "margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "1860 \u00b1 1060", "ParentId": "3a113a4e-582b-48b3-bc61-a49cd18f49f9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">(57%)</p>", "ID": "d8211735-c0a2-4ab6-8b7a-0019d46fbebe", "Styles": "margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "(57%)", "ParentId": "3a113a4e-582b-48b3-bc61-a49cd18f49f9"}, {"Element": "<td style=\"width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"98\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">5570 \u00b1 2780</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">(50%)</p>\n</td>", "ID": "d09c74c0-b523-413f-a46a-f627189f906f", "Styles": "width:73.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "35d274ab-0e82-4986-948f-f89336c60efc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">5570 \u00b1 2780</p>", "ID": "de0a1cf7-0f4e-4112-9fcd-a1991a9b127d", "Styles": "margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "5570 \u00b1 2780", "ParentId": "d09c74c0-b523-413f-a46a-f627189f906f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt\">(50%)</p>", "ID": "3f544399-7cf2-49d1-80cf-01b18237c796", "Styles": "margin-bottom:8.5pt;text-align:center;\n  line-height:14.0pt", "Classes": "['MsoNormal']", "Text": "(50%)", "ParentId": "d09c74c0-b523-413f-a46a-f627189f906f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">* All parameters normalized to a 50\u00a0mg/kg dose</span></p>", "ID": "08ba4050-1722-490f-956f-ca1728b32c76", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">* All parameters normalized to a 50\u00a0mg/kg dose</span>", "ID": "7b6d97c1-e7f7-418f-b6ae-9dde5f206652", "Styles": "None", "Classes": "None", "Text": "* All parameters normalized to a 50\u00a0mg/kg dose", "ParentId": "08ba4050-1722-490f-956f-ca1728b32c76"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c8b7eb82-88f6-4102-8545-d6fe7cd571a9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aba1320f-197e-4089-9dbc-d06346849645", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c8b7eb82-88f6-4102-8545-d6fe7cd571a9"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">Steady state saquinavir exposures\nobserved in paediatric trials were substantially higher than historical data in\nadults where dose- and exposure-dependent QTc and PR prolongation were observed\n(see section 4.4).</span></p>", "ID": "301484da-bfb0-4f16-ac08-6dd56140ad11", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"color:black\">Steady state saquinavir exposures\nobserved in paediatric trials were substantially higher than historical data in\nadults where dose- and exposure-dependent QTc and PR prolongation were observed\n(see section 4.4).</span>", "ID": "b144db52-785b-4a10-a7c7-8bfc7e353b2e", "Styles": "color:black", "Classes": "None", "Text": "Steady state saquinavir exposures observed in paediatric trials were substantially higher than historical data in adults where dose- and exposure-dependent QTc and PR prolongation were observed (see section 4.4).", "ParentId": "301484da-bfb0-4f16-ac08-6dd56140ad11"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d170ee67-6b87-465e-88af-dcf481890cda", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data</span></b></p>", "ID": "982cfbf5-d787-4c5b-ba3b-c960b3af52c3", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data</span></b>", "ID": "afacedbc-3ad8-4ff3-9d2c-481f917e3187", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "982cfbf5-d787-4c5b-ba3b-c960b3af52c3"}, {"Element": "<span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data</span>", "ID": "fa197295-9e08-4cf2-9874-6feb5db783d0", "Styles": "None", "Classes": "None", "Text": "5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data", "ParentId": "afacedbc-3ad8-4ff3-9d2c-481f917e3187"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8ce0b4b6-6f61-4dbb-b984-508d0a3792f7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5c2e1888-f3c8-4417-84b4-0bc99837c144", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8ce0b4b6-6f61-4dbb-b984-508d0a3792f7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">A<i>cute\nand chronic toxicity:</i></span></b><span lang=\"EN-GB\"> Saquinavir was well\ntolerated in oral acute and chronic toxicity studies in mice, rats, dogs and\nmarmosets.</span></p>", "ID": "d3119060-055d-48ad-9da7-944496cf549d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">A<i>cute\nand chronic toxicity:</i></span></b>", "ID": "1c895be2-ee46-4f67-9015-43104868632b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d3119060-055d-48ad-9da7-944496cf549d"}, {"Element": "<span lang=\"EN-GB\">A<i>cute\nand chronic toxicity:</i></span>", "ID": "f68d288f-2bd3-45b5-99de-1688eb5b7d0e", "Styles": "None", "Classes": "None", "Text": "A", "ParentId": "1c895be2-ee46-4f67-9015-43104868632b"}, {"Element": "<i>cute\nand chronic toxicity:</i>", "ID": "a8e0b2f6-b9ac-4708-b488-e73e142d51e8", "Styles": "None", "Classes": "None", "Text": "cute and chronic toxicity:", "ParentId": "f68d288f-2bd3-45b5-99de-1688eb5b7d0e"}, {"Element": "<span lang=\"EN-GB\"> Saquinavir was well\ntolerated in oral acute and chronic toxicity studies in mice, rats, dogs and\nmarmosets.</span>", "ID": "d588df16-c127-4569-a579-6e186c787ee8", "Styles": "None", "Classes": "None", "Text": " Saquinavir was well tolerated in oral acute and chronic toxicity studies in mice, rats, dogs and marmosets.", "ParentId": "d3119060-055d-48ad-9da7-944496cf549d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "27bead24-70c3-44c4-87c0-16dbc7e5627f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d1b06e5b-138a-4751-9cc0-87f7d59c2f4f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "27bead24-70c3-44c4-87c0-16dbc7e5627f"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Mutagenesis:</span></i></b><i><span lang=\"EN-GB\"> </span></i>Mutagenicity and genotoxicity studies, with and without\nmetabolic activation where appropriate, have shown that saquinavir has no\nmutagenic activity <i>in vitro</i> in either bacterial (Ames test) or mammalian\ncells (Chinese hamster lung V79/HPRT test). Saquinavir does not induce\nchromosomal damage <i>in vivo</i> in the mouse micronucleus assay or <i>in\nvitro</i> in human peripheral blood lymphocytes and does not induce primary DNA\ndamage <i>in vitro</i> in the unscheduled DNA synthesis test.</p>", "ID": "f45c965e-0dd7-4909-8094-accac5852789", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Mutagenicity and genotoxicity studies, with and without metabolic activation where appropriate, have shown that saquinavir has no mutagenic activity  in either bacterial (Ames test) or mammalian cells (Chinese hamster lung V79/HPRT test). Saquinavir does not induce chromosomal damage  in the mouse micronucleus assay or  in human peripheral blood lymphocytes and does not induce primary DNA damage  in the unscheduled DNA synthesis test.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Mutagenesis:</span></i></b>", "ID": "af686e50-9dc0-4a7c-8720-e9c272db8c45", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f45c965e-0dd7-4909-8094-accac5852789"}, {"Element": "<i><span lang=\"EN-GB\">Mutagenesis:</span></i>", "ID": "eca88f25-a687-4591-987f-4ef777e562b6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "af686e50-9dc0-4a7c-8720-e9c272db8c45"}, {"Element": "<span lang=\"EN-GB\">Mutagenesis:</span>", "ID": "eed34e28-b22b-4b61-b29e-37dbf943ac01", "Styles": "None", "Classes": "None", "Text": "Mutagenesis:", "ParentId": "eca88f25-a687-4591-987f-4ef777e562b6"}, {"Element": "<i><span lang=\"EN-GB\"> </span></i>", "ID": "3daae824-f9c9-4139-b416-a972ac9dfef8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f45c965e-0dd7-4909-8094-accac5852789"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "9b572073-1829-49ec-9baf-aa28bb345b01", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "3daae824-f9c9-4139-b416-a972ac9dfef8"}, {"Element": "<i>in vitro</i>", "ID": "a0f0f154-8cb9-4df3-bb4d-a16be9706b57", "Styles": "None", "Classes": "None", "Text": "in vitro", "ParentId": "f45c965e-0dd7-4909-8094-accac5852789"}, {"Element": "<i>in vivo</i>", "ID": "79dcee65-4125-42df-b6d8-d8e0f4f210b7", "Styles": "None", "Classes": "None", "Text": "in vivo", "ParentId": "f45c965e-0dd7-4909-8094-accac5852789"}, {"Element": "<i>in\nvitro</i>", "ID": "80398d3c-4413-42f2-b101-ceec7cd5c643", "Styles": "None", "Classes": "None", "Text": "in vitro", "ParentId": "f45c965e-0dd7-4909-8094-accac5852789"}, {"Element": "<i>in vitro</i>", "ID": "2a57ef14-4bb9-40e8-b4c2-89a5a67c343d", "Styles": "None", "Classes": "None", "Text": "in vitro", "ParentId": "f45c965e-0dd7-4909-8094-accac5852789"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "a81819fe-e4a2-4451-99a5-d51346aef14b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "aa1f5d30-3d6a-41b7-800e-017378b44d8b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a81819fe-e4a2-4451-99a5-d51346aef14b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ef6cd279-bc9a-4fe7-a96f-24cce74cbfab", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aa1f5d30-3d6a-41b7-800e-017378b44d8b"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Carcinogenesis:</span></i></b><i><span lang=\"EN-GB\"> </span></i><span lang=\"EN-GB\">There was no evidence of carcinogenic\nactivity after the administration of saquinavir mesilate for 96 to 104 weeks to\nrats and mice. The plasma exposures (AUC values) in </span>rats (maximum dose\n1000\u00a0mg/kg/day) and in mice (maximum dose 2500\u00a0mg/kg/day) were lower\nthan<span lang=\"EN-GB\"> the expected plasma exposures obtained in humans at the\nrecommended clinical dose of ritonavir boosted Invirase. </span></p>", "ID": "1861eaac-13bd-4383-9ecb-6286fd4ab204", "Styles": "None", "Classes": "['MsoNormal']", "Text": "rats (maximum dose 1000\u00a0mg/kg/day) and in mice (maximum dose 2500\u00a0mg/kg/day) were lower than", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Carcinogenesis:</span></i></b>", "ID": "a3e02bf7-f8cd-4e05-98db-87853891d2e3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1861eaac-13bd-4383-9ecb-6286fd4ab204"}, {"Element": "<i><span lang=\"EN-GB\">Carcinogenesis:</span></i>", "ID": "0f68c98c-6e55-469e-a0cb-7a8366406cbf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a3e02bf7-f8cd-4e05-98db-87853891d2e3"}, {"Element": "<span lang=\"EN-GB\">Carcinogenesis:</span>", "ID": "8bdbc764-3f91-4d23-b1cd-9a0ebe2d77fe", "Styles": "None", "Classes": "None", "Text": "Carcinogenesis:", "ParentId": "0f68c98c-6e55-469e-a0cb-7a8366406cbf"}, {"Element": "<i><span lang=\"EN-GB\"> </span></i>", "ID": "39cb022f-2cd4-487d-94d1-8eb0404aaa82", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1861eaac-13bd-4383-9ecb-6286fd4ab204"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "a86fa010-4ea7-4387-886a-568288c1d9ce", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "39cb022f-2cd4-487d-94d1-8eb0404aaa82"}, {"Element": "<span lang=\"EN-GB\">There was no evidence of carcinogenic\nactivity after the administration of saquinavir mesilate for 96 to 104 weeks to\nrats and mice. The plasma exposures (AUC values) in </span>", "ID": "fdba6936-88f1-4ff0-b753-552b97107f0b", "Styles": "None", "Classes": "None", "Text": "There was no evidence of carcinogenic activity after the administration of saquinavir mesilate for 96 to 104 weeks to rats and mice. The plasma exposures (AUC values) in ", "ParentId": "1861eaac-13bd-4383-9ecb-6286fd4ab204"}, {"Element": "<span lang=\"EN-GB\"> the expected plasma exposures obtained in humans at the\nrecommended clinical dose of ritonavir boosted Invirase. </span>", "ID": "7cbf3362-0df3-4bf7-948d-98af58c56485", "Styles": "None", "Classes": "None", "Text": " the expected plasma exposures obtained in humans at the recommended clinical dose of ritonavir boosted Invirase. ", "ParentId": "1861eaac-13bd-4383-9ecb-6286fd4ab204"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "70fe9187-42ec-415b-a2a2-ce3340e555cc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0bf0ab33-fcc7-4bbd-9aba-fb5fd68e672d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "70fe9187-42ec-415b-a2a2-ce3340e555cc"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">Reproductive toxicity:</span></i></b><i><span lang=\"EN-GB\"> </span></i><span lang=\"EN-GB\">Fertility, peri- and postnatal\ndevelopment were not affected, and e</span>mbryotoxic / teratogenic effects\nwere not observed in rats or rabbits at plasma exposures lower than those\nachieved in humans <span lang=\"EN-GB\" style=\"layout-grid-mode:line\">at the\nrecommended clinical dose</span> of <span lang=\"EN-GB\">ritonavir boosted\nInvirase. Distribution studies in these species showed that the placental transfer\nof saquinavir is low (less than 5% of maternal plasma concentrations).</span></p>", "ID": "72dc7172-0b7f-40ca-b6b5-e8853a540c0e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "mbryotoxic / teratogenic effects were not observed in rats or rabbits at plasma exposures lower than those achieved in humans  of ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Reproductive toxicity:</span></i></b>", "ID": "9196b60a-a77b-402b-a260-d809f040a3af", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "72dc7172-0b7f-40ca-b6b5-e8853a540c0e"}, {"Element": "<i><span lang=\"EN-GB\">Reproductive toxicity:</span></i>", "ID": "4164015e-9cc7-4151-b643-766a52e13f87", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9196b60a-a77b-402b-a260-d809f040a3af"}, {"Element": "<span lang=\"EN-GB\">Reproductive toxicity:</span>", "ID": "4209be34-5116-46cc-8e5d-32c5c3c071b6", "Styles": "None", "Classes": "None", "Text": "Reproductive toxicity:", "ParentId": "4164015e-9cc7-4151-b643-766a52e13f87"}, {"Element": "<i><span lang=\"EN-GB\"> </span></i>", "ID": "0b3b672b-3aba-48fb-805c-6cacead719b3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "72dc7172-0b7f-40ca-b6b5-e8853a540c0e"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "04eea129-06aa-403b-8c17-2f7de736c1c8", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "0b3b672b-3aba-48fb-805c-6cacead719b3"}, {"Element": "<span lang=\"EN-GB\">Fertility, peri- and postnatal\ndevelopment were not affected, and e</span>", "ID": "2ed314a3-4294-4666-9853-8ceec870379f", "Styles": "None", "Classes": "None", "Text": "Fertility, peri- and postnatal development were not affected, and e", "ParentId": "72dc7172-0b7f-40ca-b6b5-e8853a540c0e"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">at the\nrecommended clinical dose</span>", "ID": "e6d5463b-8943-4206-ac73-5befa22a0ae0", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "at the recommended clinical dose", "ParentId": "72dc7172-0b7f-40ca-b6b5-e8853a540c0e"}, {"Element": "<span lang=\"EN-GB\">ritonavir boosted\nInvirase. Distribution studies in these species showed that the placental transfer\nof saquinavir is low (less than 5% of maternal plasma concentrations).</span>", "ID": "4b4aa480-5ee5-4608-a165-b581ec660c92", "Styles": "None", "Classes": "None", "Text": "ritonavir boosted Invirase. Distribution studies in these species showed that the placental transfer of saquinavir is low (less than 5% of maternal plasma concentrations).", "ParentId": "72dc7172-0b7f-40ca-b6b5-e8853a540c0e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6fd6e0bb-5c98-4bd7-8465-a145494a0b25", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "935db64b-a01e-46a4-9d72-fbaa942fc4b6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6fd6e0bb-5c98-4bd7-8465-a145494a0b25"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><i><span lang=\"EN-GB\">Safety\npharmacology:</span></i></b><b><span lang=\"EN-GB\"> </span></b><span lang=\"EN-GB\">C</span><span lang=\"EN-GB\">loned human cardiac potassium channel (hERG) trafficking <i>in vitro</i>\nwas inhibited by 75% at 30</span><span lang=\"DE\">\u03bc</span><span lang=\"EN-GB\">M\nof saquinavir. Saquinavir inhibited both hERG current and L-type Ca++ channel\ncurrent with respective IC50s of 4.7 and 6.3 </span><span lang=\"DE\">\u03bc</span><span lang=\"EN-GB\">M. In a myocardial distribution study in the rat an approximately\n2-fold accumulation of saquinavir was observed in the heart compared to plasma\nafter coadministration of saquinavir and ritonavir. The clinical relevance of\nthese preclinical results are unknown, however cardiac conduction and\nrepolarisation abnormalities in humans have been observed with saquinavir and\nritonavir combination therapy (see section 4.4 and 5.1).</span></p>", "ID": "a8a41d77-d33f-400c-a630-37dadda849af", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">Safety\npharmacology:</span></i></b>", "ID": "6aa10d69-5d02-4ee1-aa4f-6c4d6be569a6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a8a41d77-d33f-400c-a630-37dadda849af"}, {"Element": "<i><span lang=\"EN-GB\">Safety\npharmacology:</span></i>", "ID": "eaaccd36-1dae-4503-ad4e-176375e32809", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6aa10d69-5d02-4ee1-aa4f-6c4d6be569a6"}, {"Element": "<span lang=\"EN-GB\">Safety\npharmacology:</span>", "ID": "1b18b82e-e714-43b5-9d3e-be39e792bbc2", "Styles": "None", "Classes": "None", "Text": "Safety pharmacology:", "ParentId": "eaaccd36-1dae-4503-ad4e-176375e32809"}, {"Element": "<b><span lang=\"EN-GB\"> </span></b>", "ID": "b0c0ac95-bb24-40bb-a3da-b253410a5ec1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a8a41d77-d33f-400c-a630-37dadda849af"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "7f0b290a-5e66-40d6-8cd8-5e5f1d322431", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "b0c0ac95-bb24-40bb-a3da-b253410a5ec1"}, {"Element": "<span lang=\"EN-GB\">C</span>", "ID": "af499555-2cf9-4daf-a8ca-f84a3444de9d", "Styles": "None", "Classes": "None", "Text": "C", "ParentId": "a8a41d77-d33f-400c-a630-37dadda849af"}, {"Element": "<span lang=\"EN-GB\">loned human cardiac potassium channel (hERG) trafficking <i>in vitro</i>\nwas inhibited by 75% at 30</span>", "ID": "3d4691b7-fd83-4dfe-8c37-622af43e1a39", "Styles": "None", "Classes": "None", "Text": "loned human cardiac potassium channel (hERG) trafficking  was inhibited by 75% at 30", "ParentId": "a8a41d77-d33f-400c-a630-37dadda849af"}, {"Element": "<i>in vitro</i>", "ID": "a9308fad-1554-4c1d-b826-e0f6ca10cbd2", "Styles": "None", "Classes": "None", "Text": "in vitro", "ParentId": "3d4691b7-fd83-4dfe-8c37-622af43e1a39"}, {"Element": "<span lang=\"DE\">\u03bc</span>", "ID": "816d3adb-7dc5-419a-a4a1-9502710ad0ad", "Styles": "None", "Classes": "None", "Text": "\u03bc", "ParentId": "a8a41d77-d33f-400c-a630-37dadda849af"}, {"Element": "<span lang=\"EN-GB\">M\nof saquinavir. Saquinavir inhibited both hERG current and L-type Ca++ channel\ncurrent with respective IC50s of 4.7 and 6.3 </span>", "ID": "78ae6518-b4bb-4830-b6f2-0f3568655cf4", "Styles": "None", "Classes": "None", "Text": "M of saquinavir. Saquinavir inhibited both hERG current and L-type Ca++ channel current with respective IC50s of 4.7 and 6.3 ", "ParentId": "a8a41d77-d33f-400c-a630-37dadda849af"}, {"Element": "<span lang=\"DE\">\u03bc</span>", "ID": "47606d59-e05c-49d7-9807-3b759d1c88a1", "Styles": "None", "Classes": "None", "Text": "\u03bc", "ParentId": "a8a41d77-d33f-400c-a630-37dadda849af"}, {"Element": "<span lang=\"EN-GB\">M. In a myocardial distribution study in the rat an approximately\n2-fold accumulation of saquinavir was observed in the heart compared to plasma\nafter coadministration of saquinavir and ritonavir. The clinical relevance of\nthese preclinical results are unknown, however cardiac conduction and\nrepolarisation abnormalities in humans have been observed with saquinavir and\nritonavir combination therapy (see section 4.4 and 5.1).</span>", "ID": "b8c19377-9090-412e-a582-ef986fb70ac8", "Styles": "None", "Classes": "None", "Text": "M. In a myocardial distribution study in the rat an approximately 2-fold accumulation of saquinavir was observed in the heart compared to plasma after coadministration of saquinavir and ritonavir. The clinical relevance of these preclinical results are unknown, however cardiac conduction and repolarisation abnormalities in humans have been observed with saquinavir and ritonavir combination therapy (see section 4.4 and 5.1).", "ParentId": "a8a41d77-d33f-400c-a630-37dadda849af"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "65a3636d-a28e-4184-af8d-0d1752cb8f30", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b53c0913-7d11-4750-81a7-353741ad542b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "65a3636d-a28e-4184-af8d-0d1752cb8f30"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "367d38b8-ea44-496e-842c-fb7ae01c1098", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6423e0f6-47c7-46ea-840e-0cfdff08b554", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "367d38b8-ea44-496e-842c-fb7ae01c1098"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nPARTICULARS</span></b></p>", "ID": "e8612093-efaa-488f-8f93-8699bb6cff55", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nPARTICULARS</span></b>", "ID": "bc104070-9ab3-472b-a875-d8a8f8b6a56f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e8612093-efaa-488f-8f93-8699bb6cff55"}, {"Element": "<span lang=\"EN-GB\" style=\"text-transform:uppercase\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nPARTICULARS</span>", "ID": "0ee90b72-e43d-4e00-9582-4ad27825cf25", "Styles": "text-transform:uppercase", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS", "ParentId": "bc104070-9ab3-472b-a875-d8a8f8b6a56f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e3e55bd4-9580-4ccf-94ce-021931078080", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "43e922f7-0659-4092-9442-9e0617aace78", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e3e55bd4-9580-4ccf-94ce-021931078080"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of excipients</span></b></p>", "ID": "502a7496-bc91-4155-a627-9107912512ba", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of excipients</span></b>", "ID": "0dcf7875-2aa9-4634-9776-6c7ad2403540", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "502a7496-bc91-4155-a627-9107912512ba"}, {"Element": "<span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of excipients</span>", "ID": "c7a00b57-fb98-4a7b-aaec-5eaedeb048f7", "Styles": "None", "Classes": "None", "Text": "6.1\u00a0\u00a0\u00a0\u00a0 List of excipients", "ParentId": "0dcf7875-2aa9-4634-9776-6c7ad2403540"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "eeee782b-7bae-4c55-be6f-c7b808d93172", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "39832c57-a1ef-4250-8605-bca2cae8e2ed", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "eeee782b-7bae-4c55-be6f-c7b808d93172"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2cc01cef-5e62-468f-b7ab-767a6ee16d3d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "39832c57-a1ef-4250-8605-bca2cae8e2ed"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Tablet core: </i></p>", "ID": "20d60839-40ef-4469-82ad-4df54cfcbed4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<i>Tablet core: </i>", "ID": "872e1d13-1e74-46a3-a251-18c3e139d624", "Styles": "None", "Classes": "None", "Text": "Tablet core: ", "ParentId": "20d60839-40ef-4469-82ad-4df54cfcbed4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"IT\">Microcrystalline\ncellulose,</span></p>", "ID": "265dde55-d478-4781-904d-3017170ad846", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"IT\">Microcrystalline\ncellulose,</span>", "ID": "419b81c5-df17-45b7-976d-ab1e9fb05e82", "Styles": "None", "Classes": "None", "Text": "Microcrystalline cellulose,", "ParentId": "265dde55-d478-4781-904d-3017170ad846"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Croscarmellose sodium,</span></p>", "ID": "d5f53a32-0bb9-4cc3-a59c-aa1b5dd6c93a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"IT\">Croscarmellose sodium,</span>", "ID": "676ec851-9543-4e24-b551-35f336fa4f50", "Styles": "None", "Classes": "None", "Text": "Croscarmellose sodium,", "ParentId": "d5f53a32-0bb9-4cc3-a59c-aa1b5dd6c93a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Povidone,</span></p>", "ID": "2a3a6b2e-b04f-457a-954d-be49894070b9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"IT\">Povidone,</span>", "ID": "9d205bbd-757f-4c3a-bbd9-9a2352b93983", "Styles": "None", "Classes": "None", "Text": "Povidone,", "ParentId": "2a3a6b2e-b04f-457a-954d-be49894070b9"}, {"Element": "<p class=\"MsoNormal\">Lactose (monohydrate),</p>", "ID": "a8bfdeb2-26dc-42c8-be44-f0c8a24a8113", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Lactose (monohydrate),", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">Magnesium stearate.</p>", "ID": "fbd11cde-a36c-44cd-963c-8bf181fa8207", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Magnesium stearate.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "205b21cd-31f8-4d4d-ac6c-dc5a466f3456", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><i>Tablet coat:</i></p>", "ID": "f1f27d1c-b149-4228-b8e5-ee1483304396", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<i>Tablet coat:</i>", "ID": "0fbc6f03-6919-4c29-b958-f6ac33a22bbb", "Styles": "None", "Classes": "None", "Text": "Tablet coat:", "ParentId": "f1f27d1c-b149-4228-b8e5-ee1483304396"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Hypromellose,</span></p>", "ID": "8350867a-853a-4c44-82a9-670086a10f2d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"IT\">Hypromellose,</span>", "ID": "66c5d672-4e04-47ac-897f-36c829beb307", "Styles": "None", "Classes": "None", "Text": "Hypromellose,", "ParentId": "8350867a-853a-4c44-82a9-670086a10f2d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Titanium dioxide (E 171),</span></p>", "ID": "fed63de9-77da-42d3-803c-7a6fd5237bb3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"IT\">Titanium dioxide (E 171),</span>", "ID": "91c786f8-6550-43e7-b921-df081498e644", "Styles": "None", "Classes": "None", "Text": "Titanium dioxide (E 171),", "ParentId": "fed63de9-77da-42d3-803c-7a6fd5237bb3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Talc,</span></p>", "ID": "c66d03a6-f665-4297-b3c2-b6ae3bbfb55d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"IT\">Talc,</span>", "ID": "4122a03a-8a58-453e-8a6d-58b755201698", "Styles": "None", "Classes": "None", "Text": "Talc,", "ParentId": "c66d03a6-f665-4297-b3c2-b6ae3bbfb55d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ES\">Glycerol triacetate,</span></p>", "ID": "85d30533-3c94-4b85-8972-3ae35adfb581", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"ES\">Glycerol triacetate,</span>", "ID": "2fbc1549-d91b-4d4f-9003-e1535e6a9fb3", "Styles": "None", "Classes": "None", "Text": "Glycerol triacetate,", "ParentId": "85d30533-3c94-4b85-8972-3ae35adfb581"}, {"Element": "<p class=\"MsoNormal\">Iron oxide yellow and red (E172).</p>", "ID": "ab1e408a-0179-4546-bfb4-7e9ab9157d88", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Iron oxide yellow and red (E172).", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "31dc1f4c-98af-4438-83a7-0f0db13a86ee", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c7162759-233c-4bba-9dda-eb28551cc7f6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "31dc1f4c-98af-4438-83a7-0f0db13a86ee"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></b></p>", "ID": "4334c644-0061-4729-9306-0c06f2207420", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></b>", "ID": "f5771287-37ad-412b-a2fe-9913d07f45c1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4334c644-0061-4729-9306-0c06f2207420"}, {"Element": "<span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span>", "ID": "bd65fd1f-953e-4a21-aa6b-3206f8663307", "Styles": "None", "Classes": "None", "Text": "6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities", "ParentId": "f5771287-37ad-412b-a2fe-9913d07f45c1"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "20fcda50-faef-441d-a76f-4df2fe03cd30", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "99ea120f-9707-42e3-af68-ba14d7a51fc3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "20fcda50-faef-441d-a76f-4df2fe03cd30"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7d466dac-ff82-43c7-81dc-e26aa6061062", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "99ea120f-9707-42e3-af68-ba14d7a51fc3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not applicable.</span></p>", "ID": "08737ff9-9d1b-48bb-af6c-281788412fff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Not applicable.</span>", "ID": "c780abcc-0a0e-491d-b966-6b663a147b71", "Styles": "None", "Classes": "None", "Text": "Not applicable.", "ParentId": "08737ff9-9d1b-48bb-af6c-281788412fff"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "743ff89e-b3a7-44db-adb0-b5e725b55105", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c76f6e5e-728b-45c1-972a-46638bf0930c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "743ff89e-b3a7-44db-adb0-b5e725b55105"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span></b></p>", "ID": "662ce5e1-e570-4c91-90eb-26f17cf03386", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span></b>", "ID": "54f966b7-08a4-40f2-bc0c-4493570c36c8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "662ce5e1-e570-4c91-90eb-26f17cf03386"}, {"Element": "<span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span>", "ID": "e9ffa4b6-44c3-44f9-84a2-b5657bf17ae0", "Styles": "None", "Classes": "None", "Text": "6.3\u00a0\u00a0\u00a0\u00a0 Shelf life", "ParentId": "54f966b7-08a4-40f2-bc0c-4493570c36c8"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "c5fd9756-4440-423d-80fa-4b9e31773087", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "9b80a217-2274-4e11-8ba8-7242c3dd9c73", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c5fd9756-4440-423d-80fa-4b9e31773087"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e3ba9dcf-da7a-47a8-8587-3d82c97b3202", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9b80a217-2274-4e11-8ba8-7242c3dd9c73"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">3 years.</span></p>", "ID": "07f6d05e-16ec-4873-b8ea-385521ae7c8a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">3 years.</span>", "ID": "d98fffa1-6b97-4fa5-b600-90da467f39f5", "Styles": "None", "Classes": "None", "Text": "3 years.", "ParentId": "07f6d05e-16ec-4873-b8ea-385521ae7c8a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6e9ec480-26ce-4c32-b470-44095c5b4b1f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "06a2e4f1-a32e-4dff-a0bb-ed1e0adba335", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6e9ec480-26ce-4c32-b470-44095c5b4b1f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for storage</span></b></p>", "ID": "9f3afbd4-3045-4091-aa5b-7a74a859fedf", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for storage</span></b>", "ID": "8b31be3b-075c-4dbb-8540-497f52df041f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9f3afbd4-3045-4091-aa5b-7a74a859fedf"}, {"Element": "<span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for storage</span>", "ID": "e7b32a06-b9e2-4400-ae05-d402e322d1a6", "Styles": "None", "Classes": "None", "Text": "6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for storage", "ParentId": "8b31be3b-075c-4dbb-8540-497f52df041f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b1ba3f97-7514-48d9-b585-7ad6480a3cdb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "13f5164f-0bba-4ffe-a4ca-9799972c4aad", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b1ba3f97-7514-48d9-b585-7ad6480a3cdb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">This medicinal product does not require any\nspecial storage conditions.</span></p>", "ID": "a1b03727-cdd8-4cde-be41-81ca5020e6c4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">This medicinal product does not require any\nspecial storage conditions.</span>", "ID": "b78176b8-23d2-4335-903a-135d7f7e1242", "Styles": "None", "Classes": "None", "Text": "This medicinal product does not require any special storage conditions.", "ParentId": "a1b03727-cdd8-4cde-be41-81ca5020e6c4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f4cde61c-2afe-40e9-9e1b-4477289a5604", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1093f085-6bdf-4f43-b85d-0f9bd0852eba", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f4cde61c-2afe-40e9-9e1b-4477289a5604"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of container</span></b></p>", "ID": "86feacbe-7d32-4fb5-8ef9-432dfe19915a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of container</span></b>", "ID": "bfa779aa-3f71-4192-a166-75bfd79c2763", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "86feacbe-7d32-4fb5-8ef9-432dfe19915a"}, {"Element": "<span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of container</span>", "ID": "744c297f-de7e-4298-bff8-643e22f1564e", "Styles": "None", "Classes": "None", "Text": "6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of container", "ParentId": "bfa779aa-3f71-4192-a166-75bfd79c2763"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e47c16c3-6400-451d-be60-c8e8106a74a1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a5d81268-dc8d-4919-96de-fd312b28540c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e47c16c3-6400-451d-be60-c8e8106a74a1"}, {"Element": "<p class=\"MsoNormal\">Plastic bottles (HDPE) containing 120 tablets.</p>", "ID": "17501712-71e1-4a20-a906-e8fe20a7be89", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Plastic bottles (HDPE) containing 120 tablets.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8687a565-b75a-41c3-97bc-b7895751d6fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9a11c406-38a8-4d1c-8db8-af864a694a9f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8687a565-b75a-41c3-97bc-b7895751d6fd"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0 Special precautions for disposal</span></b></p>", "ID": "82d970ac-db2b-4375-bec8-abd709baa28f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0 Special precautions for disposal</span></b>", "ID": "48cdcd7d-e295-4965-9464-2dc711344bfe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "82d970ac-db2b-4375-bec8-abd709baa28f"}, {"Element": "<span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0 Special precautions for disposal</span>", "ID": "34817dbd-416f-4700-92e7-9d0acf46e2e0", "Styles": "None", "Classes": "None", "Text": "6.6\u00a0\u00a0\u00a0\u00a0 Special precautions for disposal", "ParentId": "48cdcd7d-e295-4965-9464-2dc711344bfe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a66ed107-6d99-42c0-9f9e-53ef7f7e4739", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "80d60d28-f219-4d9d-8263-57c08f42b922", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a66ed107-6d99-42c0-9f9e-53ef7f7e4739"}, {"Element": "<p class=\"MsoNormal\">No special requirements for disposal.</p>", "ID": "8de9a506-9e22-4810-a07f-a24cd2f1eb49", "Styles": "None", "Classes": "['MsoNormal']", "Text": "No special requirements for disposal.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0fa7d1f9-73a9-4f8f-a505-9efccbb51dd8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f4d47577-f4dc-4696-938a-ff1391c9e0a6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0fa7d1f9-73a9-4f8f-a505-9efccbb51dd8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "74929c2a-3955-4447-a461-4772b33c8e18", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "156fdbc5-be0e-4502-9b25-f77c298764e9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "74929c2a-3955-4447-a461-4772b33c8e18"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION HOLDER</span></b></p>", "ID": "6f8f2b5c-1182-4466-8137-3500470b5dd7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION HOLDER</span></b>", "ID": "063c4bd4-736a-4022-98bd-f76abc8dcf31", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6f8f2b5c-1182-4466-8137-3500470b5dd7"}, {"Element": "<span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION HOLDER</span>", "ID": "68ba4fce-00ed-49a8-b15c-8be7a8584b43", "Styles": "None", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION HOLDER", "ParentId": "063c4bd4-736a-4022-98bd-f76abc8dcf31"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3f3b1f8a-2a09-4e5e-922f-0342c1d33472", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "990bf435-14b3-4a75-bd8d-80ceecaae4ca", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3f3b1f8a-2a09-4e5e-922f-0342c1d33472"}, {"Element": "<p class=\"MsoNormal\">Roche Registration GmbH </p>", "ID": "69ad6887-834f-4c22-a5be-8cb67d4c07db", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Roche Registration GmbH ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">Emil-Barell-Strasse 1</p>", "ID": "75671143-8850-4964-9972-7ae4133da15d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Emil-Barell-Strasse 1", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">79639 Grenzach-Wyhlen</p>", "ID": "478f06b7-f4fc-4bbe-94a7-cbebe9064509", "Styles": "None", "Classes": "['MsoNormal']", "Text": "79639 Grenzach-Wyhlen", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">Germany</p>", "ID": "d828691e-b9de-4ef2-bf0b-9453a908e702", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Germany", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "30bcc4a5-7b95-4699-969d-4bc7c8a90935", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "696b4831-d25f-4867-bc5a-4f3b0857a5ca", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "30bcc4a5-7b95-4699-969d-4bc7c8a90935"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7c30d394-828f-446f-bffe-2d05eb7aa4ce", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1ae8e69d-0f0a-4c6e-9b29-70ba0148d852", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7c30d394-828f-446f-bffe-2d05eb7aa4ce"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION\nNUMBER </span></b></p>", "ID": "910d6aa1-204b-4529-99ab-3916db1b921b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION\nNUMBER </span></b>", "ID": "d15d6c28-0d26-48b4-bb5a-1c3636e71366", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "910d6aa1-204b-4529-99ab-3916db1b921b"}, {"Element": "<span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION\nNUMBER </span>", "ID": "da78ee11-6fce-4b75-9336-36b170df822f", "Styles": "None", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER ", "ParentId": "d15d6c28-0d26-48b4-bb5a-1c3636e71366"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2aa5cccc-ed80-4547-aa9d-5a36ad2d5dd2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "91cb631c-5af4-44ac-bca8-bd2a32df717b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2aa5cccc-ed80-4547-aa9d-5a36ad2d5dd2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/96/026/002</span></p>", "ID": "f3f3093e-2ce5-4687-8308-8fbdd8d777fa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">EU/1/96/026/002</span>", "ID": "80764cfd-a909-4e23-b9c2-72385f3a1dbf", "Styles": "None", "Classes": "None", "Text": "EU/1/96/026/002", "ParentId": "f3f3093e-2ce5-4687-8308-8fbdd8d777fa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f8656807-54a4-4f13-8ff8-ec6f90373f43", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a0005847-b441-477d-b1a7-9357ff3194c5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f8656807-54a4-4f13-8ff8-ec6f90373f43"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "94b55c4a-ffb5-4294-a676-87f2082f31b7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "30b27115-3fcf-49af-af61-5e00a29de3f6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "94b55c4a-ffb5-4294-a676-87f2082f31b7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST\nAUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>", "ID": "32564c07-6f20-46a0-87c9-b4934675b9ac", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST\nAUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b>", "ID": "141e0c63-0616-435e-b7a6-c801de65bf95", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "32564c07-6f20-46a0-87c9-b4934675b9ac"}, {"Element": "<span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST\nAUTHORISATION/RENEWAL OF THE AUTHORISATION</span>", "ID": "65cbca29-fb41-4fc3-9575-654884343b93", "Styles": "None", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION", "ParentId": "141e0c63-0616-435e-b7a6-c801de65bf95"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "29545e46-176e-40a0-89c4-6aa2b7627b8e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "612836d2-adf7-45db-89c1-d7aa6e59b5e2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "29545e46-176e-40a0-89c4-6aa2b7627b8e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Date of\nfirst authorisation: 04 October 1996</span></p>", "ID": "b96aaac4-1321-4046-8487-0a70b7af1287", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Date of\nfirst authorisation: 04 October 1996</span>", "ID": "649b7a8a-e4a1-42e1-aa2d-946d8b88de0c", "Styles": "None", "Classes": "None", "Text": "Date of first authorisation: 04 October 1996", "ParentId": "b96aaac4-1321-4046-8487-0a70b7af1287"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of latest renewal: 04 October 2006</span></p>", "ID": "2ee555da-d24e-4deb-bab2-8413ac09a638", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Date of latest renewal: 04 October 2006</span>", "ID": "e2199960-df26-4425-880d-ef0b218bc1f5", "Styles": "None", "Classes": "None", "Text": "Date of latest renewal: 04 October 2006", "ParentId": "2ee555da-d24e-4deb-bab2-8413ac09a638"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "11fdcd8c-7154-4520-a380-8ea092844402", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8e91fa58-2e74-420f-8594-43eb2f783ef2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "11fdcd8c-7154-4520-a380-8ea092844402"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "187ef118-20d7-4c8c-a1bd-6db9185224f1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "43071814-fed2-4887-b5af-198b76617022", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "187ef118-20d7-4c8c-a1bd-6db9185224f1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE TEXT</span></b></p>", "ID": "7032ade9-7cfa-4f2e-9765-e72d4c8daaa9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE TEXT</span></b>", "ID": "f4459419-76b8-465b-bc7d-fcb601b10ef3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7032ade9-7cfa-4f2e-9765-e72d4c8daaa9"}, {"Element": "<span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE TEXT</span>", "ID": "8859381b-aaaa-49ee-95d0-fe8aed38421e", "Styles": "None", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE TEXT", "ParentId": "f4459419-76b8-465b-bc7d-fcb601b10ef3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "63db9335-5a03-4d9e-980c-71c1ee276ca3", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "73ec4d1b-62d8-4d73-83d7-e0ff7032e501", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "63db9335-5a03-4d9e-980c-71c1ee276ca3"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1e1b662d-5f8b-4c39-9d7d-8396c1c0048c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "73ec4d1b-62d8-4d73-83d7-e0ff7032e501"}, {"Element": "<p class=\"MsoNormal\">Detailed information on this product is available on the\nwebsite of the European Medicines Agency <a href=\"http://www.ema.europa.eu/\">http://www.ema.europa.eu</a></p>", "ID": "01281d49-b5c0-42f2-80d9-e6a7fffc08dd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Detailed information on this product is available on the website of the European Medicines Agency ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<a href=\"http://www.ema.europa.eu/\">http://www.ema.europa.eu</a>", "ID": "849661cf-6304-4fca-9b0d-173cf47319ce", "Styles": "None", "Classes": "None", "Text": "http://www.ema.europa.eu", "ParentId": "01281d49-b5c0-42f2-80d9-e6a7fffc08dd"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "b78a7e44-1014-487e-b741-41da1a4d2c19", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "9d03401c-ea4c-4ea4-936c-69c15fb1eed4", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "b78a7e44-1014-487e-b741-41da1a4d2c19"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c05850e1-fc9b-4360-ab30-71d5e1a03c4a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5520d58d-661f-4347-89d5-74c79b071873", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c05850e1-fc9b-4360-ab30-71d5e1a03c4a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "194c948d-07b0-433c-a29c-cf44b3c727d5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "45deb59a-ca92-4eda-9076-fbfa5190702a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "194c948d-07b0-433c-a29c-cf44b3c727d5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "215f8763-ed73-4e1e-923c-ba516887523a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "665dd93c-5f92-4cb3-bfa9-ab62789b5dac", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "215f8763-ed73-4e1e-923c-ba516887523a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6385ab93-e8db-4a67-960f-d30cc888e32b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a0ea48da-9042-4fbf-8c35-f4a7a1edab8c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6385ab93-e8db-4a67-960f-d30cc888e32b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "554e51e6-c2ab-452b-bbe7-89f7ab2bf636", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "09270461-f607-48d4-9c9e-6196034a8146", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "554e51e6-c2ab-452b-bbe7-89f7ab2bf636"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bfe2483b-3662-4a8e-b442-0445fcd59fc2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "59bfc599-4ea1-4fe0-8b40-20a89a8882b5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bfe2483b-3662-4a8e-b442-0445fcd59fc2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "264055fb-bc21-4edc-87a1-4e1360221757", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "444ef0db-382e-4429-963f-2be8b97d7d89", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "264055fb-bc21-4edc-87a1-4e1360221757"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9e97a806-e806-480a-8c4a-107f2bc5853f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d7a53f13-2837-413b-8d0b-0869c02285a5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9e97a806-e806-480a-8c4a-107f2bc5853f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "db8e8c26-2663-4195-b86b-cdcaf1ca5c55", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ac8c942b-d109-4942-bc82-2f3743ac47b9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "db8e8c26-2663-4195-b86b-cdcaf1ca5c55"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ab562fe8-59e1-4a2d-8968-9979237c7a3e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ded919de-20b2-47c2-b6d9-88f2dca5a820", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ab562fe8-59e1-4a2d-8968-9979237c7a3e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1f66ad2b-7310-4f06-bbe9-cb65a28636ee", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4186a7fc-af8f-4194-a8e8-4899a1558b69", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1f66ad2b-7310-4f06-bbe9-cb65a28636ee"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6836fbb4-57f0-4b86-87c1-443de391a52e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bc432eca-d87c-4d07-90f3-70bee74f4e6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6836fbb4-57f0-4b86-87c1-443de391a52e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "75af2796-8f53-4925-9797-dbf43799f974", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6adc8e62-b47b-4081-9d0c-4e0091748b09", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "75af2796-8f53-4925-9797-dbf43799f974"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "05f712fd-42a9-41e5-8e84-341a2fe0e780", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "145845ad-7c1e-4b2b-ba2d-3005b5a9b227", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "05f712fd-42a9-41e5-8e84-341a2fe0e780"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "13a989d8-1028-4f30-91a3-ed3d1b09bca3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "83520ff1-56a9-4522-9326-245c23df4a3e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "13a989d8-1028-4f30-91a3-ed3d1b09bca3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "78b4e6ae-bf4e-42f2-af1e-5b904337ed94", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c665c2cd-fea0-4416-8733-ea48eb7c941f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "78b4e6ae-bf4e-42f2-af1e-5b904337ed94"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9a6f0029-9c95-4ad5-893e-76d7d6de9be1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1961ed47-055c-45c7-ace7-6b88ca7b4928", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9a6f0029-9c95-4ad5-893e-76d7d6de9be1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8391a176-f145-4e41-a006-d3b652d1791f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1b06fba9-c006-4f2d-8b85-d9263c54ea64", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8391a176-f145-4e41-a006-d3b652d1791f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "61c221bd-908a-4a41-8f11-96d022980817", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "58950b8b-00ac-4dbc-8956-e4afa4bfcb52", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "61c221bd-908a-4a41-8f11-96d022980817"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c7e3f193-6e3a-47b6-be3f-59c0ed66ef9b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "559fc4a2-0f54-4dc7-8a26-ea0c5dd4c959", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c7e3f193-6e3a-47b6-be3f-59c0ed66ef9b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "79737832-359e-40f9-a498-1aedc1c2dbfa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1aba28b1-71c9-43c3-96d9-9a1f12c81c73", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "79737832-359e-40f9-a498-1aedc1c2dbfa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "88863c60-c1a9-4b40-9e79-22b2a702cc1c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b605375a-4f91-483e-aa0a-09005aa3ef7c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "88863c60-c1a9-4b40-9e79-22b2a702cc1c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "81679801-d342-4d71-82c7-2eb730f0f625", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dfb83db1-ae48-4ae8-94a9-7dda37fab356", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "81679801-d342-4d71-82c7-2eb730f0f625"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\nII</span></b></p>", "ID": "4357b754-53ae-4b10-9a51-41873b97370c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">ANNEX\nII</span></b>", "ID": "3964421e-ac4b-40fe-937d-0bd9fd74795b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4357b754-53ae-4b10-9a51-41873b97370c"}, {"Element": "<span lang=\"EN-GB\">ANNEX\nII</span>", "ID": "7f3a26dc-4a7b-4204-b127-1fbadd17f38c", "Styles": "None", "Classes": "None", "Text": "ANNEX II", "ParentId": "3964421e-ac4b-40fe-937d-0bd9fd74795b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4332addb-f46c-43b6-8b2f-de219176b2d4", "Styles": "margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "64d0813b-d6ea-40b7-91ef-28b5d51fb33e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4332addb-f46c-43b6-8b2f-de219176b2d4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) RESPONSIBLE FOR\nBATCH RELEASE</span></b></p>", "ID": "5af6e3be-7760-4a57-8030-62f47f7f7063", "Styles": "margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) RESPONSIBLE FOR\nBATCH RELEASE</span></b>", "ID": "44ceadee-cbe7-4d80-9084-bb95d7f8998e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5af6e3be-7760-4a57-8030-62f47f7f7063"}, {"Element": "<span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) RESPONSIBLE FOR\nBATCH RELEASE</span>", "ID": "e4b1c15f-c416-4d6b-8260-191f9bffc13e", "Styles": "None", "Classes": "None", "Text": "A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE", "ParentId": "44ceadee-cbe7-4d80-9084-bb95d7f8998e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "5bc3098e-6bf3-4a9b-bd02-b8958ddabb3f", "Styles": "margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "05c8ab15-1f63-4b6d-b3c7-2265e4ff30ef", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5bc3098e-6bf3-4a9b-bd02-b8958ddabb3f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e31fd237-98b2-498d-9df2-646036bfb029", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "05c8ab15-1f63-4b6d-b3c7-2265e4ff30ef"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:56.7pt;margin-bottom:.0001pt\"><b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR </span></b><b>RESTRICTIONS REGARDING \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SUPPLY\nAND USE</b></p>", "ID": "5067e2ad-3ba4-4f2b-89e0-652b6ac4d614", "Styles": "margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:56.7pt;margin-bottom:.0001pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR </span></b>", "ID": "4214fde7-095f-40f9-9e99-ae1bea7bf62e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5067e2ad-3ba4-4f2b-89e0-652b6ac4d614"}, {"Element": "<span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR </span>", "ID": "1650fcc9-75f4-4499-8efd-9495c74054d9", "Styles": "None", "Classes": "None", "Text": "B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR ", "ParentId": "4214fde7-095f-40f9-9e99-ae1bea7bf62e"}, {"Element": "<b>RESTRICTIONS REGARDING \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SUPPLY\nAND USE</b>", "ID": "60c84636-f91a-4fa9-b7f1-b8b2fdbd307e", "Styles": "None", "Classes": "None", "Text": "RESTRICTIONS REGARDING \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SUPPLY AND USE", "ParentId": "5067e2ad-3ba4-4f2b-89e0-652b6ac4d614"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:56.7pt;margin-bottom:.0001pt\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "3f96edf4-ea13-4760-a9c7-fedf96b5c37c", "Styles": "margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:56.7pt;margin-bottom:.0001pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "4ccbbf6b-d17d-4b5c-ad64-2f43a7fab81a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3f96edf4-ea13-4760-a9c7-fedf96b5c37c"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "51aac3b5-0b32-44d7-a310-df8516b1d189", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4ccbbf6b-d17d-4b5c-ad64-2f43a7fab81a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:56.7pt;margin-bottom:.0001pt\"><b>C. \u00a0\u00a0\u00a0\u00a0 OTHER\nCONDITIONS AND REQUIREMENTS OF THE \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION</b></p>", "ID": "0a0bfdc5-70e5-40e3-854f-fd760e3ef235", "Styles": "margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:56.7pt;margin-bottom:.0001pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>C. \u00a0\u00a0\u00a0\u00a0 OTHER\nCONDITIONS AND REQUIREMENTS OF THE \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION</b>", "ID": "d3d101e6-2764-4cff-b615-ea55a53065cc", "Styles": "None", "Classes": "None", "Text": "C. \u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION", "ParentId": "0a0bfdc5-70e5-40e3-854f-fd760e3ef235"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:56.7pt;margin-bottom:.0001pt\"><b>\u00a0</b></p>", "ID": "fd7b591f-865c-4336-a606-bf40e1d44ce8", "Styles": "margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:56.7pt;margin-bottom:.0001pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>\u00a0</b>", "ID": "9b4212eb-4895-420f-b831-bd8ecea747e2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fd7b591f-865c-4336-a606-bf40e1d44ce8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt\"><b>D.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <span style=\"text-transform:uppercase\">conditions or restrictions with regard to the\nsafe and effective use of the medicinal product</span></b></p>", "ID": "343bb585-2d20-43cb-b3f4-67b530e39af3", "Styles": "margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>D.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <span style=\"text-transform:uppercase\">conditions or restrictions with regard to the\nsafe and effective use of the medicinal product</span></b>", "ID": "f9c73c26-2fa1-4f85-bc00-613a05d20839", "Styles": "None", "Classes": "None", "Text": "D.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "343bb585-2d20-43cb-b3f4-67b530e39af3"}, {"Element": "<span style=\"text-transform:uppercase\">conditions or restrictions with regard to the\nsafe and effective use of the medicinal product</span>", "ID": "4f5801b8-803f-4fa9-848e-a21ccdc15b46", "Styles": "text-transform:uppercase", "Classes": "None", "Text": "conditions or restrictions with regard to the safe and effective use of the medicinal product", "ParentId": "f9c73c26-2fa1-4f85-bc00-613a05d20839"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:56.7pt;margin-bottom:.0001pt\"><b>\u00a0</b></p>", "ID": "cc583fb0-4ac4-4236-b3f0-c4890701a845", "Styles": "margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:56.7pt;margin-bottom:.0001pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>\u00a0</b>", "ID": "71797ae9-d57c-46e1-a374-7a948635a17b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cc583fb0-4ac4-4236-b3f0-c4890701a845"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "38863f10-5b9e-472c-a3b9-0bcd362663b8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "61722eaa-f833-4ea6-b3e9-f9b715544bb5", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "38863f10-5b9e-472c-a3b9-0bcd362663b8"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "8a3d5227-4c4d-4ee2-a28b-dea8a3eda297", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "61722eaa-f833-4ea6-b3e9-f9b715544bb5"}, {"Element": "<p class=\"AnnexHeading\"><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S)\nRESPONSIBLE FOR BATCH RELEASE</span></p>", "ID": "76d6e4b5-4bd2-4219-9faf-e375b0e043d2", "Styles": "None", "Classes": "['AnnexHeading']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S)\nRESPONSIBLE FOR BATCH RELEASE</span>", "ID": "896bd1fb-2bd1-4016-9e29-b4cbb5b58a3b", "Styles": "None", "Classes": "None", "Text": "A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE", "ParentId": "76d6e4b5-4bd2-4219-9faf-e375b0e043d2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:70.8pt;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "61ffe318-3f04-4492-a5f0-d8af3e0f5591", "Styles": "margin-right:70.8pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1f83fa4f-41ad-429e-be30-e6e5020f6593", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "61ffe318-3f04-4492-a5f0-d8af3e0f5591"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Name and address of the manufacturer\nresponsible for batch release</span></u></p>", "ID": "fce51d2c-54de-410c-9c60-2a05c83140e3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<u><span lang=\"EN-GB\">Name and address of the manufacturer\nresponsible for batch release</span></u>", "ID": "8d52a1f4-d5f1-4dda-a7d8-e36a633cc354", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fce51d2c-54de-410c-9c60-2a05c83140e3"}, {"Element": "<span lang=\"EN-GB\">Name and address of the manufacturer\nresponsible for batch release</span>", "ID": "365e3428-b7c7-4ecf-95e5-790b852eaa98", "Styles": "None", "Classes": "None", "Text": "Name and address of the manufacturer responsible for batch release", "ParentId": "8d52a1f4-d5f1-4dda-a7d8-e36a633cc354"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:70.8pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e462edf8-7cb4-43c0-a52f-3a03712f0cb7", "Styles": "margin-right:70.8pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "783bfc29-beda-4e21-8f47-f129a70b35db", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e462edf8-7cb4-43c0-a52f-3a03712f0cb7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG<br/>\nEmil-Barell-Str. </span><span lang=\"EN-GB\">1,<br/>\n79639 Grenzach-Wyhlen,<br/>\nGermany.</span></p>", "ID": "a76aebae-7ba7-4905-8451-3c2d81dfe8b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"DE-CH\">Roche Pharma AG<br/>\nEmil-Barell-Str. </span>", "ID": "71d87e85-b1d7-4046-9c6c-4143986ecc84", "Styles": "None", "Classes": "None", "Text": "Roche Pharma AG Emil-Barell-Str. ", "ParentId": "a76aebae-7ba7-4905-8451-3c2d81dfe8b8"}, {"Element": "<br/>", "ID": "b4bd80a0-16df-4967-8c51-d1fe9de32b85", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "71d87e85-b1d7-4046-9c6c-4143986ecc84"}, {"Element": "<span lang=\"EN-GB\">1,<br/>\n79639 Grenzach-Wyhlen,<br/>\nGermany.</span>", "ID": "43621779-05d1-4a96-ba43-21ba8de7c913", "Styles": "None", "Classes": "None", "Text": "1, 79639 Grenzach-Wyhlen, Germany.", "ParentId": "a76aebae-7ba7-4905-8451-3c2d81dfe8b8"}, {"Element": "<br/>", "ID": "db0bb69d-bba0-4d5d-b231-8059fe670719", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "43621779-05d1-4a96-ba43-21ba8de7c913"}, {"Element": "<br/>", "ID": "a86e155b-6eda-4791-a5ee-b9bdea168ae2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "43621779-05d1-4a96-ba43-21ba8de7c913"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "633c34fa-3fef-4d72-8048-baea42fe1c93", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ce403371-f5d7-4ed2-8ce6-c860b05df7b0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "633c34fa-3fef-4d72-8048-baea42fe1c93"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1b9eb986-9c50-437c-9a7d-dbc0b387d5e5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "30b77f41-0d72-4117-8992-29a45a7d3811", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1b9eb986-9c50-437c-9a7d-dbc0b387d5e5"}, {"Element": "<p class=\"AnnexHeading\"><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS REGARDING SUPPLY AND USE </span></p>", "ID": "6dba58aa-2474-4e3a-8ec2-8c8f3d07a810", "Styles": "None", "Classes": "['AnnexHeading']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS REGARDING SUPPLY AND USE </span>", "ID": "a4b81657-0a28-4c9e-9621-8e8b0ee3dfbe", "Styles": "None", "Classes": "None", "Text": "B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE ", "ParentId": "6dba58aa-2474-4e3a-8ec2-8c8f3d07a810"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cbd0324e-6853-41f3-86e3-3bc3f4be8d85", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d4acbfe9-ddf1-4a07-b3fc-13116dd906cd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cbd0324e-6853-41f3-86e3-3bc3f4be8d85"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicinal product subject to restricted\nmedical prescription (See Annex I: Summary of Product Characteristics, section\n4.2).</span></p>", "ID": "6adf9d50-668b-4d30-a400-c7489e31085b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Medicinal product subject to restricted\nmedical prescription (See Annex I: Summary of Product Characteristics, section\n4.2).</span>", "ID": "60d3c61d-1b3e-43e2-ac7f-a0a2800e7929", "Styles": "None", "Classes": "None", "Text": "Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).", "ParentId": "6adf9d50-668b-4d30-a400-c7489e31085b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f8577dbd-28cd-47f2-a202-7a17d871485a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8bdea317-56cc-4baf-92aa-8038a5f8566f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "23d0313d-473d-40d8-83ba-cb6b583ed75d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8bdea317-56cc-4baf-92aa-8038a5f8566f"}, {"Element": "<p class=\"AnnexHeading\"><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER </span>CONDITIONS\nAND REQUIREMENTS OF THE MARKETING AUTHORISATION</p>", "ID": "6f3975b0-3ae6-46de-a418-a6d6e789ba2c", "Styles": "None", "Classes": "['AnnexHeading']", "Text": "CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER </span>", "ID": "65c172b3-6f0a-4bfb-8df2-4adc7c1b00b8", "Styles": "None", "Classes": "None", "Text": "C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER ", "ParentId": "6f3975b0-3ae6-46de-a418-a6d6e789ba2c"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b>\u00a0</b></p>", "ID": "9b448426-e623-428f-8bd8-526546775677", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>\u00a0</b>", "ID": "174d4c5f-0924-44e8-a53a-26887526ad87", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9b448426-e623-428f-8bd8-526546775677"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:13.0pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><b>Periodic\nSafety Update Reports </b></p>", "ID": "ebb5d911-a927-4c88-98e7-920c18b923eb", "Styles": "margin-left:.5in;text-indent:-.5in;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "55f128aa-b9b3-4647-9fab-f4b7c717236f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ebb5d911-a927-4c88-98e7-920c18b923eb"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "daac709e-243f-4295-a9a9-dc4dd45ff255", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ebb5d911-a927-4c88-98e7-920c18b923eb"}, {"Element": "<b>Periodic\nSafety Update Reports </b>", "ID": "f9017f19-34a5-4628-8791-37bf376d0854", "Styles": "None", "Classes": "None", "Text": "Periodic Safety Update Reports ", "ParentId": "ebb5d911-a927-4c88-98e7-920c18b923eb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "602bc887-91be-4fa8-9145-e9c8102eef6d", "Styles": "margin-right:-.05pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "abcb3325-1bdd-4ef9-8cc9-82f450000894", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "602bc887-91be-4fa8-9145-e9c8102eef6d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><span lang=\"EN-GB\">The\nrequirements for submission of periodic safety update reports for this\nmedicinal product are set out in the list of Union reference dates (EURD list)\nprovided for under Article 107c(7) of Directive 2001/83/EC and any subsequent\nupdates published on the European medicines web-portal.</span></p>", "ID": "b22a567d-da32-4c42-8def-5747a3abb4f4", "Styles": "margin-right:-.05pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">The\nrequirements for submission of periodic safety update reports for this\nmedicinal product are set out in the list of Union reference dates (EURD list)\nprovided for under Article 107c(7) of Directive 2001/83/EC and any subsequent\nupdates published on the European medicines web-portal.</span>", "ID": "df858b47-f8a8-48d9-b2f0-0beaef9c10da", "Styles": "None", "Classes": "None", "Text": "The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.", "ParentId": "b22a567d-da32-4c42-8def-5747a3abb4f4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "99a7609e-d233-4614-ab7c-abfe88c2c160", "Styles": "margin-right:-.05pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "347201bd-ac3b-4e81-aa97-d62cf7ed9306", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "99a7609e-d233-4614-ab7c-abfe88c2c160"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0f85a52f-ca2c-4a0f-8612-e7d26f614317", "Styles": "margin-right:-.05pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f22fdc8e-4472-476a-9479-b2c76fabf4c0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0f85a52f-ca2c-4a0f-8612-e7d26f614317"}, {"Element": "<p class=\"AnnexHeading\"><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\nPRODUCT\u00a0 </span></p>", "ID": "92ee0349-e54f-4173-9b48-7536dfca2f03", "Styles": "None", "Classes": "['AnnexHeading']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\nPRODUCT\u00a0 </span>", "ID": "b37b0a74-9f75-450a-9ed0-5fe7e996ec22", "Styles": "None", "Classes": "None", "Text": "D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT\u00a0 ", "ParentId": "92ee0349-e54f-4173-9b48-7536dfca2f03"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt\">\u00a0</p>", "ID": "a20e6803-88ec-4879-8d3e-fba0ea08e743", "Styles": "margin-right:-.05pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:13.0pt;\ntext-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span><b>Risk\nManagement Plan (RMP)</b></p>", "ID": "c3e73a82-d8be-42f2-bdd7-5780819157d5", "Styles": "margin-left:.5in;text-indent:-.5in;line-height:13.0pt;\ntext-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "789c822b-6bde-4606-85be-5f939a1be640", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c3e73a82-d8be-42f2-bdd7-5780819157d5"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "0f3211e3-9fc5-4dd8-a647-9ee3888ee79c", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c3e73a82-d8be-42f2-bdd7-5780819157d5"}, {"Element": "<b>Risk\nManagement Plan (RMP)</b>", "ID": "ca54dfff-0bba-4e81-b7bf-7d9d431cf6f4", "Styles": "None", "Classes": "None", "Text": "Risk Management Plan (RMP)", "ParentId": "c3e73a82-d8be-42f2-bdd7-5780819157d5"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">The MAH shall perform the\nrequired pharmacovigilance activities and interventions detailed in the agreed\nRMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed\nsubsequent updates of the RMP.</p>", "ID": "9bb8d3a5-bdcf-4979-aa96-518f8ed1c1a6", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed subsequent updates of the RMP.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8b05cacb-c295-4452-a043-0a9ae7951618", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">An updated RMP should be\nsubmitted:</p>", "ID": "88366e76-b6e0-4f94-bb94-3f9d5fa5912b", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "An updated RMP should be submitted:", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in;text-autospace:\nnone\">-\u00a0\u00a0\u00a0\u00a0 At the request of the European Medicines\nAgency;</p>", "ID": "8db55863-ae65-4916-a0d3-474c02b7869a", "Styles": "margin-left:.75in;text-indent:-.25in;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "-\u00a0\u00a0\u00a0\u00a0 At the request of the European Medicines Agency;", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in;text-autospace:\nnone\">-\u00a0\u00a0\u00a0\u00a0 Whenever the risk management system is\nmodified, especially as the result of new information being received that may lead\nto a significant change to the benefit/risk profile or as the result of an\nimportant (pharmacovigilance or risk minimisation) milestone being reached.</p>", "ID": "c22e0ed8-5274-472b-bd7b-dc44bebd2a37", "Styles": "margin-left:.75in;text-indent:-.25in;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "-\u00a0\u00a0\u00a0\u00a0 Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in;text-autospace:\nnone\">\u00a0</p>", "ID": "c2a49d6f-e09b-4c55-a0fe-ebf72029ff82", "Styles": "margin-left:.75in;text-indent:-.25in;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt\">\u00a0</p>", "ID": "52790a55-eeb4-44dc-8ddc-d88880d864a9", "Styles": "margin-right:-.05pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "5c23c69e-5c7e-405f-9dff-f464eb691c4b", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "1b4743c1-a465-4dac-aa33-aa6aa25b3422", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "5c23c69e-5c7e-405f-9dff-f464eb691c4b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4d336db1-9b1d-4d0e-8456-c76c2e81b068", "Styles": "margin-right:-.05pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "780e0504-2119-4d06-9bc8-46c80326b451", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4d336db1-9b1d-4d0e-8456-c76c2e81b068"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d8ad8180-a8a0-43f2-b364-416a202e8cbb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "26ee417f-4651-4ca9-ac06-83ee02f09e8f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d8ad8180-a8a0-43f2-b364-416a202e8cbb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e1ec83b9-8814-437a-8512-fa48de7bffa0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e776da83-1bc6-4dfe-b232-824fc8edae5f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e1ec83b9-8814-437a-8512-fa48de7bffa0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0c60a276-c523-4bbd-92a5-58d3e1cc45ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4a81c0e0-c9e3-44f0-84a4-a99447e506c9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0c60a276-c523-4bbd-92a5-58d3e1cc45ca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a7c9986a-f2ad-4d1f-a6d9-94e8ce982b44", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4744fe41-08c1-4f4d-ae07-40c8bab58b73", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a7c9986a-f2ad-4d1f-a6d9-94e8ce982b44"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f55643b6-4d3f-49a0-b92a-18e42c8b6ca5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d3ddd9f8-06bc-4606-89ec-25044d228278", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f55643b6-4d3f-49a0-b92a-18e42c8b6ca5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "870a0c94-99ea-4547-8c4e-a4d7026615e7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c3a523eb-5efa-42c5-a31a-c8b274e19bee", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "870a0c94-99ea-4547-8c4e-a4d7026615e7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "917a35a2-853e-41ca-8f32-baf9acd4cd77", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7f92820f-fd55-45d8-94ad-20da549bae5f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "917a35a2-853e-41ca-8f32-baf9acd4cd77"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "26e48f37-c348-4153-ae38-f02e21baff17", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "313cfee4-deab-4e38-8e5a-0545e0f6737e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "26e48f37-c348-4153-ae38-f02e21baff17"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8fab4191-085f-47df-9b00-97a91ac1cba5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fb0b034a-7c2d-45ce-b24b-1a4389916d51", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8fab4191-085f-47df-9b00-97a91ac1cba5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f49154e5-ce96-4d02-8357-bf1609da8f83", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "35b16446-1f58-4ea1-9bb4-65e4579bcd3a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f49154e5-ce96-4d02-8357-bf1609da8f83"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fc16259f-0390-4f9d-b3ef-b326b02aa371", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b8e2b4f6-d054-497a-8a1b-f60cef7094d2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fc16259f-0390-4f9d-b3ef-b326b02aa371"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "26bf5363-274e-4a17-a906-957ae4687051", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "591f347d-d65e-4209-b900-c7d96718d5db", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "26bf5363-274e-4a17-a906-957ae4687051"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "15cc7609-ddc3-406d-894d-e3863a6f4bf0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7f30b3f6-687b-42ad-b92c-be3bf3d4348f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "15cc7609-ddc3-406d-894d-e3863a6f4bf0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "687ee8b3-00b7-4f72-bbc5-6074bbdc9d78", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "56319433-2615-4c0c-9e1e-77debdd8bbec", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "687ee8b3-00b7-4f72-bbc5-6074bbdc9d78"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "35b1e242-0a49-4742-a4c3-21ebf7e5ee4e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0ac4b3ee-10fc-4187-a9ab-977e05477767", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "35b1e242-0a49-4742-a4c3-21ebf7e5ee4e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0152b725-8c99-4854-a739-9b2e360188fb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e1ec075b-c0ea-4d71-9b57-8d8236ee5732", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0152b725-8c99-4854-a739-9b2e360188fb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8c87cff1-44ff-4775-9494-9cfb5ad6186b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6c7d01fa-5861-44f9-a395-06333acafa1d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8c87cff1-44ff-4775-9494-9cfb5ad6186b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b8e7ac65-9a76-4bc5-86b9-d757ea66587c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "96b4a6a1-91cb-4000-81ab-cf6d2319bfc8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b8e7ac65-9a76-4bc5-86b9-d757ea66587c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b6e32f78-e5d1-4e3e-8160-9170ad8bc850", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b192336b-e49b-46c9-b5d9-39a82c2304e7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b6e32f78-e5d1-4e3e-8160-9170ad8bc850"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2f556e98-1c5c-4419-8eca-85bb26895e67", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "560155cd-cd75-4fbe-90d6-e03a87c7534e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2f556e98-1c5c-4419-8eca-85bb26895e67"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3de05b75-b0e3-42de-9eba-183ab5316ec8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e059ac51-c369-42cf-92f1-4fbabf0c3216", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3de05b75-b0e3-42de-9eba-183ab5316ec8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5752ac2a-d1e5-4891-9bda-58e297a9ad66", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2e123494-fd84-4c7e-a206-259d9b945875", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5752ac2a-d1e5-4891-9bda-58e297a9ad66"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\nIII</span></b></p>", "ID": "44c8f0f1-484d-48fd-89c3-1a8815286d97", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">ANNEX\nIII</span></b>", "ID": "c9047dc2-af02-4188-b037-0542ca2a72a8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "44c8f0f1-484d-48fd-89c3-1a8815286d97"}, {"Element": "<span lang=\"EN-GB\">ANNEX\nIII</span>", "ID": "a1d0d09e-8fd6-4cc6-bcb7-7ceb3294f0ad", "Styles": "None", "Classes": "None", "Text": "ANNEX III", "ParentId": "c9047dc2-af02-4188-b037-0542ca2a72a8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "11ea6f93-eef6-4150-8c5b-371fae36e889", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "414ae81c-faa5-42c8-ad9b-67273b033769", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "11ea6f93-eef6-4150-8c5b-371fae36e889"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b94c2cf7-5fb9-498e-b4f5-4335fc926d2a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "414ae81c-faa5-42c8-ad9b-67273b033769"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">LABELLING\nAND PACKAGE LEAFLET</span></b></p>", "ID": "91cf6d47-823c-40de-b331-917d514097ac", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">LABELLING\nAND PACKAGE LEAFLET</span></b>", "ID": "ae68b4eb-d814-4faa-8d42-2a98ca298417", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "91cf6d47-823c-40de-b331-917d514097ac"}, {"Element": "<span lang=\"EN-GB\">LABELLING\nAND PACKAGE LEAFLET</span>", "ID": "3f2f3f22-a9d0-4355-a584-8f2a6c587e0a", "Styles": "None", "Classes": "None", "Text": "LABELLING AND PACKAGE LEAFLET", "ParentId": "ae68b4eb-d814-4faa-8d42-2a98ca298417"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "561d6932-4e9b-4884-9ecc-092ae5305c37", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fb4a2ca2-b7a7-47cf-8e24-20b171dac811", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "561d6932-4e9b-4884-9ecc-092ae5305c37"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1f0ac7d3-0615-427c-9afe-35a57710fdf5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "93145206-c6c9-4751-9448-d84ef4248c8c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1f0ac7d3-0615-427c-9afe-35a57710fdf5"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "94fab696-3c91-4e31-a9d8-e6f7874573bb", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "9def23b5-9676-4c71-adbf-7d35c7306d28", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "94fab696-3c91-4e31-a9d8-e6f7874573bb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6f84a5f0-39a4-4920-a245-887d213655c8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e726df4c-cb9c-4e19-8616-33ea1499d2fc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6f84a5f0-39a4-4920-a245-887d213655c8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5335719c-647c-442d-be45-7756ac08f1cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b3a662d4-3f86-44ad-a5b2-4819dececb68", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5335719c-647c-442d-be45-7756ac08f1cb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e32ec8c4-df9b-440b-9971-770f31536233", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "79e1f7bd-2f45-46d0-bd7d-951d9027f05d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e32ec8c4-df9b-440b-9971-770f31536233"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8f8f01e5-9c9e-475b-9ec3-fcdf10baab43", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e53a7527-d56e-4fdd-bd9d-0f2470074cd6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8f8f01e5-9c9e-475b-9ec3-fcdf10baab43"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "647e2702-f78f-47b5-a5bd-fe0d0fe7f831", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "99af3419-e771-4463-b9ab-fe0d25fd8553", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "647e2702-f78f-47b5-a5bd-fe0d0fe7f831"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "724d4cc9-9436-4bf9-b1d2-6cdf0c46ab6b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3e80a7a7-a2f7-4fbe-839d-788ef8d4e205", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "724d4cc9-9436-4bf9-b1d2-6cdf0c46ab6b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "027fdb9a-a856-4831-933f-0ac56aed8c0f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "88119d6f-a68a-485a-801f-a7a0d182f1dc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "027fdb9a-a856-4831-933f-0ac56aed8c0f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c537e687-0a68-456a-a9ad-f7b7fc90819e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d2bb8ac1-0b46-4174-ae03-c34514a23176", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c537e687-0a68-456a-a9ad-f7b7fc90819e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7ff0ff78-8526-4e3d-8588-82fb8b999475", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "374373fe-668a-4f57-8e74-c1f34b5135b5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7ff0ff78-8526-4e3d-8588-82fb8b999475"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "724ce5d2-e90c-41f8-b447-e86e37167977", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b7c9928c-f27d-450f-85a3-392cab92a4aa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "724ce5d2-e90c-41f8-b447-e86e37167977"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1db4777e-7c26-44e6-9886-b37c394d2763", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "74069523-ca57-4ba9-b858-07fb48a17d6b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1db4777e-7c26-44e6-9886-b37c394d2763"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ae708706-cc4f-400e-8f16-dffac1200ddd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "60976838-fd52-46f6-a473-82701aa0a531", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ae708706-cc4f-400e-8f16-dffac1200ddd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "32291d5e-51e7-405a-8f4b-fcc5a6cb42cc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ca443ea6-520b-4e11-86cf-b2c0341b7f58", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "32291d5e-51e7-405a-8f4b-fcc5a6cb42cc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8d9a66bc-51d2-40d7-99dc-6bddd95bf076", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0f87570d-537a-47f3-8d4b-1bc299a32dd5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8d9a66bc-51d2-40d7-99dc-6bddd95bf076"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cfc49e8b-5658-4073-a6b2-8a6c3899cf0a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8d520d53-1a9d-452f-8597-bc453ad8641e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cfc49e8b-5658-4073-a6b2-8a6c3899cf0a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6dda59ad-d539-4777-aed2-55b17c8dbd46", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "baaaa15f-0514-416a-87a6-c194eaeedca2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6dda59ad-d539-4777-aed2-55b17c8dbd46"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8f57a9dc-c0b6-4b58-94a4-75d2f9d2af0a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "26e2307e-bf60-486c-a5dd-97c266875ebb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8f57a9dc-c0b6-4b58-94a4-75d2f9d2af0a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "87d6b71d-6762-4bd3-9fd6-3fef3670e6a9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1a8e4eca-ee89-447b-9e6e-695b80256214", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "87d6b71d-6762-4bd3-9fd6-3fef3670e6a9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "db3a8373-6d8b-4519-aa81-bf7b28588520", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "50101bfd-01bf-45dd-a81d-d1d9f1049fd1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "db3a8373-6d8b-4519-aa81-bf7b28588520"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "00be30e0-735d-400d-9e04-95fc1085421e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6b47a3e4-a1ee-4d40-b0a5-2376fa9396ee", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "00be30e0-735d-400d-9e04-95fc1085421e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9b4ab022-78af-4edb-bbb4-a82cf6172c07", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4f821bba-9fe5-418f-a061-04216045640c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9b4ab022-78af-4edb-bbb4-a82cf6172c07"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6fc52f5f-1e7c-4ec3-8218-32ce6b1b337d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b2038127-0cdc-4818-be4c-90e94ab97e0d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6fc52f5f-1e7c-4ec3-8218-32ce6b1b337d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2185e3d5-1868-46a3-9246-cb8a554ee072", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e1f1f594-5679-4a21-b832-a36b719780b6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2185e3d5-1868-46a3-9246-cb8a554ee072"}, {"Element": "<p class=\"Annex\"><span lang=\"EN-GB\">A. LABELLING</span></p>", "ID": "9049c595-ab13-458b-b2e1-65d3355d1e2c", "Styles": "None", "Classes": "['Annex']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">A. LABELLING</span>", "ID": "48b88748-9e23-487e-9bc1-cbb4b99adf4a", "Styles": "None", "Classes": "None", "Text": "A. LABELLING", "ParentId": "9049c595-ab13-458b-b2e1-65d3355d1e2c"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "2f613094-96be-407e-a761-06e3d197b415", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black", "Classes": "None", "Text": " ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "fbbd3d09-50b0-44e1-90c3-e5cc597538eb", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "2f613094-96be-407e-a761-06e3d197b415"}, {"Element": "<p class=\"MsoNormal\" style=\"background:white\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ba8db955-9835-45eb-94af-802bd4e61a61", "Styles": "background:white", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "24d2f78e-04ae-4de3-b90b-f504d9d4872d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ba8db955-9835-45eb-94af-802bd4e61a61"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>\n<p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span style=\"color:black\">TEXT FOR THE OUTER CARTON</span></b></p>\n</div>", "ID": "c4148aca-b7ea-4a09-8b3d-59675cbd0227", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "   ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>", "ID": "90206506-887f-4e3a-9790-2980d5024579", "Styles": "background:white;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c4148aca-b7ea-4a09-8b3d-59675cbd0227"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b>", "ID": "08f47695-cf29-424c-8525-e70a17a0d52b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "90206506-887f-4e3a-9790-2980d5024579"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span>", "ID": "ea5610b4-12d2-4d4b-837d-263e50dd8830", "Styles": "color:black", "Classes": "None", "Text": "PARTICULARS TO APPEAR ON THE OUTER PACKAGING ", "ParentId": "08f47695-cf29-424c-8525-e70a17a0d52b"}, {"Element": "<p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span style=\"color:black\">TEXT FOR THE OUTER CARTON</span></b></p>", "ID": "d6e7a619-539d-4586-b984-617ba01d2cbe", "Styles": "background:white;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c4148aca-b7ea-4a09-8b3d-59675cbd0227"}, {"Element": "<b><span style=\"color:black\">TEXT FOR THE OUTER CARTON</span></b>", "ID": "baacadcf-5c83-4b86-97ce-11345cd74cc9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d6e7a619-539d-4586-b984-617ba01d2cbe"}, {"Element": "<span style=\"color:black\">TEXT FOR THE OUTER CARTON</span>", "ID": "54f677e6-e4af-4cf0-ad2f-d49db18adc2a", "Styles": "color:black", "Classes": "None", "Text": "TEXT FOR THE OUTER CARTON", "ParentId": "baacadcf-5c83-4b86-97ce-11345cd74cc9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7216bb94-885e-459e-bfaa-aa41abdb42ae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eeebb206-7f02-42ce-a622-7063b5853926", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7216bb94-885e-459e-bfaa-aa41abdb42ae"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ae7122eb-7946-44c5-a5c6-6e969768bd1e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c7b82264-5954-4558-bf40-d2ffa56c7aea", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ae7122eb-7946-44c5-a5c6-6e969768bd1e"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b></p>\n</div>", "ID": "935f3f04-90f2-4d81-a1ce-1126b2b968e9", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b></p>", "ID": "6bca5cc2-562c-46fa-8f5e-4de0c9510d4d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "935f3f04-90f2-4d81-a1ce-1126b2b968e9"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b>", "ID": "ba83c7b8-4e03-4755-a063-cb01f69c0d97", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6bca5cc2-562c-46fa-8f5e-4de0c9510d4d"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span>", "ID": "80c71c0a-f403-4ce5-ab10-e4347332d435", "Styles": "color:black", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT", "ParentId": "ba83c7b8-4e03-4755-a063-cb01f69c0d97"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d209d566-b803-47f0-a573-ebfc2d1046ad", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9b8ab9ca-8207-4482-a5d7-58a3c2f6532a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d209d566-b803-47f0-a573-ebfc2d1046ad"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase 500\u00a0mg </span>film-coated\ntablets</p>", "ID": "dfa093fe-5392-412f-9761-f42fd0f69b63", "Styles": "None", "Classes": "['MsoNormal']", "Text": "film-coated tablets", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Invirase 500\u00a0mg </span>", "ID": "78dc836a-4b26-4dcb-a4b4-4dd31763096f", "Styles": "None", "Classes": "None", "Text": "Invirase 500\u00a0mg ", "ParentId": "dfa093fe-5392-412f-9761-f42fd0f69b63"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Saquinavir</span></p>", "ID": "115395fe-0311-4c35-a7f9-888a6106648d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Saquinavir</span>", "ID": "68a2f8c1-280f-4ac8-bd6a-4a25c809285c", "Styles": "None", "Classes": "None", "Text": "Saquinavir", "ParentId": "115395fe-0311-4c35-a7f9-888a6106648d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "050ce8b4-35d6-41a9-8408-104993e1da51", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c3cbba69-c298-4d59-be35-1f95736300ab", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "050ce8b4-35d6-41a9-8408-104993e1da51"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8ad2f9c7-92f5-4ca1-acb6-b99e9742ac40", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b51df932-992c-4b3d-abb9-0b70cfd9eadf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8ad2f9c7-92f5-4ca1-acb6-b99e9742ac40"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b></p>\n</div>", "ID": "2de4a4cd-6d77-4f46-ac39-7902f83511e3", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b></p>", "ID": "d6905472-ec70-4a2c-8178-8def43a1c92f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2de4a4cd-6d77-4f46-ac39-7902f83511e3"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b>", "ID": "0b16b3dc-0f21-4785-80f0-94b3fa6fe829", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d6905472-ec70-4a2c-8178-8def43a1c92f"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span>", "ID": "9b45c3ae-3c11-4a71-a900-ea2d696b8ed6", "Styles": "color:black", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)", "ParentId": "0b16b3dc-0f21-4785-80f0-94b3fa6fe829"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f24ce88c-23d7-4bf5-a07f-dcb3d9cd2e0a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2abe78c8-7115-4b0f-94d3-ab88cff39e31", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f24ce88c-23d7-4bf5-a07f-dcb3d9cd2e0a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each </span>film-coated tablet<span lang=\"EN-GB\"> contains 500\u00a0mg of saquinavir as saquinavir mesilate.</span></p>", "ID": "a07a7b0d-50d0-4c8b-99a8-8a191bdfa8d2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "film-coated tablet", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Each </span>", "ID": "e1bfab53-2a61-4d7f-bf6b-acdf1b176b7b", "Styles": "None", "Classes": "None", "Text": "Each ", "ParentId": "a07a7b0d-50d0-4c8b-99a8-8a191bdfa8d2"}, {"Element": "<span lang=\"EN-GB\"> contains 500\u00a0mg of saquinavir as saquinavir mesilate.</span>", "ID": "92e3f28e-7178-4327-99ad-bb4db61e536e", "Styles": "None", "Classes": "None", "Text": " contains 500\u00a0mg of saquinavir as saquinavir mesilate.", "ParentId": "a07a7b0d-50d0-4c8b-99a8-8a191bdfa8d2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "93f8e918-dc04-4849-9e71-8fbbba7262c7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "36a7628c-65fe-41c8-8b3b-490e661e328d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "93f8e918-dc04-4849-9e71-8fbbba7262c7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5df756a1-19c6-459b-9b24-1d948938ab60", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7a60b5b6-4d31-4a15-9fc9-a130c9392852", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5df756a1-19c6-459b-9b24-1d948938ab60"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b></p>\n</div>", "ID": "3148c364-05a1-4c88-8e33-04cc91a46753", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b></p>", "ID": "d7d4cca0-87f1-4f0d-a929-2dec6799c065", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3148c364-05a1-4c88-8e33-04cc91a46753"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b>", "ID": "3976d656-2c34-47b4-8ad8-2a81113372d6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d7d4cca0-87f1-4f0d-a929-2dec6799c065"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span>", "ID": "94d6c9d6-66ea-45b0-8d8b-3560a1d24f3c", "Styles": "color:black", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS", "ParentId": "3976d656-2c34-47b4-8ad8-2a81113372d6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "94a2cc57-506f-4fd5-b3b9-8d923d064634", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "307eada6-3836-4ebf-b56c-4d77209f8c73", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "94a2cc57-506f-4fd5-b3b9-8d923d064634"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Also contains lactose (</span>monohydrate<span lang=\"EN-GB\">) </span>38.5\u00a0<span lang=\"EN-GB\">mg, colourants (titanium dioxide\nE 171, iron oxide E 172) and other constituents. See package leaflet for\nfurther information.</span></p>", "ID": "0c3ba9f1-9263-4c8e-af04-b4a2592f393a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "monohydrate38.5\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Also contains lactose (</span>", "ID": "7571579c-1c5b-49fc-8dda-d6e3b115a21e", "Styles": "None", "Classes": "None", "Text": "Also contains lactose (", "ParentId": "0c3ba9f1-9263-4c8e-af04-b4a2592f393a"}, {"Element": "<span lang=\"EN-GB\">) </span>", "ID": "d670b0c4-a771-4ca8-a318-fe045675e40a", "Styles": "None", "Classes": "None", "Text": ") ", "ParentId": "0c3ba9f1-9263-4c8e-af04-b4a2592f393a"}, {"Element": "<span lang=\"EN-GB\">mg, colourants (titanium dioxide\nE 171, iron oxide E 172) and other constituents. See package leaflet for\nfurther information.</span>", "ID": "0b3ef0c4-3c11-49c7-9f35-85918e92b514", "Styles": "None", "Classes": "None", "Text": "mg, colourants (titanium dioxide E 171, iron oxide E 172) and other constituents. See package leaflet for further information.", "ParentId": "0c3ba9f1-9263-4c8e-af04-b4a2592f393a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8b90e70e-58cf-40bf-a44e-d8760dfec1bb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "be647f29-b433-4c27-ab30-b3c48c072d90", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8b90e70e-58cf-40bf-a44e-d8760dfec1bb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "869b7084-a442-4ebe-af92-4bd47be76339", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c25c02f3-6431-4196-879c-90667f9ab7a4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "869b7084-a442-4ebe-af92-4bd47be76339"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b></p>\n</div>", "ID": "58c649e6-7dbb-41b4-a76c-286b6727c6ad", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b></p>", "ID": "f3d7d00a-1b54-4197-a021-d595922e6789", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "58c649e6-7dbb-41b4-a76c-286b6727c6ad"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b>", "ID": "2ea1f87a-4717-4703-92b6-a6497f8c7a40", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f3d7d00a-1b54-4197-a021-d595922e6789"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span>", "ID": "aaf49ec9-296d-4774-8da7-53038296b694", "Styles": "color:black", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM AND CONTENTS", "ParentId": "2ea1f87a-4717-4703-92b6-a6497f8c7a40"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "15ba60de-32e7-4c6c-aed6-c637b7d6dcf0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "59b8b769-7aed-433d-b29a-b7fe5817cac2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "15ba60de-32e7-4c6c-aed6-c637b7d6dcf0"}, {"Element": "<p class=\"MsoNormal\">120 film-coated tablets</p>", "ID": "b7a6e645-d87a-42f2-b24b-ed45bac312ea", "Styles": "None", "Classes": "['MsoNormal']", "Text": "120 film-coated tablets", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d5cc8725-9637-42b5-a67f-548e651d1910", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dee45f79-2ac4-45ed-a141-de68be3677e4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d5cc8725-9637-42b5-a67f-548e651d1910"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "46d60e30-cd00-4b01-86d1-171a0aeb5895", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bacc2968-1dcb-444b-9293-bda43c3984d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "46d60e30-cd00-4b01-86d1-171a0aeb5895"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>", "ID": "7c06bb98-5cc8-430d-a8b2-b843c05c2237", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>", "ID": "0eef4fa8-60e4-424a-b014-c88cc83f065c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7c06bb98-5cc8-430d-a8b2-b843c05c2237"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b>", "ID": "57f07200-bb28-4cd0-ba13-a2ee0eccc929", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0eef4fa8-60e4-424a-b014-c88cc83f065c"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span>", "ID": "09cdfc81-4e0e-4837-aeab-d881fd60e6fa", "Styles": "color:black", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION", "ParentId": "57f07200-bb28-4cd0-ba13-a2ee0eccc929"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6ba553b7-b7a1-4cf9-8be1-49abdd7e2a28", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4a1ee811-4551-42c0-b57d-ed56e994c0be", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6ba553b7-b7a1-4cf9-8be1-49abdd7e2a28"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Oral use</span></p>", "ID": "0ddd545d-fbf3-4404-b1ff-a3eec65529c1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Oral use</span>", "ID": "4a7f5d3f-2f47-44a1-862c-337eee5bc07a", "Styles": "None", "Classes": "None", "Text": "Oral use", "ParentId": "0ddd545d-fbf3-4404-b1ff-a3eec65529c1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The film-coated tablets should be swallowed\nwhole</span></p>", "ID": "af4c9033-5e7c-4cde-b10f-9c449fd0dc93", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">The film-coated tablets should be swallowed\nwhole</span>", "ID": "3c9eb4d4-6600-463f-b875-a9f5cf738399", "Styles": "None", "Classes": "None", "Text": "The film-coated tablets should be swallowed whole", "ParentId": "af4c9033-5e7c-4cde-b10f-9c449fd0dc93"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use</span></p>", "ID": "4341b0b9-b407-41c5-b732-18ea97312640", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Read the package leaflet before use</span>", "ID": "cdda2c37-6396-4e23-824c-2ba5e97bea69", "Styles": "None", "Classes": "None", "Text": "Read the package leaflet before use", "ParentId": "4341b0b9-b407-41c5-b732-18ea97312640"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a490792d-e274-49e6-b6c0-d1b72c528865", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f2fd670f-7b1b-4f22-bb6f-61a0e7922ff4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a490792d-e274-49e6-b6c0-d1b72c528865"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2d7e8ac0-1912-462c-8917-113d122dfa8c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1ee3ee1b-1b4e-4f7a-9937-70742ed69d07", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2d7e8ac0-1912-462c-8917-113d122dfa8c"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span></b></p>\n</div>", "ID": "7a74a4d0-fdd3-4d7b-bda1-c1b09a3ae569", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span></b></p>", "ID": "bacd94ea-3168-4f3e-8c23-263f3867c87f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7a74a4d0-fdd3-4d7b-bda1-c1b09a3ae569"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span></b>", "ID": "f8443f7e-f7f4-43ce-bad4-00a7c003e327", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bacd94ea-3168-4f3e-8c23-263f3867c87f"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span>", "ID": "9a517bd9-f0b5-4ab6-978d-382427f25013", "Styles": "color:black", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN", "ParentId": "f8443f7e-f7f4-43ce-bad4-00a7c003e327"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d9dc76c0-27ba-444d-98de-b18516a469ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fba5eac5-d8f8-4e74-95b2-20429ba347c8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d9dc76c0-27ba-444d-98de-b18516a469ca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children</span></p>", "ID": "483a7946-a6c3-4a5a-a7d2-56935c848c90", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Keep out of the sight and reach of children</span>", "ID": "29e684aa-49fa-4286-9ef7-12c51804badc", "Styles": "None", "Classes": "None", "Text": "Keep out of the sight and reach of children", "ParentId": "483a7946-a6c3-4a5a-a7d2-56935c848c90"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "141b53e1-aaad-41a1-99d1-723e288169b7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "80f6aa78-9db4-49bc-8d2e-7702560ab026", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "141b53e1-aaad-41a1-99d1-723e288169b7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c6ebe05f-9004-4539-a1b4-c19c3a88bfbf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "89a98d18-3edc-423d-81d1-20d539eeb207", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c6ebe05f-9004-4539-a1b4-c19c3a88bfbf"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b></p>\n</div>", "ID": "dae6f001-a3b7-4ede-ab26-d0d0c7af052e", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b></p>", "ID": "8b5dcde7-1bd1-43a8-b960-681df85a5df5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dae6f001-a3b7-4ede-ab26-d0d0c7af052e"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b>", "ID": "6e2c7dd9-2d75-421a-ba25-5366dcb32ced", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8b5dcde7-1bd1-43a8-b960-681df85a5df5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span>", "ID": "c27328df-7032-420f-9f2e-adc661b846ef", "Styles": "color:black", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF NECESSARY", "ParentId": "6e2c7dd9-2d75-421a-ba25-5366dcb32ced"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ec2b825f-018d-48f0-aab7-9ba3214d441d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "12e6b0c5-c286-4ca8-8124-916c291e85db", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ec2b825f-018d-48f0-aab7-9ba3214d441d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2172648d-d729-4cf4-a771-bfb905f466df", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "92d4cd51-3c56-4ce9-b690-1d41ff15ed22", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2172648d-d729-4cf4-a771-bfb905f466df"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>\n</div>", "ID": "bc23f2a3-b3d3-4005-82af-70e9953a5440", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>", "ID": "d6f9a6c4-8bc3-45e1-9c86-c826795cb694", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bc23f2a3-b3d3-4005-82af-70e9953a5440"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b>", "ID": "043c17e8-67b5-4238-a792-50a6de497e40", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d6f9a6c4-8bc3-45e1-9c86-c826795cb694"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span>", "ID": "e09a543a-1d8c-46df-9bb7-9fe2318bc700", "Styles": "color:black", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE", "ParentId": "043c17e8-67b5-4238-a792-50a6de497e40"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "976cb35e-b95e-4fb1-ae91-80f734dd1665", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f117afdc-a5c4-439b-a89e-d9581ea37fb8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "976cb35e-b95e-4fb1-ae91-80f734dd1665"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>", "ID": "6dde7d7d-d7c5-4d7e-8a2a-a621cac30a75", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">EXP</span>", "ID": "900dc4d9-18ff-4fd1-a59b-eaecd6b73be3", "Styles": "None", "Classes": "None", "Text": "EXP", "ParentId": "6dde7d7d-d7c5-4d7e-8a2a-a621cac30a75"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8ad5d259-3839-4065-ab70-93fa69b5d5be", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8bbd7164-9402-4d56-8fd7-949f425d5c21", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8ad5d259-3839-4065-ab70-93fa69b5d5be"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "564459ff-67cd-4914-b1e7-1cc872fb221f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c254e851-bd45-4930-abb2-eed297822dc4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "564459ff-67cd-4914-b1e7-1cc872fb221f"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span></b></p>\n</div>", "ID": "a4383583-8715-4f46-a13a-1886b15565e6", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span></b></p>", "ID": "d675fe5e-baed-4d43-9a50-9442bde3e2ed", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a4383583-8715-4f46-a13a-1886b15565e6"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span></b>", "ID": "a577c6fc-6098-4d42-8101-17bfec252ade", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d675fe5e-baed-4d43-9a50-9442bde3e2ed"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span>", "ID": "6b949356-d596-4ab9-9c21-5363aadb311e", "Styles": "color:black", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS", "ParentId": "a577c6fc-6098-4d42-8101-17bfec252ade"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "44866ea2-ac80-4117-8ed7-be83d4b88f87", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ca334f9e-8f45-4613-931f-dd802d061851", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "44866ea2-ac80-4117-8ed7-be83d4b88f87"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cb61b732-d13d-40f0-902a-5efdb297838f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7a978943-8192-4084-8ad2-76136e5b8c09", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cb61b732-d13d-40f0-902a-5efdb297838f"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>\n</div>", "ID": "afa459aa-5e8e-43f4-9414-84fc11eaae78", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>", "ID": "c7a65b60-4162-4a4e-a305-96a472dfe6f8", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "afa459aa-5e8e-43f4-9414-84fc11eaae78"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b>", "ID": "4afd5472-1cff-411a-a8ec-1c448b6f9a5c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c7a65b60-4162-4a4e-a305-96a472dfe6f8"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span>", "ID": "fac3a6a9-83db-4fe3-8238-3c13c5447c19", "Styles": "color:black", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE", "ParentId": "4afd5472-1cff-411a-a8ec-1c448b6f9a5c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "85f67108-fa7a-4a17-b698-ed82507631e8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cd3aca95-dcd8-47e7-a4d9-2710a596ce19", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "85f67108-fa7a-4a17-b698-ed82507631e8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "25f06d31-c28e-444e-9228-d87125b74358", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0edacdc5-7078-4d7b-84d3-b5f5905256ff", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "25f06d31-c28e-444e-9228-d87125b74358"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>\n</div>", "ID": "a5307b39-bebd-4eab-a957-6c092810a33f", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>", "ID": "7eef178f-6bfb-4450-b675-844729ae9c05", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a5307b39-bebd-4eab-a957-6c092810a33f"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">11.\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b>", "ID": "1d1778ae-b020-499c-a9a8-880a3056c80d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7eef178f-6bfb-4450-b675-844729ae9c05"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">11.\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span>", "ID": "42d9d042-4589-4337-b9be-99a41ffc50e1", "Styles": "color:black", "Classes": "None", "Text": "11.\u00a0\u00a0\u00a0\u00a0 NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER", "ParentId": "1d1778ae-b020-499c-a9a8-880a3056c80d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0c56dff3-9a09-4379-a2f4-4770faa2cfe5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aa214a18-96b3-4b28-bd33-6a373b212267", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0c56dff3-9a09-4379-a2f4-4770faa2cfe5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Registration GmbH </span></p>", "ID": "89a89155-51bb-47e7-a2ad-b842914874cc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"DE-CH\">Roche Registration GmbH </span>", "ID": "dd567301-0ab3-4784-b8f6-c439bf1cf399", "Styles": "None", "Classes": "None", "Text": "Roche Registration GmbH ", "ParentId": "89a89155-51bb-47e7-a2ad-b842914874cc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Emil-Barell-Strasse 1</span></p>", "ID": "332d04c1-0cc2-4d79-a93e-233a914d8385", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"DE-CH\">Emil-Barell-Strasse 1</span>", "ID": "bb3b3fe1-952e-4f2d-af71-52557e88b36e", "Styles": "None", "Classes": "None", "Text": "Emil-Barell-Strasse 1", "ParentId": "332d04c1-0cc2-4d79-a93e-233a914d8385"}, {"Element": "<p class=\"MsoNormal\">79639 Grenzach-Wyhlen</p>", "ID": "83305c45-3592-4404-935d-86232ab3a08a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "79639 Grenzach-Wyhlen", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">Germany</p>", "ID": "30f04e6b-aaf3-476e-9a3f-1ea587f1d1d9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Germany", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f8524d08-aff5-492e-8903-9dcf9d400660", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "09f440fb-a67f-4e2a-9ab5-15dddccf11db", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f8524d08-aff5-492e-8903-9dcf9d400660"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dd8c296a-67c7-47d1-9159-d5a374c85177", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9c188adf-c0ff-49fb-8373-c61a073a70f4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dd8c296a-67c7-47d1-9159-d5a374c85177"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>\n</div>", "ID": "006b4b98-c61a-44b0-887b-2df2b648c793", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>", "ID": "a6253641-d82e-4a74-b7d6-78d9cf90552d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "006b4b98-c61a-44b0-887b-2df2b648c793"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b>", "ID": "b8a41acb-c932-4046-9652-714227020235", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a6253641-d82e-4a74-b7d6-78d9cf90552d"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span>", "ID": "6cef1d3e-105f-41e0-b154-aa8c0e6368da", "Styles": "color:black", "Classes": "None", "Text": "12.\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)", "ParentId": "b8a41acb-c932-4046-9652-714227020235"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fff9d407-3eeb-4fba-bace-4c42f7153c36", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "62577fff-9e6f-49b9-9d1a-af67b0dc9d70", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fff9d407-3eeb-4fba-bace-4c42f7153c36"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/96/026/002</span></p>", "ID": "d3743e8a-a8a5-4a63-bf0c-bf3757e56cdc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">EU/1/96/026/002</span>", "ID": "16370778-9ca4-4e48-b99e-d0898c642f6a", "Styles": "None", "Classes": "None", "Text": "EU/1/96/026/002", "ParentId": "d3743e8a-a8a5-4a63-bf0c-bf3757e56cdc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "49dde165-b123-476c-9098-ac8e6f1b87f8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ca609440-a202-45de-b0aa-3eb9072a7a92", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "49dde165-b123-476c-9098-ac8e6f1b87f8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a648330e-640c-4fa5-9d03-b7022a67b579", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4a341c2b-8aba-495b-b56b-809874c9c316", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a648330e-640c-4fa5-9d03-b7022a67b579"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>", "ID": "7a68aecb-3fb2-486a-a978-1d5aece0d837", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>", "ID": "28d4fbda-a1f0-40bf-a45c-72f9b6eca5c9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7a68aecb-3fb2-486a-a978-1d5aece0d837"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b>", "ID": "6564c7f5-22d5-46b7-9d46-38463c3944ce", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "28d4fbda-a1f0-40bf-a45c-72f9b6eca5c9"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span>", "ID": "2e1a3a38-d0cd-4f94-95e2-12f9aca94c9c", "Styles": "color:black", "Classes": "None", "Text": "13.\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER", "ParentId": "6564c7f5-22d5-46b7-9d46-38463c3944ce"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9b2e91e9-6d5d-4612-b1c0-7571a51b657b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c1e3161b-edfd-46fb-bb5d-ec5bff8af73f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9b2e91e9-6d5d-4612-b1c0-7571a51b657b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch</span></p>", "ID": "c8a17a8d-759d-401f-88bd-b829e3a48aa3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Batch</span>", "ID": "49b31353-0240-4cc4-be6c-d0f08f91f722", "Styles": "None", "Classes": "None", "Text": "Batch", "ParentId": "c8a17a8d-759d-401f-88bd-b829e3a48aa3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "51d7d0de-f7c5-4707-b00b-d680c554cf86", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ca5d1f41-5d82-4e29-b80d-3b155442cf17", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "51d7d0de-f7c5-4707-b00b-d680c554cf86"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f2fb9678-58f5-4f05-8bca-63c90e0c5963", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5882f6b4-5fe2-4015-9942-1d5906f175e1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f2fb9678-58f5-4f05-8bca-63c90e0c5963"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></b></p>\n</div>", "ID": "e58fd847-2bb1-4929-9fcc-068184382675", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></b></p>", "ID": "6d12f943-842a-4081-8a72-e5295fa8ebc8", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e58fd847-2bb1-4929-9fcc-068184382675"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></b>", "ID": "eaa31eef-0e55-49d5-8d2b-b422282e57b1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6d12f943-842a-4081-8a72-e5295fa8ebc8"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span>", "ID": "50365c86-b29e-41f7-96e4-01e0864e0e5d", "Styles": "color:black", "Classes": "None", "Text": "14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY", "ParentId": "eaa31eef-0e55-49d5-8d2b-b422282e57b1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2300d09a-f5fa-4a14-aeea-7ac9e00b75f5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8593d017-5d24-43ce-97db-4c1a36d5f6ce", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2300d09a-f5fa-4a14-aeea-7ac9e00b75f5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicinal product subject to medical\nprescription</span></p>", "ID": "bf1e82cd-a25e-4b9b-bf0c-09937f97bbd1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Medicinal product subject to medical\nprescription</span>", "ID": "d14a0cdb-d67d-48cb-af3f-fb453beaecad", "Styles": "None", "Classes": "None", "Text": "Medicinal product subject to medical prescription", "ParentId": "bf1e82cd-a25e-4b9b-bf0c-09937f97bbd1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "409f1814-7158-4732-904a-12276fd4eadb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f2839796-d42e-46fe-ac34-2a23796e0209", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "409f1814-7158-4732-904a-12276fd4eadb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6f3874ca-e0d5-4257-ac15-94679af6634c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ec692986-5fcd-487a-a35b-813e8a8d72af", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6f3874ca-e0d5-4257-ac15-94679af6634c"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>\n</div>", "ID": "13e25ff3-ce67-4b6f-9613-1871375112c4", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>", "ID": "4a41cbc7-89a0-4cb0-b2be-b6e2b7e0a4f3", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "13e25ff3-ce67-4b6f-9613-1871375112c4"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b>", "ID": "e356b980-3a00-4c08-bf33-b9cf405133e5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4a41cbc7-89a0-4cb0-b2be-b6e2b7e0a4f3"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span>", "ID": "3e7e7047-c244-4103-bee6-13423659e6ac", "Styles": "color:black", "Classes": "None", "Text": "15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS ON USE", "ParentId": "e356b980-3a00-4c08-bf33-b9cf405133e5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a40bc548-e59b-4705-b691-279c0448206a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c508fc87-2128-4222-9e6e-91d7fae7982f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a40bc548-e59b-4705-b691-279c0448206a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d63fa99b-008b-4413-816a-d816aeacf18f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2d8bf5c0-dfda-4fb0-b56e-5a188c16caef", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d63fa99b-008b-4413-816a-d816aeacf18f"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN\nBRAILLE</span></b></p>\n</div>", "ID": "64210853-744d-489a-bda0-36ab500be309", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN\nBRAILLE</span></b></p>", "ID": "2a9fc212-a03c-40b3-8489-91ff4ec623cb", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "64210853-744d-489a-bda0-36ab500be309"}, {"Element": "<b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN\nBRAILLE</span></b>", "ID": "e613251d-89ce-4984-b702-31ed0f83d119", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2a9fc212-a03c-40b3-8489-91ff4ec623cb"}, {"Element": "<span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN\nBRAILLE</span>", "ID": "41f1f15d-4d6a-4973-a56e-a8152a39d4a9", "Styles": "None", "Classes": "None", "Text": "16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE", "ParentId": "e613251d-89ce-4984-b702-31ed0f83d119"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0d02d984-7cce-40f3-9270-473a68fcbdb6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "961f1ecb-9fdd-4921-9bff-66f31d401d5c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0d02d984-7cce-40f3-9270-473a68fcbdb6"}, {"Element": "<p class=\"MsoNormal\">invirase 500\u00a0mg</p>", "ID": "8feda1cf-56bf-4cca-8bc1-d2670bd30ca0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "invirase 500\u00a0mg", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d95fef02-bcf9-4c07-b06a-64d1d537a378", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "b04cb35a-915f-4bff-985d-db1efc8d40b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</span></b></p>\n</div>", "ID": "fbc06ce3-6a71-4e16-b68a-9b77fb7020d5", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</span></b></p>", "ID": "87d245e3-0540-408a-b9b8-a46341e51b40", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fbc06ce3-6a71-4e16-b68a-9b77fb7020d5"}, {"Element": "<b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</span></b>", "ID": "f823070e-6b6b-4fe2-b39a-9d0dcffd19ed", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "87d245e3-0540-408a-b9b8-a46341e51b40"}, {"Element": "<span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</span>", "ID": "99732f17-0c63-49ae-87df-4a3f1da8d53c", "Styles": "None", "Classes": "None", "Text": "17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE", "ParentId": "f823070e-6b6b-4fe2-b39a-9d0dcffd19ed"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "95ecd704-42d3-438a-971c-fda66b4cb301", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9b5d786b-a45e-4128-bcce-a19966933ede", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "95ecd704-42d3-438a-971c-fda66b4cb301"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">&lt;2D barcode\ncarrying the unique identifier included.&gt;</span></p>", "ID": "fc1b9a8c-36c2-41dc-8835-fb0cae83a5f3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">&lt;2D barcode\ncarrying the unique identifier included.&gt;</span>", "ID": "284a7cca-cf5d-41c1-ad08-db793e3c3d58", "Styles": "background:silver", "Classes": "None", "Text": "<2D barcode carrying the unique identifier included.>", "ParentId": "fc1b9a8c-36c2-41dc-8835-fb0cae83a5f3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\">\u00a0</span></p>", "ID": "f042c8c1-5e21-45cb-a906-51715450bca1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"background:#CCCCCC\">\u00a0</span>", "ID": "346866b2-8fed-4860-91d6-96f57bb33b4f", "Styles": "background:#CCCCCC", "Classes": "None", "Text": "\u00a0", "ParentId": "f042c8c1-5e21-45cb-a906-51715450bca1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8c3322f9-e831-4e21-9322-f0c35e530df9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "74aed84c-f959-40a1-abe3-c56faeef79d7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8c3322f9-e831-4e21-9322-f0c35e530df9"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</span></b></p>\n</div>", "ID": "8186b002-d073-4557-b242-536f06381b65", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</span></b></p>", "ID": "5cc95a3a-5f3c-4510-a088-10ab826676f7", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8186b002-d073-4557-b242-536f06381b65"}, {"Element": "<b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</span></b>", "ID": "bf9251e1-23e4-47c8-91cb-d51d34073910", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5cc95a3a-5f3c-4510-a088-10ab826676f7"}, {"Element": "<span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</span>", "ID": "03e35e8f-c5dd-4fcb-9041-10ddb3d201e9", "Styles": "None", "Classes": "None", "Text": "18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA", "ParentId": "bf9251e1-23e4-47c8-91cb-d51d34073910"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0d041839-bcc7-40fb-a3bc-5720609dd56a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3e3dea01-d8c4-469d-bb28-c563e0e9d3b2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0d041839-bcc7-40fb-a3bc-5720609dd56a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"EN-GB\">PC: </span></p>", "ID": "e563ce23-9b32-4bb5-9abc-b5625d013e13", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">PC: </span>", "ID": "938a5abf-408c-447b-b6e8-edf9a2e3d1e7", "Styles": "None", "Classes": "None", "Text": "PC: ", "ParentId": "e563ce23-9b32-4bb5-9abc-b5625d013e13"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"EN-GB\">SN: </span></p>", "ID": "ea807d4f-4293-405f-a5a2-47808f2b04d0", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">SN: </span>", "ID": "aa9cac30-125e-4653-acd2-aec871e1d980", "Styles": "None", "Classes": "None", "Text": "SN: ", "ParentId": "ea807d4f-4293-405f-a5a2-47808f2b04d0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"EN-GB\">NN: </span></p>", "ID": "c274ec21-0ddc-4750-8f4c-6d5d8ba8bddd", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">NN: </span>", "ID": "f1383aa6-ed91-4293-9f32-0945c57a78eb", "Styles": "None", "Classes": "None", "Text": "NN: ", "ParentId": "c274ec21-0ddc-4750-8f4c-6d5d8ba8bddd"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "50488443-401d-4bc6-bf76-c901cc954cbf", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black", "Classes": "None", "Text": " ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "09f8e217-9f07-43a0-bf7a-4480b3b1bec3", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "50488443-401d-4bc6-bf76-c901cc954cbf"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING</span></b></p>\n<p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span style=\"color:black\">TEXT FOR THE BOTTLE LABEL </span></b></p>\n</div>", "ID": "fd538fc4-09bb-40b0-bee3-4651ce97e80c", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "    ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING</span></b></p>", "ID": "82ac5846-6d50-4290-a05a-0a017adaa422", "Styles": "background:white;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd538fc4-09bb-40b0-bee3-4651ce97e80c"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING</span></b>", "ID": "55cbe0d6-d3bd-4668-a833-9d738d80a6a4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "82ac5846-6d50-4290-a05a-0a017adaa422"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING</span>", "ID": "0239c561-c865-4bfa-8494-1db5d56cabfc", "Styles": "color:black", "Classes": "None", "Text": "PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING", "ParentId": "55cbe0d6-d3bd-4668-a833-9d738d80a6a4"}, {"Element": "<p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b>\u00a0</b></p>", "ID": "6bec3f90-6a56-4925-b699-29e5d0c52aea", "Styles": "background:white;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd538fc4-09bb-40b0-bee3-4651ce97e80c"}, {"Element": "<b>\u00a0</b>", "ID": "40c6ef5e-ac8a-44a1-a19e-154b1a8f1174", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6bec3f90-6a56-4925-b699-29e5d0c52aea"}, {"Element": "<p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span style=\"color:black\">TEXT FOR THE BOTTLE LABEL </span></b></p>", "ID": "cab77cee-06f5-4366-a400-bea04e99f2f2", "Styles": "background:white;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd538fc4-09bb-40b0-bee3-4651ce97e80c"}, {"Element": "<b><span style=\"color:black\">TEXT FOR THE BOTTLE LABEL </span></b>", "ID": "49be5197-02a7-4531-a6ab-65cf32e55ae4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cab77cee-06f5-4366-a400-bea04e99f2f2"}, {"Element": "<span style=\"color:black\">TEXT FOR THE BOTTLE LABEL </span>", "ID": "2dcefe74-2bd9-4ef2-9858-c08ba9a5b05b", "Styles": "color:black", "Classes": "None", "Text": "TEXT FOR THE BOTTLE LABEL ", "ParentId": "49be5197-02a7-4531-a6ab-65cf32e55ae4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "115d753c-b35a-4378-b3f2-4e744e749cd3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c497ffd6-e209-46fb-b405-f1afb0849125", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "115d753c-b35a-4378-b3f2-4e744e749cd3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "635d782b-de88-4651-8a07-89c5783ee678", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4d161bbc-1260-48a0-b6b6-34ef8e72b033", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "635d782b-de88-4651-8a07-89c5783ee678"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b></p>\n</div>", "ID": "eb021c62-cb96-4205-a368-1d2951382fc2", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b></p>", "ID": "5fb18bff-3dc0-44d6-bc31-42286ce7c083", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eb021c62-cb96-4205-a368-1d2951382fc2"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b>", "ID": "a2fb0cc6-4850-4130-b325-257dd8a1d270", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5fb18bff-3dc0-44d6-bc31-42286ce7c083"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span>", "ID": "2b7a5a6f-1bc0-4e3a-bc17-446c604909e6", "Styles": "color:black", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT", "ParentId": "a2fb0cc6-4850-4130-b325-257dd8a1d270"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "764cf448-73e4-4122-8976-49fb106383d3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fcb94613-a00c-4615-ac8e-69db752683d3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "764cf448-73e4-4122-8976-49fb106383d3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase 500\u00a0mg </span>film-coated\ntablets</p>", "ID": "a136aeab-c739-4e70-91bf-39835584a97e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "film-coated tablets", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Invirase 500\u00a0mg </span>", "ID": "60de50e4-54ec-48f3-a9a9-2bb236247d11", "Styles": "None", "Classes": "None", "Text": "Invirase 500\u00a0mg ", "ParentId": "a136aeab-c739-4e70-91bf-39835584a97e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Saquinavir</span></p>", "ID": "17296556-45a2-4d85-80cd-6b1cbf5af084", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Saquinavir</span>", "ID": "206ba83a-72ce-4c6c-b801-200224fba986", "Styles": "None", "Classes": "None", "Text": "Saquinavir", "ParentId": "17296556-45a2-4d85-80cd-6b1cbf5af084"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e7303b9b-8e1e-43f2-8e6a-ed025803cb67", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "609c788d-a254-4e35-900a-310021a85093", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e7303b9b-8e1e-43f2-8e6a-ed025803cb67"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3ea6a7f4-8f39-441f-adcc-390938efc80e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d4a56510-5ae8-42b8-9c39-6f00df19de6e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3ea6a7f4-8f39-441f-adcc-390938efc80e"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b></p>\n</div>", "ID": "420cf3a8-9a5c-4af2-a1b4-215a535a91c9", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b></p>", "ID": "4edd7240-dbf2-4672-a115-5c5eb25da34c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "420cf3a8-9a5c-4af2-a1b4-215a535a91c9"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b>", "ID": "4bd3d796-122f-4a23-bb13-02a80cebfab4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4edd7240-dbf2-4672-a115-5c5eb25da34c"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span>", "ID": "bb6fa9e8-6cbe-4df4-8636-e08945aff785", "Styles": "color:black", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)", "ParentId": "4bd3d796-122f-4a23-bb13-02a80cebfab4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ba48d507-50fd-4615-9807-36d0860412bd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "acd1d356-afab-4448-b14d-ea902a1b1785", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ba48d507-50fd-4615-9807-36d0860412bd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each </span>film-coated tablet<span lang=\"EN-GB\"> contains 500\u00a0mg of saquinavir as saquinavir mesilate.</span></p>", "ID": "b6ed6547-6e1d-4f14-89a1-d9086f67de32", "Styles": "None", "Classes": "['MsoNormal']", "Text": "film-coated tablet", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Each </span>", "ID": "4907d924-400c-464a-b856-9603af1e6306", "Styles": "None", "Classes": "None", "Text": "Each ", "ParentId": "b6ed6547-6e1d-4f14-89a1-d9086f67de32"}, {"Element": "<span lang=\"EN-GB\"> contains 500\u00a0mg of saquinavir as saquinavir mesilate.</span>", "ID": "d57cdac4-c044-492d-90d1-228efe49488d", "Styles": "None", "Classes": "None", "Text": " contains 500\u00a0mg of saquinavir as saquinavir mesilate.", "ParentId": "b6ed6547-6e1d-4f14-89a1-d9086f67de32"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "550d1490-baaf-4e5d-b648-63ec4d67dac1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "17b1939c-2e89-423d-a1a9-ef564185f55c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "550d1490-baaf-4e5d-b648-63ec4d67dac1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f1d981cf-e4c3-4e00-8f26-d6b192c2cc38", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fc16ad37-a445-441d-9eb3-54e7260f32e9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f1d981cf-e4c3-4e00-8f26-d6b192c2cc38"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b></p>\n</div>", "ID": "6cd957a8-8c9a-4025-a9a9-56e3d3fa3daa", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b></p>", "ID": "6f88421a-2eb4-4d28-ad07-c4e78139a07f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6cd957a8-8c9a-4025-a9a9-56e3d3fa3daa"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b>", "ID": "e8f72a92-6116-47b0-9f15-95fbc77218b0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6f88421a-2eb4-4d28-ad07-c4e78139a07f"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span>", "ID": "554c549f-c4d5-4005-8ecb-a0bb42b09942", "Styles": "color:black", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS", "ParentId": "e8f72a92-6116-47b0-9f15-95fbc77218b0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2191fbc2-a66b-4b27-bcea-ef6cd8ee3f36", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aa442032-bdf6-4a81-a34b-0bf1136137df", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2191fbc2-a66b-4b27-bcea-ef6cd8ee3f36"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Also contains lactose (</span>monohydrate<span lang=\"EN-GB\">) </span>38.5\u00a0<span lang=\"EN-GB\">mg, colourants (titanium dioxide\nE 171, iron oxide E 172) and other constituents. See package leaflet for further\ninformation.</span></p>", "ID": "4d3475d5-669e-4886-8ff9-566e7aac7773", "Styles": "None", "Classes": "['MsoNormal']", "Text": "monohydrate38.5\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Also contains lactose (</span>", "ID": "783fe2ee-61f0-4b9e-adf4-9e3d7df977fa", "Styles": "None", "Classes": "None", "Text": "Also contains lactose (", "ParentId": "4d3475d5-669e-4886-8ff9-566e7aac7773"}, {"Element": "<span lang=\"EN-GB\">) </span>", "ID": "fddeed62-25fd-4ed8-8622-93ad2487ad73", "Styles": "None", "Classes": "None", "Text": ") ", "ParentId": "4d3475d5-669e-4886-8ff9-566e7aac7773"}, {"Element": "<span lang=\"EN-GB\">mg, colourants (titanium dioxide\nE 171, iron oxide E 172) and other constituents. See package leaflet for further\ninformation.</span>", "ID": "ab7f4127-721d-49c6-ba90-70f2ed5617c9", "Styles": "None", "Classes": "None", "Text": "mg, colourants (titanium dioxide E 171, iron oxide E 172) and other constituents. See package leaflet for further information.", "ParentId": "4d3475d5-669e-4886-8ff9-566e7aac7773"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "93834e1a-56da-448b-b7b7-4d10c25a0907", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "438371fb-e072-4efe-854d-78b1b877a1b1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "93834e1a-56da-448b-b7b7-4d10c25a0907"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "677f6e5b-b3a7-47c6-93f6-1efc38447a8c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ddc49cfe-c917-40eb-bb63-13ce24837105", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "677f6e5b-b3a7-47c6-93f6-1efc38447a8c"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b></p>\n</div>", "ID": "d59fea4c-dc70-4021-b8e3-0e2252e5dd73", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b></p>", "ID": "e971169d-690d-444a-a088-367f6573be67", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d59fea4c-dc70-4021-b8e3-0e2252e5dd73"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b>", "ID": "47d222e3-cfea-4481-b47d-b199ef327a98", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e971169d-690d-444a-a088-367f6573be67"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span>", "ID": "f1b41079-b46b-45d9-9373-11c97194257f", "Styles": "color:black", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM AND CONTENTS", "ParentId": "47d222e3-cfea-4481-b47d-b199ef327a98"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3f81c7d3-c8d6-4316-ba79-d94623ba191b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e30a1807-d969-46ed-8c4b-f18886bf89fa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3f81c7d3-c8d6-4316-ba79-d94623ba191b"}, {"Element": "<p class=\"MsoNormal\">120 film-coated tablets</p>", "ID": "95386485-be59-4d4d-b660-15b5519ee7ab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "120 film-coated tablets", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aa1c820c-e717-496b-8d4e-d1d0d08a8317", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "39691bf2-d8b1-4664-b090-0395abe1930c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aa1c820c-e717-496b-8d4e-d1d0d08a8317"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "06cade5a-c48b-4ec2-ab2c-b00497dc3361", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ca72a1e4-43cf-46eb-b00f-adfb1eb86467", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "06cade5a-c48b-4ec2-ab2c-b00497dc3361"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>", "ID": "51745a02-c62d-4955-b390-92d850ca3202", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>", "ID": "fd5b679f-dd8e-4ea1-a273-df110d3fa0af", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "51745a02-c62d-4955-b390-92d850ca3202"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b>", "ID": "6985225d-6a3e-4a50-867f-0d05271fb96c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fd5b679f-dd8e-4ea1-a273-df110d3fa0af"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span>", "ID": "e6ea8abe-6ac5-4100-9143-0ff5be320b90", "Styles": "color:black", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION", "ParentId": "6985225d-6a3e-4a50-867f-0d05271fb96c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4f324bc5-91c8-4608-bd27-57f0dbef1879", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "25928e10-05e1-4a16-b1d4-04ae6b10f713", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4f324bc5-91c8-4608-bd27-57f0dbef1879"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Oral use</span></p>", "ID": "fa7cc77e-8077-4cd5-9ca1-7194023a51c6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Oral use</span>", "ID": "04f0a508-1d0a-4fb3-b46c-a3fb404bfa79", "Styles": "None", "Classes": "None", "Text": "Oral use", "ParentId": "fa7cc77e-8077-4cd5-9ca1-7194023a51c6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The film-coated tablets should be swallowed\nwhole</span></p>", "ID": "e4e7145d-f9e2-4252-8121-68dfa705f24b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">The film-coated tablets should be swallowed\nwhole</span>", "ID": "e582451a-fce5-4834-a6e8-10e2ecb03f08", "Styles": "None", "Classes": "None", "Text": "The film-coated tablets should be swallowed whole", "ParentId": "e4e7145d-f9e2-4252-8121-68dfa705f24b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use</span></p>", "ID": "45f42b10-0426-4246-b5fb-299ac3103d25", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Read the package leaflet before use</span>", "ID": "dcd118a7-cc1c-4b87-9d29-6d9dbf949406", "Styles": "None", "Classes": "None", "Text": "Read the package leaflet before use", "ParentId": "45f42b10-0426-4246-b5fb-299ac3103d25"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "88674d2b-495d-4b1f-86d2-985b8cf9c677", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a507f1f0-1228-4451-9aa0-1c0ff2f0153d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "88674d2b-495d-4b1f-86d2-985b8cf9c677"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1e19c98a-54c6-4993-92dc-57537f0d912c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8e887c3d-c4a2-493d-8d9a-11a7f9cdf197", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1e19c98a-54c6-4993-92dc-57537f0d912c"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span></b></p>\n</div>", "ID": "dd23b0c3-9aaf-45b7-b4f6-c311be96218c", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span></b></p>", "ID": "fb30d997-53cb-4c6b-9612-de2e7e1c06cc", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dd23b0c3-9aaf-45b7-b4f6-c311be96218c"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span></b>", "ID": "b3cda539-8eff-4b59-83da-93578c03aeff", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fb30d997-53cb-4c6b-9612-de2e7e1c06cc"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span>", "ID": "1530f6c9-641c-4859-8e01-d668bb6ae0a1", "Styles": "color:black", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN", "ParentId": "b3cda539-8eff-4b59-83da-93578c03aeff"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9ac17b8f-47c2-4da4-bee7-db968e217c0a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "02e94637-5039-4187-a088-327fe7aeeb99", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9ac17b8f-47c2-4da4-bee7-db968e217c0a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children</span></p>", "ID": "3861d26c-2b23-4828-8e8a-c6f1ca765578", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Keep out of the sight and reach of children</span>", "ID": "6d8722fa-ff5d-4b67-bf37-43b167e47d29", "Styles": "None", "Classes": "None", "Text": "Keep out of the sight and reach of children", "ParentId": "3861d26c-2b23-4828-8e8a-c6f1ca765578"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1277016e-5457-44b9-b5e8-04c9e9b89257", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "924b624d-da87-4447-afc6-5cea59819366", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1277016e-5457-44b9-b5e8-04c9e9b89257"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "883146aa-ed70-40fa-b708-e2d2d168b46e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c32c5071-c922-495e-9ab3-16b45f7c2201", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "883146aa-ed70-40fa-b708-e2d2d168b46e"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b></p>\n</div>", "ID": "471eee19-48db-420b-b8f7-ac997f25e022", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b></p>", "ID": "7bc07a84-0a05-415a-b4a9-393b0795cddc", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "471eee19-48db-420b-b8f7-ac997f25e022"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b>", "ID": "555c3e5e-ebbf-426c-a52b-9f40f45b6e1a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7bc07a84-0a05-415a-b4a9-393b0795cddc"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span>", "ID": "b1df7406-5962-431f-b93a-89ad7bd3e0d7", "Styles": "color:black", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF NECESSARY", "ParentId": "555c3e5e-ebbf-426c-a52b-9f40f45b6e1a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "64367461-cc08-4797-ac3c-70f6f1c26f3c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5410bcfd-836f-40e6-8c39-d487c944858c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "64367461-cc08-4797-ac3c-70f6f1c26f3c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6be2afa4-40d4-4791-b69b-6f3b4ac3dff8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0d0f8d32-90df-4495-ad4f-0b055cfda46a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6be2afa4-40d4-4791-b69b-6f3b4ac3dff8"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>\n</div>", "ID": "f4d75506-1157-480c-b0b2-07f80176b226", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>", "ID": "a5bce27c-ca75-4b7c-aeca-15bcbd80e42c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f4d75506-1157-480c-b0b2-07f80176b226"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b>", "ID": "b379dca1-41b5-4fb5-bd5e-4a65600d3348", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a5bce27c-ca75-4b7c-aeca-15bcbd80e42c"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span>", "ID": "62f0e9c4-354d-4b2c-b92d-fbedb268cf3e", "Styles": "color:black", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE", "ParentId": "b379dca1-41b5-4fb5-bd5e-4a65600d3348"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e0e8d08c-bb2a-4e13-8842-1522d82d76ff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ac24d906-08c6-4f39-ab15-c51f671617c0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e0e8d08c-bb2a-4e13-8842-1522d82d76ff"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>", "ID": "1cc4c52b-5c24-4a7d-a02c-36534399cff4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">EXP</span>", "ID": "d6935ae2-74c9-4d07-8c0f-9176199392a4", "Styles": "None", "Classes": "None", "Text": "EXP", "ParentId": "1cc4c52b-5c24-4a7d-a02c-36534399cff4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "60340dac-c781-482f-bd5c-493fde51001d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "74113063-1e90-45e5-a488-261f6d6cfa6f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "60340dac-c781-482f-bd5c-493fde51001d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "82dd1d5c-7801-45bd-8853-831e1abc7594", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0f127b63-d2bc-429c-8039-1a9f77a75404", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "82dd1d5c-7801-45bd-8853-831e1abc7594"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span></b></p>\n</div>", "ID": "c8c17d12-1cad-4f26-99d4-721e08cffabd", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span></b></p>", "ID": "0c5c43ac-6ac3-45c7-bca6-dbe294a0093d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c8c17d12-1cad-4f26-99d4-721e08cffabd"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span></b>", "ID": "21dd06b3-0f24-45cd-a8b3-582a230bea55", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0c5c43ac-6ac3-45c7-bca6-dbe294a0093d"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span>", "ID": "fb2346c9-566d-4b98-9584-72868c4b9bd2", "Styles": "color:black", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS", "ParentId": "21dd06b3-0f24-45cd-a8b3-582a230bea55"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d878692b-2597-46d4-9948-47332241ece2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e2dc0c03-900d-441c-82f6-47f8e28982b9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d878692b-2597-46d4-9948-47332241ece2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a304400c-eec9-4713-b287-f321e1fd0961", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "74b468dc-1d89-45bb-99bd-b10d60640975", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a304400c-eec9-4713-b287-f321e1fd0961"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>\n</div>", "ID": "bad74bfe-67db-4458-a95a-4424bb9b4e51", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>", "ID": "c299ece7-9773-4632-984d-f63db80f8ff8", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bad74bfe-67db-4458-a95a-4424bb9b4e51"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b>", "ID": "c04a012b-ab7a-47a7-92e0-37914fe219b2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c299ece7-9773-4632-984d-f63db80f8ff8"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span>", "ID": "236bf1e7-db1a-4730-b890-34164be8604c", "Styles": "color:black", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE", "ParentId": "c04a012b-ab7a-47a7-92e0-37914fe219b2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "87f02fe0-0b47-48d8-ba68-016fcff62831", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "12de5f0b-5329-4360-8939-d221fcc15103", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "87f02fe0-0b47-48d8-ba68-016fcff62831"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e749c2f9-207e-41ca-bad6-94d96c4bf7cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "88ee1cc7-6937-4d47-b3b6-bbc82440d615", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e749c2f9-207e-41ca-bad6-94d96c4bf7cb"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>\n</div>", "ID": "6010dce7-45e9-4d36-9205-9da3f79d3c5c", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">11.\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>", "ID": "ef03daab-6c34-4cae-b57a-73d956d2712b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6010dce7-45e9-4d36-9205-9da3f79d3c5c"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">11.\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b>", "ID": "0a56e38b-e9fc-4e79-a594-d262b2a59e02", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ef03daab-6c34-4cae-b57a-73d956d2712b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">11.\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span>", "ID": "76e3dfbd-df3c-4981-8c96-891dc223a399", "Styles": "color:black", "Classes": "None", "Text": "11.\u00a0\u00a0\u00a0\u00a0 NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER", "ParentId": "0a56e38b-e9fc-4e79-a594-d262b2a59e02"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b5340e63-f13a-4c92-9899-80cfd9f41fdd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1fae1bd3-38e3-42d0-a9ea-0c13ff1ca46e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b5340e63-f13a-4c92-9899-80cfd9f41fdd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Registration GmbH </span></p>", "ID": "a5653670-293c-42d2-85c6-8609c678ce8b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"DE-CH\">Roche Registration GmbH </span>", "ID": "bd3ebcbc-06fc-405c-8eb3-f1f27b81cca7", "Styles": "None", "Classes": "None", "Text": "Roche Registration GmbH ", "ParentId": "a5653670-293c-42d2-85c6-8609c678ce8b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Emil-Barell-Strasse 1</span></p>", "ID": "6e5d6b76-8420-4e6d-b1cb-621be3fa9520", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"DE-CH\">Emil-Barell-Strasse 1</span>", "ID": "20309054-cc94-4460-a6d2-20e2ff5e42a3", "Styles": "None", "Classes": "None", "Text": "Emil-Barell-Strasse 1", "ParentId": "6e5d6b76-8420-4e6d-b1cb-621be3fa9520"}, {"Element": "<p class=\"MsoNormal\">79639 Grenzach-Wyhlen</p>", "ID": "5a6b764d-7f7b-4d44-b893-700e51248040", "Styles": "None", "Classes": "['MsoNormal']", "Text": "79639 Grenzach-Wyhlen", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">Germany</p>", "ID": "218fa68e-ec1c-4ad2-b3d4-66d2f03ecd70", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Germany", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "07f3614e-fe47-4463-b70d-50e5e0019743", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3df94523-b388-4e77-a718-97d0c747647a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "07f3614e-fe47-4463-b70d-50e5e0019743"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "51158099-8963-415e-9be4-3e01a04ade19", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8629a7a9-a19d-4685-aa48-2146f3214bec", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "51158099-8963-415e-9be4-3e01a04ade19"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>\n</div>", "ID": "aed029b3-9026-4d2f-867f-e8f3f96e369e", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>", "ID": "57f7882b-fcf9-4609-8f8a-b5a088ade957", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aed029b3-9026-4d2f-867f-e8f3f96e369e"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b>", "ID": "7876b77e-0ceb-48ae-a93e-a97e31537a29", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "57f7882b-fcf9-4609-8f8a-b5a088ade957"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span>", "ID": "6a0c5eaa-87cd-4224-a175-ec1a2c794ff0", "Styles": "color:black", "Classes": "None", "Text": "12.\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)", "ParentId": "7876b77e-0ceb-48ae-a93e-a97e31537a29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d3ac3da4-ffc1-434d-bd11-1363a365100a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ca5061fa-aba7-4a81-958f-84d5baebf523", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d3ac3da4-ffc1-434d-bd11-1363a365100a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/96/026/002</span></p>", "ID": "a2dbe31c-18c0-4c1c-9227-c9b7473bc1a9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">EU/1/96/026/002</span>", "ID": "37fc4b66-629a-4cb7-ac91-8d46d51f2d78", "Styles": "None", "Classes": "None", "Text": "EU/1/96/026/002", "ParentId": "a2dbe31c-18c0-4c1c-9227-c9b7473bc1a9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a0eba9dd-0e48-45ac-a51d-0ec73df5e0ad", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "21d335e5-d979-4729-892e-16a06681aaa7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a0eba9dd-0e48-45ac-a51d-0ec73df5e0ad"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bf116284-d14f-458d-877e-4109ee2675ad", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e3fa24f3-df18-4795-b157-dde5e83cd487", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bf116284-d14f-458d-877e-4109ee2675ad"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>", "ID": "4515abac-2ccc-478e-a35e-a95a5f993a57", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>", "ID": "068fad29-3845-4173-aab9-d35c554b8184", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4515abac-2ccc-478e-a35e-a95a5f993a57"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b>", "ID": "87ee3e60-5298-450c-b09c-0df095a3c82f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "068fad29-3845-4173-aab9-d35c554b8184"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span>", "ID": "2b5c3f6e-1f99-406d-b076-1ef083596dd8", "Styles": "color:black", "Classes": "None", "Text": "13.\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER", "ParentId": "87ee3e60-5298-450c-b09c-0df095a3c82f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "db76cf34-067a-4fe5-9c89-2dc15158aed6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1c5429d3-9081-4b1c-8025-a59a6c2b685c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "db76cf34-067a-4fe5-9c89-2dc15158aed6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch</span></p>", "ID": "7c6bbf34-a0ff-4552-997b-0b231533ee11", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Batch</span>", "ID": "ac49e121-5c35-4c90-adca-928ee3c41058", "Styles": "None", "Classes": "None", "Text": "Batch", "ParentId": "7c6bbf34-a0ff-4552-997b-0b231533ee11"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "550a25d6-4814-472b-8301-6234c966910c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "963e2f14-f132-4535-b0cd-9616e7d52a8b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "550a25d6-4814-472b-8301-6234c966910c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c72a28a2-bee9-47df-b5e2-138033c42b92", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aee998b1-e90c-4b07-8d48-f50671f19256", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c72a28a2-bee9-47df-b5e2-138033c42b92"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></b></p>\n</div>", "ID": "d48e0741-9bed-4e2f-8566-45a07f26ca04", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></b></p>", "ID": "98c08b17-f0a0-44a8-b017-6632e001b038", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d48e0741-9bed-4e2f-8566-45a07f26ca04"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></b>", "ID": "83360c23-10a5-4088-aefe-f1a072067115", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "98c08b17-f0a0-44a8-b017-6632e001b038"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span>", "ID": "5ad44bc7-8b5a-4333-881a-8f981e23dcc3", "Styles": "color:black", "Classes": "None", "Text": "14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY", "ParentId": "83360c23-10a5-4088-aefe-f1a072067115"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "80479608-6b2d-4026-9a0b-78e14606eb10", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f9623b8a-c540-4c50-9fe4-f61f7988e840", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "80479608-6b2d-4026-9a0b-78e14606eb10"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicinal product subject to medical\nprescription</span></p>", "ID": "11b9d492-1c1b-4255-8fe4-edb24eb93a91", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Medicinal product subject to medical\nprescription</span>", "ID": "6fcc5625-ee43-4f09-867c-d9c2d13d8089", "Styles": "None", "Classes": "None", "Text": "Medicinal product subject to medical prescription", "ParentId": "11b9d492-1c1b-4255-8fe4-edb24eb93a91"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "65b03726-91d4-4840-8087-540138f69cba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "97a01486-dee1-4ecc-bd5a-a7971fe23530", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "65b03726-91d4-4840-8087-540138f69cba"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "76160876-5ebe-4d3b-b79e-15993a8a2cfe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9ff5fde8-d1a8-4971-8f78-239df4caf736", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "76160876-5ebe-4d3b-b79e-15993a8a2cfe"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>\n</div>", "ID": "707053f4-9c87-4c74-a65a-c9d0e6410bda", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\nbackground:white", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>", "ID": "42bc2031-15dd-4f34-9739-5daee3f3ade4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;background:\nwhite;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "707053f4-9c87-4c74-a65a-c9d0e6410bda"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b>", "ID": "7f119efe-2c5c-4f68-b854-cf482afd69db", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "42bc2031-15dd-4f34-9739-5daee3f3ade4"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span>", "ID": "41a3adc0-8dce-4914-ba1d-3040f4605acd", "Styles": "color:black", "Classes": "None", "Text": "15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS ON USE", "ParentId": "7f119efe-2c5c-4f68-b854-cf482afd69db"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e2ff73e4-77b4-4d64-b505-e6ac74411608", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cd6d79a6-46f7-4720-8c9f-6d3e34ef569c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e2ff73e4-77b4-4d64-b505-e6ac74411608"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "691e8d0b-dee7-443e-a73b-dd05a93afa61", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f21fe8dd-da50-49b6-830f-91446f066b79", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "691e8d0b-dee7-443e-a73b-dd05a93afa61"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN\nBRAILLE</span></b></p>\n</div>", "ID": "5ec9547d-9020-426d-a1e8-6fc14f55ef0c", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN\nBRAILLE</span></b></p>", "ID": "9520669c-54b9-484e-8a9a-a6b209c85bab", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5ec9547d-9020-426d-a1e8-6fc14f55ef0c"}, {"Element": "<b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN\nBRAILLE</span></b>", "ID": "ed5ff1ef-a633-4063-8dfc-142a882c7276", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9520669c-54b9-484e-8a9a-a6b209c85bab"}, {"Element": "<span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN\nBRAILLE</span>", "ID": "e613e920-6df0-43b0-8d3d-6cad87c87f5b", "Styles": "None", "Classes": "None", "Text": "16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE", "ParentId": "ed5ff1ef-a633-4063-8dfc-142a882c7276"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bf1e9572-9a57-4f44-9b59-37de11c93c54", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0d8c6ed5-1760-4811-ad07-a557d29c3dc5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bf1e9572-9a57-4f44-9b59-37de11c93c54"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "4e27d35e-ade7-4f91-91e0-88560dc756b3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</span></b></p>\n</div>", "ID": "dc914b15-f5d3-4d42-8bb8-7e1167359c76", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</span></b></p>", "ID": "c1bb1637-53d5-45c7-9484-89fba486f440", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dc914b15-f5d3-4d42-8bb8-7e1167359c76"}, {"Element": "<b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</span></b>", "ID": "f1289920-932d-4a5a-b370-842cdf9210d2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c1bb1637-53d5-45c7-9484-89fba486f440"}, {"Element": "<span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</span>", "ID": "f8b944c6-55b2-4b9e-beb9-e2422e7b143d", "Styles": "None", "Classes": "None", "Text": "17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE", "ParentId": "f1289920-932d-4a5a-b370-842cdf9210d2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f9a66e17-3d53-4fb9-8ac2-7520dc2f7b69", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f3507720-45a8-4e6c-8f2f-d3d748230c81", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f9a66e17-3d53-4fb9-8ac2-7520dc2f7b69"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not applicable</span></p>", "ID": "abab2ebc-b08d-475d-8c7e-1b03e4e2b89f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Not applicable</span>", "ID": "2ded88da-abc8-46de-a3b2-6ac70fb6348c", "Styles": "None", "Classes": "None", "Text": "Not applicable", "ParentId": "abab2ebc-b08d-475d-8c7e-1b03e4e2b89f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\">\u00a0</span></p>", "ID": "c348fc83-7449-4dd2-81aa-ffa692d09d1e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"background:#CCCCCC\">\u00a0</span>", "ID": "b15a5e92-b527-46e3-bf48-d1b334956c27", "Styles": "background:#CCCCCC", "Classes": "None", "Text": "\u00a0", "ParentId": "c348fc83-7449-4dd2-81aa-ffa692d09d1e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eb66f6be-d276-4fac-807d-3a9ed88c3b0d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "950ff793-5454-4efc-b991-15e30afbbe65", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eb66f6be-d276-4fac-807d-3a9ed88c3b0d"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</span></b></p>\n</div>", "ID": "7e75bbe7-8004-4862-8705-df47d95a56a0", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</span></b></p>", "ID": "d2340460-33f7-471b-bb85-0fd77d4ebadc", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7e75bbe7-8004-4862-8705-df47d95a56a0"}, {"Element": "<b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</span></b>", "ID": "d9cf6225-fa96-4609-8cd8-3e851fe8eec1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d2340460-33f7-471b-bb85-0fd77d4ebadc"}, {"Element": "<span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</span>", "ID": "9c95e30d-6951-43c0-8b08-3f4f0bb9e112", "Styles": "None", "Classes": "None", "Text": "18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA", "ParentId": "d9cf6225-fa96-4609-8cd8-3e851fe8eec1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1c5eff6b-9b6b-4c7a-8815-9e5014edbc44", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f68de5af-3436-4795-904d-24d53ae402fa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1c5eff6b-9b6b-4c7a-8815-9e5014edbc44"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not applicable</span></p>", "ID": "eda6c044-f228-4bf5-8781-92dd792e95a9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Not applicable</span>", "ID": "5fc75c55-e5a7-433b-8c90-fa9ecf523f63", "Styles": "None", "Classes": "None", "Text": "Not applicable", "ParentId": "eda6c044-f228-4bf5-8781-92dd792e95a9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "afc70495-6d98-400c-84e9-c2a535482377", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "189d5732-72e4-4fa4-b555-7567f0859f2f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "afc70495-6d98-400c-84e9-c2a535482377"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "89874684-bdc7-4682-bdca-2ed495b1cef1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c07ccc33-d6ea-446f-b04d-d149fe5405d8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "405abe73-4aa2-41a2-b613-2e6f7a87ccbb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c07ccc33-d6ea-446f-b04d-d149fe5405d8"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "2a97b769-3e56-4490-bd8b-f4d0180823b4", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "0b84e7bc-2621-4b23-8adf-20f331a4c229", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "2a97b769-3e56-4490-bd8b-f4d0180823b4"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ab7e3589-999b-4726-ac2c-356b255c86c2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b8815ea0-6b03-4784-9ce8-c28cc4ee4d45", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1d209e24-9c27-4108-a6d7-c65a96be0d1a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b8815ea0-6b03-4784-9ce8-c28cc4ee4d45"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1e2d66d3-3310-495b-8c0f-b64b58f91a0f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6407837d-7ccf-4c5d-b9fc-95101f24c6e0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1e2d66d3-3310-495b-8c0f-b64b58f91a0f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "230a20f6-8e23-4c4d-abd7-d36b6ea20b37", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "de30416b-320b-44ee-9671-a04b0c6c387f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "230a20f6-8e23-4c4d-abd7-d36b6ea20b37"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9c286032-d3b4-4f43-ace3-2c79d1e6628b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9ac0a13d-d3ce-4a6f-b9b1-1f3fb4299ea6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9c286032-d3b4-4f43-ace3-2c79d1e6628b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "30dd6458-4626-48ac-b8bd-bce7b08b6d30", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e7680bac-3149-49ca-9b96-60a4cbf450a6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "30dd6458-4626-48ac-b8bd-bce7b08b6d30"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ef5d72c8-fb3b-40dc-af5d-343ba7486ed9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b3330ca5-ef4e-43c7-b83f-6cd3bfd627dd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ef5d72c8-fb3b-40dc-af5d-343ba7486ed9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ec56790f-c4e4-43e8-ad18-4f537480a35b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4a70f7df-bd6e-47f3-a61e-3166bfe2351b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ec56790f-c4e4-43e8-ad18-4f537480a35b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ba7c624c-c269-486f-83f9-40011c79bc9c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c9506cd0-b02b-4e07-9a3e-ca633ec59b64", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ba7c624c-c269-486f-83f9-40011c79bc9c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "237ef1eb-bf03-4869-afa5-d5adbe3cb486", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8df4047c-d67e-4f1b-b54b-6b2c7ee26ce3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "237ef1eb-bf03-4869-afa5-d5adbe3cb486"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "97ff10f0-2832-495d-84ec-71cdbfb41509", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3d1b74ef-55d4-4866-9c81-a81f9027d8d1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "97ff10f0-2832-495d-84ec-71cdbfb41509"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ee56e441-c1e3-4ec5-b1b6-0d5a159abf2a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a5f5d8d7-8069-4ea1-8cad-8065ae1e9099", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ee56e441-c1e3-4ec5-b1b6-0d5a159abf2a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2e222d14-f4a0-480b-b583-50c1fc071ae1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e4e0b7b5-4a7e-486d-b02c-b1c53c96169a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2e222d14-f4a0-480b-b583-50c1fc071ae1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f71f6be8-2d45-446d-8016-1177f25e6af7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3f05601f-346f-418d-aa19-75e9e2d7c6f6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f71f6be8-2d45-446d-8016-1177f25e6af7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f85ade30-2eda-4597-949f-a607d74c5d17", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9cb93516-cb4c-4e8d-ae05-3c314084a366", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f85ade30-2eda-4597-949f-a607d74c5d17"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6db883fe-a136-49fd-b744-0f23163f7196", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9d414c41-4d59-437a-9d0e-dec9f8a987cd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6db883fe-a136-49fd-b744-0f23163f7196"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "505fec6f-922e-4da8-a239-11e609f6ceff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2a3d4425-1b47-4d3e-b1e9-b8f98f5286ea", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "505fec6f-922e-4da8-a239-11e609f6ceff"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4228af37-4265-495e-bfaf-c210a4ed4934", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b285b003-a52c-4e9e-955a-3957a46b2c6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4228af37-4265-495e-bfaf-c210a4ed4934"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0ed95dfe-202f-4e90-8a0b-109638e41816", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f5742f56-4fb0-4182-b92b-3b841722adee", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0ed95dfe-202f-4e90-8a0b-109638e41816"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d35fd6a2-d8c2-48eb-806d-3a6dba108a90", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ee9a32e9-52fd-4871-8fdf-f76367be155f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d35fd6a2-d8c2-48eb-806d-3a6dba108a90"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7ea5109f-52ab-485f-9be8-a50e92003736", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6c081431-6cb3-4a90-8261-f1cd4d5fb88d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7ea5109f-52ab-485f-9be8-a50e92003736"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0f2dc9b3-3b58-4c9d-8500-67f8c4c841f0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "69101962-2a15-4f47-9878-9d4520e482dd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0f2dc9b3-3b58-4c9d-8500-67f8c4c841f0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "823d67a3-da79-41e3-bd3e-045d9491c2c5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2b29afb0-e7fa-4d5f-bd7b-ff207ec624b3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "823d67a3-da79-41e3-bd3e-045d9491c2c5"}, {"Element": "<p class=\"Annex\"><span lang=\"EN-GB\">B. PACKAGE LEAFLET</span></p>", "ID": "da56ae82-d999-4cc9-b71e-8c99764f23a5", "Styles": "None", "Classes": "['Annex']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">B. PACKAGE LEAFLET</span>", "ID": "155faaa9-a83a-488b-9a2c-b4837e39991c", "Styles": "None", "Classes": "None", "Text": "B. PACKAGE LEAFLET", "ParentId": "da56ae82-d999-4cc9-b71e-8c99764f23a5"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "2027b20d-6971-48ec-b536-a5843367772e", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "37f4df1a-10b1-4010-9dd9-e6e55ec8f338", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "2027b20d-6971-48ec-b536-a5843367772e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>", "ID": "944cccec-740c-4c2d-acf6-819feff84222", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>\u00a0</b>", "ID": "eb854cb1-88c2-4439-b9d4-21f77f0eb0d3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "944cccec-740c-4c2d-acf6-819feff84222"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>Package Leaflet:\nInformation for the user</b></p>", "ID": "2dbc18c9-52cd-4ffc-bbe6-116089c9f23b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>Package Leaflet:\nInformation for the user</b>", "ID": "31c5c027-78ed-4054-b7de-9ce8238da7f8", "Styles": "None", "Classes": "None", "Text": "Package Leaflet: Information for the user", "ParentId": "2dbc18c9-52cd-4ffc-bbe6-116089c9f23b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>", "ID": "006fe87e-01c1-49ac-b40d-aebc8d31632c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>\u00a0</b>", "ID": "aa6b0c90-6975-4b8b-86ae-7abdbeea56fd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "006fe87e-01c1-49ac-b40d-aebc8d31632c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Invirase\n500\u00a0mg </span>film-coated tablet</b><b><span lang=\"EN-GB\">s</span></b></p>", "ID": "82fa020e-56c4-4907-b9fc-d85e2b8b371d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">Invirase\n500\u00a0mg </span>film-coated tablet</b>", "ID": "f7cf52c1-937b-4486-9795-30bd394b84ae", "Styles": "None", "Classes": "None", "Text": "film-coated tablet", "ParentId": "82fa020e-56c4-4907-b9fc-d85e2b8b371d"}, {"Element": "<span lang=\"EN-GB\">Invirase\n500\u00a0mg </span>", "ID": "84765359-5089-4bfe-922f-7dbe26411247", "Styles": "None", "Classes": "None", "Text": "Invirase 500\u00a0mg ", "ParentId": "f7cf52c1-937b-4486-9795-30bd394b84ae"}, {"Element": "<b><span lang=\"EN-GB\">s</span></b>", "ID": "781cd001-ff3a-44e1-b380-15c685cae2d0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "82fa020e-56c4-4907-b9fc-d85e2b8b371d"}, {"Element": "<span lang=\"EN-GB\">s</span>", "ID": "21ea0113-8fac-464a-ae36-138f47dc0af5", "Styles": "None", "Classes": "None", "Text": "s", "ParentId": "781cd001-ff3a-44e1-b380-15c685cae2d0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Saquinavir</span></b></p>", "ID": "c91dc58d-a0d1-4dab-b33e-cfe1cb255f79", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">Saquinavir</span></b>", "ID": "48b54488-4b27-4b5f-b788-1abd3286c136", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c91dc58d-a0d1-4dab-b33e-cfe1cb255f79"}, {"Element": "<span lang=\"EN-GB\">Saquinavir</span>", "ID": "b7e81a33-be68-4c49-8b1b-910f74ad4321", "Styles": "None", "Classes": "None", "Text": "Saquinavir", "ParentId": "48b54488-4b27-4b5f-b788-1abd3286c136"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4a5d8451-e240-4595-bbd4-eb7dd321cebb", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8c43326d-454a-4e66-b717-6689cf1ca133", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4a5d8451-e240-4595-bbd4-eb7dd321cebb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">Read all of\nthis leaflet carefully before you start taking this medicine </span>because it\ncontains important information for you</b><b><span lang=\"EN-GB\">.</span></b></p>", "ID": "b1a2d10c-67a6-41b4-9f49-c63343afb12b", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">Read all of\nthis leaflet carefully before you start taking this medicine </span>because it\ncontains important information for you</b>", "ID": "ccf21439-82c3-48d0-9ece-9d9f7a882f0c", "Styles": "None", "Classes": "None", "Text": "because it contains important information for you", "ParentId": "b1a2d10c-67a6-41b4-9f49-c63343afb12b"}, {"Element": "<span lang=\"EN-GB\">Read all of\nthis leaflet carefully before you start taking this medicine </span>", "ID": "9c360ccb-484d-4f8b-8304-495d50ffc3cb", "Styles": "None", "Classes": "None", "Text": "Read all of this leaflet carefully before you start taking this medicine ", "ParentId": "ccf21439-82c3-48d0-9ece-9d9f7a882f0c"}, {"Element": "<b><span lang=\"EN-GB\">.</span></b>", "ID": "05d7fbe1-a697-4743-8c60-10b19366e0f6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b1a2d10c-67a6-41b4-9f49-c63343afb12b"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "8d1f7397-7207-4b8f-b137-f729cb6b10be", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "05d7fbe1-a697-4743-8c60-10b19366e0f6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 Keep\nthis leaflet. You may need to read it again.</span></p>", "ID": "0f77a931-d98b-4068-81bc-38305c633cc0", "Styles": "margin-left:.25in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "504428b2-c1d9-4f42-a867-8a4dc6c88935", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0f77a931-d98b-4068-81bc-38305c633cc0"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 Keep\nthis leaflet. You may need to read it again.</span>", "ID": "027c6336-160b-4a02-ac9c-822a4b3ae3b0", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 Keep this leaflet. You may need to read it again.", "ParentId": "0f77a931-d98b-4068-81bc-38305c633cc0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 If\nyou have any further questions, ask your doctor or pharmacist.</span></p>", "ID": "171eb442-08e7-43bf-8e2f-61699dccbcce", "Styles": "margin-left:.25in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "294f76f7-ff92-487a-b0dc-64fc68b0b0e8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "171eb442-08e7-43bf-8e2f-61699dccbcce"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 If\nyou have any further questions, ask your doctor or pharmacist.</span>", "ID": "0cdf94c4-bb4e-4c92-964f-62cc534d3661", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 If you have any further questions, ask your doctor or pharmacist.", "ParentId": "171eb442-08e7-43bf-8e2f-61699dccbcce"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0 This\nmedicine has been prescribed for you only. Do not pass it on to others. It may\nharm them, even if their signs of illness are the same as yours.</span></p>", "ID": "c8ece3dc-698d-404b-b56b-72d8078b0b9e", "Styles": "margin-left:.25in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "bcef1c6d-563e-442e-8a68-c8c8529fac08", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c8ece3dc-698d-404b-b56b-72d8078b0b9e"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0 This\nmedicine has been prescribed for you only. Do not pass it on to others. It may\nharm them, even if their signs of illness are the same as yours.</span>", "ID": "b4a297e4-9cab-4c1f-8ae4-fa5439c4b606", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.", "ParentId": "c8ece3dc-698d-404b-b56b-72d8078b0b9e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 If you get any\nside effects, talk to your doctor or pharmacist. This includes any possible\nside effects not listed in this leaflet. See section 4.</p>", "ID": "7bc9be15-d325-42bc-8559-550d65fc4247", "Styles": "margin-left:.25in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "eee6dbde-a157-4234-8d92-1a505e902e67", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "7bc9be15-d325-42bc-8559-550d65fc4247"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "19f17418-7f69-42e4-8b37-10acafc2bdf1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4dca76c7-1796-40ca-a987-b5f00fe7c6d0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "19f17418-7f69-42e4-8b37-10acafc2bdf1"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">What is in this leaflet:</span></b></p>", "ID": "3b143cc4-17bc-4312-abdf-b02e5d98ed4b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">What is in this leaflet:</span></b>", "ID": "ac989213-c624-4c72-aef1-1b49c0f07f75", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3b143cc4-17bc-4312-abdf-b02e5d98ed4b"}, {"Element": "<span lang=\"EN-GB\">What is in this leaflet:</span>", "ID": "2cda49a1-30bb-4ce0-b7a5-adc6824ae75b", "Styles": "None", "Classes": "None", "Text": "What is in this leaflet:", "ParentId": "ac989213-c624-4c72-aef1-1b49c0f07f75"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nInvirase is and what it is used for</span></p>", "ID": "7797237f-be81-435b-86f2-05fd4a3aa4b9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nInvirase is and what it is used for</span>", "ID": "26baacd1-a258-4f23-8536-ac2cafed016c", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Invirase is and what it is used for", "ParentId": "7797237f-be81-435b-86f2-05fd4a3aa4b9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>What\nyou need to know b<span lang=\"EN-GB\">efore you take Invirase</span></p>", "ID": "0bc609cb-94e3-4acc-9335-fa5286b56e53", "Styles": "None", "Classes": "['MsoNormal']", "Text": "What you need to know b", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "54f4e738-7910-4bc2-b621-84fe6445d4e8", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "0bc609cb-94e3-4acc-9335-fa5286b56e53"}, {"Element": "<span lang=\"EN-GB\">efore you take Invirase</span>", "ID": "5d752f95-6492-494b-8bd9-1e1a80cf148e", "Styles": "None", "Classes": "None", "Text": "efore you take Invirase", "ParentId": "0bc609cb-94e3-4acc-9335-fa5286b56e53"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto take Invirase</span></p>", "ID": "f87e1368-c25e-45bc-b9db-028ec4c035c3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto take Invirase</span>", "ID": "c8c18f3c-4a40-4e9f-84fe-11cc2e3cf113", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to take Invirase", "ParentId": "f87e1368-c25e-45bc-b9db-028ec4c035c3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span></p>", "ID": "21625fc6-1295-42af-8ddf-91a00fbbecb9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span>", "ID": "1cfd2d4a-7e1c-4b08-a626-059a6aa52735", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects", "ParentId": "21625fc6-1295-42af-8ddf-91a00fbbecb9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Invirase</span></p>", "ID": "ea9dab46-9107-4361-b0f6-9ba8ef2cd0c2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Invirase</span>", "ID": "45f4013c-3818-4f3f-a9f1-91c4dc045028", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Invirase", "ParentId": "ea9dab46-9107-4361-b0f6-9ba8ef2cd0c2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>Contents\nof the pack and other <span lang=\"EN-GB\">information</span></p>", "ID": "62c9c0c6-79eb-45c7-b728-f5d2a96c6477", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Contents of the pack and other ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "11d95759-48f1-444e-a17d-ebe57e2aa589", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "62c9c0c6-79eb-45c7-b728-f5d2a96c6477"}, {"Element": "<span lang=\"EN-GB\">information</span>", "ID": "899d1031-09b5-4e4f-ab1a-4d1be7798113", "Styles": "None", "Classes": "None", "Text": "information", "ParentId": "62c9c0c6-79eb-45c7-b728-f5d2a96c6477"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4866e630-655e-40bf-adfd-b4394f746a3a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "facef6bd-1de3-4778-a0fe-df594b9b9b07", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4866e630-655e-40bf-adfd-b4394f746a3a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b3f07b72-60a9-40df-ae27-63bb731d5a79", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f1d2dd23-bfbf-4f0e-9454-54a73457b511", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b3f07b72-60a9-40df-ae27-63bb731d5a79"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Invirase\nis and what it is used for</span></b></p>", "ID": "f8f86d23-fc37-41c4-8264-46434cf89762", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Invirase\nis and what it is used for</span></b>", "ID": "a70fbde6-5acf-44b0-aaff-393a26fd1785", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f8f86d23-fc37-41c4-8264-46434cf89762"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Invirase\nis and what it is used for</span>", "ID": "570630d3-81fe-466a-8558-d4b2e89163eb", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Invirase is and what it is used for", "ParentId": "a70fbde6-5acf-44b0-aaff-393a26fd1785"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ef4cc76c-e2b9-44a5-83a2-74b8f66ef068", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8254f4cc-ec64-417e-8ff3-4e110ede9e6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ef4cc76c-e2b9-44a5-83a2-74b8f66ef068"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase contains the active substance saquinavir\nwhich is an antiviral agent. It is a member of a class of medicines called\nprotease inhibitors. It is for the treatment of infection with the human\nimmunodeficiency virus (HIV).</span></p>", "ID": "79487fa6-28ff-4d9d-8773-b2be88b11aa9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Invirase contains the active substance saquinavir\nwhich is an antiviral agent. It is a member of a class of medicines called\nprotease inhibitors. It is for the treatment of infection with the human\nimmunodeficiency virus (HIV).</span>", "ID": "a8395d9a-1f7b-4840-8b2d-61d42ad95f21", "Styles": "None", "Classes": "None", "Text": "Invirase contains the active substance saquinavir which is an antiviral agent. It is a member of a class of medicines called protease inhibitors. It is for the treatment of infection with the human immunodeficiency virus (HIV).", "ParentId": "79487fa6-28ff-4d9d-8773-b2be88b11aa9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e182a7f3-5137-432f-820d-615cdf8d68df", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9a90eb07-b5e8-4da5-b946-9ccbb55ab4b9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e182a7f3-5137-432f-820d-615cdf8d68df"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase is used by HIV-1-infected adults.\nInvirase is prescribed for use in combination with ritonavir (Norvir) and other\nantiretroviral medicines.</span></p>", "ID": "eb50e63a-1553-4533-ac37-b79f0a0c60b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Invirase is used by HIV-1-infected adults.\nInvirase is prescribed for use in combination with ritonavir (Norvir) and other\nantiretroviral medicines.</span>", "ID": "8a86c12c-3d96-45b9-9583-e283d5fa769f", "Styles": "None", "Classes": "None", "Text": "Invirase is used by HIV-1-infected adults. Invirase is prescribed for use in combination with ritonavir (Norvir) and other antiretroviral medicines.", "ParentId": "eb50e63a-1553-4533-ac37-b79f0a0c60b8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8c9b7fd2-b698-4de5-aba9-e1109546ff17", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eb65b090-1c46-4587-a034-48d265cac9fd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8c9b7fd2-b698-4de5-aba9-e1109546ff17"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f3368752-3bca-4211-a7bb-e772ebce6c68", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d16e58d3-7c83-43ee-9b11-f0cee38fe1d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f3368752-3bca-4211-a7bb-e772ebce6c68"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need\nto know before you take Invirase</span></b></p>", "ID": "4be12aec-cd9e-4c7d-990d-1f5b25c7208e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need\nto know before you take Invirase</span></b>", "ID": "e0fb1b6f-ee36-4245-9d89-211a77ae0032", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4be12aec-cd9e-4c7d-990d-1f5b25c7208e"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need\nto know before you take Invirase</span>", "ID": "9068929c-eb9f-42bc-8fbe-6a8b0cc041b0", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you take Invirase", "ParentId": "e0fb1b6f-ee36-4245-9d89-211a77ae0032"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bcea2d40-1e43-4956-a7dd-6bc8aa482532", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "746b7630-1358-4347-854d-76a0566835cc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bcea2d40-1e43-4956-a7dd-6bc8aa482532"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Do not\ntake Invirase if you have:</span></b></p>", "ID": "506caa53-2c41-4b32-9900-1a9c4ffa271f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">Do not\ntake Invirase if you have:</span></b>", "ID": "1cabf9ca-59fe-483b-9c56-1a0fccc12100", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "506caa53-2c41-4b32-9900-1a9c4ffa271f"}, {"Element": "<span lang=\"EN-GB\">Do not\ntake Invirase if you have:</span>", "ID": "9b8c7246-ea19-42dc-b691-e6afaa831a1f", "Styles": "None", "Classes": "None", "Text": "Do not take Invirase if you have:", "ParentId": "1cabf9ca-59fe-483b-9c56-1a0fccc12100"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 an\nallergy to saquinavir, ritonavir or any of the other ingredients</span> (see\n\u201cInvirase contains lactose\u201d later in this section and \u201cWhat\nInvirase contains\u201d in Section 6)</p>", "ID": "0c2b1f45-f7d1-4c53-8583-bc4ef664c23c", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": " (see \u201cInvirase contains lactose\u201d later in this section and \u201cWhat Invirase contains\u201d in Section 6)", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "081a37da-6107-4e12-b426-5b8b8798871e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0c2b1f45-f7d1-4c53-8583-bc4ef664c23c"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 an\nallergy to saquinavir, ritonavir or any of the other ingredients</span>", "ID": "0ce4f0b0-007f-46ed-a4fd-e572385d87c0", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 an allergy to saquinavir, ritonavir or any of the other ingredients", "ParentId": "0c2b1f45-f7d1-4c53-8583-bc4ef664c23c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span style=\"color:black\">\u00a0\u00a0\u00a0\u00a0\u00a0 any\nheart problems that show on an electrocardiogram (ECG, electrical recording of\nthe heart)</span><span lang=\"EN-GB\"> - you may have been born with that</span></p>", "ID": "c2b04493-2306-434b-9e19-c0f73dabb0c7", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol;color:black\">\u00b7</span>", "ID": "3802858b-fe60-48ae-84af-bb1905fe219a", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "c2b04493-2306-434b-9e19-c0f73dabb0c7"}, {"Element": "<span style=\"color:black\">\u00a0\u00a0\u00a0\u00a0\u00a0 any\nheart problems that show on an electrocardiogram (ECG, electrical recording of\nthe heart)</span>", "ID": "110da71c-d9ef-44eb-98d1-27d9c3292e57", "Styles": "color:black", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 any heart problems that show on an electrocardiogram (ECG, electrical recording of the heart)", "ParentId": "c2b04493-2306-434b-9e19-c0f73dabb0c7"}, {"Element": "<span lang=\"EN-GB\"> - you may have been born with that</span>", "ID": "77b5e9cc-0502-4c38-8d7e-74a3e32652ce", "Styles": "None", "Classes": "None", "Text": " - you may have been born with that", "ParentId": "c2b04493-2306-434b-9e19-c0f73dabb0c7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span style=\"color:black\">\u00a0\u00a0\u00a0\u00a0\u00a0 a\nvery slow heart rate (bradycardia)</span></p>", "ID": "3cd9e972-9cce-4e46-8939-b87915b42a61", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol;color:black\">\u00b7</span>", "ID": "fea00cc7-7bbd-46dc-ac50-6f88cce4f373", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "3cd9e972-9cce-4e46-8939-b87915b42a61"}, {"Element": "<span style=\"color:black\">\u00a0\u00a0\u00a0\u00a0\u00a0 a\nvery slow heart rate (bradycardia)</span>", "ID": "5526898f-4af2-4cc8-bbda-34ef85dddc58", "Styles": "color:black", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 a very slow heart rate (bradycardia)", "ParentId": "3cd9e972-9cce-4e46-8939-b87915b42a61"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span style=\"color:black\">\u00a0\u00a0\u00a0\u00a0\u00a0 a\nweak heart (heart failure)</span></p>", "ID": "6e4b19a8-e326-4f7d-8e88-007cd47ebee0", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol;color:black\">\u00b7</span>", "ID": "b9e0760c-186a-401e-9a7f-b9730beac531", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "6e4b19a8-e326-4f7d-8e88-007cd47ebee0"}, {"Element": "<span style=\"color:black\">\u00a0\u00a0\u00a0\u00a0\u00a0 a\nweak heart (heart failure)</span>", "ID": "0fd84a17-b3a4-44e2-b177-ca6e28dfec1c", "Styles": "color:black", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 a weak heart (heart failure)", "ParentId": "6e4b19a8-e326-4f7d-8e88-007cd47ebee0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span style=\"color:black\">\u00a0\u00a0\u00a0\u00a0\u00a0 a\nhistory of an irregular heart beat (arrhythmias)</span></p>", "ID": "40c85379-45db-4ed4-a770-3d4279a28975", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol;color:black\">\u00b7</span>", "ID": "6e33b03f-3cc4-4e19-a9ae-eed9d8ea0e62", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "40c85379-45db-4ed4-a770-3d4279a28975"}, {"Element": "<span style=\"color:black\">\u00a0\u00a0\u00a0\u00a0\u00a0 a\nhistory of an irregular heart beat (arrhythmias)</span>", "ID": "bdc5287e-b08c-4709-bb6a-41c8208c1aed", "Styles": "color:black", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 a history of an irregular heart beat (arrhythmias)", "ParentId": "40c85379-45db-4ed4-a770-3d4279a28975"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol;color:black\">\u00b7</span><span style=\"color:black\">\u00a0\u00a0\u00a0\u00a0 a\nsalt imbalance in your blood, especially low blood concentrations of potassium\n(hypokalaemia), which is not currently controlled by treatment</span></p>", "ID": "4c72bcee-c20b-4c8b-a377-c241ebc476d3", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol;color:black\">\u00b7</span>", "ID": "eb63c8bf-dc2a-4684-bf47-f5710c64d56a", "Styles": "font-family:Symbol;color:black", "Classes": "None", "Text": "\u00b7", "ParentId": "4c72bcee-c20b-4c8b-a377-c241ebc476d3"}, {"Element": "<span style=\"color:black\">\u00a0\u00a0\u00a0\u00a0 a\nsalt imbalance in your blood, especially low blood concentrations of potassium\n(hypokalaemia), which is not currently controlled by treatment</span>", "ID": "70ea0273-74fe-4bcc-86e1-2e6059c9e1c4", "Styles": "color:black", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 a salt imbalance in your blood, especially low blood concentrations of potassium (hypokalaemia), which is not currently controlled by treatment", "ParentId": "4c72bcee-c20b-4c8b-a377-c241ebc476d3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 severe\nliver problems such as jaundice, hepatitis</span> or liver failure - where your\nbelly fills with fluid, you get confused or your oesophagus (the tube that runs\nfrom your mouth to your stomach) bleeds</p>", "ID": "23cf113a-bff5-49d2-80fd-66571544812e", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": " or liver failure - where your belly fills with fluid, you get confused or your oesophagus (the tube that runs from your mouth to your stomach) bleeds", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "68346572-5de1-4675-91fa-68ea4ed9e93a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "23cf113a-bff5-49d2-80fd-66571544812e"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 severe\nliver problems such as jaundice, hepatitis</span>", "ID": "ae5abb8a-c3c6-4d68-bb72-a89d21bf3909", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 severe liver problems such as jaundice, hepatitis", "ParentId": "23cf113a-bff5-49d2-80fd-66571544812e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 recently\ntaken the HIV medicine rilpivirine</span>.</p>", "ID": "b3f0d907-2fa5-4c71-b902-fdd588a0859e", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": ".", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "ce70f2a2-1f2c-4bc7-a575-d8742cc060f2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b3f0d907-2fa5-4c71-b902-fdd588a0859e"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 recently\ntaken the HIV medicine rilpivirine</span>", "ID": "3f828e75-f1ae-4374-bc10-890c7a20d1b0", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 recently taken the HIV medicine rilpivirine", "ParentId": "b3f0d907-2fa5-4c71-b902-fdd588a0859e"}, {"Element": "<p class=\"MsoNormal\">Do not take Invirase if any of the above applies to you. If\nyou are not sure, talk to your doctor or pharmacist before taking Invirase.</p>", "ID": "947b3e60-a2da-4ca2-af00-0d020b217c94", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Do not take Invirase if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking Invirase.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Do not take Invirase <span style=\"color:black\">if you are taking any of the following medicines:</span></b></p>", "ID": "517bfafb-da81-4ed5-8d7e-9c473e4de5d0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>Do not take Invirase <span style=\"color:black\">if you are taking any of the following medicines:</span></b>", "ID": "c7b1d599-2e67-45c7-9d24-f99b06b6815a", "Styles": "None", "Classes": "None", "Text": "Do not take Invirase ", "ParentId": "517bfafb-da81-4ed5-8d7e-9c473e4de5d0"}, {"Element": "<span style=\"color:black\">if you are taking any of the following medicines:</span>", "ID": "1c1c9a6a-b662-40ff-81ad-8a532fa4c71c", "Styles": "color:black", "Classes": "None", "Text": "if you are taking any of the following medicines:", "ParentId": "c7b1d599-2e67-45c7-9d24-f99b06b6815a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span style=\"color:black\">Any\nmedicine that can change your heart beat, </span></b><span style=\"color:black\">such\nas:</span></p>", "ID": "22327155-29c5-4014-80a6-122960b629b3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span style=\"color:black\">Any\nmedicine that can change your heart beat, </span></b>", "ID": "47ec3ce8-b2cf-4730-9252-6559368fe5a1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "22327155-29c5-4014-80a6-122960b629b3"}, {"Element": "<span style=\"color:black\">Any\nmedicine that can change your heart beat, </span>", "ID": "9400e822-fa3e-4d01-8405-6f0335696c42", "Styles": "color:black", "Classes": "None", "Text": "Any medicine that can change your heart beat, ", "ParentId": "47ec3ce8-b2cf-4730-9252-6559368fe5a1"}, {"Element": "<span style=\"color:black\">such\nas:</span>", "ID": "0ac77677-196b-405c-9a59-74c729a05a04", "Styles": "color:black", "Classes": "None", "Text": "such as:", "ParentId": "22327155-29c5-4014-80a6-122960b629b3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain medicines for HIV - such as\natazanavir, lopinavir, rilpivirine</span></p>", "ID": "ac20a7bd-882f-4390-8e8e-dc8e439e1560", "Styles": "margin-left:.3in;text-indent:-.3in;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "03539938-9fac-47b2-97e2-1938da2fac29", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ac20a7bd-882f-4390-8e8e-dc8e439e1560"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain medicines for HIV - such as\natazanavir, lopinavir, rilpivirine</span>", "ID": "237f1a4b-778f-45d6-a06d-e28cb7399313", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 certain medicines for HIV - such as atazanavir, lopinavir, rilpivirine", "ParentId": "ac20a7bd-882f-4390-8e8e-dc8e439e1560"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nheart medicines - </span>amiodarone, bepridil, disopyramide, dofetilide,\nflecainide, hydroquinidine, ibutilide, lidocaine, propafenone, quinidine,\nsotalol</p>", "ID": "f9040f4c-cf06-424b-89eb-88544f5ba238", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "amiodarone, bepridil, disopyramide, dofetilide, flecainide, hydroquinidine, ibutilide, lidocaine, propafenone, quinidine, sotalol", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "60bf3ffd-77b6-4c54-8f49-b1b1e4f92deb", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f9040f4c-cf06-424b-89eb-88544f5ba238"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nheart medicines - </span>", "ID": "aca8c91e-323a-444b-8891-b54071601f6b", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 certain heart medicines - ", "ParentId": "f9040f4c-cf06-424b-89eb-88544f5ba238"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nmedicines for depression - amitriptyline, imipramine, trazodone, maprotiline</span></p>", "ID": "64572e43-b5f3-4e55-9761-2c0bd5738aab", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "7887e069-7d68-421d-a0e1-f5bd100b4956", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "64572e43-b5f3-4e55-9761-2c0bd5738aab"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nmedicines for depression - amitriptyline, imipramine, trazodone, maprotiline</span>", "ID": "e6283704-7237-4444-8eb5-fb42bd0239c7", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 certain medicines for depression - amitriptyline, imipramine, trazodone, maprotiline", "ParentId": "64572e43-b5f3-4e55-9761-2c0bd5738aab"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nfor other severe mental health problems - such as </span>clozapine, haloperidol,<br/>\nmesoridazine, phenothiazines, sertindole, sultopride, thioridazine, ziprasidone</p>", "ID": "8aab409f-7e6c-41c0-a5c0-237f8bfaa061", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "clozapine, haloperidol, mesoridazine, phenothiazines, sertindole, sultopride, thioridazine, ziprasidone", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "67c7a171-189f-4e37-b8d8-c5c6fe84cb8f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "8aab409f-7e6c-41c0-a5c0-237f8bfaa061"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nfor other severe mental health problems - such as </span>", "ID": "fbea1f96-c3fc-44d1-9169-243dff11cef1", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 medicines for other severe mental health problems - such as ", "ParentId": "8aab409f-7e6c-41c0-a5c0-237f8bfaa061"}, {"Element": "<br/>", "ID": "4c41c448-501f-43c4-b31c-b6e6aca78c77", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8aab409f-7e6c-41c0-a5c0-237f8bfaa061"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nmedicines for infection - such as clarithromycin, dapsone, erythromycin,\nhalofantrine, pentamidine, sparfloxacin</span></p>", "ID": "e6db1e2d-9721-492c-bdda-0574d8323e84", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "c0311f57-c765-49d9-a7ce-ae19a6d23df1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e6db1e2d-9721-492c-bdda-0574d8323e84"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nmedicines for infection - such as clarithromycin, dapsone, erythromycin,\nhalofantrine, pentamidine, sparfloxacin</span>", "ID": "b1242043-0d85-4e38-b44d-407389dfc84f", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 certain medicines for infection - such as clarithromycin, dapsone, erythromycin, halofantrine, pentamidine, sparfloxacin", "ParentId": "e6db1e2d-9721-492c-bdda-0574d8323e84"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nstrong pain killers (narcotics)</span> - such as alfentanyl, fentanyl, methadone</p>", "ID": "8400ab49-6975-4d5c-b0bb-406120126363", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": " - such as alfentanyl, fentanyl, methadone", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "b046b94d-6768-4cba-9630-b82de00d577c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "8400ab49-6975-4d5c-b0bb-406120126363"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nstrong pain killers (narcotics)</span>", "ID": "73d7258e-20b8-4b19-9340-0e76c6834a49", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 certain strong pain killers (narcotics)", "ParentId": "8400ab49-6975-4d5c-b0bb-406120126363"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 medicines\nfor erectile dysfunction - sildenafil, vardenafil, tadalafil</span></p>", "ID": "79d5d9e2-103d-457d-ab1f-577e5d6fb37e", "Styles": "margin-left:21.3pt;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "77a8654d-4077-423e-b399-8db4e2aaa5ee", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "79d5d9e2-103d-457d-ab1f-577e5d6fb37e"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 medicines\nfor erectile dysfunction - sildenafil, vardenafil, tadalafil</span>", "ID": "aeb59ac3-af2a-410f-b787-d8b75780c173", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 medicines for erectile dysfunction - sildenafil, vardenafil, tadalafil", "ParentId": "79d5d9e2-103d-457d-ab1f-577e5d6fb37e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0 certain\nmedicines that may be used for a variety of things: cisapride, diphemanil,\nmizolastine, quinine, vincamine.</p>", "ID": "d9b63ee0-63e2-4af4-9c2e-a594a33c7b03", "Styles": "margin-left:21.3pt;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0 certain medicines that may be used for a variety of things: cisapride, diphemanil, mizolastine, quinine, vincamine.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "e80c9b0c-3b57-42e3-a6e6-271f81478a29", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d9b63ee0-63e2-4af4-9c2e-a594a33c7b03"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 </span>certain\nmedicines used to prevent rejection of new organs after a transplant operation\nsuch as tacrolimus</p>", "ID": "aec4cb37-f63a-47ad-b9c9-3b09199f992a", "Styles": "margin-left:21.3pt;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "certain medicines used to prevent rejection of new organs after a transplant operation such as tacrolimus", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "226d66da-55e4-4f61-ba8b-e0f374fff456", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "aec4cb37-f63a-47ad-b9c9-3b09199f992a"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "c494114c-e9e9-44a2-b347-7d92c71b19f9", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "aec4cb37-f63a-47ad-b9c9-3b09199f992a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0 certain medicines\nused to treat the symptoms of Benign Prostatic Hyperplasia (an increase in size\nof the prostate) such as alfuzosin</p>", "ID": "e5a2f0c4-aeab-492c-a628-d863609df7ab", "Styles": "margin-left:21.3pt;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0 certain medicines used to treat the symptoms of Benign Prostatic Hyperplasia (an increase in size of the prostate) such as alfuzosin", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "bd39a036-5ddb-4416-85fa-ce22bea56599", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e5a2f0c4-aeab-492c-a628-d863609df7ab"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0 certain\nmedicines <span lang=\"EN-GB\">commonly used for allergy symptoms such as terfenadine\nand astemizole</span></p>", "ID": "20d844ff-1067-47b9-b5f1-74a247c20783", "Styles": "margin-left:21.3pt;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0 certain medicines ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "55d328d7-eef1-4a7f-9473-fe2381119214", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "20d844ff-1067-47b9-b5f1-74a247c20783"}, {"Element": "<span lang=\"EN-GB\">commonly used for allergy symptoms such as terfenadine\nand astemizole</span>", "ID": "a067ae99-07cb-4d2e-bd3a-fa9ffa98377b", "Styles": "None", "Classes": "None", "Text": "commonly used for allergy symptoms such as terfenadine and astemizole", "ParentId": "20d844ff-1067-47b9-b5f1-74a247c20783"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0 certain\nmedicines <span lang=\"EN-GB\">for severe mental health problems such as pimozide </span></p>", "ID": "0b0170c8-a01f-4cb1-b109-c348218bb7a4", "Styles": "margin-left:21.3pt;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0 certain medicines ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "c5fa00a0-074a-4f0e-a2ef-c025ee22ebac", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0b0170c8-a01f-4cb1-b109-c348218bb7a4"}, {"Element": "<span lang=\"EN-GB\">for severe mental health problems such as pimozide </span>", "ID": "c0136222-e184-4717-9862-c2211ed74924", "Styles": "None", "Classes": "None", "Text": "for severe mental health problems such as pimozide ", "ParentId": "0b0170c8-a01f-4cb1-b109-c348218bb7a4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0 certain\nmedicines <span lang=\"EN-GB\">(so called tyrosine kinase inhibitors) used to treat\ndifferent types of cancer such as dasatinib and sunitinib</span>.</p>", "ID": "d7426ddd-d429-4797-ae05-b2b129871749", "Styles": "margin-left:21.3pt;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0 certain medicines .", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "beef1f18-e36e-4360-88ee-42cf6d41ea37", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d7426ddd-d429-4797-ae05-b2b129871749"}, {"Element": "<span lang=\"EN-GB\">(so called tyrosine kinase inhibitors) used to treat\ndifferent types of cancer such as dasatinib and sunitinib</span>", "ID": "8881cdf0-c3dc-45ec-b8fa-86b0924fa5a7", "Styles": "None", "Classes": "None", "Text": "(so called tyrosine kinase inhibitors) used to treat different types of cancer such as dasatinib and sunitinib", "ParentId": "d7426ddd-d429-4797-ae05-b2b129871749"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\">\u00a0</p>", "ID": "5fbcc8d0-1f58-4f70-b7fc-b6e463a9c894", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Any of these other medicines:</span></p>", "ID": "3983647c-6480-4ba1-a4d2-7b782ad17168", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Any of these other medicines:</span>", "ID": "5a249183-9c13-4733-810d-a69c700959be", "Styles": "None", "Classes": "None", "Text": "Any of these other medicines:", "ParentId": "3983647c-6480-4ba1-a4d2-7b782ad17168"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 ergot\nalkaloids - for migraine attacks</span></p>", "ID": "d2cdc29e-976b-4163-992a-8a26c37de344", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "8715a855-5459-4e4e-b3e9-f999ad18321e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d2cdc29e-976b-4163-992a-8a26c37de344"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 ergot\nalkaloids - for migraine attacks</span>", "ID": "264ae7ce-0f85-436c-93cd-a6056b7a4e24", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 ergot alkaloids - for migraine attacks", "ParentId": "d2cdc29e-976b-4163-992a-8a26c37de344"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 triazolam\nand midazolam </span>(taken by mouth)<span lang=\"EN-GB\"> - to help you sleep or\nfor anxiety</span></p>", "ID": "bca3cb40-64e2-4c7c-b20b-266f800f64a9", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "(taken by mouth)", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "fcfd35e4-9309-4902-9344-ab541cf98d8b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "bca3cb40-64e2-4c7c-b20b-266f800f64a9"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 triazolam\nand midazolam </span>", "ID": "8e64061b-b628-4de8-a9db-8bf575331a34", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 triazolam and midazolam ", "ParentId": "bca3cb40-64e2-4c7c-b20b-266f800f64a9"}, {"Element": "<span lang=\"EN-GB\"> - to help you sleep or\nfor anxiety</span>", "ID": "e4a47b4f-46b0-46f7-b6d4-0d00436804c4", "Styles": "None", "Classes": "None", "Text": " - to help you sleep or for anxiety", "ParentId": "bca3cb40-64e2-4c7c-b20b-266f800f64a9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 rifampicin\n- for preventing or treating tuberculosis</span></p>", "ID": "14b4ae16-1d41-4821-a6b6-a053ae7c88a9", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "121b713c-7b75-476f-b4e3-fa36879a31d9", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "14b4ae16-1d41-4821-a6b6-a053ae7c88a9"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 rifampicin\n- for preventing or treating tuberculosis</span>", "ID": "8f56171d-ad3d-439c-9245-796b47c26e5b", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 rifampicin - for preventing or treating tuberculosis", "ParentId": "14b4ae16-1d41-4821-a6b6-a053ae7c88a9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 simvastatin\nand lovastatin - for lowering blood cholesterol</span></p>", "ID": "60f228fe-69f6-4394-abc7-f0b3c55d0890", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "31780e56-b0cc-4eac-bb99-a3203d661559", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "60f228fe-69f6-4394-abc7-f0b3c55d0890"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 simvastatin\nand lovastatin - for lowering blood cholesterol</span>", "ID": "2c3ec3c1-063e-4c8c-9df3-211f68fdb890", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 simvastatin and lovastatin - for lowering blood cholesterol", "ParentId": "60f228fe-69f6-4394-abc7-f0b3c55d0890"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-21.3pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">quetiapine \u2013 used to treat schizophrenia, bipolar disorder and\nmajor depressive disorder</span></p>", "ID": "bd21928e-2891-4829-a1f8-72a00ec9e883", "Styles": "margin-left:21.3pt;text-indent:-21.3pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "fbe769c3-f4bf-4658-a30f-dd908bd5b4c9", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "bd21928e-2891-4829-a1f8-72a00ec9e883"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "23d5dda7-458e-468d-9a3c-cba15a91f705", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "bd21928e-2891-4829-a1f8-72a00ec9e883"}, {"Element": "<span lang=\"EN-GB\">quetiapine \u2013 used to treat schizophrenia, bipolar disorder and\nmajor depressive disorder</span>", "ID": "17d098c6-b926-4694-b5f7-d090b940367f", "Styles": "None", "Classes": "None", "Text": "quetiapine \u2013 used to treat schizophrenia, bipolar disorder and major depressive disorder", "ParentId": "bd21928e-2891-4829-a1f8-72a00ec9e883"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-21.3pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 </span><span lang=\"EN-GB\">lurasidone \u2013 used to treat schizophrenia.</span></p>", "ID": "477b7dea-c70d-43c2-877b-1c9749c7ebe7", "Styles": "margin-left:21.3pt;text-indent:-21.3pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "194e7a36-90c9-44c8-8c08-aa25566bfba1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "477b7dea-c70d-43c2-877b-1c9749c7ebe7"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "52f40b69-23c2-4fac-903e-02c62563f3bc", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "477b7dea-c70d-43c2-877b-1c9749c7ebe7"}, {"Element": "<span lang=\"EN-GB\">lurasidone \u2013 used to treat schizophrenia.</span>", "ID": "7ba90263-0cf9-485e-9b87-66398e25f84e", "Styles": "None", "Classes": "None", "Text": "lurasidone \u2013 used to treat schizophrenia.", "ParentId": "477b7dea-c70d-43c2-877b-1c9749c7ebe7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:21.3pt;text-indent:-21.3pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "581d3e87-8c50-4df1-92d8-8a993b7008e9", "Styles": "margin-left:21.3pt;text-indent:-21.3pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "439d00aa-347d-4673-8126-48445d553bd5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "581d3e87-8c50-4df1-92d8-8a993b7008e9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not take Invirase with any other drug\nunless you have talked to your doctor first.\u00a0 The drugs listed above might\ncause serious side effects if you take them together with Invirase.</span></p>", "ID": "5ec7eac8-a19f-4868-8d79-39852ffd72bd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Do not take Invirase with any other drug\nunless you have talked to your doctor first.\u00a0 The drugs listed above might\ncause serious side effects if you take them together with Invirase.</span>", "ID": "3f03dc78-a886-4910-ad55-4772ac855f3a", "Styles": "None", "Classes": "None", "Text": "Do not take Invirase with any other drug unless you have talked to your doctor first.\u00a0 The drugs listed above might cause serious side effects if you take them together with Invirase.", "ParentId": "5ec7eac8-a19f-4868-8d79-39852ffd72bd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3c01d189-6c09-4ecb-b4bb-50317bb91209", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a168a4ed-e418-4bdc-92a6-3727bde7c3a5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3c01d189-6c09-4ecb-b4bb-50317bb91209"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not take Invirase if any of the above\napplies to you. If you are not sure, talk to your doctor or pharmacist before\ntaking Invirase.</span></p>", "ID": "7973d5ad-86d0-4dd4-8e9c-1b2043c0e9e4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Do not take Invirase if any of the above\napplies to you. If you are not sure, talk to your doctor or pharmacist before\ntaking Invirase.</span>", "ID": "a1703d01-a446-4403-8555-18c859ddb687", "Styles": "None", "Classes": "None", "Text": "Do not take Invirase if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking Invirase.", "ParentId": "7973d5ad-86d0-4dd4-8e9c-1b2043c0e9e4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d740afc2-3d06-4732-ab11-3999ee3936fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fafe3115-a8f1-48b3-931d-a9ffe1657273", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d740afc2-3d06-4732-ab11-3999ee3936fd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings\nand precautions</span></b></p>", "ID": "eb7e02aa-8f20-4d22-9cc2-7c0a6a5a1de7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">Warnings\nand precautions</span></b>", "ID": "afb1d746-707c-44fc-977a-df4031452942", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "eb7e02aa-8f20-4d22-9cc2-7c0a6a5a1de7"}, {"Element": "<span lang=\"EN-GB\">Warnings\nand precautions</span>", "ID": "84af1338-f5d4-458a-94e5-af1790873742", "Styles": "None", "Classes": "None", "Text": "Warnings and precautions", "ParentId": "afb1d746-707c-44fc-977a-df4031452942"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">You should know that Invirase/ritonavir is\nnot a cure for HIV infection and that you may continue to develop infections or\nother illnesses associated with HIV disease. You should, therefore, remain\nunder the care of your doctor while taking Invirase/ritonavir.</span></p>", "ID": "f38918b3-65f1-4f9d-81a1-05c41d42cbc7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">You should know that Invirase/ritonavir is\nnot a cure for HIV infection and that you may continue to develop infections or\nother illnesses associated with HIV disease. You should, therefore, remain\nunder the care of your doctor while taking Invirase/ritonavir.</span>", "ID": "fae6b2fc-bd4a-44c0-955a-8c6fc8e14b5b", "Styles": "None", "Classes": "None", "Text": "You should know that Invirase/ritonavir is not a cure for HIV infection and that you may continue to develop infections or other illnesses associated with HIV disease. You should, therefore, remain under the care of your doctor while taking Invirase/ritonavir.", "ParentId": "f38918b3-65f1-4f9d-81a1-05c41d42cbc7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6c1a1ce9-5d36-406d-a434-c371980d6fa3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6ab9c4de-7221-402c-9a2e-00299c10c197", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6c1a1ce9-5d36-406d-a434-c371980d6fa3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">You can still pass on HIV when taking this\nmedicine, although the risk is lowered by effective antiretroviral therapy.\nDiscuss with your physician the precautions needed to avoid infecting other\npeople.</span></p>", "ID": "20ff0fcd-76e4-4184-8e42-399774e0cea4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">You can still pass on HIV when taking this\nmedicine, although the risk is lowered by effective antiretroviral therapy.\nDiscuss with your physician the precautions needed to avoid infecting other\npeople.</span>", "ID": "1002c34b-da59-4004-a536-db70c0e6061a", "Styles": "None", "Classes": "None", "Text": "You can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy. Discuss with your physician the precautions needed to avoid infecting other people.", "ParentId": "20ff0fcd-76e4-4184-8e42-399774e0cea4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eb612ed8-f1f1-4176-adbc-934b75617cc0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "01b26e54-6fa4-485f-b5cc-eb858c0650a7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eb612ed8-f1f1-4176-adbc-934b75617cc0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">At present, there is only limited\ninformation on the use of Invirase/ritonavir in children and in adults over the\nage of 60\u00a0years.</span></p>", "ID": "796a93f4-be63-4b57-8cb9-f673f1a96108", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">At present, there is only limited\ninformation on the use of Invirase/ritonavir in children and in adults over the\nage of 60\u00a0years.</span>", "ID": "dd914277-63e0-41e3-9823-6aeb343387fe", "Styles": "None", "Classes": "None", "Text": "At present, there is only limited information on the use of Invirase/ritonavir in children and in adults over the age of 60\u00a0years.", "ParentId": "796a93f4-be63-4b57-8cb9-f673f1a96108"}, {"Element": "<p class=\"MsoNormal\"><b><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></b></p>", "ID": "f894a1c2-bd5d-4b43-9bae-bf1c25d20939", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></b>", "ID": "db37e488-47d9-44c2-8ebb-59cf1cb682d7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f894a1c2-bd5d-4b43-9bae-bf1c25d20939"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "6ffc7f54-6a59-4fe9-8696-b410fe9724c3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "db37e488-47d9-44c2-8ebb-59cf1cb682d7"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "b140ac78-7be6-4d59-ad45-261ab6bb79b5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6ffc7f54-6a59-4fe9-8696-b410fe9724c3"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "4c86c328-b0fb-4286-8732-4a2d3096d08e", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "b140ac78-7be6-4d59-ad45-261ab6bb79b5"}, {"Element": "<p class=\"MsoNormal\"><b><u>Abnormal heart rhythms (arrhythmias):</u></b></p>", "ID": "5ef8b93b-4dc3-436e-bd1b-d61b3df6618a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><u>Abnormal heart rhythms (arrhythmias):</u></b>", "ID": "19dae198-967a-470e-b06f-64c598066bbc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5ef8b93b-4dc3-436e-bd1b-d61b3df6618a"}, {"Element": "<u>Abnormal heart rhythms (arrhythmias):</u>", "ID": "6556cbed-490b-4227-ab36-a1f1d354e923", "Styles": "None", "Classes": "None", "Text": "Abnormal heart rhythms (arrhythmias):", "ParentId": "19dae198-967a-470e-b06f-64c598066bbc"}, {"Element": "<p class=\"MsoNormal\">Invirase can change how your heart beats - this can be\nserious. This can happen especially if you are female or elderly. </p>", "ID": "7bc7cf2a-b924-442e-aefb-a638083155cc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Invirase can change how your heart beats - this can be serious. This can happen especially if you are female or elderly. ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 If you\nare taking any medicine that decreases your blood potassium levels talk to your\ndoctor before taking Invirase. </p>", "ID": "f78d8b6e-422c-4519-83d6-ab61a892fc9e", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 If you are taking any medicine that decreases your blood potassium levels talk to your doctor before taking Invirase. ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "8dbb3d7d-0687-4635-aa3f-f5bfb4a7cd66", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f78d8b6e-422c-4519-83d6-ab61a892fc9e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><b><span style=\"font-family:Symbol\">\u00b7</span></b><b>\u00a0\u00a0\u00a0\u00a0 Contact\nyour doctor immediately, if you get palpitations or an irregular heart beat\nduring treatment.</b> Your doctor may wish to do an ECG to check your heart\nbeat.</p>", "ID": "36b98111-d24e-4084-863b-22cb46c6ac86", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": " Your doctor may wish to do an ECG to check your heart beat.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span style=\"font-family:Symbol\">\u00b7</span></b>", "ID": "3fa1083b-38e7-410a-a7d4-a87c3bd33c86", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "36b98111-d24e-4084-863b-22cb46c6ac86"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "680d7eb2-569d-4106-82a0-a6df26fdb79c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3fa1083b-38e7-410a-a7d4-a87c3bd33c86"}, {"Element": "<b>\u00a0\u00a0\u00a0\u00a0 Contact\nyour doctor immediately, if you get palpitations or an irregular heart beat\nduring treatment.</b>", "ID": "db92e460-3ea5-4bf3-afde-bc2dd49b9e55", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 Contact your doctor immediately, if you get palpitations or an irregular heart beat during treatment.", "ParentId": "36b98111-d24e-4084-863b-22cb46c6ac86"}, {"Element": "<p class=\"MsoNormal\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "2c73d0a9-512c-4eb9-b1a2-d88779ad4941", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "3d57c4e3-fc0f-4c1a-a5fd-9c57dad1eafa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2c73d0a9-512c-4eb9-b1a2-d88779ad4941"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "58a561e6-f17a-4bcd-84ad-8061bb776362", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "3d57c4e3-fc0f-4c1a-a5fd-9c57dad1eafa"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other conditions</span></b></p>", "ID": "7e8e42f3-2f0d-4e61-8508-bbb7df995bf9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">Other conditions</span></b>", "ID": "ea60ac77-e287-4b31-af4c-f273432d777e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7e8e42f3-2f0d-4e61-8508-bbb7df995bf9"}, {"Element": "<span lang=\"EN-GB\">Other conditions</span>", "ID": "ae651ba8-cbf9-46e1-b6f0-fef2532ac836", "Styles": "None", "Classes": "None", "Text": "Other conditions", "ParentId": "ea60ac77-e287-4b31-af4c-f273432d777e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There are certain conditions, which you may\nhave, or have had, which require special care before or while taking\nInvirase/ritonavir. Therefore, before taking this medicine, you should have\ntold your doctor if you suffer from diarrhoea, or if you have allergies (see\nSection 4)</span> or if you have an intolerance to some sugars (see section \u201cInvirase\ncontains lactose\u201d)<span lang=\"EN-GB\">.</span></p>", "ID": "bf1cb3ed-52f3-4691-8989-609f7f8d4bc7", "Styles": "None", "Classes": "['MsoNormal']", "Text": " or if you have an intolerance to some sugars (see section \u201cInvirase contains lactose\u201d)", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">There are certain conditions, which you may\nhave, or have had, which require special care before or while taking\nInvirase/ritonavir. Therefore, before taking this medicine, you should have\ntold your doctor if you suffer from diarrhoea, or if you have allergies (see\nSection 4)</span>", "ID": "48222d48-f200-4954-984d-53baf594ecb3", "Styles": "None", "Classes": "None", "Text": "There are certain conditions, which you may have, or have had, which require special care before or while taking Invirase/ritonavir. Therefore, before taking this medicine, you should have told your doctor if you suffer from diarrhoea, or if you have allergies (see Section 4)", "ParentId": "bf1cb3ed-52f3-4691-8989-609f7f8d4bc7"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "ad32d7b5-ae93-4d14-adb3-39f0ce79bc15", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "bf1cb3ed-52f3-4691-8989-609f7f8d4bc7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4282c961-bbbf-4641-bddb-867eefdcaf64", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3ef36cb9-1a4c-4f76-adc3-3d60bf4e870c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4282c961-bbbf-4641-bddb-867eefdcaf64"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Kidney\ndisease: Consult your doctor if you have a history of kidney disease.</span></p>", "ID": "e086eb36-1c0a-4f7c-ab1e-4229512340c6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Kidney\ndisease: Consult your doctor if you have a history of kidney disease.</span>", "ID": "86d5f6d2-b930-40ab-a4eb-429210912c57", "Styles": "None", "Classes": "None", "Text": "Kidney disease: Consult your doctor if you have a history of kidney disease.", "ParentId": "e086eb36-1c0a-4f7c-ab1e-4229512340c6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></s></p>", "ID": "9b2d04ab-cb24-4c64-abed-89aa4e9b89df", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<s><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></s>", "ID": "2414832e-f97f-407c-a8e9-766fed8a9e60", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9b2d04ab-cb24-4c64-abed-89aa4e9b89df"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "c70d5213-465f-4017-ad15-7c9d8f0db108", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2414832e-f97f-407c-a8e9-766fed8a9e60"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "ff1b67a4-568d-49c7-aac1-a5b0c0b442ab", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "c70d5213-465f-4017-ad15-7c9d8f0db108"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Liver\ndisease: Please speak with your doctor if you have a history of liver disease.\nPatients with chronic hepatitis B or C and treated with antiretroviral agents\nare at increased risk of severe and potentially fatal liver adverse events and\nmay require blood tests for control of liver function.</span></p>", "ID": "71c3eaf4-2fba-4af5-a497-994884b57a9f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Liver\ndisease: Please speak with your doctor if you have a history of liver disease.\nPatients with chronic hepatitis B or C and treated with antiretroviral agents\nare at increased risk of severe and potentially fatal liver adverse events and\nmay require blood tests for control of liver function.</span>", "ID": "0ed65267-70f3-4965-9096-3419ac665343", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Liver disease: Please speak with your doctor if you have a history of liver disease. Patients with chronic hepatitis B or C and treated with antiretroviral agents are at increased risk of severe and potentially fatal liver adverse events and may require blood tests for control of liver function.", "ParentId": "71c3eaf4-2fba-4af5-a497-994884b57a9f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "efe192eb-f025-41de-810b-02900525c318", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "28583e6a-5d67-477b-b1ed-6a845cb24e55", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "efe192eb-f025-41de-810b-02900525c318"}, {"Element": "<p class=\"MsoNormal\">Infection: In some patients with advanced HIV infection\n(AIDS) and a history of opportunistic infection, signs and symptoms of\ninflammation from previous infections may occur soon after anti-HIV treatment\nis started. It is believed that these symptoms are due to an improvement in the\nbody\u2019s immune response, enabling the body to fight infections that may\nhave been present with no obvious symptoms. If you notice any symptoms of\ninfection, please inform your doctor immediately (see Section 4).</p>", "ID": "d63501fe-9e15-4b59-9515-2d43b35f5413", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Infection: In some patients with advanced HIV infection (AIDS) and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body\u2019s immune response, enabling the body to fight infections that may have been present with no obvious symptoms. If you notice any symptoms of infection, please inform your doctor immediately (see Section 4).", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "5bbed102-7e01-41a4-9bcb-44e5a3b7c059", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In addition to the opportunistic\ninfections, autoimmune disorders (a condition that occurs when the immune\nsystem attacks healthy body tissue) may also occur after you start taking\nmedicines for the treatment of your HIV infection. Autoimmune disorders may\noccur many months after the start of treatment. If you notice any symptoms of\ninfection or other symptoms such as muscle weakness, weakness beginning in the\nhands and feet and moving up towards the trunk of the body, palpitations,\ntremor or hyperactivity, please inform your doctor immediately to seek\nnecessary treatment.</span></p>", "ID": "c6711001-5fca-4bb1-9e68-86de27024432", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">In addition to the opportunistic\ninfections, autoimmune disorders (a condition that occurs when the immune\nsystem attacks healthy body tissue) may also occur after you start taking\nmedicines for the treatment of your HIV infection. Autoimmune disorders may\noccur many months after the start of treatment. If you notice any symptoms of\ninfection or other symptoms such as muscle weakness, weakness beginning in the\nhands and feet and moving up towards the trunk of the body, palpitations,\ntremor or hyperactivity, please inform your doctor immediately to seek\nnecessary treatment.</span>", "ID": "13922cef-eb5e-42dd-a8d1-e51189e8c449", "Styles": "None", "Classes": "None", "Text": "In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.", "ParentId": "c6711001-5fca-4bb1-9e68-86de27024432"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "056400b9-be12-40c9-bd25-8dc0702b0c2d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fd7b841a-4a5a-4819-bb64-163690edf55b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "056400b9-be12-40c9-bd25-8dc0702b0c2d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bone problems: </span><span lang=\"EN-GB\">Some\npatients taking combination antiretroviral therapy may develop a bone disease\ncalled osteonecrosis (death of bone tissue caused by loss of blood supply to\nthe bone). The length of combination antiretroviral therapy, corticosteroid\nuse, alcohol consumption, severe immunosuppression, higher body mass index,\namong others, may be some of the many risk factors for developing this disease.\nSigns of osteonecrosis are joint stiffness, aches and pains (especially of the\nhip, knee and shoulder) and difficulty in movement. If you notice any of these\nsymptoms please inform your doctor. </span></p>", "ID": "e6fda2be-0ca6-4874-b37e-e0bf031bc86e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Bone problems: </span>", "ID": "c16bd5e2-a7e3-4ba8-8051-4517afafdf6f", "Styles": "None", "Classes": "None", "Text": "Bone problems: ", "ParentId": "e6fda2be-0ca6-4874-b37e-e0bf031bc86e"}, {"Element": "<span lang=\"EN-GB\">Some\npatients taking combination antiretroviral therapy may develop a bone disease\ncalled osteonecrosis (death of bone tissue caused by loss of blood supply to\nthe bone). The length of combination antiretroviral therapy, corticosteroid\nuse, alcohol consumption, severe immunosuppression, higher body mass index,\namong others, may be some of the many risk factors for developing this disease.\nSigns of osteonecrosis are joint stiffness, aches and pains (especially of the\nhip, knee and shoulder) and difficulty in movement. If you notice any of these\nsymptoms please inform your doctor. </span>", "ID": "4f7cc7ad-78e7-4880-bc3d-8bd2b3bb5081", "Styles": "None", "Classes": "None", "Text": "Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index, among others, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement. If you notice any of these symptoms please inform your doctor. ", "ParentId": "e6fda2be-0ca6-4874-b37e-e0bf031bc86e"}, {"Element": "<p class=\"MsoNormal\"><b><i><span lang=\"EN-GB\">\u00a0</span></i></b></p>", "ID": "4bcb833c-adee-4586-ab4a-fae40c274d9c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><i><span lang=\"EN-GB\">\u00a0</span></i></b>", "ID": "cc321108-c939-4398-b149-78c779ece78e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4bcb833c-adee-4586-ab4a-fae40c274d9c"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "25212f81-f053-45e9-89db-e61be4837de3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cc321108-c939-4398-b149-78c779ece78e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e350cdb5-bfa6-4cb4-b68d-6f1a48b5682a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "25212f81-f053-45e9-89db-e61be4837de3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Other\nmedicines and Invirase</span></b></p>", "ID": "9704f094-cf87-46bf-96f8-2269476e4c66", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">Other\nmedicines and Invirase</span></b>", "ID": "3fdf1db9-baef-4a35-a15c-eb973d5fcfaa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9704f094-cf87-46bf-96f8-2269476e4c66"}, {"Element": "<span lang=\"EN-GB\">Other\nmedicines and Invirase</span>", "ID": "27f93aec-a2e4-42c4-87ed-b0192196e437", "Styles": "None", "Classes": "None", "Text": "Other medicines and Invirase", "ParentId": "3fdf1db9-baef-4a35-a15c-eb973d5fcfaa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor or pharmacist if you are\ntaking, have recently taken or might take any other medicines. </span></p>", "ID": "406683d6-c327-42c2-b6d9-cd53ec26f0bb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor or pharmacist if you are\ntaking, have recently taken or might take any other medicines. </span>", "ID": "578f8508-d540-4efd-af05-3007d4f52362", "Styles": "None", "Classes": "None", "Text": "Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. ", "ParentId": "406683d6-c327-42c2-b6d9-cd53ec26f0bb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b677ee72-54ec-49e8-8c15-8c8918ef9d36", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3e4db79b-5867-4f19-8841-5dc3fdf23805", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b677ee72-54ec-49e8-8c15-8c8918ef9d36"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase/ritonavir <i>may be taken</i> with\na number of other medications that are commonly used in HIV infection.</span></p>", "ID": "f2da6a2f-a297-4028-8f6f-9a4530f94a92", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Invirase/ritonavir <i>may be taken</i> with\na number of other medications that are commonly used in HIV infection.</span>", "ID": "a03c7b0c-46e1-47bf-81ad-a0a62eaa1531", "Styles": "None", "Classes": "None", "Text": "Invirase/ritonavir  with a number of other medications that are commonly used in HIV infection.", "ParentId": "f2da6a2f-a297-4028-8f6f-9a4530f94a92"}, {"Element": "<i>may be taken</i>", "ID": "c2edc856-a49e-4f54-9ae3-387aea088ecb", "Styles": "None", "Classes": "None", "Text": "may be taken", "ParentId": "a03c7b0c-46e1-47bf-81ad-a0a62eaa1531"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7ded05a2-ff08-4071-8d86-1762565b77c7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "76ec3442-79d5-4068-8021-28cd044bca5f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7ded05a2-ff08-4071-8d86-1762565b77c7"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">There are some medications that must not\nbe taken with Invirase/ritonavir (see section \"Do not take Invirase if you\nare taking any of the following medicines:\" above)</span></u><span lang=\"EN-GB\">. There are also some medicines that <i>require dosage reduction</i>\nof that medicine or Invirase or ritonavir (see section \u201cMedicines that\ncan interact with saquinavir or ritonavir include:\u201d below). Ask your\ndoctor or pharmacist for more information about taking Invirase/ritonavir with\nother medicines.</span></p>", "ID": "c2db0944-d363-475e-999e-285873aaa432", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<u><span lang=\"EN-GB\">There are some medications that must not\nbe taken with Invirase/ritonavir (see section \"Do not take Invirase if you\nare taking any of the following medicines:\" above)</span></u>", "ID": "58ae09e4-1eb2-49f9-a6fe-6576b2aa12d1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c2db0944-d363-475e-999e-285873aaa432"}, {"Element": "<span lang=\"EN-GB\">There are some medications that must not\nbe taken with Invirase/ritonavir (see section \"Do not take Invirase if you\nare taking any of the following medicines:\" above)</span>", "ID": "0478411f-ab82-4b28-84b5-8c1df743135f", "Styles": "None", "Classes": "None", "Text": "There are some medications that must not be taken with Invirase/ritonavir (see section \"Do not take Invirase if you are taking any of the following medicines:\" above)", "ParentId": "58ae09e4-1eb2-49f9-a6fe-6576b2aa12d1"}, {"Element": "<span lang=\"EN-GB\">. There are also some medicines that <i>require dosage reduction</i>\nof that medicine or Invirase or ritonavir (see section \u201cMedicines that\ncan interact with saquinavir or ritonavir include:\u201d below). Ask your\ndoctor or pharmacist for more information about taking Invirase/ritonavir with\nother medicines.</span>", "ID": "d4b81e3a-4c35-4358-88e3-fb6d1a3d4db9", "Styles": "None", "Classes": "None", "Text": ". There are also some medicines that  of that medicine or Invirase or ritonavir (see section \u201cMedicines that can interact with saquinavir or ritonavir include:\u201d below). Ask your doctor or pharmacist for more information about taking Invirase/ritonavir with other medicines.", "ParentId": "c2db0944-d363-475e-999e-285873aaa432"}, {"Element": "<i>require dosage reduction</i>", "ID": "f0cddc37-9dfd-48fd-9206-1afad1a58862", "Styles": "None", "Classes": "None", "Text": "require dosage reduction", "ParentId": "d4b81e3a-4c35-4358-88e3-fb6d1a3d4db9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "86fd408c-e0b7-4eb2-9b63-e707352a0688", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cd2f7b98-f864-41a9-aeb3-c170771a2a9b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "86fd408c-e0b7-4eb2-9b63-e707352a0688"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicines that can interact with saquinavir\nor ritonavir include:</span></p>", "ID": "0ee5c6fa-187c-45f2-aea8-5428019ff42b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Medicines that can interact with saquinavir\nor ritonavir include:</span>", "ID": "aa35f1f8-acb3-420d-9e5f-ea9f0f6cfef3", "Styles": "None", "Classes": "None", "Text": "Medicines that can interact with saquinavir or ritonavir include:", "ParentId": "0ee5c6fa-187c-45f2-aea8-5428019ff42b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 other\nHIV medicines - such as nelfinavir, indinavir, nevirapine, delavirdine,\nefavirenz, maraviroc, cobicistat</span></p>", "ID": "beaf0598-4b1b-4276-ba55-dad5ef536c87", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "fe833e17-0be7-4d2e-8055-a3bf6c842940", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "beaf0598-4b1b-4276-ba55-dad5ef536c87"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 other\nHIV medicines - such as nelfinavir, indinavir, nevirapine, delavirdine,\nefavirenz, maraviroc, cobicistat</span>", "ID": "bd5c7f6d-5a3b-490d-b992-b6a2a890a4d2", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 other HIV medicines - such as nelfinavir, indinavir, nevirapine, delavirdine, efavirenz, maraviroc, cobicistat", "ParentId": "beaf0598-4b1b-4276-ba55-dad5ef536c87"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 some\nmedicines affecting the immune system - such as ciclosporin, sirolimus\n(rapamycin), tacrolimus</span></p>", "ID": "d4130e16-478d-4d78-85c4-d80b67a5620a", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "a3c9ee9b-6834-424e-8166-50d0174dac09", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d4130e16-478d-4d78-85c4-d80b67a5620a"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 some\nmedicines affecting the immune system - such as ciclosporin, sirolimus\n(rapamycin), tacrolimus</span>", "ID": "645344af-6be1-4067-9dc3-4b71d235833e", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 some medicines affecting the immune system - such as ciclosporin, sirolimus (rapamycin), tacrolimus", "ParentId": "d4130e16-478d-4d78-85c4-d80b67a5620a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 various\nsteroids - such as dexamethasone, ethinyl estradiol, fluticasone</span></p>", "ID": "9643c55c-7a23-4e26-aedc-e711a88be769", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "90066d4f-97a3-4374-8f2a-58a169b46d81", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "9643c55c-7a23-4e26-aedc-e711a88be769"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 various\nsteroids - such as dexamethasone, ethinyl estradiol, fluticasone</span>", "ID": "53451121-6f6d-4159-b505-629e57de121b", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 various steroids - such as dexamethasone, ethinyl estradiol, fluticasone", "ParentId": "9643c55c-7a23-4e26-aedc-e711a88be769"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nheart medicines - such as calcium channel blockers, quinidine, digoxin</span></p>", "ID": "a5d17b8e-5fb9-4d17-bdab-90215e17229c", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "d752ce3d-ad3b-45c4-88f7-4d7c8b157989", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a5d17b8e-5fb9-4d17-bdab-90215e17229c"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nheart medicines - such as calcium channel blockers, quinidine, digoxin</span>", "ID": "fe4cabc8-8eb7-4907-a74a-382e2a77cbab", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 certain heart medicines - such as calcium channel blockers, quinidine, digoxin", "ParentId": "a5d17b8e-5fb9-4d17-bdab-90215e17229c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nused to lower blood cholesterol - such as statins</span></p>", "ID": "3faf703f-e8b5-453e-8c3f-3c173c75376f", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "9d028861-524a-4559-8bad-b05ad82a5b73", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3faf703f-e8b5-453e-8c3f-3c173c75376f"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nused to lower blood cholesterol - such as statins</span>", "ID": "4e219e20-c37b-4bd0-a817-9b03f9c6c3db", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 medicines used to lower blood cholesterol - such as statins", "ParentId": "3faf703f-e8b5-453e-8c3f-3c173c75376f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 antifungals\n- ketoconazole, itraconazole, fluconazole, miconazole</span></p>", "ID": "d9e5eee8-c129-4b50-8bb4-b5426fe3fadf", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "7cca84d7-3b0b-4271-8d6c-a10abde9e742", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d9e5eee8-c129-4b50-8bb4-b5426fe3fadf"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 antifungals\n- ketoconazole, itraconazole, fluconazole, miconazole</span>", "ID": "1e4e98f9-0d2d-41d6-9390-757c847f8ed6", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 antifungals - ketoconazole, itraconazole, fluconazole, miconazole", "ParentId": "d9e5eee8-c129-4b50-8bb4-b5426fe3fadf"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 anticonvulsants\n- such as phenobarbital, phenytoin, carbamazepine</span></p>", "ID": "1ca308b0-50dd-40d2-a445-9b0bb312b07b", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "07e7be54-a4ed-47cc-a5bf-1f285bcee3a3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1ca308b0-50dd-40d2-a445-9b0bb312b07b"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 anticonvulsants\n- such as phenobarbital, phenytoin, carbamazepine</span>", "ID": "63a2fb60-dc98-4463-96e0-8c197156f87a", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 anticonvulsants - such as phenobarbital, phenytoin, carbamazepine", "ParentId": "1ca308b0-50dd-40d2-a445-9b0bb312b07b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 sedative\nagents - such as midazolam administered by injection</p>", "ID": "f5c1b96a-abda-44d2-a826-cffa5b9eec79", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 sedative agents - such as midazolam administered by injection", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "a9716e65-da24-41e7-8724-4b252dec1ada", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f5c1b96a-abda-44d2-a826-cffa5b9eec79"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"FR\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 certain\nantibiotics <span lang=\"EN-GB\">- such as </span>quinupristin/dalfopristin,\nrifabutin, fusidic acid</p>", "ID": "d55efc76-4002-488e-a3d1-2554b9a25075", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 certain antibiotics quinupristin/dalfopristin, rifabutin, fusidic acid", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"FR\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "9b1b4a29-4605-470d-a20b-0b4734afe48c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d55efc76-4002-488e-a3d1-2554b9a25075"}, {"Element": "<span lang=\"EN-GB\">- such as </span>", "ID": "b6f4339e-3fa9-4cb2-ad6a-c104cae82e5c", "Styles": "None", "Classes": "None", "Text": "- such as ", "ParentId": "d55efc76-4002-488e-a3d1-2554b9a25075"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nto treat depression - such as nefazodone, tricyclic antidepressants</span></p>", "ID": "bbb13151-d0dc-423b-bd93-9def92605334", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "aa5e9f32-39cb-4218-8795-73a26dbe16c2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "bbb13151-d0dc-423b-bd93-9def92605334"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nto treat depression - such as nefazodone, tricyclic antidepressants</span>", "ID": "cc9f22d6-ba19-4532-b76d-3b63e5b00e19", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 medicines to treat depression - such as nefazodone, tricyclic antidepressants", "ParentId": "bbb13151-d0dc-423b-bd93-9def92605334"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nfor anticoagulation - warfarin</span></p>", "ID": "0eed2f9a-abe6-4969-87a4-615deb70faab", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "d7eec256-0ffc-4575-aec9-7be0752943d8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0eed2f9a-abe6-4969-87a4-615deb70faab"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nfor anticoagulation - warfarin</span>", "ID": "fe411e6b-9c86-4ef0-a628-78e2db267fec", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 medicines for anticoagulation - warfarin", "ParentId": "0eed2f9a-abe6-4969-87a4-615deb70faab"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 herbal\npreparations containing St. John\u2019s wort or garlic capsules</span></p>", "ID": "0ab4e654-211b-42ab-900e-fc44da9c3147", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "c3b8e85d-baeb-4796-bf1b-a8c605e97651", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0ab4e654-211b-42ab-900e-fc44da9c3147"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 herbal\npreparations containing St. John\u2019s wort or garlic capsules</span>", "ID": "3b8985b0-343c-4813-8aab-e4c9af0afc8e", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 herbal preparations containing St. John\u2019s wort or garlic capsules", "ParentId": "0ab4e654-211b-42ab-900e-fc44da9c3147"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 some\nmedicines that treat diseases related to the acid in the stomach <span lang=\"EN-GB\">- such as </span>omeprazole or other proton pump inhibitors</p>", "ID": "f2a232b0-6d56-4c78-b435-b7c24ca468cd", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 some medicines that treat diseases related to the acid in the stomach omeprazole or other proton pump inhibitors", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "59e2dc2d-ed56-42b9-af69-d4b36ef87cc1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f2a232b0-6d56-4c78-b435-b7c24ca468cd"}, {"Element": "<span lang=\"EN-GB\">- such as </span>", "ID": "62eb8e1f-5510-4911-885e-3ce5888c4ea2", "Styles": "None", "Classes": "None", "Text": "- such as ", "ParentId": "f2a232b0-6d56-4c78-b435-b7c24ca468cd"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nused to treat asthma or other chest illness such as Chronic Obstructive\nPulmonary Disease (COPD) such as salmeterol</p>", "ID": "56bea1a3-7282-4c30-9c5a-4b9b58c82b02", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 medicines used to treat asthma or other chest illness such as Chronic Obstructive Pulmonary Disease (COPD) such as salmeterol", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "9a760869-ef64-433e-809b-0a6a3e4a2f1e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "56bea1a3-7282-4c30-9c5a-4b9b58c82b02"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nfor gout, such as colchicine</p>", "ID": "259e10ef-1e0d-48dd-8e19-8303a47d9019", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 medicines for gout, such as colchicine", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "0d93255c-c53a-4f6c-8654-3bd76f673299", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "259e10ef-1e0d-48dd-8e19-8303a47d9019"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 medicines\nused to treat high blood pressure in the arteries of the lungs (a disease known\nas pulmonary arterial hypertension) such as bosentan.</p>", "ID": "8b80d0f8-b96b-4b7b-9951-657ad1b1262b", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 medicines used to treat high blood pressure in the arteries of the lungs (a disease known as pulmonary arterial hypertension) such as bosentan.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "36873685-0897-42b4-9008-bb753b4381b1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "8b80d0f8-b96b-4b7b-9951-657ad1b1262b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4277117f-bacf-4371-975a-aa6a17cf8dbf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9d091614-342f-4584-8f01-7dc0bbb3d53d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4277117f-bacf-4371-975a-aa6a17cf8dbf"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Therefore\nyou should not take Invirase/ritonavir with other medicines without your\ndoctor\u2019s consent. </span></p>", "ID": "dfeda68c-cd2f-4c48-af0c-cbbd973705e6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Therefore\nyou should not take Invirase/ritonavir with other medicines without your\ndoctor\u2019s consent. </span>", "ID": "78092bf3-0820-495d-9930-aa222cb87b6d", "Styles": "None", "Classes": "None", "Text": "Therefore you should not take Invirase/ritonavir with other medicines without your doctor\u2019s consent. ", "ParentId": "dfeda68c-cd2f-4c48-af0c-cbbd973705e6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f9fef42a-4476-48c5-a388-de929de8c40c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c848b22a-a527-41a9-b22c-d75c2ee46470", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f9fef42a-4476-48c5-a388-de929de8c40c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you are taking an oral contraceptive to\nprevent pregnancy, you should use an additional or different type of\ncontraception since ritonavir may reduce the effectiveness of oral\ncontraceptives.</span></p>", "ID": "acd67dec-0c82-4be9-8a4b-0ccb29b95697", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">If you are taking an oral contraceptive to\nprevent pregnancy, you should use an additional or different type of\ncontraception since ritonavir may reduce the effectiveness of oral\ncontraceptives.</span>", "ID": "3fbda0da-4fc6-45f5-8aab-445e30058431", "Styles": "None", "Classes": "None", "Text": "If you are taking an oral contraceptive to prevent pregnancy, you should use an additional or different type of contraception since ritonavir may reduce the effectiveness of oral contraceptives.", "ParentId": "acd67dec-0c82-4be9-8a4b-0ccb29b95697"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "92a3d9e8-7cdb-4f4f-a605-b6e0138b07c8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b6f4dce8-71f1-4d10-9433-223aaa1736e9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "92a3d9e8-7cdb-4f4f-a605-b6e0138b07c8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Invirase\nwith food and drink</span></b></p>", "ID": "dc421704-b400-4ec0-addf-279753eac2fc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">Invirase\nwith food and drink</span></b>", "ID": "e4fdf1f5-9d59-4dfc-8028-7e77f253e0a0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dc421704-b400-4ec0-addf-279753eac2fc"}, {"Element": "<span lang=\"EN-GB\">Invirase\nwith food and drink</span>", "ID": "b20caf54-0eb5-411c-8d75-883e5718766c", "Styles": "None", "Classes": "None", "Text": "Invirase with food and drink", "ParentId": "e4fdf1f5-9d59-4dfc-8028-7e77f253e0a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase must be taken together with\nritonavir and with or after food. </span></p>", "ID": "12704ebe-fa7a-44e2-bbe5-58806d5f9f87", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Invirase must be taken together with\nritonavir and with or after food. </span>", "ID": "eeaf53ba-0c02-4181-9237-de0a862d01da", "Styles": "None", "Classes": "None", "Text": "Invirase must be taken together with ritonavir and with or after food. ", "ParentId": "12704ebe-fa7a-44e2-bbe5-58806d5f9f87"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c17adde1-fcab-46ff-bd12-77007902b09d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "01207123-daf7-455b-b11e-6882ed764bc5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c17adde1-fcab-46ff-bd12-77007902b09d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Pregnancy\nand breast-feeding</span></b></p>", "ID": "048a8bd3-d5d3-4ba3-8888-6aae929e6f99", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">Pregnancy\nand breast-feeding</span></b>", "ID": "92745710-41d3-4479-99a1-53c0d4f79413", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "048a8bd3-d5d3-4ba3-8888-6aae929e6f99"}, {"Element": "<span lang=\"EN-GB\">Pregnancy\nand breast-feeding</span>", "ID": "826deb3b-f86b-4504-ae85-65e5c05cfc02", "Styles": "None", "Classes": "None", "Text": "Pregnancy and breast-feeding", "ParentId": "92745710-41d3-4479-99a1-53c0d4f79413"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ask your doctor or pharmacist for advice\nbefore taking any medicine. Inform your doctor if you are pregnant or planning\nto become pregnant. This medicine should be taken during pregnancy only after\nconsultation with your doctor.</span></p>", "ID": "74d52337-a800-4bc6-a4e6-1b08df752a4e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Ask your doctor or pharmacist for advice\nbefore taking any medicine. Inform your doctor if you are pregnant or planning\nto become pregnant. This medicine should be taken during pregnancy only after\nconsultation with your doctor.</span>", "ID": "f8f610dd-115a-4c86-9826-c6ea79757b0b", "Styles": "None", "Classes": "None", "Text": "Ask your doctor or pharmacist for advice before taking any medicine. Inform your doctor if you are pregnant or planning to become pregnant. This medicine should be taken during pregnancy only after consultation with your doctor.", "ParentId": "74d52337-a800-4bc6-a4e6-1b08df752a4e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "06bb530c-e043-4cdf-8258-6f2fc7976aef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2aa54577-0fcd-424c-8c02-6ffa24abe0e9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "06bb530c-e043-4cdf-8258-6f2fc7976aef"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">You should not breast-feed your baby if you\nare taking Invirase/ritonavir.</span></p>", "ID": "fd2c2481-c9bb-4559-8a37-3c608260572d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">You should not breast-feed your baby if you\nare taking Invirase/ritonavir.</span>", "ID": "1b4d7920-966d-4272-adaa-26a110e2e658", "Styles": "None", "Classes": "None", "Text": "You should not breast-feed your baby if you are taking Invirase/ritonavir.", "ParentId": "fd2c2481-c9bb-4559-8a37-3c608260572d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "760f0ca8-631b-4379-9148-ab23affa6530", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9217ceeb-0303-481f-a6de-d910b6763890", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "760f0ca8-631b-4379-9148-ab23affa6530"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Driving\nand using machines</span></b></p>", "ID": "facef910-7b49-4df1-ad6c-82b4896cbc36", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">Driving\nand using machines</span></b>", "ID": "738eafb1-fd7c-4d93-8206-0e8c2de87349", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "facef910-7b49-4df1-ad6c-82b4896cbc36"}, {"Element": "<span lang=\"EN-GB\">Driving\nand using machines</span>", "ID": "9a39ca66-b5f0-4e44-af0d-0e7354699a9f", "Styles": "None", "Classes": "None", "Text": "Driving and using machines", "ParentId": "738eafb1-fd7c-4d93-8206-0e8c2de87349"}, {"Element": "<p class=\"MsoNormal\">Invirase has not been tested for its effect on your ability\nto drive a car or operate machinery. However, dizziness, fatigue and visual\nimpairment have been reported during treatment with Invirase. Do not drive or\noperate machines if you experience these symptoms.</p>", "ID": "c945032d-992a-4869-ad3a-a0ece8b0e76a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Invirase has not been tested for its effect on your ability to drive a car or operate machinery. However, dizziness, fatigue and visual impairment have been reported during treatment with Invirase. Do not drive or operate machines if you experience these symptoms.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3590a5f7-a86a-49a9-844e-2f05b7a78ec6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5ecec9b1-85bc-4560-a1bd-284c2036d341", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3590a5f7-a86a-49a9-844e-2f05b7a78ec6"}, {"Element": "<p class=\"MsoNormal\"><b>Invirase contains lactose</b></p>", "ID": "80127a9d-0f92-43ec-bef6-f13d9e5c77f7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>Invirase contains lactose</b>", "ID": "71551a3d-726a-42f3-b80a-9fa20c2cd00b", "Styles": "None", "Classes": "None", "Text": "Invirase contains lactose", "ParentId": "80127a9d-0f92-43ec-bef6-f13d9e5c77f7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each </span>film-coated tablet<span lang=\"EN-GB\"> contains lactose (</span>monohydrate<span lang=\"EN-GB\">) </span>38.5<span lang=\"EN-GB\">\u00a0mg. If you have been told by your doctor that you have an\nintolerance to some sugars, contact your doctor before taking this medicine.</span></p>", "ID": "608979b0-4a80-48f4-8286-36988510036e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "film-coated tabletmonohydrate38.5", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Each </span>", "ID": "29c79fed-64e6-4d1d-950a-046eb6acbd37", "Styles": "None", "Classes": "None", "Text": "Each ", "ParentId": "608979b0-4a80-48f4-8286-36988510036e"}, {"Element": "<span lang=\"EN-GB\"> contains lactose (</span>", "ID": "2b4aff7a-5f27-4244-ba38-89ab7c298bbb", "Styles": "None", "Classes": "None", "Text": " contains lactose (", "ParentId": "608979b0-4a80-48f4-8286-36988510036e"}, {"Element": "<span lang=\"EN-GB\">) </span>", "ID": "be35d244-046f-422b-b9ea-8be64294ef6c", "Styles": "None", "Classes": "None", "Text": ") ", "ParentId": "608979b0-4a80-48f4-8286-36988510036e"}, {"Element": "<span lang=\"EN-GB\">\u00a0mg. If you have been told by your doctor that you have an\nintolerance to some sugars, contact your doctor before taking this medicine.</span>", "ID": "7dec8e7c-998e-403d-b232-70a0f6e26b6f", "Styles": "None", "Classes": "None", "Text": "\u00a0mg. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.", "ParentId": "608979b0-4a80-48f4-8286-36988510036e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "68d3d8d1-7174-4c27-bc30-f1e6bae52496", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9e644e01-2555-46b6-a55b-392765722a6d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "68d3d8d1-7174-4c27-bc30-f1e6bae52496"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dd8dbb8b-5e85-4384-b20e-d05c3e05da07", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cfe2c9b7-7ef2-4b1e-be4d-60ce76df2f7a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dd8dbb8b-5e85-4384-b20e-d05c3e05da07"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to take\nInvirase</span></b></p>", "ID": "1ea4123a-278b-4237-91c3-d4a4a875258f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to take\nInvirase</span></b>", "ID": "e587588f-33fb-4dfa-a679-c25cc1fac09c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1ea4123a-278b-4237-91c3-d4a4a875258f"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to take\nInvirase</span>", "ID": "36a62ccf-9f11-4915-8d46-2f3327c6accd", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to take Invirase", "ParentId": "e587588f-33fb-4dfa-a679-c25cc1fac09c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "93cbea19-05c2-4cff-8127-254a0f5410cb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9a8595a0-47b3-41b5-8db2-72e0e836b454", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "93cbea19-05c2-4cff-8127-254a0f5410cb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Always take this medicine exactly as your\ndoctor has told you. Check with your doctor or pharmacist if you are not sure.\nInvirase comes as a 500\u00a0mg </span>film-coated tablet.<span lang=\"EN-GB\">\nYour doctor will prescribe Invirase in combination with ritonavir (Norvir) and\nother HIV medicines.</span></p>", "ID": "b1aed57c-6ad6-4a79-801a-c95f38afe172", "Styles": "None", "Classes": "['MsoNormal']", "Text": "film-coated tablet.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Always take this medicine exactly as your\ndoctor has told you. Check with your doctor or pharmacist if you are not sure.\nInvirase comes as a 500\u00a0mg </span>", "ID": "f0d308c2-f0ba-4b9b-8d04-6532dc80f170", "Styles": "None", "Classes": "None", "Text": "Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Invirase comes as a 500\u00a0mg ", "ParentId": "b1aed57c-6ad6-4a79-801a-c95f38afe172"}, {"Element": "<span lang=\"EN-GB\">\nYour doctor will prescribe Invirase in combination with ritonavir (Norvir) and\nother HIV medicines.</span>", "ID": "e85020df-089b-43ac-bcee-e93fdd4e636a", "Styles": "None", "Classes": "None", "Text": " Your doctor will prescribe Invirase in combination with ritonavir (Norvir) and other HIV medicines.", "ParentId": "b1aed57c-6ad6-4a79-801a-c95f38afe172"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "958adcc0-6eac-48c8-bf03-0ff40afc5c10", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7dc9c437-7f7f-4d73-b33f-ecc763740df9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "958adcc0-6eac-48c8-bf03-0ff40afc5c10"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">How to take</span></b></p>", "ID": "0674faad-704e-4d6e-8601-aa011c0b02f1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">How to take</span></b>", "ID": "83f6dcff-9c4d-419d-adb1-c3e9bf5db94c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0674faad-704e-4d6e-8601-aa011c0b02f1"}, {"Element": "<span lang=\"EN-GB\">How to take</span>", "ID": "c06dc666-e590-4ba1-9ead-c975dbec7514", "Styles": "None", "Classes": "None", "Text": "How to take", "ParentId": "83f6dcff-9c4d-419d-adb1-c3e9bf5db94c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Take\nInvirase at the same time as your ritonavir (Norvir) capsules.</span></p>", "ID": "f7bb9e6f-1f96-428f-af51-4efc057619c0", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "e9b83e3d-a8ff-4807-afa6-ea32a9229a42", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f7bb9e6f-1f96-428f-af51-4efc057619c0"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Take\nInvirase at the same time as your ritonavir (Norvir) capsules.</span>", "ID": "ff475a5b-981a-4cf9-9494-000dbc0dcc5c", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 Take Invirase at the same time as your ritonavir (Norvir) capsules.", "ParentId": "f7bb9e6f-1f96-428f-af51-4efc057619c0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Take\nyour Invirase film-coated tablets with or after food.</span></p>", "ID": "4d70d815-533e-433e-a3d6-5fdcaf087351", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "f60e2b84-375d-43fd-a87d-75287e44b93a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4d70d815-533e-433e-a3d6-5fdcaf087351"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Take\nyour Invirase film-coated tablets with or after food.</span>", "ID": "7b73434c-fcf3-4069-8a9c-b3f2eee4dbb9", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 Take your Invirase film-coated tablets with or after food.", "ParentId": "4d70d815-533e-433e-a3d6-5fdcaf087351"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Swallow\nthem whole with water.</span></p>", "ID": "b17f6894-9dd5-4841-9d7a-36cc787d997a", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "c1545b7a-8d0f-4c77-b22e-5d78e98d52b1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b17f6894-9dd5-4841-9d7a-36cc787d997a"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Swallow\nthem whole with water.</span>", "ID": "bccad71f-33a9-448f-b975-bb5fcd1686e9", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 Swallow them whole with water.", "ParentId": "b17f6894-9dd5-4841-9d7a-36cc787d997a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6b805aef-bcbc-48c2-9432-6d310eecea7a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bab35a32-2fdb-4e39-9a95-02996a4bb32d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6b805aef-bcbc-48c2-9432-6d310eecea7a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">How much to take</span></b></p>", "ID": "92ee8c4c-43b1-4759-862d-9e41a7d5ca67", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">How much to take</span></b>", "ID": "f6aa0cfc-de2f-46db-ba1f-ba051ebe098d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "92ee8c4c-43b1-4759-862d-9e41a7d5ca67"}, {"Element": "<span lang=\"EN-GB\">How much to take</span>", "ID": "deaa949e-3b3b-44c4-b83c-eef3353db202", "Styles": "None", "Classes": "None", "Text": "How much to take", "ParentId": "f6aa0cfc-de2f-46db-ba1f-ba051ebe098d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "292e1fdf-2a24-43ef-a343-063e823a94c3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2977bdb5-e0cb-489b-ac4e-81ff95d505eb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "292e1fdf-2a24-43ef-a343-063e823a94c3"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Standard dose</span></b></p>", "ID": "a45c7e80-42ba-47bd-9b00-b5b8d906752e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">Standard dose</span></b>", "ID": "76b7fc43-7e09-42ea-a576-be5d87f13473", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a45c7e80-42ba-47bd-9b00-b5b8d906752e"}, {"Element": "<span lang=\"EN-GB\">Standard dose</span>", "ID": "347e8ce7-f56c-4d24-b742-beea3baa0db2", "Styles": "None", "Classes": "None", "Text": "Standard dose", "ParentId": "76b7fc43-7e09-42ea-a576-be5d87f13473"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0 Take\ntwo 500\u00a0mg </span>film-coated tablets<span lang=\"EN-GB\"> of Invirase twice a\nday.</span></p>", "ID": "d033ac72-b346-4155-ae2c-b0e57805f892", "Styles": "margin-left:.75in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "film-coated tablets", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "14dcf7f1-bba6-4fa8-96d7-4545bdc05ee7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d033ac72-b346-4155-ae2c-b0e57805f892"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0 Take\ntwo 500\u00a0mg </span>", "ID": "c857a383-e58f-4759-9a8b-d25006c8a319", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0 Take two 500\u00a0mg ", "ParentId": "d033ac72-b346-4155-ae2c-b0e57805f892"}, {"Element": "<span lang=\"EN-GB\"> of Invirase twice a\nday.</span>", "ID": "ef7659eb-66e1-4b27-a824-14ba14ce9f32", "Styles": "None", "Classes": "None", "Text": " of Invirase twice a day.", "ParentId": "d033ac72-b346-4155-ae2c-b0e57805f892"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0 Take\none 100\u00a0mg capsule of ritonavir (Norvir) twice a day. </span></p>", "ID": "fc314eba-e51c-42c6-b6e7-d3d1c8bdb5c7", "Styles": "margin-left:.75in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "631430af-5564-4ff8-99c0-206fea2f8287", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "fc314eba-e51c-42c6-b6e7-d3d1c8bdb5c7"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0 Take\none 100\u00a0mg capsule of ritonavir (Norvir) twice a day. </span>", "ID": "7e040f9a-2f5a-4e54-b1af-0d210d6be5a8", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0 Take one 100\u00a0mg capsule of ritonavir (Norvir) twice a day. ", "ParentId": "fc314eba-e51c-42c6-b6e7-d3d1c8bdb5c7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.75in;text-indent:-.25in\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cac38dbe-b03a-4537-8347-49f71f4fe8ba", "Styles": "margin-left:.75in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5c1a3824-2c07-4fe3-8f8e-cc1333d2b94a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cac38dbe-b03a-4537-8347-49f71f4fe8ba"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">If this\nis your first medicine for HIV or the first time you are taking ritonavir\n(Norvir)</span></b></p>", "ID": "c15dfd69-649f-4404-96d4-b2ad16edfc45", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">If this\nis your first medicine for HIV or the first time you are taking ritonavir\n(Norvir)</span></b>", "ID": "4f9c9ee2-c30a-4497-a721-cd6e7e7a92ca", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c15dfd69-649f-4404-96d4-b2ad16edfc45"}, {"Element": "<span lang=\"EN-GB\">If this\nis your first medicine for HIV or the first time you are taking ritonavir\n(Norvir)</span>", "ID": "596499db-d0f7-46fc-8bca-fccb9d24cc12", "Styles": "None", "Classes": "None", "Text": "If this is your first medicine for HIV or the first time you are taking ritonavir (Norvir)", "ParentId": "4f9c9ee2-c30a-4497-a721-cd6e7e7a92ca"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">You need to\ntake a lower dose of Invirase for your first week. </span></p>", "ID": "5f597709-1b5d-42ad-86c5-988ac499588b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">You need to\ntake a lower dose of Invirase for your first week. </span>", "ID": "bf71a7ac-1093-415d-92a8-9e21b06e3d05", "Styles": "None", "Classes": "None", "Text": "You need to take a lower dose of Invirase for your first week. ", "ParentId": "5f597709-1b5d-42ad-86c5-988ac499588b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in;page-break-after:\navoid\"><span lang=\"EN-GB\">Week 1:</span></p>", "ID": "f3b134d8-17dd-457a-9d4f-922849100ae3", "Styles": "margin-left:.3in;text-indent:-.3in;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Week 1:</span>", "ID": "faaf8bb8-c344-42c6-8e55-a3c828f88743", "Styles": "None", "Classes": "None", "Text": "Week 1:", "ParentId": "f3b134d8-17dd-457a-9d4f-922849100ae3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Take one 500\u00a0mg film-coated\ntablet of Invirase twice a day.</span></p>", "ID": "971ba7a7-2d8a-4cb9-a538-c20f59f4bcc0", "Styles": "margin-left:.3in;text-indent:-.3in;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "4a7596eb-ab26-4e3d-84c4-1f46e6e11b70", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "971ba7a7-2d8a-4cb9-a538-c20f59f4bcc0"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Take one 500\u00a0mg film-coated\ntablet of Invirase twice a day.</span>", "ID": "a20ac065-bd30-46f7-914d-57e5c05fbf0f", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 Take one 500\u00a0mg film-coated tablet of Invirase twice a day.", "ParentId": "971ba7a7-2d8a-4cb9-a538-c20f59f4bcc0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Take\none 100\u00a0mg capsule of ritonavir (Norvir) twice a day. </span></p>", "ID": "f33943eb-cebb-437d-b4a5-da01a554ada4", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "ff282a46-9c8b-4ae4-b35a-b7560883b160", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f33943eb-cebb-437d-b4a5-da01a554ada4"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Take\none 100\u00a0mg capsule of ritonavir (Norvir) twice a day. </span>", "ID": "e12cf705-5d10-48d3-84ac-7716f806e0bf", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 Take one 100\u00a0mg capsule of ritonavir (Norvir) twice a day. ", "ParentId": "f33943eb-cebb-437d-b4a5-da01a554ada4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "412a4798-1f04-4d36-9a29-cb5eea0d7170", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b2aaaa2b-ee55-4fa3-a77f-0b41b0be64bc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "412a4798-1f04-4d36-9a29-cb5eea0d7170"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week 2 onwards:</span></p>", "ID": "e1ae97a4-b95d-489e-a4e1-11fcef66c923", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Week 2 onwards:</span>", "ID": "7dc54987-41c2-44e6-a87c-412bd3bcf40c", "Styles": "None", "Classes": "None", "Text": "Week 2 onwards:", "ParentId": "e1ae97a4-b95d-489e-a4e1-11fcef66c923"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Continue\nwith the standard dose.</span></p>", "ID": "fc950c0c-f394-4ac2-ada6-e4d7c67f9347", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "1ec209c0-bebd-4e26-9f84-11272a3778e8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "fc950c0c-f394-4ac2-ada6-e4d7c67f9347"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 Continue\nwith the standard dose.</span>", "ID": "16639ce3-8069-425e-b475-c5f6e48882eb", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 Continue with the standard dose.", "ParentId": "fc950c0c-f394-4ac2-ada6-e4d7c67f9347"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3b93a994-1a87-4189-8cc6-16e878426b0c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e15d4b36-a5dc-4c7d-b3df-918dd82ace45", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3b93a994-1a87-4189-8cc6-16e878426b0c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">If you\ntake more Invirase than you should<i> </i></span></b></p>", "ID": "235ac526-7128-4953-86f4-52473ae53e36", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">If you\ntake more Invirase than you should<i> </i></span></b>", "ID": "cf3eaa79-67b1-4588-a532-a2667975cf7b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "235ac526-7128-4953-86f4-52473ae53e36"}, {"Element": "<span lang=\"EN-GB\">If you\ntake more Invirase than you should<i> </i></span>", "ID": "1e3c2d9c-544d-407d-9810-0e6814ccdd3f", "Styles": "None", "Classes": "None", "Text": "If you take more Invirase than you should", "ParentId": "cf3eaa79-67b1-4588-a532-a2667975cf7b"}, {"Element": "<i> </i>", "ID": "39dca294-93e3-4424-bd08-b76b1598f3a9", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "1e3c2d9c-544d-407d-9810-0e6814ccdd3f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you have taken more than the prescribed\ndose of Invirase/ritonavir you must contact your doctor or pharmacist.</span></p>", "ID": "4b33e025-af98-4ce7-b7fe-b00a8b178b73", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">If you have taken more than the prescribed\ndose of Invirase/ritonavir you must contact your doctor or pharmacist.</span>", "ID": "9861e667-e0cc-459d-885f-441fcc8790c5", "Styles": "None", "Classes": "None", "Text": "If you have taken more than the prescribed dose of Invirase/ritonavir you must contact your doctor or pharmacist.", "ParentId": "4b33e025-af98-4ce7-b7fe-b00a8b178b73"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "62c5d9dc-0765-4277-9d87-f817be0df101", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "c2ddd5cc-67fa-421e-aa55-d3637e0e4258", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "62c5d9dc-0765-4277-9d87-f817be0df101"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "57ac8e59-d77b-4df8-8e37-7b9e91c79d02", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c2ddd5cc-67fa-421e-aa55-d3637e0e4258"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "c72f4f26-5322-4ad6-b0ec-5ce3a34b2f6d", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "57ac8e59-d77b-4df8-8e37-7b9e91c79d02"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">If you\nforget to take Invirase</span></b></p>", "ID": "a0d2b2a8-e675-4ed0-9208-cdfa4cce8037", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">If you\nforget to take Invirase</span></b>", "ID": "bd1cddca-ee6b-48df-b485-a43d035383fc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a0d2b2a8-e675-4ed0-9208-cdfa4cce8037"}, {"Element": "<span lang=\"EN-GB\">If you\nforget to take Invirase</span>", "ID": "34182946-375a-4365-9d4b-f881407e1e62", "Styles": "None", "Classes": "None", "Text": "If you forget to take Invirase", "ParentId": "bd1cddca-ee6b-48df-b485-a43d035383fc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not take a double dose to make up for a\nforgotten individual dose. If you forget to take one dose, take this dose as\nsoon as you remember together with some food. Then go on with the regular\nschedule as prescribed. Do not change the prescribed dose yourself.</span></p>", "ID": "c4c43dbe-4a1e-4c0f-b5d5-48d7024e4896", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Do not take a double dose to make up for a\nforgotten individual dose. If you forget to take one dose, take this dose as\nsoon as you remember together with some food. Then go on with the regular\nschedule as prescribed. Do not change the prescribed dose yourself.</span>", "ID": "851c8258-8340-455d-ba5c-706826d9e78b", "Styles": "None", "Classes": "None", "Text": "Do not take a double dose to make up for a forgotten individual dose. If you forget to take one dose, take this dose as soon as you remember together with some food. Then go on with the regular schedule as prescribed. Do not change the prescribed dose yourself.", "ParentId": "c4c43dbe-4a1e-4c0f-b5d5-48d7024e4896"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f91bb864-fe98-4388-b011-c26124276694", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "14c05f72-2a91-44e7-84ad-b257d0f9e5f6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f91bb864-fe98-4388-b011-c26124276694"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">If you\nstop taking Invirase<i> </i></span></b></p>", "ID": "2b214e95-f80a-481e-90ed-f94734cbe73d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">If you\nstop taking Invirase<i> </i></span></b>", "ID": "09c3bb97-db94-48d6-a6ca-7de3709ed57d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2b214e95-f80a-481e-90ed-f94734cbe73d"}, {"Element": "<span lang=\"EN-GB\">If you\nstop taking Invirase<i> </i></span>", "ID": "57ed2d6d-7159-490b-aa26-45226f32f8f6", "Styles": "None", "Classes": "None", "Text": "If you stop taking Invirase", "ParentId": "09c3bb97-db94-48d6-a6ca-7de3709ed57d"}, {"Element": "<i> </i>", "ID": "f0613ebc-2d5f-4ab9-9040-ddb44c37120c", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "57ed2d6d-7159-490b-aa26-45226f32f8f6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Continue to take this medicine until your\ndoctor tells you otherwise.</span></p>", "ID": "41594d07-b729-4064-b9c4-521df066faf9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Continue to take this medicine until your\ndoctor tells you otherwise.</span>", "ID": "2d3c4494-9715-4d85-9fcc-426ebfe31517", "Styles": "None", "Classes": "None", "Text": "Continue to take this medicine until your doctor tells you otherwise.", "ParentId": "41594d07-b729-4064-b9c4-521df066faf9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you have any further questions on the\nuse of this medicine, ask your doctor or pharmascist.</span></p>", "ID": "c975db67-b3e0-4274-9d78-63ae66bd83fe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">If you have any further questions on the\nuse of this medicine, ask your doctor or pharmascist.</span>", "ID": "5f7e21a8-3bee-4728-a4f7-32f960df67fa", "Styles": "None", "Classes": "None", "Text": "If you have any further questions on the use of this medicine, ask your doctor or pharmascist.", "ParentId": "c975db67-b3e0-4274-9d78-63ae66bd83fe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8b998736-d54d-4ce8-a1cd-a217123744bf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "419a7d22-0dd5-43d1-9fcf-5f15d1f802d7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8b998736-d54d-4ce8-a1cd-a217123744bf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7f1340d4-2c6e-4cb8-a3f1-6eb18aad9c9b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "426a6b4a-c564-4f69-a5fb-24aa69fc5127", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7f1340d4-2c6e-4cb8-a3f1-6eb18aad9c9b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side\neffects</span></b></p>", "ID": "e9138055-e569-4d97-8f52-ef4c97ed713d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side\neffects</span></b>", "ID": "8dd13dea-5ba3-423f-bf8e-6e6a77216a54", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e9138055-e569-4d97-8f52-ef4c97ed713d"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side\neffects</span>", "ID": "95ecfe58-042b-46a5-9ad3-057437a8c3f8", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects", "ParentId": "8dd13dea-5ba3-423f-bf8e-6e6a77216a54"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "021ba728-fc0a-4f41-b5a2-7086242d32dc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "d93b4071-ddc6-4f20-ba03-8b0177c870c2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "021ba728-fc0a-4f41-b5a2-7086242d32dc"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e9e2fca2-66b5-4363-90a8-b0e4092b3bb2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d93b4071-ddc6-4f20-ba03-8b0177c870c2"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Like all\nmedicines, this medicine can cause side effects, </span>although not everybody\ngets them<span lang=\"EN-GB\">.</span></p>", "ID": "fddfc218-7e22-4f23-afd9-37b224a84806", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "although not everybody gets them", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Like all\nmedicines, this medicine can cause side effects, </span>", "ID": "d7f08d48-5be4-4df1-b51c-bc77ac505a30", "Styles": "None", "Classes": "None", "Text": "Like all medicines, this medicine can cause side effects, ", "ParentId": "fddfc218-7e22-4f23-afd9-37b224a84806"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "e8388636-77c8-4b39-ab9f-8862c399f90b", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "fddfc218-7e22-4f23-afd9-37b224a84806"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "aa3e9010-0c2e-4cdf-924a-4b7d98d17a2a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">During HIV therapy there may be an increase in weight and in\nlevels of blood lipids and glucose. This is partly linked to restored health\nand lifestyle, and in the case of blood lipids sometimes to the HIV medicines\nthemselves. Your doctor will test for these changes. </p>", "ID": "4915a6c7-7e40-4550-b9b6-23d1d28e3ebb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and lifestyle, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes. ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ff070c4f-425e-458f-8000-5396b32f99a7", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cbc2cbf4-d351-42ae-b1d5-3a7a8390b15f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ff070c4f-425e-458f-8000-5396b32f99a7"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">When treating\nHIV infection it is not always possible to differentiate between unwanted\neffects caused by Invirase or by any other medicines you take at the same time\nor by the complications of the infection. For these reasons it is very\nimportant to inform your doctor of any change in your condition.</span></p>", "ID": "ec5a39e7-eeaa-4db5-9ac3-1fa371742466", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">When treating\nHIV infection it is not always possible to differentiate between unwanted\neffects caused by Invirase or by any other medicines you take at the same time\nor by the complications of the infection. For these reasons it is very\nimportant to inform your doctor of any change in your condition.</span>", "ID": "d33f726a-2c7a-4a5c-bf41-1f52efbf1578", "Styles": "None", "Classes": "None", "Text": "When treating HIV infection it is not always possible to differentiate between unwanted effects caused by Invirase or by any other medicines you take at the same time or by the complications of the infection. For these reasons it is very important to inform your doctor of any change in your condition.", "ParentId": "ec5a39e7-eeaa-4db5-9ac3-1fa371742466"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d60198ce-8079-4334-a081-4d9859203565", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0f380e4c-c762-4fd6-ab20-417ae7afe562", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d60198ce-8079-4334-a081-4d9859203565"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The most frequently <i>(in more than ten in\na hundred persons) </i>reported side effects of saquinavir taken with ritonavir\nconcern the gastrointestinal tract, with feeling sick, diarrhoea, tiredness,\nvomiting, wind and abdominal pain being the most common. Also, changes in\nlaboratory markers </span>(e.g., blood or urine tests)<span lang=\"EN-GB\"> have\nbeen reported very commonly.</span></p>", "ID": "a1335d51-6211-4404-96bc-3f2ca2a61826", "Styles": "None", "Classes": "['MsoNormal']", "Text": "(e.g., blood or urine tests)", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">The most frequently <i>(in more than ten in\na hundred persons) </i>reported side effects of saquinavir taken with ritonavir\nconcern the gastrointestinal tract, with feeling sick, diarrhoea, tiredness,\nvomiting, wind and abdominal pain being the most common. Also, changes in\nlaboratory markers </span>", "ID": "0c1dbc5f-9ba3-4d34-b4a1-bad379c4f370", "Styles": "None", "Classes": "None", "Text": "The most frequently reported side effects of saquinavir taken with ritonavir concern the gastrointestinal tract, with feeling sick, diarrhoea, tiredness, vomiting, wind and abdominal pain being the most common. Also, changes in laboratory markers ", "ParentId": "a1335d51-6211-4404-96bc-3f2ca2a61826"}, {"Element": "<i>(in more than ten in\na hundred persons) </i>", "ID": "57a954ed-7699-4bbd-994c-ae3ed4d07698", "Styles": "None", "Classes": "None", "Text": "(in more than ten in a hundred persons) ", "ParentId": "0c1dbc5f-9ba3-4d34-b4a1-bad379c4f370"}, {"Element": "<span lang=\"EN-GB\"> have\nbeen reported very commonly.</span>", "ID": "758d73c8-ef47-43fc-9886-858d0077de31", "Styles": "None", "Classes": "None", "Text": " have been reported very commonly.", "ParentId": "a1335d51-6211-4404-96bc-3f2ca2a61826"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "490c8f9b-9e37-47eb-9451-99469a462db9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c753bf2b-4cd7-4ee0-b9c5-134ae753b7af", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "490c8f9b-9e37-47eb-9451-99469a462db9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Other reported side effects (<i>in more\nthan one in a hundred but less than one in ten persons)</i>, which may occur\nare: rash, itching, eczema and dry skin, hair loss, dry mouth, headache,\nperipheral neuropathy (a disturbance of the nerves in the feet and hands that\nmay take the form of numbness, pins and needles, shooting or burning pain),\nweakness, dizziness, libido problems, taste alteration, mouth ulcers, dry lips,\nabdominal discomfort, indigestion, weight loss,constipation, increased\nappetite,\u00a0 muscle spasms and shortness of breath. </span></p>", "ID": "699ea837-3c5d-441e-9ca4-9252f085f20f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Other reported side effects (<i>in more\nthan one in a hundred but less than one in ten persons)</i>, which may occur\nare: rash, itching, eczema and dry skin, hair loss, dry mouth, headache,\nperipheral neuropathy (a disturbance of the nerves in the feet and hands that\nmay take the form of numbness, pins and needles, shooting or burning pain),\nweakness, dizziness, libido problems, taste alteration, mouth ulcers, dry lips,\nabdominal discomfort, indigestion, weight loss,constipation, increased\nappetite,\u00a0 muscle spasms and shortness of breath. </span>", "ID": "10566791-1993-4ff2-9708-b4d5b2db1e14", "Styles": "None", "Classes": "None", "Text": "Other reported side effects (, which may occur are: rash, itching, eczema and dry skin, hair loss, dry mouth, headache, peripheral neuropathy (a disturbance of the nerves in the feet and hands that may take the form of numbness, pins and needles, shooting or burning pain), weakness, dizziness, libido problems, taste alteration, mouth ulcers, dry lips, abdominal discomfort, indigestion, weight loss,constipation, increased appetite,\u00a0 muscle spasms and shortness of breath. ", "ParentId": "699ea837-3c5d-441e-9ca4-9252f085f20f"}, {"Element": "<i>in more\nthan one in a hundred but less than one in ten persons)</i>", "ID": "fc2c56c9-0cee-4b16-846c-db2b8c312377", "Styles": "None", "Classes": "None", "Text": "in more than one in a hundred but less than one in ten persons)", "ParentId": "10566791-1993-4ff2-9708-b4d5b2db1e14"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2e4bccbf-aa45-4029-bfc4-d77470f3f647", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7f474cfd-2b48-4298-9b79-73b87cbc548d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2e4bccbf-aa45-4029-bfc4-d77470f3f647"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0Other less frequently reported side effects\n(<i>in more than one in one thousand persons but less than one in a hundred\npersons) </i>include: decreased appetite, visual disturbance, inflammation of\nthe liver, fits, allergic reactions, blisters, sleepiness, abnormal renal\nfunction, inflammation of the pancreas, yellowing of the skin or whites of the\neyes caused by liver problems and Steven\u2019s Johnson syndrome (a serious\nillness with blistering of the skin, eyes, mouth and genitals). </span></p>", "ID": "1403d37c-3672-4631-b5db-fcebb49b5a6e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0Other less frequently reported side effects\n(<i>in more than one in one thousand persons but less than one in a hundred\npersons) </i>include: decreased appetite, visual disturbance, inflammation of\nthe liver, fits, allergic reactions, blisters, sleepiness, abnormal renal\nfunction, inflammation of the pancreas, yellowing of the skin or whites of the\neyes caused by liver problems and Steven\u2019s Johnson syndrome (a serious\nillness with blistering of the skin, eyes, mouth and genitals). </span>", "ID": "b7f7467d-eaab-493d-839a-f28d407571c0", "Styles": "None", "Classes": "None", "Text": "\u00a0Other less frequently reported side effects (include: decreased appetite, visual disturbance, inflammation of the liver, fits, allergic reactions, blisters, sleepiness, abnormal renal function, inflammation of the pancreas, yellowing of the skin or whites of the eyes caused by liver problems and Steven\u2019s Johnson syndrome (a serious illness with blistering of the skin, eyes, mouth and genitals). ", "ParentId": "1403d37c-3672-4631-b5db-fcebb49b5a6e"}, {"Element": "<i>in more than one in one thousand persons but less than one in a hundred\npersons) </i>", "ID": "a6a6fcb5-d788-495e-a690-069bfaa21713", "Styles": "None", "Classes": "None", "Text": "in more than one in one thousand persons but less than one in a hundred persons) ", "ParentId": "b7f7467d-eaab-493d-839a-f28d407571c0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c46ab46d-24fd-44ba-8602-f5f36e4e8936", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f2045192-12ae-4ee2-a120-2b3bb1f7c1bd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c46ab46d-24fd-44ba-8602-f5f36e4e8936"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients with haemophilia type A and B,\nthere have been reports of increased bleeding while taking this treatment or\nanother protease inhibitor. Should this happen to you, seek immediate advice\nfrom your doctor.</span></p>", "ID": "bf9e4946-3339-49a0-be74-aee609d8d5ef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">In patients with haemophilia type A and B,\nthere have been reports of increased bleeding while taking this treatment or\nanother protease inhibitor. Should this happen to you, seek immediate advice\nfrom your doctor.</span>", "ID": "ee1f6c1a-9170-477a-8ea6-f858ff7c0467", "Styles": "None", "Classes": "None", "Text": "In patients with haemophilia type A and B, there have been reports of increased bleeding while taking this treatment or another protease inhibitor. Should this happen to you, seek immediate advice from your doctor.", "ParentId": "bf9e4946-3339-49a0-be74-aee609d8d5ef"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d9341314-9288-4c8c-84c8-ad22d9dffe66", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d3d256c5-52ce-490b-8021-7ecf867c8c86", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d9341314-9288-4c8c-84c8-ad22d9dffe66"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There have been reports of muscle pain,\ntenderness or weakness, particularly with combination antiretroviral therapy\nincluding protease inhibitors and nucleoside analogues. On rare occasions these\nmuscle disorders have been serious (rhabdomyolysis).</span></p>", "ID": "ff2f6461-06b0-4d85-a132-71acd4f15120", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">There have been reports of muscle pain,\ntenderness or weakness, particularly with combination antiretroviral therapy\nincluding protease inhibitors and nucleoside analogues. On rare occasions these\nmuscle disorders have been serious (rhabdomyolysis).</span>", "ID": "bae229f7-c801-42c5-aa96-99d82eab62db", "Styles": "None", "Classes": "None", "Text": "There have been reports of muscle pain, tenderness or weakness, particularly with combination antiretroviral therapy including protease inhibitors and nucleoside analogues. On rare occasions these muscle disorders have been serious (rhabdomyolysis).", "ParentId": "ff2f6461-06b0-4d85-a132-71acd4f15120"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b5bcdad6-72a0-440c-b5b4-64553c9c7240", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4611f4c6-a762-4aa8-9d8e-806bf5395877", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b5bcdad6-72a0-440c-b5b4-64553c9c7240"}, {"Element": "<p class=\"MsoNormal\"><b>Reporting of side effects</b></p>", "ID": "5611ae12-0d55-4e09-a93b-0de22bf62b03", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>Reporting of side effects</b>", "ID": "46a9bdc0-94c5-4d7a-9849-e4f92d9a23b5", "Styles": "None", "Classes": "None", "Text": "Reporting of side effects", "ParentId": "5611ae12-0d55-4e09-a93b-0de22bf62b03"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you get any side effects, talk to your\ndoctor, pharmacist or nurse.\u00a0 This includes any possible side effects not\nlisted in this leaflet. </span>You can also report side effects directly via <span style=\"background:silver\">the national reporting system listed in </span><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:silver\">Appendix V</span></a><span lang=\"EN-GB\" style=\"background:silver\">.</span><span lang=\"EN-GB\"> By reporting side effects\nyou can help provide more information on the safety of this medicine.</span></p>", "ID": "09f3d152-34f4-479e-841b-030d1f51a0eb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "You can also report side effects directly via ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">If you get any side effects, talk to your\ndoctor, pharmacist or nurse.\u00a0 This includes any possible side effects not\nlisted in this leaflet. </span>", "ID": "36b70810-6d57-4c48-866d-83fad6496ea8", "Styles": "None", "Classes": "None", "Text": "If you get any side effects, talk to your doctor, pharmacist or nurse.\u00a0 This includes any possible side effects not listed in this leaflet. ", "ParentId": "09f3d152-34f4-479e-841b-030d1f51a0eb"}, {"Element": "<span style=\"background:silver\">the national reporting system listed in </span>", "ID": "ad0c298b-f6ce-409f-98bc-841e96dd0ebf", "Styles": "background:silver", "Classes": "None", "Text": "the national reporting system listed in ", "ParentId": "09f3d152-34f4-479e-841b-030d1f51a0eb"}, {"Element": "<a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:silver\">Appendix V</span></a>", "ID": "83f901eb-10f8-4d8c-badf-b4618966b175", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "09f3d152-34f4-479e-841b-030d1f51a0eb"}, {"Element": "<span style=\"background:silver\">Appendix V</span>", "ID": "52f69f7f-cef6-4d6f-ad85-1a86eb30b696", "Styles": "background:silver", "Classes": "None", "Text": "Appendix V", "ParentId": "83f901eb-10f8-4d8c-badf-b4618966b175"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">.</span>", "ID": "1ab222ff-76ba-419a-983d-770c93063b9f", "Styles": "background:silver", "Classes": "None", "Text": ".", "ParentId": "09f3d152-34f4-479e-841b-030d1f51a0eb"}, {"Element": "<span lang=\"EN-GB\"> By reporting side effects\nyou can help provide more information on the safety of this medicine.</span>", "ID": "aef7bcae-f38a-462e-bf1c-68db4f1e0c17", "Styles": "None", "Classes": "None", "Text": " By reporting side effects you can help provide more information on the safety of this medicine.", "ParentId": "09f3d152-34f4-479e-841b-030d1f51a0eb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2e78be42-d04b-4ca3-a1c6-c017a47b0d01", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "426dd443-3b1c-43ac-806d-72abdd384076", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2e78be42-d04b-4ca3-a1c6-c017a47b0d01"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "96813213-bd8d-4abb-86c4-fbde0b9d2043", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b691cb7d-1967-426c-b3f0-d569cb4254bc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "96813213-bd8d-4abb-86c4-fbde0b9d2043"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store\nInvirase</span></b></p>", "ID": "157859c3-fee9-4df6-a5fd-dd72d8b500e2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store\nInvirase</span></b>", "ID": "0f2e8f4a-ca19-422a-b2f0-5271ee34c264", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "157859c3-fee9-4df6-a5fd-dd72d8b500e2"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store\nInvirase</span>", "ID": "9cc09157-8f40-4ec5-b74b-6ed5980757e3", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Invirase", "ParentId": "0f2e8f4a-ca19-422a-b2f0-5271ee34c264"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ea19ea3b-0ca4-487b-ad75-7d5c55cb1c8f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2104d86e-26eb-46bc-bad0-a3ac74e0bd48", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ea19ea3b-0ca4-487b-ad75-7d5c55cb1c8f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Keep this\nmedicine out of the sight and reach of children.</span></p>", "ID": "6d242cfe-9987-4ccb-8c62-8f585f58b0aa", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Keep this\nmedicine out of the sight and reach of children.</span>", "ID": "4dd1f2a9-4bf3-49ca-a794-4fcca7f970ae", "Styles": "None", "Classes": "None", "Text": "Keep this medicine out of the sight and reach of children.", "ParentId": "6d242cfe-9987-4ccb-8c62-8f585f58b0aa"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Do not use this medicine\nafter the expiry date (EXP) which is stated on the bottle and carton. The\nexpiry date refers to the last day of that month.</p>", "ID": "1f8230e8-0247-49ab-ac31-e4c5889c84e3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Do not use this medicine after the expiry date (EXP) which is stated on the bottle and carton. The expiry date refers to the last day of that month.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6e91bd9d-9d3e-473f-84a6-fe3d56c6da5f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "13fab166-3a16-4cba-be53-e18c0ac260cf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6e91bd9d-9d3e-473f-84a6-fe3d56c6da5f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Invirase does not require any special\nstorage conditions.</span></p>", "ID": "e5e1a992-4092-4989-8bc2-414cac1fdd10", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">Invirase does not require any special\nstorage conditions.</span>", "ID": "bfa5ebb7-b3ef-4d3d-80b8-b497ae3f81b7", "Styles": "None", "Classes": "None", "Text": "Invirase does not require any special storage conditions.", "ParentId": "e5e1a992-4092-4989-8bc2-414cac1fdd10"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "685831b4-6920-4ca8-8cba-4e33879c2894", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7b6389b7-5d0f-4131-9f8a-6fafd95c1dea", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "685831b4-6920-4ca8-8cba-4e33879c2894"}, {"Element": "<p class=\"MsoNormal\">Do not throw away any medicines via wastewater or household\nwaste. Ask your pharmacist how to throw away medicines you no longer use. These\nmeasures will help to protect the environment.</p>", "ID": "bae03857-79b0-4dea-bd2d-5d85496ce20d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "37cdca27-7bb3-48ac-9281-4d0dee590cd5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "be8f1f0b-b755-480a-acf1-7c5ad3243026", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "37cdca27-7bb3-48ac-9281-4d0dee590cd5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9fecbe91-960b-40bb-9545-74aa416c9b8f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cb36f5ae-a6cf-4010-827f-60a5ae786c5c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9fecbe91-960b-40bb-9545-74aa416c9b8f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of\nthe pack and other information</span></b></p>", "ID": "b7522ac4-a3ed-4fb7-a896-a46613aec2b7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of\nthe pack and other information</span></b>", "ID": "c04f8c76-2dcf-4dcf-9b02-47f2ae2c06ca", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b7522ac4-a3ed-4fb7-a896-a46613aec2b7"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of\nthe pack and other information</span>", "ID": "6d416245-558b-4ff6-a476-08ce7d58c417", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information", "ParentId": "c04f8c76-2dcf-4dcf-9b02-47f2ae2c06ca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cf59ac33-e355-417d-8bb5-0fb18b9d59a1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5292189a-d208-47fb-8f2a-4a00dbe1ba25", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cf59ac33-e355-417d-8bb5-0fb18b9d59a1"}, {"Element": "<p class=\"MsoNormal\"><b>What Invirase contains</b></p>", "ID": "fcc9ad05-d4c9-4cf1-b9c8-9cc1c71d9f64", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>What Invirase contains</b>", "ID": "e01524a1-9e85-4270-9a70-274ac1b48e8a", "Styles": "None", "Classes": "None", "Text": "What Invirase contains", "ParentId": "fcc9ad05-d4c9-4cf1-b9c8-9cc1c71d9f64"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "42c05988-42a5-42d6-98be-2b3308e55a7d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f823377b-1bbd-4907-8f9b-4255a38fa4f6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "42c05988-42a5-42d6-98be-2b3308e55a7d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 The\nactive substance is saquinavir. One </span>film-coated tablet<span lang=\"EN-GB\">\nof Invirase contains </span>500<span lang=\"EN-GB\">\u00a0mg of saquinavir as\nsaquinavir mesilate.</span></p>", "ID": "dfd0d7d4-b81a-4fb1-a8e0-7dfac2b817eb", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": "film-coated tablet500", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "5b3c79b2-fc21-41a7-aaec-de5493b4dc79", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "dfd0d7d4-b81a-4fb1-a8e0-7dfac2b817eb"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 The\nactive substance is saquinavir. One </span>", "ID": "b589ee60-2ecb-4574-a2d4-50b858ebe69d", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 The active substance is saquinavir. One ", "ParentId": "dfd0d7d4-b81a-4fb1-a8e0-7dfac2b817eb"}, {"Element": "<span lang=\"EN-GB\">\nof Invirase contains </span>", "ID": "96719dd2-2dfd-45c1-9503-62d3094b9c05", "Styles": "None", "Classes": "None", "Text": " of Invirase contains ", "ParentId": "dfd0d7d4-b81a-4fb1-a8e0-7dfac2b817eb"}, {"Element": "<span lang=\"EN-GB\">\u00a0mg of saquinavir as\nsaquinavir mesilate.</span>", "ID": "fbf68273-0b10-4919-b3f3-55edb4b69683", "Styles": "None", "Classes": "None", "Text": "\u00a0mg of saquinavir as saquinavir mesilate.", "ParentId": "dfd0d7d4-b81a-4fb1-a8e0-7dfac2b817eb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.3in;text-indent:-.3in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 The\nother ingredients (excipients) are</span> microcrystalline cellulose,\ncroscarmellose sodium, povidone, lactose (monohydrate) 38.5\u00a0mg, magnesium\nstearate, hypromellose, titanium dioxide (E171), talc, glycerol triacetate,\niron oxide yellow (E172) and iron oxide red (E172).</p>", "ID": "9a4f4642-b699-47c8-9ea3-4ab4f9c71e2d", "Styles": "margin-left:.3in;text-indent:-.3in", "Classes": "['MsoNormal']", "Text": " microcrystalline cellulose, croscarmellose sodium, povidone, lactose (monohydrate) 38.5\u00a0mg, magnesium stearate, hypromellose, titanium dioxide (E171), talc, glycerol triacetate, iron oxide yellow (E172) and iron oxide red (E172).", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "3a738972-c6a3-4753-a8e7-d07922cb376f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "9a4f4642-b699-47c8-9ea3-4ab4f9c71e2d"}, {"Element": "<span lang=\"EN-GB\">\u00a0\u00a0\u00a0\u00a0\u00a0 The\nother ingredients (excipients) are</span>", "ID": "498868c2-503a-4ce5-9802-a33eb9b2d735", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 The other ingredients (excipients) are", "ParentId": "9a4f4642-b699-47c8-9ea3-4ab4f9c71e2d"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "d8c5b385-e790-483a-a2ea-973cc128aef4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>\u00a0</b>", "ID": "1846d638-bf48-485f-bd4d-a0b0e20fbb3e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d8c5b385-e790-483a-a2ea-973cc128aef4"}, {"Element": "<p class=\"MsoNormal\"><b>What Invirase looks like and contents of the pack</b></p>", "ID": "107ebfde-014b-4913-ad70-fbefa8ffea50", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>What Invirase looks like and contents of the pack</b>", "ID": "59c2511a-6f0f-45b7-a2da-4cdd984b4804", "Styles": "None", "Classes": "None", "Text": "What Invirase looks like and contents of the pack", "ParentId": "107ebfde-014b-4913-ad70-fbefa8ffea50"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "1f6a22e7-997a-4871-97b8-67b4ac40df0a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>\u00a0</b>", "ID": "cb63e9da-74ea-4cf1-b787-6da66e2785d0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1f6a22e7-997a-4871-97b8-67b4ac40df0a"}, {"Element": "<p class=\"MsoNormal\">Invirase 500\u00a0mg film-coated tablet<span lang=\"EN-GB\">s\nare light orange to greyish or brownish orange tablets of oval shape with the\nmarking \"SQV 500\" on one side and \"ROCHE\" on the other\nside. One </span>plastic (HDPE) bottle contains 120 tablets.</p>", "ID": "2f1c54d9-33f1-43e4-b4e5-b858fd12ae27", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Invirase 500\u00a0mg film-coated tabletplastic (HDPE) bottle contains 120 tablets.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">s\nare light orange to greyish or brownish orange tablets of oval shape with the\nmarking \"SQV 500\" on one side and \"ROCHE\" on the other\nside. One </span>", "ID": "593c4a69-09a6-4643-87d7-978d5b4e7dfe", "Styles": "None", "Classes": "None", "Text": "s are light orange to greyish or brownish orange tablets of oval shape with the marking \"SQV 500\" on one side and \"ROCHE\" on the other side. One ", "ParentId": "2f1c54d9-33f1-43e4-b4e5-b858fd12ae27"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "cdba3d5b-a49c-49aa-aa9e-8fe5283c301b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>\u00a0</b>", "ID": "9601ff52-aab4-48ce-b8e8-5ca380d1e62c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cdba3d5b-a49c-49aa-aa9e-8fe5283c301b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Marketing Authorisation\nHolder and Manufacturer</b></p>", "ID": "0238d64a-d055-494f-80f2-4cf83d3c6a48", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>Marketing Authorisation\nHolder and Manufacturer</b>", "ID": "8a1085e8-0111-4395-bbfb-003e03dcbef5", "Styles": "None", "Classes": "None", "Text": "Marketing Authorisation Holder and Manufacturer", "ParentId": "0238d64a-d055-494f-80f2-4cf83d3c6a48"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8db5a18b-4bc3-4f9f-97f2-bde88b511325", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7ab615ab-af49-4b47-bf57-ed4d45baa1e9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8db5a18b-4bc3-4f9f-97f2-bde88b511325"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder</span></b></p>", "ID": "34345a28-2201-4999-b76e-4057d2602e78", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">Marketing Authorisation Holder</span></b>", "ID": "6122f439-3109-415b-9753-55fcd44d605d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "34345a28-2201-4999-b76e-4057d2602e78"}, {"Element": "<span lang=\"EN-GB\">Marketing Authorisation Holder</span>", "ID": "3e637301-fb1c-4dcc-b727-8fe7c076a019", "Styles": "None", "Classes": "None", "Text": "Marketing Authorisation Holder", "ParentId": "6122f439-3109-415b-9753-55fcd44d605d"}, {"Element": "<p class=\"MsoNormal\">Roche Registration GmbH </p>", "ID": "5d3b5c58-a1c2-4593-b5d6-8d46eb74399e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Roche Registration GmbH ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">Emil-Barell-Strasse 1</p>", "ID": "aa8c5a4b-1d94-4624-9b10-b26fe009b3d2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Emil-Barell-Strasse 1", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">79639 Grenzach-Wyhlen</p>", "ID": "71fbeb4b-9963-4ce4-a0e2-73db7c734ffd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "79639 Grenzach-Wyhlen", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">Germany</p>", "ID": "54dda3dd-38de-496a-beec-79479b3c54fa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Germany", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "16a311f5-b3e0-4bd4-907f-476fc086d16b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e701c44c-ad01-4dba-ac5d-be47dd851e92", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "16a311f5-b3e0-4bd4-907f-476fc086d16b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Manufacturer </b></p>", "ID": "d950b13c-d1a9-4a3b-b390-fb7c90e3543f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>Manufacturer </b>", "ID": "729d4917-dd98-4cfd-be8b-1be4d3b66105", "Styles": "None", "Classes": "None", "Text": "Manufacturer ", "ParentId": "d950b13c-d1a9-4a3b-b390-fb7c90e3543f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE-CH\">Roche Pharma\nAG, </span></p>", "ID": "7944bf32-d29b-450e-9a0b-87fba73258f9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"DE-CH\">Roche Pharma\nAG, </span>", "ID": "e0181635-02fb-410b-8bef-3d2918c24078", "Styles": "None", "Classes": "None", "Text": "Roche Pharma AG, ", "ParentId": "7944bf32-d29b-450e-9a0b-87fba73258f9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE-CH\">Emil-Barell-Strasse\n1,</span></p>", "ID": "2dbd273f-f40c-452a-ab8b-4d3f80a09952", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"DE-CH\">Emil-Barell-Strasse\n1,</span>", "ID": "097a8407-1e64-4433-8295-55089ff6342d", "Styles": "None", "Classes": "None", "Text": "Emil-Barell-Strasse 1,", "ParentId": "2dbd273f-f40c-452a-ab8b-4d3f80a09952"}, {"Element": "<p class=\"MsoNormal\">79639 Grenzach-Wyhlen,</p>", "ID": "c328b804-a289-42d6-ac28-ea74158c81af", "Styles": "None", "Classes": "['MsoNormal']", "Text": "79639 Grenzach-Wyhlen,", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\">Germany.</p>", "ID": "ceb7c507-1e38-4d70-bf3c-552d140e758e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Germany.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0d7fa2ad-540e-44f1-a46b-dbea46fb5b31", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e60ed725-35d1-4c1d-820f-d8ce8815beee", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0d7fa2ad-540e-44f1-a46b-dbea46fb5b31"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">For any\ninformation about this medicine, please contact the local representative of the\nMarketing Authorisation Holder:</span></p>", "ID": "f7d0c971-950a-451f-9dfd-a0ae74c967fd", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">For any\ninformation about this medicine, please contact the local representative of the\nMarketing Authorisation Holder:</span>", "ID": "ec81f806-2abc-41a0-9b82-41618b0a5413", "Styles": "None", "Classes": "None", "Text": "For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:", "ParentId": "f7d0c971-950a-451f-9dfd-a0ae74c967fd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "e814dc99-e9cb-4d0c-8a21-9ba8f6cc3c11", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"FR\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FR\">N.V. Roche\n  S.A.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FR\">T\u00e9l/Tel:\n  +32 (0) 2 525 82 11</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"FR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Lietuva</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">UAB \u201cRoche Lietuva\u201d</span></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">Tel: +370 5 </span><span lang=\"DE-CH\">2546799</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"BG\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u0420\u043e\u0448\n  \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u0422\u0435\u043b:\n  +359 2\u00a0818 44 44</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE-CH\">(Voir/siehe\n  Belgique/Belgien)</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"CS\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"CS\">Roche s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"CS\">Tel: +420 - 2 20382111</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Magyarorsz</b><b><span lang=\"CS\">\u00e1g</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"CS\">Roche\n  (Magyarorsz\u00e1g) Kft.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"CS\">Tel: +36 - 23\n  446 800</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Danmark</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +45 - 36 39 99 99</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(See </span>Ireland<span lang=\"EN-GB\">)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"NL\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"NL\">Roche Nederland B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +31 (</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">0) 348 438050</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Eesti</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">Roche Eesti O\u00dc</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 372 - 6 177 380</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Roche Norge\n  AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Tlf: +47 -\n  22 78 90 00</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche (Hellas) A.E. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +30 210 61 66 100</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Austria GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Roche Farma S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +34 - 91 324 81 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PL\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PL\">Roche Polska Sp.z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +48 - 22 345 18 88</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">France</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">Roche</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">T\u00e9l: +33 (0) 1 47 61 40 00</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT\">Portugal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">Roche Farmac\u00eautica Qu\u00edmica, Lda</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">Tel: +351 - 21 425 70 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 385 1 47 22 333</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">Roche Rom\u00e2nia S.R.L.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +40 21 206 47 01</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products (Ireland) Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +353 (0) 1 469 0700</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche farmacevtska dru\u017eba d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +386 - 1 360 26 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">\u00cdsland\n  </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">c/o Icepharma hf</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">S</span><span lang=\"CS\">\u00ed</span><span lang=\"PT-BR\">mi</span><span lang=\"PT\" style=\"layout-grid-mode:line\">: +354 540\n  8000</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"PT\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT\">Slovensk\u00e1 republika </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SK\">Roche Slovensko, s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">Tel: +421 - 2 52638201</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"PT\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche S.p.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +39 - 039 2471</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">K</span></b><b><span lang=\"EL\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b><span lang=\"EL\" style='font-size:10.0pt;font-family:\"Arial\",sans-serif'> </span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u0393.\u0391.\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2\n  &amp; \u03a3\u03b9\u03b1 \u039b\u03c4\u03b4.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb</span>: +357 - 22 76 62\n  76</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Sverige</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche AB</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +46 (0) 8 726 1200</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Latvija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"LV\">Roche Latvija SIA</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 \u2013 6 7039831</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"IT\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 (0) 1707 366000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n</table>", "ID": "2953fa40-15e1-484c-8c5b-89c652676a34", "Styles": "border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "                ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"FR\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FR\">N.V. Roche\n  S.A.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FR\">T\u00e9l/Tel:\n  +32 (0) 2 525 82 11</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"FR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Lietuva</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">UAB \u201cRoche Lietuva\u201d</span></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">Tel: +370 5 </span><span lang=\"DE-CH\">2546799</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "a939295f-bf29-4375-a2d7-916b0396b7f5", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "2953fa40-15e1-484c-8c5b-89c652676a34"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"FR\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FR\">N.V. Roche\n  S.A.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FR\">T\u00e9l/Tel:\n  +32 (0) 2 525 82 11</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"FR\">\u00a0</span></b></p>\n</td>", "ID": "c65eadbf-3e7b-4829-a2af-9f3b984294fc", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "a939295f-bf29-4375-a2d7-916b0396b7f5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"FR\">Belgi\u00eb/Belgique/Belgien</span></b></p>", "ID": "25b49273-fc00-4d82-a1f8-6cbbc5ee4595", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c65eadbf-3e7b-4829-a2af-9f3b984294fc"}, {"Element": "<b><span lang=\"FR\">Belgi\u00eb/Belgique/Belgien</span></b>", "ID": "3c35939d-3673-40b1-9dbf-5dfa7a143904", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "25b49273-fc00-4d82-a1f8-6cbbc5ee4595"}, {"Element": "<span lang=\"FR\">Belgi\u00eb/Belgique/Belgien</span>", "ID": "55daaa4e-e4ce-4561-8ee7-031dcd6311de", "Styles": "None", "Classes": "None", "Text": "Belgi\u00eb/Belgique/Belgien", "ParentId": "3c35939d-3673-40b1-9dbf-5dfa7a143904"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FR\">N.V. Roche\n  S.A.</span></p>", "ID": "dbbd6f0f-a796-4ce5-8024-8e40325c5c70", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c65eadbf-3e7b-4829-a2af-9f3b984294fc"}, {"Element": "<span lang=\"FR\">N.V. Roche\n  S.A.</span>", "ID": "79484353-2661-49f0-94c7-23fe9f9c10d5", "Styles": "None", "Classes": "None", "Text": "N.V. Roche   S.A.", "ParentId": "dbbd6f0f-a796-4ce5-8024-8e40325c5c70"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FR\">T\u00e9l/Tel:\n  +32 (0) 2 525 82 11</span></p>", "ID": "50995239-48f3-4788-b140-d2e8fa7d2c4e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c65eadbf-3e7b-4829-a2af-9f3b984294fc"}, {"Element": "<span lang=\"FR\">T\u00e9l/Tel:\n  +32 (0) 2 525 82 11</span>", "ID": "1e138031-d97a-4d61-82c4-edbfea6fe05c", "Styles": "None", "Classes": "None", "Text": "T\u00e9l/Tel:   +32 (0) 2 525 82 11", "ParentId": "50995239-48f3-4788-b140-d2e8fa7d2c4e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"FR\">\u00a0</span></b></p>", "ID": "829da092-dd7c-4a45-85ae-8d97d5258fce", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c65eadbf-3e7b-4829-a2af-9f3b984294fc"}, {"Element": "<b><span lang=\"FR\">\u00a0</span></b>", "ID": "4e3e1032-b590-4f15-b4e4-bd73e3fec878", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "829da092-dd7c-4a45-85ae-8d97d5258fce"}, {"Element": "<span lang=\"FR\">\u00a0</span>", "ID": "e514f5fc-9eb3-4392-acb2-d2c30abbbced", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4e3e1032-b590-4f15-b4e4-bd73e3fec878"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Lietuva</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">UAB \u201cRoche Lietuva\u201d</span></p>\n<p class=\"MsoNormal\"><span lang=\"FI\">Tel: +370 5 </span><span lang=\"DE-CH\">2546799</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>", "ID": "18f3907e-b4de-46ec-9ab1-df147ae499be", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "a939295f-bf29-4375-a2d7-916b0396b7f5"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Lietuva</span></b></p>", "ID": "3a486c20-c566-46a5-aaa5-664aa177b8b2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18f3907e-b4de-46ec-9ab1-df147ae499be"}, {"Element": "<b><span lang=\"DE-CH\">Lietuva</span></b>", "ID": "d1b215f8-b094-4fed-9254-aa27e66e62fe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3a486c20-c566-46a5-aaa5-664aa177b8b2"}, {"Element": "<span lang=\"DE-CH\">Lietuva</span>", "ID": "394df771-dfe0-429f-9853-d3c3568fb2fb", "Styles": "None", "Classes": "None", "Text": "Lietuva", "ParentId": "d1b215f8-b094-4fed-9254-aa27e66e62fe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">UAB \u201cRoche Lietuva\u201d</span></p>", "ID": "631b240d-95a1-4f9f-b3ea-3a91b4759135", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18f3907e-b4de-46ec-9ab1-df147ae499be"}, {"Element": "<span lang=\"DE-CH\">UAB \u201cRoche Lietuva\u201d</span>", "ID": "3f917577-9ae4-40b0-98d5-3b1e494a332a", "Styles": "None", "Classes": "None", "Text": "UAB \u201cRoche Lietuva\u201d", "ParentId": "631b240d-95a1-4f9f-b3ea-3a91b4759135"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FI\">Tel: +370 5 </span><span lang=\"DE-CH\">2546799</span></p>", "ID": "5a25732d-2d95-4d76-bed1-9e9f3a9f5280", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18f3907e-b4de-46ec-9ab1-df147ae499be"}, {"Element": "<span lang=\"FI\">Tel: +370 5 </span>", "ID": "9c1f7d4d-bbd4-49b5-abc3-26ac01a7f065", "Styles": "None", "Classes": "None", "Text": "Tel: +370 5 ", "ParentId": "5a25732d-2d95-4d76-bed1-9e9f3a9f5280"}, {"Element": "<span lang=\"DE-CH\">2546799</span>", "ID": "d7eb1195-3092-464b-b6e0-33b880c83535", "Styles": "None", "Classes": "None", "Text": "2546799", "ParentId": "5a25732d-2d95-4d76-bed1-9e9f3a9f5280"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>", "ID": "fbc19bd4-8cd4-40b9-b22a-a7cac60534b1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18f3907e-b4de-46ec-9ab1-df147ae499be"}, {"Element": "<b><span lang=\"DE-CH\">\u00a0</span></b>", "ID": "79d5901e-0cb0-4210-8205-184fe4f2a615", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fbc19bd4-8cd4-40b9-b22a-a7cac60534b1"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "a65dc757-81d7-4ae6-883c-0f2f60d2cc06", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "79d5901e-0cb0-4210-8205-184fe4f2a615"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"BG\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u0420\u043e\u0448\n  \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u0422\u0435\u043b:\n  +359 2\u00a0818 44 44</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE-CH\">(Voir/siehe\n  Belgique/Belgien)</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u00a0</span></p>\n</td>\n</tr>", "ID": "c534be53-3d53-486e-a498-c081c38f180e", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "2953fa40-15e1-484c-8c5b-89c652676a34"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"BG\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u0420\u043e\u0448\n  \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u0422\u0435\u043b:\n  +359 2\u00a0818 44 44</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u00a0</span></p>\n</td>", "ID": "3ecdbad8-3cd9-4f83-9316-b016c154e8e2", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "c534be53-3d53-486e-a498-c081c38f180e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"BG\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>", "ID": "88a32aa7-94b7-40f4-9eae-883a30cdd528", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3ecdbad8-3cd9-4f83-9316-b016c154e8e2"}, {"Element": "<b><span lang=\"BG\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b>", "ID": "fe898600-e716-4a28-8e0a-edc3e80b31b1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "88a32aa7-94b7-40f4-9eae-883a30cdd528"}, {"Element": "<span lang=\"BG\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span>", "ID": "45df794b-5bf0-4160-88b8-115f177339b6", "Styles": "None", "Classes": "None", "Text": "\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f", "ParentId": "fe898600-e716-4a28-8e0a-edc3e80b31b1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u0420\u043e\u0448\n  \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</span></p>", "ID": "abae5d65-e4a0-4c49-ad88-3bd1fa3091a2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3ecdbad8-3cd9-4f83-9316-b016c154e8e2"}, {"Element": "<span lang=\"BG\">\u0420\u043e\u0448\n  \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</span>", "ID": "40d6ae2d-7c36-4a44-b8d7-fda00ebbfca5", "Styles": "None", "Classes": "None", "Text": "\u0420\u043e\u0448   \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f   \u0415\u041e\u041e\u0414", "ParentId": "abae5d65-e4a0-4c49-ad88-3bd1fa3091a2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u0422\u0435\u043b:\n  +359 2\u00a0818 44 44</span></p>", "ID": "4c635db6-0261-486d-b18b-096b3678ae96", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3ecdbad8-3cd9-4f83-9316-b016c154e8e2"}, {"Element": "<span lang=\"BG\">\u0422\u0435\u043b:\n  +359 2\u00a0818 44 44</span>", "ID": "391eaaea-8ea0-4a4c-8931-e806a4cfa69e", "Styles": "None", "Classes": "None", "Text": "\u0422\u0435\u043b:   +359 2\u00a0818 44 44", "ParentId": "4c635db6-0261-486d-b18b-096b3678ae96"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u00a0</span></p>", "ID": "dbf972ed-dd41-4aa7-88cb-5cafc8085dbd", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3ecdbad8-3cd9-4f83-9316-b016c154e8e2"}, {"Element": "<span lang=\"BG\">\u00a0</span>", "ID": "84824070-28ab-48d1-b8b2-6eea7b9f6099", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dbf972ed-dd41-4aa7-88cb-5cafc8085dbd"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE-CH\">(Voir/siehe\n  Belgique/Belgien)</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u00a0</span></p>\n</td>", "ID": "191dcafc-6e80-4615-b28a-92346df13d33", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "c534be53-3d53-486e-a498-c081c38f180e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>", "ID": "a343e07a-2a79-405f-9e31-4ee1953ded68", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "191dcafc-6e80-4615-b28a-92346df13d33"}, {"Element": "<b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b>", "ID": "a0900e2d-44b5-4a1a-a7c6-37827384044b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a343e07a-2a79-405f-9e31-4ee1953ded68"}, {"Element": "<span lang=\"DE-CH\">Luxembourg/Luxemburg</span>", "ID": "c4502027-5a7f-476a-8ac8-87f646679e18", "Styles": "None", "Classes": "None", "Text": "Luxembourg/Luxemburg", "ParentId": "a0900e2d-44b5-4a1a-a7c6-37827384044b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE-CH\">(Voir/siehe\n  Belgique/Belgien)</span></p>", "ID": "1bdf0089-088f-4bf9-9975-24d61b08e20a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "191dcafc-6e80-4615-b28a-92346df13d33"}, {"Element": "<span lang=\"DE-CH\">(Voir/siehe\n  Belgique/Belgien)</span>", "ID": "4a80b130-0646-4c43-9bd4-01e5a3423f80", "Styles": "None", "Classes": "None", "Text": "(Voir/siehe   Belgique/Belgien)", "ParentId": "1bdf0089-088f-4bf9-9975-24d61b08e20a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"BG\">\u00a0</span></p>", "ID": "b9addb51-49fa-47e9-bd9a-acf921aff060", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "191dcafc-6e80-4615-b28a-92346df13d33"}, {"Element": "<span lang=\"BG\">\u00a0</span>", "ID": "b23e3f38-ce6c-4bfc-b052-588349943f32", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b9addb51-49fa-47e9-bd9a-acf921aff060"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"CS\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"CS\">Roche s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"CS\">Tel: +420 - 2 20382111</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Magyarorsz</b><b><span lang=\"CS\">\u00e1g</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"CS\">Roche\n  (Magyarorsz\u00e1g) Kft.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"CS\">Tel: +36 - 23\n  446 800</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>\n</td>\n</tr>", "ID": "76690075-f739-4082-9775-0027abd20be5", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "2953fa40-15e1-484c-8c5b-89c652676a34"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"CS\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"CS\">Roche s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"CS\">Tel: +420 - 2 20382111</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>", "ID": "e2493253-b915-4ca5-af00-6a0c52dd325e", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "76690075-f739-4082-9775-0027abd20be5"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"CS\">\u010cesk\u00e1 republika</span></b></p>", "ID": "38930daf-3969-42c4-bbbf-71d351f867aa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e2493253-b915-4ca5-af00-6a0c52dd325e"}, {"Element": "<b><span lang=\"CS\">\u010cesk\u00e1 republika</span></b>", "ID": "ababa0ed-8c22-4c0b-8acb-972ac8ad5ac8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "38930daf-3969-42c4-bbbf-71d351f867aa"}, {"Element": "<span lang=\"CS\">\u010cesk\u00e1 republika</span>", "ID": "b10d1079-699a-4644-9e36-ae69f5edb83e", "Styles": "None", "Classes": "None", "Text": "\u010cesk\u00e1 republika", "ParentId": "ababa0ed-8c22-4c0b-8acb-972ac8ad5ac8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"CS\">Roche s. r. o.</span></p>", "ID": "f79dfc35-e5d0-45db-a637-dbfc0b89bbe6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e2493253-b915-4ca5-af00-6a0c52dd325e"}, {"Element": "<span lang=\"CS\">Roche s. r. o.</span>", "ID": "3d3a9954-6080-4404-aead-ad25789853b8", "Styles": "None", "Classes": "None", "Text": "Roche s. r. o.", "ParentId": "f79dfc35-e5d0-45db-a637-dbfc0b89bbe6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"CS\">Tel: +420 - 2 20382111</span></p>", "ID": "e66c4bc4-a920-48fd-bf5a-7691d361b806", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e2493253-b915-4ca5-af00-6a0c52dd325e"}, {"Element": "<span lang=\"CS\">Tel: +420 - 2 20382111</span>", "ID": "eef1f188-90fe-452f-9131-576fe3e21514", "Styles": "None", "Classes": "None", "Text": "Tel: +420 - 2 20382111", "ParentId": "e66c4bc4-a920-48fd-bf5a-7691d361b806"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>", "ID": "b57111d5-6bbe-4742-9a87-e25686caba35", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e2493253-b915-4ca5-af00-6a0c52dd325e"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "d9587d8b-4ae0-42de-9ada-be34f1cb7e1d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b57111d5-6bbe-4742-9a87-e25686caba35"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Magyarorsz</b><b><span lang=\"CS\">\u00e1g</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"CS\">Roche\n  (Magyarorsz\u00e1g) Kft.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"CS\">Tel: +36 - 23\n  446 800</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>\n</td>", "ID": "77ac5047-5509-4303-81f1-8fead1eb1ee3", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "76690075-f739-4082-9775-0027abd20be5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Magyarorsz</b><b><span lang=\"CS\">\u00e1g</span></b></p>", "ID": "2ae6d1af-d225-43b0-89e4-037f9fb57f75", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "77ac5047-5509-4303-81f1-8fead1eb1ee3"}, {"Element": "<b>Magyarorsz</b>", "ID": "ec44bb6d-96ce-43a0-9e4c-bc4e640c5093", "Styles": "None", "Classes": "None", "Text": "Magyarorsz", "ParentId": "2ae6d1af-d225-43b0-89e4-037f9fb57f75"}, {"Element": "<b><span lang=\"CS\">\u00e1g</span></b>", "ID": "c2238d68-b9a6-483c-ac14-dc469e0d9336", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2ae6d1af-d225-43b0-89e4-037f9fb57f75"}, {"Element": "<span lang=\"CS\">\u00e1g</span>", "ID": "0b5bdaf9-1fc4-42de-bb8d-144e2453d759", "Styles": "None", "Classes": "None", "Text": "\u00e1g", "ParentId": "c2238d68-b9a6-483c-ac14-dc469e0d9336"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"CS\">Roche\n  (Magyarorsz\u00e1g) Kft.</span></p>", "ID": "6e02c2f2-7f7b-4a3e-8c85-800205ddca5e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "77ac5047-5509-4303-81f1-8fead1eb1ee3"}, {"Element": "<span lang=\"CS\">Roche\n  (Magyarorsz\u00e1g) Kft.</span>", "ID": "31cb689f-cc3a-4181-af1a-855cfd2d80a4", "Styles": "None", "Classes": "None", "Text": "Roche   (Magyarorsz\u00e1g) Kft.", "ParentId": "6e02c2f2-7f7b-4a3e-8c85-800205ddca5e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"CS\">Tel: +36 - 23\n  446 800</span></p>", "ID": "f75faaf6-59c9-4c08-91d6-e967dd345caf", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "77ac5047-5509-4303-81f1-8fead1eb1ee3"}, {"Element": "<span lang=\"CS\">Tel: +36 - 23\n  446 800</span>", "ID": "c4ad5ad4-b2bd-40c6-a117-1d7a323b2634", "Styles": "None", "Classes": "None", "Text": "Tel: +36 - 23   446 800", "ParentId": "f75faaf6-59c9-4c08-91d6-e967dd345caf"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>", "ID": "857a099a-f4a9-4730-b223-af176485abdb", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "77ac5047-5509-4303-81f1-8fead1eb1ee3"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Danmark</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +45 - 36 39 99 99</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(See </span>Ireland<span lang=\"EN-GB\">)</span></p>\n</td>\n</tr>", "ID": "a82d0d0e-ef96-422c-9b43-d70595d6744b", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "2953fa40-15e1-484c-8c5b-89c652676a34"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Danmark</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +45 - 36 39 99 99</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "54b8696b-f57b-4d5e-b72f-bfaa6360c2b0", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "a82d0d0e-ef96-422c-9b43-d70595d6744b"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Danmark</span></b></p>", "ID": "6b781ee2-5ae7-4396-a0fb-807d38af7050", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "54b8696b-f57b-4d5e-b72f-bfaa6360c2b0"}, {"Element": "<b><span lang=\"EN-GB\">Danmark</span></b>", "ID": "7c8acac5-2feb-4d23-88ef-b7b2686c8a39", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6b781ee2-5ae7-4396-a0fb-807d38af7050"}, {"Element": "<span lang=\"EN-GB\">Danmark</span>", "ID": "22d98d77-1032-4612-ab4b-f231a000698e", "Styles": "None", "Classes": "None", "Text": "Danmark", "ParentId": "7c8acac5-2feb-4d23-88ef-b7b2686c8a39"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche a/s</span></p>", "ID": "1c349ed6-e1ee-4e23-bbeb-865b2945a39c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "54b8696b-f57b-4d5e-b72f-bfaa6360c2b0"}, {"Element": "<span lang=\"EN-GB\">Roche a/s</span>", "ID": "31be1b83-4537-458a-a341-92cf1596dbbe", "Styles": "None", "Classes": "None", "Text": "Roche a/s", "ParentId": "1c349ed6-e1ee-4e23-bbeb-865b2945a39c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +45 - 36 39 99 99</span></p>", "ID": "801e3ee2-90a4-4fd8-9a6b-9dc551498bd9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "54b8696b-f57b-4d5e-b72f-bfaa6360c2b0"}, {"Element": "<span lang=\"EN-GB\">Tlf: +45 - 36 39 99 99</span>", "ID": "df6b77fa-8e94-4c5e-a753-5ce20d95f60b", "Styles": "None", "Classes": "None", "Text": "Tlf: +45 - 36 39 99 99", "ParentId": "801e3ee2-90a4-4fd8-9a6b-9dc551498bd9"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "166299c5-c7e9-4b2d-8eeb-bec99c4d496e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "54b8696b-f57b-4d5e-b72f-bfaa6360c2b0"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "1c065369-ad34-4376-a65c-596d9bb39f2a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "166299c5-c7e9-4b2d-8eeb-bec99c4d496e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f2b6e4bf-c8f7-4295-885d-1526fb43c01f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1c065369-ad34-4376-a65c-596d9bb39f2a"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(See </span>Ireland<span lang=\"EN-GB\">)</span></p>\n</td>", "ID": "a5cf20c3-4ec6-47c2-8a53-a4f1431cd6f3", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "a82d0d0e-ef96-422c-9b43-d70595d6744b"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Malta</span></b></p>", "ID": "4c880c1a-82a0-405e-93b5-23e10484e039", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a5cf20c3-4ec6-47c2-8a53-a4f1431cd6f3"}, {"Element": "<b><span lang=\"EN-GB\">Malta</span></b>", "ID": "511bc28a-9c08-4ac1-8c90-4fa6f9960af9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4c880c1a-82a0-405e-93b5-23e10484e039"}, {"Element": "<span lang=\"EN-GB\">Malta</span>", "ID": "4bbce009-780b-489f-8d19-fe7bea1dd54f", "Styles": "None", "Classes": "None", "Text": "Malta", "ParentId": "511bc28a-9c08-4ac1-8c90-4fa6f9960af9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">(See </span>Ireland<span lang=\"EN-GB\">)</span></p>", "ID": "b24e20dd-404c-43aa-800c-1f4e0e538de8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Ireland", "ParentId": "a5cf20c3-4ec6-47c2-8a53-a4f1431cd6f3"}, {"Element": "<span lang=\"EN-GB\">(See </span>", "ID": "07141d20-5974-4172-8db1-6bdae09a834a", "Styles": "None", "Classes": "None", "Text": "(See ", "ParentId": "b24e20dd-404c-43aa-800c-1f4e0e538de8"}, {"Element": "<span lang=\"EN-GB\">)</span>", "ID": "9c4ee566-db50-4bdd-92be-72fe77f0098b", "Styles": "None", "Classes": "None", "Text": ")", "ParentId": "b24e20dd-404c-43aa-800c-1f4e0e538de8"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"NL\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"NL\">Roche Nederland B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +31 (</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">0) 348 438050</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "099378a8-e881-46b9-8266-a36201b0b0cc", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "2953fa40-15e1-484c-8c5b-89c652676a34"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE\">\u00a0</span></b></p>\n</td>", "ID": "017b58a9-5a07-4969-b362-9f1dd8460590", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "099378a8-e881-46b9-8266-a36201b0b0cc"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE\">Deutschland</span></b></p>", "ID": "a7437b4a-16ec-474f-98d3-7b357dc7c436", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "017b58a9-5a07-4969-b362-9f1dd8460590"}, {"Element": "<b><span lang=\"DE\">Deutschland</span></b>", "ID": "956d0e41-a54a-4289-aea8-d3309f7f9432", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a7437b4a-16ec-474f-98d3-7b357dc7c436"}, {"Element": "<span lang=\"DE\">Deutschland</span>", "ID": "e485d350-9c41-4762-ab8e-92a8a7fe1785", "Styles": "None", "Classes": "None", "Text": "Deutschland", "ParentId": "956d0e41-a54a-4289-aea8-d3309f7f9432"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>", "ID": "c0fce62e-470e-49bf-8a53-c198f9489d32", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "017b58a9-5a07-4969-b362-9f1dd8460590"}, {"Element": "<span lang=\"DE-CH\">Roche Pharma AG</span>", "ID": "3ba2b7b6-3694-46b5-bc64-7952a6da23a3", "Styles": "None", "Classes": "None", "Text": "Roche Pharma AG", "ParentId": "c0fce62e-470e-49bf-8a53-c198f9489d32"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span></p>", "ID": "e4ee6470-66d9-40ec-9f73-61e4081df71a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "017b58a9-5a07-4969-b362-9f1dd8460590"}, {"Element": "<span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span>", "ID": "b8bcac77-7cf5-4567-9d91-811099bda617", "Styles": "None", "Classes": "None", "Text": "Tel: +49 (0) 7624 140", "ParentId": "e4ee6470-66d9-40ec-9f73-61e4081df71a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE\">\u00a0</span></b></p>", "ID": "b83406a6-06ce-414d-a138-6896d2cab73a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "017b58a9-5a07-4969-b362-9f1dd8460590"}, {"Element": "<b><span lang=\"DE\">\u00a0</span></b>", "ID": "23b72b34-06dc-4cf0-b0d5-8c32f39bb5dd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b83406a6-06ce-414d-a138-6896d2cab73a"}, {"Element": "<span lang=\"DE\">\u00a0</span>", "ID": "9c2a2585-579d-4813-88eb-cd8204f23f33", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "23b72b34-06dc-4cf0-b0d5-8c32f39bb5dd"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"NL\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"NL\">Roche Nederland B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +31 (</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">0) 348 438050</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "33b70cef-1754-493e-a47f-aa15ce94a76c", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "099378a8-e881-46b9-8266-a36201b0b0cc"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"NL\">Nederland</span></b></p>", "ID": "02ff9790-783b-4e17-89fc-4e3a175be7d5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "33b70cef-1754-493e-a47f-aa15ce94a76c"}, {"Element": "<b><span lang=\"NL\">Nederland</span></b>", "ID": "069f4201-53a2-4db7-a197-7271a601954b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "02ff9790-783b-4e17-89fc-4e3a175be7d5"}, {"Element": "<span lang=\"NL\">Nederland</span>", "ID": "fa059317-4410-430d-87fa-e0d00e137aff", "Styles": "None", "Classes": "None", "Text": "Nederland", "ParentId": "069f4201-53a2-4db7-a197-7271a601954b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"NL\">Roche Nederland B.V.</span></p>", "ID": "3801143c-3f82-4468-bf5e-7e17c6fb8aba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "33b70cef-1754-493e-a47f-aa15ce94a76c"}, {"Element": "<span lang=\"NL\">Roche Nederland B.V.</span>", "ID": "86a695c2-484b-4d90-82e0-8a5907808887", "Styles": "None", "Classes": "None", "Text": "Roche Nederland B.V.", "ParentId": "3801143c-3f82-4468-bf5e-7e17c6fb8aba"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +31 (</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">0) 348 438050</span></p>", "ID": "5ecf8626-587d-45ad-bfad-30da6222f39f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "33b70cef-1754-493e-a47f-aa15ce94a76c"}, {"Element": "<span lang=\"EN-GB\">Tel: +31 (</span>", "ID": "922a6603-6c7f-48c9-ba0a-5064bc66a679", "Styles": "None", "Classes": "None", "Text": "Tel: +31 (", "ParentId": "5ecf8626-587d-45ad-bfad-30da6222f39f"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">0) 348 438050</span>", "ID": "1a09c9d6-9b96-4026-91cd-da9a22248084", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "0) 348 438050", "ParentId": "5ecf8626-587d-45ad-bfad-30da6222f39f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9b8c5e7d-22e4-43e7-a0f8-c404cede11b9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "33b70cef-1754-493e-a47f-aa15ce94a76c"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "192219b1-d822-4b1d-8e95-b299c6fea01a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9b8c5e7d-22e4-43e7-a0f8-c404cede11b9"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Eesti</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">Roche Eesti O\u00dc</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 372 - 6 177 380</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Roche Norge\n  AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Tlf: +47 -\n  22 78 90 00</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>", "ID": "20509970-fa16-4805-a8fe-15269db2b60a", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "2953fa40-15e1-484c-8c5b-89c652676a34"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Eesti</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ET\">Roche Eesti O\u00dc</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 372 - 6 177 380</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "a2ed00ed-6a5e-4685-ac64-179218970a9c", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "20509970-fa16-4805-a8fe-15269db2b60a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">Eesti</span></b></p>", "ID": "e88a2bc4-914a-4148-b2f9-9c95567e6e24", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a2ed00ed-6a5e-4685-ac64-179218970a9c"}, {"Element": "<b><span lang=\"IT\">Eesti</span></b>", "ID": "4d09e568-3206-4d91-9e42-35ed49e1f35a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e88a2bc4-914a-4148-b2f9-9c95567e6e24"}, {"Element": "<span lang=\"IT\">Eesti</span>", "ID": "fc1c86aa-3982-4341-b926-b8d76402aa67", "Styles": "None", "Classes": "None", "Text": "Eesti", "ParentId": "4d09e568-3206-4d91-9e42-35ed49e1f35a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ET\">Roche Eesti O\u00dc</span></p>", "ID": "4a197336-a457-41e6-b964-4fbf76655290", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a2ed00ed-6a5e-4685-ac64-179218970a9c"}, {"Element": "<span lang=\"ET\">Roche Eesti O\u00dc</span>", "ID": "790a2deb-bb25-40da-b418-1e7be74724dc", "Styles": "None", "Classes": "None", "Text": "Roche Eesti O\u00dc", "ParentId": "4a197336-a457-41e6-b964-4fbf76655290"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 372 - 6 177 380</span></p>", "ID": "a9ef075f-f880-4869-8853-9c2442dce6c4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a2ed00ed-6a5e-4685-ac64-179218970a9c"}, {"Element": "<span lang=\"IT\">Tel: + 372 - 6 177 380</span>", "ID": "72a6f74d-8c8a-4d9f-8cc8-487a7f3def07", "Styles": "None", "Classes": "None", "Text": "Tel: + 372 - 6 177 380", "ParentId": "a9ef075f-f880-4869-8853-9c2442dce6c4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>", "ID": "9b231a98-b133-414f-a804-2f4d1c3ead9f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a2ed00ed-6a5e-4685-ac64-179218970a9c"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "ec50358a-9d04-44ad-9120-139eaf921b58", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9b231a98-b133-414f-a804-2f4d1c3ead9f"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Roche Norge\n  AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Tlf: +47 -\n  22 78 90 00</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "8719bfc8-d819-4a87-8316-d27502147c68", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "20509970-fa16-4805-a8fe-15269db2b60a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Norge</span></b></p>", "ID": "3679c3b6-6231-405d-a26a-2285750e6ea6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8719bfc8-d819-4a87-8316-d27502147c68"}, {"Element": "<b><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Norge</span></b>", "ID": "6fee9a5b-11d5-45d2-bc9c-f80e98c73c46", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3679c3b6-6231-405d-a26a-2285750e6ea6"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Norge</span>", "ID": "777619f7-8e96-43c5-88d2-9e64fdbf269c", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Norge", "ParentId": "6fee9a5b-11d5-45d2-bc9c-f80e98c73c46"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Roche Norge\n  AS</span></p>", "ID": "af9e16f3-2c87-4d3f-bcd0-b20e700ff84d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8719bfc8-d819-4a87-8316-d27502147c68"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Roche Norge\n  AS</span>", "ID": "ea55342c-fc17-4d2a-bb2b-fc5edab484bb", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Roche Norge   AS", "ParentId": "af9e16f3-2c87-4d3f-bcd0-b20e700ff84d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Tlf: +47 -\n  22 78 90 00</span></p>", "ID": "7de1c2e5-743b-44ee-a15b-c30f5c027b96", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8719bfc8-d819-4a87-8316-d27502147c68"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Tlf: +47 -\n  22 78 90 00</span>", "ID": "9df0ab3d-bdf5-4e9f-955c-387c0c1de1b3", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Tlf: +47 -   22 78 90 00", "ParentId": "7de1c2e5-743b-44ee-a15b-c30f5c027b96"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "5ae3679e-f59d-4307-b330-31c48f5f437a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "8719bfc8-d819-4a87-8316-d27502147c68"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche (Hellas) A.E. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +30 210 61 66 100</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Austria GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>", "ID": "84939f06-5e8c-4177-85a9-2cc1bdb489f7", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "2953fa40-15e1-484c-8c5b-89c652676a34"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche (Hellas) A.E. </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +30 210 61 66 100</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>", "ID": "1623d764-40e1-4620-9132-313e0153f3f5", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "84939f06-5e8c-4177-85a9-2cc1bdb489f7"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>", "ID": "92779717-aa33-4be2-83d9-793f8c7ffa12", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1623d764-40e1-4620-9132-313e0153f3f5"}, {"Element": "<b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b>", "ID": "e31074f6-a157-47a7-83fb-7c914882de7c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "92779717-aa33-4be2-83d9-793f8c7ffa12"}, {"Element": "<span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span>", "ID": "013ca610-ab25-412c-adca-f1770c841818", "Styles": "None", "Classes": "None", "Text": "\u0395\u03bb\u03bb\u03ac\u03b4\u03b1", "ParentId": "e31074f6-a157-47a7-83fb-7c914882de7c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche (Hellas) A.E. </span></p>", "ID": "f9fbcba5-9c09-4988-91e7-d34b9eaa3e0f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1623d764-40e1-4620-9132-313e0153f3f5"}, {"Element": "<span lang=\"EN-GB\">Roche (Hellas) A.E. </span>", "ID": "380d9ce1-d578-43e3-91f7-118ea64a8f94", "Styles": "None", "Classes": "None", "Text": "Roche (Hellas) A.E. ", "ParentId": "f9fbcba5-9c09-4988-91e7-d34b9eaa3e0f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +30 210 61 66 100</span></p>", "ID": "38e212de-8e09-49d8-8d98-d8fe2e92352f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1623d764-40e1-4620-9132-313e0153f3f5"}, {"Element": "<span lang=\"EN-GB\">\u03a4\u03b7\u03bb: +30 210 61 66 100</span>", "ID": "33d97cfe-2b88-424f-a2ac-faba36f14d76", "Styles": "None", "Classes": "None", "Text": "\u03a4\u03b7\u03bb: +30 210 61 66 100", "ParentId": "38e212de-8e09-49d8-8d98-d8fe2e92352f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>", "ID": "53e5dd40-b065-44ac-ba2e-a8190c255f1e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1623d764-40e1-4620-9132-313e0153f3f5"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "4f3abef5-ae20-4247-9d37-7fc6a367f955", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "53e5dd40-b065-44ac-ba2e-a8190c255f1e"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Austria GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>", "ID": "46432a11-cda4-4c9f-a71f-42c142f11153", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "84939f06-5e8c-4177-85a9-2cc1bdb489f7"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00d6sterreich</span></b></p>", "ID": "01b581ff-55eb-4eff-8f7d-749e8c36b4ce", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "46432a11-cda4-4c9f-a71f-42c142f11153"}, {"Element": "<b><span lang=\"DE-CH\">\u00d6sterreich</span></b>", "ID": "dac09aa2-7990-475f-9fd9-c79df6e2ccd9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "01b581ff-55eb-4eff-8f7d-749e8c36b4ce"}, {"Element": "<span lang=\"DE-CH\">\u00d6sterreich</span>", "ID": "716b9ff0-5c28-4bb2-ab51-14e73b51f826", "Styles": "None", "Classes": "None", "Text": "\u00d6sterreich", "ParentId": "dac09aa2-7990-475f-9fd9-c79df6e2ccd9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Austria GmbH</span></p>", "ID": "14860939-3c17-4ddd-8b94-8e2b3a691e87", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "46432a11-cda4-4c9f-a71f-42c142f11153"}, {"Element": "<span lang=\"DE-CH\">Roche Austria GmbH</span>", "ID": "d100defc-e855-42fb-a2e2-722eacb228d3", "Styles": "None", "Classes": "None", "Text": "Roche Austria GmbH", "ParentId": "14860939-3c17-4ddd-8b94-8e2b3a691e87"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span></p>", "ID": "7ebe7b16-5493-4fe4-944f-5556d7c87b13", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "46432a11-cda4-4c9f-a71f-42c142f11153"}, {"Element": "<span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span>", "ID": "9c6e0d87-46d7-407b-8aa9-25e278d5862c", "Styles": "None", "Classes": "None", "Text": "Tel: +43 (0) 1 27739", "ParentId": "7ebe7b16-5493-4fe4-944f-5556d7c87b13"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>", "ID": "75388016-94ea-4eac-b23f-e9608ad462fb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "46432a11-cda4-4c9f-a71f-42c142f11153"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "29e6dc6c-aa5a-41b8-aeea-a6675fde25ac", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "75388016-94ea-4eac-b23f-e9608ad462fb"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Roche Farma S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +34 - 91 324 81 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PL\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PL\">Roche Polska Sp.z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +48 - 22 345 18 88</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "28127e9b-a0c8-41be-882c-114354fb99c7", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "2953fa40-15e1-484c-8c5b-89c652676a34"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Roche Farma S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +34 - 91 324 81 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "8f097f5b-4c58-4350-873f-eb31e076bf91", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "28127e9b-a0c8-41be-882c-114354fb99c7"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>", "ID": "3eb65282-c2c3-4e1c-ad6b-1692a2cdc13c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8f097f5b-4c58-4350-873f-eb31e076bf91"}, {"Element": "<b><span lang=\"ES\">Espa\u00f1a</span></b>", "ID": "04464296-d454-4f00-8e6f-96afad9cb7c2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3eb65282-c2c3-4e1c-ad6b-1692a2cdc13c"}, {"Element": "<span lang=\"ES\">Espa\u00f1a</span>", "ID": "c930083c-cf85-4225-9ee7-1d3c84484553", "Styles": "None", "Classes": "None", "Text": "Espa\u00f1a", "ParentId": "04464296-d454-4f00-8e6f-96afad9cb7c2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ES\">Roche Farma S.A.</span></p>", "ID": "d8a0b95e-9fa1-496a-b05a-70177c9e0fbd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8f097f5b-4c58-4350-873f-eb31e076bf91"}, {"Element": "<span lang=\"ES\">Roche Farma S.A.</span>", "ID": "a368633f-eb0a-44ab-9663-a05636380d0f", "Styles": "None", "Classes": "None", "Text": "Roche Farma S.A.", "ParentId": "d8a0b95e-9fa1-496a-b05a-70177c9e0fbd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +34 - 91 324 81 00</span></p>", "ID": "143268c4-b892-4c38-98e6-256ae9f4563d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8f097f5b-4c58-4350-873f-eb31e076bf91"}, {"Element": "<span lang=\"EN-GB\">Tel: +34 - 91 324 81 00</span>", "ID": "a2a04c49-6407-424f-9705-1fc1761c48c8", "Styles": "None", "Classes": "None", "Text": "Tel: +34 - 91 324 81 00", "ParentId": "143268c4-b892-4c38-98e6-256ae9f4563d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "41b922e6-f7e8-4ed6-886b-1b6a362a50a5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8f097f5b-4c58-4350-873f-eb31e076bf91"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "200fba45-e5cd-4b24-90ab-2d6257875d46", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "41b922e6-f7e8-4ed6-886b-1b6a362a50a5"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PL\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PL\">Roche Polska Sp.z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +48 - 22 345 18 88</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">\u00a0</span></p>\n</td>", "ID": "60ed6703-e997-44ed-8574-3557fe5adf36", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "28127e9b-a0c8-41be-882c-114354fb99c7"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"PL\">Polska</span></b></p>", "ID": "d896ea74-0ce1-4412-b5f8-ba1dd490d246", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "60ed6703-e997-44ed-8574-3557fe5adf36"}, {"Element": "<b><span lang=\"PL\">Polska</span></b>", "ID": "4c7a07e0-c9f4-4219-a8bc-09c44e16bb52", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d896ea74-0ce1-4412-b5f8-ba1dd490d246"}, {"Element": "<span lang=\"PL\">Polska</span>", "ID": "8595643a-a72a-4595-8e58-702b0eae5d01", "Styles": "None", "Classes": "None", "Text": "Polska", "ParentId": "4c7a07e0-c9f4-4219-a8bc-09c44e16bb52"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PL\">Roche Polska Sp.z o.o.</span></p>", "ID": "9c486023-e98b-4669-96d8-9592f42eecb1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "60ed6703-e997-44ed-8574-3557fe5adf36"}, {"Element": "<span lang=\"PL\">Roche Polska Sp.z o.o.</span>", "ID": "3819665e-ce39-41d8-9a4e-244bcf21401e", "Styles": "None", "Classes": "None", "Text": "Roche Polska Sp.z o.o.", "ParentId": "9c486023-e98b-4669-96d8-9592f42eecb1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +48 - 22 345 18 88</span></p>", "ID": "e104529a-23c1-4985-aef4-cc977bea615a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "60ed6703-e997-44ed-8574-3557fe5adf36"}, {"Element": "<span lang=\"EN-GB\">Tel: +48 - 22 345 18 88</span>", "ID": "27ea08e8-97be-44c7-b749-0bec65fd5995", "Styles": "None", "Classes": "None", "Text": "Tel: +48 - 22 345 18 88", "ParentId": "e104529a-23c1-4985-aef4-cc977bea615a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\">\u00a0</span></p>", "ID": "fba1a436-d797-47fe-abc4-ff359a3c3ef9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "60ed6703-e997-44ed-8574-3557fe5adf36"}, {"Element": "<span lang=\"PT\">\u00a0</span>", "ID": "58e294ab-eaa4-48bf-8d66-007cca817b84", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fba1a436-d797-47fe-abc4-ff359a3c3ef9"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">France</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">Roche</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">T\u00e9l: +33 (0) 1 47 61 40 00</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT\">Portugal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">Roche Farmac\u00eautica Qu\u00edmica, Lda</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">Tel: +351 - 21 425 70 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "edff8d34-d378-4ab8-8390-f96beeae64db", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "2953fa40-15e1-484c-8c5b-89c652676a34"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">France</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">Roche</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">T\u00e9l: +33 (0) 1 47 61 40 00</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>", "ID": "d8d6925b-ff06-455f-945a-2cee23436e6f", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "edff8d34-d378-4ab8-8390-f96beeae64db"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">France</span></b></p>", "ID": "457101f6-9d11-4bb6-95a5-8d2235852996", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d8d6925b-ff06-455f-945a-2cee23436e6f"}, {"Element": "<b><span lang=\"FR-CH\">France</span></b>", "ID": "f08dd1cc-6cdb-4791-8a36-3edb155222a6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "457101f6-9d11-4bb6-95a5-8d2235852996"}, {"Element": "<span lang=\"FR-CH\">France</span>", "ID": "c27134ca-d1e2-460e-a37c-21f1cf3c06b0", "Styles": "None", "Classes": "None", "Text": "France", "ParentId": "f08dd1cc-6cdb-4791-8a36-3edb155222a6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FR-CH\">Roche</span></p>", "ID": "6beb60a0-e4c1-4833-a00e-258847c86203", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d8d6925b-ff06-455f-945a-2cee23436e6f"}, {"Element": "<span lang=\"FR-CH\">Roche</span>", "ID": "0cd74cf8-080d-4f68-b3f4-05244fd9ff41", "Styles": "None", "Classes": "None", "Text": "Roche", "ParentId": "6beb60a0-e4c1-4833-a00e-258847c86203"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FR-CH\">T\u00e9l: +33 (0) 1 47 61 40 00</span></p>", "ID": "b75822f6-a804-4026-b04c-38d5505a0356", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d8d6925b-ff06-455f-945a-2cee23436e6f"}, {"Element": "<span lang=\"FR-CH\">T\u00e9l: +33 (0) 1 47 61 40 00</span>", "ID": "60a870b5-a731-42e6-a34e-d3f48472bcc6", "Styles": "None", "Classes": "None", "Text": "T\u00e9l: +33 (0) 1 47 61 40 00", "ParentId": "b75822f6-a804-4026-b04c-38d5505a0356"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>", "ID": "6b9334d4-8474-4ea4-b07e-db85716501fb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d8d6925b-ff06-455f-945a-2cee23436e6f"}, {"Element": "<b><span lang=\"DE-CH\">\u00a0</span></b>", "ID": "9be2673e-df8f-470b-b779-d662fdb26a1c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6b9334d4-8474-4ea4-b07e-db85716501fb"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "867e6b85-6cd8-4178-90ff-ea00a1386149", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9be2673e-df8f-470b-b779-d662fdb26a1c"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT\">Portugal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">Roche Farmac\u00eautica Qu\u00edmica, Lda</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">Tel: +351 - 21 425 70 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "b013ee87-a49f-4a59-8735-e2eea7fedf8c", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "edff8d34-d378-4ab8-8390-f96beeae64db"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"PT\">Portugal</span></b></p>", "ID": "d1373dee-d32a-4c79-aa72-10edb6117e48", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b013ee87-a49f-4a59-8735-e2eea7fedf8c"}, {"Element": "<b><span lang=\"PT\">Portugal</span></b>", "ID": "74037cf1-b39e-4840-99da-e1d79fe49233", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d1373dee-d32a-4c79-aa72-10edb6117e48"}, {"Element": "<span lang=\"PT\">Portugal</span>", "ID": "fe0b86f5-4c09-4845-9629-418a8f4085b7", "Styles": "None", "Classes": "None", "Text": "Portugal", "ParentId": "74037cf1-b39e-4840-99da-e1d79fe49233"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\">Roche Farmac\u00eautica Qu\u00edmica, Lda</span></p>", "ID": "a273cb13-8e1f-4921-a0ca-7bb82ba8395d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b013ee87-a49f-4a59-8735-e2eea7fedf8c"}, {"Element": "<span lang=\"PT\">Roche Farmac\u00eautica Qu\u00edmica, Lda</span>", "ID": "efc908d3-1e72-40c6-a6d7-e2824c959439", "Styles": "None", "Classes": "None", "Text": "Roche Farmac\u00eautica Qu\u00edmica, Lda", "ParentId": "a273cb13-8e1f-4921-a0ca-7bb82ba8395d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\">Tel: +351 - 21 425 70 00</span></p>", "ID": "7cf29107-4940-4f88-b49f-4f14097cbe77", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b013ee87-a49f-4a59-8735-e2eea7fedf8c"}, {"Element": "<span lang=\"PT\">Tel: +351 - 21 425 70 00</span>", "ID": "09ecfbd2-fcf1-4b4a-be0b-a69ea7536b7d", "Styles": "None", "Classes": "None", "Text": "Tel: +351 - 21 425 70 00", "ParentId": "7cf29107-4940-4f88-b49f-4f14097cbe77"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>", "ID": "91457ee5-88d2-41fb-af30-3b076baeb6d8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b013ee87-a49f-4a59-8735-e2eea7fedf8c"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "0d797c6f-487f-43a7-ace4-90f2bcc13241", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "91457ee5-88d2-41fb-af30-3b076baeb6d8"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 385 1 47 22 333</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">Roche Rom\u00e2nia S.R.L.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +40 21 206 47 01</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "5425c399-5f64-46b9-a753-910376157b9a", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "2953fa40-15e1-484c-8c5b-89c652676a34"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 385 1 47 22 333</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "9068907b-08de-4b86-890c-56af1c5468f1", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "5425c399-5f64-46b9-a753-910376157b9a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">Hrvatska</span></b></p>", "ID": "ea803d47-7721-4cb0-9cfb-867257226c96", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9068907b-08de-4b86-890c-56af1c5468f1"}, {"Element": "<b><span lang=\"IT\">Hrvatska</span></b>", "ID": "ac442baf-d0d2-4287-91b4-720142a7d8ed", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ea803d47-7721-4cb0-9cfb-867257226c96"}, {"Element": "<span lang=\"IT\">Hrvatska</span>", "ID": "e3340f12-df48-4513-962d-345f9e281160", "Styles": "None", "Classes": "None", "Text": "Hrvatska", "ParentId": "ac442baf-d0d2-4287-91b4-720142a7d8ed"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Roche d.o.o.</span></p>", "ID": "99f87872-f062-48e9-b4dd-aa4668366808", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9068907b-08de-4b86-890c-56af1c5468f1"}, {"Element": "<span lang=\"IT\">Roche d.o.o.</span>", "ID": "a4edfb87-b8f4-4243-9bce-8659fc75d022", "Styles": "None", "Classes": "None", "Text": "Roche d.o.o.", "ParentId": "99f87872-f062-48e9-b4dd-aa4668366808"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 385 1 47 22 333</span></p>", "ID": "481e006c-02c8-4449-92ec-8c36bc4d6686", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9068907b-08de-4b86-890c-56af1c5468f1"}, {"Element": "<span lang=\"IT\">Tel: + 385 1 47 22 333</span>", "ID": "3fb18085-5aab-4de1-922c-6a572425beb3", "Styles": "None", "Classes": "None", "Text": "Tel: + 385 1 47 22 333", "ParentId": "481e006c-02c8-4449-92ec-8c36bc4d6686"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "1888800b-92d2-4f52-b6ac-91a5115bf830", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9068907b-08de-4b86-890c-56af1c5468f1"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "88a5987c-61aa-45f6-8086-e13533a21d42", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1888800b-92d2-4f52-b6ac-91a5115bf830"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4be137ab-ce78-4c6c-94d4-b1560d011edd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "88a5987c-61aa-45f6-8086-e13533a21d42"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">Roche Rom\u00e2nia S.R.L.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +40 21 206 47 01</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "08eeb054-6e2a-4196-b314-78162dc52a55", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "5425c399-5f64-46b9-a753-910376157b9a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">Rom\u00e2nia</span></b></p>", "ID": "590af8c4-c674-4f5d-9c01-af85d0353873", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "08eeb054-6e2a-4196-b314-78162dc52a55"}, {"Element": "<b><span lang=\"FR-CH\">Rom\u00e2nia</span></b>", "ID": "6bac83e4-7500-4030-b83e-71c5e5e3d4b4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "590af8c4-c674-4f5d-9c01-af85d0353873"}, {"Element": "<span lang=\"FR-CH\">Rom\u00e2nia</span>", "ID": "61d08d6a-ff3a-48c5-9e88-e1562fc430bc", "Styles": "None", "Classes": "None", "Text": "Rom\u00e2nia", "ParentId": "6bac83e4-7500-4030-b83e-71c5e5e3d4b4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FR-CH\">Roche Rom\u00e2nia S.R.L.</span></p>", "ID": "50c845ca-b933-4338-b547-d5239e6fa5d1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "08eeb054-6e2a-4196-b314-78162dc52a55"}, {"Element": "<span lang=\"FR-CH\">Roche Rom\u00e2nia S.R.L.</span>", "ID": "d86668cd-40e0-4a3a-b058-87d34bbd6f17", "Styles": "None", "Classes": "None", "Text": "Roche Rom\u00e2nia S.R.L.", "ParentId": "50c845ca-b933-4338-b547-d5239e6fa5d1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +40 21 206 47 01</span></p>", "ID": "6d1b4a6a-d1eb-421e-9ab9-9e0bc1045376", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "08eeb054-6e2a-4196-b314-78162dc52a55"}, {"Element": "<span lang=\"EN-GB\">Tel: +40 21 206 47 01</span>", "ID": "b5011a07-dd0f-415c-9521-1751b9ac13dc", "Styles": "None", "Classes": "None", "Text": "Tel: +40 21 206 47 01", "ParentId": "6d1b4a6a-d1eb-421e-9ab9-9e0bc1045376"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "e605090c-989d-46a4-92d5-d62786e96d42", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "08eeb054-6e2a-4196-b314-78162dc52a55"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "f12fe1f1-e0b1-4724-bf9b-b99d194f5618", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e605090c-989d-46a4-92d5-d62786e96d42"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "997c627f-d8a8-4411-abdd-9eb156cd1a06", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f12fe1f1-e0b1-4724-bf9b-b99d194f5618"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products (Ireland) Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +353 (0) 1 469 0700</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche farmacevtska dru\u017eba d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +386 - 1 360 26 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>\n</tr>", "ID": "59362d16-ae70-4fb3-befa-8ae0a8f24406", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "2953fa40-15e1-484c-8c5b-89c652676a34"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products (Ireland) Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +353 (0) 1 469 0700</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "11360ae5-027d-4ded-bc81-5da5af88ca61", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "59362d16-ae70-4fb3-befa-8ae0a8f24406"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>", "ID": "f0160c36-991d-40e7-81f3-1b7992f7df62", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "11360ae5-027d-4ded-bc81-5da5af88ca61"}, {"Element": "<b><span lang=\"EN-GB\">Ireland</span></b>", "ID": "18e1f0cd-7a5f-46cb-8a26-882252449d58", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f0160c36-991d-40e7-81f3-1b7992f7df62"}, {"Element": "<span lang=\"EN-GB\">Ireland</span>", "ID": "9638add1-dccb-469b-a137-7dca6fb453da", "Styles": "None", "Classes": "None", "Text": "Ireland", "ParentId": "18e1f0cd-7a5f-46cb-8a26-882252449d58"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products (Ireland) Ltd.</span></p>", "ID": "15ebbddc-32cb-4d53-8137-a9d15a0a2723", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "11360ae5-027d-4ded-bc81-5da5af88ca61"}, {"Element": "<span lang=\"EN-GB\">Roche Products (Ireland) Ltd.</span>", "ID": "4b0508dd-3b71-4aba-be50-4fa492c57b51", "Styles": "None", "Classes": "None", "Text": "Roche Products (Ireland) Ltd.", "ParentId": "15ebbddc-32cb-4d53-8137-a9d15a0a2723"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +353 (0) 1 469 0700</span></p>", "ID": "6eb461ec-36f5-401e-b72b-4ec462124cad", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "11360ae5-027d-4ded-bc81-5da5af88ca61"}, {"Element": "<span lang=\"EN-GB\">Tel: +353 (0) 1 469 0700</span>", "ID": "4c10b2a3-4d5b-48e4-a5e4-1339ed30d854", "Styles": "None", "Classes": "None", "Text": "Tel: +353 (0) 1 469 0700", "ParentId": "6eb461ec-36f5-401e-b72b-4ec462124cad"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bb5f71cf-721d-4f3e-b8c0-2d567c63ff07", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "11360ae5-027d-4ded-bc81-5da5af88ca61"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dd84dea3-6d2a-4aa2-8d98-c321ea4cec21", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bb5f71cf-721d-4f3e-b8c0-2d567c63ff07"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche farmacevtska dru\u017eba d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +386 - 1 360 26 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>\n</td>", "ID": "6d240802-8806-4c24-b2d6-f80905b3ce07", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "59362d16-ae70-4fb3-befa-8ae0a8f24406"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>", "ID": "3928c996-5b5b-4d07-9a94-e3c4411f7c77", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6d240802-8806-4c24-b2d6-f80905b3ce07"}, {"Element": "<b><span lang=\"EN-GB\">Slovenija</span></b>", "ID": "70adb006-9ab9-40ed-9b91-bffb9410a358", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3928c996-5b5b-4d07-9a94-e3c4411f7c77"}, {"Element": "<span lang=\"EN-GB\">Slovenija</span>", "ID": "5452345a-6fdd-4e75-9eea-71e21a091733", "Styles": "None", "Classes": "None", "Text": "Slovenija", "ParentId": "70adb006-9ab9-40ed-9b91-bffb9410a358"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche farmacevtska dru\u017eba d.o.o.</span></p>", "ID": "90977d80-326e-4931-825e-ebb23f3d2a9b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6d240802-8806-4c24-b2d6-f80905b3ce07"}, {"Element": "<span lang=\"EN-GB\">Roche farmacevtska dru\u017eba d.o.o.</span>", "ID": "dc30488e-42de-4deb-8037-e71013a807a5", "Styles": "None", "Classes": "None", "Text": "Roche farmacevtska dru\u017eba d.o.o.", "ParentId": "90977d80-326e-4931-825e-ebb23f3d2a9b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +386 - 1 360 26 00</span></p>", "ID": "5e800bd0-a789-4b98-99c6-3406848fa81f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6d240802-8806-4c24-b2d6-f80905b3ce07"}, {"Element": "<span lang=\"IT\">Tel: +386 - 1 360 26 00</span>", "ID": "5cbc7d7b-220e-475f-b659-eef7d8cbaab1", "Styles": "None", "Classes": "None", "Text": "Tel: +386 - 1 360 26 00", "ParentId": "5e800bd0-a789-4b98-99c6-3406848fa81f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">\u00a0</span></p>", "ID": "acfb2f17-7042-4350-b7a0-7e0e748383cd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6d240802-8806-4c24-b2d6-f80905b3ce07"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "fe5ac4f8-e7bf-4f5e-8434-415782194835", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "acfb2f17-7042-4350-b7a0-7e0e748383cd"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">\u00cdsland\n  </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">c/o Icepharma hf</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">S</span><span lang=\"CS\">\u00ed</span><span lang=\"PT-BR\">mi</span><span lang=\"PT\" style=\"layout-grid-mode:line\">: +354 540\n  8000</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"PT\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT\">Slovensk\u00e1 republika </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SK\">Roche Slovensko, s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">Tel: +421 - 2 52638201</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"PT\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "96c008ae-bc63-4190-b94a-2a876fbe7d16", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "2953fa40-15e1-484c-8c5b-89c652676a34"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">\u00cdsland\n  </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">c/o Icepharma hf</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">S</span><span lang=\"CS\">\u00ed</span><span lang=\"PT-BR\">mi</span><span lang=\"PT\" style=\"layout-grid-mode:line\">: +354 540\n  8000</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"PT\">\u00a0</span></b></p>\n</td>", "ID": "9b8b6d2c-6314-4e21-8f9c-5f6b725da5ad", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "96c008ae-bc63-4190-b94a-2a876fbe7d16"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">\u00cdsland\n  </span></b></p>", "ID": "6db7f2ef-0ed0-4627-abb8-22abed29ced2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9b8b6d2c-6314-4e21-8f9c-5f6b725da5ad"}, {"Element": "<b><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">\u00cdsland\n  </span></b>", "ID": "7b22c5f4-fba4-4faa-9d9a-0af42aaf8414", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6db7f2ef-0ed0-4627-abb8-22abed29ced2"}, {"Element": "<span lang=\"PT-BR\" style=\"layout-grid-mode:line\">\u00cdsland\n  </span>", "ID": "8b1710b7-5a87-487a-ad3e-ba170dc76868", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00cdsland   ", "ParentId": "7b22c5f4-fba4-4faa-9d9a-0af42aaf8414"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">Roche a/s</span></p>", "ID": "b4274acd-640d-4e3b-9ed0-549a2cc4e86f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9b8b6d2c-6314-4e21-8f9c-5f6b725da5ad"}, {"Element": "<span lang=\"PT-BR\" style=\"layout-grid-mode:line\">Roche a/s</span>", "ID": "05238b3d-5b69-4108-b211-b8a774b711f7", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Roche a/s", "ParentId": "b4274acd-640d-4e3b-9ed0-549a2cc4e86f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\">c/o Icepharma hf</span></p>", "ID": "5a9865d1-28f1-438f-aa26-0bf37a41bf6b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9b8b6d2c-6314-4e21-8f9c-5f6b725da5ad"}, {"Element": "<span lang=\"PT\">c/o Icepharma hf</span>", "ID": "54b1a650-30b9-449a-989c-ca4b2330f355", "Styles": "None", "Classes": "None", "Text": "c/o Icepharma hf", "ParentId": "5a9865d1-28f1-438f-aa26-0bf37a41bf6b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT-BR\">S</span><span lang=\"CS\">\u00ed</span><span lang=\"PT-BR\">mi</span><span lang=\"PT\" style=\"layout-grid-mode:line\">: +354 540\n  8000</span></p>", "ID": "d574b2aa-0a9d-46cf-a70f-f69ec1537971", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9b8b6d2c-6314-4e21-8f9c-5f6b725da5ad"}, {"Element": "<span lang=\"PT-BR\">S</span>", "ID": "1038c081-4248-4960-a515-5bd3c9028841", "Styles": "None", "Classes": "None", "Text": "S", "ParentId": "d574b2aa-0a9d-46cf-a70f-f69ec1537971"}, {"Element": "<span lang=\"CS\">\u00ed</span>", "ID": "4e6ab656-a0c9-4be6-99ba-27314d48dd23", "Styles": "None", "Classes": "None", "Text": "\u00ed", "ParentId": "d574b2aa-0a9d-46cf-a70f-f69ec1537971"}, {"Element": "<span lang=\"PT-BR\">mi</span>", "ID": "1368046a-fe65-41c1-b85c-843960674e22", "Styles": "None", "Classes": "None", "Text": "mi", "ParentId": "d574b2aa-0a9d-46cf-a70f-f69ec1537971"}, {"Element": "<span lang=\"PT\" style=\"layout-grid-mode:line\">: +354 540\n  8000</span>", "ID": "01967218-b8c9-415d-b263-4d473b1fe0b1", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": ": +354 540   8000", "ParentId": "d574b2aa-0a9d-46cf-a70f-f69ec1537971"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"PT\">\u00a0</span></b></p>", "ID": "a9da318a-4c66-4a48-a197-5b2f310a3f04", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9b8b6d2c-6314-4e21-8f9c-5f6b725da5ad"}, {"Element": "<b><span lang=\"PT\">\u00a0</span></b>", "ID": "60f7f746-d715-4bf6-ac0b-7e3116c3d8a1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a9da318a-4c66-4a48-a197-5b2f310a3f04"}, {"Element": "<span lang=\"PT\">\u00a0</span>", "ID": "19d58d92-c2c1-4e0c-9a1a-6d7b14a6c980", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "60f7f746-d715-4bf6-ac0b-7e3116c3d8a1"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT\">Slovensk\u00e1 republika </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"SK\">Roche Slovensko, s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT\">Tel: +421 - 2 52638201</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"PT\">\u00a0</span></b></p>\n</td>", "ID": "3ad8b280-16ad-42f2-a9d5-44897995aa30", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "96c008ae-bc63-4190-b94a-2a876fbe7d16"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"PT\">Slovensk\u00e1 republika </span></b></p>", "ID": "4e8ce6af-eadc-4949-bba7-6869d2a3100b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3ad8b280-16ad-42f2-a9d5-44897995aa30"}, {"Element": "<b><span lang=\"PT\">Slovensk\u00e1 republika </span></b>", "ID": "7230b1d3-c00e-42da-88cf-94801842133b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4e8ce6af-eadc-4949-bba7-6869d2a3100b"}, {"Element": "<span lang=\"PT\">Slovensk\u00e1 republika </span>", "ID": "dccb9b68-9177-4b14-a8eb-30b89ceb23e9", "Styles": "None", "Classes": "None", "Text": "Slovensk\u00e1 republika ", "ParentId": "7230b1d3-c00e-42da-88cf-94801842133b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"SK\">Roche Slovensko, s.r.o.</span></p>", "ID": "481a5f92-dc58-4598-85a3-c030a8d78341", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3ad8b280-16ad-42f2-a9d5-44897995aa30"}, {"Element": "<span lang=\"SK\">Roche Slovensko, s.r.o.</span>", "ID": "5dd43aff-8836-4a79-a36e-12b94c46d5c5", "Styles": "None", "Classes": "None", "Text": "Roche Slovensko, s.r.o.", "ParentId": "481a5f92-dc58-4598-85a3-c030a8d78341"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\">Tel: +421 - 2 52638201</span></p>", "ID": "277de019-b5d3-465d-8998-067f273c4fd7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3ad8b280-16ad-42f2-a9d5-44897995aa30"}, {"Element": "<span lang=\"PT\">Tel: +421 - 2 52638201</span>", "ID": "ac74d25a-ff63-47a7-afd5-be0e379ee5a7", "Styles": "None", "Classes": "None", "Text": "Tel: +421 - 2 52638201", "ParentId": "277de019-b5d3-465d-8998-067f273c4fd7"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"PT\">\u00a0</span></b></p>", "ID": "29c8e9dd-0650-4b6a-a677-ed7ed73023fe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3ad8b280-16ad-42f2-a9d5-44897995aa30"}, {"Element": "<b><span lang=\"PT\">\u00a0</span></b>", "ID": "9fad5252-f782-4fac-9ce3-488384c58879", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "29c8e9dd-0650-4b6a-a677-ed7ed73023fe"}, {"Element": "<span lang=\"PT\">\u00a0</span>", "ID": "d5edf7ca-030b-4cc9-8015-21120155387e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9fad5252-f782-4fac-9ce3-488384c58879"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche S.p.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +39 - 039 2471</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>", "ID": "55b27c41-acee-4b08-b9c3-10bd6f6b218a", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "2953fa40-15e1-484c-8c5b-89c652676a34"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche S.p.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +39 - 039 2471</span></p>\n</td>", "ID": "111f7cc9-d4c2-4cbe-9d78-3d035cf165b2", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "55b27c41-acee-4b08-b9c3-10bd6f6b218a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>", "ID": "4989ee5e-a90d-4455-8de1-6bfe416672d4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "111f7cc9-d4c2-4cbe-9d78-3d035cf165b2"}, {"Element": "<b><span lang=\"IT\">Italia</span></b>", "ID": "89da221b-b6a0-46d2-86cb-3feb11892acc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4989ee5e-a90d-4455-8de1-6bfe416672d4"}, {"Element": "<span lang=\"IT\">Italia</span>", "ID": "ea1c52a3-8a89-4ac4-b9cf-e50b7bf048b9", "Styles": "None", "Classes": "None", "Text": "Italia", "ParentId": "89da221b-b6a0-46d2-86cb-3feb11892acc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Roche S.p.A.</span></p>", "ID": "d8893cea-4cf8-49fd-ab3b-febf14c80018", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "111f7cc9-d4c2-4cbe-9d78-3d035cf165b2"}, {"Element": "<span lang=\"IT\">Roche S.p.A.</span>", "ID": "547c8cbf-37a8-41c5-85c8-21721bd23a31", "Styles": "None", "Classes": "None", "Text": "Roche S.p.A.", "ParentId": "d8893cea-4cf8-49fd-ab3b-febf14c80018"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +39 - 039 2471</span></p>", "ID": "a5d52ccf-88d6-47e1-9700-1edb05cea85f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "111f7cc9-d4c2-4cbe-9d78-3d035cf165b2"}, {"Element": "<span lang=\"DE-CH\">Tel: +39 - 039 2471</span>", "ID": "5be0e8fc-03f1-4c27-8191-0f07cd07944b", "Styles": "None", "Classes": "None", "Text": "Tel: +39 - 039 2471", "ParentId": "a5d52ccf-88d6-47e1-9700-1edb05cea85f"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>", "ID": "74e510c4-7df6-44d7-a000-6eee4dbf32e7", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "55b27c41-acee-4b08-b9c3-10bd6f6b218a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Suomi/Finland</span></b></p>", "ID": "1b6d0ab9-3f8e-4e00-9744-2601da0ce34a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "74e510c4-7df6-44d7-a000-6eee4dbf32e7"}, {"Element": "<b><span lang=\"DE-CH\">Suomi/Finland</span></b>", "ID": "b0209571-99cd-48e4-b7a6-94512a05e406", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1b6d0ab9-3f8e-4e00-9744-2601da0ce34a"}, {"Element": "<span lang=\"DE-CH\">Suomi/Finland</span>", "ID": "6890c613-c2fa-4ba8-9e67-a49052425858", "Styles": "None", "Classes": "None", "Text": "Suomi/Finland", "ParentId": "b0209571-99cd-48e4-b7a6-94512a05e406"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span></p>", "ID": "060977bb-a660-4be4-a07e-f558dfaa988c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "74e510c4-7df6-44d7-a000-6eee4dbf32e7"}, {"Element": "<span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span>", "ID": "4276608f-573e-4966-987b-50f5c0222b52", "Styles": "None", "Classes": "None", "Text": "Roche Oy", "ParentId": "060977bb-a660-4be4-a07e-f558dfaa988c"}, {"Element": "<span style=\"layout-grid-mode:\n  line\"> </span>", "ID": "f962ecda-aeb5-4caf-a674-75d4309d82b7", "Styles": "layout-grid-mode:\n  line", "Classes": "None", "Text": " ", "ParentId": "4276608f-573e-4966-987b-50f5c0222b52"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span></p>", "ID": "f2aa00b9-c389-4b45-8e08-4edcdda707dd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "74e510c4-7df6-44d7-a000-6eee4dbf32e7"}, {"Element": "<span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span>", "ID": "e8b78abe-b216-4fdc-8ef9-f9b0ba71a4c2", "Styles": "None", "Classes": "None", "Text": "Puh/Tel: +358 (0) 10 554 500", "ParentId": "f2aa00b9-c389-4b45-8e08-4edcdda707dd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>", "ID": "adc8fdf3-bc9e-45fa-8e27-dde2f31c2b79", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "74e510c4-7df6-44d7-a000-6eee4dbf32e7"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "5fae18b4-0b35-4171-a437-72084b86c10e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "adc8fdf3-bc9e-45fa-8e27-dde2f31c2b79"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">K</span></b><b><span lang=\"EL\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b><span lang=\"EL\" style='font-size:10.0pt;font-family:\"Arial\",sans-serif'> </span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u0393.\u0391.\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2\n  &amp; \u03a3\u03b9\u03b1 \u039b\u03c4\u03b4.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb</span>: +357 - 22 76 62\n  76</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Sverige</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche AB</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +46 (0) 8 726 1200</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>", "ID": "e6a7d563-4e90-427d-aa3f-a5404402534e", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "2953fa40-15e1-484c-8c5b-89c652676a34"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">K</span></b><b><span lang=\"EL\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b><span lang=\"EL\" style='font-size:10.0pt;font-family:\"Arial\",sans-serif'> </span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u0393.\u0391.\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2\n  &amp; \u03a3\u03b9\u03b1 \u039b\u03c4\u03b4.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb</span>: +357 - 22 76 62\n  76</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "a09b4e66-c9b0-4d44-a455-0e5c4f94641b", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "e6a7d563-4e90-427d-aa3f-a5404402534e"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">K</span></b><b><span lang=\"EL\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b><span lang=\"EL\" style='font-size:10.0pt;font-family:\"Arial\",sans-serif'> </span></p>", "ID": "029c64a0-be0a-4003-be75-e7cbcf002332", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a09b4e66-c9b0-4d44-a455-0e5c4f94641b"}, {"Element": "<b><span lang=\"DE-CH\">K</span></b>", "ID": "bd8d5843-efe0-4fd0-91a2-4afda35cec24", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "029c64a0-be0a-4003-be75-e7cbcf002332"}, {"Element": "<span lang=\"DE-CH\">K</span>", "ID": "adcb118c-30eb-4aec-afb7-353161637d68", "Styles": "None", "Classes": "None", "Text": "K", "ParentId": "bd8d5843-efe0-4fd0-91a2-4afda35cec24"}, {"Element": "<b><span lang=\"EL\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b>", "ID": "5d91a648-263b-49f3-a758-eb19331c03c9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "029c64a0-be0a-4003-be75-e7cbcf002332"}, {"Element": "<span lang=\"EL\">\u03cd\u03c0\u03c1\u03bf\u03c2</span>", "ID": "1a92a5b1-35ba-4ffb-8150-47957b6491c7", "Styles": "None", "Classes": "None", "Text": "\u03cd\u03c0\u03c1\u03bf\u03c2", "ParentId": "5d91a648-263b-49f3-a758-eb19331c03c9"}, {"Element": "<span lang=\"EL\" style='font-size:10.0pt;font-family:\"Arial\",sans-serif'> </span>", "ID": "8d0fcd70-c886-4442-8634-7fbeeb098705", "Styles": "font-size:10.0pt;font-family:\"Arial\",sans-serif", "Classes": "None", "Text": " ", "ParentId": "029c64a0-be0a-4003-be75-e7cbcf002332"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EL\">\u0393.\u0391.\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2\n  &amp; \u03a3\u03b9\u03b1 \u039b\u03c4\u03b4.</span></p>", "ID": "81708057-cf1a-400f-8a7f-40ba58505b96", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a09b4e66-c9b0-4d44-a455-0e5c4f94641b"}, {"Element": "<span lang=\"EL\">\u0393.\u0391.\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2\n  &amp; \u03a3\u03b9\u03b1 \u039b\u03c4\u03b4.</span>", "ID": "82ccbd1a-3ba0-4504-986d-53d5125b1b74", "Styles": "None", "Classes": "None", "Text": "\u0393.\u0391.\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2   & \u03a3\u03b9\u03b1 \u039b\u03c4\u03b4.", "ParentId": "81708057-cf1a-400f-8a7f-40ba58505b96"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb</span>: +357 - 22 76 62\n  76</p>", "ID": "7dafcff9-2a16-4eff-8af1-e209717b7976", "Styles": "None", "Classes": "['MsoNormal']", "Text": ": +357 - 22 76 62   76", "ParentId": "a09b4e66-c9b0-4d44-a455-0e5c4f94641b"}, {"Element": "<span lang=\"EL\">\u03a4\u03b7\u03bb</span>", "ID": "b8e3a1c1-114e-472c-86cd-d4f8c958aefd", "Styles": "None", "Classes": "None", "Text": "\u03a4\u03b7\u03bb", "ParentId": "7dafcff9-2a16-4eff-8af1-e209717b7976"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "08763d74-c4fd-486b-aae5-93694fe59baf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "a09b4e66-c9b0-4d44-a455-0e5c4f94641b"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Sverige</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche AB</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +46 (0) 8 726 1200</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "da44e576-22c3-488c-8263-6358e0189334", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "e6a7d563-4e90-427d-aa3f-a5404402534e"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Sverige</span></b></p>", "ID": "aa40760c-046f-44fd-8cbd-2b0b950349d1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "da44e576-22c3-488c-8263-6358e0189334"}, {"Element": "<b><span lang=\"EN-GB\">Sverige</span></b>", "ID": "ae61bfc5-5a1c-4731-974f-57efb1b2400d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "aa40760c-046f-44fd-8cbd-2b0b950349d1"}, {"Element": "<span lang=\"EN-GB\">Sverige</span>", "ID": "911775ca-deeb-4e7a-be92-18f3783074e0", "Styles": "None", "Classes": "None", "Text": "Sverige", "ParentId": "ae61bfc5-5a1c-4731-974f-57efb1b2400d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche AB</span></p>", "ID": "8e528850-2b65-4e71-97fb-837de15f0408", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "da44e576-22c3-488c-8263-6358e0189334"}, {"Element": "<span lang=\"EN-GB\">Roche AB</span>", "ID": "d9e39a5d-d9bc-4539-bec6-eb2cb465706a", "Styles": "None", "Classes": "None", "Text": "Roche AB", "ParentId": "8e528850-2b65-4e71-97fb-837de15f0408"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +46 (0) 8 726 1200</span></p>", "ID": "2c8043ec-bc96-4226-a70c-c5c3a31fdf89", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "da44e576-22c3-488c-8263-6358e0189334"}, {"Element": "<span lang=\"EN-GB\">Tel: +46 (0) 8 726 1200</span>", "ID": "fd499e00-1cb7-4d5c-82c7-afdd04bd893b", "Styles": "None", "Classes": "None", "Text": "Tel: +46 (0) 8 726 1200", "ParentId": "2c8043ec-bc96-4226-a70c-c5c3a31fdf89"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d9d3acdc-b3ef-434a-b049-cdfc2ef4f9dd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "da44e576-22c3-488c-8263-6358e0189334"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Latvija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"LV\">Roche Latvija SIA</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 \u2013 6 7039831</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"IT\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 (0) 1707 366000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "7d10a96b-9b3b-420b-a1ab-57efecf58944", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "2953fa40-15e1-484c-8c5b-89c652676a34"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Latvija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"LV\">Roche Latvija SIA</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 \u2013 6 7039831</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"IT\">\u00a0</span></b></p>\n</td>", "ID": "9138e627-f941-4b2b-8169-ce3a280db26c", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "7d10a96b-9b3b-420b-a1ab-57efecf58944"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">Latvija</span></b></p>", "ID": "d40645ba-05a3-43d6-9a48-8e4608373ee2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9138e627-f941-4b2b-8169-ce3a280db26c"}, {"Element": "<b><span lang=\"IT\">Latvija</span></b>", "ID": "51a5fb51-8b40-4e2a-a50d-84b154717582", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d40645ba-05a3-43d6-9a48-8e4608373ee2"}, {"Element": "<span lang=\"IT\">Latvija</span>", "ID": "ddaa10fe-c4d9-4a26-a377-44ecb799d6a9", "Styles": "None", "Classes": "None", "Text": "Latvija", "ParentId": "51a5fb51-8b40-4e2a-a50d-84b154717582"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"LV\">Roche Latvija SIA</span></p>", "ID": "51f609f8-7cea-4831-8661-0de9b2fdb0be", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9138e627-f941-4b2b-8169-ce3a280db26c"}, {"Element": "<span lang=\"LV\">Roche Latvija SIA</span>", "ID": "e421d3f6-4175-4fbe-8202-c02c995ad21e", "Styles": "None", "Classes": "None", "Text": "Roche Latvija SIA", "ParentId": "51f609f8-7cea-4831-8661-0de9b2fdb0be"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 \u2013 6 7039831</span></p>", "ID": "3cae5e01-8663-4baa-aba7-b06701b9ad88", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9138e627-f941-4b2b-8169-ce3a280db26c"}, {"Element": "<span lang=\"IT\">Tel: +371 \u2013 6 7039831</span>", "ID": "7cb5623c-5d7c-4ad3-8cea-ba654be02371", "Styles": "None", "Classes": "None", "Text": "Tel: +371 \u2013 6 7039831", "ParentId": "3cae5e01-8663-4baa-aba7-b06701b9ad88"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">\u00a0</span></b></p>", "ID": "5d99a7e3-23ad-43c2-8472-c5e22810ed40", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9138e627-f941-4b2b-8169-ce3a280db26c"}, {"Element": "<b><span lang=\"IT\">\u00a0</span></b>", "ID": "c28bdbd5-2899-48a1-8390-4e71ff59c7da", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5d99a7e3-23ad-43c2-8472-c5e22810ed40"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "1711aab7-6ce6-4d49-8074-f8a8ab26fb35", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c28bdbd5-2899-48a1-8390-4e71ff59c7da"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products Ltd.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 (0) 1707 366000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "7c69c32d-0018-42ea-99a6-8caa268911e8", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "7d10a96b-9b3b-420b-a1ab-57efecf58944"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>", "ID": "f4c7b2e1-e62e-4c1e-b004-f6133faa8224", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7c69c32d-0018-42ea-99a6-8caa268911e8"}, {"Element": "<b><span lang=\"EN-GB\">United Kingdom</span></b>", "ID": "c22509dd-296f-419c-aa80-0ecb24b59ef1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f4c7b2e1-e62e-4c1e-b004-f6133faa8224"}, {"Element": "<span lang=\"EN-GB\">United Kingdom</span>", "ID": "253d9b6b-fb49-4b49-a0c4-c619f9524175", "Styles": "None", "Classes": "None", "Text": "United Kingdom", "ParentId": "c22509dd-296f-419c-aa80-0ecb24b59ef1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Roche Products Ltd.</span></p>", "ID": "b8303bb2-932f-424e-a699-b172723523f8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7c69c32d-0018-42ea-99a6-8caa268911e8"}, {"Element": "<span lang=\"EN-GB\">Roche Products Ltd.</span>", "ID": "6e212efd-44d4-44d7-aa74-5707400e0d39", "Styles": "None", "Classes": "None", "Text": "Roche Products Ltd.", "ParentId": "b8303bb2-932f-424e-a699-b172723523f8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 (0) 1707 366000</span></p>", "ID": "77002cba-4e94-45ed-b1c2-e211a8c996d6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7c69c32d-0018-42ea-99a6-8caa268911e8"}, {"Element": "<span lang=\"EN-GB\">Tel: +44 (0) 1707 366000</span>", "ID": "1a4126a5-3382-4d72-8695-12532fd6df0e", "Styles": "None", "Classes": "None", "Text": "Tel: +44 (0) 1707 366000", "ParentId": "77002cba-4e94-45ed-b1c2-e211a8c996d6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5dc13d1a-5b92-4239-bf57-3f74767c545f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7c69c32d-0018-42ea-99a6-8caa268911e8"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7f8fcf4c-db56-4e29-a3df-8cfb5571f444", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5dc13d1a-5b92-4239-bf57-3f74767c545f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5b129e7d-55ed-4d16-b57d-8fdd2d92231c", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a30b857e-9114-445d-95aa-d1e5ceee9cc2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5b129e7d-55ed-4d16-b57d-8fdd2d92231c"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">This leaflet was last revised in </span></b></p>", "ID": "190d8a98-8a96-4a00-a77b-0ec903fe706f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">This leaflet was last revised in </span></b>", "ID": "40c0352e-01e2-4d0f-9ec0-1f435d4595af", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "190d8a98-8a96-4a00-a77b-0ec903fe706f"}, {"Element": "<span lang=\"EN-GB\">This leaflet was last revised in </span>", "ID": "0a017750-716d-4e53-bd54-8e3971100e52", "Styles": "None", "Classes": "None", "Text": "This leaflet was last revised in ", "ParentId": "40c0352e-01e2-4d0f-9ec0-1f435d4595af"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "2a990dc8-a67c-4797-bcc1-c6f89c21f1f5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "c5e08ded-5387-44b2-968a-63de86ec7006", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2a990dc8-a67c-4797-bcc1-c6f89c21f1f5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "29951dd4-d52f-464f-8cf9-8413ee7d6cb6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c5e08ded-5387-44b2-968a-63de86ec7006"}, {"Element": "<p class=\"MsoNormal\"><b>Other sources of information</b></p>", "ID": "9e92efeb-d6c7-4163-886a-2c7aaad018dc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<b>Other sources of information</b>", "ID": "31af9f06-2cef-4494-b932-2eb2c5488b9f", "Styles": "None", "Classes": "None", "Text": "Other sources of information", "ParentId": "9e92efeb-d6c7-4163-886a-2c7aaad018dc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c91058c5-ff5b-46e7-9e5b-1daf37e29a59", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "585b4ef0-0d80-4f4d-a885-8791026da7f0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c91058c5-ff5b-46e7-9e5b-1daf37e29a59"}, {"Element": "<p class=\"MsoNormal\">Detailed information on this medicine is available on the\nEuropean Medicines Agency web site: <a href=\"http://www.ema.europa.eu/\">http://www.ema.europa.eu</a></p>", "ID": "43ab0764-1559-4d48-996b-a64a253cc7f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Detailed information on this medicine is available on the European Medicines Agency web site: ", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<a href=\"http://www.ema.europa.eu/\">http://www.ema.europa.eu</a>", "ID": "7aac91bd-ccce-440a-9005-9859ecd61b53", "Styles": "None", "Classes": "None", "Text": "http://www.ema.europa.eu", "ParentId": "43ab0764-1559-4d48-996b-a64a253cc7f2"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:blue\">\u00a0</span></p>", "ID": "5dbd19af-fc97-471f-a245-98e57e9029d7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span style=\"color:blue\">\u00a0</span>", "ID": "2b1ff963-a3f1-4285-b497-e3428f9faada", "Styles": "color:blue", "Classes": "None", "Text": "\u00a0", "ParentId": "5dbd19af-fc97-471f-a245-98e57e9029d7"}, {"Element": "<p class=\"MsoNormal\">This leaflet is available in all EU/EEA languages on the\nEuropean Medicines Agency website.</p>", "ID": "22edc8e4-b573-4c04-a78c-68597c544f23", "Styles": "None", "Classes": "['MsoNormal']", "Text": "This leaflet is available in all EU/EEA languages on the European Medicines Agency website.", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4481067b-2471-47d9-8fe2-7305527acc55", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18c87d4c-3ee1-49c5-b180-e82be687ae29"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ee138103-3f02-4a05-9199-0dad9a7c5c4f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4481067b-2471-47d9-8fe2-7305527acc55"}]}